<SEC-DOCUMENT>0001628280-22-027550.txt : 20221101
<SEC-HEADER>0001628280-22-027550.hdr.sgml : 20221101
<ACCEPTANCE-DATETIME>20221101160619
ACCESSION NUMBER:		0001628280-22-027550
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		70
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221101
DATE AS OF CHANGE:		20221101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABBOTT LABORATORIES
		CENTRAL INDEX KEY:			0000001800
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				360698440
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-02189
		FILM NUMBER:		221350236

	BUSINESS ADDRESS:	
		STREET 1:		100 ABBOTT PARK ROAD
		CITY:			ABBOTT PARK
		STATE:			IL
		ZIP:			60064-3500
		BUSINESS PHONE:		2246676100

	MAIL ADDRESS:	
		STREET 1:		100 ABBOTT PARK ROAD
		CITY:			ABBOTT PARK
		STATE:			IL
		ZIP:			60064-3500
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>abt-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:19ee09c1-7a67-41f5-aa0d-f1189dd14b54,g:ff04be54-28ba-406d-b68f-d5381de01f45,d:b0ff9808fe764fdea19589324372f96b--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:abt="http://www.abbott.com/20220930" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>abt-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80L2ZyYWc6Njc0NDY0Y2U0NDY4NGIzOWEyNWE5NGNjNzM3OTI2ZTcvdGFibGU6NWViMjRkY2Y3ZmUyNGMyOWIzYjkxNDU1NTc3Yjc1Y2EvdGFibGVyYW5nZTo1ZWIyNGRjZjdmZTI0YzI5YjNiOTE0NTU1NzdiNzVjYV8yLTEtMS0xLTE3ODY4_4eaaeac8-85b2-496d-a419-aae9524859d5">0000001800</ix:nonNumeric><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80L2ZyYWc6Njc0NDY0Y2U0NDY4NGIzOWEyNWE5NGNjNzM3OTI2ZTcvdGFibGU6NWViMjRkY2Y3ZmUyNGMyOWIzYjkxNDU1NTc3Yjc1Y2EvdGFibGVyYW5nZTo1ZWIyNGRjZjdmZTI0YzI5YjNiOTE0NTU1NzdiNzVjYV8zLTEtMS0xLTE3ODY4_3f2f8326-f4c1-4f18-ac5a-874377f2cd8b">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80L2ZyYWc6Njc0NDY0Y2U0NDY4NGIzOWEyNWE5NGNjNzM3OTI2ZTcvdGFibGU6NWViMjRkY2Y3ZmUyNGMyOWIzYjkxNDU1NTc3Yjc1Y2EvdGFibGVyYW5nZTo1ZWIyNGRjZjdmZTI0YzI5YjNiOTE0NTU1NzdiNzVjYV80LTEtMS0xLTE3ODY4_50dc7d2f-10b5-4a11-a1b2-8c9678e65b0c">2022</ix:nonNumeric><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80L2ZyYWc6Njc0NDY0Y2U0NDY4NGIzOWEyNWE5NGNjNzM3OTI2ZTcvdGFibGU6NWViMjRkY2Y3ZmUyNGMyOWIzYjkxNDU1NTc3Yjc1Y2EvdGFibGVyYW5nZTo1ZWIyNGRjZjdmZTI0YzI5YjNiOTE0NTU1NzdiNzVjYV81LTEtMS0xLTE3ODY4_3019bba2-3873-4692-bdb7-29c5f761543d">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80L2ZyYWc6Njc0NDY0Y2U0NDY4NGIzOWEyNWE5NGNjNzM3OTI2ZTcvdGFibGU6NWViMjRkY2Y3ZmUyNGMyOWIzYjkxNDU1NTc3Yjc1Y2EvdGFibGVyYW5nZTo1ZWIyNGRjZjdmZTI0YzI5YjNiOTE0NTU1NzdiNzVjYV82LTEtMS0xLTE3ODY4_743c084b-6ded-4bb7-be40-ae0abd05f679">false</ix:nonNumeric><ix:nonNumeric contextRef="i75c98c84b66f4cfa973544e07e3a54c4_D20220101-20220930" name="abt:MinimumLengthOfTimeHedgedInCashFlowHedge" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNjQ1_49b14940-1788-44d4-b632-7d72eb48a1c0">P12M</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="abt-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaa425fa3d3747d6ad2878dffdb267d0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XCHI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59773e96f1294946be35567fa420b29a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife5c2b9c51b24905939dfe6b3d3e4056_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i318af3e554204da2b38e2945f4629296_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f1d1e1ca3304ec8bafbf0a80a96bd80_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7b8a9dc239044a6b1a2b862dd61b7fc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29242515a9cd41d3929b65fa4ab2da75_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ec2d32ee1c543f89872966939398c80_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13853862ec4e4a8f9dd87d9d1f5a0eba_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84388393a8aa4ea4ad5e48e8c7f24e44_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f2db6dc6a8f4d8d97404a772b976d3d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a2381935eb3479c8272fe544f91e498_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0384842a3a44e638930735a2b593396_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee53b5e2f57b467bafb6a07b010ce7b8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdd95633e0b74ebebb2ef9d790e7e133_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6cd17f6345343d188d64dda2acbc2ba_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib605aa77a1694292a23c576b3cbe9f51_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6675c4a62c704c83b04414e2e96f9f15_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a9d779acbe44e3bacba61c64c39e891_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffc3d7b1f7924f49a467f9de89cf4580_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93502cdb071b40d78c7d41a2b5166b24_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3efcbced2c284e42846b07cbce02af0f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42f5fd859ca5425389497f80eb2c653e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76df37ef10134753b1301a961c801516_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib49fbe36bbba46d5a960a042585a8ca3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1445a4f41614df3b5934c37b319c6c4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff7c2622a69b432d86720be37f7e2a16_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ef7377540aa4e4c823d715421f8fd87_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d04e8e8dc804bc79e6cf5d8fac6d42b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7057ecd5f0c1428ba00d5cc5b5ed8119_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib97d8339fa5a4a14be94890cbc7535a3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i088ce8132a864ce3a40176de183626a8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1504c2dad3014570b5b401bc387b8c52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d042e1363a74135b1ff431769cbdd3c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2633c881b0854a9387e79c0bf0e90227_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00352c2d1368429694fe5d87533d4a96_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cfae92185d549208e196b57add32000_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida0d59058b594e578193e429a2f6c056_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b724be0df7a469ba9c898710b2dbf1a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6098fe1fbe54bc9a82cd2c345421c2c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i852ddcd4489e42389a31b5f021e6e092_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa7c44803cf240068637223e01d8287e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdca6cdd2c3846f6ad4787b16fed5ea4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5e6626a450843eba3abf231608db97f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0d9d6801c8c4803a0622083412ac492_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f3f735442774afcb720cdb3ae2b9822_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id78baae4639244558d7fbe8dde9cdbaa_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc6ae1cd7a5648a9876bfd212f13b5fa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc59d11b30d140339de2cf7f2ac54561_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide6a9cde9eec42f099b747ac02363030_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide40706d122541aa80614540c148de08_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i621d2ad3316543a1886bf830d26e3ffa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3397ef3061f44f36bc9ca7c33654a5de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bf57bd89e8649de9b14b6f40f63d3b6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>abt:segment</xbrli:measure></xbrli:unit><xbrli:context id="ifdd6935a04684767a7df321fc7d8e04b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20dea8b9fbad40a38c94c202b5a06584_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i553b1f411dac4315b9a061214928d19f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fd8b94ecb894e8195d49738629f7663_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab868753d235445d83b1848d574f0930_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9377afb46605449ba04338e3aed6ebac_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb9ead876d79497b81d1a4e75fa4b045_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb241d31511748689ba74aba957986b9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if08d89d55ab546df94df4e9acd51d621_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i392c359c05c842bdbf2ea56e22942b96_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a2976080c494443a4931b79f76745ad_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i356b34bf48444864bd8276a14a0a84e4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1992bffa64a74127b5f3ce81b21991bf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic22fc4ec43f24128aae74e88776149f8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1e67684e5e949128a2dec705cc5342d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f479639da464db4b609d3fa8cba57e3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d8adee8e3b749c59dcd592b973fe816_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifffc59617b4841e6842d4164adb3ad90_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i938d14e18c764f7591831cee2b53ef86_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3d4661d9eae4662a6bc7af372b39a7f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0270bd857761409ca80dff389f4005fb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5684517b411b4be6b66e253acbe21100_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94a3d528fe5c493698dcfd7f6cdbd624_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4c46ec7babe4d8d98a3a5f521e8605a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ce87a21a2074f99b7e3a9096bf4bc2c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3981790b8e294829b7fce3da94293b1a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idee15a5bd7a94f2a92b34458fffd592d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5d4fcd289e94e72b4495606b599fffc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8fe4e7fed8d4ca39d192d7298446b1b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56ce1b628bc24fbba472f845695459c7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i262c247a794c4eefad4c4426111eda88_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d37f71b97414ca0a196529d4e6c3728_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8fa29318db7448c942a75e199de1be5_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i248ff18b88c14ec0b9b3fa1462dc670e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84b6259abeb9432c9b1f4f981322d6e2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f3203f3fae46e1ae8028fc5a27e29c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia256be207eb1438f97b1a7c44dda87d3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5dcca58e8964d269d6d18f5bae1e53d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40d8bf57ab5544cf81d04120e139dabf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia86213c5d496444e8758ca35cdaeb05c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c1f5c24bb5841378c451a90d43000f2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b897bac92554d069fad477918947757_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b4a4864d2ff4c4e8574e011f96d543b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8377a58ea461458c9ebd573507a2eb81_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8800ac73633d482e852c78a6b3b8d03d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cda9249440a4ababf23d348f31db81e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec3890031ec84733b487409a7fff947e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29f47d268de74c4bb30f8f0125aeccc5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30e9486b2c674fe99294020e754c817f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6366c00282d04fa5a78abdb1ee423aed_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79d29b0d89e645e0bcb31189ca823228_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20ea475fdf0c48e98e083f8dff8056a9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i003dbc498c9a441d89cc0b04ebbd771a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i975d74cca0954d4da1bd068770b41605_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d047d8dfd414c5d869bcd80fcd41acd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i737b2378d74d4e7492bfe82a019bb4ab_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i769d3ce030b942ae9d850540e53df223_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida0bffdbe968459c98f06e252484ccc3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id63c448a841840358193db0fad40f4c5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic56a546e33244e07a2c5e1ab9ecb4292_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fee55729a8c4e7185f644e1bfe2485b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2140596e31a1496bafdd0b9ee4a2e6a6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09ee6e9676f048f79f0471399c05b638_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id19d1f5e16084839a8c193bc0d1b0b6b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd6b40c44ce54ba1bde4642cb23e69f6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4186212e28d4b569b09c70bbface083_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id659a1190f7b4070a747d070536ed33b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6480973800e4bb4b9ae80722ce16e59_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d61af67909049b9a444fc24e14717ea_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if890618fe578485fa3a4db43677fe34e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34397dbe2fe94c6295a14a8d146a8e33_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f8368e30efc48f7b56ba92dc4adc061_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i928d6fe7e0df441780768f564d2effcd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f24ca1db60e4a9da9ffd86e0dd87fe7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i822021d7a9e249bab1fe800a9aedfb9b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ab1d9822ff84b4480b3cd3b8cc641bf_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if718f850e60e4378916dbadb60c282ad_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e82029ad78c409e9753b65d01cfa2d5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedef7300876e4675ba5cd753aef79d39_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d1631e3346a480c9d5b5659e244276e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77aac3496d504b269d56bad2b76e5104_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i780ba98a53b04c0abf1fcfadfe606d7f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic59cae3887574b7b9d34a8c5fd1fb0b6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i228ab2341a2243eeb1c80b00645ce995_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2294cc5729724ad4beb4eca7c9cdd070_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide82ac8a034040ebbe46d3d3b8e71a00_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dc02637faf8456f8e9ffb0ddcae89e6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4030aeb71c94f9bbc3b600344c1518a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i921fd3c95d3b4f22ad34e4bc60148ba2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3145c2c6bd974f55ac9749bc3df087bf_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b5c721c4b474f6ea1f090bb7b8e4fd0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35e0589ff3084f539d0a76d845294702_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34e8d657434743fe827a4089fc230ba9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08e9a03bf16d46ea811c32e2fd25a006_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i570d7e8aa51741029b8421acbd7e89ee_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35c10ac918394db8b1c3491c2981f0e5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d04f4545b8b43d7bcd56adb5418487d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a32eb2db2de4ba4b33ad343ddc6021a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1583d120070b4c648cbb100c9764e0a7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i683987d035904d219c421b72bf0f8f88_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a64fbf194cd46d1a5f071cd845567da_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9adf53e54b3447a88875f2f71694d649_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica898e019d964049bedef258b5226f95_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c4b4059d40945188d652327f054645d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8056ef31a802430fa929e0598584b1c7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia16e81903f114d79b6e640358306f75a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1005eed0e87a4f6ca75ca475d4fb2b94_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i351b1476da8947a8a63c6a3ff672aee0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff8daa2d825a48a298a1cc610189cf7c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a811c943c8c43aa93ad41f1bdcb253d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91226d7ee83f4e5298c5a54390a1eccc_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10e8ad512c2f4a09873c90ec51a3e052_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9911c8668779460c87a6b1bfc290914f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2c236dcb265432793429913b3061d27_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id73b999e6aee402da9f298dad7a6ac0b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i069f4c6f209746c789a3cc531b1374c1_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e1452c0c5d145a29227070d32c787ac_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93831c5392ae4927b11006f81f940e3c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0a7f44a74844847a52a461dc905dc00_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ef09987de6c4adeb7fa5bf0cf0c7704_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf27976a942a4fc19586a8236e981bc0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1349d737be5b4ef59e79e923b2ac2288_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i453afdd41ffd4a8f9d41a110816ebc00_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b9d6f53ba814d1b95c967e665c217ea_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iada0437a2d644f70bb7d16cf91f31b89_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cade4bab8cd43e19b63a86b43643ef5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i361870a0e2f94355b13e0b60175a2edb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i134a99d86b0243888efe2cec770050b5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i690d3ee447044de5b2a11910dd16abaf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31f2c0a0ad5d4d44bb78b1dc657ab16d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i554353f0dd4640f1b215201bed46099d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifec2214696a74f5fa73835f5d611690a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6e6c2d98d8f46038f546582021c6a94_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9a4321960004899b56bca3a97bccffd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i102907d306274282b184801c40f69f97_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad208ef1d3254acaa72d25a179cf7d24_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92e9ca2b2e18494baca77d7365fc681a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40287ad92f234638a3f0573ebae44eca_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88535b01ff934a65be5cc199bcb770b6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icecdc6a5fc1c478c8f0fdbb2c241e43e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i708d2529d4054b78a3b367c21aaa1820_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c90b3c1db944b208e77b4076259563c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia34a1de062a34934a0a112436ec8d560_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1345044a56d74824ac553b8f40f2c74d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic52e79d5447c4977917c82e49b86fb4e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e840f2b6e62404898af58c0cbc62fbf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a8d70dcf5384658960d5b5ea48dfbb7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43915f754bb04fb5a0040abb37d51123_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41d6039c97b64dbc820635198caf3dc4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i258f0ca4a6f44bcd94d893ebab9cc9c1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e3063d3a8aa47c784ad799aceff5e06_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea4b8d31930d4018a5338e7cf5435676_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i176c1169defa4bb381f30ee2fe87a5d3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie585e82674e94179ab887b7f775c682b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie623ae8b28ba4c44b6fec7b856d08e06_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35395fcaaf34451c9cbfa534d8d7ce9a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30091a5d3bab43efa63d14e4a226925c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1596bb0bf8f43fd80c7d6d3d9119a9b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i248be60308a146df85a86a26a0fc60f8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i151bd5c29f3c46848ec98ccbecda7c02_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b056141550548c3be6dd5b036db3ff1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e31728b4def4db89b236907c78b2797_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia75bb1a2605e4d8ea6e25aa3afb20121_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaa33587aec14e3c92b0c60d0a771555_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62abea3acfae48e8890da0175c0339ac_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if933b85d1d764e94956ab214e194e081_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d65665918964adeb3fff6362875e715_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i381802cbd03a48bf88e11eee86e25b7f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id56510d8ef1842c0ae332b5fed72a26a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i775838a7944846a986221b63ebbe9b64_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba87ee33146849a291c62b0745bb5f5d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d36392cd74f4d26a9d42617161eafaf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a75adec61da4340b39d6915dcb31f11_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9cf76723706485f8673bd279ede2bf5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3769aaf2e984527ab4d6cd5c5790c6a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d0f4ef4f7424767974f102dbe69d978_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ea63032d5234ccd932e6fd8c70cf960_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i390a22555acc4884934c9d58d45d11d2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49197e2409e34e65a96c75e9f85a6de5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b4a4436b7e3437ebd0171fc877d29e3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43eff708b8824e8da4d9838d6a4f5e3f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1103a7e9b8c9470d9eb268366aaf62b7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0287b1ef094c4fad8318d6eca7385301_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e49e1388c1b47c883e46629b8e2b191_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59bf5ff82ae5408b905d3c438eb99949_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib084a5804053469ab97816e5c1ee7359_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72d0903dbdb14905994e7b293b54456f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4974eb5146784a269db4203e8c6fa7e6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66b90b7445ea43d9b419aa50bb82b8e5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc14a44dcf1344559829bf251b14704d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00bbc05a48e34b0895b143638542cf98_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4ab9bd729548cdbc214c561241cdc1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id965fbb08df843a7b71062949bd75de8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f23fb6c9b6b40f996df1df9c7d4d1b0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59ade9da924b40b8b3b22b5c8d7085b2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63931e4da08749c89fc6a8bd235b4ef4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d48c3bb559c4a829632103b69a3a872_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f1f89cdf584d59a1701cdbbeead083_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if86c316bd32140fcb1db26b35d96f19a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9da5f32878ef4ff2bb7b73e8340888d3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85330517d5a14b5eb736122a3a5bcebc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i899221de84bb4f4da22a481ff4200823_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f3b2c7957554d658f3db970c6d6b430_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec90285d812f4f068310c71aedbc8afa_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i152ee6da621e4956b226578681a95301_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e8d82e7deaf4edbb04c1b33ba231943_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadf482c8b62342cabd96a8f08883e08f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdfc6bf7155d4385a0a3ab7ed7d09c3a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia12ba51821814d288ee081fbaa8ce473_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74fa6dbf7cce4f75b02f642d1f599489_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0df3bfdd84f14f64ba3f84ad0dc9a807_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1935bf7c22124130bed4e1a214f63308_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedb59d3d7f814dd5a908dfbd889da9d7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabd1755cc8654a2692d559c24619a01b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f0c0e2be49847eda32a1bc8f4a3d0a4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i603417b878634bc7b3c6c7e28e82df50_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30de540bbd614a38a4d9b0e11618a079_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46266d118c974a5aa2d9e68681b6b922_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ebd6bf1d71d4400b4815379954178a3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b829deb2ae74f13a56fe33a45c6e829_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6e1e30c4e804011b00a91294e5115f6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4463afae1e5544929d49ae0a34367c96_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3476fa0ac234ff2842cfecc49b3e986_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if64d98f713314bb9833a430722b4386d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9857ddf749154af092177a27b3317c19_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18e9f36c179f44e3bfaec15ee0847c98_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3859aeb3184c430cad30ee39666a826e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cd2a1a447c34980acee85e3b68e0919_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37249fb3b9b7438bae34cc8f3ddc38da_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82e117f9b22f4ad18dde00710f85564b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0deea721100d42d2aa599ecbc0b6ee95_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47b80c5b0ee9422a85373b6736cab652_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08308c9f9c6a446496b0ba98a0a5fa36_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6041fbdff4649fb80901f2a88fc9805_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i165fe1c62d6e440d91dc4abc8a0dee83_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i417cf26f3afb43a3a54f1bb81556fdd8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25afbf02cb5a452089cc6973c24865ab_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81462640315a4b09a820a1f604b6aa3d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic909cb81fa33496693b9dc997788164a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee4f114b62e84287ad7fc6130c023ad9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic07c5110a61643c2a55c992dde280072_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07c1d47dd14647d0964914f96057eefe_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3382e3eaaaa846039edbe767cda3d3e8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b228ed718b140b2a339fb6308161ea7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99c7716e33994105b40cddd5474333b2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69cecf5a94a046b59d942b45947a7002_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf4171e1cd304992aba32032b32e09ae_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i991a1bda2a6e4464a4b0a7be66e27ead_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id035b12c3f014d2bafdba8da0f64bb42_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62bee42564544f0d9b3280c51a9cc02c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c7dafe2cfba49daa19fb3f0283b449f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i20fe539eb4a74b7492123682cd84ae45_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22df9ace730b4d42bc4be5744f0a1bad_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aa796dac9664691b74441abe1256b0d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06b3500e4f5c4314a3d8cf6b4089c98e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d0dbddbfdc84cd0ab7a31f5e8fdf16e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7c97d1edcfa444cb20aa7be67ab0d50_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fa4384e8a504eeda1c27de655e4e9d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b879570db6940ef8d990b6465f15c41_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abt:StJudeMedicalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f5a2e21895448f88c750459f871dbf2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abt:WalkVascularLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i495e1acb6ab646e1be98f86d888adf7c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11d15dbdba194d4ea258e34ec953d6bd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i415827a77ac0453d839b9593bd2f924c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1fe447f6ae64a75be725ca40d0bc9da_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i964adde7ff6b4fdc8165d93476caeb82_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie15dbca7371a44c29034f90ed736efd2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd59cc26c1dd433798bec018b3ccbb28_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aa011bcd53148e7baa700ba02afe7ec_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17e4add20e234af2a1a931e4e20817bf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9696538c691b42caac0b357c13f12bac_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e0af11ae9ab4bbcacc64379488edc44_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e81d4049c794423a14e1d1c1af22cc7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i427e7206d73746e6898e10c2092b8bbc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i967b4d49862b4a9c90ab0df452b406c3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i819bcaf6924348468ba7ae6973f92309_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95867ab5ff4a46c2b64acfbbad20d613_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23ed49d742db4ba5b2f23508085a61cb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4466aaca90a4878b4208479546c953a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i874ac07585e34b5781c671c1bc0b74c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cdf5c348d5b4b53b9a6c86bb4a3e3c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e549a342ce24de7b2b4542ffdabcbee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7de505469f274ea4a34eb536d8434973_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c966c996c54468f969135a6a97d474a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6e9ff01f8fd42f38aa515217549336f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaba0b25f7ac490d965f16df9dcbf02c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9341a3223163491aafcd6fe2d673a55a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if502b2d6402f4818a6bd6e4dd318d573_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iede3d406d2714638aca592a7412cf559_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65f21a35a5f64266baecf8e128ca0727_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2212cc9951e446de85154e63b59c05bc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4be71fc1af9b4576bbbec0f3973e74bc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d3eeb93a75a4a2cbd31ad08fd494ee9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2602c6bfcec4afcb539d839ccd375bd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib718c9002df547a9bb6009289d5ab871_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73865c3e534643d5ab15aa1266d200db_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:FixedAssetWriteDownsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32e1a3f5ab2a404ca01cc18696529902_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:InventoryRelatedChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36df938cc26341c18a1b3e9570bcec52_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:OtherExitCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53e8568bc39d4cb19a2c23541737716d_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i527c49b1d22240058f22784151a891f3_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:OtherExitCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5061818384c4b19aae354446d336fd1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:InventoryRelatedChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c70ec7c6d944192a4c8aaf8042cb9f6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:FixedAssetWriteDownsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d67be86a0834dfeb506f82b11589377_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:OtherExitCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd32e0ec232449a093586b6ac423eb4f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1b41672050b4f62a5208c5e716d43f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:InventoryRelatedChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i901a35e981d14756b34a5adff1083cf4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:FixedAssetWriteDownsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7235f22a8e74924b42a859bb232635a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:OtherExitCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifda673e60ee8405ea4371f6fba8fc86f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d18df850f834757a75a53bf2cdc1ca9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:InventoryRelatedChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eef48e6721d4174ad61b0c4bacfd4ef_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:FixedAssetWriteDownsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dfe1081e2a7492d8113f7b5208ba611_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:OtherExitCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e0db81ff25a4a54b0211447d6b1257a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic210a4881e7a4bfc8506d1330434b1b9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:InventoryRelatedChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8624555d304424fb6b08adc08120a68_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:FixedAssetWriteDownsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ba1fc8cda234a89b835a4e348ba3cef_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:OtherExitCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i562dbdedf98e492987bde41c83f41e48_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4794a110deb7433cbee3148cdeb358b8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibabb70918fa246128ee74b2f2f3ccaf0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abt:CostOfGoodsAndServicesSoldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83f541eac1144e6bba42b451c74c7720_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2df776b1f8948a8af5d5968a2f003d9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d232a4fb6cb42509c44225cb0f739e3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i025aec3dc4f441b783d28fd3085d2f29_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id22fc873c34b4c30b31390c7c0722eab_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d7dd7f42af3454e98ea0cd9e0de9533_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief8174a37ce742efb72aee7ec66f0b45_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abt:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e93f70390524d65aa024c34612f8203_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33f19560992c435a88092f47daf02b5b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0b29ca98ef14de0a3be8cd36653449b_D20220315-20220315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abt:A255LongTermNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-15</xbrli:startDate><xbrli:endDate>2022-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb2e6dec32fd457dab072263060d0e7f_I20220315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abt:A255LongTermNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76a875a71c9d425d9d761f5b9b84a5e2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf6d0188932d469bac5c2cf700f6c5e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75c98c84b66f4cfa973544e07e3a54c4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7768645f0e3548ef8fa07c72bb1ea50a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib70687d909df4adf951907f9e4120aa4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i362cc950c402435b85ccd22cc23f812e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abt:YenDenominatedLongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i549e4e2eae714c2daeb70c21f201d001_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abt:YenDenominatedLongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie414f701cbf142b7b9b601b415e450e9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abt:YenDenominatedLongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3273ef5ba89846a6b3579791ad4114a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abt:YenDenominatedLongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37b05ec060e14d3a94f524f71c4a509a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7159ef591665413e9beeecc68ac31d2d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec45d80b0bae4c32b4f36d6967676878_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abt:DeferredIncomeTaxesAndOtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3c67e54492a410491b80a24aa671e4c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abt:DeferredIncomeTaxesAndOtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b9ef5b827994c42a6595f4e0c623688_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abt:PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ec5a2619fbe4414981ad28228a6b87f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abt:PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cb408ff61494ac1a4b289c86d1de300_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abt:PrepaidExpensesAndOtherReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea63a66bbec848d5af23efa2feb1ab3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abt:PrepaidExpensesAndOtherReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia26c1f62062f4ea0a07843e03153843d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0dc5c19ed38405a941c3edfc0d6963e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cdc399d14e84bc6a02151fe08ebeac0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abt:PrepaidExpensesAndOtherReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65c2fb65db7845fb87663d6e762d2d63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abt:PrepaidExpensesAndOtherReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2505f0c40f0d485cb42f96d4df9ad116_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e3df89ca5cd458499f4fddc42ea907e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea1dfa89210b49259cbcc86f33bc5af3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd9937735c2340e2a5e5e7ccb99a641e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5397677ab93a49019eae8c9a0bb21d79_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dcc53ef71a34fb88566cf49ebd25f9f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie72837af6cc147a5874155b6990bf8c9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65ae9ecf6fd5486287c43691fc391e33_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3506a1ed3b6c452f90c9f839466ac4e4_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5be187d8164445380ced526aa943a0c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cdf77deb3954cceb710b7273d79ecc6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf6360515a084a56b0e124d0c9a4b858_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a8804aef7ab405a9bd7994c3c7fc41c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6840ccb5da6c4ad4bda53b49c4cd3231_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6afdc8cb667a4638a732ba5f45eb54ba_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i091abb1e8fe94a55b833b101e4414fe1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88b7ee098ae642899deeab2cddde1c6d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1277200202a84547aa376e37e03fd635_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia237ff4511bb4929b3bba3623e099990_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cd680e248c64638be6c598cf72ebfad_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e53ec310eb54a098325e121ff28338f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dcc8e7c28ee4309824c37c0f1ba79d8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i301f40be6d6f4ebb92077078845bdb8c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa54db95946a4086a4914e1aa90c5af3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedd4976f99c842058ae43f0aefe27d73_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9db10f8a54af4a0aaa440b1f3206a5d2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44e6cf7c4a144759b6e10215356df268_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i199db302b74f4397862dc61ac1c91c79_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i132737fb549d49b2af4b792fb9883efb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic595c192e42f4320bb74ffe5f79848fa_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9130097464e4c8abfc4ebc47a8bf3db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic386176ec45b4cb29e70f8de930f1a01_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6d54ddc609d499383aafcf6ba76dd93_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib18fc392e579454d8f85e5dc41070311_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1f2a644ac84481c931d626da6d56b5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1940cafbfda44622acb910b14b1f0a51_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie698bf737c3e45f2bb1ceb02130904bb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">abt:LegalProceedingsAndEnvironmentalExposuresMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia383194c19ba4900ae6daf189c3fb80d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">abt:LegalProceedingsAndEnvironmentalExposuresMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0f82983e37f491aa82bf6e3c57ef4d8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">abt:LegalProceedingsAndEnvironmentalExposuresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic55e17708b144d149c97d0b172bd426e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf9e8de48606409d948398115c9f7699_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40386c7e28f341b4ae443602056c8368_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i229532fb1b884a2b865d6f39735f6e86_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6b147cc106249baa28781e370ab66ec_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae69ef505e864efdaa37bebaf468436c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08ff00d9980745d3b2b0e1c3d2eefd08_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1099be209597485a9a6ade72499f0853_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c3c6424ac1343408381b0dd7b44aae4_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a9d35abc82344dd90c2c98e1ecdaa09_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bf83d91e28e4b25a1e93ffb4e5cc448_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d7ba7ecde044f91a11577ec17c7a3cd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc718d211ed24b9d86b6822747cccf0f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic04e27180eea452fabf297f6b5a3fb8f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d59739e470d42f5ae66f7d538c62253_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6f6799cbf824e39b44c30362ca2098b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54d09e1c87b34a10a7dd79336679c8d9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f4b8383f4d6400996c6ee0273a48d8f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6ddcd9bbd2f4feaa5056904c8dc104b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000001800</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib0ff9808fe764fdea19589324372f96b_1"></div><div style="min-height:27pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xODM4_a76e7008-2061-4ad1-8399-c6a8f097cf57">10-Q</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.527%"><tr><td style="width:1.0%"></td><td style="width:3.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6YzE3Mzk0ZmY5NzBiNDMzY2FmMTA0YmQ4YWVkMjQ1NGYvdGFibGVyYW5nZTpjMTczOTRmZjk3MGI0MzNjYWYxMDRiZDhhZWQyNDU0Zl8wLTAtMS0xLTE3ODY4_5857281c-c04b-4ec2-b76b-cb9f84bd8806">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xMzM_49d38512-ad89-4c81-9947-7c731f02515c">September 30, 2022</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.527%"><tr><td style="width:1.0%"></td><td style="width:3.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6MmQ0Y2ZjMWRjZmE1NGI5ZGI1Y2VlMDI3ZmYxNDBhZDEvdGFibGVyYW5nZToyZDRjZmMxZGNmYTU0YjlkYjVjZWUwMjdmZjE0MGFkMV8wLTAtMS0xLTE3ODY4_3301bc90-8960-4e69-8723-a9ec6ec3531c">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to </span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xODQz_99072e9e-5dc1-4add-83ff-49b96cd25ae6">1-2189</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xODQ0_365133b9-000a-4f3b-ab96-2366cc62f21b">ABBOTT LABORATORIES</ix:nonNumeric></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">An <ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6NWY3N2FkNTZiMGQ4NDkwM2FjYWY1YmE3MTcwMDUzNTQvdGFibGVyYW5nZTo1Zjc3YWQ1NmIwZDg0OTAzYWNhZjViYTcxNzAwNTM1NF8wLTAtMS0xLTE3ODY4L3RleHRyZWdpb246ZTgwMjQ1MzUxMGI1NDQ1ZGFiOTIxMWFhMDIxNTk1ZTRfNw_2c1f3eee-522e-429c-ab00-e687085fe4a0">Illinois</ix:nonNumeric> Corporation</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I.R.S. Employer Identification No.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6NWY3N2FkNTZiMGQ4NDkwM2FjYWY1YmE3MTcwMDUzNTQvdGFibGVyYW5nZTo1Zjc3YWQ1NmIwZDg0OTAzYWNhZjViYTcxNzAwNTM1NF8xLTEtMS0xLTE3ODY4_0ec025b1-6419-4087-96ac-78c3d4f3c23b">36-0698440</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8yMzk_337c1930-de71-45cd-ad9d-b7c646a4ef1f">100 Abbott Park Road</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8yNDI_4b132994-4ad9-405f-8b36-a70c26710c72">Abbott Park</ix:nonNumeric>, <ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8yNDY_7d0d7546-d3b0-4248-87be-4ecb0d606121">Illinois</ix:nonNumeric> <ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8yNDk_2564abbf-c8a3-4c5b-8631-b9a64938ae81">60064-6400</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Telephone: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xODM5_a020ab5a-4771-4ae8-90a2-82918f7ebfe3">224</ix:nonNumeric>) <ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xODQw_0381a5bc-e517-45a1-bd1f-ee07f3fc5744">667-6100</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities Registered Pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt;padding-left:3.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.527%"><tr><td style="width:1.0%"></td><td style="width:38.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.810%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title of Each Class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icaa425fa3d3747d6ad2878dffdb267d0_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6YzY1NWVjNzUzMzI4NGYxNGIyZWU2MDE2NjEyNWRhOGIvdGFibGVyYW5nZTpjNjU1ZWM3NTMzMjg0ZjE0YjJlZTYwMTY2MTI1ZGE4Yl8yLTAtMS0xLTE3ODY4_ad449f61-9f17-435f-b6b4-4b2fcdee62fd"><ix:nonNumeric contextRef="i59773e96f1294946be35567fa420b29a_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6YzY1NWVjNzUzMzI4NGYxNGIyZWU2MDE2NjEyNWRhOGIvdGFibGVyYW5nZTpjNjU1ZWM3NTMzMjg0ZjE0YjJlZTYwMTY2MTI1ZGE4Yl8yLTAtMS0xLTE3ODY4_bf84ae93-3535-443c-94fd-66d248573588">Common Shares, Without Par Value</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icaa425fa3d3747d6ad2878dffdb267d0_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6YzY1NWVjNzUzMzI4NGYxNGIyZWU2MDE2NjEyNWRhOGIvdGFibGVyYW5nZTpjNjU1ZWM3NTMzMjg0ZjE0YjJlZTYwMTY2MTI1ZGE4Yl8yLTEtMS0xLTE3ODY4_54b68d94-6492-406b-9cc6-48f25b94a44b"><ix:nonNumeric contextRef="i59773e96f1294946be35567fa420b29a_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6YzY1NWVjNzUzMzI4NGYxNGIyZWU2MDE2NjEyNWRhOGIvdGFibGVyYW5nZTpjNjU1ZWM3NTMzMjg0ZjE0YjJlZTYwMTY2MTI1ZGE4Yl8yLTEtMS0xLTE3ODY4_a1536d56-69aa-40ab-8ab2-676151642bff">ABT</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i59773e96f1294946be35567fa420b29a_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6YzY1NWVjNzUzMzI4NGYxNGIyZWU2MDE2NjEyNWRhOGIvdGFibGVyYW5nZTpjNjU1ZWM3NTMzMjg0ZjE0YjJlZTYwMTY2MTI1ZGE4Yl8yLTItMS0xLTE3ODY4L3RleHRyZWdpb246MmVlNzRhYWZlYmM2NDc2M2IzNzUyZTY1NjUyNTM5OThfNQ_072e4e22-4c38-4fa3-b411-69892dc8e034">New York Stock Exchange</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icaa425fa3d3747d6ad2878dffdb267d0_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6YzY1NWVjNzUzMzI4NGYxNGIyZWU2MDE2NjEyNWRhOGIvdGFibGVyYW5nZTpjNjU1ZWM3NTMzMjg0ZjE0YjJlZTYwMTY2MTI1ZGE4Yl8yLTItMS0xLTE3ODY4L3RleHRyZWdpb246MmVlNzRhYWZlYmM2NDc2M2IzNzUyZTY1NjUyNTM5OThfOA_fb450a8b-021e-4b33-b55f-0a9e093f3c19">Chicago Stock Exchange, Inc.</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xODQ1_5960b6ee-e8fe-4bef-8693-245a055a921e">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xODQx_4915dd4c-f090-4281-a712-a9ffa7ceb3e5">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6N2Y2Yzg3NTQyZWY0NGUyNjkyMjQwMTBjYjJlOGU3ZGUvdGFibGVyYW5nZTo3ZjZjODc1NDJlZjQ0ZTI2OTIyNDAxMGNiMmU4ZTdkZV8wLTAtMS0xLTE3ODY4L3RleHRyZWdpb246MGQxM2NmMjNhMzczNDU5MzhjM2NiMjc1YmE2YzVhYjJfNA_b5fac75f-b1f9-4c94-94b0-732ef06ebcbf">Large Accelerated Filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated Filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Accelerated Filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6N2Y2Yzg3NTQyZWY0NGUyNjkyMjQwMTBjYjJlOGU3ZGUvdGFibGVyYW5nZTo3ZjZjODc1NDJlZjQ0ZTI2OTIyNDAxMGNiMmU4ZTdkZV8yLTEtMS0xLTE3ODY4_7fbb2507-18f2-449c-b008-42d6b8377fd7"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></ix:nonNumeric></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6N2Y2Yzg3NTQyZWY0NGUyNjkyMjQwMTBjYjJlOGU3ZGUvdGFibGVyYW5nZTo3ZjZjODc1NDJlZjQ0ZTI2OTIyNDAxMGNiMmU4ZTdkZV80LTEtMS0xLTE3ODY4_6ce0fed0-6970-4c06-b3e0-27a41b600eaf"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></ix:nonNumeric></div></td></tr></table></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xODQy_a4ba5941-3e45-419d-a46b-786fa4b45144">x</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, Abbott Laboratories had <ix:nonFraction unitRef="shares" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xMDk5NTExNjI5Nzc5_549533f1-8001-4da9-b4a8-1cfb61fb1b4b">1,743,573,777</ix:nonFraction> common shares without par value outstanding.</span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;margin-top:24pt;text-align:center"><span><br/></span></div></div></div><div id="ib0ff9808fe764fdea19589324372f96b_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Contents</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:86.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_10">Part I - Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_13">Item 1. Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_16">Condensed Consolidated Statement of Earnings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib0ff9808fe764fdea19589324372f96b_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_19">Condensed Consolidated Statement of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib0ff9808fe764fdea19589324372f96b_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_22">Condensed Consolidated Balance Sheet</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib0ff9808fe764fdea19589324372f96b_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_25">Condensed Consolidated Statement of Shareholders&#8217; Investment</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib0ff9808fe764fdea19589324372f96b_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_28">Condensed Consolidated Statement of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib0ff9808fe764fdea19589324372f96b_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_31">Notes to the Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib0ff9808fe764fdea19589324372f96b_31">9</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_79">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib0ff9808fe764fdea19589324372f96b_79">22</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_103">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib0ff9808fe764fdea19589324372f96b_103">28</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_106">Part II - Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib0ff9808fe764fdea19589324372f96b_106">28</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_109">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib0ff9808fe764fdea19589324372f96b_109">28</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_112">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib0ff9808fe764fdea19589324372f96b_112">28</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_115">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib0ff9808fe764fdea19589324372f96b_115">29</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_118">Signature</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib0ff9808fe764fdea19589324372f96b_118">30</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="ib0ff9808fe764fdea19589324372f96b_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_13"></div><div><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statement of Earnings</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions except per share data; shares in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMy0xLTEtMS0xNzg2OA_49817899-a5f0-4509-aa25-f0d11bd7b323">10,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMy0zLTEtMS0xNzg2OA_5058b4c4-c5d4-43fb-b01d-3fb569148c64">10,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMy01LTEtMS0xNzg2OA_51d45413-ad19-4e9d-ac2a-a53f21c6673c">33,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMy03LTEtMS0xNzg2OA_60d34563-72ce-4541-b8a9-069922686196">31,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold, excluding amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNS0xLTEtMS0xNzg2OA_966defd9-3d41-4857-87ce-04c495fd306c">4,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNS0zLTEtMS0xNzg2OA_74f7facf-0c1d-4ad5-939b-d90ae48ea14c">4,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNS01LTEtMS0xNzg2OA_ed88e7e9-5d17-41d3-97aa-611b3f6af9a7">14,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNS03LTEtMS0xNzg2OA_12eda92f-da41-4dbd-94cf-d0290a435aed">13,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNi0xLTEtMS0xNzg2OA_51d4e935-6924-454d-b778-09b027569f7c">498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNi0zLTEtMS0xNzg2OA_48797f2c-57d5-433f-a716-c3cf0d651c7e">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNi01LTEtMS0xNzg2OA_9dad01b7-b275-4fd4-9312-c84fd11a5a7d">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNi03LTEtMS0xNzg2OA_b2285418-eaed-4fb6-a683-c4843b5a4d71">1,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNy0xLTEtMS0xNzg2OA_2b4ba563-a1d1-459a-9cde-616e7e9ec5de">782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNy0zLTEtMS0xNzg2OA_0b94913b-9dde-413c-bf3c-9608a27128fd">672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNy01LTEtMS0xNzg2OA_c31c7e0b-7c08-4c4b-b4aa-af20a58906db">2,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNy03LTEtMS0xNzg2OA_5277ef0b-70d6-4bc3-ba44-2ee2d8396e52">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfOC0xLTEtMS0xNzg2OA_7a0d6fc9-6008-4e79-915a-6614145d0310">2,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfOC0zLTEtMS0xNzg2OA_dc03f945-2fd5-4852-af02-d2022558537c">2,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfOC01LTEtMS0xNzg2OA_1c912b19-669c-48cf-aba4-6f7e6dda85d9">8,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfOC03LTEtMS0xNzg2OA_322ac259-3c1f-44a9-a3b7-65d03a3bfcd8">8,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating cost and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfOS0xLTEtMS0xNzg2OA_bc463ef4-3ce2-41d0-8884-be0328338632">8,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfOS0zLTEtMS0xNzg2OA_378968aa-f5d7-46ea-b5b2-6f79bfbc5f96">8,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfOS01LTEtMS0xNzg2OA_7a3edf77-6500-45b2-83dd-d703ccf2889c">26,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfOS03LTEtMS0xNzg2OA_ff1d159d-3db3-4e4c-b867-eae584eca6ca">25,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTEtMS0xLTEtMTc4Njg_d52bb521-062b-440b-9ebd-d037a851cd1b">1,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTEtMy0xLTEtMTc4Njg_5e3cf824-7427-4dcd-9f39-63a0b479bcd8">2,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTEtNS0xLTEtMTc4Njg_0c42c9ea-f875-4957-b4be-06b38b48ea43">7,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTEtNy0xLTEtMTc4Njg_573cd700-ee16-4fe6-9c6e-1da772a9ecae">6,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTMtMS0xLTEtMTc4Njg_76559864-0878-4b51-995b-c35a0d37995e">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTMtMy0xLTEtMTc4Njg_039e3441-a430-4857-8990-3fd8c1ea5c28">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTMtNS0xLTEtMTc4Njg_0f1338f5-a714-4439-8be6-08b0ae94868a">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTMtNy0xLTEtMTc4Njg_31d33abd-d6f4-4c7b-b4ee-349e16bc82a0">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTQtMS0xLTEtMTc4Njg_f502b2f5-0343-44a7-a8f4-0a842a68ff81">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTQtMy0xLTEtMTc4Njg_d113d973-6db4-4d91-b45e-47b5ef0a313f">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTQtNS0xLTEtMTc4Njg_9bea4115-0add-4ab9-9eec-4a453cc4939b">95</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTQtNy0xLTEtMTc4Njg_b6e539f7-026d-44f7-8295-5abf55e45ff5">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign exchange (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTUtMS0xLTEtMTc4Njg_a954bbdd-927f-4d41-a099-327c4b7e7a9b">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTUtMy0xLTEtMTc4Njg_e0a67c57-d7b3-4795-945d-c09ba1ba7868">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTUtNS0xLTEtMTc4Njg_0f5e84ec-dd9b-42b9-a12c-d7035c4bfbc5">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTUtNy0xLTEtMTc4Njg_4040741e-23dd-473c-89f3-a3144b0854eb">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTYtMS0xLTEtMTc4Njg_860ea2cb-76c8-4214-a507-7483ca68f020">93</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTYtMy0xLTEtMTc4Njg_23048a92-70ec-49e3-8db0-99d9d7592761">74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTYtNS0xLTEtMTc4Njg_caeab90c-0574-46fd-a789-e78996d7a2ef">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTYtNy0xLTEtMTc4Njg_57778ecc-16dd-4f53-b11b-a4df5e6b880f">214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTctMS0xLTEtMTc4Njg_c1c6bc20-53d4-487e-9782-b4fed5bd1b4d">1,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTctMy0xLTEtMTc4Njg_a9307866-040f-4555-988d-54c59af21fee">2,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTctNS0xLTEtMTc4Njg_18ea6bf4-a99c-4f2b-a357-9bd0694bafc2">6,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTctNy0xLTEtMTc4Njg_9fe227ba-38a9-4646-9766-19ee97a5e0f1">5,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes on earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTgtMS0xLTEtMTc4Njg_32b50073-b948-451c-a63f-e28d2904dec2">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTgtMy0xLTEtMTc4Njg_5972ad36-c7a0-4c61-a7ea-0a95b75f40e2">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTgtNS0xLTEtMTc4Njg_961fb605-d3a4-471e-a3a3-2509d9e1fa64">1,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTgtNy0xLTEtMTc4Njg_a84c8da7-e762-44d7-9f45-af2d3fc19285">802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Earnings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTktMS0xLTEtMTc4Njg_3631ef4b-b3a2-49e6-9943-4cac2bc61023">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTktMy0xLTEtMTc4Njg_61369dd7-0c34-42b1-a71d-9e35712f6a45">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTktNS0xLTEtMTc4Njg_c6c175ee-8dfa-4234-a006-3255854b0d27">5,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTktNy0xLTEtMTc4Njg_2c8b6e52-9063-4a11-b360-d6a5848dd74f">5,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic Earnings Per Common Share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjEtMS0xLTEtMTc4Njg_958fb907-a53c-4d31-9375-be5cd9c4faf2">0.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjEtMy0xLTEtMTc4Njg_b7f00a63-1adb-4b6e-8b3a-53b09afffe96">1.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjEtNS0xLTEtMTc4Njg_0dbb7573-4d96-4805-ae39-2f307adb3519">3.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjEtNy0xLTEtMTc4Njg_bd120ff5-f8f8-4d01-baad-dce56b202be8">2.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted Earnings Per Common Share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjMtMS0xLTEtMTc4Njg_c031830f-320b-457e-b1be-5de86fb8e0b2">0.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjMtMy0xLTEtMTc4Njg_f8632043-bf35-4189-97bd-a5f26a6e2f4d">1.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjMtNS0xLTEtMTc4Njg_b9029f4f-cc2a-406c-be0d-59f51a2a80f4">3.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjMtNy0xLTEtMTc4Njg_1b04ee2b-9d3e-4663-ade9-1e25f31b58c5">2.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjUtMS0xLTEtMTc4Njg_66a6aa95-9001-49d9-b21c-467c4efe0677">1,752,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjUtMy0xLTEtMTc4Njg_b88f1766-ac45-49a2-8cda-739e354e65a3">1,774,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjUtNS0xLTEtMTc4Njg_a3b15a8c-bef8-46a3-968a-53db15ea985b">1,756,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjUtNy0xLTEtMTc4Njg_4afd2373-f512-4c5f-9d28-9ca0e770a3e2">1,776,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive Common Stock Options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjYtMS0xLTEtMTc4Njg_9be962a7-4cac-4676-bcd3-d74ad723442f">10,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjYtMy0xLTEtMTc4Njg_ddf13721-f302-42e3-8c0f-79a08d95868d">14,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjYtNS0xLTEtMTc4Njg_01f0e8b4-8c9c-4ac6-9670-1556ace0bd54">11,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjYtNy0xLTEtMTc4Njg_cde29cb8-e546-47d3-a734-2e38ac9d2bec">14,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjctMS0xLTEtMTc4Njg_eb216da7-4c66-4742-bd70-6c0ebf3cc6c3">1,763,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjctMy0xLTEtMTc4Njg_df389df9-125a-4a23-a855-bd6a25ed7962">1,788,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjctNS0xLTEtMTc4Njg_88e753c6-99b6-4786-a59e-c34ccd3e62a7">1,767,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjctNy0xLTEtMTc4Njg_06fd953d-171b-438d-8796-f8b86392c2c3">1,791,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding Common Stock Options Having No Dilutive Effect</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjktMS0xLTEtMTc4Njg_7bba17bf-1a2b-4aaf-94d5-7f90ab2f6a7b">5,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjktMy0xLTEtMTc4Njg_e90d9069-1681-44b6-85c6-a98a8e2c3cff">2,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjktNS0xLTEtMTc4Njg_5ddfe742-b308-4063-a3bc-123da50a78ac">2,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjktNy0xLTEtMTc4Njg_f22eff5c-6f99-4807-b72f-f365448762a9">2,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="ib0ff9808fe764fdea19589324372f96b_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statement of Comprehensive Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Earnings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfMy0xLTEtMS0xNzg2OA_474eae53-a05e-4ada-9d08-c19e28217d4e">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfMy0zLTEtMS0xNzg2OA_6cf096ff-017c-4b31-bd54-e585bc59bc36">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfMy01LTEtMS0xNzg2OA_857d5921-ce3c-4a90-aba5-c1c8452230a5">5,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfMy03LTEtMS0xNzg2OA_5d83e1f2-82a8-4a3f-8a32-d9d55b7ebc9b">5,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gain (loss) adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNC0xLTEtMS0xNzg2OA_c9117d24-1350-4ec7-b17e-b9061ddda273">1,008</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNC0zLTEtMS0xNzg2OA_f8073a6b-5d42-4049-a010-fdee92d68395">391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNC01LTEtMS0xNzg2OA_9ae8832c-6a94-4633-9d6b-f83b021a7504">1,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNC03LTEtMS0xNzg2OA_d76ac2de-09dd-42d9-952c-3431c69c69cc">762</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $<ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNS0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjllZGM1NjMzZjUxZjRjM2M5ZDJkYTYyMzQwYmU0NzIxXzEyNw_f433843b-f6a9-4f7b-9fdf-c26cd3e13058">11</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNS0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjllZGM1NjMzZjUxZjRjM2M5ZDJkYTYyMzQwYmU0NzIxXzEzNA_a78c5a3d-1524-41a7-aa5d-b4f038270897">36</ix:nonFraction> in 2022 and $<ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNS0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjllZGM1NjMzZjUxZjRjM2M5ZDJkYTYyMzQwYmU0NzIxXzE0Nw_5ef35f83-e0ba-45aa-a8e4-a552f4a10d53">18</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNS0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjllZGM1NjMzZjUxZjRjM2M5ZDJkYTYyMzQwYmU0NzIxXzE1NA_211ac1e9-b4de-4a69-b0ec-1580a26bff9e">54</ix:nonFraction> in 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNS0xLTEtMS0xNzg2OA_42234238-203c-4c36-886e-a2cb75e1e9be">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNS0zLTEtMS0xNzg2OA_3d7008a0-b88e-414f-8fe6-ea7778e28472">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNS01LTEtMS0xNzg2OA_830086fd-7cc6-4f73-98ac-08a0627b5cfc">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNS03LTEtMS0xNzg2OA_2a1d6623-3b67-4792-90d4-2bf683e33fba">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $<ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNi0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOmUyNzU2OTBhYTRlZTRmMDliYzY1YjU0NmQ1Y2E2ZDA3XzEwOA_07d16fad-c0f5-4024-b5e7-5291a760b984">50</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNi0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOmUyNzU2OTBhYTRlZTRmMDliYzY1YjU0NmQ1Y2E2ZDA3XzExNQ_f6c50bfe-88d7-40a5-85b2-703a2fb22576">96</ix:nonFraction> in 2022 and $<ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNi0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOmUyNzU2OTBhYTRlZTRmMDliYzY1YjU0NmQ1Y2E2ZDA3XzEyOA_d4d2eb94-bff7-4676-9450-45c4e78cfa53">50</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNi0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOmUyNzU2OTBhYTRlZTRmMDliYzY1YjU0NmQ1Y2E2ZDA3XzEzNQ_7ae5bcd7-4089-45bd-a1dd-bc70a204e408">98</ix:nonFraction> in 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNi0xLTEtMS0xNzg2OA_0f3102d7-a24b-4158-a598-520c598dd4b2">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNi0zLTEtMS0xNzg2OA_4d0d2c14-2d99-4a3e-9623-7f2e3256bb23">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNi01LTEtMS0xNzg2OA_90a1cab1-afe6-423a-a724-8897d37ec605">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNi03LTEtMS0xNzg2OA_8b71d0cd-2726-44c0-bc17-183aac498591">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNy0xLTEtMS0xNzg2OA_3492d2bf-6908-410a-953c-cf21fc84b29e">739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNy0zLTEtMS0xNzg2OA_f378625f-92a5-49dc-9e2e-c48ec6cba283">174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNy01LTEtMS0xNzg2OA_15c3654c-14e5-4e47-b082-165be16b3d46">1,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNy03LTEtMS0xNzg2OA_42c40118-fa0b-4e33-b2e2-71b4dbda6ac2">294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive Income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfOC0xLTEtMS0xNzg2OA_d77243d3-26b7-4057-834f-645a7a110835">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfOC0zLTEtMS0xNzg2OA_3901b267-153a-4cd1-ba88-b87902bcfcbe">1,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfOC01LTEtMS0xNzg2OA_a119c32b-5e62-4d4e-8fea-b1f2e3ab879d">4,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfOC03LTEtMS0xNzg2OA_e5bd0429-a92e-40c2-be13-d5aa3028b0ad">4,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:74.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.516%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative foreign currency translation (loss) adjustments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjBhZTI2MzM2ZWJhMjQzMzg4MTU3ZWNmMzQzZmU2MzQ3L3RhYmxlcmFuZ2U6MGFlMjYzMzZlYmEyNDMzODgxNTdlY2YzNDNmZTYzNDdfMi0xLTEtMS0xNzg2OA_75d15e2d-af7e-4913-aa06-9da99984496c">7,268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjBhZTI2MzM2ZWJhMjQzMzg4MTU3ZWNmMzQzZmU2MzQ3L3RhYmxlcmFuZ2U6MGFlMjYzMzZlYmEyNDMzODgxNTdlY2YzNDNmZTYzNDdfMi0zLTEtMS0xNzg2OA_7c13eb3b-738e-4c1e-bda0-e3e1c721d991">5,839</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (losses) and prior service (costs) and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjBhZTI2MzM2ZWJhMjQzMzg4MTU3ZWNmMzQzZmU2MzQ3L3RhYmxlcmFuZ2U6MGFlMjYzMzZlYmEyNDMzODgxNTdlY2YzNDNmZTYzNDdfMy0xLTEtMS0xNzg2OA_7b804ca0-206a-402a-9a14-eda7992be1c7">2,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjBhZTI2MzM2ZWJhMjQzMzg4MTU3ZWNmMzQzZmU2MzQ3L3RhYmxlcmFuZ2U6MGFlMjYzMzZlYmEyNDMzODgxNTdlY2YzNDNmZTYzNDdfMy0zLTEtMS0xNzg2OA_47703934-c08c-48d3-bcc0-39f97348a61f">2,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjBhZTI2MzM2ZWJhMjQzMzg4MTU3ZWNmMzQzZmU2MzQ3L3RhYmxlcmFuZ2U6MGFlMjYzMzZlYmEyNDMzODgxNTdlY2YzNDNmZTYzNDdfNC0xLTEtMS0xNzg2OA_53df0870-a224-4709-962e-d2e34056e509">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjBhZTI2MzM2ZWJhMjQzMzg4MTU3ZWNmMzQzZmU2MzQ3L3RhYmxlcmFuZ2U6MGFlMjYzMzZlYmEyNDMzODgxNTdlY2YzNDNmZTYzNDdfNC0zLTEtMS0xNzg2OA_dacdf6a1-bbea-41ac-9edd-a0c25f3c063b">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjBhZTI2MzM2ZWJhMjQzMzg4MTU3ZWNmMzQzZmU2MzQ3L3RhYmxlcmFuZ2U6MGFlMjYzMzZlYmEyNDMzODgxNTdlY2YzNDNmZTYzNDdfNS0xLTEtMS0xNzg2OA_26c09a41-6e8d-4105-8dd6-aba3e6c2e586">9,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjBhZTI2MzM2ZWJhMjQzMzg4MTU3ZWNmMzQzZmU2MzQ3L3RhYmxlcmFuZ2U6MGFlMjYzMzZlYmEyNDMzODgxNTdlY2YzNDNmZTYzNDdfNS0zLTEtMS0xNzg2OA_e0155b9a-7930-452c-9d60-2cb9ccf51677">8,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="ib0ff9808fe764fdea19589324372f96b_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Balance Sheet</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMy0xLTEtMS0xNzg2OA_8ca40d68-0b67-4d03-b8f6-ad74081318d2">9,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMy0zLTEtMS0xNzg2OA_8feb9c7e-0d92-4f1f-9b44-fe383f1352aa">9,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNC0xLTEtMS0xNzg2OA_d449e088-ec4f-4400-b123-e7406637670c">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNC0zLTEtMS0xNzg2OA_3ba6af97-c6bc-4070-a016-6ecbfa8792fb">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables, less allowances of $<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNS0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjQ1NmMyMWQ4NTRiYjRkYzViNDY2MTgxNmQ5YTU0MzZlXzQy_9a4486da-ea0e-4ea9-ac13-e5e8c9cc2ef6">520</ix:nonFraction> in 2022 and $<ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNS0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjQ1NmMyMWQ4NTRiYjRkYzViNDY2MTgxNmQ5YTU0MzZlXzU1_3f961409-3e62-4da4-abae-5892388a3653">519</ix:nonFraction> in 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNS0xLTEtMS0xNzg2OA_34939715-de69-4200-a62c-5ee22b3e2551">6,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNS0zLTEtMS0xNzg2OA_0a05389a-933d-4a81-9474-c5c94736ade3">6,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNy0xLTEtMS0xNzg2OA_0f3fd6ad-cb55-4338-81ec-9047a2fd8c4e">3,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNy0zLTEtMS0xNzg2OA_8b88250c-076b-445c-9fca-9b9985a23738">3,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfOC0xLTEtMS0xNzg2OA_5d1f1f51-1dc8-48f0-8d42-c82ccafd63f5">726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfOC0zLTEtMS0xNzg2OA_f434799e-e78d-49f6-a75a-702416e4a350">694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfOS0xLTEtMS0xNzg2OA_76daf8bb-8244-4db1-a106-e2776bf20cbf">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfOS0zLTEtMS0xNzg2OA_698ad899-9616-44ef-a7d4-3166637fff2f">1,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTAtMS0xLTEtMTc4Njg_39dc3d16-bd24-45dc-a9f8-f66a420870b8">5,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTAtMy0xLTEtMTc4Njg_bfa79450-2504-440a-b86d-4ba154359ab4">5,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="abt:PrepaidExpenseAndOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTEtMS0xLTEtMTc4Njg_79db51bc-fc93-4b01-9f29-cbaef2496297">2,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="abt:PrepaidExpenseAndOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTEtMy0xLTEtMTc4Njg_dcc9768f-af12-49e7-aa24-5b67ad59d2da">2,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Current Assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTItMS0xLTEtMTc4Njg_198de426-59dc-4a9c-8ca2-2f1b5e177ec9">24,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTItMy0xLTEtMTc4Njg_e5c1078c-90d2-4cb6-8e75-1f6d4a72d904">24,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTMtMS0xLTEtMTc4Njg_e1bada71-9221-4fc1-b002-8b8acd6f30ed">764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTMtMy0xLTEtMTc4Njg_0faf52d1-a2f1-4820-a9e3-1ebf73b5999f">816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTQtMS0xLTEtMTc4Njg_458d2cac-7994-4ac4-bc1c-135cbde9e058">19,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTQtMy0xLTEtMTc4Njg_026fc982-c751-4c1a-815b-eb3d38dcdcc5">19,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTUtMS0xLTEtMTc4Njg_66672224-38af-46be-94a4-e6f06abce2fe">10,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTUtMy0xLTEtMTc4Njg_e4e1c57a-e512-472b-add4-8c3d8e7cd931">10,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTYtMS0xLTEtMTc4Njg_6da7023d-9e0a-4052-88cf-64f5873da71f">8,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTYtMy0xLTEtMTc4Njg_299ab2d7-8c2a-40b7-9d75-2eca7400c72b">8,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net of amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTctMS0xLTEtMTc4Njg_54317994-6057-4afb-af05-51bab68d341e">10,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTctMy0xLTEtMTc4Njg_064d5715-e3f1-4b6a-b475-a5e147220a58">12,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTgtMS0xLTEtMTc4Njg_f461add4-7565-4884-905b-d703f17776a8">22,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTgtMy0xLTEtMTc4Njg_1f796c19-2510-4ea2-86c2-1fa5e2f8e400">23,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTktMS0xLTEtMTc4Njg_3f7d25fc-5e46-43a0-8afa-03177ac82291">5,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTktMy0xLTEtMTc4Njg_3b954258-8fb5-49e4-8906-994d9b76f59a">5,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjAtMS0xLTEtMTc4Njg_70de742e-2fd1-4a62-b77b-f5d0532fb633">72,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjAtMy0xLTEtMTc4Njg_e984481f-997b-4b49-9d1f-0cb4fdd7b2f8">75,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities and Shareholders&#8217; Investment</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:AccountsPayableTradeCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjMtMS0xLTEtMTc4Njg_6b8ff413-803f-40e4-9b5f-5db975f33787">4,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:AccountsPayableTradeCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjMtMy0xLTEtMTc4Njg_c62df9b7-7d65-4e65-87d7-83fc28aba03a">4,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salaries, wages and commissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjQtMS0xLTEtMTc4Njg_dae186f0-5673-4b7e-b858-66f845083e06">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjQtMy0xLTEtMTc4Njg_cead212e-0203-4d13-a53b-da655ccc2d4e">1,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjUtMS0xLTEtMTc4Njg_6c13b28b-5002-491e-bd82-a829d722ef4d">5,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjUtMy0xLTEtMTc4Njg_24b22644-11cb-426a-b67e-f2f8cb3fbfba">5,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjYtMS0xLTEtMTc4Njg_fa4971e3-4923-4b1f-98c0-c56dcef19971">820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjYtMy0xLTEtMTc4Njg_36391678-46f0-4186-8323-04832b06e82a">831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjctMS0xLTEtMTc4Njg_b6f7b9b2-4dbc-4011-b25e-3940e80e0a8d">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjctMy0xLTEtMTc4Njg_6b5521c1-6a78-4a4b-ba91-55c974d8b41c">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjgtMS0xLTEtMTc4Njg_28a5806e-7522-4406-8c33-0058eac4d582">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjgtMy0xLTEtMTc4Njg_129119a1-ca70-4a2c-8846-8d24b7cc011b">754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Current Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjktMS0xLTEtMTc4Njg_eb1ff2e2-6955-44d4-bbf6-e665539faa94">13,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjktMy0xLTEtMTc4Njg_72287aa3-3073-41a0-a710-b52fd026613f">13,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzAtMS0xLTEtMTc4Njg_08d4f424-c183-429b-8fbd-558c9050120b">15,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzAtMy0xLTEtMTc4Njg_cbaa39f2-2624-487d-ae04-99efff69e5ec">17,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Post-employment obligations, deferred income taxes and other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="abt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzEtMS0xLTEtMTc4Njg_e29c760f-4f75-4690-b5e9-1dc562b97b2a">8,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="abt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzEtMy0xLTEtMTc4Njg_a01819c8-cf4d-4ff3-9889-8a28e4051259">8,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and Contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzItMS0xLTEtMTc4Njg_4ef6a919-1140-4b29-a869-50ff0c9fcbba"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzItMy0xLTEtMTc4Njg_ed5584b7-10d3-4b53-b677-30711f66a1cb"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shareholders&#8217; Investment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred shares, <ix:nonFraction unitRef="usdPerShare" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjphODkxY2E2NDdkMDY0ZGQ4OTYxYmI0NjhiMDFlODUyMl8yMg_0f3bddc8-761a-4e8b-8642-6cd264f15e7c"><ix:nonFraction unitRef="usdPerShare" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjphODkxY2E2NDdkMDY0ZGQ4OTYxYmI0NjhiMDFlODUyMl8yMg_7cd87e62-fe1b-4109-9eb5-3206a5576df1">one</ix:nonFraction></ix:nonFraction> dollar par value Authorized &#8212; <ix:nonFraction unitRef="shares" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjphODkxY2E2NDdkMDY0ZGQ4OTYxYmI0NjhiMDFlODUyMl81NQ_1ef806f3-3894-47ce-99dd-6e5002ab5d37"><ix:nonFraction unitRef="shares" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjphODkxY2E2NDdkMDY0ZGQ4OTYxYmI0NjhiMDFlODUyMl81NQ_bfa4dccd-1ddf-44a2-a1bc-7beede1e2449">1,000,000</ix:nonFraction></ix:nonFraction> shares, <ix:nonFraction unitRef="shares" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjphODkxY2E2NDdkMDY0ZGQ4OTYxYmI0NjhiMDFlODUyMl82Ng_9546d799-01da-42c1-aa73-e75d9712e44b"><ix:nonFraction unitRef="shares" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjphODkxY2E2NDdkMDY0ZGQ4OTYxYmI0NjhiMDFlODUyMl82Ng_d7ba7593-321d-4750-a9fb-3a884c304bcf">none</ix:nonFraction></ix:nonFraction> issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzQtMS0xLTEtMTc4Njg_8198e645-0e13-435d-95f4-7bc1d39f7476">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzQtMy0xLTEtMTc4Njg_2065becb-1c5b-452e-b1bb-e513595a8da4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common shares, without par value Authorized &#8212; <ix:nonFraction unitRef="shares" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzUtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjozNjYyNWVkNTcxYjg0N2I2YWZmODljNWQwZDNjYzg0ZF81MA_83594fa4-7162-4989-a5e0-45e1a2ae7b7f"><ix:nonFraction unitRef="shares" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzUtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjozNjYyNWVkNTcxYjg0N2I2YWZmODljNWQwZDNjYzg0ZF81MA_f021d291-2c95-4174-bd2b-0725729c60b7">2,400,000,000</ix:nonFraction></ix:nonFraction> shares </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issued at stated capital amount &#8212; Shares: 2022: <ix:nonFraction unitRef="shares" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzUtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjozNjYyNWVkNTcxYjg0N2I2YWZmODljNWQwZDNjYzg0ZF8xMDc_1c9ac0b6-f505-4916-8017-7873c4097b93">1,985,919,440</ix:nonFraction>; 2021: <ix:nonFraction unitRef="shares" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzUtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjozNjYyNWVkNTcxYjg0N2I2YWZmODljNWQwZDNjYzg0ZF8xMTU_24b241c6-1203-4466-a584-b2bf5a5cf452">1,985,273,421</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzUtMS0xLTEtMTc4Njg_db785a41-fe91-4f4f-b083-2f8012d68404">24,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzUtMy0xLTEtMTc4Njg_86067153-9fab-4185-9158-089f13bbb92e">24,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common shares held in treasury, at cost &#8212; Shares: 2022: <ix:nonFraction unitRef="shares" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzYtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo2YjdkMDcxM2RiMzM0MzMzYTNiN2ZkYTQxZDI4Mzk1M181OA_3c11e0e5-3cb2-4dbc-af16-7cabf392dcb2">242,345,663</ix:nonFraction>; 2021: <ix:nonFraction unitRef="shares" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzYtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo2YjdkMDcxM2RiMzM0MzMzYTNiN2ZkYTQxZDI4Mzk1M182Ng_197ad5ec-2e04-4374-901a-dcce8ee8899f">221,191,228</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzYtMS0xLTEtMTc4Njg_befac003-8371-4b9f-b43e-e7b0ca6efec7">14,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzYtMy0xLTEtMTc4Njg_7e112bf9-e8df-434e-a9ae-348d02e9ed3f">11,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings employed in the business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzctMS0xLTEtMTc4Njg_3f5883a0-8b30-4c6a-ae7c-65910eb2f407">35,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzctMy0xLTEtMTc4Njg_7a2cc1ce-40e8-4e20-bc04-55c59988f59c">31,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzgtMS0xLTEtMTc4Njg_4474c2ca-4998-4cb7-8429-fece122be42d">9,445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzgtMy0xLTEtMTc4Njg_0f28d5c3-bc4d-4c8a-a66b-27563350b833">8,374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Abbott Shareholders&#8217; Investment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzktMS0xLTEtMTc4Njg_b5fadf41-2122-4dd8-a15c-39acf7aa7e69">35,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzktMy0xLTEtMTc4Njg_d8f6badc-9d1e-4fc0-b4d1-07c53cbcb0b4">35,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling Interests in Subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNDAtMS0xLTEtMTc4Njg_cd131c6e-fc08-4925-b60e-04f9c35d6d8d">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNDAtMy0xLTEtMTc4Njg_47d5584f-de67-4109-84e6-4eff2892c8e1">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Shareholders&#8217; Investment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNDEtMS0xLTEtMTc4Njg_1e5778e5-4ebd-4660-9824-2a6a3fcabf04">35,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNDEtMy0xLTEtMTc4Njg_4bfeba8b-4469-44d5-9392-1dfdab833fa0">36,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNDItMS0xLTEtMTc4Njg_4c4573ca-e233-40fe-b372-eedc7b78cc03">72,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNDItMy0xLTEtMTc4Njg_2ba76cd8-a5ab-40b2-b7c2-827920bbef91">75,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="ib0ff9808fe764fdea19589324372f96b_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statement of Shareholders&#8217; Investment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in millions except shares and per share data)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares: 2022: <ix:nonFraction unitRef="shares" contextRef="ife5c2b9c51b24905939dfe6b3d3e4056_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNC0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOmRhMzA4MDZiNzYyZDQyZmViODQwYzgyZDQxOGEyNWJjXzE2_c3544a26-aa31-4fb4-b015-87f9c447b35d">1,985,676,735</ix:nonFraction>; 2021: <ix:nonFraction unitRef="shares" contextRef="i318af3e554204da2b38e2945f4629296_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNC0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOmRhMzA4MDZiNzYyZDQyZmViODQwYzgyZDQxOGEyNWJjXzI0_3225348d-a590-47b5-8ab3-294ab0c7696b">1,982,553,488</ix:nonFraction></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5c2b9c51b24905939dfe6b3d3e4056_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNC0xLTEtMS0xNzg2OA_ea9b0a97-0834-493e-b8cb-a7ebc8cbe4f2">24,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318af3e554204da2b38e2945f4629296_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNC0zLTEtMS0xNzg2OA_809032c9-7792-40d7-9a18-724c89caa62c">24,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued under incentive stock programs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares: 2022: <ix:nonFraction unitRef="shares" contextRef="i9f1d1e1ca3304ec8bafbf0a80a96bd80_D20220701-20220930" decimals="INF" name="abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNi0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOmQ1N2VmY2Y3Yjg1MjQzN2M4OGM1OWYwZGM4ZWNiZGI4XzE2_fbea0a0a-bff4-4bb4-9f63-831953ac34eb">242,705</ix:nonFraction>; 2021: <ix:nonFraction unitRef="shares" contextRef="ib7b8a9dc239044a6b1a2b862dd61b7fc_D20210701-20210930" decimals="INF" name="abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNi0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOmQ1N2VmY2Y3Yjg1MjQzN2M4OGM1OWYwZGM4ZWNiZGI4XzI0_c63e234a-eccf-4fcb-86ec-f0906a067ba9">550,366</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1d1e1ca3304ec8bafbf0a80a96bd80_D20220701-20220930" decimals="-6" name="abt:StockIssuedDuringPeriodValueIncentiveStockPrograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNi0xLTEtMS0xNzg2OA_dd75419a-b911-4f7d-92cd-3d490ca46949">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8a9dc239044a6b1a2b862dd61b7fc_D20210701-20210930" decimals="-6" name="abt:StockIssuedDuringPeriodValueIncentiveStockPrograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNi0zLTEtMS0xNzg2OA_f3e4fb6c-b68f-4acc-b9e1-283c91f8d5cb">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1d1e1ca3304ec8bafbf0a80a96bd80_D20220701-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNy0xLTEtMS0xNzg2OA_72af38b6-107e-402a-ba7e-3f7725a3f29c">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b8a9dc239044a6b1a2b862dd61b7fc_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNy0zLTEtMS0xNzg2OA_d8ad1755-87b3-4403-be72-2965d8f013d0">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f1d1e1ca3304ec8bafbf0a80a96bd80_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfOC0xLTEtMS0xNzg2OA_4695e62d-97c2-476d-9984-083e43f4c1c9">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7b8a9dc239044a6b1a2b862dd61b7fc_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfOC0zLTEtMS0xNzg2OA_8471320e-36d0-48d4-8738-1ae43a91406c">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares: 2022: <ix:nonFraction unitRef="shares" contextRef="i29242515a9cd41d3929b65fa4ab2da75_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTAtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo0MzhiYWM1NmIzZjA0OWIzODBhZDBkNjdiYzkxNjM3M18xNg_e31590f7-fcd9-4106-8dd5-ff818409a7a6">1,985,919,440</ix:nonFraction>; 2021: <ix:nonFraction unitRef="shares" contextRef="i0ec2d32ee1c543f89872966939398c80_I20210930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTAtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo0MzhiYWM1NmIzZjA0OWIzODBhZDBkNjdiYzkxNjM3M18yNA_e4c065aa-5d92-4ba0-a895-7f27c2e9465f">1,983,103,854</ix:nonFraction></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29242515a9cd41d3929b65fa4ab2da75_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTAtMS0xLTEtMTc4Njg_55d26d71-91ec-4219-851e-44bcdad46292">24,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ec2d32ee1c543f89872966939398c80_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTAtMy0xLTEtMTc4Njg_0c7b1cdf-cfa0-4d88-8d33-2aaf599f032f">24,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Held in Treasury:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares: 2022: <ix:nonFraction unitRef="shares" contextRef="i13853862ec4e4a8f9dd87d9d1f5a0eba_I20220630" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjpjNWRkY2VmNjI1OTk0YjFhOWIxZDc1YjA0YTM3MzVkMV8xNg_27a4cc9a-98a9-4fcc-b68d-a0efa1e31120">234,456,992</ix:nonFraction>; 2021: <ix:nonFraction unitRef="shares" contextRef="i84388393a8aa4ea4ad5e48e8c7f24e44_I20210630" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjpjNWRkY2VmNjI1OTk0YjFhOWIxZDc1YjA0YTM3MzVkMV8yNA_3deb2dfa-40de-40ff-bd72-d59271250832">209,736,139</ix:nonFraction></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13853862ec4e4a8f9dd87d9d1f5a0eba_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTQtMS0xLTEtMTc4Njg_8a9bd000-22b5-456e-b31d-9a8ddd482b8f">13,720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84388393a8aa4ea4ad5e48e8c7f24e44_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTQtMy0xLTEtMTc4Njg_f9798284-2656-4d9d-b2a0-06c2d4901b68">10,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued under incentive stock programs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares: 2022: <ix:nonFraction unitRef="shares" contextRef="i2f2db6dc6a8f4d8d97404a772b976d3d_D20220701-20220930" decimals="INF" name="abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTYtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo0MmFlZjYzMGMyZWE0MDkxYTRlNjgzNDVlNzk4OGJhZF8xNg_d4aa52b9-8efa-4f33-988a-8ab697c94806">528,436</ix:nonFraction>; 2021: <ix:nonFraction unitRef="shares" contextRef="i5a2381935eb3479c8272fe544f91e498_D20210701-20210930" decimals="INF" name="abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTYtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo0MmFlZjYzMGMyZWE0MDkxYTRlNjgzNDVlNzk4OGJhZF8yNA_2ef8cd08-ec9d-44fd-aa1b-7dbe3ecf8a86">545,860</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2db6dc6a8f4d8d97404a772b976d3d_D20220701-20220930" decimals="-6" name="abt:StockIssuedDuringPeriodValueIncentiveStockPrograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTYtMS0xLTEtMTc4Njg_731044c9-109d-4e41-b694-7beb21170582">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2381935eb3479c8272fe544f91e498_D20210701-20210930" decimals="-6" name="abt:StockIssuedDuringPeriodValueIncentiveStockPrograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTYtMy0xLTEtMTc4Njg_7f4ed89c-ed96-468c-a7e5-54f822348245">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares: 2022: <ix:nonFraction unitRef="shares" contextRef="i2f2db6dc6a8f4d8d97404a772b976d3d_D20220701-20220930" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTgtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo4OWQ4ZGZiNWJkOGE0YTRkYWNjODBmMjE4NjdmZWFlYV8xNg_f85cf389-ece5-47ca-85b0-26aea016e755">8,417,107</ix:nonFraction>; 2021: <ix:nonFraction unitRef="shares" contextRef="i5a2381935eb3479c8272fe544f91e498_D20210701-20210930" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTgtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo4OWQ4ZGZiNWJkOGE0YTRkYWNjODBmMjE4NjdmZWFlYV8yNA_64636b03-9435-4070-8a2c-0e4f15c98f66">5,626,606</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f2db6dc6a8f4d8d97404a772b976d3d_D20220701-20220930" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTgtMS0xLTEtMTc4Njg_d28b0078-b9b6-4d90-ace0-f5e80abfd346">866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a2381935eb3479c8272fe544f91e498_D20210701-20210930" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTgtMy0xLTEtMTc4Njg_a3935753-e90f-43b2-bd70-15e1e0118bf5">685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares: 2022: <ix:nonFraction unitRef="shares" contextRef="ib0384842a3a44e638930735a2b593396_I20220930" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjAtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo3NzFjMzY1MzNlMDk0YTJjOWJiMDZiZDc0MmI4MzIxM18xNg_9dad3c23-1cf4-4d45-b3c8-78ecbfab80e8">242,345,663</ix:nonFraction>; 2021: <ix:nonFraction unitRef="shares" contextRef="iee53b5e2f57b467bafb6a07b010ce7b8_I20210930" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjAtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo3NzFjMzY1MzNlMDk0YTJjOWJiMDZiZDc0MmI4MzIxM18yNA_92921201-7737-435f-aafb-1b7f2c8f2eeb">214,816,885</ix:nonFraction></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0384842a3a44e638930735a2b593396_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjAtMS0xLTEtMTc4Njg_67c5d400-e3c5-46c1-ba60-d430fc4ca387">14,555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee53b5e2f57b467bafb6a07b010ce7b8_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjAtMy0xLTEtMTc4Njg_aa994c2e-8223-401d-a19c-fe5f5e3f6b44">10,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings Employed in the Business:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd95633e0b74ebebb2ef9d790e7e133_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjMtMS0xLTEtMTc4Njg_7a14676f-4105-4cca-8248-b55242e29eb6">34,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6cd17f6345343d188d64dda2acbc2ba_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjMtMy0xLTEtMTc4Njg_094cba70-5799-4181-a998-f7442c717bd9">29,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib605aa77a1694292a23c576b3cbe9f51_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjQtMS0xLTEtMTc4Njg_8ccab4bc-47ee-4d50-a3c9-00955a82e1b5">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6675c4a62c704c83b04414e2e96f9f15_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjQtMy0xLTEtMTc4Njg_e46ed3de-7406-473a-8e8f-e63189be4090">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends declared on common shares (per share &#8212; 2022: $<ix:nonFraction unitRef="usdPerShare" contextRef="ib605aa77a1694292a23c576b3cbe9f51_D20220701-20220930" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjUtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjozNDBiZmYyYzA3ZDU0MjNkYTM4N2YzMjNkMzBlNDk1Nl82Mg_69cfc095-206a-43f2-8b36-2457d50c8d4f">0.47</ix:nonFraction>; 2021: $<ix:nonFraction unitRef="usdPerShare" contextRef="i6675c4a62c704c83b04414e2e96f9f15_D20210701-20210930" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjUtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjozNDBiZmYyYzA3ZDU0MjNkYTM4N2YzMjNkMzBlNDk1Nl83MA_abba3b85-ae3f-46bf-a7c3-9a4875fb706e">0.45</ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib605aa77a1694292a23c576b3cbe9f51_D20220701-20220930" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjUtMS0xLTEtMTc4Njg_c6648017-eb68-48ac-9b80-12addd22c9c1">822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6675c4a62c704c83b04414e2e96f9f15_D20210701-20210930" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjUtMy0xLTEtMTc4Njg_2de65509-e8f2-4dcd-a19c-b7ffaefc6dbf">799</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of common and treasury share transactions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib605aa77a1694292a23c576b3cbe9f51_D20220701-20220930" decimals="-6" sign="-" name="abt:EffectOfCommonAndTreasuryShareTransactions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjYtMS0xLTEtMTc4Njg_35e1403e-9b52-4204-a69f-b12b471ef056">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6675c4a62c704c83b04414e2e96f9f15_D20210701-20210930" decimals="-6" sign="-" name="abt:EffectOfCommonAndTreasuryShareTransactions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjYtMy0xLTEtMTc4Njg_493024be-c33c-4844-9062-eeaca0e1467f">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a9d779acbe44e3bacba61c64c39e891_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjctMS0xLTEtMTc4Njg_14871c43-eca9-4619-a4ba-8d95981cc40c">35,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc3d7b1f7924f49a467f9de89cf4580_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjctMy0xLTEtMTc4Njg_0686338e-b6bc-4e79-90a7-028b6c373461">30,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income (Loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93502cdb071b40d78c7d41a2b5166b24_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzAtMS0xLTEtMTc4Njg_41b14495-0e60-4b3f-accd-a839b290aa2b">8,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3efcbced2c284e42846b07cbce02af0f_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzAtMy0xLTEtMTc4Njg_eb4b7a59-7e57-4bb1-b2d1-b9079a8fcdce">9,066</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42f5fd859ca5425389497f80eb2c653e_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzEtMS0xLTEtMTc4Njg_cb2dfe7a-2064-4ffd-aa51-3f891b3696f7">739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76df37ef10134753b1301a961c801516_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzEtMy0xLTEtMTc4Njg_dc93273b-9a47-4b92-926f-63e364f733a1">174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib49fbe36bbba46d5a960a042585a8ca3_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzItMS0xLTEtMTc4Njg_0af2916f-bde3-48a9-8c7d-3a33aa32d638">9,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1445a4f41614df3b5934c37b319c6c4_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzItMy0xLTEtMTc4Njg_ead29812-166d-4109-8e36-379477bb9035">9,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling Interests in Subsidiaries:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7c2622a69b432d86720be37f7e2a16_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzUtMS0xLTEtMTc4Njg_08e21d85-8ce6-4364-a908-0ea4644c7ade">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef7377540aa4e4c823d715421f8fd87_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzUtMy0xLTEtMTc4Njg_ede74b68-4feb-46b8-bff1-e336b5f84db5">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling Interests&#8217; share of income, business combinations, net of distributions and share repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d04e8e8dc804bc79e6cf5d8fac6d42b_D20220701-20220930" decimals="-6" sign="-" name="abt:NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzYtMS0xLTEtMTc4Njg_eb35ebea-ca6c-45bd-9cc4-accb75ba9109">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7057ecd5f0c1428ba00d5cc5b5ed8119_D20210701-20210930" decimals="-6" sign="-" name="abt:NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzYtMy0xLTEtMTc4Njg_ff7f053d-1bac-48b5-a852-6e8afbe7b688">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97d8339fa5a4a14be94890cbc7535a3_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzctMS0xLTEtMTc4Njg_ab61259a-ffaa-4b8e-a39c-75474e89fd0f">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088ce8132a864ce3a40176de183626a8_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzctMy0xLTEtMTc4Njg_02270554-8968-4642-84b0-921e93104baa">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to condensed consolidated financial statements are an integral part of this statement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statement of Shareholders&#8217; Investment</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in millions except shares and per share data)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares: 2022: <ix:nonFraction unitRef="shares" contextRef="i1504c2dad3014570b5b401bc387b8c52_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNC0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjgzZDEzM2I3OWE4MjRkNGRhOTYzOGRjOTk2MzhhNTZlXzE2_b52df573-2713-4943-be72-ffa5ed6f912e">1,985,273,421</ix:nonFraction>; 2021: <ix:nonFraction unitRef="shares" contextRef="i6d042e1363a74135b1ff431769cbdd3c_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNC0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjgzZDEzM2I3OWE4MjRkNGRhOTYzOGRjOTk2MzhhNTZlXzI0_d19ebfce-f588-4aaa-b9a2-3fa31b6e6626">1,981,156,896</ix:nonFraction></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1504c2dad3014570b5b401bc387b8c52_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNC0xLTEtMS0xNzg2OA_f2ffaede-9dfc-4c61-884d-30038e803563">24,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d042e1363a74135b1ff431769cbdd3c_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNC0zLTEtMS0xNzg2OA_5f0f0531-6b9a-49bb-9169-68b12d5e5322">24,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued under incentive stock programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares: 2022: <ix:nonFraction unitRef="shares" contextRef="i2633c881b0854a9387e79c0bf0e90227_D20220101-20220930" decimals="INF" name="abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNi0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjg2YjAxNzMwNjA4YjQyZTY5MWE1NGIyNzZmY2MyOWUwXzE2_50282b56-cee6-479e-a025-11324d1ad2aa">646,019</ix:nonFraction>; 2021: <ix:nonFraction unitRef="shares" contextRef="i00352c2d1368429694fe5d87533d4a96_D20210101-20210930" decimals="INF" name="abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNi0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjg2YjAxNzMwNjA4YjQyZTY5MWE1NGIyNzZmY2MyOWUwXzI0_069ec46e-edb1-49bf-b1c9-49ed09f1da21">1,946,958</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2633c881b0854a9387e79c0bf0e90227_D20220101-20220930" decimals="-6" name="abt:StockIssuedDuringPeriodValueIncentiveStockPrograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNi0xLTEtMS0xNzg2OA_dc6672c3-7b15-49a3-ac40-5b960f39bb1a">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00352c2d1368429694fe5d87533d4a96_D20210101-20210930" decimals="-6" name="abt:StockIssuedDuringPeriodValueIncentiveStockPrograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNi0zLTEtMS0xNzg2OA_96d9f9bf-c735-40ee-8e90-825f0cc8849e">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2633c881b0854a9387e79c0bf0e90227_D20220101-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNy0xLTEtMS0xNzg2OA_760aa257-167f-46e7-adc1-7ab37d6b06f9">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00352c2d1368429694fe5d87533d4a96_D20210101-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNy0zLTEtMS0xNzg2OA_89556791-65d0-4402-b638-6586fad00616">536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2633c881b0854a9387e79c0bf0e90227_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfOC0xLTEtMS0xNzg2OA_ca2dbf99-105d-4c0e-8186-acc0e5ff1c70">518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00352c2d1368429694fe5d87533d4a96_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfOC0zLTEtMS0xNzg2OA_e08e11dc-aac4-4103-9b2e-b1839d4cd7d5">487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares: 2022: <ix:nonFraction unitRef="shares" contextRef="i29242515a9cd41d3929b65fa4ab2da75_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTAtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjowNDRjOWQ5NzdmMmM0MzQwOGViNmIzN2Y4NDJmMzc4OV8xNg_48d388f6-37cf-4b6e-85c1-4d3ed3800f1c">1,985,919,440</ix:nonFraction>; 2021: <ix:nonFraction unitRef="shares" contextRef="i0ec2d32ee1c543f89872966939398c80_I20210930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTAtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjowNDRjOWQ5NzdmMmM0MzQwOGViNmIzN2Y4NDJmMzc4OV8yNA_3b730d55-1ee9-48a8-8783-d85166d569ad">1,983,103,854</ix:nonFraction></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29242515a9cd41d3929b65fa4ab2da75_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTAtMS0xLTEtMTc4Njg_bb140e5a-3359-4ee4-986c-d67139648fca">24,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ec2d32ee1c543f89872966939398c80_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTAtMy0xLTEtMTc4Njg_71167d38-f7c8-4e7d-b353-b682714dad07">24,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares Held in Treasury:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares: 2022: <ix:nonFraction unitRef="shares" contextRef="i5cfae92185d549208e196b57add32000_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjpjNzVjZWRkZDY3Yzk0ZWJjYmU4M2QwYjYwYzY4ZWY1ZV8xNg_29059a4f-1179-4d8d-82ba-50f2a4b14b7c">221,191,228</ix:nonFraction>; 2021: <ix:nonFraction unitRef="shares" contextRef="ida0d59058b594e578193e429a2f6c056_I20201231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjpjNzVjZWRkZDY3Yzk0ZWJjYmU4M2QwYjYwYzY4ZWY1ZV8yNA_14ce9ee6-3f0f-4372-b461-2b56f24a3761">209,926,622</ix:nonFraction></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cfae92185d549208e196b57add32000_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTQtMS0xLTEtMTc4Njg_8fcea808-2b56-42bd-a310-048e69970b6f">11,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida0d59058b594e578193e429a2f6c056_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTQtMy0xLTEtMTc4Njg_2324f878-5d05-4f84-ac3c-a0a63f096b99">10,042</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued under incentive stock programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares: 2022: <ix:nonFraction unitRef="shares" contextRef="i4b724be0df7a469ba9c898710b2dbf1a_D20220101-20220930" decimals="INF" name="abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTYtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjozNmRkMmVkODMxZjk0NjIyOTZjNGY1ZjdmYzNiNzVjY18xNg_e1e62711-d4e4-490e-9bd3-4e4e28653e93">4,808,575</ix:nonFraction>; 2021: <ix:nonFraction unitRef="shares" contextRef="ie6098fe1fbe54bc9a82cd2c345421c2c_D20210101-20210930" decimals="INF" name="abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTYtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjozNmRkMmVkODMxZjk0NjIyOTZjNGY1ZjdmYzNiNzVjY18yNA_8e5c7a06-736c-42be-a02a-490e0e88a04e">5,524,291</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b724be0df7a469ba9c898710b2dbf1a_D20220101-20220930" decimals="-6" name="abt:StockIssuedDuringPeriodValueIncentiveStockPrograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTYtMS0xLTEtMTc4Njg_ae3bcfda-fc82-43bc-913d-6041c1fa106e">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6098fe1fbe54bc9a82cd2c345421c2c_D20210101-20210930" decimals="-6" name="abt:StockIssuedDuringPeriodValueIncentiveStockPrograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTYtMy0xLTEtMTc4Njg_fa988edc-104c-4813-bea0-d9f594778b78">265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares: 2022: <ix:nonFraction unitRef="shares" contextRef="i4b724be0df7a469ba9c898710b2dbf1a_D20220101-20220930" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTgtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjpkNzM5ZDA4NDAyNGQ0NTBkOTdjNjZhYWRmNzM2MzdmZl8xNg_a686b9ff-1260-40ea-812c-e37562557eab">25,963,010</ix:nonFraction>; 2021: <ix:nonFraction unitRef="shares" contextRef="ie6098fe1fbe54bc9a82cd2c345421c2c_D20210101-20210930" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTgtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjpkNzM5ZDA4NDAyNGQ0NTBkOTdjNjZhYWRmNzM2MzdmZl8yNA_7b5a74d6-b80b-4d70-a2e1-115b9947ef56">10,414,554</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b724be0df7a469ba9c898710b2dbf1a_D20220101-20220930" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTgtMS0xLTEtMTc4Njg_0b5fc02f-f5e6-48e7-ae1c-fcc970d0b4ca">2,994</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6098fe1fbe54bc9a82cd2c345421c2c_D20210101-20210930" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTgtMy0xLTEtMTc4Njg_b5c47529-839d-4681-bba1-4c4de9aeadda">1,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares: 2022: <ix:nonFraction unitRef="shares" contextRef="ib0384842a3a44e638930735a2b593396_I20220930" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjAtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo0NGQ3NjlkZWY3Nzk0ZjFiOGJjMmQ1MGJkYzhiZDU0OV8xNg_ed5aa859-20fd-4e9c-97d7-0ada103c67db">242,345,663</ix:nonFraction>; 2021: <ix:nonFraction unitRef="shares" contextRef="iee53b5e2f57b467bafb6a07b010ce7b8_I20210930" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjAtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo0NGQ3NjlkZWY3Nzk0ZjFiOGJjMmQ1MGJkYzhiZDU0OV8yNA_38de9d19-baba-489e-a025-5f4b9db91627">214,816,885</ix:nonFraction></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0384842a3a44e638930735a2b593396_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjAtMS0xLTEtMTc4Njg_feb7b622-521c-4319-8bc2-aafd63d3af83">14,555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee53b5e2f57b467bafb6a07b010ce7b8_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjAtMy0xLTEtMTc4Njg_e4e70d61-2fe7-43e9-a1e6-365b12eb1c92">10,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings Employed in the Business:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852ddcd4489e42389a31b5f021e6e092_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjMtMS0xLTEtMTc4Njg_a886ccd4-b499-4736-b774-26d03defa574">31,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7c44803cf240068637223e01d8287e_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjMtMy0xLTEtMTc4Njg_03f8240b-e193-4114-b7ea-a478686b4cab">27,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdca6cdd2c3846f6ad4787b16fed5ea4_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjQtMS0xLTEtMTc4Njg_83a94f44-e0bc-4781-8a2a-343395852cdd">5,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e6626a450843eba3abf231608db97f_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjQtMy0xLTEtMTc4Njg_1ab3d214-c8dd-4361-a2dd-b909259cd4a4">5,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends declared on common shares (per share &#8212; 2022: $<ix:nonFraction unitRef="usdPerShare" contextRef="ibdca6cdd2c3846f6ad4787b16fed5ea4_D20220101-20220930" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjUtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo4NzQ2OGJmMzU3ODY0NTdkYWE0NmRhOThjMGMyNmZlMF82Mg_96040555-4396-4362-a07a-d6e32632aece">1.41</ix:nonFraction>; 2021: $<ix:nonFraction unitRef="usdPerShare" contextRef="ic5e6626a450843eba3abf231608db97f_D20210101-20210930" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjUtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo4NzQ2OGJmMzU3ODY0NTdkYWE0NmRhOThjMGMyNmZlMF83MA_a4676b99-7d8c-4cc8-827f-956e41884e30">1.35</ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdca6cdd2c3846f6ad4787b16fed5ea4_D20220101-20220930" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjUtMS0xLTEtMTc4Njg_2b362754-4f35-4692-87fb-a11af5174dc6">2,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5e6626a450843eba3abf231608db97f_D20210101-20210930" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjUtMy0xLTEtMTc4Njg_91bc6deb-8bb3-4be7-95bb-a20cfbcccfc4">2,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of common and treasury share transactions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdca6cdd2c3846f6ad4787b16fed5ea4_D20220101-20220930" decimals="-6" sign="-" name="abt:EffectOfCommonAndTreasuryShareTransactions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjYtMS0xLTEtMTc4Njg_9561be56-fd44-48d0-b433-f95a7d9a30bf">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e6626a450843eba3abf231608db97f_D20210101-20210930" decimals="-6" sign="-" name="abt:EffectOfCommonAndTreasuryShareTransactions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjYtMy0xLTEtMTc4Njg_444ca5d7-8534-4abb-b1b8-cc7f601fa63b">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a9d779acbe44e3bacba61c64c39e891_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjctMS0xLTEtMTc4Njg_fa327c4c-c4c3-4fe3-a51f-8c508faabada">35,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc3d7b1f7924f49a467f9de89cf4580_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjctMy0xLTEtMTc4Njg_0c4ec2c3-1dc4-4aaa-bd7d-4d8900a7807d">30,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income (Loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0d9d6801c8c4803a0622083412ac492_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzAtMS0xLTEtMTc4Njg_2b561326-c132-46c9-ad87-c8cce103032b">8,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f3f735442774afcb720cdb3ae2b9822_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzAtMy0xLTEtMTc4Njg_b12353e3-f384-4441-8fa0-2970e3a2ba24">8,946</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id78baae4639244558d7fbe8dde9cdbaa_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzEtMS0xLTEtMTc4Njg_244e34e1-7ccf-4fda-9641-9eb47dfe2c15">1,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc6ae1cd7a5648a9876bfd212f13b5fa_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzEtMy0xLTEtMTc4Njg_454643f2-9cd4-4ab4-90c2-1ba850209a31">294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib49fbe36bbba46d5a960a042585a8ca3_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzItMS0xLTEtMTc4Njg_b756ea53-9e44-4344-b44d-fa7e4ac5b387">9,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1445a4f41614df3b5934c37b319c6c4_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzItMy0xLTEtMTc4Njg_3cd33ab3-a6cd-4951-a0a3-1322c951ba60">9,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling Interests in Subsidiaries:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc59d11b30d140339de2cf7f2ac54561_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzUtMS0xLTEtMTc4Njg_0c38ab25-84a8-4f0d-bb3b-5fc000f38266">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6a9cde9eec42f099b747ac02363030_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzUtMy0xLTEtMTc4Njg_4d5442fe-dce8-41c9-9b94-c57ec5f18dde">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling Interests&#8217; share of income, business combinations, net of distributions and share repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide40706d122541aa80614540c148de08_D20220101-20220930" decimals="-6" sign="-" name="abt:NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzYtMS0xLTEtMTc4Njg_7b47d5c8-8953-48e3-8f4e-e413d70f38a4">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i621d2ad3316543a1886bf830d26e3ffa_D20210101-20210930" decimals="-6" sign="-" name="abt:NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzYtMy0xLTEtMTc4Njg_5078d9ad-1668-4b97-827c-0203beaec2de">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97d8339fa5a4a14be94890cbc7535a3_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzctMS0xLTEtMTc4Njg_1272dea1-9783-4d70-b8ed-7e91a865a458">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088ce8132a864ce3a40176de183626a8_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzctMy0xLTEtMTc4Njg_049f2f4e-83fc-4508-bd79-6a0ac22ccdc4">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to condensed consolidated financial statements are an integral part of this statement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><div id="ib0ff9808fe764fdea19589324372f96b_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statement of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"></td><td style="width:68.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Flow From (Used in) Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMy0xLTEtMS0xNzg2OA_a718c7f8-2c27-4c03-8ac4-c5eebfea04cd">5,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMy0zLTEtMS0xNzg2OA_52ec0393-e073-4d57-867a-46f03a50023a">5,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings to net cash from operating activities &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfNS0xLTEtMS0xNzg2OA_b742def5-dcf2-4353-8495-2ddcc2f2a342">943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfNS0zLTEtMS0xNzg2OA_d31a461c-f0dd-4ee2-88f4-92276c7a17c4">1,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfNi0xLTEtMS0xNzg2OA_210464e3-0519-4680-b97d-f78e07c5f146">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfNi0zLTEtMS0xNzg2OA_bf0ed8c1-61eb-4bbb-8f4c-6228de9a1c92">1,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfNy0xLTEtMS0xNzg2OA_7587a0d1-96a8-4b38-84ef-964c86175285">570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfNy0zLTEtMS0xNzg2OA_c31f131a-d5ca-49ad-8d4f-dfec0f9fba7f">534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfOC0xLTEtMS0xNzg2OA_0b1f4599-4746-4f0a-9afe-0a325c8864f4">409</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfOC0zLTEtMS0xNzg2OA_04b0853d-7645-4588-a17d-562f1f2c278e">194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfOS0xLTEtMS0xNzg2OA_efde2801-a2d0-42ca-816b-3014f1739033">1,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfOS0zLTEtMS0xNzg2OA_bed51d9b-4b75-4c4a-a4e8-8455c8b5aa2b">471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTAtMS0xLTEtMTc4Njg_60d6d3cb-dbad-494f-aebe-39f692de9130">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTAtMy0xLTEtMTc4Njg_6b4b6f46-9d4b-4293-9b12-72b7f51af577">140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash From Operating Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTEtMS0xLTEtMTc4Njg_2dabf650-56a5-493b-96ed-818ce964b896">7,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTEtMy0xLTEtMTc4Njg_7bb1a78d-4372-484f-a08c-295188a279ac">7,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Flow From (Used in) Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTQtMS0xLTEtMTc4Njg_a396b801-c7a7-4460-82ff-4f405ffa410d">1,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTQtMy0xLTEtMTc4Njg_2a6aff8e-5a90-40a2-9136-fe18c7f88666">1,271</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions of businesses and technologies, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="abt:PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTUtMS0xLTEtMTc4Njg_8cf94476-b693-4a69-8916-e8d210f8dc46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="abt:PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTUtMy0xLTEtMTc4Njg_1eca013f-17fa-4a99-8a49-127494ed7453">187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from business dispositions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTYtMS0xLTEtMTc4Njg_aabc5b93-ab88-4572-bc9c-51b7dd04c2a5">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTYtMy0xLTEtMTc4Njg_7d3236ee-c4be-43fb-821a-dd20161efd37">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales (purchases) of other investment securities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsForProceedsFromInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTctMS0xLTEtMTc4Njg_437fd13b-3d39-4b36-ab69-e96202cc7169">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsForProceedsFromInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTctMy0xLTEtMTc4Njg_382a4633-0ae4-4089-bd60-47cfef63a443">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTgtMS0xLTEtMTc4Njg_890cda09-f5ef-49a5-ab6a-5219f31b7025">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTgtMy0xLTEtMTc4Njg_f30dac6a-95f7-409b-9f9b-c4c8c5220888">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash From (Used in) Investing Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTktMS0xLTEtMTc4Njg_e0a99a8d-05d5-451b-8f2e-21f6c0d6a044">1,108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTktMy0xLTEtMTc4Njg_b9380a71-799a-4132-b8a4-3655f5726491">1,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Flow From (Used in) Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net borrowings (repayments) of short-term debt and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjItMS0xLTEtMTc4Njg_4ef3e32a-5298-4acc-bf86-a0bda8752ecb">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjItMy0xLTEtMTc4Njg_199813ab-bb7a-4776-a591-c70beef4c111">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjMtMS0xLTEtMTc4Njg_045be4ee-ee5f-444e-b9b3-1d2b5b4fac39">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjMtMy0xLTEtMTc4Njg_5a383ef5-238f-41ca-9cd9-cc56ca1fd697">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjQtMS0xLTEtMTc4Njg_d987c2f0-ff09-4ccb-80fc-c579e3eb191f">753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjQtMy0xLTEtMTc4Njg_58612a58-acab-4b87-a0af-cc0a338148ab">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjUtMS0xLTEtMTc4Njg_26004153-2167-4e82-abb6-497a3008f057">3,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjUtMy0xLTEtMTc4Njg_c354a32f-e3f6-4889-b29d-da9a07e5ab21">1,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjYtMS0xLTEtMTc4Njg_6f0181f6-5da3-473b-a263-a4f6d727ff84">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjYtMy0xLTEtMTc4Njg_59e824cc-6148-4714-977f-fac4df9a237d">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjctMS0xLTEtMTc4Njg_cc81d62a-2f2b-49f4-8408-0699d40c3f4f">2,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjctMy0xLTEtMTc4Njg_400d31b3-c49b-42c7-9066-8a76008f9c03">2,404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash From (Used in) Financing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjgtMS0xLTEtMTc4Njg_3b99f8d2-6efd-4980-bf01-2c7153057e7b">6,179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjgtMy0xLTEtMTc4Njg_48c0b96c-39f3-4845-a6c0-c35ecc46952a">3,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMzAtMS0xLTEtMTc4Njg_4b8e365c-05ea-4867-ae3a-2b4f8efabed2">173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMzAtMy0xLTEtMTc4Njg_8ca79bc7-1f31-4174-91ed-5f19b4456b40">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Increase (Decrease) in Cash and Cash Equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMzItMS0xLTEtMTc4Njg_2cb80018-0b69-4b10-80f7-127950f69a3f">205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMzItMy0xLTEtMTc4Njg_21aead67-01f9-4e1e-abd9-3b4ca4c5b875">2,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents, Beginning of Year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMzMtMS0xLTEtMTc4Njg_c8f6eb45-937c-4de8-9aa6-d54d94bdc49e">9,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3397ef3061f44f36bc9ca7c33654a5de_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMzMtMy0xLTEtMTc4Njg_c3f5e17a-7035-45a4-9995-702da542054f">6,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents, End of Period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMzQtMS0xLTEtMTc4Njg_df0aed94-a880-4749-b171-f7b8ac982359">9,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf57bd89e8649de9b14b6f40f63d3b6_I20210930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMzQtMy0xLTEtMTc4Njg_60f6b06c-59ae-441c-9196-d9352c39a121">9,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><div id="ib0ff9808fe764fdea19589324372f96b_31"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><div><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_34"></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNC9mcmFnOjNmNjgyM2FhZDI5NzRjZTg4OWFlM2E3MTcxMDYxYmRkL3RleHRyZWdpb246M2Y2ODIzYWFkMjk3NGNlODg5YWUzYTcxNzEwNjFiZGRfODE3_5e506e19-5489-4b82-8a9a-426a651baed9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 1 &#8212; Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_37"></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RleHRyZWdpb246YmIwM2Q2NjdkMjQ2NGY4Yzg2MTExOGYyZmJiMDAzNDNfMzM4_3baaf0c4-7e31-43c7-a98c-d17b5063b1c4" continuedAt="ie2a5a0c221a746a494119d28b45ba46c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 2 &#8212; Revenue</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott&#8217;s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has <ix:nonFraction unitRef="segment" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RleHRyZWdpb246YmIwM2Q2NjdkMjQ2NGY4Yzg2MTExOGYyZmJiMDAzNDNfMTU2_9ff8148d-c840-4e56-a462-d45331374e70"><ix:nonFraction unitRef="segment" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RleHRyZWdpb246YmIwM2Q2NjdkMjQ2NGY4Yzg2MTExOGYyZmJiMDAzNDNfMTU2_b5e986b8-0a0a-4b04-a393-f937aeeadd1b"><ix:nonFraction unitRef="segment" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RleHRyZWdpb246YmIwM2Q2NjdkMjQ2NGY4Yzg2MTExOGYyZmJiMDAzNDNfMTU2_ccfb94bb-d305-4b74-afd1-f9bedee29362"><ix:nonFraction unitRef="segment" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RleHRyZWdpb246YmIwM2Q2NjdkMjQ2NGY4Yzg2MTExOGYyZmJiMDAzNDNfMTU2_d435c934-c0c4-47f7-bc53-8826f82c28c7">four</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RleHRyZWdpb246YmIwM2Q2NjdkMjQ2NGY4Yzg2MTExOGYyZmJiMDAzNDNfMzM5_6ac5f4c7-197c-4d3c-adb3-8eba5f39144c" continuedAt="i729e65850c724f4f9a636b01410560f7" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide detail by sales category:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products &#8212; </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdd6935a04684767a7df321fc7d8e04b_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMy0yLTEtMS0xNzg2OA_0a4310c1-94f9-4194-9bd6-a31ff3c8099e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20dea8b9fbad40a38c94c202b5a06584_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMy00LTEtMS0xNzg2OA_967baf65-d730-477b-abde-9d78843e8801">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i553b1f411dac4315b9a061214928d19f_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMy02LTEtMS0xNzg2OA_5d27bdf8-212f-4f3a-8f33-68cbd0980c84">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd8b94ecb894e8195d49738629f7663_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMy04LTEtMS0xNzg2OA_ca008849-7c3d-48d8-84e8-820fb413260b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab868753d235445d83b1848d574f0930_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMy0xMC0xLTEtMTc4Njg_aece119e-e9d9-4780-a321-fbc7fb821ffb">936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9377afb46605449ba04338e3aed6ebac_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMy0xMi0xLTEtMTc4Njg_902785c1-2405-47c4-b821-d0ea8d28d6cc">936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb9ead876d79497b81d1a4e75fa4b045_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNC0yLTEtMS0xNzg2OA_cb710407-cd42-46aa-bce6-dcdb0794ea33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb241d31511748689ba74aba957986b9_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNC00LTEtMS0xNzg2OA_0bad085b-abe6-49ce-b877-e5de38b1d2ed">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08d89d55ab546df94df4e9acd51d621_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNC02LTEtMS0xNzg2OA_5bc1a5e9-5cd3-488a-89ac-fc07c5379d3d">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392c359c05c842bdbf2ea56e22942b96_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNC04LTEtMS0xNzg2OA_7a8f02fc-0215-4717-ac6d-f259229f428b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a2976080c494443a4931b79f76745ad_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNC0xMC0xLTEtMTc4Njg_6e9107eb-6468-4cdd-a903-bbea1a3a4586">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i356b34bf48444864bd8276a14a0a84e4_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNC0xMi0xLTEtMTc4Njg_4e6189b7-0874-420c-9598-2b224811b886">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1992bffa64a74127b5f3ce81b21991bf_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNS0yLTEtMS0xNzg2OA_a1975d79-6845-41cc-913a-951978f5c2d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22fc4ec43f24128aae74e88776149f8_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNS00LTEtMS0xNzg2OA_0f9e2c05-703d-4227-a34b-0116b4fc426c">1,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e67684e5e949128a2dec705cc5342d_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNS02LTEtMS0xNzg2OA_a50b8d9d-0778-45db-b833-ee1afa7d4a2c">1,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f479639da464db4b609d3fa8cba57e3_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNS04LTEtMS0xNzg2OA_efa85bf5-6864-4117-bf74-b3c8203e4fcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d8adee8e3b749c59dcd592b973fe816_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNS0xMC0xLTEtMTc4Njg_068d57d6-9beb-4a3e-bd8f-13bfcbab2c50">1,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffc59617b4841e6842d4164adb3ad90_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNS0xMi0xLTEtMTc4Njg_6fc02f61-4821-4ba5-afb4-c372554d1a7b">1,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938d14e18c764f7591831cee2b53ef86_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNy0yLTEtMS0xNzg2OA_2ed4e506-1899-4dde-ac59-060dd8862dd3">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d4661d9eae4662a6bc7af372b39a7f_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNy00LTEtMS0xNzg2OA_31e81c28-4b01-4e34-a427-5ceb4228bd98">470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0270bd857761409ca80dff389f4005fb_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNy02LTEtMS0xNzg2OA_2878eb71-0747-41eb-ac1b-47756ece22ad">827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5684517b411b4be6b66e253acbe21100_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNy04LTEtMS0xNzg2OA_621d9ee0-89e1-4c91-bfbd-e37045a155d9">586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94a3d528fe5c493698dcfd7f6cdbd624_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNy0xMC0xLTEtMTc4Njg_eaf5e971-b976-42fc-b3cd-1fc18bb52319">514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c46ec7babe4d8d98a3a5f521e8605a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNy0xMi0xLTEtMTc4Njg_f6b46338-558e-4906-9551-337be9ed437e">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce87a21a2074f99b7e3a9096bf4bc2c_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOC0yLTEtMS0xNzg2OA_db2e9d92-d751-4594-9234-d5215e777901">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3981790b8e294829b7fce3da94293b1a_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOC00LTEtMS0xNzg2OA_a9e532ce-58f3-4a99-8331-7eb814928e68">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idee15a5bd7a94f2a92b34458fffd592d_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOC02LTEtMS0xNzg2OA_380ff371-28a2-42ad-b083-c3c98ec9eb31">968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d4fcd289e94e72b4495606b599fffc_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOC04LTEtMS0xNzg2OA_122f8f01-592b-4486-a8cf-78e5994f0d88">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fe4e7fed8d4ca39d192d7298446b1b_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOC0xMC0xLTEtMTc4Njg_ad1768f4-ef07-4059-8beb-9b5535ab314e">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ce1b628bc24fbba472f845695459c7_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOC0xMi0xLTEtMTc4Njg_a87e1661-b57b-4010-b9ff-6a92d4a7894b">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262c247a794c4eefad4c4426111eda88_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOS0yLTEtMS0xNzg2OA_7398b2f7-24b0-4996-bb08-e13b62af0d30">686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d37f71b97414ca0a196529d4e6c3728_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOS00LTEtMS0xNzg2OA_8bdaa4ec-38bf-48ba-a93f-c0d023c63497">1,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8fa29318db7448c942a75e199de1be5_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOS02LTEtMS0xNzg2OA_cddb7d0b-3f19-4519-9374-80e6d1216eca">1,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248ff18b88c14ec0b9b3fa1462dc670e_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOS04LTEtMS0xNzg2OA_5365df2e-4a8f-4503-834c-52c1fa860d10">919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84b6259abeb9432c9b1f4f981322d6e2_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOS0xMC0xLTEtMTc4Njg_63be25d1-ba87-4ebc-b1f1-b3fb082f7240">1,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3203f3fae46e1ae8028fc5a27e29c_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOS0xMi0xLTEtMTc4Njg_a562c333-735d-4a5e-9d87-b0b67b9ff3e9">2,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics &#8212; </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia256be207eb1438f97b1a7c44dda87d3_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTEtMi0xLTEtMTc4Njg_001142f8-f371-4b67-9a82-cb445970fb2f">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5dcca58e8964d269d6d18f5bae1e53d_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTEtNC0xLTEtMTc4Njg_88feb6f2-6777-4750-b9e2-c35bbabd34c8">938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d8bf57ab5544cf81d04120e139dabf_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTEtNi0xLTEtMTc4Njg_550df209-dc8f-4373-8dd2-ed2d5a344398">1,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86213c5d496444e8758ca35cdaeb05c_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTEtOC0xLTEtMTc4Njg_58f8a886-94f3-40f3-90fe-e0a39794f6bf">291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1f5c24bb5841378c451a90d43000f2_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTEtMTAtMS0xLTE3ODY4_c8f05de4-2b52-467d-891d-22342c185ae1">1,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b897bac92554d069fad477918947757_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTEtMTItMS0xLTE3ODY4_1c98b451-08d2-49ff-bc12-0531a8f5802d">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b4a4864d2ff4c4e8574e011f96d543b_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTItMi0xLTEtMTc4Njg_08df279f-24b9-4aa2-a04d-bea243c815e0">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8377a58ea461458c9ebd573507a2eb81_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTItNC0xLTEtMTc4Njg_b2756997-3dc6-492d-87e0-54f84707f582">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8800ac73633d482e852c78a6b3b8d03d_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTItNi0xLTEtMTc4Njg_3fe2b8c9-446b-4a00-a9b0-1b79229bbb05">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cda9249440a4ababf23d348f31db81e_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTItOC0xLTEtMTc4Njg_a6e9cdc6-c14d-4b06-a957-9c9ff857e111">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec3890031ec84733b487409a7fff947e_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTItMTAtMS0xLTE3ODY4_3cf6a3d8-6029-4f66-a083-add89851afd1">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f47d268de74c4bb30f8f0125aeccc5_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTItMTItMS0xLTE3ODY4_c067eb4a-de68-4f39-96bd-f2264c54cdd1">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30e9486b2c674fe99294020e754c817f_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTMtMi0xLTEtMTc4Njg_115e9e74-c553-44c9-b941-f4a99f081f24">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6366c00282d04fa5a78abdb1ee423aed_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTMtNC0xLTEtMTc4Njg_ce3d67c2-a224-4a98-ad59-542006ace06f">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79d29b0d89e645e0bcb31189ca823228_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTMtNi0xLTEtMTc4Njg_5afabfec-9505-4db7-a5a1-9808ac31a93f">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20ea475fdf0c48e98e083f8dff8056a9_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTMtOC0xLTEtMTc4Njg_3f472c2c-662b-45a5-bbc1-fef340a4a03a">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003dbc498c9a441d89cc0b04ebbd771a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTMtMTAtMS0xLTE3ODY4_e1e6c113-5214-4aa6-bf22-74d34ed5cb61">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975d74cca0954d4da1bd068770b41605_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTMtMTItMS0xLTE3ODY4_533cee79-79b6-47d5-93d5-e7f6b4da73a6">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d047d8dfd414c5d869bcd80fcd41acd_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTQtMi0xLTEtMTc4Njg_a84aea8d-0121-4db3-a80d-f42d0db4f2d2">1,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i737b2378d74d4e7492bfe82a019bb4ab_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTQtNC0xLTEtMTc4Njg_723b6fa6-aad5-47fd-9dad-3b091a3e0b2b">839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i769d3ce030b942ae9d850540e53df223_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTQtNi0xLTEtMTc4Njg_095a180b-785f-4067-b2c1-24e62010b1dd">2,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0bffdbe968459c98f06e252484ccc3_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTQtOC0xLTEtMTc4Njg_ebe5039f-4e88-4d97-87d8-7067058bd2af">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id63c448a841840358193db0fad40f4c5_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTQtMTAtMS0xLTE3ODY4_c226428b-1d71-4031-81c5-61f95a1625c6">746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56a546e33244e07a2c5e1ab9ecb4292_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTQtMTItMS0xLTE3ODY4_c6ee7cab-99ca-4eb9-b13c-d9e74233f73c">2,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fee55729a8c4e7185f644e1bfe2485b_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTUtMi0xLTEtMTc4Njg_34d8bc76-71a8-413f-8e18-97935c100527">1,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2140596e31a1496bafdd0b9ee4a2e6a6_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTUtNC0xLTEtMTc4Njg_3839b917-e978-4652-b3d0-e4ab6dbe31b8">1,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ee6e9676f048f79f0471399c05b638_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTUtNi0xLTEtMTc4Njg_6f3b89f7-40c4-4d70-a245-5b9cc668f2d5">3,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id19d1f5e16084839a8c193bc0d1b0b6b_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTUtOC0xLTEtMTc4Njg_37a6e0b1-1ea3-46e4-91e5-e1cef7290f9c">1,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd6b40c44ce54ba1bde4642cb23e69f6_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTUtMTAtMS0xLTE3ODY4_9e4a41a7-2dcb-416c-854d-9260f42fc654">1,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4186212e28d4b569b09c70bbface083_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTUtMTItMS0xLTE3ODY4_ba997ff6-db82-432b-b93f-c378ace4e075">3,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id659a1190f7b4070a747d070536ed33b_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTctMi0xLTEtMTc4Njg_52d405ec-1844-477b-9081-81ca9d4c3b32">263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6480973800e4bb4b9ae80722ce16e59_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTctNC0xLTEtMTc4Njg_91282d40-3260-4601-882b-aefa1d7ff438">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d61af67909049b9a444fc24e14717ea_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTctNi0xLTEtMTc4Njg_4df21009-782d-4386-9c9f-95c72ffe4e56">533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if890618fe578485fa3a4db43677fe34e_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTctOC0xLTEtMTc4Njg_103220cf-14ab-4010-ae13-38ceb0afd660">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34397dbe2fe94c6295a14a8d146a8e33_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTctMTAtMS0xLTE3ODY4_62a570fc-a918-44d6-bd29-86b1662a5acb">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8368e30efc48f7b56ba92dc4adc061_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTctMTItMS0xLTE3ODY4_22bc5eb7-5db0-4bbe-b73a-cc65d621e3a6">571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i928d6fe7e0df441780768f564d2effcd_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTgtMi0xLTEtMTc4Njg_32837afa-b19f-4fce-bd38-440d2a1167ef">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f24ca1db60e4a9da9ffd86e0dd87fe7_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTgtNC0xLTEtMTc4Njg_4861537d-1b91-4792-b047-60a64cddcf52">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i822021d7a9e249bab1fe800a9aedfb9b_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTgtNi0xLTEtMTc4Njg_1b760cd7-1415-4b63-9b3a-6880b57d58b4">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ab1d9822ff84b4480b3cd3b8cc641bf_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTgtOC0xLTEtMTc4Njg_e28117b8-916d-4c46-bb28-a865dac4b7d2">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if718f850e60e4378916dbadb60c282ad_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTgtMTAtMS0xLTE3ODY4_194c7c3b-f66b-4696-a0e6-a23b674cba15">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e82029ad78c409e9753b65d01cfa2d5_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTgtMTItMS0xLTE3ODY4_db565a59-2ae6-458b-8253-141631b13eaa">485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedef7300876e4675ba5cd753aef79d39_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTktMi0xLTEtMTc4Njg_04714945-70d4-4b68-b5fa-d315e51a05dd">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d1631e3346a480c9d5b5659e244276e_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTktNC0xLTEtMTc4Njg_f301d0bc-81e1-4d83-b5ad-0f71fe55ef7e">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77aac3496d504b269d56bad2b76e5104_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTktNi0xLTEtMTc4Njg_ec26dc55-284b-4500-adc3-72290ba5afbc">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i780ba98a53b04c0abf1fcfadfe606d7f_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTktOC0xLTEtMTc4Njg_8919f931-9041-4974-8016-89125fe97100">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic59cae3887574b7b9d34a8c5fd1fb0b6_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTktMTAtMS0xLTE3ODY4_d253d750-4ca7-4b0c-876a-d7ca306ac623">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228ab2341a2243eeb1c80b00645ce995_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTktMTItMS0xLTE3ODY4_7a82a5fd-2722-4cd5-805e-403bf59e150e">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2294cc5729724ad4beb4eca7c9cdd070_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjAtMi0xLTEtMTc4Njg_fa9f201c-35df-4cd4-a8ea-7b07e344ab5f">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide82ac8a034040ebbe46d3d3b8e71a00_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjAtNC0xLTEtMTc4Njg_0af31bb5-5ea3-4d1f-b3ce-8653be910c41">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dc02637faf8456f8e9ffb0ddcae89e6_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjAtNi0xLTEtMTc4Njg_47c73f0b-2d6a-4816-b040-dca1c27ab440">606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4030aeb71c94f9bbc3b600344c1518a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjAtOC0xLTEtMTc4Njg_09e4d74b-ab9f-4dab-aedd-36126f9a403e">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i921fd3c95d3b4f22ad34e4bc60148ba2_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjAtMTAtMS0xLTE3ODY4_18fefe00-ae6c-4236-923f-7252c95bd749">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3145c2c6bd974f55ac9749bc3df087bf_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjAtMTItMS0xLTE3ODY4_8ff52f0d-4e53-4fae-a1dc-55a4d25eeb9e">644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5c721c4b474f6ea1f090bb7b8e4fd0_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjEtMi0xLTEtMTc4Njg_88255012-e5a9-427a-9c0d-b0babd3e5be2">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e0589ff3084f539d0a76d845294702_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjEtNC0xLTEtMTc4Njg_90e1a0c0-dd4b-4c3c-bdc6-84ef5888e88b">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34e8d657434743fe827a4089fc230ba9_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjEtNi0xLTEtMTc4Njg_a1f29af1-78af-42b7-b0dc-77d25b0a7402">420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e9a03bf16d46ea811c32e2fd25a006_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjEtOC0xLTEtMTc4Njg_e1470a0b-f7c9-4471-b491-71457cac78ba">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i570d7e8aa51741029b8421acbd7e89ee_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjEtMTAtMS0xLTE3ODY4_12e579ac-4af5-446f-be7d-9ddfecbf792e">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35c10ac918394db8b1c3491c2981f0e5_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjEtMTItMS0xLTE3ODY4_be36c51d-e6ef-4c20-a213-65399506d484">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d04f4545b8b43d7bcd56adb5418487d_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjItMi0xLTEtMTc4Njg_26cab113-85df-4a1d-bf65-26bd3e6d4b02">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a32eb2db2de4ba4b33ad343ddc6021a_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjItNC0xLTEtMTc4Njg_316fe859-eb8a-4a61-8828-165b52e39598">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1583d120070b4c648cbb100c9764e0a7_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjItNi0xLTEtMTc4Njg_65141c81-b0c0-4c3c-a01b-c56509403832">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i683987d035904d219c421b72bf0f8f88_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjItOC0xLTEtMTc4Njg_9de02406-9a48-4ed6-8488-8afb006f7d07">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a64fbf194cd46d1a5f071cd845567da_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjItMTAtMS0xLTE3ODY4_2df1db48-ec21-4310-9955-30c5cdc82cf5">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9adf53e54b3447a88875f2f71694d649_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjItMTItMS0xLTE3ODY4_d8f2697b-1059-4bfd-9495-e87676fbb282">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica898e019d964049bedef258b5226f95_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjMtMi0xLTEtMTc4Njg_62903bf4-3181-4549-8c3b-be9f1afb518b">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4b4059d40945188d652327f054645d_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjMtNC0xLTEtMTc4Njg_85170a7d-4c90-4c3e-9533-65e9e00bd998">744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8056ef31a802430fa929e0598584b1c7_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjMtNi0xLTEtMTc4Njg_261d8f2e-e9ee-462d-bb83-0f50ad614518">1,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia16e81903f114d79b6e640358306f75a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjMtOC0xLTEtMTc4Njg_c20c084a-14c0-4af3-a018-b50dcc955b4f">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1005eed0e87a4f6ca75ca475d4fb2b94_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjMtMTAtMS0xLTE3ODY4_f5eaf19e-92e1-4ded-9e9d-01946468a8e1">798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i351b1476da8947a8a63c6a3ff672aee0_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjMtMTItMS0xLTE3ODY4_4f370366-d051-449e-8217-41aa4ab6b0d5">1,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff8daa2d825a48a298a1cc610189cf7c_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjQtMi0xLTEtMTc4Njg_e6b64cd1-eeed-4d53-960e-0abe8b454192">1,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a811c943c8c43aa93ad41f1bdcb253d_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjQtNC0xLTEtMTc4Njg_179e342d-0197-4371-b837-ed98db35a3c0">1,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91226d7ee83f4e5298c5a54390a1eccc_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjQtNi0xLTEtMTc4Njg_c68690c0-32f4-44ad-8f79-161a5fa44423">3,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10e8ad512c2f4a09873c90ec51a3e052_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjQtOC0xLTEtMTc4Njg_80473528-f9dc-43d6-8986-87c29312e76c">1,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9911c8668779460c87a6b1bfc290914f_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjQtMTAtMS0xLTE3ODY4_1c54badc-4603-47a6-8deb-6343f28c412c">2,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2c236dcb265432793429913b3061d27_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjQtMTItMS0xLTE3ODY4_24458ee6-5b26-4ca0-8b51-4a2f6e446b4b">3,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73b999e6aee402da9f298dad7a6ac0b_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjYtMi0xLTEtMTc4Njg_4abc7ede-ccad-47e3-ba05-8f088e27d4c4">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i069f4c6f209746c789a3cc531b1374c1_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjYtNC0xLTEtMTc4Njg_8bc5dcd5-be2f-45b4-9232-d7ed569ec3fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e1452c0c5d145a29227070d32c787ac_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjYtNi0xLTEtMTc4Njg_a9d96adf-5df0-497b-acc6-e9b623200f8f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93831c5392ae4927b11006f81f940e3c_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjYtOC0xLTEtMTc4Njg_23b420bc-690a-4339-a672-f3fbee40b9ef">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0a7f44a74844847a52a461dc905dc00_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjYtMTAtMS0xLTE3ODY4_2f367a89-824c-4e6f-a2d6-be2b23e8de2e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ef09987de6c4adeb7fa5bf0cf0c7704_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjYtMTItMS0xLTE3ODY4_17a627f7-a6c9-4e76-816a-3d81fefac64e">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf27976a942a4fc19586a8236e981bc0_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjgtMi0xLTEtMTc4Njg_c9ce204e-19d3-49a8-a80c-f0ef3b5dc00a">4,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1349d737be5b4ef59e79e923b2ac2288_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjgtNC0xLTEtMTc4Njg_b7c38778-ce23-45c5-8964-a6298d598192">6,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjgtNi0xLTEtMTc4Njg_bc8e12a1-5b6f-4670-8446-950181c7f4a5">10,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i453afdd41ffd4a8f9d41a110816ebc00_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjgtOC0xLTEtMTc4Njg_a2a46355-51c6-409a-8ed0-66683a93e465">4,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9d6f53ba814d1b95c967e665c217ea_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjgtMTAtMS0xLTE3ODY4_9b1e1384-d02f-45a5-a287-8f5a9229514c">6,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjgtMTItMS0xLTE3ODY4_20d541f3-119b-4ef7-ae1f-7a8a07fec024">10,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><div id="ib0ff9808fe764fdea19589324372f96b_40"></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 2 &#8212; Revenue (Continued)</span></div></div><ix:continuation id="ie2a5a0c221a746a494119d28b45ba46c" continuedAt="i74d4f46252be4c6a89738bbafb96b408"><div><ix:continuation id="i729e65850c724f4f9a636b01410560f7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada0437a2d644f70bb7d16cf91f31b89_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMy0yLTEtMS0xNzg2OA_cf4063c3-edb7-4318-9706-827d901d5e35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cade4bab8cd43e19b63a86b43643ef5_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMy00LTEtMS0xNzg2OA_c1d64034-1c52-4f40-b874-b31cbf60da35">2,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361870a0e2f94355b13e0b60175a2edb_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMy02LTEtMS0xNzg2OA_aecd10e5-352a-445c-966b-0546396f2555">2,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i134a99d86b0243888efe2cec770050b5_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMy04LTEtMS0xNzg2OA_88fe2cef-a07c-43b9-9085-1e9c765ab64e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i690d3ee447044de5b2a11910dd16abaf_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMy0xMC0xLTEtMTc4Njg_ea47a617-b03c-4723-b313-0af787a8f677">2,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31f2c0a0ad5d4d44bb78b1dc657ab16d_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMy0xMi0xLTEtMTc4Njg_b8eaf661-5c70-4524-8878-31ff54d53448">2,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554353f0dd4640f1b215201bed46099d_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNC0yLTEtMS0xNzg2OA_2cdd0814-c2a2-42f7-b90d-18852d666c0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifec2214696a74f5fa73835f5d611690a_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNC00LTEtMS0xNzg2OA_56164637-9812-44b7-9cf5-05abc36ad937">870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e6c2d98d8f46038f546582021c6a94_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNC02LTEtMS0xNzg2OA_3e6d46c9-9119-421a-b981-8cb9d9f4b58d">870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a4321960004899b56bca3a97bccffd_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNC04LTEtMS0xNzg2OA_66e49c82-b68a-4ac5-bed9-8801d7cb16e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i102907d306274282b184801c40f69f97_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNC0xMC0xLTEtMTc4Njg_47004d0d-f1b0-4d2b-a0f6-0e7b67e4a1fe">843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad208ef1d3254acaa72d25a179cf7d24_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNC0xMi0xLTEtMTc4Njg_d2015de1-4349-412b-82ff-40c0a93446fc">843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92e9ca2b2e18494baca77d7365fc681a_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNS0yLTEtMS0xNzg2OA_4140014a-1a91-44c5-92fd-c87467dda91e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40287ad92f234638a3f0573ebae44eca_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNS00LTEtMS0xNzg2OA_3793fff3-8490-4f23-9aeb-f5e75e110793">3,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88535b01ff934a65be5cc199bcb770b6_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNS02LTEtMS0xNzg2OA_6d028957-46fc-4d81-809e-2ffbe2fba5ca">3,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icecdc6a5fc1c478c8f0fdbb2c241e43e_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNS04LTEtMS0xNzg2OA_bc130e99-455e-4b0b-8291-b6920250bdb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708d2529d4054b78a3b367c21aaa1820_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNS0xMC0xLTEtMTc4Njg_d970fcde-0647-4ed3-9c1c-7ffd9ca54650">3,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c90b3c1db944b208e77b4076259563c_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNS0xMi0xLTEtMTc4Njg_d82e851e-ebf9-4d99-8125-8a00018e4fe8">3,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34a1de062a34934a0a112436ec8d560_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNy0yLTEtMS0xNzg2OA_f15bec24-172f-48cb-931e-cb80cc39e9a1">1,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1345044a56d74824ac553b8f40f2c74d_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNy00LTEtMS0xNzg2OA_d8107eab-3b75-4a63-8928-e721a19f5b6e">1,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic52e79d5447c4977917c82e49b86fb4e_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNy02LTEtMS0xNzg2OA_422ac4bb-5311-41b1-bf5e-8c2702dfe20e">2,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e840f2b6e62404898af58c0cbc62fbf_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNy04LTEtMS0xNzg2OA_1fd0e72b-ccfa-4415-950e-e6b7d7ff350f">1,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a8d70dcf5384658960d5b5ea48dfbb7_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNy0xMC0xLTEtMTc4Njg_94c0ce47-1ac9-499b-8350-190412152844">1,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43915f754bb04fb5a0040abb37d51123_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNy0xMi0xLTEtMTc4Njg_cf844cfb-8046-4314-b8af-372d25486c14">3,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41d6039c97b64dbc820635198caf3dc4_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOC0yLTEtMS0xNzg2OA_270eb083-c825-4615-90ce-42c15f3843bf">1,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258f0ca4a6f44bcd94d893ebab9cc9c1_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOC00LTEtMS0xNzg2OA_d3bb9ef9-688a-4599-bf58-bff4536749b8">2,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e3063d3a8aa47c784ad799aceff5e06_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOC02LTEtMS0xNzg2OA_ee8414f1-080b-4fb6-b837-68ec81876d7a">3,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea4b8d31930d4018a5338e7cf5435676_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOC04LTEtMS0xNzg2OA_8ef3db9f-9263-4612-b08f-039b638c2e4a">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176c1169defa4bb381f30ee2fe87a5d3_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOC0xMC0xLTEtMTc4Njg_3a1a0ef7-1173-48d9-b589-48d13722381e">1,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie585e82674e94179ab887b7f775c682b_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOC0xMi0xLTEtMTc4Njg_a89e81b3-4e27-4048-b359-553ea49b5b1e">2,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie623ae8b28ba4c44b6fec7b856d08e06_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOS0yLTEtMS0xNzg2OA_4e083b7a-b8ba-4fcb-acde-e926bb9b78a7">2,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35395fcaaf34451c9cbfa534d8d7ce9a_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOS00LTEtMS0xNzg2OA_4b71e7bf-7325-471e-9d63-9405945ca7df">3,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30091a5d3bab43efa63d14e4a226925c_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOS02LTEtMS0xNzg2OA_074e6269-1e9a-4529-80ad-f860c3ccda2b">5,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1596bb0bf8f43fd80c7d6d3d9119a9b_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOS04LTEtMS0xNzg2OA_f289dd5d-4a4d-452c-8675-84613b588401">2,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248be60308a146df85a86a26a0fc60f8_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOS0xMC0xLTEtMTc4Njg_ee1cef3d-e301-45d6-a0e4-d7f4c7f12874">3,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151bd5c29f3c46848ec98ccbecda7c02_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOS0xMi0xLTEtMTc4Njg_aa04e518-6503-4539-b873-a1f2037832fa">6,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b056141550548c3be6dd5b036db3ff1_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTEtMi0xLTEtMTc4Njg_5fae7b43-afef-4547-9e21-327e0c8156c9">836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e31728b4def4db89b236907c78b2797_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTEtNC0xLTEtMTc4Njg_c442d5a0-05cb-471c-9c90-ae9555b25f53">2,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75bb1a2605e4d8ea6e25aa3afb20121_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTEtNi0xLTEtMTc4Njg_23ed9262-45ac-4266-8a45-0c40518c9284">3,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaa33587aec14e3c92b0c60d0a771555_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTEtOC0xLTEtMTc4Njg_28bc5e6e-3821-4603-9c4e-766b3c66c479">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62abea3acfae48e8890da0175c0339ac_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTEtMTAtMS0xLTE3ODY4_53de4401-d389-4fe7-a8b9-48b830622231">2,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if933b85d1d764e94956ab214e194e081_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTEtMTItMS0xLTE3ODY4_9268f000-57bf-4fcc-ba6e-b2e2196ab1b3">3,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d65665918964adeb3fff6362875e715_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTItMi0xLTEtMTc4Njg_566f8691-e0db-44a8-a573-298a5c475d50">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i381802cbd03a48bf88e11eee86e25b7f_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTItNC0xLTEtMTc4Njg_a8c0c4f3-0244-4c8f-bd6b-79ba136b5303">507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id56510d8ef1842c0ae332b5fed72a26a_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTItNi0xLTEtMTc4Njg_1d26800a-372a-4756-be9c-a75e2cd39f90">815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i775838a7944846a986221b63ebbe9b64_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTItOC0xLTEtMTc4Njg_e15d1511-37bf-450e-88c7-b7ca9d6c9aa6">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba87ee33146849a291c62b0745bb5f5d_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTItMTAtMS0xLTE3ODY4_8cd71789-893f-4945-b6ad-3aae1ec56519">651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d36392cd74f4d26a9d42617161eafaf_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTItMTItMS0xLTE3ODY4_cb903f2d-350f-4322-b2dd-41a55f1a0230">1,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a75adec61da4340b39d6915dcb31f11_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTMtMi0xLTEtMTc4Njg_6c14a42e-4a64-4494-aa12-61496badd37c">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9cf76723706485f8673bd279ede2bf5_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTMtNC0xLTEtMTc4Njg_d2988916-9e11-4442-9ed3-2bf0b4216274">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3769aaf2e984527ab4d6cd5c5790c6a_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTMtNi0xLTEtMTc4Njg_e2a2ad7a-184c-48d2-a95d-e02eb1433caa">394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d0f4ef4f7424767974f102dbe69d978_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTMtOC0xLTEtMTc4Njg_2b0eb344-7216-4906-afb7-ee0f7fe86b5b">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea63032d5234ccd932e6fd8c70cf960_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTMtMTAtMS0xLTE3ODY4_c5b5ff2a-3836-4d28-97e3-c85a4e926192">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i390a22555acc4884934c9d58d45d11d2_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTMtMTItMS0xLTE3ODY4_459f3207-9750-43e5-be0d-8202b1281035">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49197e2409e34e65a96c75e9f85a6de5_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTQtMi0xLTEtMTc4Njg_4195af59-0ef8-4b91-b445-0b97490607f5">5,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b4a4436b7e3437ebd0171fc877d29e3_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTQtNC0xLTEtMTc4Njg_cf959004-43c9-469e-bfb0-75a7ac2cd95c">2,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43eff708b8824e8da4d9838d6a4f5e3f_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTQtNi0xLTEtMTc4Njg_02f69c43-4f05-4a9e-bd46-842267749772">8,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1103a7e9b8c9470d9eb268366aaf62b7_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTQtOC0xLTEtMTc4Njg_042880f9-5f5c-4917-b353-64c446209e5a">3,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0287b1ef094c4fad8318d6eca7385301_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTQtMTAtMS0xLTE3ODY4_a0384696-59ea-42f6-8be7-f85d6722a7e3">2,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e49e1388c1b47c883e46629b8e2b191_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTQtMTItMS0xLTE3ODY4_84603913-2be8-4907-bda4-96ff9e43edcf">5,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59bf5ff82ae5408b905d3c438eb99949_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTUtMi0xLTEtMTc4Njg_f3905c34-64eb-4b3b-8562-db4b88d3b228">6,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib084a5804053469ab97816e5c1ee7359_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTUtNC0xLTEtMTc4Njg_86713266-80e5-46c4-a56f-755c48810297">6,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d0903dbdb14905994e7b293b54456f_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTUtNi0xLTEtMTc4Njg_64d2d88c-85ad-4943-9d16-69e0a90fd5c8">13,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4974eb5146784a269db4203e8c6fa7e6_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTUtOC0xLTEtMTc4Njg_22ff5069-d1f1-40a8-9bd3-63bc5c2e9e2d">4,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b90b7445ea43d9b419aa50bb82b8e5_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTUtMTAtMS0xLTE3ODY4_d4427878-724f-4089-86c2-a65ba8aca210">6,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc14a44dcf1344559829bf251b14704d_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTUtMTItMS0xLTE3ODY4_40dc305d-94b0-48ea-986b-ca28eb135325">11,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00bbc05a48e34b0895b143638542cf98_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTctMi0xLTEtMTc4Njg_28c2a2ec-6f2d-48cd-95f6-fba6ff664a91">775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4ab9bd729548cdbc214c561241cdc1_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTctNC0xLTEtMTc4Njg_d63c575c-3d6b-4e46-bd82-3bb9f45d0a09">830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id965fbb08df843a7b71062949bd75de8_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTctNi0xLTEtMTc4Njg_22acd5a7-70b9-42c3-b8b6-fe0c63e076f2">1,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f23fb6c9b6b40f996df1df9c7d4d1b0_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTctOC0xLTEtMTc4Njg_53a1f51b-e0d0-4c35-931c-c1b475429d94">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ade9da924b40b8b3b22b5c8d7085b2_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTctMTAtMS0xLTE3ODY4_cb59a83d-76da-4554-9912-e95edbeec4c2">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63931e4da08749c89fc6a8bd235b4ef4_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTctMTItMS0xLTE3ODY4_92e52cba-65c3-46d8-ac87-352bbca3fa21">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d48c3bb559c4a829632103b69a3a872_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTgtMi0xLTEtMTc4Njg_d257d1a4-b706-4930-b504-c702104d25ce">667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f1f89cdf584d59a1701cdbbeead083_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTgtNC0xLTEtMTc4Njg_cde8ea4e-43ab-4d04-b175-2a46ad694322">773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if86c316bd32140fcb1db26b35d96f19a_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTgtNi0xLTEtMTc4Njg_72f4a2bb-c5da-48a4-9e6d-6fd20de1b0b5">1,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da5f32878ef4ff2bb7b73e8340888d3_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTgtOC0xLTEtMTc4Njg_afc66f88-03ec-4bf9-a6f0-3cf05a922970">580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85330517d5a14b5eb736122a3a5bcebc_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTgtMTAtMS0xLTE3ODY4_11980195-2bde-4000-afe5-ff8e096c7b49">823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i899221de84bb4f4da22a481ff4200823_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTgtMTItMS0xLTE3ODY4_430389b6-56a6-41cb-9336-edf2b482b409">1,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f3b2c7957554d658f3db970c6d6b430_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTktMi0xLTEtMTc4Njg_6b180882-aab6-41ab-bfed-adb80c2f631b">523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec90285d812f4f068310c71aedbc8afa_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTktNC0xLTEtMTc4Njg_d6f6004b-2537-4e5f-b72e-ba6541c29d2b">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152ee6da621e4956b226578681a95301_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTktNi0xLTEtMTc4Njg_f9af8c34-3d96-4b0b-aaf8-6a95a7e5c2d8">690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e8d82e7deaf4edbb04c1b33ba231943_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTktOC0xLTEtMTc4Njg_dccea81b-b117-4e33-bd17-d3ac79502059">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf482c8b62342cabd96a8f08883e08f_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTktMTAtMS0xLTE3ODY4_792f0246-1376-453a-a551-c90b9422261b">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdfc6bf7155d4385a0a3ab7ed7d09c3a_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTktMTItMS0xLTE3ODY4_88148155-f14d-4a7a-a7e4-806a0f5882e5">650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia12ba51821814d288ee081fbaa8ce473_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjAtMi0xLTEtMTc4Njg_71932dd6-5bc8-49ca-85f5-668b159aedab">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74fa6dbf7cce4f75b02f642d1f599489_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjAtNC0xLTEtMTc4Njg_ed3a6ec8-44c7-4cc9-9d34-d3c63323f2ca">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0df3bfdd84f14f64ba3f84ad0dc9a807_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjAtNi0xLTEtMTc4Njg_f6a6593b-003b-47b1-a79f-31067cc31ba5">1,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1935bf7c22124130bed4e1a214f63308_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjAtOC0xLTEtMTc4Njg_ba3b9676-fcdf-4ece-85d9-f67af0d6c185">684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedb59d3d7f814dd5a908dfbd889da9d7_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjAtMTAtMS0xLTE3ODY4_cad11e36-61e9-482d-8a66-797b5827afc4">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd1755cc8654a2692d559c24619a01b_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjAtMTItMS0xLTE3ODY4_0247d6d0-03df-47ac-a324-174c74f2e95a">1,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f0c0e2be49847eda32a1bc8f4a3d0a4_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjEtMi0xLTEtMTc4Njg_32781e36-cb80-4314-862e-02802cf9fdf6">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i603417b878634bc7b3c6c7e28e82df50_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjEtNC0xLTEtMTc4Njg_f189bfbc-7ea9-41d8-8413-db417e116328">667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30de540bbd614a38a4d9b0e11618a079_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjEtNi0xLTEtMTc4Njg_d2a8dbba-ec1b-4308-9419-9801a406158d">1,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46266d118c974a5aa2d9e68681b6b922_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjEtOC0xLTEtMTc4Njg_c97e79cd-514e-4549-ae65-3947de93aa7a">537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebd6bf1d71d4400b4815379954178a3_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjEtMTAtMS0xLTE3ODY4_459040fd-7605-4b20-ad32-b23243a32a21">654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b829deb2ae74f13a56fe33a45c6e829_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjEtMTItMS0xLTE3ODY4_5074636b-5b10-4728-ae02-65f26e5c1db7">1,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6e1e30c4e804011b00a91294e5115f6_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjItMi0xLTEtMTc4Njg_90aff5ad-9310-40d4-a1f6-c9924495847f">456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4463afae1e5544929d49ae0a34367c96_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjItNC0xLTEtMTc4Njg_1859794f-0043-4cae-8ba7-309b2d4e3482">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3476fa0ac234ff2842cfecc49b3e986_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjItNi0xLTEtMTc4Njg_20d2c6c7-21d4-4ad7-9de0-f9f1e34f6f2a">568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if64d98f713314bb9833a430722b4386d_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjItOC0xLTEtMTc4Njg_497293d4-d128-41f8-a926-eaa867b6514f">460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9857ddf749154af092177a27b3317c19_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjItMTAtMS0xLTE3ODY4_dc75ca70-24ca-4771-bb52-d7ad0eedcfe3">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18e9f36c179f44e3bfaec15ee0847c98_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjItMTItMS0xLTE3ODY4_c19dd138-c821-4c95-ac53-c6667ec106d5">584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3859aeb3184c430cad30ee39666a826e_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjMtMi0xLTEtMTc4Njg_19772cc9-61fe-42f6-8220-65a081eda951">1,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cd2a1a447c34980acee85e3b68e0919_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjMtNC0xLTEtMTc4Njg_5b5e52d4-d912-4168-9624-d4d47cd11d63">2,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37249fb3b9b7438bae34cc8f3ddc38da_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjMtNi0xLTEtMTc4Njg_5a0dc391-3b33-4701-8b4f-9562e0a84811">3,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82e117f9b22f4ad18dde00710f85564b_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjMtOC0xLTEtMTc4Njg_4db6ac6d-5123-4a8d-9352-ed1c3fb07dab">865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0deea721100d42d2aa599ecbc0b6ee95_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjMtMTAtMS0xLTE3ODY4_ba6bc13d-00e7-460a-96f2-3282cbd57e2c">2,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b80c5b0ee9422a85373b6736cab652_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjMtMTItMS0xLTE3ODY4_598ec29f-e745-4bc6-a54e-ec8466a49bf8">3,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08308c9f9c6a446496b0ba98a0a5fa36_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjQtMi0xLTEtMTc4Njg_0d1645bf-7f5e-45ad-880e-10b2247bbdd8">4,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6041fbdff4649fb80901f2a88fc9805_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjQtNC0xLTEtMTc4Njg_ffa851d9-5533-424e-9182-1b90b275a878">6,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i165fe1c62d6e440d91dc4abc8a0dee83_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjQtNi0xLTEtMTc4Njg_f5914f95-2609-4cbf-a3ba-de8f96788fbc">10,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i417cf26f3afb43a3a54f1bb81556fdd8_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjQtOC0xLTEtMTc4Njg_ce3b653d-6155-4dae-8780-01869691f32a">4,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25afbf02cb5a452089cc6973c24865ab_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjQtMTAtMS0xLTE3ODY4_b2167b6b-b820-43bc-bbc4-a9ebaaab70b5">6,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81462640315a4b09a820a1f604b6aa3d_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjQtMTItMS0xLTE3ODY4_78bed76c-7e0b-42d4-a9fe-d21e1b16b923">10,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic909cb81fa33496693b9dc997788164a_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjYtMi0xLTEtMTc4Njg_82b898ef-3fb6-4e73-8cc8-3d6e4b17b373">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4f114b62e84287ad7fc6130c023ad9_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjYtNC0xLTEtMTc4Njg_991c7fd7-f8c4-40fa-aa3c-167ab3ecf8ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic07c5110a61643c2a55c992dde280072_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjYtNi0xLTEtMTc4Njg_3090397a-eafe-4c15-af28-20b0daee11dc">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c1d47dd14647d0964914f96057eefe_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjYtOC0xLTEtMTc4Njg_81816501-4dbb-44a3-a928-650f5dc85d9e">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3382e3eaaaa846039edbe767cda3d3e8_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjYtMTAtMS0xLTE3ODY4_3a6a4acc-f76f-4bbe-a590-96c47b84e663">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b228ed718b140b2a339fb6308161ea7_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjYtMTItMS0xLTE3ODY4_c1d9ebff-3c1f-4076-bedb-a75050c3931f">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c7716e33994105b40cddd5474333b2_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjgtMi0xLTEtMTc4Njg_787e6ae7-4c60-431e-ae66-9065fbdd2c18">13,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69cecf5a94a046b59d942b45947a7002_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjgtNC0xLTEtMTc4Njg_db576f7f-7c66-42ab-9d4a-edc29f6ff752">19,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjgtNi0xLTEtMTc4Njg_7df016d0-a3e5-4633-91a0-e039ae0188cc">33,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf4171e1cd304992aba32032b32e09ae_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjgtOC0xLTEtMTc4Njg_80e7c619-7276-49b9-8a91-6c995e810615">11,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i991a1bda2a6e4464a4b0a7be66e27ead_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjgtMTAtMS0xLTE3ODY4_c7fcc1c6-95ff-45e0-b786-ce15a2cfb597">19,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjgtMTItMS0xLTE3ODY4_fe071a48-3818-40bf-83a8-c302d34486ab">31,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $<ix:nonFraction unitRef="usd" contextRef="id035b12c3f014d2bafdba8da0f64bb42_I20220930" decimals="-8" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RleHRyZWdpb246NTk4ZmI2NzViZjI0NDFkNGIyNmU1NDAxODY3ZjA0MjRfMjE2_c163c48e-ae8a-4e4c-ad91-bf8d2273cd84">3.9</ix:nonFraction> billion in the Diagnostics segment and approximately $<ix:nonFraction unitRef="usd" contextRef="i62bee42564544f0d9b3280c51a9cc02c_I20220930" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RleHRyZWdpb246NTk4ZmI2NzViZjI0NDFkNGIyNmU1NDAxODY3ZjA0MjRfMjY0_38900cec-1a85-469e-8554-bad076659224">433</ix:nonFraction> million in the Medical Devices segment. Abbott expects to recognize revenue on approximately <ix:nonFraction unitRef="number" contextRef="i0c7dafe2cfba49daa19fb3f0283b449f_D20220101-20220930" decimals="2" name="abt:RevenueRemainingPerformanceObligationExpectedTimingPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RleHRyZWdpb246NTk4ZmI2NzViZjI0NDFkNGIyNmU1NDAxODY3ZjA0MjRfMzUy_2896d2e3-134c-4dd8-9c56-edec2d5f1b23">60</ix:nonFraction> percent of these remaining performance obligations over the next <ix:nonNumeric contextRef="i20fe539eb4a74b7492123682cd84ae45_I20220930" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RleHRyZWdpb246NTk4ZmI2NzViZjI0NDFkNGIyNmU1NDAxODY3ZjA0MjRfNDEy_bdf2e747-1b03-423f-9dae-434b2d29bfbc">24</ix:nonNumeric> months, approximately <ix:nonFraction unitRef="number" contextRef="i22df9ace730b4d42bc4be5744f0a1bad_D20220101-20220930" decimals="2" name="abt:RevenueRemainingPerformanceObligationExpectedTimingPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RleHRyZWdpb246NTk4ZmI2NzViZjI0NDFkNGIyNmU1NDAxODY3ZjA0MjRfNDMw_ec2d6411-b881-4ab1-b351-d713f1d2f162">16</ix:nonFraction> percent over the subsequent <ix:nonNumeric contextRef="i6aa796dac9664691b74441abe1256b0d_I20220930" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RleHRyZWdpb246NTk4ZmI2NzViZjI0NDFkNGIyNmU1NDAxODY3ZjA0MjRfNDUz_16bc1452-0e8b-4828-ab61-6f03c0cf2a46">12</ix:nonNumeric> months and the remainder thereafter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 2 &#8212; Revenue (Continued)</span></div></div><ix:continuation id="i74d4f46252be4c6a89738bbafb96b408"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Contract Assets and Liabilities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott&#8217;s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott&#8217;s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RleHRyZWdpb246NTk4ZmI2NzViZjI0NDFkNGIyNmU1NDAxODY3ZjA0MjRfMTg3OQ_6f927f22-fed9-4686-a382-6c2aabbe19da" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the contract liabilities during the period are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmVlOTUxMzI1ZTQ0NDQyYzRhOWU5ZTE0MWVlODM0YzIwL3RhYmxlcmFuZ2U6ZWU5NTEzMjVlNDQ0NDJjNGE5ZTllMTQxZWU4MzRjMjBfMi0yLTEtMS0xNzg2OA_b9cc1ffa-842e-47b4-b093-a198dde4e01a">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue from cash received during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="abt:ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmVlOTUxMzI1ZTQ0NDQyYzRhOWU5ZTE0MWVlODM0YzIwL3RhYmxlcmFuZ2U6ZWU5NTEzMjVlNDQ0NDJjNGE5ZTllMTQxZWU4MzRjMjBfMy0yLTEtMS0xNzg2OA_be99e087-87b8-4321-915a-93e819be7ec0">466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized related to contract liability balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmVlOTUxMzI1ZTQ0NDQyYzRhOWU5ZTE0MWVlODM0YzIwL3RhYmxlcmFuZ2U6ZWU5NTEzMjVlNDQ0NDJjNGE5ZTllMTQxZWU4MzRjMjBfNC0yLTEtMS0xNzg2OA_07438b7a-3e82-4abe-959a-db0f1b9cf3f8">508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmVlOTUxMzI1ZTQ0NDQyYzRhOWU5ZTE0MWVlODM0YzIwL3RhYmxlcmFuZ2U6ZWU5NTEzMjVlNDQ0NDJjNGE5ZTllMTQxZWU4MzRjMjBfNS0yLTEtMS0xNzg2OA_a67b1a71-4cb6-44b0-8401-dbd687230e05">478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_43"></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfMjYxOQ_d020f982-eae9-4666-b372-f190ed8c88ae" continuedAt="ibd43799381a14c82b612d79b6038a660" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 3 &#8212; Supplemental Financial Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended September&#160;30, 2022 and 2021 were $<ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfNDA5_7f167e19-6fd6-457f-b92c-c96f8576520a">1.429</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfNDE2_4d5122b2-0e88-44bf-b06c-2c86ea7abbe3">2.092</ix:nonFraction> billion, respectively, and for the nine months ended September&#160;30, 2022 and 2021 were $<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfNDc3_775f9915-38c2-45c1-bd8f-6faa9c5d5d3a">5.876</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfNDg0_82db709c-e95e-4904-af0e-fb730409342c">5.061</ix:nonFraction> billion, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first nine months of 2022 includes $<ix:nonFraction unitRef="usd" contextRef="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfNjQ1_278b8bcf-e920-491c-9794-6cb07b8fd9dc">362</ix:nonFraction> million of pension contributions and the payment of cash taxes of approximately $<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsForOtherTaxes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfNzIw_220dd95c-8eac-4f4e-956f-50d8fd62c2d4">987</ix:nonFraction> million. The first nine months of 2021 includes $<ix:nonFraction unitRef="usd" contextRef="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfNzU5_bd9c3f60-2dd0-44be-98a5-d4da3d8ec241">366</ix:nonFraction> million of pension contributions and the payment of cash taxes of approximately $<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsForOtherTaxes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfODM0_cd8f7848-8951-4b8f-b5d6-e66fdaa6862e">990</ix:nonFraction> million.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfMjYyMA_c8444ec8-24aa-482c-b3ab-1f28d1554806" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity for the first nine months of 2022 related to the allowance for doubtful accounts as of September&#160;30, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for Doubtful Accounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOjNmMjliZWM2Nzg2NjRkNWNiYTRhYTA0NGNhN2M5NjZkL3RhYmxlcmFuZ2U6M2YyOWJlYzY3ODY2NGQ1Y2JhNGFhMDQ0Y2E3Yzk2NmRfMi0yLTEtMS0xNzg2OA_4eee6650-5408-4ebb-a84e-2591a2454d93">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions/charges to income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOjNmMjliZWM2Nzg2NjRkNWNiYTRhYTA0NGNhN2M5NjZkL3RhYmxlcmFuZ2U6M2YyOWJlYzY3ODY2NGQ1Y2JhNGFhMDQ0Y2E3Yzk2NmRfMy0yLTEtMS0xNzg2OA_e9fe7f72-422c-4d94-a354-4bd2582f87a3">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged off and other deductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOjNmMjliZWM2Nzg2NjRkNWNiYTRhYTA0NGNhN2M5NjZkL3RhYmxlcmFuZ2U6M2YyOWJlYzY3ODY2NGQ1Y2JhNGFhMDQ0Y2E3Yzk2NmRfNC0yLTEtMS0xNzg2OA_9e2d7a12-9ffc-4945-a9f3-7370048b4f23">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOjNmMjliZWM2Nzg2NjRkNWNiYTRhYTA0NGNhN2M5NjZkL3RhYmxlcmFuZ2U6M2YyOWJlYzY3ODY2NGQ1Y2JhNGFhMDQ0Y2E3Yzk2NmRfNS0yLTEtMS0xNzg2OA_c3d3225a-8fd7-4bff-8b96-51c8f7d71fc8">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 3 &#8212; Supplemental Financial Information (Continued)</span></div></div><ix:continuation id="ibd43799381a14c82b612d79b6038a660"><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="abt:ScheduleOfLongTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfMjYyMQ_ec5b701b-2b47-4a87-b6aa-895c6b0b6c8d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term investments as of September&#160;30, 2022 and December&#160;31, 2021 are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b3500e4f5c4314a3d8cf6b4089c98e_I20220930" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOmE3N2U5ZDc3NzlmMDQ2MGJhNTVlOWE0ZGQwNmIzZDQ0L3RhYmxlcmFuZ2U6YTc3ZTlkNzc3OWYwNDYwYmE1NWU5YTRkZDA2YjNkNDRfMi0yLTEtMS0xNzg2OA_b8366d7e-acc8-4f7b-94d9-841c7c2b25f9">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d0dbddbfdc84cd0ab7a31f5e8fdf16e_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOmE3N2U5ZDc3NzlmMDQ2MGJhNTVlOWE0ZGQwNmIzZDQ0L3RhYmxlcmFuZ2U6YTc3ZTlkNzc3OWYwNDYwYmE1NWU5YTRkZDA2YjNkNDRfMi00LTEtMS0xNzg2OA_86e215eb-f687-4739-a755-b6fb1fdad660">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7c97d1edcfa444cb20aa7be67ab0d50_I20220930" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOmE3N2U5ZDc3NzlmMDQ2MGJhNTVlOWE0ZGQwNmIzZDQ0L3RhYmxlcmFuZ2U6YTc3ZTlkNzc3OWYwNDYwYmE1NWU5YTRkZDA2YjNkNDRfMy0yLTEtMS0xNzg2OA_e3516eaa-18d1-4fec-8abf-11cd80ea4f22">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fa4384e8a504eeda1c27de655e4e9d5_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOmE3N2U5ZDc3NzlmMDQ2MGJhNTVlOWE0ZGQwNmIzZDQ0L3RhYmxlcmFuZ2U6YTc3ZTlkNzc3OWYwNDYwYmE1NWU5YTRkZDA2YjNkNDRfMy00LTEtMS0xNzg2OA_8d64141f-ab76-4ce0-beff-f92032fbc89a">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOmE3N2U5ZDc3NzlmMDQ2MGJhNTVlOWE0ZGQwNmIzZDQ0L3RhYmxlcmFuZ2U6YTc3ZTlkNzc3OWYwNDYwYmE1NWU5YTRkZDA2YjNkNDRfNC0yLTEtMS0xNzg2OA_3012285c-739a-48e0-818f-d107ad7ed1ee">764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOmE3N2U5ZDc3NzlmMDQ2MGJhNTVlOWE0ZGQwNmIzZDQ0L3RhYmxlcmFuZ2U6YTc3ZTlkNzc3OWYwNDYwYmE1NWU5YTRkZDA2YjNkNDRfNC00LTEtMS0xNzg2OA_93a66f02-78d6-42f9-a7f9-8b8c3ed66a70">816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Abbott&#8217;s long-term investments as of September&#160;30, 2022 versus the balance as of December&#160;31, 2021 primarily relates to a decrease in the value of investments held in a rabbi trust and the impact of equity method investment losses partially offset by an investment in long-term time deposits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott&#8217;s equity securities as of September&#160;30, 2022, include $<ix:nonFraction unitRef="usd" contextRef="i3b879570db6940ef8d990b6465f15c41_I20220930" decimals="-6" name="us-gaap:CommonStockSharesHeldInEmployeeTrust" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfMTk0OQ_0fd4e1fc-88a4-4802-84a2-2f3f1ae1c1db">285</ix:nonFraction> million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott also holds certain investments as of September&#160;30, 2022 with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfMjQzMw_60a4b336-2159-40d4-9425-2a63d7444af0">228</ix:nonFraction> million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfMjU2NQ_19017287-1837-4c0e-b853-492911bf73ab">83</ix:nonFraction> million that do not have a readily determinable fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2021, Abbott acquired <ix:nonFraction unitRef="number" contextRef="i3f5a2e21895448f88c750459f871dbf2_I20210930" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfMTA5OTUxMTYzMTkxMg_3386aac9-caf5-46b6-b0e5-591932c865e9">100</ix:nonFraction> percent of Walk Vascular, LLC (Walk Vascular), a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots. The purchase price, the allocation of acquired assets and liabilities, and the revenue and net income contributed by Walk Vascular since the date of acquisition are not material to Abbott&#8217;s condensed consolidated financial statements.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_46"></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RleHRyZWdpb246OTBiODVhZTJhNTRiNDM5Nzg3ZTRjZGEyOWY5MmVkZThfMzI4_ea9eb664-e529-42c3-b8e2-f53aa9e520d4" continuedAt="i6400bf2f530840478a072911bec61c85" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 4 &#8212; Changes In Accumulated Other Comprehensive Income (Loss)</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RleHRyZWdpb246OTBiODVhZTJhNTRiNDM5Nzg3ZTRjZGEyOWY5MmVkZThfMzI5_1f4ac7ee-ff5b-48d5-8b24-a189d9b85dd6" continuedAt="iaa140daa000c4d2fb0793c42ca9b5305" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow<br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i495e1acb6ab646e1be98f86d888adf7c_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfMy0yLTEtMS0xNzg2OA_944bc75c-0416-4b66-8f65-9d2d29cf25c0">6,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11d15dbdba194d4ea258e34ec953d6bd_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfMy00LTEtMS0xNzg2OA_6b3422dc-c5b5-4536-b852-d67fd1df40e4">5,230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i415827a77ac0453d839b9593bd2f924c_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfMy02LTEtMS0xNzg2OA_75c8881e-0dcc-44c8-a39e-968a3b496902">2,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1fe447f6ae64a75be725ca40d0bc9da_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfMy04LTEtMS0xNzg2OA_19a14b12-7bad-44e6-9659-07b21c1e158e">3,738</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i964adde7ff6b4fdc8165d93476caeb82_I20220630" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfMy0xMC0xLTEtMTc4Njg_cd05e8ed-0ff0-4688-a31d-ff4c67c1432a">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie15dbca7371a44c29034f90ed736efd2_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfMy0xMi0xLTEtMTc4Njg_8782d622-5d62-4d2b-ba7e-212159b78356">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd59cc26c1dd433798bec018b3ccbb28_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNC0yLTEtMS0xNzg2OA_bc7b122d-d99e-4305-8392-d653c3103e24">1,008</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1aa011bcd53148e7baa700ba02afe7ec_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNC00LTEtMS0xNzg2OA_13f6dba0-f9d1-4be4-9d90-2d65aca823c6">391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e4add20e234af2a1a931e4e20817bf_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNC02LTEtMS0xNzg2OA_70611886-8063-4a2e-9837-f02263d027dd">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9696538c691b42caac0b357c13f12bac_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNC04LTEtMS0xNzg2OA_4df67708-f62a-4178-9395-e7c3c15df21a">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0af11ae9ab4bbcacc64379488edc44_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNC0xMC0xLTEtMTc4Njg_c853acd4-e95f-4b41-abf8-9a692eb52819">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e81d4049c794423a14e1d1c1af22cc7_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNC0xMi0xLTEtMTc4Njg_12ac57e7-1d89-48fc-8a59-180da44fb8b5">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd59cc26c1dd433798bec018b3ccbb28_D20220701-20220930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNS0yLTEtMS0xNzg2OA_d26695ef-d7cb-4ea3-b801-819684fe7773">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aa011bcd53148e7baa700ba02afe7ec_D20210701-20210930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNS00LTEtMS0xNzg2OA_b967fd0e-a1a2-4300-8481-b679eeb78815">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e4add20e234af2a1a931e4e20817bf_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNS02LTEtMS0xNzg2OA_cecb695a-6a3f-45f6-ac32-57d9b9e515bd">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9696538c691b42caac0b357c13f12bac_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNS04LTEtMS0xNzg2OA_8cc5f078-acce-4d03-9a48-406e16fb7e3e">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e0af11ae9ab4bbcacc64379488edc44_D20220701-20220930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNS0xMC0xLTEtMTc4Njg_c47627b3-0f92-4e1a-abfe-359ec3f68b52">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e81d4049c794423a14e1d1c1af22cc7_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNS0xMi0xLTEtMTc4Njg_7f2b4d25-fbc5-49b1-a70d-e8b49422bc76">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd59cc26c1dd433798bec018b3ccbb28_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNi0yLTEtMS0xNzg2OA_46a6e248-333f-4be4-9cc7-15c3056a7c3c">1,008</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1aa011bcd53148e7baa700ba02afe7ec_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNi00LTEtMS0xNzg2OA_be555c3e-f9d4-420e-af74-b45ebf322c79">391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e4add20e234af2a1a931e4e20817bf_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNi02LTEtMS0xNzg2OA_48468a9d-21ad-4388-94ac-afe1b8e9cb78">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9696538c691b42caac0b357c13f12bac_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNi04LTEtMS0xNzg2OA_a27187a6-5220-4868-babb-955383f28d9f">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0af11ae9ab4bbcacc64379488edc44_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNi0xMC0xLTEtMTc4Njg_8447eb5a-4cce-4e52-b909-abf8f9df2b34">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e81d4049c794423a14e1d1c1af22cc7_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNi0xMi0xLTEtMTc4Njg_27796e6f-212f-47ca-bd91-ea50c188db19">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i427e7206d73746e6898e10c2092b8bbc_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNy0yLTEtMS0xNzg2OA_8d697180-bad7-4216-a9c1-a1e6298926e8">7,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i967b4d49862b4a9c90ab0df452b406c3_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNy00LTEtMS0xNzg2OA_c07af5ee-1d29-466e-8096-e8e53b03a395">5,621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i819bcaf6924348468ba7ae6973f92309_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNy02LTEtMS0xNzg2OA_42f596c3-b5ca-4b9d-aa70-151e0b229fa8">2,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95867ab5ff4a46c2b64acfbbad20d613_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNy04LTEtMS0xNzg2OA_117de8c2-61af-4923-8334-9636982daf84">3,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23ed49d742db4ba5b2f23508085a61cb_I20220930" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNy0xMC0xLTEtMTc4Njg_f338971c-27c9-4c5d-bceb-93c056d2735f">321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4466aaca90a4878b4208479546c953a_I20210930" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNy0xMi0xLTEtMTc4Njg_9b90d0f8-6375-470c-9d5a-ce060d0eef9e">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 4 &#8212; Changes In Accumulated Other Comprehensive Income (Loss) (Continued)</span></div></div><ix:continuation id="i6400bf2f530840478a072911bec61c85"><div><ix:continuation id="iaa140daa000c4d2fb0793c42ca9b5305"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow <br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i874ac07585e34b5781c671c1bc0b74c1_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfMy0yLTEtMS0xNzg2OA_cd6496e9-f33f-450f-90b6-72bc2e91f788">5,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cdf5c348d5b4b53b9a6c86bb4a3e3c6_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfMy00LTEtMS0xNzg2OA_238708dc-65a2-41cc-bc06-f27057150c3a">4,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e549a342ce24de7b2b4542ffdabcbee_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfMy02LTEtMS0xNzg2OA_dfe19359-3673-4f37-935f-b4e0112bb2a7">2,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7de505469f274ea4a34eb536d8434973_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfMy04LTEtMS0xNzg2OA_4ff1a730-0b3d-4789-a10b-a197538e5d01">3,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c966c996c54468f969135a6a97d474a_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfMy0xMC0xLTEtMTc4Njg_000316c0-59de-46bb-913b-617f2e027c72">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6e9ff01f8fd42f38aa515217549336f_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfMy0xMi0xLTEtMTc4Njg_7a1cbb41-1bf9-4a7c-b042-af356e44f71f">216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaba0b25f7ac490d965f16df9dcbf02c_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNC0yLTEtMS0xNzg2OA_7d6f966a-044a-48ce-b6e8-3e13157ec25c">1,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9341a3223163491aafcd6fe2d673a55a_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNC00LTEtMS0xNzg2OA_0d5a4a95-4a44-4bc9-8be3-52166e687891">762</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if502b2d6402f4818a6bd6e4dd318d573_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNC02LTEtMS0xNzg2OA_0e3fe1d4-86c9-4b06-bd23-f07ac971f1c0">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede3d406d2714638aca592a7412cf559_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNC04LTEtMS0xNzg2OA_736ff874-153f-4eda-82b1-82e3f6c5eb59">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f21a35a5f64266baecf8e128ca0727_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNC0xMC0xLTEtMTc4Njg_b780efa6-8375-4170-98a4-82cf9a47e713">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2212cc9951e446de85154e63b59c05bc_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNC0xMi0xLTEtMTc4Njg_8101cc24-6fc6-423e-8fa3-d9cf1d8d812e">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaba0b25f7ac490d965f16df9dcbf02c_D20220101-20220930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNS0yLTEtMS0xNzg2OA_750fdd57-5cdd-4085-8df0-b301893b4feb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9341a3223163491aafcd6fe2d673a55a_D20210101-20210930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNS00LTEtMS0xNzg2OA_f3658d13-52ca-406c-8b11-ccc8ad4692df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if502b2d6402f4818a6bd6e4dd318d573_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNS02LTEtMS0xNzg2OA_7b37f394-e6fb-4ac7-bda4-25f088554699">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede3d406d2714638aca592a7412cf559_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNS04LTEtMS0xNzg2OA_686cb904-a70c-439b-9bd3-1962838b817a">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65f21a35a5f64266baecf8e128ca0727_D20220101-20220930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNS0xMC0xLTEtMTc4Njg_9259907c-6f65-4073-af73-d5487f7489b7">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2212cc9951e446de85154e63b59c05bc_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNS0xMi0xLTEtMTc4Njg_00f1aa9e-1b24-4473-bfd7-e397e53ed7d8">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaba0b25f7ac490d965f16df9dcbf02c_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNi0yLTEtMS0xNzg2OA_65274006-b28f-4cb1-ac85-c3abf1991f45">1,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9341a3223163491aafcd6fe2d673a55a_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNi00LTEtMS0xNzg2OA_4c3fb4cf-4b77-40aa-847e-f26707b93531">762</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if502b2d6402f4818a6bd6e4dd318d573_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNi02LTEtMS0xNzg2OA_dd3b6dd9-a5a0-4681-801b-6b1ad3f14323">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede3d406d2714638aca592a7412cf559_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNi04LTEtMS0xNzg2OA_cc0ae5a9-4d1d-4de3-b01b-d7a235c14240">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f21a35a5f64266baecf8e128ca0727_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNi0xMC0xLTEtMTc4Njg_ada4bf9b-0053-43be-aaf9-fa419721c171">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2212cc9951e446de85154e63b59c05bc_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNi0xMi0xLTEtMTc4Njg_50a8bfe0-6876-42b9-8b62-c43bd330e378">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i427e7206d73746e6898e10c2092b8bbc_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNy0yLTEtMS0xNzg2OA_e06108e6-1bf0-4c09-b459-2707052acad4">7,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i967b4d49862b4a9c90ab0df452b406c3_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNy00LTEtMS0xNzg2OA_e1523175-aa44-475d-bb8a-9c674df1d07b">5,621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i819bcaf6924348468ba7ae6973f92309_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNy02LTEtMS0xNzg2OA_fc3a811a-5dfa-41c0-a16f-bb67c3fcc163">2,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95867ab5ff4a46c2b64acfbbad20d613_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNy04LTEtMS0xNzg2OA_a87f2903-f37f-4f70-90c6-52d263d78fed">3,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23ed49d742db4ba5b2f23508085a61cb_I20220930" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNy0xMC0xLTEtMTc4Njg_8c8b5a7c-b0e8-4084-9d74-87e97556453d">321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4466aaca90a4878b4208479546c953a_I20210930" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNy0xMi0xLTEtMTc4Njg_596228f8-9898-4946-8283-4263ceefe0e0">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 11 for additional details.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_49"></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfMTEwNA_6e7a4b90-9c95-4b67-8a47-2ccfac0ced47" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 5 &#8212; Goodwill and Intangible Assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of goodwill reported was $<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-8" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNTE_07ee8472-abbc-43aa-a2fa-a4fd0c80669f">22.3</ix:nonFraction> billion at September&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-8" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNjQ_3750c554-ec61-4297-9ceb-a06538de4b1c">23.2</ix:nonFraction> billion at December&#160;31, 2021. Foreign currency translation adjustments decreased goodwill by approximately $<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfMTQ0_e8487b72-b2b8-448e-9f40-45bb237cee6b">946</ix:nonFraction> million in the first nine months of 2022. The amount of goodwill related to reportable segments at September&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i4be71fc1af9b4576bbbec0f3973e74bc_I20220930" decimals="-8" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfMjQx_4d9ab0ce-c517-4467-b223-a508020cab1a">2.6</ix:nonFraction> billion for the Established Pharmaceutical Products segment, $<ix:nonFraction unitRef="usd" contextRef="i8d3eeb93a75a4a2cbd31ad08fd494ee9_I20220930" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfMjk3_d02bdf54-060c-490a-b8a6-fdab58103a2e">286</ix:nonFraction> million for the Nutritional Products segment, $<ix:nonFraction unitRef="usd" contextRef="id035b12c3f014d2bafdba8da0f64bb42_I20220930" decimals="-8" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfMzM4_25d412ad-a7a7-44ce-97e6-5839110ef176">3.5</ix:nonFraction> billion for the Diagnostic Products segment, and $<ix:nonFraction unitRef="usd" contextRef="i62bee42564544f0d9b3280c51a9cc02c_I20220930" decimals="-8" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfMzgy_66887fae-9cf5-4eb7-92ea-73184b6e40d2">15.9</ix:nonFraction> billion for the Medical Devices segment. There was <ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-8" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNDI4_a1185aac-9a0a-4746-8165-1ea8fd2aa0d5">no</ix:nonFraction> reduction of goodwill relating to impairments in the first nine months of 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross amount of amortizable intangible assets, primarily product rights and technology, was $<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNjA0_5bf81dfa-e0e5-43ad-9514-1bb7e342e9d1">26.9</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNjEx_c29141aa-f735-4e6e-9403-f2e61e862bd8">27.7</ix:nonFraction> billion as of September&#160;30, 2022 and December&#160;31, 2021, respectively. Accumulated amortization was $<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNjc0_b44e55aa-51cd-420d-9ea1-4f73f07d49c9">16.9</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNjgx_470649d6-aa41-401f-a30f-fe22274187a4">15.9</ix:nonFraction> billion as of September&#160;30, 2022 and  December&#160;31, 2021, respectively. Foreign currency translation adjustments decreased intangible assets by $<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNzgx_00ed8de0-fc85-47f4-af4c-2e3e408e0fe0">250</ix:nonFraction> million in the first nine months of 2022. Abbott&#8217;s estimated annual amortization expense for intangible assets is approximately $<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfOTAw_7662b1c2-4a7a-40d4-8109-6a4b2479323d">2.1</ix:nonFraction> billion in 2022, $<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfOTEw_4a4bc219-6ca5-4837-bf70-41e8a7eadbe1">2.0</ix:nonFraction> billion in 2023, $<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfOTIw_2eb61dd3-d38e-4197-81ad-c505889da09b">1.9</ix:nonFraction> billion in 2024, $<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfOTMw_1e246181-c983-4ba3-9908-d06db636b389">1.7</ix:nonFraction> billion in 2025 and $<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfOTQz_e06eb8f5-2931-4a50-ae7b-6bbc51178786">1.6</ix:nonFraction> billion in 2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, which relate to in-process R&amp;D (IPR&amp;D) acquired in a business combination, were approximately $<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfMTA4NA_cc138054-ce7f-412c-915f-ac7c097cb5f8">807</ix:nonFraction> million as of September&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNTQ5NzU1ODE2NzA1_190759e6-d3e1-4f11-ba53-f58212c12e46">919</ix:nonFraction> million as of December&#160;31, 2021. In the third quarter of 2022, $<ix:nonFraction unitRef="usd" contextRef="id2602c6bfcec4afcb539d839ccd375bd_D20220701-20220930" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNTQ5NzU1ODE2NzYw_8ee0209a-c604-4a75-922f-b7e420d58fb4">111</ix:nonFraction> million of impairment charges were recorded on the Research and development line of the Condensed Consolidated Statement of Earnings related to certain IPR&amp;D intangible assets associated with the Medical Devices business segment.</span></div></ix:nonNumeric><div><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_52"></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfMjIwNQ_3b7cd385-825b-4fc2-8a17-b06e92fed488" continuedAt="i4566f86a69f44380a834d0ba2fbab7d8" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 6 &#8212; Restructuring Plans </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2021, Abbott management approved a restructuring plan related to its Diagnostic Products segment to align its manufacturing network for COVID-19 diagnostic tests with changes in the second quarter in projected testing demand driven by several factors, including significant reductions in cases in the U.S. and other major developed countries, the accelerated rollout of COVID-19 vaccines globally and the U.S. health authority&#8217;s updated guidance on testing for fully vaccinated individuals. In the second quarter of 2021, Abbott recorded charges of $<ix:nonFraction unitRef="usd" contextRef="ib718c9002df547a9bb6009289d5ab871_D20210401-20210630" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfNTY4_f2dbab42-f604-42e7-9304-5c53a03a3bee">499</ix:nonFraction> million under this plan in Cost of products sold. The charge recognized in the second quarter of 2021 included fixed asset write-downs of $<ix:nonFraction unitRef="usd" contextRef="i73865c3e534643d5ab15aa1266d200db_D20210401-20210630" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfNjkz_97c67cf5-f5da-4130-80ec-beb198ea0e1d">80</ix:nonFraction> million, inventory-related charges of $<ix:nonFraction unitRef="usd" contextRef="i32e1a3f5ab2a404ca01cc18696529902_D20210401-20210630" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfNzI2_50e83982-b910-4bfe-bcca-bb8639aa661c">248</ix:nonFraction> million, and other exit costs, which included contract cancellations and employee-related costs of $<ix:nonFraction unitRef="usd" contextRef="i36df938cc26341c18a1b3e9570bcec52_D20210401-20210630" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfODIw_21fb5400-d061-46cd-a5f5-e21862bf5e38">171</ix:nonFraction> million.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 6 &#8212; Restructuring Plans (Continued)</span></div></div><ix:continuation id="i4566f86a69f44380a834d0ba2fbab7d8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second half of 2021, as the Delta and Omicron variants of COVID-19 spread and the number of new COVID-19 cases increased significantly, particularly in the U.S., demand for rapid COVID-19 tests increased significantly. As a result, in the second half of 2021, Abbott sold approximately $<ix:nonFraction unitRef="usd" contextRef="i53e8568bc39d4cb19a2c23541737716d_D20210701-20211231" decimals="-6" name="abt:InventoryNoNetRealizableValueSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfMTExMA_588d2af8-fee1-47e6-9ce0-ca108512834e">181</ix:nonFraction> million of inventory that was previously estimated to have no net realizable value under the second quarter of 2021 restructuring action. In addition, the estimate of other exit costs was reduced by a net $<ix:nonFraction unitRef="usd" contextRef="i527c49b1d22240058f22784151a891f3_D20210701-20211231" decimals="-6" name="us-gaap:RestructuringReserveAccrualAdjustment1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfMTMwOA_7ba68bd0-89fa-4ca4-9638-6d6f304c968c">58</ix:nonFraction> million as Abbott fulfilled its purchase obligations under certain contracts for which a liability was recorded in the second quarter of 2021 or Abbott settled with the counterparty in the second half of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfMjIwNg_f6622cdf-705d-4e59-982a-006516c2e1f3" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity related to this restructuring action and the status of the related accruals as of September&#160;30, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inventory-<br/>Related<br/>Charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Asset<br/>Write-Downs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Exit<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges recorded in 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5061818384c4b19aae354446d336fd1_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMS0yLTEtMS0xNzg2OA_dbf1d7bf-42f4-4010-832f-6456d2f3906e">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c70ec7c6d944192a4c8aaf8042cb9f6_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMS00LTEtMS0xNzg2OA_c7101023-61b3-49c2-b594-2516a3defcaa">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d67be86a0834dfeb506f82b11589377_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMS02LTEtMS0xNzg2OA_3fe043c7-615b-408e-8952-e5c208f4d390">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd32e0ec232449a093586b6ac423eb4f_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMS04LTEtMS0xNzg2OA_56b89738-04a3-4b78-aeda-1b1b22c5f690">441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5061818384c4b19aae354446d336fd1_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMi0yLTEtMS0xNzg2OA_a6cb6480-0950-4275-b9bb-479b5c874082">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c70ec7c6d944192a4c8aaf8042cb9f6_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMi00LTEtMS0xNzg2OA_b99ee32c-6f2b-4e3a-b3f7-6d76b5ff46e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d67be86a0834dfeb506f82b11589377_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMi02LTEtMS0xNzg2OA_b01a3f9a-6573-4bf6-910a-d65fc7bbd29e">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd32e0ec232449a093586b6ac423eb4f_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMi04LTEtMS0xNzg2OA_15ac5427-6e0e-4543-ad77-cefefa1f860d">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5061818384c4b19aae354446d336fd1_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMy0yLTEtMS0xNzg2OA_d85658fc-f1c6-49f7-90f6-e69463b22def">248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c70ec7c6d944192a4c8aaf8042cb9f6_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMy00LTEtMS0xNzg2OA_70c03f43-7867-472e-b960-d37869990a54">80</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d67be86a0834dfeb506f82b11589377_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMy02LTEtMS0xNzg2OA_4b845dc7-70dc-436f-9782-7b8c7b2adb73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd32e0ec232449a093586b6ac423eb4f_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMy04LTEtMS0xNzg2OA_345935cf-baa9-45fa-9f8e-d5502bb2ef35">328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b41672050b4f62a5208c5e716d43f1_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNC0yLTEtMS0xNzg2OA_909c6a74-8e99-49b7-9165-119f85c998ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901a35e981d14756b34a5adff1083cf4_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNC00LTEtMS0xNzg2OA_8201df6c-c1ba-4de2-8c66-8cb658d61329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7235f22a8e74924b42a859bb232635a_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNC02LTEtMS0xNzg2OA_70a0aeb0-f00c-43a3-99ab-da3ff86b1aa9">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifda673e60ee8405ea4371f6fba8fc86f_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNC04LTEtMS0xNzg2OA_b9cecad7-8b79-4dd6-8618-5aeba357b79b">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d18df850f834757a75a53bf2cdc1ca9_D20220101-20220930" decimals="-6" name="abt:RestructuringReservePeriodCashSettledAndOtherAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNS0yLTEtMS0xNzg2OA_a65a4fa2-48e3-4206-a264-b3f6b6d24b8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eef48e6721d4174ad61b0c4bacfd4ef_D20220101-20220930" decimals="-6" name="abt:RestructuringReservePeriodCashSettledAndOtherAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNS00LTEtMS0xNzg2OA_2203da1d-f654-4a0e-ae38-3bcb32ab77b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dfe1081e2a7492d8113f7b5208ba611_D20220101-20220930" decimals="-6" name="abt:RestructuringReservePeriodCashSettledAndOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNS02LTEtMS0xNzg2OA_948ae90c-8d93-409c-8eab-ff57800550ba">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e0db81ff25a4a54b0211447d6b1257a_D20220101-20220930" decimals="-6" name="abt:RestructuringReservePeriodCashSettledAndOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNS04LTEtMS0xNzg2OA_4f2c1a23-9b8a-443c-9832-c01c89d8825a">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic210a4881e7a4bfc8506d1330434b1b9_I20220930" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNi0yLTEtMS0xNzg2OA_0d6967d0-6c09-4e79-9ffd-2712341bb62b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8624555d304424fb6b08adc08120a68_I20220930" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNi00LTEtMS0xNzg2OA_b6c2bd80-0174-4734-ab66-3b1000ff6d17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ba1fc8cda234a89b835a4e348ba3cef_I20220930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNi02LTEtMS0xNzg2OA_46e71149-cfaf-4ddc-b93f-557dd40e76b5">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562dbdedf98e492987bde41c83f41e48_I20220930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNi04LTEtMS0xNzg2OA_9960eae0-0e99-4fc2-90af-4c2abce64781">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in Abbott&#8217;s diagnostic, established pharmaceutical, and nutritional businesses. In 2022 and 2021, Abbott management approved plans to streamline operations in its medical devices segment. Abbott recorded employees-related severance and other charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i4794a110deb7433cbee3148cdeb358b8_D20220101-20220930" decimals="-6" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfOTg5NTYwNDY1Mjk4NA_ffa08c3f-99e1-4a98-b4e0-ba126b3acf1d">12</ix:nonFraction> million in the first nine months of 2022 of which approximately $<ix:nonFraction unitRef="usd" contextRef="ibabb70918fa246128ee74b2f2f3ccaf0_D20220101-20220930" decimals="-6" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfOTg5NTYwNDY1MzAxNA_86108081-beea-4a46-8620-9f1f29735960">5</ix:nonFraction>&#160;million was recorded in Cost of products sold, approximately $<ix:nonFraction unitRef="usd" contextRef="i83f541eac1144e6bba42b451c74c7720_D20220101-20220930" decimals="-6" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfOTg5NTYwNDY1MzAzMg_3527cafc-5145-4099-8c7c-7f499d606dd2">2</ix:nonFraction> million was recorded in Research and development, and approximately $<ix:nonFraction unitRef="usd" contextRef="ie2df776b1f8948a8af5d5968a2f003d9_D20220101-20220930" decimals="-6" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfOTg5NTYwNDY1MzA0OA_05fd476a-2d26-4c88-8bf6-340d90c91cc3">5</ix:nonFraction>&#160;million was recorded in Selling, general and administrative expense.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfMjIwNw_49910d3c-ddac-4805-b60f-350a93aa43de" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity for these restructurings:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges recorded in 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d232a4fb6cb42509c44225cb0f739e3_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjMwOTY2ZGMxYjZhOTRlZjY4NzIwOTViNmZlZWMyZTZmL3RhYmxlcmFuZ2U6MzA5NjZkYzFiNmE5NGVmNjg3MjA5NWI2ZmVlYzJlNmZfMS0yLTEtMS0yNzY1OQ_fa98b45d-51db-4946-8a59-8165f0d6640e">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d232a4fb6cb42509c44225cb0f739e3_D20210101-20211231" decimals="-6" name="abt:RestructuringReservePeriodCashSettledAndOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjMwOTY2ZGMxYjZhOTRlZjY4NzIwOTViNmZlZWMyZTZmL3RhYmxlcmFuZ2U6MzA5NjZkYzFiNmE5NGVmNjg3MjA5NWI2ZmVlYzJlNmZfMi0yLTEtMS0yNzcxNQ_65f86033-6a53-40de-ad10-7937f9f52a5f">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i025aec3dc4f441b783d28fd3085d2f29_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjMwOTY2ZGMxYjZhOTRlZjY4NzIwOTViNmZlZWMyZTZmL3RhYmxlcmFuZ2U6MzA5NjZkYzFiNmE5NGVmNjg3MjA5NWI2ZmVlYzJlNmZfMy0yLTEtMS0xNzg2OA_e82889b3-d731-4388-af33-7556d6d15189">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges recorded in 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4794a110deb7433cbee3148cdeb358b8_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjMwOTY2ZGMxYjZhOTRlZjY4NzIwOTViNmZlZWMyZTZmL3RhYmxlcmFuZ2U6MzA5NjZkYzFiNmE5NGVmNjg3MjA5NWI2ZmVlYzJlNmZfNC0yLTEtMS0yNjg3OA_c60d44d3-e2ed-4476-8621-a6d8bdcad120">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4794a110deb7433cbee3148cdeb358b8_D20220101-20220930" decimals="-6" name="abt:RestructuringReservePeriodCashSettledAndOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjMwOTY2ZGMxYjZhOTRlZjY4NzIwOTViNmZlZWMyZTZmL3RhYmxlcmFuZ2U6MzA5NjZkYzFiNmE5NGVmNjg3MjA5NWI2ZmVlYzJlNmZfNC0yLTEtMS0xNzg2OA_e2140fa3-2f0d-4e48-abf1-da919018726c">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22fc873c34b4c30b31390c7c0722eab_I20220930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjMwOTY2ZGMxYjZhOTRlZjY4NzIwOTViNmZlZWMyZTZmL3RhYmxlcmFuZ2U6MzA5NjZkYzFiNmE5NGVmNjg3MjA5NWI2ZmVlYzJlNmZfNS0yLTEtMS0xNzg2OA_d981e049-6fd9-466c-81de-8f5d7fb60125">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_55"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><span><br/></span></div></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RleHRyZWdpb246YmY1NDc1ZDM5Njk2NGVmNzk1NTk3Y2Y4Yzc3OTc5MTJfNDY1_2c6c7651-f5bf-48fc-84a7-f833c076dc25" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 7 &#8212; Incentive Stock Program</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first nine months of 2022, Abbott granted <ix:nonFraction unitRef="shares" contextRef="i3d7dd7f42af3454e98ea0cd9e0de9533_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RleHRyZWdpb246YmY1NDc1ZDM5Njk2NGVmNzk1NTk3Y2Y4Yzc3OTc5MTJfNTQ_6afeeb84-1603-4253-8e6f-c26ab7a824e4">2,634,647</ix:nonFraction> stock options, <ix:nonFraction unitRef="shares" contextRef="ief8174a37ce742efb72aee7ec66f0b45_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RleHRyZWdpb246YmY1NDc1ZDM5Njk2NGVmNzk1NTk3Y2Y4Yzc3OTc5MTJfNzI_80d44d5c-0324-41b5-899a-609dfc33001c">514,205</ix:nonFraction> restricted stock awards and <ix:nonFraction unitRef="shares" contextRef="i4e93f70390524d65aa024c34612f8203_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RleHRyZWdpb246YmY1NDc1ZDM5Njk2NGVmNzk1NTk3Y2Y4Yzc3OTc5MTJfMTAz_4e3ab1d9-5688-4a1d-99ad-27d0f604243f">5,427,697</ix:nonFraction> restricted stock units under its incentive stock program. At September&#160;30, 2022, approximately <ix:nonFraction unitRef="shares" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RleHRyZWdpb246YmY1NDc1ZDM5Njk2NGVmNzk1NTk3Y2Y4Yzc3OTc5MTJfMTg1_c7f6a31a-26fe-4366-a65d-d576801e035d">87</ix:nonFraction> million shares were reserved for future grants. <ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RleHRyZWdpb246YmY1NDc1ZDM5Njk2NGVmNzk1NTk3Y2Y4Yzc3OTc5MTJfNDY3_e7809869-80a1-475d-9ad2-763d00ad1d60" continuedAt="i68cd19e3fe7b4754b65c577b499ce666" escape="true">Information regarding the number of options outstanding and exercisable at September&#160;30, 2022 is as follows:</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div><ix:continuation id="i68cd19e3fe7b4754b65c577b499ce666"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33f19560992c435a88092f47daf02b5b_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RhYmxlOjBkMzg2NTI1YzZiNTQzNWM4NzJhODg2NmVlZjY4MjQ4L3RhYmxlcmFuZ2U6MGQzODY1MjVjNmI1NDM1Yzg3MmE4ODY2ZWVmNjgyNDhfMS0yLTEtMS0xNzg2OA_1e689900-db55-470e-9151-3a6b4cd0d08c">29,048,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33f19560992c435a88092f47daf02b5b_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RhYmxlOjBkMzg2NTI1YzZiNTQzNWM4NzJhODg2NmVlZjY4MjQ4L3RhYmxlcmFuZ2U6MGQzODY1MjVjNmI1NDM1Yzg3MmE4ODY2ZWVmNjgyNDhfMS00LTEtMS0xNzg2OA_e98c0418-2ca3-4745-a83b-c755a1623187">23,310,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3d7dd7f42af3454e98ea0cd9e0de9533_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RhYmxlOjBkMzg2NTI1YzZiNTQzNWM4NzJhODg2NmVlZjY4MjQ4L3RhYmxlcmFuZ2U6MGQzODY1MjVjNmI1NDM1Yzg3MmE4ODY2ZWVmNjgyNDhfMi0yLTEtMS0xNzg2OA_b69de965-d5dd-4fc0-85a7-c1aeed52f07c">5.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3d7dd7f42af3454e98ea0cd9e0de9533_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RhYmxlOjBkMzg2NTI1YzZiNTQzNWM4NzJhODg2NmVlZjY4MjQ4L3RhYmxlcmFuZ2U6MGQzODY1MjVjNmI1NDM1Yzg3MmE4ODY2ZWVmNjgyNDhfMi00LTEtMS0xNzg2OA_4ad87d20-7a1d-466b-828f-b026812c0a20">4.6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33f19560992c435a88092f47daf02b5b_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RhYmxlOjBkMzg2NTI1YzZiNTQzNWM4NzJhODg2NmVlZjY4MjQ4L3RhYmxlcmFuZ2U6MGQzODY1MjVjNmI1NDM1Yzg3MmE4ODY2ZWVmNjgyNDhfMy0yLTEtMS0xNzg2OA_9c2c4457-1dd6-4913-a2b9-466e17dcea1f">70.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33f19560992c435a88092f47daf02b5b_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RhYmxlOjBkMzg2NTI1YzZiNTQzNWM4NzJhODg2NmVlZjY4MjQ4L3RhYmxlcmFuZ2U6MGQzODY1MjVjNmI1NDM1Yzg3MmE4ODY2ZWVmNjgyNDhfMy00LTEtMS0xNzg2OA_2a17f461-43db-4fd0-8a93-24e705446e54">59.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f19560992c435a88092f47daf02b5b_I20220930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RhYmxlOjBkMzg2NTI1YzZiNTQzNWM4NzJhODg2NmVlZjY4MjQ4L3RhYmxlcmFuZ2U6MGQzODY1MjVjNmI1NDM1Yzg3MmE4ODY2ZWVmNjgyNDhfNC0yLTEtMS0xNzg2OA_90fd3ea0-3854-4f6c-9223-ec60e77ff698">901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f19560992c435a88092f47daf02b5b_I20220930" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RhYmxlOjBkMzg2NTI1YzZiNTQzNWM4NzJhODg2NmVlZjY4MjQ4L3RhYmxlcmFuZ2U6MGQzODY1MjVjNmI1NDM1Yzg3MmE4ODY2ZWVmNjgyNDhfNC00LTEtMS0xNzg2OA_c51df1a2-aa96-49d7-ac38-f061032aee5e">890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total unrecognized share-based compensation cost at September&#160;30, 2022 amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RleHRyZWdpb246YmY1NDc1ZDM5Njk2NGVmNzk1NTk3Y2Y4Yzc3OTc5MTJfNDEw_82a23fae-d721-4d3b-9bf5-760568923940">600</ix:nonFraction> million which is expected to be recognized over the next <ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RleHRyZWdpb246YmY1NDc1ZDM5Njk2NGVmNzk1NTk3Y2Y4Yzc3OTc5MTJfNDYy_d55b60b8-1cb3-41d1-b96c-248318471a24">three years</ix:nonNumeric>.</span></div></ix:nonNumeric><div><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_58"></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81OC9mcmFnOmFiMmYzYmZiNjE5NDQyMzBhM2RiZmNjOTJhNDRlMjA4L3RleHRyZWdpb246YWIyZjNiZmI2MTk0NDIzMGEzZGJmY2M5MmE0NGUyMDhfOTY_f46e6c5d-c13a-4fc5-9acb-ffc907a7850c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 8 &#8212; Debt and Lines of Credit</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;15, 2022, Abbott repaid the $<ix:nonFraction unitRef="usd" contextRef="ib0b29ca98ef14de0a3be8cd36653449b_D20220315-20220315" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81OC9mcmFnOmFiMmYzYmZiNjE5NDQyMzBhM2RiZmNjOTJhNDRlMjA4L3RleHRyZWdpb246YWIyZjNiZmI2MTk0NDIzMGEzZGJmY2M5MmE0NGUyMDhfMzQ_8c6dc8b0-278b-43f4-be12-f12485f06fcb">750</ix:nonFraction> million outstanding principal amount of its <ix:nonFraction unitRef="number" contextRef="icb2e6dec32fd457dab072263060d0e7f_I20220315" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81OC9mcmFnOmFiMmYzYmZiNjE5NDQyMzBhM2RiZmNjOTJhNDRlMjA4L3RleHRyZWdpb246YWIyZjNiZmI2MTk0NDIzMGEzZGJmY2M5MmE0NGUyMDhfNzM_38f89095-728a-4037-97d4-992251c68d8e">2.55</ix:nonFraction>% Notes upon maturity.</span></div></ix:nonNumeric><div><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_61"></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNDUwMA_9824efbf-b0e5-454b-a1e7-b22f286f7f63" continuedAt="i6ff8d9c6757c4b7b9fe12aeebde8e9d0" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 9 &#8212; Financial Instruments, Derivatives and Fair Value Measures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $<ix:nonFraction unitRef="usd" contextRef="i76a875a71c9d425d9d761f5b9b84a5e2_I20220930" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMzM1_0ca8ddac-fe26-48a4-914e-511b12beb027">7.9</ix:nonFraction> billion at September&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="iaf6d0188932d469bac5c2cf700f6c5e3_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMzQ4_ed3a2088-4ef2-41d0-afe7-a1db5258fe0d">8.6</ix:nonFraction> billion at December&#160;31, 2021, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of September&#160;30, 2022 will be included in Cost of products sold at the time the products are sold, generally through the next <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNjQ1_49b14940-1788-44d4-b632-7d72eb48a1c0">twelve</span> to <ix:nonNumeric contextRef="i75c98c84b66f4cfa973544e07e3a54c4_D20220101-20220930" name="us-gaap:MaximumLengthOfTimeHedgedInCashFlowHedge1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNjUx_02f143c0-f435-4599-8e99-d5e84c8c7855">eighteen months</ix:nonNumeric>.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At September&#160;30, 2022 and December&#160;31, 2021, Abbott held the gross notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i7768645f0e3548ef8fa07c72bb1ea50a_I20220930" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMTM2Ng_0423c1e6-262a-4234-917d-6dc7649cc28f">10.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ib70687d909df4adf951907f9e4120aa4_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMTM3Mw_cc8f3c89-6fba-4e11-aa97-7cfb3e1d6d73">12.2</ix:nonFraction> billion, respectively, of such foreign currency forward exchange contracts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott has designated a yen-denominated, <ix:nonNumeric contextRef="i362cc950c402435b85ccd22cc23f812e_D20220101-20220930" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMTQ4Ng_4e7326ae-3a2f-4823-a283-d196255adafa"><ix:nonNumeric contextRef="i549e4e2eae714c2daeb70c21f201d001_D20210101-20211231" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMTQ4Ng_59ca2b57-5df0-48f6-823d-092a8df1defa">5</ix:nonNumeric></ix:nonNumeric>-year term loan of approximately $<ix:nonFraction unitRef="usd" contextRef="ie414f701cbf142b7b9b601b415e450e9_I20220930" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMTUyMQ_6b4933b0-b883-43fc-9e71-8599f4891d44">413</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3273ef5ba89846a6b3579791ad4114a8_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMTUyOA_e91f18e2-7165-48af-92ce-7d83ebedfb66">521</ix:nonFraction> million as of September&#160;30, 2022 and December&#160;31, 2021, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott is a party to interest rate hedge contracts with notional values totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i37b05ec060e14d3a94f524f71c4a509a_I20220930" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMTg2NQ_211b09f5-62be-4ad2-a36c-e8d02d2ab366"><ix:nonFraction unitRef="usd" contextRef="i7159ef591665413e9beeecc68ac31d2d_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMTg2NQ_d0157d99-7f63-4106-8731-afd30c94d550">2.9</ix:nonFraction></ix:nonFraction> billion at September&#160;30, 2022 and December&#160;31, 2021 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 9 &#8212; Financial Instruments, Derivatives and Fair Value Measures (Continued)</span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i6ff8d9c6757c4b7b9fe12aeebde8e9d0" continuedAt="i621b1c26fd7745e4a3e5ebfbd676326a"><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNDUwMg_762ace3e-ce0e-47f4-8cde-cd0dea7bc108" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts and location of certain derivative financial instruments as of September&#160;30, 2022 and December&#160;31, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dec. 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dec. 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec45d80b0bae4c32b4f36d6967676878_I20220930" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfMi0yLTEtMS0xNzg2OA_f9736537-d8e0-4b58-9ac0-bd0d955ecace">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3c67e54492a410491b80a24aa671e4c_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfMi00LTEtMS0xNzg2OA_d7936b8f-36c9-4a9d-8b3c-b825028553e7">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b9ef5b827994c42a6595f4e0c623688_I20220930" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfMi04LTEtMS0xNzg2OA_2a05c395-068e-4b3d-8c6d-347753a71b26">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ec5a2619fbe4414981ad28228a6b87f_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfMi0xMC0xLTEtMTc4Njg_662e62d4-95b0-4a03-bbd7-b10377b63936">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Post-employment obligations, deferred income taxes and other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cb408ff61494ac1a4b289c86d1de300_I20220930" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNC0yLTEtMS0xNzg2OA_bb8b8546-88e2-411a-9de5-fd50447f35a0">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea63a66bbec848d5af23efa2feb1ab3c_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNC00LTEtMS0xNzg2OA_8d84cf2c-4d02-4dfb-a051-e13e46f637f5">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia26c1f62062f4ea0a07843e03153843d_I20220930" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNC04LTEtMS0xNzg2OA_8549a0bd-97ba-4075-ba47-be065b39fbbb">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0dc5c19ed38405a941c3edfc0d6963e_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNC0xMC0xLTEtMTc4Njg_334855e1-e0f0-42e6-ae98-e0ea2eeac7bb">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Others not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cdc399d14e84bc6a02151fe08ebeac0_I20220930" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNS0yLTEtMS0xNzg2OA_b8c27caa-36e2-459c-8867-659e201990aa">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c2fb65db7845fb87663d6e762d2d63_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNS00LTEtMS0xNzg2OA_18d56a54-d4f9-4ed0-968b-02cc91f71616">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2505f0c40f0d485cb42f96d4df9ad116_I20220930" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNS04LTEtMS0xNzg2OA_d61232b5-7bc7-4698-b971-703898948028">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e3df89ca5cd458499f4fddc42ea907e_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNS0xMC0xLTEtMTc4Njg_90ccac65-065b-4195-9dc2-e8ff1272e41a">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea1dfa89210b49259cbcc86f33bc5af3_I20220930" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNi04LTEtMS0xNzg2OA_2a502eb3-ee08-4a1e-a17d-00322b007334">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd9937735c2340e2a5e5e7ccb99a641e_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNi0xMC0xLTEtMTc4Njg_613e6304-1090-4494-ad6d-d2242febc781">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNy0yLTEtMS0xNzg2OA_6ec5d7f1-f440-4b25-9424-ae79b6b5bd15">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNy00LTEtMS0xNzg2OA_50e12d63-e838-40a6-ac29-e477c7844ce4">379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNy04LTEtMS0xNzg2OA_68a76a80-f17f-4091-bc04-3ccd57233053">786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNy0xMC0xLTEtMTc4Njg_57180693-0d3e-4841-a08e-54aebbd86159">618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNDUwNA_6e2db637-0359-424c-87cc-60110f96cb66" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September&#160;30, 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain (loss) Recognized in Other <br/>Comprehensive Income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (expense) and Gain (loss)<br/>Reclassified into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5397677ab93a49019eae8c9a0bb21d79_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfMy0yLTEtMS0xNzg2OA_e92909c7-6dd1-4b9a-88de-4a6fa7be2dab">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcc53ef71a34fb88566cf49ebd25f9f_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfMy00LTEtMS0xNzg2OA_f3b24a7f-08d1-4287-81f6-94ab3d4c0d7b">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72837af6cc147a5874155b6990bf8c9_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfMy02LTEtMS0xNzg2OA_ca720148-1741-4c5e-bbb9-14ff314bd1b9">442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65ae9ecf6fd5486287c43691fc391e33_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfMy04LTEtMS0xNzg2OA_bdfc3271-d5fc-4c69-911d-939a7060ef3a">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5397677ab93a49019eae8c9a0bb21d79_D20220701-20220930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfMy0xMC0xLTEtMTc4Njg_11c68bfe-eb9c-4d3e-9413-aa1d32edf4ec">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcc53ef71a34fb88566cf49ebd25f9f_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfMy0xMi0xLTEtMTc4Njg_42dee4a1-4a52-4817-8834-70ae823528fc">92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72837af6cc147a5874155b6990bf8c9_D20220101-20220930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfMy0xNC0xLTEtMTc4Njg_d6b4582f-8f25-4a2d-8b92-1c2dbbf3c84c">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65ae9ecf6fd5486287c43691fc391e33_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfMy0xNi0xLTEtMTc4Njg_31fd5eb2-1134-4ae8-abd3-3d5413f21b60">207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3506a1ed3b6c452f90c9f839466ac4e4_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfNC0yLTEtMS0xNzg2OA_23f3e974-8b6a-4396-ac39-3363a33b6266">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5be187d8164445380ced526aa943a0c_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfNC00LTEtMS0xNzg2OA_1fda8a80-11fc-4cae-9945-3c8802372fb7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cdf77deb3954cceb710b7273d79ecc6_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfNC02LTEtMS0xNzg2OA_dcd1d91b-b7b0-4a94-820c-9432aa47f9cf">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf6360515a084a56b0e124d0c9a4b858_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfNC04LTEtMS0xNzg2OA_74ba8d62-927e-48b4-ab82-26da5c9fa5b2">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a8804aef7ab405a9bd7994c3c7fc41c_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfNS0xMC0xLTEtMTc4Njg_66dfe6c2-db7f-407d-895d-7280b0114b37">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6840ccb5da6c4ad4bda53b49c4cd3231_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfNS0xMi0xLTEtMTc4Njg_88d00a2e-e9bd-4ec8-9c63-4496e02e6825">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6afdc8cb667a4638a732ba5f45eb54ba_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfNS0xNC0xLTEtMTc4Njg_763cc9f5-53f2-435c-aca3-1a4f297c70ed">253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i091abb1e8fe94a55b833b101e4414fe1_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfNS0xNi0xLTEtMTc4Njg_c6db9d57-baf1-4b71-95c5-3ac8071a2d4b">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 9 &#8212; Financial Instruments, Derivatives and Fair Value Measures (Continued)</span></div></div><ix:continuation id="i621b1c26fd7745e4a3e5ebfbd676326a" continuedAt="if4c642dd5edf43609b2f8012a2a11e7b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Losses of $<ix:nonFraction unitRef="usd" contextRef="i88b7ee098ae642899deeab2cddde1c6d_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMjc5OQ_ce95c530-ffd7-4bea-a192-e4ac9dd40e5b">27</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1277200202a84547aa376e37e03fd635_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMjgwNw_6ae2c396-58a7-43a0-9a19-2ec63c52007b">18</ix:nonFraction> million were recognized in the three months ended September&#160;30, 2022 and 2021, respectively, related to foreign currency forward exchange contracts not designated as a hedge. Gains of $<ix:nonFraction unitRef="usd" contextRef="ia237ff4511bb4929b3bba3623e099990_D20220101-20220930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMjk2NA_cea73ada-a6a6-4512-93af-36ef04e113f2">225</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8cd680e248c64638be6c598cf72ebfad_D20210101-20210930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMjk3Mg_e2901a4d-1be2-43eb-89aa-b80a72750acc">15</ix:nonFraction> million were recognized in the nine months ended September&#160;30, 2022 and 2021, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNDUwNQ_ecdd286a-487e-4e1a-8f94-36f1fc0c73c8" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values and fair values of certain financial instruments as of September&#160;30, 2022 and December&#160;31, 2021 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investment Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e53ec310eb54a098325e121ff28338f_I20220930" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMy0yLTEtMS0xNzg2OA_979345e9-ac79-4268-b1ed-5418ff3deff8">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dcc8e7c28ee4309824c37c0f1ba79d8_I20220930" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMy00LTEtMS0xNzg2OA_b02fd853-ff84-4aac-9a2a-6fd60f316a1c">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i301f40be6d6f4ebb92077078845bdb8c_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMy02LTEtMS0xNzg2OA_8326a942-c9f7-464a-8ed8-f1e6d480453b">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa54db95946a4086a4914e1aa90c5af3_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMy04LTEtMS0xNzg2OA_d4c3f37c-699b-4788-85cf-ca2e4d937c90">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedd4976f99c842058ae43f0aefe27d73_I20220930" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNC0yLTEtMS0xNzg2OA_4e19e6de-42f5-4a41-b4a6-f965f880f4d8">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9db10f8a54af4a0aaa440b1f3206a5d2_I20220930" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNC00LTEtMS0xNzg2OA_954bca80-633f-41e5-ba0e-900343959542">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e6cf7c4a144759b6e10215356df268_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNC02LTEtMS0xNzg2OA_5e700b8e-b680-40f4-8ba6-2b1b9031a762">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i199db302b74f4397862dc61ac1c91c79_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNC04LTEtMS0xNzg2OA_db363419-3c90-4085-9516-84674682dce8">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i132737fb549d49b2af4b792fb9883efb_I20220930" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNS0yLTEtMS0xNzg2OA_7314c2d3-07c8-4dc1-89f2-73438d3e4ff9">16,414</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic595c192e42f4320bb74ffe5f79848fa_I20220930" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNS00LTEtMS0xNzg2OA_41da45f2-65f9-4a68-b7f3-d6930460b29d">15,821</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9130097464e4c8abfc4ebc47a8bf3db_I20211231" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNS02LTEtMS0xNzg2OA_aa09955a-d58e-4921-a6f0-b06b44f5c4da">18,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic386176ec45b4cb29e70f8de930f1a01_I20211231" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNS04LTEtMS0xNzg2OA_12fb5b7e-112d-4084-8279-943229b5d10b">21,152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Forward Exchange Contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132737fb549d49b2af4b792fb9883efb_I20220930" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNy0yLTEtMS0xNzg2OA_6647ecd8-0f14-4ce1-9648-182ef0b6ac67">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic595c192e42f4320bb74ffe5f79848fa_I20220930" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNy00LTEtMS0xNzg2OA_568e7834-2009-4479-a824-1e894ad9a22e">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9130097464e4c8abfc4ebc47a8bf3db_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNy02LTEtMS0xNzg2OA_ed9ceb41-1af8-421b-841e-d1377f05e907">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic386176ec45b4cb29e70f8de930f1a01_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNy04LTEtMS0xNzg2OA_a6375119-0616-4c0e-a131-b344c0c54db6">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i132737fb549d49b2af4b792fb9883efb_I20220930" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfOC0yLTEtMS0xNzg2OA_cdee36a8-ea31-4461-b49f-79b76c58d5ed">207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic595c192e42f4320bb74ffe5f79848fa_I20220930" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfOC00LTEtMS0xNzg2OA_ab532618-35e2-44f2-9a05-08debc9f00bd">207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9130097464e4c8abfc4ebc47a8bf3db_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfOC02LTEtMS0xNzg2OA_ac3ab9f2-f4bf-4f97-b07b-4df601cb15da">97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic386176ec45b4cb29e70f8de930f1a01_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfOC04LTEtMS0xNzg2OA_2ddc6747-d93e-4c53-8e51-69679736b05a">97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Hedge Contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132737fb549d49b2af4b792fb9883efb_I20220930" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMTAtMi0xLTEtMTc4Njg_90021c49-c519-4b29-988e-a19a81f1e216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic595c192e42f4320bb74ffe5f79848fa_I20220930" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMTAtNC0xLTEtMTc4Njg_1353256f-537e-4956-8777-8da34a10b4d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9130097464e4c8abfc4ebc47a8bf3db_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMTAtNi0xLTEtMTc4Njg_658bdcb9-331b-4e34-b8be-bc4b4b609a53">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic386176ec45b4cb29e70f8de930f1a01_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMTAtOC0xLTEtMTc4Njg_02ca14f9-a2ac-47e5-a4ad-6f1512c59ee5">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i132737fb549d49b2af4b792fb9883efb_I20220930" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMTEtMi0xLTEtMTc4Njg_fccd85f4-eab5-4c53-b098-b82f2956a246">166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic595c192e42f4320bb74ffe5f79848fa_I20220930" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMTEtNC0xLTEtMTc4Njg_48e9d8c8-2e30-4a33-8e99-90cdecc5ac03">166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9130097464e4c8abfc4ebc47a8bf3db_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMTEtNi0xLTEtMTc4Njg_c6879b36-0a30-4621-8e1d-c7da383febbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic386176ec45b4cb29e70f8de930f1a01_I20211231" decimals="-6" name="us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMTEtOC0xLTEtMTc4Njg_b80b2dde-5afa-40c4-a778-fc210330cdf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the debt was determined based on significant other observable inputs, including current interest rates.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 9 &#8212; Financial Instruments, Derivatives and Fair Value Measures (Continued)</span></div></div><ix:continuation id="if4c642dd5edf43609b2f8012a2a11e7b"><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNDUwNg_8d8eeb61-ac78-4efe-aae6-e916505d896f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding<br/>Balances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d54ddc609d499383aafcf6ba76dd93_I20220930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMy0yLTEtMS0xNzg2OA_1584614e-e303-4931-b8b6-639ec566cf7d">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMy00LTEtMS0xNzg2OA_6597639d-b9f9-4569-894c-7a03f1fe2a7d">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMy02LTEtMS0xNzg2OA_204e7b95-978c-4c73-aa36-57288f23402b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18fc392e579454d8f85e5dc41070311_I20220930" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMy04LTEtMS0xNzg2OA_12b39101-8c39-4867-ad73-2b050688ce3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d54ddc609d499383aafcf6ba76dd93_I20220930" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNC0yLTEtMS0xNzg2OA_354a0dfb-79c8-4c47-893c-510e1e70a16e">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNC00LTEtMS0xNzg2OA_e7535746-ecef-48d6-9200-97f7a9f07b32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNC02LTEtMS0xNzg2OA_accc8894-dd45-43c4-8a8c-241788e6f3cc">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18fc392e579454d8f85e5dc41070311_I20220930" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNC04LTEtMS0xNzg2OA_39318e31-73f9-443c-a35a-3785e7991f0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d54ddc609d499383aafcf6ba76dd93_I20220930" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNS0yLTEtMS0xNzg2OA_a42b3775-5ce0-4898-bfea-1fcf2ea14183">1,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNS00LTEtMS0xNzg2OA_b26651be-2ed7-4edf-ad5f-8297322b7e86">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNS02LTEtMS0xNzg2OA_dd448843-1525-47e2-ae2c-5e6ada244e17">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18fc392e579454d8f85e5dc41070311_I20220930" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNS04LTEtMS0xNzg2OA_0f6ecb4a-ac91-4d32-b51b-515f04ef33fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d54ddc609d499383aafcf6ba76dd93_I20220930" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNy0yLTEtMS0xNzg2OA_89dd9ddf-bf40-47a2-96dc-d7de7183739f">2,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNy00LTEtMS0xNzg2OA_caba650b-a22b-44da-a47a-9cb2af1d0dc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNy02LTEtMS0xNzg2OA_bfe415e8-8870-4ac1-9c5e-e57b40405444">2,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18fc392e579454d8f85e5dc41070311_I20220930" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNy04LTEtMS0xNzg2OA_80c7d717-daab-4a58-a621-d7c95157c3c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d54ddc609d499383aafcf6ba76dd93_I20220930" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfOC0yLTEtMS0xNzg2OA_f3400582-7715-4faf-9fe5-f2400afd2781">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfOC00LTEtMS0xNzg2OA_adb4c54f-b6bf-4357-86fd-43b31838366a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfOC02LTEtMS0xNzg2OA_cc9ef0f0-654d-4038-9a29-e489bf81b851">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18fc392e579454d8f85e5dc41070311_I20220930" decimals="-6" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfOC04LTEtMS0xNzg2OA_1bce38b0-6adc-41d6-b2b0-633019ba6c3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d54ddc609d499383aafcf6ba76dd93_I20220930" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfOS0yLTEtMS0xNzg2OA_97b2ab11-0be3-40b3-8d1f-91dcaccb3c41">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfOS00LTEtMS0xNzg2OA_27543035-6ede-4f22-9e98-b0e46873e793">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfOS02LTEtMS0xNzg2OA_57207b7c-7e3c-4ea2-9dba-2bede82e75d1">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18fc392e579454d8f85e5dc41070311_I20220930" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfOS04LTEtMS0xNzg2OA_20f4b16d-67fb-4ec9-adef-4f8e91729935">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d54ddc609d499383aafcf6ba76dd93_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTAtMi0xLTEtMTc4Njg_ba3c3dea-da45-4be3-bba6-850231cea4f6">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTAtNC0xLTEtMTc4Njg_e19c04f1-819b-43ab-8343-e0381465f3c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTAtNi0xLTEtMTc4Njg_8582f2f8-05ed-46aa-9350-e4020995fa7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18fc392e579454d8f85e5dc41070311_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTAtOC0xLTEtMTc4Njg_3cabe06a-7625-4eb4-890c-ffb5bee41f6c">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d54ddc609d499383aafcf6ba76dd93_I20220930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTEtMi0xLTEtMTc4Njg_733e8cf7-718c-4d6f-b953-b6c02a5a8f21">3,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTEtNC0xLTEtMTc4Njg_79f30c6c-944e-4613-8c0c-6bf3243ab857">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTEtNi0xLTEtMTc4Njg_110ac013-8157-43da-8abf-e5dce55b6e79">3,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18fc392e579454d8f85e5dc41070311_I20220930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTEtOC0xLTEtMTc4Njg_eac23811-0335-49bb-9d8d-d1d8e6221e7c">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTQtMi0xLTEtMTc4Njg_ac4844be-feaa-4534-9dbb-78627f8848e0">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f2a644ac84481c931d626da6d56b5a_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTQtNC0xLTEtMTc4Njg_64526c17-9f2e-4485-b65a-d3bb7a804c63">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1940cafbfda44622acb910b14b1f0a51_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTQtNi0xLTEtMTc4Njg_7069d389-5867-468a-b16e-3f3de5a77d1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTQtOC0xLTEtMTc4Njg_e1ba0974-0db0-4aef-a5de-e2de3cfebc6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTUtMi0xLTEtMTc4Njg_151a30db-c439-436d-851f-f92826cd19af">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f2a644ac84481c931d626da6d56b5a_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTUtNC0xLTEtMTc4Njg_9e283e62-019d-4249-bb83-300073a02549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1940cafbfda44622acb910b14b1f0a51_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTUtNi0xLTEtMTc4Njg_a12a7c2b-91a9-4803-a3ae-7d303f901dff">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231" decimals="-6" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTUtOC0xLTEtMTc4Njg_f0f62fde-118b-4b0f-8400-2e7484131e80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTYtMi0xLTEtMTc4Njg_2bba3449-baac-4406-aa03-dd1511587757">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f2a644ac84481c931d626da6d56b5a_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTYtNC0xLTEtMTc4Njg_a35637c9-cfc8-4bc2-a418-949e2f54eb88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1940cafbfda44622acb910b14b1f0a51_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTYtNi0xLTEtMTc4Njg_1de3c0b9-41ea-45ca-b7cf-010ceafe6da2">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTYtOC0xLTEtMTc4Njg_3ea1b56e-1a50-4a03-8385-c445c3ca018a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTctMi0xLTEtMTc4Njg_6496efc1-e181-4582-a26c-a27da080f2d2">781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f2a644ac84481c931d626da6d56b5a_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTctNC0xLTEtMTc4Njg_36902231-4973-4cc4-a15d-b5a7e44b5d17">402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1940cafbfda44622acb910b14b1f0a51_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTctNi0xLTEtMTc4Njg_ce98f844-d7cf-45bb-9958-5c1b20316de7">379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTctOC0xLTEtMTc4Njg_642081ef-6ad6-4791-b885-ae3e284e838c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTktMi0xLTEtMTc4Njg_f7f93d42-c04f-42e1-ab82-a832f65873d7">2,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f2a644ac84481c931d626da6d56b5a_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTktNC0xLTEtMTc4Njg_7bf58050-0900-46dc-90b7-b8d1211e5c7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1940cafbfda44622acb910b14b1f0a51_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTktNi0xLTEtMTc4Njg_803460f1-912d-4d49-b28f-a67c4935121b">2,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTktOC0xLTEtMTc4Njg_47408d7c-3629-4d44-af54-d0793197f1ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjAtMi0xLTEtMTc4Njg_afce6ec9-9481-4faa-a397-5eadc005733d">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f2a644ac84481c931d626da6d56b5a_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjAtNC0xLTEtMTc4Njg_e0248c14-3b73-4194-ae50-14e1cb29e12a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1940cafbfda44622acb910b14b1f0a51_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjAtNi0xLTEtMTc4Njg_ca381ca4-e602-445b-8830-3fe3eeb716ba">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjAtOC0xLTEtMTc4Njg_26f2cc04-38b8-45d5-91b5-31b9a89af585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjEtMi0xLTEtMTc4Njg_515a00d8-b416-4a3a-92c5-0f0cb29c8119">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f2a644ac84481c931d626da6d56b5a_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjEtNC0xLTEtMTc4Njg_1ecd262f-d1b0-40ac-9a6a-925e6cb245f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1940cafbfda44622acb910b14b1f0a51_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjEtNi0xLTEtMTc4Njg_3aadd2b8-adbc-485c-b630-5c3a1305c283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjEtOC0xLTEtMTc4Njg_e8b74d68-85e6-4112-b60a-8527ada59ccf">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjItMi0xLTEtMTc4Njg_2e41e4db-f9e7-404a-9ce1-35f598d97a31">3,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f2a644ac84481c931d626da6d56b5a_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjItNC0xLTEtMTc4Njg_a364a90f-62dd-4ceb-bebb-f1e6012ecf18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1940cafbfda44622acb910b14b1f0a51_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjItNi0xLTEtMTc4Njg_094c095b-df8f-42d2-b158-e83decb83301">3,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjItOC0xLTEtMTc4Njg_c540460a-8b70-46ff-a6e0-d0c5fa6e90af">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_64"></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82NC9mcmFnOjhlNjExZjg0NjVmMjQzNDg4NmJhMDgwNDJiZGU0MDA3L3RleHRyZWdpb246OGU2MTFmODQ2NWYyNDM0ODg2YmEwODA0MmJkZTQwMDdfMTM0Mg_dad30976-381d-46b2-8968-ff6b730e4a9a" continuedAt="i5ec8414cf608469d92b68fe83512896f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 10 &#8212; Litigation and Environmental Matters</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="abt:LossContingencyRangeOfPossibleLossMaximumIndividualSite" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82NC9mcmFnOjhlNjExZjg0NjVmMjQzNDg4NmJhMDgwNDJiZGU0MDA3L3RleHRyZWdpb246OGU2MTFmODQ2NWYyNDM0ODg2YmEwODA0MmJkZTQwMDdfNDgw_766c7957-64ec-4138-bc4c-6d1abe95bd1b">4</ix:nonFraction> million, and the aggregate cleanup exposure is not expected to exceed $<ix:nonFraction unitRef="usd" contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930" decimals="-6" name="abt:LossContingencyRangeOfPossibleLossMaximumAggregateSites" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82NC9mcmFnOjhlNjExZjg0NjVmMjQzNDg4NmJhMDgwNDJiZGU0MDA3L3RleHRyZWdpb246OGU2MTFmODQ2NWYyNDM0ODg2YmEwODA0MmJkZTQwMDdfNTQ1_ffacafed-c4d3-40ee-85fe-a66dc388545f">10</ix:nonFraction> million.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 10 &#8212; Litigation and Environmental Matters (Continued)</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5ec8414cf608469d92b68fe83512896f">Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $<ix:nonFraction unitRef="usd" contextRef="ie698bf737c3e45f2bb1ceb02130904bb_I20220930" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82NC9mcmFnOjhlNjExZjg0NjVmMjQzNDg4NmJhMDgwNDJiZGU0MDA3L3RleHRyZWdpb246OGU2MTFmODQ2NWYyNDM0ODg2YmEwODA0MmJkZTQwMDdfNzM3_f093a3c5-79ad-4305-a46e-03b961426551">40</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="ia383194c19ba4900ae6daf189c3fb80d_I20220930" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82NC9mcmFnOjhlNjExZjg0NjVmMjQzNDg4NmJhMDgwNDJiZGU0MDA3L3RleHRyZWdpb246OGU2MTFmODQ2NWYyNDM0ODg2YmEwODA0MmJkZTQwMDdfNzQz_c8b642e7-6c88-489b-9f23-74230f10e100">50</ix:nonFraction> million. The recorded accrual balance at September&#160;30, 2022 for these proceedings and exposures was approximately $<ix:nonFraction unitRef="usd" contextRef="id0f82983e37f491aa82bf6e3c57ef4d8_I20220930" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82NC9mcmFnOjhlNjExZjg0NjVmMjQzNDg4NmJhMDgwNDJiZGU0MDA3L3RleHRyZWdpb246OGU2MTFmODQ2NWYyNDM0ODg2YmEwODA0MmJkZTQwMDdfODM2_c40d2066-6137-469f-b8ed-e8f534d54d13">45</ix:nonFraction> million. This accrual represents management&#8217;s best estimate of probable loss, as defined by FASB ASC No. 450, &#8220;Contingencies.&#8221; Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott&#8217;s financial position, cash flows, or results of operations.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_67"></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:PostemploymentBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RleHRyZWdpb246OTJiNTcyNDg0MzBkNDdiN2E0ZWVhNDIzY2FhYWE5NTJfOTE1_24eaf328-44c7-497e-b15f-be22b0d32f22" continuedAt="i3f2500dccb2a40148a8cfb58c182cca8" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 11 &#8212; Post-Employment Benefits</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. <ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RleHRyZWdpb246OTJiNTcyNDg0MzBkNDdiN2E0ZWVhNDIzY2FhYWE5NTJfOTE2_53a8ff76-bd1a-4d2f-bead-14dd64b377b7" continuedAt="ie5979f64b6f14fc78680c10a59b4f65e" escape="true">Net cost recognized for the three and nine months ended September&#160;30 for Abbott&#8217;s major defined benefit plans and post-employment medical and dental benefit plans is as follows:</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div><ix:continuation id="ie5979f64b6f14fc78680c10a59b4f65e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical and Dental Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine  Months <br/>Ended Sept. 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine  Months <br/>Ended Sept. 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost - benefits earned during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55e17708b144d149c97d0b172bd426e_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfMy0yLTEtMS0xNzg2OA_e16afc75-965e-48a3-b580-7ed77e8cfe7e">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf9e8de48606409d948398115c9f7699_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfMy00LTEtMS0xNzg2OA_cdd1d51d-a631-49d7-99d8-5422a338d214">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfMy02LTEtMS0xNzg2OA_71a9edfd-7f31-4cd5-a594-67da3a5d98e8">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfMy04LTEtMS0xNzg2OA_ad3b512c-3ab6-449a-960d-4e6d93b2408d">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40386c7e28f341b4ae443602056c8368_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfMy0xMC0xLTEtMTc4Njg_22563f56-dd80-4ef1-be66-2363defd7386">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i229532fb1b884a2b865d6f39735f6e86_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfMy0xMi0xLTEtMTc4Njg_8ecc15b3-ef37-476b-8bcc-335745f0cdb9">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b147cc106249baa28781e370ab66ec_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfMy0xNC0xLTEtMTc4Njg_95be01a1-4eb0-45de-a691-06c090be4de6">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae69ef505e864efdaa37bebaf468436c_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfMy0xNi0xLTEtMTc4Njg_095552d1-376f-4941-bd81-6c5189d022b3">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost on projected benefit obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55e17708b144d149c97d0b172bd426e_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNC0yLTEtMS0xNzg2OA_3d7a6886-117e-4529-b6d1-e7cc4c3fc2d0">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf9e8de48606409d948398115c9f7699_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNC00LTEtMS0xNzg2OA_f8a4085e-66fc-4068-b120-fe65e4719818">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNC02LTEtMS0xNzg2OA_43b29e20-834c-4b26-8588-9fce26e24318">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNC04LTEtMS0xNzg2OA_4cb07d5f-f2ff-4a08-99e6-1c656643cde7">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40386c7e28f341b4ae443602056c8368_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNC0xMC0xLTEtMTc4Njg_59fcb263-1d5b-4afd-b61e-8cc702ffc38b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i229532fb1b884a2b865d6f39735f6e86_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNC0xMi0xLTEtMTc4Njg_b13a332d-55c9-48ef-9de0-99d3383e2a3e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b147cc106249baa28781e370ab66ec_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNC0xNC0xLTEtMTc4Njg_f0dc5e30-4d60-444e-8a30-8b4e61954606">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae69ef505e864efdaa37bebaf468436c_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNC0xNi0xLTEtMTc4Njg_483cc596-de19-460c-ad95-c51139fcfe1f">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic55e17708b144d149c97d0b172bd426e_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNS0yLTEtMS0xNzg2OA_92560eee-404e-469d-ae10-e83db73e8c79">231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf9e8de48606409d948398115c9f7699_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNS00LTEtMS0xNzg2OA_fe01d452-66d5-4ec8-807d-af5ab4bb942f">211</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNS02LTEtMS0xNzg2OA_578fe312-08d9-4b79-b268-ef3968e900cb">701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNS04LTEtMS0xNzg2OA_481cbf3e-5d6b-4e7b-8232-7445693851f4">633</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40386c7e28f341b4ae443602056c8368_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNS0xMC0xLTEtMTc4Njg_9731951a-f1af-4675-b838-2ab20c5ccf2d">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i229532fb1b884a2b865d6f39735f6e86_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNS0xMi0xLTEtMTc4Njg_96d9fad2-62b9-44e6-a184-34ce61a3066b">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6b147cc106249baa28781e370ab66ec_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNS0xNC0xLTEtMTc4Njg_1c16a4c3-e6f8-4f9a-8f2b-7dd46366db2d">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae69ef505e864efdaa37bebaf468436c_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNS0xNi0xLTEtMTc4Njg_ad31b2fd-bbba-4cd2-915b-2be559276eec">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amortization of:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial loss, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55e17708b144d149c97d0b172bd426e_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNy0yLTEtMS0xNzg2OA_3c7fcfa2-f1ae-47a1-a960-dbfe4a0f19e8">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf9e8de48606409d948398115c9f7699_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNy00LTEtMS0xNzg2OA_e7025aab-b549-49b1-b76c-ad030dd3f05b">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNy02LTEtMS0xNzg2OA_48663cf5-4e84-4904-a6ca-d825213eb8c4">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNy04LTEtMS0xNzg2OA_ad7882a5-06d7-4692-8241-75d42186511d">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40386c7e28f341b4ae443602056c8368_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNy0xMC0xLTEtMTc4Njg_27b33682-b6fb-4222-b097-ed00171deb6b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i229532fb1b884a2b865d6f39735f6e86_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNy0xMi0xLTEtMTc4Njg_d546f8e7-b47e-4497-a164-1261681a426a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b147cc106249baa28781e370ab66ec_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNy0xNC0xLTEtMTc4Njg_733e1629-bd15-488a-a69c-620a517f7537">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae69ef505e864efdaa37bebaf468436c_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNy0xNi0xLTEtMTc4Njg_cba9386f-c68a-4d46-a839-13262dffe85a">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55e17708b144d149c97d0b172bd426e_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOC0yLTEtMS0xNzg2OA_400e7f3f-d618-4f6f-a603-e3383824ec7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf9e8de48606409d948398115c9f7699_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOC00LTEtMS0xNzg2OA_5f357e32-196c-49a3-a8e0-51f52907d50d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOC02LTEtMS0xNzg2OA_1f6ffde2-b590-4c4b-a08a-1f736d059e89">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOC04LTEtMS0xNzg2OA_d53601c1-6662-4a84-a7ba-b11981120afe">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40386c7e28f341b4ae443602056c8368_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOC0xMC0xLTEtMTc4Njg_c2b76e73-263d-402d-96ef-eac522a2d557">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i229532fb1b884a2b865d6f39735f6e86_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOC0xMi0xLTEtMTc4Njg_af68c7cf-a82c-496d-a241-02a9a5153725">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6b147cc106249baa28781e370ab66ec_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOC0xNC0xLTEtMTc4Njg_d5485541-3b73-45fb-b042-763fdcc4b2f3">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae69ef505e864efdaa37bebaf468436c_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOC0xNi0xLTEtMTc4Njg_9126d4eb-8bb5-435b-b84a-4d0d3e3aa134">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cost (credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic55e17708b144d149c97d0b172bd426e_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOS0yLTEtMS0xNzg2OA_4167aeed-8c71-4a40-82e8-362572e639d7">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf9e8de48606409d948398115c9f7699_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOS00LTEtMS0xNzg2OA_ec21e0da-f40d-46f3-91e9-6ce1e0cb0c40">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOS02LTEtMS0xNzg2OA_ee283dad-3476-4234-b8d1-d4f22590bf45">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOS04LTEtMS0xNzg2OA_6fdd7254-c63f-4085-983e-c742e86ce5da">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40386c7e28f341b4ae443602056c8368_D20220701-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOS0xMC0xLTEtMTc4Njg_8ffdf535-b0fc-4169-a525-ae311d8d9f6d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i229532fb1b884a2b865d6f39735f6e86_D20210701-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOS0xMi0xLTEtMTc4Njg_28113fbf-a985-4ae3-b130-76ad769db34b">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b147cc106249baa28781e370ab66ec_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOS0xNC0xLTEtMTc4Njg_3e8915e5-33c1-4173-962d-d90955992481">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae69ef505e864efdaa37bebaf468436c_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOS0xNi0xLTEtMTc4Njg_e9847635-8b5f-447d-bf1a-674ee7e80b8e">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i3f2500dccb2a40148a8cfb58c182cca8" continuedAt="i1abd76f023a14307b1d0ee1ae75aa69e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first nine months of 2022 and 2021, $<ix:nonFraction unitRef="usd" contextRef="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RleHRyZWdpb246OTJiNTcyNDg0MzBkNDdiN2E0ZWVhNDIzY2FhYWE5NTJfNjQ1_192fa17f-2dac-4750-a6e0-d2c3f7c340c1">362</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RleHRyZWdpb246OTJiNTcyNDg0MzBkNDdiN2E0ZWVhNDIzY2FhYWE5NTJfNjUy_652e7c62-ede7-45fb-9d4b-44b5ce468ce5">366</ix:nonFraction> million, respectively, were contributed to defined benefit plans. In the first nine months of 2022 and 2021, $<ix:nonFraction unitRef="usd" contextRef="ib6b147cc106249baa28781e370ab66ec_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RleHRyZWdpb246OTJiNTcyNDg0MzBkNDdiN2E0ZWVhNDIzY2FhYWE5NTJfNzQz_3b8dbc9e-68cd-41ad-a006-f2874065cd84">28</ix:nonFraction> million</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="iae69ef505e864efdaa37bebaf468436c_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RleHRyZWdpb246OTJiNTcyNDg0MzBkNDdiN2E0ZWVhNDIzY2FhYWE5NTJfMTA5OTUxMTYyODkxMA_27705bf1-f7ae-4c25-ba06-cecc6f3e1066">26</ix:nonFraction>&#160;million, respectively</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1abd76f023a14307b1d0ee1ae75aa69e"> were contributed to the post-employment medical and dental plans.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_70"></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83MC9mcmFnOjEzMDU0ZmU5OTYwZDQ3YzA5ZjQ0OTEwZTY2NGMwMmFjL3RleHRyZWdpb246MTMwNTRmZTk5NjBkNDdjMDlmNDQ5MTBlNjY0YzAyYWNfODIz_74a64e60-a69b-45da-adc5-41148de8f7ea" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 12 &#8212; Taxes on Earnings</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2022 and 2021, taxes on earnings include approximately $<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="abt:ExcessTaxBenefitFromShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83MC9mcmFnOjEzMDU0ZmU5OTYwZDQ3YzA5ZjQ0OTEwZTY2NGMwMmFjL3RleHRyZWdpb246MTMwNTRmZTk5NjBkNDdjMDlmNDQ5MTBlNjY0YzAyYWNfMTk3_d242ed21-8120-45ce-9474-69bf072082ae">36</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="abt:ExcessTaxBenefitFromShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83MC9mcmFnOjEzMDU0ZmU5OTYwZDQ3YzA5ZjQ0OTEwZTY2NGMwMmFjL3RleHRyZWdpb246MTMwNTRmZTk5NjBkNDdjMDlmNDQ5MTBlNjY0YzAyYWNfMjA0_0c0b812e-a64a-415f-805b-c90a55ebbdad">97</ix:nonFraction> million, respectively, in excess tax benefits associated with share-based compensation. In the first nine months of 2022, taxes on earnings also include approximately $<ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83MC9mcmFnOjEzMDU0ZmU5OTYwZDQ3YzA5ZjQ0OTEwZTY2NGMwMmFjL3RleHRyZWdpb246MTMwNTRmZTk5NjBkNDdjMDlmNDQ5MTBlNjY0YzAyYWNfMzYy_7dd57035-9b28-4355-bc23-819145a949ab">20</ix:nonFraction> million of tax expense as the result of the resolution of various tax positions related to prior years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax authorities in various jurisdictions regularly review Abbott&#8217;s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $<ix:nonFraction unitRef="usd" contextRef="i08ff00d9980745d3b2b0e1c3d2eefd08_I20220930" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83MC9mcmFnOjEzMDU0ZmU5OTYwZDQ3YzA5ZjQ0OTEwZTY2NGMwMmFjL3RleHRyZWdpb246MTMwNTRmZTk5NjBkNDdjMDlmNDQ5MTBlNjY0YzAyYWNfNjgz_17fe4e04-d386-4bbc-95b5-21a09c62076a">75</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i1099be209597485a9a6ade72499f0853_I20220930" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83MC9mcmFnOjEzMDU0ZmU5OTYwZDQ3YzA5ZjQ0OTEwZTY2NGMwMmFjL3RleHRyZWdpb246MTMwNTRmZTk5NjBkNDdjMDlmNDQ5MTBlNjY0YzAyYWNfNjg5_c5b7ff7c-6399-4a03-a518-41bb5acacdc9">100</ix:nonFraction> million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><div id="ib0ff9808fe764fdea19589324372f96b_73"></div><hr style="page-break-after:always"/><div style="min-height:103.46pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></div><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83My9mcmFnOmQ1NjNmMDFlZmY1YzRlM2I4YjBiZWI2M2QwOWYxYTA2L3RleHRyZWdpb246ZDU2M2YwMWVmZjVjNGUzYjhiMGJlYjYzZDA5ZjFhMDZfMjA4NA_2c8c995f-3493-4eec-aef3-f76aab765fc2" continuedAt="i596c1b142eba4b46aaa9129e11c3e778" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 13 &#8212; Segment Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott&#8217;s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott&#8217;s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians&#8217; offices and government agencies throughout the world.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott&#8217;s reportable segments are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Established Pharmaceutical Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; International sales of a broad line of branded generic pharmaceutical products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nutritional Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Worldwide sales of a broad line of adult and pediatric nutritional products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diagnostic Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physician offices and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Devices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott&#8217;s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment&#8217;s assets.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><div id="ib0ff9808fe764fdea19589324372f96b_76"></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott Laboratories and Subsidiaries</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Condensed Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 13 &#8212; Segment Information (Continued)</span></div></div><ix:continuation id="i596c1b142eba4b46aaa9129e11c3e778"><ix:nonNumeric contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RleHRyZWdpb246NGExNmViMDI2MmIyNDNmZWFkZDE3NGMyNDZiOTcwZWNfMzE2_c317704a-ed0e-411d-bfac-6cf3da721d9c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Sales to External Customers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended Sept. 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended Sept. 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Established Pharmaceutical Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e67684e5e949128a2dec705cc5342d_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMy0yLTEtMS0xNzg2OA_999c96a2-3e3b-4af1-b5fa-63bfa0c8bfc4">1,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffc59617b4841e6842d4164adb3ad90_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMy00LTEtMS0xNzg2OA_75f1c065-982e-4bef-99cd-16ec29feb13b">1,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88535b01ff934a65be5cc199bcb770b6_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMy02LTEtMS0xNzg2OA_9c92c2cb-27bb-421e-b2f2-9f74c9670003">3,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c90b3c1db944b208e77b4076259563c_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMy04LTEtMS0xNzg2OA_7f339e9d-43b2-46fa-9971-6d1666b3979e">3,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e67684e5e949128a2dec705cc5342d_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMy0xMC0xLTEtMTc4Njg_52ef2795-ab3f-4556-8b39-f21e15b163d2">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffc59617b4841e6842d4164adb3ad90_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMy0xMi0xLTEtMTc4Njg_5281416f-8c9f-460d-8db5-e2a4dd03a455">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88535b01ff934a65be5cc199bcb770b6_D20220101-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMy0xNC0xLTEtMTc4Njg_2d0051b7-cc23-4746-941b-10f34f8cf8cd">831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c90b3c1db944b208e77b4076259563c_D20210101-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMy0xNi0xLTEtMTc4Njg_6c4c3913-ef08-46c9-aced-a1ecb7b71f78">682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nutritional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8fa29318db7448c942a75e199de1be5_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNC0yLTEtMS0xNzg2OA_77a5ad93-5fa2-45bb-96f3-473f7d43cf31">1,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3203f3fae46e1ae8028fc5a27e29c_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNC00LTEtMS0xNzg2OA_8538ec58-949f-47e7-8554-046542f53a8b">2,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30091a5d3bab43efa63d14e4a226925c_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNC02LTEtMS0xNzg2OA_ac37f9d4-3c3b-4b64-b218-28954c86e0b0">5,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151bd5c29f3c46848ec98ccbecda7c02_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNC04LTEtMS0xNzg2OA_4b72d31a-0494-4eb0-913b-587eeafd30c4">6,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8fa29318db7448c942a75e199de1be5_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNC0xMC0xLTEtMTc4Njg_004a9898-f158-4238-8f16-38ffcf026bc0">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f3203f3fae46e1ae8028fc5a27e29c_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNC0xMi0xLTEtMTc4Njg_f978efc5-133e-4e12-ba7d-ef4519a0b9a9">431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30091a5d3bab43efa63d14e4a226925c_D20220101-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNC0xNC0xLTEtMTc4Njg_c1f1fcc6-0d2a-47ec-bea9-8217864a0857">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151bd5c29f3c46848ec98ccbecda7c02_D20210101-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNC0xNi0xLTEtMTc4Njg_59e05929-493b-47d0-b33e-92b206f3e022">1,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ee6e9676f048f79f0471399c05b638_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNS0yLTEtMS0xNzg2OA_7e76fdc2-42af-49f4-bbec-59608496899f">3,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4186212e28d4b569b09c70bbface083_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNS00LTEtMS0xNzg2OA_3ab29e52-ad87-4bcf-ac2b-e48cdd554d04">3,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d0903dbdb14905994e7b293b54456f_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNS02LTEtMS0xNzg2OA_043219ea-6f87-4b6a-a5a7-bdf4ea0682e2">13,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc14a44dcf1344559829bf251b14704d_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNS04LTEtMS0xNzg2OA_dd18498d-016f-48fb-843e-2709e7c5938c">11,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ee6e9676f048f79f0471399c05b638_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNS0xMC0xLTEtMTc4Njg_b831577d-868e-4e58-9aef-84d3b658b6f5">1,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4186212e28d4b569b09c70bbface083_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNS0xMi0xLTEtMTc4Njg_7925ab87-e4f5-48d8-9f99-018964ef2ac0">1,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d0903dbdb14905994e7b293b54456f_D20220101-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNS0xNC0xLTEtMTc4Njg_3e5fea1c-3c72-49c3-9139-40adf33a77e8">5,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc14a44dcf1344559829bf251b14704d_D20210101-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNS0xNi0xLTEtMTc4Njg_10a50345-1824-496a-8c2e-5a5f8bf3ffcb">4,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91226d7ee83f4e5298c5a54390a1eccc_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNi0yLTEtMS0xNzg2OA_71d587c9-f53e-4112-ab60-d0c011166db8">3,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2c236dcb265432793429913b3061d27_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNi00LTEtMS0xNzg2OA_02566a9f-537c-43a5-b502-c4d6b03294b8">3,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i165fe1c62d6e440d91dc4abc8a0dee83_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNi02LTEtMS0xNzg2OA_70f54183-57f8-4128-ae29-1e94eb6cfc65">10,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81462640315a4b09a820a1f604b6aa3d_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNi04LTEtMS0xNzg2OA_cf03a6a5-c3cb-4f96-b8af-6aa818b25eec">10,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91226d7ee83f4e5298c5a54390a1eccc_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNi0xMC0xLTEtMTc4Njg_b24cdc6f-63bc-4925-be45-45f170272686">1,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2c236dcb265432793429913b3061d27_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNi0xMi0xLTEtMTc4Njg_83be29da-99ce-428a-85b4-474babde478f">1,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i165fe1c62d6e440d91dc4abc8a0dee83_D20220101-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNi0xNC0xLTEtMTc4Njg_308e7d52-803f-4179-9af4-542775440e72">3,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81462640315a4b09a820a1f604b6aa3d_D20210101-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNi0xNi0xLTEtMTc4Njg_206666a9-44f8-4695-8245-6b0d912b435c">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Reportable Segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3c6424ac1343408381b0dd7b44aae4_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNy0yLTEtMS0xNzg2OA_c379dcdf-2258-4995-9626-812a806c5313">10,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a9d35abc82344dd90c2c98e1ecdaa09_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNy00LTEtMS0xNzg2OA_0d7f72bb-cb44-4b37-9bf6-5b44893c1a94">10,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf83d91e28e4b25a1e93ffb4e5cc448_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNy02LTEtMS0xNzg2OA_e109b470-01a8-40f6-a8e1-7e10f281d6c1">33,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d7ba7ecde044f91a11577ec17c7a3cd_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNy04LTEtMS0xNzg2OA_031ca468-f6c7-4c9e-ab0e-c7da40dc607f">31,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3c6424ac1343408381b0dd7b44aae4_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNy0xMC0xLTEtMTc4Njg_7938ca18-64c0-40f5-9f17-a42d54d27a3f">2,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a9d35abc82344dd90c2c98e1ecdaa09_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNy0xMi0xLTEtMTc4Njg_cf9312a6-8f48-4b38-b810-2b3072444383">3,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf83d91e28e4b25a1e93ffb4e5cc448_D20220101-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNy0xNC0xLTEtMTc4Njg_e6760a8f-8a14-4776-b7a1-86037672583d">10,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d7ba7ecde044f91a11577ec17c7a3cd_D20210101-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNy0xNi0xLTEtMTc4Njg_193886b3-04e9-4213-807f-b217a5f1bd71">9,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e1452c0c5d145a29227070d32c787ac_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfOC0yLTEtMS0xNzg2OA_56d87460-501f-47c7-94f3-98bf7ed1c715">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ef09987de6c4adeb7fa5bf0cf0c7704_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfOC00LTEtMS0xNzg2OA_dde92c43-064c-440d-a3e6-35378a33d78e">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic07c5110a61643c2a55c992dde280072_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfOC02LTEtMS0xNzg2OA_1cb4dc00-6da8-4fbb-a049-f8a5f49e5229">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b228ed718b140b2a339fb6308161ea7_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfOC04LTEtMS0xNzg2OA_3ebf086b-9fac-49a2-84d7-998076e4c1f2">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfOS0yLTEtMS0xNzg2OA_d5951474-7f6d-4a2a-b358-dfea7b3346f7">10,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfOS00LTEtMS0xNzg2OA_ee24a45a-12ed-4181-8d28-fbb78504da99">10,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfOS02LTEtMS0xNzg2OA_33301128-70aa-41ee-aa96-937338b86b13">33,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfOS04LTEtMS0xNzg2OA_3c77164c-dcdd-49f0-8b85-4aa8b30d92df">31,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate functions and benefit plan costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc718d211ed24b9d86b6822747cccf0f_D20220701-20220930" decimals="-6" name="abt:CorporateAndBenefitPlanCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTAtMTAtMS0xLTE3ODY4_a877e2ef-dead-491b-beec-ca05bcd6a0a9">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic04e27180eea452fabf297f6b5a3fb8f_D20210701-20210930" decimals="-6" name="abt:CorporateAndBenefitPlanCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTAtMTItMS0xLTE3ODY4_02bfdd2c-c885-4acf-a08f-9fdcba360e71">204</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d59739e470d42f5ae66f7d538c62253_D20220101-20220930" decimals="-6" name="abt:CorporateAndBenefitPlanCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTAtMTQtMS0xLTE3ODY4_95144a41-22d5-4ff9-a4de-e71f2b943085">352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6f6799cbf824e39b44c30362ca2098b_D20210101-20210930" decimals="-6" name="abt:CorporateAndBenefitPlanCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTAtMTYtMS0xLTE3ODY4_25d97049-df70-4788-8ded-3ff306b82ae7">450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc718d211ed24b9d86b6822747cccf0f_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTEtMTAtMS0xLTE3ODY4_73efda72-b3d3-41c7-a0aa-2d4233d40fb2">86</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic04e27180eea452fabf297f6b5a3fb8f_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTEtMTItMS0xLTE3ODY4_36016094-0723-44b6-bfd0-f5b0a92e9fee">123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d59739e470d42f5ae66f7d538c62253_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTEtMTQtMS0xLTE3ODY4_c345b7b9-a7a7-4faa-8f31-f7411bae993c">309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6f6799cbf824e39b44c30362ca2098b_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTEtMTYtMS0xLTE3ODY4_9080d11c-b0b9-4eeb-a91c-6554213859b3">370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (a) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc718d211ed24b9d86b6822747cccf0f_D20220701-20220930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTItMTAtMS0xLTE3ODY4_21f22d88-cd80-49af-8930-23b96d02e86b">123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic04e27180eea452fabf297f6b5a3fb8f_D20210701-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTItMTItMS0xLTE3ODY4_1972467b-9927-4bbb-b8b9-6759a95502fa">114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d59739e470d42f5ae66f7d538c62253_D20220101-20220930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTItMTQtMS0xLTE3ODY4_6d7c6809-c400-48c8-89d9-1acfb4263aff">570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6f6799cbf824e39b44c30362ca2098b_D20210101-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTItMTYtMS0xLTE3ODY4_4754e483-111b-4f19-878e-ac024c511754">534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc718d211ed24b9d86b6822747cccf0f_D20220701-20220930" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTMtMTAtMS0xLTE3ODY4_055ecd91-691a-45fc-a608-c1622d97a21f">498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic04e27180eea452fabf297f6b5a3fb8f_D20210701-20210930" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTMtMTItMS0xLTE3ODY4_71020c2c-f996-43a2-868b-ed0d76aa020e">520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d59739e470d42f5ae66f7d538c62253_D20220101-20220930" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTMtMTQtMS0xLTE3ODY4_be29b632-2d69-4185-9256-17f3196ea070">1,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6f6799cbf824e39b44c30362ca2098b_D20210101-20210930" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTMtMTYtMS0xLTE3ODY4_0a2f8044-a298-4058-a631-e62dc0cb6cad">1,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc718d211ed24b9d86b6822747cccf0f_D20220701-20220930" decimals="-6" name="abt:OtherCostAndExpenseOperatingAndNonoperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTQtMTAtMS0xLTE3ODY4_65999f9f-4312-45c0-8fef-9fb4092771fa">211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic04e27180eea452fabf297f6b5a3fb8f_D20210701-20210930" decimals="-6" name="abt:OtherCostAndExpenseOperatingAndNonoperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTQtMTItMS0xLTE3ODY4_db86feef-d1d9-4bc6-acbe-97a6c272a940">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d59739e470d42f5ae66f7d538c62253_D20220101-20220930" decimals="-6" name="abt:OtherCostAndExpenseOperatingAndNonoperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTQtMTQtMS0xLTE3ODY4_f38ed3ac-65dd-453d-9f63-b6a96939474c">550</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6f6799cbf824e39b44c30362ca2098b_D20210101-20210930" decimals="-6" name="abt:OtherCostAndExpenseOperatingAndNonoperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTQtMTYtMS0xLTE3ODY4_240b1afe-06a6-4bb9-86e7-9e9928bf3129">1,103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTUtMTAtMS0xLTE3ODY4_c2c21baf-4041-43e3-8016-adb0d1bf5721">1,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTUtMTItMS0xLTE3ODY4_e313164a-7008-4fed-95b9-d12c6f6fbbd5">2,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTUtMTQtMS0xLTE3ODY4_f8224e30-abfd-4578-b9eb-1550cc3332d8">6,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTUtMTYtMS0xLTE3ODY4_c2e77fb8-78f9-4b86-a678-2570a3862a57">5,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="number" contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930" decimals="2" name="abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjg2N2JlYmEyMGY3ODQ1ZGZiNTg3NjFjOTI2MzNlMjRhL3RhYmxlcmFuZ2U6ODY3YmViYTIwZjc4NDVkZmI1ODc2MWM5MjYzM2UyNGFfMC0xLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjllZjAxMjQxN2Y5NzQ4OWY5MTRjOWIxYjkzYTRmMTUzXzE4_01288e8b-a187-411c-ac13-2606c6b6efdb"><ix:nonFraction unitRef="number" contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930" decimals="2" name="abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjg2N2JlYmEyMGY3ODQ1ZGZiNTg3NjFjOTI2MzNlMjRhL3RhYmxlcmFuZ2U6ODY3YmViYTIwZjc4NDVkZmI1ODc2MWM5MjYzM2UyNGFfMC0xLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjllZjAxMjQxN2Y5NzQ4OWY5MTRjOWIxYjkzYTRmMTUzXzE4_15b1a722-f342-4081-b060-85b68772b223"><ix:nonFraction unitRef="number" contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930" decimals="2" name="abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjg2N2JlYmEyMGY3ODQ1ZGZiNTg3NjFjOTI2MzNlMjRhL3RhYmxlcmFuZ2U6ODY3YmViYTIwZjc4NDVkZmI1ODc2MWM5MjYzM2UyNGFfMC0xLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjllZjAxMjQxN2Y5NzQ4OWY5MTRjOWIxYjkzYTRmMTUzXzE4_169d0f28-897a-4e9b-81bc-319b436960ec"><ix:nonFraction unitRef="number" contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930" decimals="2" name="abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjg2N2JlYmEyMGY3ODQ1ZGZiNTg3NjFjOTI2MzNlMjRhL3RhYmxlcmFuZ2U6ODY3YmViYTIwZjc4NDVkZmI1ODc2MWM5MjYzM2UyNGFfMC0xLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjllZjAxMjQxN2Y5NzQ4OWY5MTRjOWIxYjkzYTRmMTUzXzE4_f623c41d-878e-4f51-8779-4d78af4d0b2d">45</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. </span></div></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other, net for the three and nine months ended September&#160;30, 2022 includes $<ix:nonFraction unitRef="usd" contextRef="i54d09e1c87b34a10a7dd79336679c8d9_D20220701-20220930" decimals="-6" name="us-gaap:InventoryRecallExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjcyNmMzZTg2ZTlkYTQ0ZDViZTIyMGIyYmIxN2QzN2FjL3RhYmxlcmFuZ2U6NzI2YzNlODZlOWRhNDRkNWJlMjIwYjJiYjE3ZDM3YWNfMC0xLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjk1NzIwOTQ1ODliNzRjNDM4NmQ3Yzk3Mzg0Njk5MzlmXzUx_f8e3dd7a-79c3-4d25-83de-446d10a06a47">10</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8f4b8383f4d6400996c6ee0273a48d8f_D20220101-20220930" decimals="-6" name="us-gaap:InventoryRecallExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjcyNmMzZTg2ZTlkYTQ0ZDViZTIyMGIyYmIxN2QzN2FjL3RhYmxlcmFuZ2U6NzI2YzNlODZlOWRhNDRkNWJlMjIwYjJiYjE3ZDM3YWNfMC0xLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjk1NzIwOTQ1ODliNzRjNDM4NmQ3Yzk3Mzg0Njk5MzlmXzU4_8bbb58e3-815d-407a-8388-43242adb725c">172</ix:nonFraction> million, respectively, of charges related to a voluntary recall within the Nutritional Products segment and $<ix:nonFraction unitRef="usd" contextRef="id2602c6bfcec4afcb539d839ccd375bd_D20220701-20220930" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjcyNmMzZTg2ZTlkYTQ0ZDViZTIyMGIyYmIxN2QzN2FjL3RhYmxlcmFuZ2U6NzI2YzNlODZlOWRhNDRkNWJlMjIwYjJiYjE3ZDM3YWNfMC0xLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjk1NzIwOTQ1ODliNzRjNDM4NmQ3Yzk3Mzg0Njk5MzlmXzU0OTc1NTgxNDU1MQ_2c3e4efa-4636-4468-a218-ad24db7bb081"><ix:nonFraction unitRef="usd" contextRef="ia6ddcd9bbd2f4feaa5056904c8dc104b_D20220101-20220930" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjcyNmMzZTg2ZTlkYTQ0ZDViZTIyMGIyYmIxN2QzN2FjL3RhYmxlcmFuZ2U6NzI2YzNlODZlOWRhNDRkNWJlMjIwYjJiYjE3ZDM3YWNfMC0xLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjk1NzIwOTQ1ODliNzRjNDM4NmQ3Yzk3Mzg0Njk5MzlmXzU0OTc1NTgxNDU1MQ_b4961fb9-2454-4765-adb0-8155f55478bb">111</ix:nonFraction></ix:nonFraction> million of charges related to the impairment of IPR&amp;D intangible assets.  Other, net for the three and nine months ended September&#160;30, 2022 and 2021 also includes integration costs associated with the acquisition of Alere and restructuring charges. Restructuring charges in 2021 include Abbott&#8217;s restructuring plan for its COVID-19 test manufacturing network. Other, net for the nine months ended September&#160;30, 2021 also includes costs related to certain litigation.</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><div id="ib0ff9808fe764fdea19589324372f96b_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="ib0ff9808fe764fdea19589324372f96b_82"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Review &#8212; Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott&#8217;s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott&#8217;s products under a contract most impact which products are sold; price controls, competition and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott&#8217;s primary products are medical devices, diagnostic testing products, nutritional products and branded generic pharmaceuticals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables detail sales by reportable segment for the three and nine months ended September 30. Percent changes are versus the prior year and are based on unrounded numbers.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Sales to External Customers</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Impact of<br/>Foreign<br/>Exchange</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Change <br/>Excl. Foreign <br/>Exchange</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Established Pharmaceutical Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nutritional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Reportable Segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,560&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Sales to External Customers</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Impact of <br/>Foreign <br/>Exchange</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Change<br/>Excl. Foreign<br/>Exchange</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Established Pharmaceutical Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nutritional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Reportable Segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,639&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Notes: </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n/m = Percent change is not meaningful</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 1.3 percent increase in total net sales during the third quarter of 2022, excluding the impact of foreign exchange, reflected growth in the Medical Devices and Established Pharmaceutical Products segments partially offset by lower Nutritional Products sales as well as a year-over-year decline in COVID-19 testing-related revenues.  Abbott&#8217;s COVID-19 testing-related sales totaled approximately $1.7 billion during the third quarter of 2022 and approximately $1.9 billion during the third quarter of 2021. Excluding the impact of COVID-19 testing-related sales, Abbott&#8217;s total net sales decreased 3.1 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott&#8217;s total net sales increased 3.2 percent. Abbott&#8217;s net sales were unfavorably impacted by changes in foreign exchange rates in the third quarter as the relatively stronger U.S. dollar decreased total international sales by 10.0 percent and total sales by 6.0 percent.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 10.9 percent increase in total net sales during the first nine months of 2022, excluding the impact of foreign exchange, reflected demand for Abbott&#8217;s rapid diagnostic tests to detect COVID-19 as well as growth in the Medical Devices and Established Pharmaceutical Products segments partially offset by lower Nutritional Products sales. Abbott&#8217;s COVID-19 testing-related sales totaled approximately $7.3 billion during the first nine months of 2022 and approximately $5.4 billion during the first nine months of 2021. Excluding the impact of COVID-19 testing-related sales, Abbott&#8217;s total net sales increased 0.1 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott&#8217;s total net sales increased 4.9 percent. Abbott&#8217;s net sales were unfavorably impacted by changes in foreign exchange rates in the first nine months as the relatively stronger U.S. dollar decreased total international sales by 7.4 percent and total sales by 4.7 percent.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the unpredictability of the duration and impact of the current COVID-19 pandemic, the future extent to which the COVID-19 pandemic will have a material effect on Abbott&#8217;s business, financial condition or results of operations is uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides detail by sales category for the nine months ended September 30. Percent changes are versus the prior year and are based on unrounded numbers.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sept. 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sept. 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Impact of <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Change <br/>Excl. Foreign <br/>Exchange</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Established Pharmaceutical Products &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Emerging Markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nutritionals &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Adult Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostics &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetes Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the unfavorable effect of foreign exchange, sales in the Key Emerging Markets for Established Pharmaceutical Products increased 12.2 percent in the first nine months of 2022, led by double-digit growth in several countries, including India and China, and therapeutic areas, including gastroenterology, central nervous system/pain management, and respiratory products. Other Emerging Markets, excluding the effect of foreign exchange, increased by 9.5 percent in the first nine months of 2022.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International Pediatric Nutritional sales, excluding the effect of foreign exchange, decreased 4.6 percent in the first nine months of 2022 versus the comparable 2021 period. The decrease reflects the impact of challenging market dynamics in the infant category in Greater China partially offset by higher sales volumes in various countries in Southeast Asia and Latin America. International Adult Nutritional sales, excluding the effect of foreign exchange, increased 9.0 percent, reflecting double digit growth of the Ensure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Glucerna</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brands in several countries in Southeast Asia and China. In the first nine months of 2022, U.S. Adult Nutritional sales increased 1.0 percent.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In U.S. Pediatric Nutritionals, Abbott initiated a voluntary recall in February 2022 of certain infant powder formula products manufactured at its facility in Sturgis, Michigan and stopped production at the facility. On May 16, 2022, Abbott entered into a consent decree with the U.S. Food and Drug Administration (FDA) on the steps necessary to resume production and maintain the Sturgis facility and operations. On July 1, Abbott restarted partial production at the facility starting with its specialty formula EleCare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and metabolic formulas. Subsequently, Abbott restarted Similac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> production. The consent decree does not affect any other Abbott plant or operation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first three quarters of 2022, Abbott took various actions to mitigate the impact of the recall on the supply of formula in the U.S. These actions included the shipment of infant formula powder into the U.S. from Abbott's FDA-registered facility in Ireland; prioritization of infant formula production at its Columbus, Ohio facility; conversion of other liquid manufacturing lines into manufacturing Similac liquid ready-to-feed product; increased production of powder infant formula at its Casa Grande, Arizona manufacturing site; and importation of product from its facility in Spain as permitted by the FDA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 31.7 percent decrease in U.S. Pediatric Nutritional sales in the first nine months of 2022 reflects the impact of the recall and the Sturgis production stoppage partially offset by increased demand for Abbott&#8217;s Pedialyte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products. U.S. sales of infant powder formula brands associated with the recall were $277 million and $900 million in the first nine months of 2022 and 2021, respectively.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 23.1 percent increase in Diagnostic Products sales in the first nine months of 2022, excluding the impact of foreign exchange, was driven by demand for Abbott&#8217;s portfolio of COVID-19 tests in Rapid Diagnostics and growth in routine diagnostic testing in Molecular Diagnostics. In Core Laboratory Diagnostics, sales increased 1.6 percent in the first nine months of 2022, excluding the effect of foreign exchange, due to the higher volume of routine diagnostic testing from the continued roll-out of the Alinity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform and an expanded menu of tests. These increases were partially offset by lower sales of Abbott&#8217;s laboratory-based tests for the detection of COVID-19 IgG and IgM antibodies, which determine if someone was previously infected with the COVID-19 virus, as well as market disruptions in China due to COVID-19 quarantine restrictions in various cities primarily during the second quarter of 2022. In the first nine months of 2022 and 2021, Core Laboratory Diagnostics IgG and IgM antibody testing-related sales on Abbott&#8217;s ARCHITECT and Alinity i platforms were $51 million and $159 million, respectively. In the first nine months of 2022, Core Laboratory Diagnostics sales decreased 1.3 percent, excluding COVID-19 testing-related sales, and increased 4.6 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 21.9 percent decrease in Molecular Diagnostics sales in the first nine months of 2022, excluding the effect of foreign exchange, was driven by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lower demand for Abbott&#8217;s laboratory-based molecular tests for COVID-19 partially offset by growth in the base business from increased routine molecular testing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the first nine months of 2022 and 2021, Molecular Diagnostics COVID-19 testing-related sales were $375 million and $699 million, respectively. In the first nine months of 2022, Molecular Diagnostics sales increased 14.9 percent, excluding COVID-19 testing-related sales, and increased 19.4 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Rapid Diagnostics, sales increased 46.7 percent in the first nine months of 2022, excluding the effect of foreign exchange, due to the demand for Abbott&#8217;s COVID-19 tests on its rapid testing platforms, including the Panbio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system, the ID NOW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform, and the BinaxNOW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> COVID-19 Ag Card test. In the first nine months of 2022 and 2021, Rapid Diagnostics COVID-19 testing-related sales were $6.9 billion and $4.5 billion, respectively. In the first nine months of 2022, Rapid Diagnostics sales increased 11.8 percent, excluding COVID-19 testing-related sales, and increased 14.6 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases reflect higher sales </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of ID NOW tests for flu, strep, and respiratory syncytial virus (RSV) as well as growth in various other Rapid Diagnostics products.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the effect of foreign exchange, total Medical Devices sales grew 8.4 percent in the first nine months of 2022, driven by growth in Diabetes Care, Electrophysiology, Structural Heart and Heart Failure. Growth in Diabetes Care sales was driven by continued growth of FreeStyle Libre</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Abbott&#8217;s continuous glucose monitoring system, in the U.S. and internationally. FreeStyle Libre sales totaled $3.1 billion in the first nine months of 2022, which reflected a 22.8 percent increase, excluding the effect of foreign exchange, over the first nine months of 2021 when FreeStyle Libre sales totaled $2.7 billion. During the third quarter of 2022, Abbott launched its FreeStyle Libre 3 system in the U.S., which automatically delivers up-to-the-minute glucose readings and 14-day accuracy in a wearable sensor.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first nine months of 2022, procedure volumes across Abbott&#8217;s cardiovascular and neuromodulation businesses were negatively impacted by new surges of COVID-19 in various geographies as well as intermittent COVID-19 lockdown restrictions in China and healthcare staffing challenges throughout the nine months. Despite such challenges, overall volume trends improved in several businesses versus the first nine months of 2021. In Electrophysiology, the 8.2 percent growth, excluding the effect of foreign exchange, reflects the increase in procedure volumes and the continued roll&#8209;out of Abbott&#8217;s EnSite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> X EP System with Ensite Omnipolar Technology (OT), a new cardiac mapping platform available in the U.S., Japan and across Europe. In January 2022, Abbott announced FDA clearance for the EnSite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> X EP System with EnSite OT. The system leverages the Advisor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> HD Grid Catheter to provide a 360&#8209;degree view of the heart without regard to the orientation of the catheter in the heart.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Growth in Structural Heart during the first nine months of 2022, excluding the effect of foreign exchange, was 12.8 percent, driven by growth across several areas of the business, including Amplatzer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;_</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amulet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Left Atrial Appendage Occluder, which offers immediate closure of the left atrial appendage, an area in the heart where blood clots can form and MitraClip</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Abbott's market-leading device for the minimally invasive treatment of mitral regurgitation, a leaky heart valve. In Vascular, sales during the first nine months of 2022, excluding the impact of foreign exchange, were virtually unchanged as higher endovascular sales were offset by the negative effect of lower average pricing for drug-eluting stents (DES) in the U.S. and a lag in the recovery of percutaneous coronary intervention case rates compared to many other cardiovascular procedures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first nine months of 2022, Medical Devices received various other product approvals. In February 2022, Abbott received FDA approval for an expanded indication for its CardioMEMS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> HF system, a small implantable sensor and remote monitoring system that can detect early warning signs of worsening heart failure. In April 2022, Abbott announced FDA approval for its Aveir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> single-chamber leadless pacemaker for the treatment of patients in the U.S. with slow heart rhythms.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_85"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross profit margin percentage was 50.7 percent for the third quarter of 2022 compared to 54.8 percent for the third quarter of 2021.  The decrease reflects the continued impact of the voluntary product recall and Sturgis manufacturing stoppage in the Nutritional business during the first half of 2022 as well as the prioritization of infant formula sales related to the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC).  The decrease also reflects higher manufacturing and supply chain costs across Abbott's businesses, including inflation, commodities and distribution expenses as well as lower COVID-19 testing-related sales in 2022 and the nonrecurrence of a favorable change in estimate in the third quarter of 2021 related to a previously recognized restructuring plan.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross profit margin was 52.1 percent for the first nine months of 2022 compared to 51.6 percent for the first nine months of 2021. The increase reflects the nonrecurrence of 2021 restructuring charges and the impact of higher sales of COVID-19 rapid tests during the first nine months of 2022. These favorable impacts were partially offset by the impact of the voluntary product recall and Sturgis manufacturing stoppage in the Nutritional business as well as higher manufacturing and supply chain costs across Abbott's businesses, including inflation and higher commodity and distribution expenses.  The future extent to which inflation, supply chain disruptions, and unfavorable foreign exchange rates will have a material effect on Abbott's operating results is uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (R&amp;D) expenses increased $110 million, or 16.2 percent, in the third quarter of 2022 and increased $183 million, or 9.2 percent, in the first nine months of 2022 compared to the prior year. The increase in the third quarter primarily reflects the impairment of certain in-process R&amp;D intangible assets in the third quarter of 2022. The increase in the first nine months was also driven by higher spending on various projects to advance products in development partially offset by the favorable impact of foreign exchange.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (SG&amp;A) expenses decreased $36 million, or 1.3 percent, in the third quarter of 2022 compared to the prior year as higher selling and marketing spending to drive growth across various businesses was more than offset by the favorable impact of foreign exchange.  SG&amp;A expenses were virtually unchanged in the first nine months of 2022 compared to the prior year as higher selling and marketing spending was offset by the nonrecurrence of certain 2021 litigation costs and the favorable impact of foreign exchange.</span></div><div><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other (Income) Expense, net</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net increased from $74 million of income in the third quarter of 2021 to $93 million of income in the third quarter of 2022 and from $214 million of income in the first nine months of 2021 to $253 million of income in the first nine months of 2022. The increases in the third quarter and the first nine months of 2022 were primarily due to higher income in 2022 related to the non-service cost components of net pension and post-retirement medical benefit costs.  In the first nine months of 2022, the higher year-to-date income related to the non-service cost components was partially offset by the nonrecurrence of a gain on the sale of an equity method investment that occurred in the second quarter of 2021.</span></div><div><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_91"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Expense, net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Interest expense, net declined $37 million in the third quarter of 2022 and $61 million in the first nine months of 2022 versus 2021 due to the impact of higher interest rates and cash and short-term investment balances on interest income and the repayment of debt in the first quarter of 2022 partially offset by the impact of interest rate hedge contracts related to certain fixed-rate debt.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes on Earnings</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2022 and 2021, taxes on earnings include approximately $36 million and $97 million, respectively, in excess tax benefits associated with share-based compensation. In the first nine months of 2022, taxes on earnings also include approximately $20 million of tax expense as the result of the resolution of various tax positions related to prior years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax authorities in various jurisdictions regularly review Abbott&#8217;s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $75 million to $100 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_97"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity and Capital Resources September&#160;30, 2022 Compared with December&#160;31, 2021</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in cash and cash equivalents from $9.8 billion at December&#160;31, 2021 to $9.6 billion at September&#160;30, 2022 primarily reflects share repurchases, the payment of dividends, capital expenditures, and the repayment of debt partially offset by the cash generated from operations in the first nine months of 2022. Working capital was $11.5 billion at September&#160;30, 2022 and $11.1 billion at December&#160;31, 2021. The increase in working capital in 2022 primarily reflects an increase in inventory partially offset by an increase in the current portion of long-term debt and a decrease in cash and cash equivalents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first nine months of 2022 totaled approximately $7.3 billion, a decrease of $211 million from the prior year primarily due to an increased investment in working capital partially offset by higher operating earnings. Net cash from operating activities includes $362 million of pension contributions and the payment of cash taxes of approximately $987 million in 2022. Net cash from operating activities includes $366 million of pension contributions and the payment of cash taxes of approximately $990 million in 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2019, the board of directors authorized the early redemption of up to $5 billion of outstanding long-term notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of September 30, 2022, $2.15 billion of the $5 billion authorization remains available.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022, Abbott&#8217;s long-term debt rating was AA- by Standard &amp; Poor&#8217;s Corporation and A1 by Moody&#8217;s Investors Service. Abbott expects to maintain an investment grade rating. Abbott has readily available financial resources, including lines of credit of $5.0 billion which expire in 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott&#8217;s common shares from time to time. The new authorization was in addition to the $1.081 billion portion of the share repurchase program authorized in 2019 that was unused as of December 31, 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first nine months of 2022, Abbott repurchased 25.7 million of its common shares for $2.965 billion which fully utilized the authorization remaining under the 2019 share repurchase program and a portion of the 2021 authorization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of September 30, 2022, $3.116 billion remains available for repurchase under the 2021 repurchase program.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of the first three quarters of 2022, Abbott declared a quarterly dividend of $0.47 per share on its common shares, which represents an increase of 4.4 percent over the $0.45 per share dividend declared in each of the first three quarters of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_100"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Legislative Issues</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott&#8217;s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the 2021 Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Private Securities Litigation Reform Act of 1995 &#8212; A Caution Concerning Forward-Looking Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions that any forward-looking statements made by Abbott are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><div id="ib0ff9808fe764fdea19589324372f96b_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Controls and Procedures</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluation of disclosure controls and procedures. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chief Executive Officer, Robert B. Ford, and Chief Financial Officer, Robert E. Funck, Jr., evaluated the effectiveness of Abbott Laboratories&#8217; disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories&#8217; disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the &#8220;Commission&#8221;) under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott&#8217;s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="padding-left:9pt;text-align:justify"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.34pt">Changes in internal control over financial reporting. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended September 30, 2022, there were no changes in Abbott&#8217;s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott&#8217;s internal control over financial reporting.</span></div><div style="padding-left:9pt;text-align:justify"><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_106"></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PART II. OTHER INFORMATION</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_109"></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Legal Proceedings</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott is involved in various claims, legal proceedings and investigations as described in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 and our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0ff9808fe764fdea19589324372f96b_112"></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.91pt">Issuer Purchases of Equity Securities</span></div><div style="padding-left:9pt;text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.379%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(a) Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares (or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Units)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(b) Average<br/>Price Paid per<br/>Share (or<br/>Unit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(c) Total Number<br/>of Shares (or<br/>Units) Purchased<br/>as Part of<br/>Publicly<br/>Announced Plans<br/>or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(d) Maximum</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number (or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Approximate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Dollar Value) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares (or Units)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">that May Yet Be</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Purchased Under</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">the Plans or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1, 2022 - July 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,981,169,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 1, 2022 - August 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,873,473,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 1, 2022 - September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,363,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,363,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,115,796,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,413,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,413,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,115,796,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">On December 10, 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><div id="ib0ff9808fe764fdea19589324372f96b_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibits</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Exhibit</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1800/000110465922100434/tm2225651d1_ex3-1.htm">By-Laws of Abbott Laboratories, as amended and restated effective September 15, 2022, filed as Exhibit 3.1 to the Abbott Laboratories Current Report on Form 8-K fi</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1800/000110465922100434/tm2225651d1_ex3-1.htm">l</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1800/000110465922100434/tm2225651d1_ex3-1.htm">e</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1800/000110465922100434/tm2225651d1_ex3-1.htm">d on September 15, 2022</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="q3202210qex311.htm">Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="q3202210qex312.htm">Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be &#8220;filed&#8221; under the Securities Exchange Act of 1934.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="q3202210qex321.htm">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="q3202210qex322.htm">Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter and nine months ended September 30, 2022, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of Shareholders&#8217; Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed Consolidated Financial Statements.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit 101).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><div id="ib0ff9808fe764fdea19589324372f96b_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib0ff9808fe764fdea19589324372f96b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURE</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ABBOTT LABORATORIES</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert E. Funck, Jr.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Funck, Jr.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Finance <br/>and Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November&#160;1, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>q3202210qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icc825a2584f74177bddf3ae18890eba0_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert B. Ford, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Abbott&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of Abbott&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in Abbott&#8217;s internal control over financial reporting that occurred during Abbott&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Abbott&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Abbott&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott&#8217;s auditors and the audit committee of Abbott&#8217;s board of directors&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Abbott&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 1, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert B. Ford</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert B. Ford</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board and Chief Executive Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>q3202210qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i725a19490a1d42b29a85ffe021ca2f1a_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert E. Funck, Jr., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Abbott&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of Abbott&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in Abbott&#8217;s internal control over financial reporting that occurred during Abbott&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Abbott&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Abbott&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott&#8217;s auditors and the audit committee of Abbott&#8217;s board of directors&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Abbott&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 1, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert E. Funck, Jr.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Funck, Jr.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Finance<br>and Chief Financial Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>q3202210qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie5fb0d4d7a5648e9b0253eaf74d12b68_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;padding-left:108pt;padding-right:108pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant To</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant To</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Abbott Laboratories (the &#8220;Company&#8221;) on Form 10-Q for the period ended September 30, 2022 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Robert B. Ford, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert B. Ford</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert B. Ford</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>q3202210qex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i69fbfd7c147b4e8c901e59912714d95e_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant To</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant To</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Abbott Laboratories (the &#8220;Company&#8221;) on Form 10-Q for the period ended September 30, 2022 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert E. Funck, Jr.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Funck, Jr.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Finance<br>and Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>abt-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:19ee09c1-7a67-41f5-aa0d-f1189dd14b54,g:ff04be54-28ba-406d-b68f-d5381de01f45-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:abt="http://www.abbott.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.abbott.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abt-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abt-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abt-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abt-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.abbott.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEarningsUnaudited" roleURI="http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited">
        <link:definition>0000002 - Statement - Condensed Consolidated Statement of Earnings (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" roleURI="http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited">
        <link:definition>0000003 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical" roleURI="http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical">
        <link:definition>0000004 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetUnaudited" roleURI="http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited">
        <link:definition>0000005 - Statement - Condensed Consolidated Balance Sheet (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetUnauditedParenthetical" roleURI="http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical">
        <link:definition>0000006 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" roleURI="http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited">
        <link:definition>0000007 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" roleURI="http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical">
        <link:definition>0000008 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofCashFlowsUnaudited" roleURI="http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited">
        <link:definition>0000009 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.abbott.com/role/BasisofPresentation">
        <link:definition>0000010 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.abbott.com/role/Revenue">
        <link:definition>0000011 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformation" roleURI="http://www.abbott.com/role/SupplementalFinancialInformation">
        <link:definition>0000012 - Disclosure - Supplemental Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ChangesinAccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLoss">
        <link:definition>0000013 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.abbott.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000014 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringPlans" roleURI="http://www.abbott.com/role/RestructuringPlans">
        <link:definition>0000015 - Disclosure - Restructuring Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncentiveStockProgram" roleURI="http://www.abbott.com/role/IncentiveStockProgram">
        <link:definition>0000016 - Disclosure - Incentive Stock Program</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandLinesofCredit" roleURI="http://www.abbott.com/role/DebtandLinesofCredit">
        <link:definition>0000017 - Disclosure - Debt and Lines of Credit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativesandFairValueMeasures" roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures">
        <link:definition>0000018 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationandEnvironmentalMatters" roleURI="http://www.abbott.com/role/LitigationandEnvironmentalMatters">
        <link:definition>0000019 - Disclosure - Litigation and Environmental Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PostEmploymentBenefits" roleURI="http://www.abbott.com/role/PostEmploymentBenefits">
        <link:definition>0000020 - Disclosure - Post-Employment Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonEarnings" roleURI="http://www.abbott.com/role/TaxesonEarnings">
        <link:definition>0000021 - Disclosure - Taxes on Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.abbott.com/role/SegmentInformation">
        <link:definition>0000022 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.abbott.com/role/RevenueTables">
        <link:definition>0000023 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationTables" roleURI="http://www.abbott.com/role/SupplementalFinancialInformationTables">
        <link:definition>0000024 - Disclosure - Supplemental Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ChangesinAccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>0000025 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringPlansTables" roleURI="http://www.abbott.com/role/RestructuringPlansTables">
        <link:definition>0000026 - Disclosure - Restructuring Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncentiveStockProgramTables" roleURI="http://www.abbott.com/role/IncentiveStockProgramTables">
        <link:definition>0000027 - Disclosure - Incentive Stock Program (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativesandFairValueMeasuresTables" roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables">
        <link:definition>0000028 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PostEmploymentBenefitsTables" roleURI="http://www.abbott.com/role/PostEmploymentBenefitsTables">
        <link:definition>0000029 - Disclosure - Post-Employment Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.abbott.com/role/SegmentInformationTables">
        <link:definition>0000030 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://www.abbott.com/role/RevenueNarrativeDetails">
        <link:definition>0000031 - Disclosure - Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails_1" roleURI="http://www.abbott.com/role/RevenueNarrativeDetails_1">
        <link:definition>0000031 - Disclosure - Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueSegmentsDetails" roleURI="http://www.abbott.com/role/RevenueSegmentsDetails">
        <link:definition>0000032 - Disclosure - Revenue - Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueOtherContractAssetsandLiabilitiesDetails" roleURI="http://www.abbott.com/role/RevenueOtherContractAssetsandLiabilitiesDetails">
        <link:definition>0000033 - Disclosure - Revenue - Other Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationNarrativeDetails" roleURI="http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails">
        <link:definition>0000034 - Disclosure - Supplemental Financial Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" roleURI="http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails">
        <link:definition>0000035 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationInvestmentsDetails" roleURI="http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails">
        <link:definition>0000036 - Disclosure - Supplemental Financial Information - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ChangesinAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>0000037 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsDetails" roleURI="http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails">
        <link:definition>0000038 - Disclosure - Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringPlansNarrativeDetails" roleURI="http://www.abbott.com/role/RestructuringPlansNarrativeDetails">
        <link:definition>0000039 - Disclosure - Restructuring Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" roleURI="http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails">
        <link:definition>0000040 - Disclosure - Restructuring Plans - Streamline of Operations and Improve Efficiencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncentiveStockProgramNarrativeDetails" roleURI="http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails">
        <link:definition>0000041 - Disclosure - Incentive Stock Program - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncentiveStockProgramOptionsDetails" roleURI="http://www.abbott.com/role/IncentiveStockProgramOptionsDetails">
        <link:definition>0000042 - Disclosure - Incentive Stock Program - Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandLinesofCreditDetails" roleURI="http://www.abbott.com/role/DebtandLinesofCreditDetails">
        <link:definition>0000043 - Disclosure - Debt and Lines of Credit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails" roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails">
        <link:definition>0000044 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails">
        <link:definition>0000045 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails" roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails">
        <link:definition>0000046 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails">
        <link:definition>0000047 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails">
        <link:definition>0000048 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationandEnvironmentalMattersDetails" roleURI="http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails">
        <link:definition>0000049 - Disclosure - Litigation and Environmental Matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PostEmploymentBenefitsDetails" roleURI="http://www.abbott.com/role/PostEmploymentBenefitsDetails">
        <link:definition>0000050 - Disclosure - Post-Employment Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PostEmploymentBenefitsNarrativeDetails" roleURI="http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails">
        <link:definition>0000051 - Disclosure - Post-Employment Benefits - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonEarningsDetails" roleURI="http://www.abbott.com/role/TaxesonEarningsDetails">
        <link:definition>0000052 - Disclosure - Taxes on Earnings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails" roleURI="http://www.abbott.com/role/SegmentInformationDetails">
        <link:definition>0000053 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="abt_RestructuringReservePeriodCashSettledAndOtherAdjustments" abstract="false" name="RestructuringReservePeriodCashSettledAndOtherAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abt_MedicalDevicesMember" abstract="true" name="MedicalDevicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_WalkVascularLLCMember" abstract="true" name="WalkVascularLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_InventoryNoNetRealizableValueSold" abstract="false" name="InventoryNoNetRealizableValueSold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abt_KeyEmergingMarketsMember" abstract="true" name="KeyEmergingMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_FixedAssetWriteDownsMember" abstract="true" name="FixedAssetWriteDownsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite" abstract="false" name="LossContingencyRangeOfPossibleLossMaximumIndividualSite" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abt_EstablishedPharmaceuticalProductsMember" abstract="true" name="EstablishedPharmaceuticalProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_A255LongTermNotesDue2022Member" abstract="true" name="A255LongTermNotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_ContractLiabilitiesRollForward" abstract="true" name="ContractLiabilitiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess" abstract="false" name="PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abt_OtherExitCostsMember" abstract="true" name="OtherExitCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent" abstract="false" name="AnnualShareBasedAwardsRecognizedInFirstQuarterPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abt_ScheduleOfGoodwillAndIntangibleAssetsTable" abstract="true" name="ScheduleOfGoodwillAndIntangibleAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="abt_RestrictedStockAwardsMember" abstract="true" name="RestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_DefinedBenefitPlanNetAmortizationCostsAbstract" abstract="true" name="DefinedBenefitPlanNetAmortizationCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abt_ExcessTaxBenefitFromShareBasedCompensation" abstract="false" name="ExcessTaxBenefitFromShareBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abt_GoodwillAndIntangibleAssetsLineItems" abstract="true" name="GoodwillAndIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abt_LegalProceedingsAndEnvironmentalExposuresMember" abstract="true" name="LegalProceedingsAndEnvironmentalExposuresMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_PrepaidExpenseAndOtherReceivables" abstract="false" name="PrepaidExpenseAndOtherReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations" abstract="false" name="NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abt_VascularMember" abstract="true" name="VascularMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember" abstract="true" name="RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_RapidDiagnosticsMember" abstract="true" name="RapidDiagnosticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_ScheduleOfLongTermInvestmentsTableTextBlock" abstract="false" name="ScheduleOfLongTermInvestmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="abt_DiabetesCareMember" abstract="true" name="DiabetesCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_MolecularMember" abstract="true" name="MolecularMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_HeartFailureMember" abstract="true" name="HeartFailureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_NutritionalProductsMember" abstract="true" name="NutritionalProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_CoreLaboratoryMember" abstract="true" name="CoreLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_YenDenominatedLongTermDebtMember" abstract="true" name="YenDenominatedLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_OtherEmergingMarketsMember" abstract="true" name="OtherEmergingMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_COVID19TestManufacturingNetworkRestructuringPlanMember" abstract="true" name="COVID19TestManufacturingNetworkRestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_StJudeMedicalIncMember" abstract="true" name="StJudeMedicalIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites" abstract="false" name="LossContingencyRangeOfPossibleLossMaximumAggregateSites" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abt_PrepaidExpensesAndOtherReceivablesMember" abstract="true" name="PrepaidExpensesAndOtherReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_PediatricNutritionalsMember" abstract="true" name="PediatricNutritionalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_RhythmManagementMember" abstract="true" name="RhythmManagementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized" abstract="false" name="ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abt_NeuromodulationMember" abstract="true" name="NeuromodulationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage" abstract="false" name="RevenueRemainingPerformanceObligationExpectedTimingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abt_AdultNutritionalsMember" abstract="true" name="AdultNutritionalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_DiagnosticProductsMember" abstract="true" name="DiagnosticProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_EffectOfCommonAndTreasuryShareTransactions" abstract="false" name="EffectOfCommonAndTreasuryShareTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities" abstract="false" name="PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abt_CostOfGoodsAndServicesSoldMember" abstract="true" name="CostOfGoodsAndServicesSoldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_InventoryRelatedChargesMember" abstract="true" name="InventoryRelatedChargesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_StructuralHeartMember" abstract="true" name="StructuralHeartMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_StockIssuedDuringPeriodValueIncentiveStockPrograms" abstract="false" name="StockIssuedDuringPeriodValueIncentiveStockPrograms" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abt_DeferredIncomeTaxesAndOtherAssetsMember" abstract="true" name="DeferredIncomeTaxesAndOtherAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_PointOfCareMember" abstract="true" name="PointOfCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_MinimumLengthOfTimeHedgedInCashFlowHedge" abstract="false" name="MinimumLengthOfTimeHedgedInCashFlowHedge" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="abt_OtherCostAndExpenseOperatingAndNonoperating" abstract="false" name="OtherCostAndExpenseOperatingAndNonoperating" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abt_CorporateAndBenefitPlanCosts" abstract="false" name="CorporateAndBenefitPlanCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abt_ElectrophysiologyMember" abstract="true" name="ElectrophysiologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms" abstract="false" name="StockIssuedDuringPeriodSharesIncentiveStockPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember" abstract="true" name="PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>abt-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:19ee09c1-7a67-41f5-aa0d-f1189dd14b54,g:ff04be54-28ba-406d-b68f-d5381de01f45-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" xlink:type="simple" xlink:href="abt-20220930.xsd#CondensedConsolidatedStatementofEarningsUnaudited"/>
  <link:calculationLink xlink:role="http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f3987ca4-d471-4419-825f-d3428b6d4a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_50143dec-1104-4aeb-abd8-b64793bce7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3987ca4-d471-4419-825f-d3428b6d4a27" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_50143dec-1104-4aeb-abd8-b64793bce7cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_dc0727f1-7b19-408d-8d5a-1c25adf8bb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3987ca4-d471-4419-825f-d3428b6d4a27" xlink:to="loc_us-gaap_CostsAndExpenses_dc0727f1-7b19-408d-8d5a-1c25adf8bb8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f9c5528b-73f0-41a7-9d6e-2f844f39cb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_809a4b13-5938-4e82-86ee-176158606fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f9c5528b-73f0-41a7-9d6e-2f844f39cb1f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_809a4b13-5938-4e82-86ee-176158606fec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ab052c89-bda6-49a4-a33d-071bf72b4cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f9c5528b-73f0-41a7-9d6e-2f844f39cb1f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ab052c89-bda6-49a4-a33d-071bf72b4cc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1b1de7f9-e685-4a14-9aaf-8426edaac31d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4f364919-9ca0-4112-8d3f-9c2acfff25b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1b1de7f9-e685-4a14-9aaf-8426edaac31d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4f364919-9ca0-4112-8d3f-9c2acfff25b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_45228354-edb2-4bad-8b8b-7285acaefd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1b1de7f9-e685-4a14-9aaf-8426edaac31d" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_45228354-edb2-4bad-8b8b-7285acaefd9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6d661588-b2bc-4b46-8b3b-e2230a247d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_47203452-ae02-4bfa-9af5-aaee43acde68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6d661588-b2bc-4b46-8b3b-e2230a247d6d" xlink:to="loc_us-gaap_OperatingIncomeLoss_47203452-ae02-4bfa-9af5-aaee43acde68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_de7c29c4-8116-41c9-b18c-da85380bc4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6d661588-b2bc-4b46-8b3b-e2230a247d6d" xlink:to="loc_us-gaap_InterestExpense_de7c29c4-8116-41c9-b18c-da85380bc4f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_615ba79a-58e6-412c-b57d-9a88de9433c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6d661588-b2bc-4b46-8b3b-e2230a247d6d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_615ba79a-58e6-412c-b57d-9a88de9433c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8b02cfcf-d06c-4366-a0fc-38e475e13619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6d661588-b2bc-4b46-8b3b-e2230a247d6d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8b02cfcf-d06c-4366-a0fc-38e475e13619" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e42f43d8-7798-43ce-b528-75424dba1fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6d661588-b2bc-4b46-8b3b-e2230a247d6d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e42f43d8-7798-43ce-b528-75424dba1fb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6722543d-5560-4ef5-8e52-28eae181711b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_eab3fe50-b5c2-4668-808a-2c9e30120f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6722543d-5560-4ef5-8e52-28eae181711b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_eab3fe50-b5c2-4668-808a-2c9e30120f9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_8c31bce2-28c8-4747-870b-94ee0fd2b2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6722543d-5560-4ef5-8e52-28eae181711b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_8c31bce2-28c8-4747-870b-94ee0fd2b2c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_05139c93-900e-4e86-8cfe-c70b83b1a386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6722543d-5560-4ef5-8e52-28eae181711b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_05139c93-900e-4e86-8cfe-c70b83b1a386" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6c5ba472-63c3-43c3-9e43-a855dce763ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_6722543d-5560-4ef5-8e52-28eae181711b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6c5ba472-63c3-43c3-9e43-a855dce763ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="abt-20220930.xsd#CondensedConsolidatedStatementofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a62110c8-95c3-4c82-91d6-3d760ed77daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6ba288a0-d1e9-43e5-9db8-fa385182f4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a62110c8-95c3-4c82-91d6-3d760ed77daa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6ba288a0-d1e9-43e5-9db8-fa385182f4cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_fc9ee684-7ef5-4321-968d-01ef1612d0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a62110c8-95c3-4c82-91d6-3d760ed77daa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_fc9ee684-7ef5-4321-968d-01ef1612d0cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_6261055a-beca-401f-acd4-b34bc5308062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a62110c8-95c3-4c82-91d6-3d760ed77daa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_6261055a-beca-401f-acd4-b34bc5308062" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b8a3c227-1e58-4ce4-b493-59bc5e028584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b47f679b-94d9-4009-a108-a3b5f90c8e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b8a3c227-1e58-4ce4-b493-59bc5e028584" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b47f679b-94d9-4009-a108-a3b5f90c8e54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_119131c9-fec3-4267-b78b-a0b8ee82b115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b8a3c227-1e58-4ce4-b493-59bc5e028584" xlink:to="loc_us-gaap_NetIncomeLoss_119131c9-fec3-4267-b78b-a0b8ee82b115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_662451f6-c42e-4db2-82de-c5d5de653060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_fc084cc2-239a-48fa-87d2-33474a281dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_662451f6-c42e-4db2-82de-c5d5de653060" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_fc084cc2-239a-48fa-87d2-33474a281dc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_dfcc530a-8ed4-4a17-8aa4-afb323da1549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_662451f6-c42e-4db2-82de-c5d5de653060" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_dfcc530a-8ed4-4a17-8aa4-afb323da1549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_02215253-f148-44fb-8f6b-bd8c4c1096de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_662451f6-c42e-4db2-82de-c5d5de653060" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_02215253-f148-44fb-8f6b-bd8c4c1096de" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" xlink:type="simple" xlink:href="abt-20220930.xsd#CondensedConsolidatedBalanceSheetUnaudited"/>
  <link:calculationLink xlink:role="http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e719713-daa4-48d3-8806-f6ed436ea177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b0592488-e137-4d61-9c38-5e10456b60b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e719713-daa4-48d3-8806-f6ed436ea177" xlink:to="loc_us-gaap_StockholdersEquity_b0592488-e137-4d61-9c38-5e10456b60b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9af64f69-90a1-423e-acba-4a004695bbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e719713-daa4-48d3-8806-f6ed436ea177" xlink:to="loc_us-gaap_MinorityInterest_9af64f69-90a1-423e-acba-4a004695bbe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0c3cc0c5-5fce-47a9-a3c8-c37730ca48ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1c511674-2c90-4ec2-acd9-d53b4a94006a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c3cc0c5-5fce-47a9-a3c8-c37730ca48ec" xlink:to="loc_us-gaap_PreferredStockValue_1c511674-2c90-4ec2-acd9-d53b4a94006a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d5b52910-a2b7-4514-b144-31d0ca45875d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c3cc0c5-5fce-47a9-a3c8-c37730ca48ec" xlink:to="loc_us-gaap_CommonStockValue_d5b52910-a2b7-4514-b144-31d0ca45875d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_61a7acc0-74eb-4e25-8f08-8b7438a973f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c3cc0c5-5fce-47a9-a3c8-c37730ca48ec" xlink:to="loc_us-gaap_TreasuryStockCommonValue_61a7acc0-74eb-4e25-8f08-8b7438a973f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f425eba7-3118-4a29-a8d3-068cdec27323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c3cc0c5-5fce-47a9-a3c8-c37730ca48ec" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f425eba7-3118-4a29-a8d3-068cdec27323" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1b37704b-9585-45f9-8f87-3c4279af4f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c3cc0c5-5fce-47a9-a3c8-c37730ca48ec" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1b37704b-9585-45f9-8f87-3c4279af4f67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a139eae2-2007-4810-ad5e-ed9b0fee0122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_22677389-0ca7-4cee-9b5b-e4f8c439d2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a139eae2-2007-4810-ad5e-ed9b0fee0122" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_22677389-0ca7-4cee-9b5b-e4f8c439d2ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_286dc2d6-d3e6-4477-ac25-eb26504edb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a139eae2-2007-4810-ad5e-ed9b0fee0122" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_286dc2d6-d3e6-4477-ac25-eb26504edb3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_c5d64de5-b2c0-4a45-92cc-7bdc3a06518d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a139eae2-2007-4810-ad5e-ed9b0fee0122" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_c5d64de5-b2c0-4a45-92cc-7bdc3a06518d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_39759dd0-250f-4e48-89f9-50ff86b84cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9207658c-53c9-4e72-898e-e0b7149c0d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_39759dd0-250f-4e48-89f9-50ff86b84cbf" xlink:to="loc_us-gaap_LiabilitiesCurrent_9207658c-53c9-4e72-898e-e0b7149c0d84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1e753fb8-9c49-477d-b1c3-42f856aa943a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_39759dd0-250f-4e48-89f9-50ff86b84cbf" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1e753fb8-9c49-477d-b1c3-42f856aa943a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities_b662837a-58e5-4ac3-8ea3-8842457b1e8c" xlink:href="abt-20220930.xsd#abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_39759dd0-250f-4e48-89f9-50ff86b84cbf" xlink:to="loc_abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities_b662837a-58e5-4ac3-8ea3-8842457b1e8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2ce210e3-4965-4a0c-9084-6c5ef5ae77a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_39759dd0-250f-4e48-89f9-50ff86b84cbf" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2ce210e3-4965-4a0c-9084-6c5ef5ae77a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8bbe972-c0fc-4c0c-8ea4-775d6b630534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_39759dd0-250f-4e48-89f9-50ff86b84cbf" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8bbe972-c0fc-4c0c-8ea4-775d6b630534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f0f8dd2e-0351-4def-9be4-c15142743e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dff1052e-094c-4123-9216-a343590d823d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f0f8dd2e-0351-4def-9be4-c15142743e85" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dff1052e-094c-4123-9216-a343590d823d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_669065ea-34ea-4af7-aa19-f079fe1df5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f0f8dd2e-0351-4def-9be4-c15142743e85" xlink:to="loc_us-gaap_ShortTermInvestments_669065ea-34ea-4af7-aa19-f079fe1df5b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_463ad657-4658-4c88-9137-95d8362b3ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f0f8dd2e-0351-4def-9be4-c15142743e85" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_463ad657-4658-4c88-9137-95d8362b3ecf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b930e754-2d52-4e4d-af20-f73ea79192b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f0f8dd2e-0351-4def-9be4-c15142743e85" xlink:to="loc_us-gaap_InventoryNet_b930e754-2d52-4e4d-af20-f73ea79192b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PrepaidExpenseAndOtherReceivables_74449280-b382-4d25-baf1-0cad05ee5067" xlink:href="abt-20220930.xsd#abt_PrepaidExpenseAndOtherReceivables"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f0f8dd2e-0351-4def-9be4-c15142743e85" xlink:to="loc_abt_PrepaidExpenseAndOtherReceivables_74449280-b382-4d25-baf1-0cad05ee5067" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_39a5c285-a730-452b-8a41-5a4b76819dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2dc0de10-2c8f-42fb-bad4-5cbd7d914cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_39a5c285-a730-452b-8a41-5a4b76819dbe" xlink:to="loc_us-gaap_AssetsCurrent_2dc0de10-2c8f-42fb-bad4-5cbd7d914cf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_b5950f97-d569-4047-8b5f-fecd53f6b592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_39a5c285-a730-452b-8a41-5a4b76819dbe" xlink:to="loc_us-gaap_LongTermInvestments_b5950f97-d569-4047-8b5f-fecd53f6b592" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_59aa367b-6c3f-49d5-873c-b72467718657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_39a5c285-a730-452b-8a41-5a4b76819dbe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_59aa367b-6c3f-49d5-873c-b72467718657" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b001c2b6-3519-42f8-85e3-045806ee12a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_39a5c285-a730-452b-8a41-5a4b76819dbe" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b001c2b6-3519-42f8-85e3-045806ee12a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7914c04e-ebc7-437c-b964-32e0190f3a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_39a5c285-a730-452b-8a41-5a4b76819dbe" xlink:to="loc_us-gaap_Goodwill_7914c04e-ebc7-437c-b964-32e0190f3a25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_d3113ff6-3450-4632-b07c-c72f714a7458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_39a5c285-a730-452b-8a41-5a4b76819dbe" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_d3113ff6-3450-4632-b07c-c72f714a7458" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3fa6dac5-71d1-4ca7-9ac8-31ad53c4401c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_34911dcb-2053-432f-96aa-7d6f1d5ee39b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3fa6dac5-71d1-4ca7-9ac8-31ad53c4401c" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_34911dcb-2053-432f-96aa-7d6f1d5ee39b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_59bb469b-37a9-45c0-8c55-5e20dec26106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3fa6dac5-71d1-4ca7-9ac8-31ad53c4401c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_59bb469b-37a9-45c0-8c55-5e20dec26106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d6aa3f4e-b544-4b80-b635-6321fbb21efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3fa6dac5-71d1-4ca7-9ac8-31ad53c4401c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d6aa3f4e-b544-4b80-b635-6321fbb21efa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_c936e312-d5ed-4060-bd44-a5e7f4d2a611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3fa6dac5-71d1-4ca7-9ac8-31ad53c4401c" xlink:to="loc_us-gaap_DividendsPayableCurrent_c936e312-d5ed-4060-bd44-a5e7f4d2a611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_5c8a5f75-dfaa-4dda-98a7-9ec396ac7fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3fa6dac5-71d1-4ca7-9ac8-31ad53c4401c" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_5c8a5f75-dfaa-4dda-98a7-9ec396ac7fae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_4ac6cfd6-db86-4751-8375-5f3b338b8ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3fa6dac5-71d1-4ca7-9ac8-31ad53c4401c" xlink:to="loc_us-gaap_LongTermDebtCurrent_4ac6cfd6-db86-4751-8375-5f3b338b8ee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_78a838e1-1feb-422f-9909-fab58e4df73b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e117898a-2f3a-4fd1-9278-f0a8bff6353c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_78a838e1-1feb-422f-9909-fab58e4df73b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e117898a-2f3a-4fd1-9278-f0a8bff6353c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d760d118-b73b-4dae-9213-a58ee9c545db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_78a838e1-1feb-422f-9909-fab58e4df73b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d760d118-b73b-4dae-9213-a58ee9c545db" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" xlink:type="simple" xlink:href="abt-20220930.xsd#CondensedConsolidatedStatementofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f776a9c-2ed7-4e8f-a304-52228915d59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3cedea59-4205-4869-bd01-8627433e91e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f776a9c-2ed7-4e8f-a304-52228915d59a" xlink:to="loc_us-gaap_NetIncomeLoss_3cedea59-4205-4869-bd01-8627433e91e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_21f17b86-22d8-4db5-88ac-30eb390e4ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f776a9c-2ed7-4e8f-a304-52228915d59a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_21f17b86-22d8-4db5-88ac-30eb390e4ac9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_37b6e381-370a-4370-a206-c3b95747085a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f776a9c-2ed7-4e8f-a304-52228915d59a" xlink:to="loc_us-gaap_Depreciation_37b6e381-370a-4370-a206-c3b95747085a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_590699c0-e3c4-4fda-ab7c-79fc329ba151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f776a9c-2ed7-4e8f-a304-52228915d59a" xlink:to="loc_us-gaap_ShareBasedCompensation_590699c0-e3c4-4fda-ab7c-79fc329ba151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4294645a-7057-4e76-bcdb-9b080fbc327c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f776a9c-2ed7-4e8f-a304-52228915d59a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4294645a-7057-4e76-bcdb-9b080fbc327c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e3284b34-c2d5-40e3-a343-38df163648d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f776a9c-2ed7-4e8f-a304-52228915d59a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e3284b34-c2d5-40e3-a343-38df163648d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_405714bf-49bd-40bf-95a8-02d9baa6071f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f776a9c-2ed7-4e8f-a304-52228915d59a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_405714bf-49bd-40bf-95a8-02d9baa6071f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4743baf7-9d6d-4bf5-bf42-bd6a231b4be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7d3049d7-9ea7-47d8-96a0-04425edc052b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4743baf7-9d6d-4bf5-bf42-bd6a231b4be6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7d3049d7-9ea7-47d8-96a0-04425edc052b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess_84ac17ce-fd2c-42a3-b01c-1fac90ab9fa8" xlink:href="abt-20220930.xsd#abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4743baf7-9d6d-4bf5-bf42-bd6a231b4be6" xlink:to="loc_abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess_84ac17ce-fd2c-42a3-b01c-1fac90ab9fa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_dd6a0b45-56b6-44ba-b09d-c4739e761ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4743baf7-9d6d-4bf5-bf42-bd6a231b4be6" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_dd6a0b45-56b6-44ba-b09d-c4739e761ed8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_0ad6d57c-d97e-41da-9f25-eaffa4c7186d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4743baf7-9d6d-4bf5-bf42-bd6a231b4be6" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments_0ad6d57c-d97e-41da-9f25-eaffa4c7186d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_47b0b68c-bfce-4631-b9a1-6652fd9fb4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4743baf7-9d6d-4bf5-bf42-bd6a231b4be6" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_47b0b68c-bfce-4631-b9a1-6652fd9fb4e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec0c095f-7110-446c-b4f9-a82cbbcee402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_5126e531-583d-4f53-9d1e-6a740a6f7c06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec0c095f-7110-446c-b4f9-a82cbbcee402" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_5126e531-583d-4f53-9d1e-6a740a6f7c06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_a4936400-c24a-49e2-bdad-bf9c881313ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec0c095f-7110-446c-b4f9-a82cbbcee402" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_a4936400-c24a-49e2-bdad-bf9c881313ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6af093d4-8adf-4bc0-90fc-32590044036e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec0c095f-7110-446c-b4f9-a82cbbcee402" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6af093d4-8adf-4bc0-90fc-32590044036e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_560a33a8-7866-4384-b3f5-3a8e33e9051c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec0c095f-7110-446c-b4f9-a82cbbcee402" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_560a33a8-7866-4384-b3f5-3a8e33e9051c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_450766ef-07fe-4733-80a9-d5fa7a6a3dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec0c095f-7110-446c-b4f9-a82cbbcee402" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_450766ef-07fe-4733-80a9-d5fa7a6a3dc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b2009bec-ee43-4ea8-9276-5911834ec265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec0c095f-7110-446c-b4f9-a82cbbcee402" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b2009bec-ee43-4ea8-9276-5911834ec265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a90e4b0-d7ff-45f6-8be7-64214acab635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_edd646af-6d9e-4030-8fb2-92c643bf35ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a90e4b0-d7ff-45f6-8be7-64214acab635" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_edd646af-6d9e-4030-8fb2-92c643bf35ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_354253de-6dc2-4951-ad12-336e212a2e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a90e4b0-d7ff-45f6-8be7-64214acab635" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_354253de-6dc2-4951-ad12-336e212a2e30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_555fcdfc-f37d-49d8-8435-7bf6d6ff98b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a90e4b0-d7ff-45f6-8be7-64214acab635" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_555fcdfc-f37d-49d8-8435-7bf6d6ff98b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_9c3b834a-3b88-444e-a49e-ee6759e311c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5a90e4b0-d7ff-45f6-8be7-64214acab635" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_9c3b834a-3b88-444e-a49e-ee6759e311c3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#ChangesinAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a702b488-19d4-4869-8de3-9969784a12ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6c5a7f09-82c9-418d-8e69-456ddf77b037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a702b488-19d4-4869-8de3-9969784a12ff" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6c5a7f09-82c9-418d-8e69-456ddf77b037" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_d80e5568-fdb1-49fd-b072-ff937b4f70c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a702b488-19d4-4869-8de3-9969784a12ff" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_d80e5568-fdb1-49fd-b072-ff937b4f70c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"/>
  <link:calculationLink xlink:role="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_ef166ea4-75ea-4d51-ae67-65d389c7c84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_4f7a07b7-dbff-4d54-bbe3-85e6e21f8d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_ef166ea4-75ea-4d51-ae67-65d389c7c84e" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_4f7a07b7-dbff-4d54-bbe3-85e6e21f8d51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_497601f7-d957-4195-b7ba-72901c36d364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_ef166ea4-75ea-4d51-ae67-65d389c7c84e" xlink:to="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_497601f7-d957-4195-b7ba-72901c36d364" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_19744ae0-5700-4acf-940e-1b8fefadf88a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_ef166ea4-75ea-4d51-ae67-65d389c7c84e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_19744ae0-5700-4acf-940e-1b8fefadf88a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue_318eb67d-a148-4f08-9f7e-5d87f3304997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_ef166ea4-75ea-4d51-ae67-65d389c7c84e" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue_318eb67d-a148-4f08-9f7e-5d87f3304997" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_411e10a4-0b81-45cb-bc43-56e378218fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d78f21e3-df20-40a2-8a29-04f41a9570c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_411e10a4-0b81-45cb-bc43-56e378218fdb" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d78f21e3-df20-40a2-8a29-04f41a9570c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_1ab113bb-f196-4f6c-835f-b29e706d57c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_411e10a4-0b81-45cb-bc43-56e378218fdb" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_1ab113bb-f196-4f6c-835f-b29e706d57c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue_97f08c1a-e0d5-44f8-9ecf-36b353efd98e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_411e10a4-0b81-45cb-bc43-56e378218fdb" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue_97f08c1a-e0d5-44f8-9ecf-36b353efd98e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/PostEmploymentBenefitsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#PostEmploymentBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.abbott.com/role/PostEmploymentBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e29aee49-cce9-48c6-8a73-59e8900ae1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_7cf5db43-a9f5-415f-baaa-bd0041f73989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e29aee49-cce9-48c6-8a73-59e8900ae1e5" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_7cf5db43-a9f5-415f-baaa-bd0041f73989" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_f67613e9-adb3-4e3a-bf1d-184997da1658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e29aee49-cce9-48c6-8a73-59e8900ae1e5" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_f67613e9-adb3-4e3a-bf1d-184997da1658" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_fe48acfa-b26d-424f-9aa7-b69ec5dac218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e29aee49-cce9-48c6-8a73-59e8900ae1e5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_fe48acfa-b26d-424f-9aa7-b69ec5dac218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_85c5c2fd-5008-4054-9fea-96e144e5669f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e29aee49-cce9-48c6-8a73-59e8900ae1e5" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_85c5c2fd-5008-4054-9fea-96e144e5669f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_7ce8416b-889f-488b-82f5-e2149297c0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e29aee49-cce9-48c6-8a73-59e8900ae1e5" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_7ce8416b-889f-488b-82f5-e2149297c0b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#SegmentInformationDetails"/>
  <link:calculationLink xlink:role="http://www.abbott.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cca26b17-78fa-41df-a3b7-29c8536a07c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5c053a05-4905-4c43-b873-e9b93a56f9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cca26b17-78fa-41df-a3b7-29c8536a07c0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5c053a05-4905-4c43-b873-e9b93a56f9b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_5f3a8d93-fd06-4a5d-b4f7-ebd971c983cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cca26b17-78fa-41df-a3b7-29c8536a07c0" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_5f3a8d93-fd06-4a5d-b4f7-ebd971c983cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_71563cbf-8aa6-4719-af5f-9cd0e8c91f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cca26b17-78fa-41df-a3b7-29c8536a07c0" xlink:to="loc_us-gaap_OperatingIncomeLoss_71563cbf-8aa6-4719-af5f-9cd0e8c91f56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_CorporateAndBenefitPlanCosts_234ac679-fe42-48bc-9da6-28bcaf7e7924" xlink:href="abt-20220930.xsd#abt_CorporateAndBenefitPlanCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cca26b17-78fa-41df-a3b7-29c8536a07c0" xlink:to="loc_abt_CorporateAndBenefitPlanCosts_234ac679-fe42-48bc-9da6-28bcaf7e7924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_OtherCostAndExpenseOperatingAndNonoperating_ad43c7f7-86ef-4be0-9a55-7954170047ee" xlink:href="abt-20220930.xsd#abt_OtherCostAndExpenseOperatingAndNonoperating"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cca26b17-78fa-41df-a3b7-29c8536a07c0" xlink:to="loc_abt_OtherCostAndExpenseOperatingAndNonoperating_ad43c7f7-86ef-4be0-9a55-7954170047ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_78b545c8-5ce4-4ac3-bc99-734ef1acd7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cca26b17-78fa-41df-a3b7-29c8536a07c0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_78b545c8-5ce4-4ac3-bc99-734ef1acd7fb" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>abt-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:19ee09c1-7a67-41f5-aa0d-f1189dd14b54,g:ff04be54-28ba-406d-b68f-d5381de01f45-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.abbott.com/role/Cover" xlink:type="simple" xlink:href="abt-20220930.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/Cover" xlink:type="extended" id="i0136464f28514de8b9ef07acf69f0d46_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_644bb62b-7fd2-4e03-baa1-4a74dc2a8191" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_DocumentType_644bb62b-7fd2-4e03-baa1-4a74dc2a8191" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_677759f2-c375-464e-a845-4b5b84f4d49f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_DocumentQuarterlyReport_677759f2-c375-464e-a845-4b5b84f4d49f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5f7db9bb-3f6f-4f93-bd9b-3b73835b5820" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_DocumentPeriodEndDate_5f7db9bb-3f6f-4f93-bd9b-3b73835b5820" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c2826a80-a59d-4e52-af63-0ffa222969bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_DocumentTransitionReport_c2826a80-a59d-4e52-af63-0ffa222969bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5be6739f-d1f5-4aaf-829d-8d60cc12956d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityFileNumber_5be6739f-d1f5-4aaf-829d-8d60cc12956d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0f45ac9a-dd69-4807-a71e-7cddf8e3e2be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityRegistrantName_0f45ac9a-dd69-4807-a71e-7cddf8e3e2be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_515c4463-3e1d-48b6-a831-d9a091475f99" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_515c4463-3e1d-48b6-a831-d9a091475f99" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_7f6e8308-82c6-4ca9-9f96-faeae1f1da6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityTaxIdentificationNumber_7f6e8308-82c6-4ca9-9f96-faeae1f1da6a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e832fda1-446a-4c69-928d-221d2144d2e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityAddressAddressLine1_e832fda1-446a-4c69-928d-221d2144d2e4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1aa5f367-8724-4aa5-b6f9-0af7d8ab4dd9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityAddressCityOrTown_1aa5f367-8724-4aa5-b6f9-0af7d8ab4dd9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_29126db9-310b-4af6-b399-3423fe6fc99e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityAddressStateOrProvince_29126db9-310b-4af6-b399-3423fe6fc99e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_81175d42-4bc3-4f69-ab6e-53ecb149d5d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityAddressPostalZipCode_81175d42-4bc3-4f69-ab6e-53ecb149d5d9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c12aac2f-2e0f-4f16-95fa-7c1e3968247c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_CityAreaCode_c12aac2f-2e0f-4f16-95fa-7c1e3968247c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_91744cda-4a80-4a3b-930b-b7ad1d9e2e81" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_LocalPhoneNumber_91744cda-4a80-4a3b-930b-b7ad1d9e2e81" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8539f332-e300-4f91-8fe3-b77ace5bed39" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_Security12bTitle_8539f332-e300-4f91-8fe3-b77ace5bed39" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f591b5cf-2a08-4b27-a049-a02de3116116" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_TradingSymbol_f591b5cf-2a08-4b27-a049-a02de3116116" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c25078fe-4e00-4c38-b5cf-df20657edd12" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_SecurityExchangeName_c25078fe-4e00-4c38-b5cf-df20657edd12" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_cf25a8ef-6ae4-40f3-ab7e-3b140cacf982" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityCurrentReportingStatus_cf25a8ef-6ae4-40f3-ab7e-3b140cacf982" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_331614e2-56a1-4268-a4cc-74170bba0541" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityInteractiveDataCurrent_331614e2-56a1-4268-a4cc-74170bba0541" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e9c55340-baa3-408d-82d3-7aa28da7e162" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityFilerCategory_e9c55340-baa3-408d-82d3-7aa28da7e162" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b9d1b9ed-225d-467c-8185-58a93ad05eca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntitySmallBusiness_b9d1b9ed-225d-467c-8185-58a93ad05eca" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_982438c8-718e-4258-86bc-2613275605bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityEmergingGrowthCompany_982438c8-718e-4258-86bc-2613275605bc" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_712de04e-093c-489c-bad5-186d54f3c591" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityShellCompany_712de04e-093c-489c-bad5-186d54f3c591" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e18989c7-39a4-4cac-b277-ef93e5be3cca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e18989c7-39a4-4cac-b277-ef93e5be3cca" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bd796172-e69c-4362-8acc-db0920965a0b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityCentralIndexKey_bd796172-e69c-4362-8acc-db0920965a0b" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_aad51c28-770c-4e7d-8d9f-eaf4e0620f4f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_CurrentFiscalYearEndDate_aad51c28-770c-4e7d-8d9f-eaf4e0620f4f" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_810b3e9b-390e-4442-aa08-0ed3d1c2992e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_DocumentFiscalYearFocus_810b3e9b-390e-4442-aa08-0ed3d1c2992e" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c801aaea-f5b6-41cd-a26c-54bac3c23a30" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c801aaea-f5b6-41cd-a26c-54bac3c23a30" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3fcc319a-19d1-4f09-b8b2-dab41890478b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_AmendmentFlag_3fcc319a-19d1-4f09-b8b2-dab41890478b" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_286a11ea-421e-4a31-b74c-f0dbc4d9a315" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_DocumentInformationTable_286a11ea-421e-4a31-b74c-f0dbc4d9a315" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_77219ae1-9ee0-42f9-96ee-489f182fbec9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_286a11ea-421e-4a31-b74c-f0dbc4d9a315" xlink:to="loc_dei_EntityListingsExchangeAxis_77219ae1-9ee0-42f9-96ee-489f182fbec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_77219ae1-9ee0-42f9-96ee-489f182fbec9_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_77219ae1-9ee0-42f9-96ee-489f182fbec9" xlink:to="loc_dei_ExchangeDomain_77219ae1-9ee0-42f9-96ee-489f182fbec9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_22eecffb-61c9-4fa2-8e54-4dd510ed2761" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_77219ae1-9ee0-42f9-96ee-489f182fbec9" xlink:to="loc_dei_ExchangeDomain_22eecffb-61c9-4fa2-8e54-4dd510ed2761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_164308db-2889-458a-9434-3d0fcd27cf98" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNYS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_22eecffb-61c9-4fa2-8e54-4dd510ed2761" xlink:to="loc_exch_XNYS_164308db-2889-458a-9434-3d0fcd27cf98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI_f765c30c-63a2-4fd2-9ea7-99ef9e56e0c2" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XCHI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_22eecffb-61c9-4fa2-8e54-4dd510ed2761" xlink:to="loc_exch_XCHI_f765c30c-63a2-4fd2-9ea7-99ef9e56e0c2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" xlink:type="simple" xlink:href="abt-20220930.xsd#CondensedConsolidatedStatementofShareholdersInvestmentUnaudited"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" xlink:type="extended" id="if1777d45b7cf42e3a2bfba94e25d4230_CondensedConsolidatedStatementofShareholdersInvestmentUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4f34d4b5-850b-4216-b009-3e48bd25990d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4f34d4b5-850b-4216-b009-3e48bd25990d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_775863b7-f66e-4515-9d36-d9acb7876003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_775863b7-f66e-4515-9d36-d9acb7876003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_StockIssuedDuringPeriodValueIncentiveStockPrograms_91445fb7-e6d8-4535-9946-4cc5e9d99328" xlink:href="abt-20220930.xsd#abt_StockIssuedDuringPeriodValueIncentiveStockPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_abt_StockIssuedDuringPeriodValueIncentiveStockPrograms_91445fb7-e6d8-4535-9946-4cc5e9d99328" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b3a352a3-a132-463d-b44f-65b85bb36a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b3a352a3-a132-463d-b44f-65b85bb36a58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_753446ff-db07-4d85-919d-65171be8867f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_753446ff-db07-4d85-919d-65171be8867f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0379fdba-257c-4239-8e47-055cc5bda8df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0379fdba-257c-4239-8e47-055cc5bda8df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3e0a5c27-932f-42a0-9272-9f414b9ee4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_us-gaap_NetIncomeLoss_3e0a5c27-932f-42a0-9272-9f414b9ee4df" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_644910a5-fef8-4e4e-bec3-4e068b746e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_us-gaap_DividendsCommonStockCash_644910a5-fef8-4e4e-bec3-4e068b746e43" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_EffectOfCommonAndTreasuryShareTransactions_d780634c-71b7-40ae-88f6-f082825e6dc3" xlink:href="abt-20220930.xsd#abt_EffectOfCommonAndTreasuryShareTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_abt_EffectOfCommonAndTreasuryShareTransactions_d780634c-71b7-40ae-88f6-f082825e6dc3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5110b6e6-aec4-4342-bd4e-e4598e153e59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5110b6e6-aec4-4342-bd4e-e4598e153e59" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations_caf92269-0cc2-45d6-8739-6122eb4478e2" xlink:href="abt-20220930.xsd#abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations_caf92269-0cc2-45d6-8739-6122eb4478e2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_31710976-c6bc-4bd6-9697-a5593b0e63ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b5ad225e-0602-4052-9e8b-f30f3c72ee23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4f34d4b5-850b-4216-b009-3e48bd25990d" xlink:to="loc_us-gaap_StatementTable_b5ad225e-0602-4052-9e8b-f30f3c72ee23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f6f19dee-d317-4b32-a94a-d66f3f7fb2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b5ad225e-0602-4052-9e8b-f30f3c72ee23" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f6f19dee-d317-4b32-a94a-d66f3f7fb2cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f6f19dee-d317-4b32-a94a-d66f3f7fb2cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f6f19dee-d317-4b32-a94a-d66f3f7fb2cb" xlink:to="loc_us-gaap_EquityComponentDomain_f6f19dee-d317-4b32-a94a-d66f3f7fb2cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4e98d0bd-443e-4b4e-b2e4-cc23e05b6532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f6f19dee-d317-4b32-a94a-d66f3f7fb2cb" xlink:to="loc_us-gaap_EquityComponentDomain_4e98d0bd-443e-4b4e-b2e4-cc23e05b6532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a48fafc6-2390-4afb-9831-11303bb9e326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4e98d0bd-443e-4b4e-b2e4-cc23e05b6532" xlink:to="loc_us-gaap_CommonStockMember_a48fafc6-2390-4afb-9831-11303bb9e326" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_74b1dd2e-645b-4a77-bebb-af35080ef045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4e98d0bd-443e-4b4e-b2e4-cc23e05b6532" xlink:to="loc_us-gaap_TreasuryStockCommonMember_74b1dd2e-645b-4a77-bebb-af35080ef045" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_834b4d68-759b-42a4-90f7-410b3e26ead6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4e98d0bd-443e-4b4e-b2e4-cc23e05b6532" xlink:to="loc_us-gaap_RetainedEarningsMember_834b4d68-759b-42a4-90f7-410b3e26ead6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b2d3dfba-a74d-4700-840a-11166152a77d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4e98d0bd-443e-4b4e-b2e4-cc23e05b6532" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b2d3dfba-a74d-4700-840a-11166152a77d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_ef455502-be62-4921-8959-203cb49695bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4e98d0bd-443e-4b4e-b2e4-cc23e05b6532" xlink:to="loc_us-gaap_NoncontrollingInterestMember_ef455502-be62-4921-8959-203cb49695bf" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" xlink:type="simple" xlink:href="abt-20220930.xsd#CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" xlink:type="extended" id="id9c5308754df4dcda3cce9e51dab2960_CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4de22e01-5043-4d9f-bada-41f3f4ff54fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5fe0226-c332-4b4a-a027-1261895bcf1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4de22e01-5043-4d9f-bada-41f3f4ff54fe" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5fe0226-c332-4b4a-a027-1261895bcf1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_11bb764e-a847-443c-a89a-ec5324c115be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5fe0226-c332-4b4a-a027-1261895bcf1e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_11bb764e-a847-443c-a89a-ec5324c115be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_624a86e2-5f84-4fa6-848c-0234bf7f8fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5fe0226-c332-4b4a-a027-1261895bcf1e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_624a86e2-5f84-4fa6-848c-0234bf7f8fe2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms_a24081a9-fea9-4f66-bdd8-faad7889cb68" xlink:href="abt-20220930.xsd#abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5fe0226-c332-4b4a-a027-1261895bcf1e" xlink:to="loc_abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms_a24081a9-fea9-4f66-bdd8-faad7889cb68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_bd52658e-bb7e-440d-8d3b-7f7a0f020c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5fe0226-c332-4b4a-a027-1261895bcf1e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_bd52658e-bb7e-440d-8d3b-7f7a0f020c1b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_fd317d1f-41cd-4938-8f4b-d0a1ac35872a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5fe0226-c332-4b4a-a027-1261895bcf1e" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_fd317d1f-41cd-4938-8f4b-d0a1ac35872a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ba773aef-53cf-49b8-8317-68846bf702aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_1f9f7dfc-b142-4223-8ff5-05f14162c9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9e0fb1a9-cc44-403f-a367-81ee6d8e5229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4de22e01-5043-4d9f-bada-41f3f4ff54fe" xlink:to="loc_us-gaap_StatementTable_9e0fb1a9-cc44-403f-a367-81ee6d8e5229" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_82c917a2-098a-4bd6-b2a1-3ac65c9527ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9e0fb1a9-cc44-403f-a367-81ee6d8e5229" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_82c917a2-098a-4bd6-b2a1-3ac65c9527ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_82c917a2-098a-4bd6-b2a1-3ac65c9527ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_82c917a2-098a-4bd6-b2a1-3ac65c9527ac" xlink:to="loc_us-gaap_EquityComponentDomain_82c917a2-098a-4bd6-b2a1-3ac65c9527ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_62422075-b48f-49ad-8dd9-8061591b9c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_82c917a2-098a-4bd6-b2a1-3ac65c9527ac" xlink:to="loc_us-gaap_EquityComponentDomain_62422075-b48f-49ad-8dd9-8061591b9c54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8f2c09ae-312d-4dec-9a22-3948d9870d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62422075-b48f-49ad-8dd9-8061591b9c54" xlink:to="loc_us-gaap_CommonStockMember_8f2c09ae-312d-4dec-9a22-3948d9870d44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_b44382ee-a4f6-49a5-9b31-bb7f0c29e3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62422075-b48f-49ad-8dd9-8061591b9c54" xlink:to="loc_us-gaap_TreasuryStockCommonMember_b44382ee-a4f6-49a5-9b31-bb7f0c29e3fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_15fd47bf-316b-4b9a-a8fa-b37f85b9d46c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62422075-b48f-49ad-8dd9-8061591b9c54" xlink:to="loc_us-gaap_RetainedEarningsMember_15fd47bf-316b-4b9a-a8fa-b37f85b9d46c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#RevenueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/RevenueNarrativeDetails" xlink:type="extended" id="ib73707685f3a420294e56292ba94eba6_RevenueNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_e75b4008-fea7-49a5-b728-e91b1afc15ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:to="loc_us-gaap_NumberOfReportableSegments_e75b4008-fea7-49a5-b728-e91b1afc15ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_0e0f4fda-a1e8-464a-b653-a01007bcd7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_0e0f4fda-a1e8-464a-b653-a01007bcd7fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage_72864081-f835-41dc-804f-99678717e965" xlink:href="abt-20220930.xsd#abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:to="loc_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage_72864081-f835-41dc-804f-99678717e965" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_84e790a9-51ea-4205-a352-2632218ef110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_84e790a9-51ea-4205-a352-2632218ef110" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9cce46a8-0dcb-4104-80a1-57517cfc3ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9cce46a8-0dcb-4104-80a1-57517cfc3ba2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_03bcde9d-58b0-472f-9c38-61d9f3eace3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9cce46a8-0dcb-4104-80a1-57517cfc3ba2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_03bcde9d-58b0-472f-9c38-61d9f3eace3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_cd2bae6c-058a-4adf-b7b5-1ba3344dd553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9cce46a8-0dcb-4104-80a1-57517cfc3ba2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_cd2bae6c-058a-4adf-b7b5-1ba3344dd553" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cd2bae6c-058a-4adf-b7b5-1ba3344dd553_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cd2bae6c-058a-4adf-b7b5-1ba3344dd553" xlink:to="loc_us-gaap_SegmentDomain_cd2bae6c-058a-4adf-b7b5-1ba3344dd553_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_76274abd-02d0-4c49-b081-c09bae002cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cd2bae6c-058a-4adf-b7b5-1ba3344dd553" xlink:to="loc_us-gaap_SegmentDomain_76274abd-02d0-4c49-b081-c09bae002cb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DiagnosticProductsMember_813721f7-6d0c-40ea-9d8b-9de6a196c338" xlink:href="abt-20220930.xsd#abt_DiagnosticProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_76274abd-02d0-4c49-b081-c09bae002cb7" xlink:to="loc_abt_DiagnosticProductsMember_813721f7-6d0c-40ea-9d8b-9de6a196c338" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_MedicalDevicesMember_ca5010cf-6b85-4303-92c3-4a12e581a54e" xlink:href="abt-20220930.xsd#abt_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_76274abd-02d0-4c49-b081-c09bae002cb7" xlink:to="loc_abt_MedicalDevicesMember_ca5010cf-6b85-4303-92c3-4a12e581a54e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/RevenueNarrativeDetails_1" xlink:type="simple" xlink:href="abt-20220930.xsd#RevenueNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/RevenueNarrativeDetails_1" xlink:type="extended" id="i7615fc18d73f49f99a824e3d6701c40f_RevenueNarrativeDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_e75b4008-fea7-49a5-b728-e91b1afc15ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:to="loc_us-gaap_NumberOfReportableSegments_e75b4008-fea7-49a5-b728-e91b1afc15ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_0e0f4fda-a1e8-464a-b653-a01007bcd7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_0e0f4fda-a1e8-464a-b653-a01007bcd7fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage_72864081-f835-41dc-804f-99678717e965" xlink:href="abt-20220930.xsd#abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:to="loc_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage_72864081-f835-41dc-804f-99678717e965" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_84e790a9-51ea-4205-a352-2632218ef110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_84e790a9-51ea-4205-a352-2632218ef110" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9cce46a8-0dcb-4104-80a1-57517cfc3ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9cce46a8-0dcb-4104-80a1-57517cfc3ba2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_cd2bae6c-058a-4adf-b7b5-1ba3344dd553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9cce46a8-0dcb-4104-80a1-57517cfc3ba2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_cd2bae6c-058a-4adf-b7b5-1ba3344dd553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cd2bae6c-058a-4adf-b7b5-1ba3344dd553_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cd2bae6c-058a-4adf-b7b5-1ba3344dd553" xlink:to="loc_us-gaap_SegmentDomain_cd2bae6c-058a-4adf-b7b5-1ba3344dd553_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_76274abd-02d0-4c49-b081-c09bae002cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cd2bae6c-058a-4adf-b7b5-1ba3344dd553" xlink:to="loc_us-gaap_SegmentDomain_76274abd-02d0-4c49-b081-c09bae002cb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DiagnosticProductsMember_813721f7-6d0c-40ea-9d8b-9de6a196c338" xlink:href="abt-20220930.xsd#abt_DiagnosticProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_76274abd-02d0-4c49-b081-c09bae002cb7" xlink:to="loc_abt_DiagnosticProductsMember_813721f7-6d0c-40ea-9d8b-9de6a196c338" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_MedicalDevicesMember_ca5010cf-6b85-4303-92c3-4a12e581a54e" xlink:href="abt-20220930.xsd#abt_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_76274abd-02d0-4c49-b081-c09bae002cb7" xlink:to="loc_abt_MedicalDevicesMember_ca5010cf-6b85-4303-92c3-4a12e581a54e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/RevenueSegmentsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#RevenueSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/RevenueSegmentsDetails" xlink:type="extended" id="i8573a3fe6a0c4bcba05ec2282ee0eea8_RevenueSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5310fc32-2a10-4c3f-a6e3-c92a6769ce83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6c16fca9-7c89-4306-9a0d-0d15ad935264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5310fc32-2a10-4c3f-a6e3-c92a6769ce83" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6c16fca9-7c89-4306-9a0d-0d15ad935264" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cfbc05d0-42ec-42ac-b610-9f0256c543ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5310fc32-2a10-4c3f-a6e3-c92a6769ce83" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cfbc05d0-42ec-42ac-b610-9f0256c543ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_00fddbf8-9e3a-4bd3-87ec-99220933d24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cfbc05d0-42ec-42ac-b610-9f0256c543ef" xlink:to="loc_us-gaap_SubsegmentsAxis_00fddbf8-9e3a-4bd3-87ec-99220933d24d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_00fddbf8-9e3a-4bd3-87ec-99220933d24d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_00fddbf8-9e3a-4bd3-87ec-99220933d24d" xlink:to="loc_us-gaap_SubsegmentsDomain_00fddbf8-9e3a-4bd3-87ec-99220933d24d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_00fddbf8-9e3a-4bd3-87ec-99220933d24d" xlink:to="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_KeyEmergingMarketsMember_9534f6f5-635b-46b2-9286-ea48799a4484" xlink:href="abt-20220930.xsd#abt_KeyEmergingMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_KeyEmergingMarketsMember_9534f6f5-635b-46b2-9286-ea48799a4484" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_OtherEmergingMarketsMember_a203d1fc-2cbc-4c6c-bcad-5fc656abcf94" xlink:href="abt-20220930.xsd#abt_OtherEmergingMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_OtherEmergingMarketsMember_a203d1fc-2cbc-4c6c-bcad-5fc656abcf94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PediatricNutritionalsMember_59dc21e0-c7f7-42e9-8f8b-8d0bd234ec6d" xlink:href="abt-20220930.xsd#abt_PediatricNutritionalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_PediatricNutritionalsMember_59dc21e0-c7f7-42e9-8f8b-8d0bd234ec6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_AdultNutritionalsMember_e419d872-6e9c-4d8a-b405-03297c95a883" xlink:href="abt-20220930.xsd#abt_AdultNutritionalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_AdultNutritionalsMember_e419d872-6e9c-4d8a-b405-03297c95a883" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_CoreLaboratoryMember_b2825a79-c212-4afb-b527-10a50aa4714b" xlink:href="abt-20220930.xsd#abt_CoreLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_CoreLaboratoryMember_b2825a79-c212-4afb-b527-10a50aa4714b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_MolecularMember_57bb6763-f164-4465-acc5-6a42f37af4b9" xlink:href="abt-20220930.xsd#abt_MolecularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_MolecularMember_57bb6763-f164-4465-acc5-6a42f37af4b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PointOfCareMember_ff757bfc-8c95-4815-b198-b4982031b13e" xlink:href="abt-20220930.xsd#abt_PointOfCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_PointOfCareMember_ff757bfc-8c95-4815-b198-b4982031b13e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RapidDiagnosticsMember_12567dbf-2efe-4d79-9f83-f36a7e997c94" xlink:href="abt-20220930.xsd#abt_RapidDiagnosticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_RapidDiagnosticsMember_12567dbf-2efe-4d79-9f83-f36a7e997c94" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RhythmManagementMember_83600d2d-c1de-4cf2-8a27-c0acd7eec718" xlink:href="abt-20220930.xsd#abt_RhythmManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_RhythmManagementMember_83600d2d-c1de-4cf2-8a27-c0acd7eec718" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_ElectrophysiologyMember_6280fcd2-80f6-43a6-9dbc-893e21c7daf3" xlink:href="abt-20220930.xsd#abt_ElectrophysiologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_ElectrophysiologyMember_6280fcd2-80f6-43a6-9dbc-893e21c7daf3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_HeartFailureMember_82295b6e-9773-4405-81e6-ebb1346d2f41" xlink:href="abt-20220930.xsd#abt_HeartFailureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_HeartFailureMember_82295b6e-9773-4405-81e6-ebb1346d2f41" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_VascularMember_907fd424-2ccb-4a03-a1b5-798a87bbd1ab" xlink:href="abt-20220930.xsd#abt_VascularMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_VascularMember_907fd424-2ccb-4a03-a1b5-798a87bbd1ab" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_StructuralHeartMember_b3c0756b-f9e3-46b0-a750-022b0c779aed" xlink:href="abt-20220930.xsd#abt_StructuralHeartMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_StructuralHeartMember_b3c0756b-f9e3-46b0-a750-022b0c779aed" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_NeuromodulationMember_ccc57ba2-afcb-4606-9ae2-81e8751bfb73" xlink:href="abt-20220930.xsd#abt_NeuromodulationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_NeuromodulationMember_ccc57ba2-afcb-4606-9ae2-81e8751bfb73" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DiabetesCareMember_43cbe98b-2c11-4272-bdbd-4d5ad0a78f28" xlink:href="abt-20220930.xsd#abt_DiabetesCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_DiabetesCareMember_43cbe98b-2c11-4272-bdbd-4d5ad0a78f28" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_012841c0-9fe8-4f89-b4b7-f45c103d5a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cfbc05d0-42ec-42ac-b610-9f0256c543ef" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_012841c0-9fe8-4f89-b4b7-f45c103d5a78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_012841c0-9fe8-4f89-b4b7-f45c103d5a78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_012841c0-9fe8-4f89-b4b7-f45c103d5a78" xlink:to="loc_us-gaap_SegmentDomain_012841c0-9fe8-4f89-b4b7-f45c103d5a78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9fa057cf-fc2d-42f6-b804-76520efa50da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_012841c0-9fe8-4f89-b4b7-f45c103d5a78" xlink:to="loc_us-gaap_SegmentDomain_9fa057cf-fc2d-42f6-b804-76520efa50da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_EstablishedPharmaceuticalProductsMember_87267824-2e63-438e-810c-2249a3bd2975" xlink:href="abt-20220930.xsd#abt_EstablishedPharmaceuticalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9fa057cf-fc2d-42f6-b804-76520efa50da" xlink:to="loc_abt_EstablishedPharmaceuticalProductsMember_87267824-2e63-438e-810c-2249a3bd2975" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_NutritionalProductsMember_b0d9ed9f-53f7-4333-b8ef-33e9d20f3054" xlink:href="abt-20220930.xsd#abt_NutritionalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9fa057cf-fc2d-42f6-b804-76520efa50da" xlink:to="loc_abt_NutritionalProductsMember_b0d9ed9f-53f7-4333-b8ef-33e9d20f3054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DiagnosticProductsMember_d5ac2c3b-7ae1-4067-b7df-6d4924a74cba" xlink:href="abt-20220930.xsd#abt_DiagnosticProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9fa057cf-fc2d-42f6-b804-76520efa50da" xlink:to="loc_abt_DiagnosticProductsMember_d5ac2c3b-7ae1-4067-b7df-6d4924a74cba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_MedicalDevicesMember_c7a4ed16-c949-48b8-802e-7218643d00f9" xlink:href="abt-20220930.xsd#abt_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9fa057cf-fc2d-42f6-b804-76520efa50da" xlink:to="loc_abt_MedicalDevicesMember_c7a4ed16-c949-48b8-802e-7218643d00f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bb40e5eb-adfc-4ab4-973c-b1834a51e21d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cfbc05d0-42ec-42ac-b610-9f0256c543ef" xlink:to="loc_srt_StatementGeographicalAxis_bb40e5eb-adfc-4ab4-973c-b1834a51e21d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bb40e5eb-adfc-4ab4-973c-b1834a51e21d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_bb40e5eb-adfc-4ab4-973c-b1834a51e21d" xlink:to="loc_srt_SegmentGeographicalDomain_bb40e5eb-adfc-4ab4-973c-b1834a51e21d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3eacea21-c8f3-42a2-bf0e-f723d1274f78" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_bb40e5eb-adfc-4ab4-973c-b1834a51e21d" xlink:to="loc_srt_SegmentGeographicalDomain_3eacea21-c8f3-42a2-bf0e-f723d1274f78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1bf2cfd4-8846-41b0-93d8-670dc5368b7e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3eacea21-c8f3-42a2-bf0e-f723d1274f78" xlink:to="loc_country_US_1bf2cfd4-8846-41b0-93d8-670dc5368b7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_001d6f3a-eadc-4eb7-b0ba-e90105aa91ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3eacea21-c8f3-42a2-bf0e-f723d1274f78" xlink:to="loc_us-gaap_NonUsMember_001d6f3a-eadc-4eb7-b0ba-e90105aa91ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a3d2bc63-051a-404d-a1e4-b96afbfef148" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cfbc05d0-42ec-42ac-b610-9f0256c543ef" xlink:to="loc_srt_ConsolidationItemsAxis_a3d2bc63-051a-404d-a1e4-b96afbfef148" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a3d2bc63-051a-404d-a1e4-b96afbfef148_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_a3d2bc63-051a-404d-a1e4-b96afbfef148" xlink:to="loc_srt_ConsolidationItemsDomain_a3d2bc63-051a-404d-a1e4-b96afbfef148_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1d42c65e-c5ce-49d8-85c3-02e23dfa22d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_a3d2bc63-051a-404d-a1e4-b96afbfef148" xlink:to="loc_srt_ConsolidationItemsDomain_1d42c65e-c5ce-49d8-85c3-02e23dfa22d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_1a752890-eb7e-4b82-8964-b0ddacc8e621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_1d42c65e-c5ce-49d8-85c3-02e23dfa22d1" xlink:to="loc_us-gaap_OperatingSegmentsMember_1a752890-eb7e-4b82-8964-b0ddacc8e621" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_f4502b8c-f306-4345-be65-f7ea84a80bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_1d42c65e-c5ce-49d8-85c3-02e23dfa22d1" xlink:to="loc_us-gaap_CorporateNonSegmentMember_f4502b8c-f306-4345-be65-f7ea84a80bf5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#SupplementalFinancialInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" xlink:type="extended" id="ib86a6641074a44e5bfc809a8ccc385af_SupplementalFinancialInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_61b11c6f-52a2-4907-983f-156099bcc48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_61b11c6f-52a2-4907-983f-156099bcc48c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_0fc9d0cd-196f-48dd-8c24-fd6b9428a285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_0fc9d0cd-196f-48dd-8c24-fd6b9428a285" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForOtherTaxes_97ffe7c2-d2e7-4ca9-8a23-06e66ca54288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForOtherTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:to="loc_us-gaap_PaymentsForOtherTaxes_97ffe7c2-d2e7-4ca9-8a23-06e66ca54288" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_514f75de-d99a-4191-adba-872a7c911092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_514f75de-d99a-4191-adba-872a7c911092" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ae3e9502-efb9-43cd-8fe5-e509169c1ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:to="loc_us-gaap_EquityMethodInvestments_ae3e9502-efb9-43cd-8fe5-e509169c1ca8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_8fbec2a3-5e98-4270-a168-f38db7f9188c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_8fbec2a3-5e98-4270-a168-f38db7f9188c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9c15e868-f63c-4940-8aae-bae9666e2438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9c15e868-f63c-4940-8aae-bae9666e2438" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementTable_81e512a2-d984-4f81-9229-d898b1a25676" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedCashFlowStatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:to="loc_srt_CondensedCashFlowStatementTable_81e512a2-d984-4f81-9229-d898b1a25676" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_0e9732d0-8fc5-4ce2-9246-77c0d11b70e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_CondensedCashFlowStatementTable_81e512a2-d984-4f81-9229-d898b1a25676" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_0e9732d0-8fc5-4ce2-9246-77c0d11b70e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_0e9732d0-8fc5-4ce2-9246-77c0d11b70e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0e9732d0-8fc5-4ce2-9246-77c0d11b70e7" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_0e9732d0-8fc5-4ce2-9246-77c0d11b70e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_03df9faa-13e7-45d7-847c-e0087a5b168c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0e9732d0-8fc5-4ce2-9246-77c0d11b70e7" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_03df9faa-13e7-45d7-847c-e0087a5b168c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_3125b154-c096-424a-920d-679620f3b6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_03df9faa-13e7-45d7-847c-e0087a5b168c" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_3125b154-c096-424a-920d-679620f3b6fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0f0e1c02-d9ba-4bf5-ae70-7877738396ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_CondensedCashFlowStatementTable_81e512a2-d984-4f81-9229-d898b1a25676" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0f0e1c02-d9ba-4bf5-ae70-7877738396ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f0e1c02-d9ba-4bf5-ae70-7877738396ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0f0e1c02-d9ba-4bf5-ae70-7877738396ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f0e1c02-d9ba-4bf5-ae70-7877738396ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e6dc49ba-d945-4edd-8567-7f0bd6544fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0f0e1c02-d9ba-4bf5-ae70-7877738396ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e6dc49ba-d945-4edd-8567-7f0bd6544fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_StJudeMedicalIncMember_7c05919d-f130-4076-bba8-57a01bf09183" xlink:href="abt-20220930.xsd#abt_StJudeMedicalIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e6dc49ba-d945-4edd-8567-7f0bd6544fd8" xlink:to="loc_abt_StJudeMedicalIncMember_7c05919d-f130-4076-bba8-57a01bf09183" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_WalkVascularLLCMember_2c1366c1-784d-4d0a-bce6-98ee33bf2767" xlink:href="abt-20220930.xsd#abt_WalkVascularLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e6dc49ba-d945-4edd-8567-7f0bd6544fd8" xlink:to="loc_abt_WalkVascularLLCMember_2c1366c1-784d-4d0a-bce6-98ee33bf2767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_326d421a-f09b-4bc0-96e6-bebdf2cd4ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_CondensedCashFlowStatementTable_81e512a2-d984-4f81-9229-d898b1a25676" xlink:to="loc_us-gaap_InvestmentTypeAxis_326d421a-f09b-4bc0-96e6-bebdf2cd4ec2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_326d421a-f09b-4bc0-96e6-bebdf2cd4ec2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_326d421a-f09b-4bc0-96e6-bebdf2cd4ec2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_326d421a-f09b-4bc0-96e6-bebdf2cd4ec2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_aa064449-1544-41aa-a638-cb9dd1f364e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_326d421a-f09b-4bc0-96e6-bebdf2cd4ec2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_aa064449-1544-41aa-a638-cb9dd1f364e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_e1d1e880-3a43-41a1-a002-fd0b6c040f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_aa064449-1544-41aa-a638-cb9dd1f364e1" xlink:to="loc_us-gaap_EquitySecuritiesMember_e1d1e880-3a43-41a1-a002-fd0b6c040f8b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#SupplementalFinancialInformationInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails" xlink:type="extended" id="i3b0a6a6760c5479c80c0ad7ba146980c_SupplementalFinancialInformationInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_29ccedf8-fafa-485a-8c78-1c1832633360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_d097fb14-6df9-4533-88a8-50430e44c957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_29ccedf8-fafa-485a-8c78-1c1832633360" xlink:to="loc_us-gaap_LongTermInvestments_d097fb14-6df9-4533-88a8-50430e44c957" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable_4f79d144-7a53-4bc4-a9d6-10efb6784eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_29ccedf8-fafa-485a-8c78-1c1832633360" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsTable_4f79d144-7a53-4bc4-a9d6-10efb6784eb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_083b5fed-f077-4c5f-9e5b-4d3812b0069a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_4f79d144-7a53-4bc4-a9d6-10efb6784eb9" xlink:to="loc_us-gaap_InvestmentTypeAxis_083b5fed-f077-4c5f-9e5b-4d3812b0069a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_083b5fed-f077-4c5f-9e5b-4d3812b0069a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_083b5fed-f077-4c5f-9e5b-4d3812b0069a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_083b5fed-f077-4c5f-9e5b-4d3812b0069a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_60a1515a-9bd2-4edb-9f2a-ff3c9760ba3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_083b5fed-f077-4c5f-9e5b-4d3812b0069a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_60a1515a-9bd2-4edb-9f2a-ff3c9760ba3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_d253d62d-f1da-4d30-a62d-f1d51508c178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_60a1515a-9bd2-4edb-9f2a-ff3c9760ba3a" xlink:to="loc_us-gaap_EquitySecuritiesMember_d253d62d-f1da-4d30-a62d-f1d51508c178" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_765892bb-9c36-4095-bbb1-e9b774a6fc17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_60a1515a-9bd2-4edb-9f2a-ff3c9760ba3a" xlink:to="loc_us-gaap_OtherInvestmentsMember_765892bb-9c36-4095-bbb1-e9b774a6fc17" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#ChangesinAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i2283f32a8f7243a2b1870ced3e6c7ea8_ChangesinAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_354a3a42-1c94-4435-a821-d2454f05728d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_caf859fe-d8bd-4ed8-a35d-ad538543e6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_354a3a42-1c94-4435-a821-d2454f05728d" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_caf859fe-d8bd-4ed8-a35d-ad538543e6b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1cdc32e9-48fa-4208-a2e4-962d6506b9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_caf859fe-d8bd-4ed8-a35d-ad538543e6b7" xlink:to="loc_us-gaap_StockholdersEquity_1cdc32e9-48fa-4208-a2e4-962d6506b9dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_02b5c076-dfa5-4c47-97dd-710596af57c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_caf859fe-d8bd-4ed8-a35d-ad538543e6b7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_02b5c076-dfa5-4c47-97dd-710596af57c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_77e1c574-a3e4-401a-a43e-9871467016d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_caf859fe-d8bd-4ed8-a35d-ad538543e6b7" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_77e1c574-a3e4-401a-a43e-9871467016d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2a739ba9-d544-44bb-939b-f8bacd46747a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_caf859fe-d8bd-4ed8-a35d-ad538543e6b7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2a739ba9-d544-44bb-939b-f8bacd46747a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1c18fedf-bbdd-4fc9-974b-2283683c4e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8c8f9b07-f342-4ced-a150-6f104857dc24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_354a3a42-1c94-4435-a821-d2454f05728d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8c8f9b07-f342-4ced-a150-6f104857dc24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d021139c-0b6c-4b5c-abec-1c9c2f7aea2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8c8f9b07-f342-4ced-a150-6f104857dc24" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d021139c-0b6c-4b5c-abec-1c9c2f7aea2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d021139c-0b6c-4b5c-abec-1c9c2f7aea2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d021139c-0b6c-4b5c-abec-1c9c2f7aea2a" xlink:to="loc_us-gaap_EquityComponentDomain_d021139c-0b6c-4b5c-abec-1c9c2f7aea2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bd0d784c-fbba-4ec0-a411-ca4d841b756d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d021139c-0b6c-4b5c-abec-1c9c2f7aea2a" xlink:to="loc_us-gaap_EquityComponentDomain_bd0d784c-fbba-4ec0-a411-ca4d841b756d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_ebb52b0e-1a24-43e2-bac9-45a7bc67388d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bd0d784c-fbba-4ec0-a411-ca4d841b756d" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_ebb52b0e-1a24-43e2-bac9-45a7bc67388d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_30cfff46-5e70-4dbf-a774-bebeaa8a5ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bd0d784c-fbba-4ec0-a411-ca4d841b756d" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_30cfff46-5e70-4dbf-a774-bebeaa8a5ba7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_55bd64e5-d6de-44d7-a322-c22dd167c7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bd0d784c-fbba-4ec0-a411-ca4d841b756d" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_55bd64e5-d6de-44d7-a322-c22dd167c7e6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#GoodwillandIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" xlink:type="extended" id="i6e4aee7350804c80af961b00b031c4c2_GoodwillandIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:href="abt-20220930.xsd#abt_GoodwillAndIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_afc1c6f2-803b-4160-8127-3278300f4f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_Goodwill_afc1c6f2-803b-4160-8127-3278300f4f3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_4c6300d8-41fb-43fd-a645-878960e68a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_4c6300d8-41fb-43fd-a645-878960e68a94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4dd28b9f-50c7-46c9-a9d2-eb4dbfeb8afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4dd28b9f-50c7-46c9-a9d2-eb4dbfeb8afc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f5db1b96-ea49-46f1-8b82-d03f4c90ec3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f5db1b96-ea49-46f1-8b82-d03f4c90ec3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_598b7434-4162-4675-932d-e6db807d6573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_598b7434-4162-4675-932d-e6db807d6573" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_9b4d6cd6-01db-4cb8-be27-d149c88da2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_9b4d6cd6-01db-4cb8-be27-d149c88da2bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b42b79f3-02bf-40ab-966e-b7a9ab98375b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b42b79f3-02bf-40ab-966e-b7a9ab98375b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_98d15663-0b31-471a-a22d-032b6e267549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_98d15663-0b31-471a-a22d-032b6e267549" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2a9da0e5-ba1d-485d-8121-ea8a1c804cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2a9da0e5-ba1d-485d-8121-ea8a1c804cfa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8f659890-2002-4ee1-8bee-0e3da799abc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8f659890-2002-4ee1-8bee-0e3da799abc8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4b7e6c7f-cf8a-4fa1-a9f9-94613c66ab45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4b7e6c7f-cf8a-4fa1-a9f9-94613c66ab45" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a4ade7aa-6bf0-415c-bacd-bbd8dee4fd68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a4ade7aa-6bf0-415c-bacd-bbd8dee4fd68" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3d8db3d2-9b84-4e3a-9afe-b5109542260c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3d8db3d2-9b84-4e3a-9afe-b5109542260c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_ScheduleOfGoodwillAndIntangibleAssetsTable_3a6dd95c-e097-4ed4-909e-c987b6d04494" xlink:href="abt-20220930.xsd#abt_ScheduleOfGoodwillAndIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_abt_ScheduleOfGoodwillAndIntangibleAssetsTable_3a6dd95c-e097-4ed4-909e-c987b6d04494" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d210362a-11b1-4e34-87e3-8300e1e3f142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abt_ScheduleOfGoodwillAndIntangibleAssetsTable_3a6dd95c-e097-4ed4-909e-c987b6d04494" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d210362a-11b1-4e34-87e3-8300e1e3f142" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d210362a-11b1-4e34-87e3-8300e1e3f142_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d210362a-11b1-4e34-87e3-8300e1e3f142" xlink:to="loc_us-gaap_SegmentDomain_d210362a-11b1-4e34-87e3-8300e1e3f142_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d98e3013-c2f9-42d2-8745-8162f87526ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d210362a-11b1-4e34-87e3-8300e1e3f142" xlink:to="loc_us-gaap_SegmentDomain_d98e3013-c2f9-42d2-8745-8162f87526ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_EstablishedPharmaceuticalProductsMember_e14aeddf-3a68-484f-83aa-26fb4ec4f052" xlink:href="abt-20220930.xsd#abt_EstablishedPharmaceuticalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d98e3013-c2f9-42d2-8745-8162f87526ca" xlink:to="loc_abt_EstablishedPharmaceuticalProductsMember_e14aeddf-3a68-484f-83aa-26fb4ec4f052" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_NutritionalProductsMember_db69ce08-30da-4b0f-9148-f0468980395b" xlink:href="abt-20220930.xsd#abt_NutritionalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d98e3013-c2f9-42d2-8745-8162f87526ca" xlink:to="loc_abt_NutritionalProductsMember_db69ce08-30da-4b0f-9148-f0468980395b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DiagnosticProductsMember_d5fd036d-41e1-46d2-b129-32fc8a098156" xlink:href="abt-20220930.xsd#abt_DiagnosticProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d98e3013-c2f9-42d2-8745-8162f87526ca" xlink:to="loc_abt_DiagnosticProductsMember_d5fd036d-41e1-46d2-b129-32fc8a098156" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_MedicalDevicesMember_6d3941f3-c89c-4c4f-86c9-962da3414f24" xlink:href="abt-20220930.xsd#abt_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d98e3013-c2f9-42d2-8745-8162f87526ca" xlink:to="loc_abt_MedicalDevicesMember_6d3941f3-c89c-4c4f-86c9-962da3414f24" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/RestructuringPlansNarrativeDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#RestructuringPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/RestructuringPlansNarrativeDetails" xlink:type="extended" id="i6106fa3a6db94e6da4111ad0d7c4da19_RestructuringPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_20545a88-860c-4f02-a04f-1d98e7e1a9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_5430328b-a0ed-4ca7-bfe5-d276997febf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_20545a88-860c-4f02-a04f-1d98e7e1a9e7" xlink:to="loc_us-gaap_RestructuringCharges_5430328b-a0ed-4ca7-bfe5-d276997febf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_InventoryNoNetRealizableValueSold_2071e326-7ad9-4c6e-8123-68d648cb86e7" xlink:href="abt-20220930.xsd#abt_InventoryNoNetRealizableValueSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_20545a88-860c-4f02-a04f-1d98e7e1a9e7" xlink:to="loc_abt_InventoryNoNetRealizableValueSold_2071e326-7ad9-4c6e-8123-68d648cb86e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_183e3ae9-a2ce-4526-bd9b-ee1b2a5dc052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_20545a88-860c-4f02-a04f-1d98e7e1a9e7" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_183e3ae9-a2ce-4526-bd9b-ee1b2a5dc052" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_09c06e64-2819-4d10-8a48-3c1019195cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_20545a88-860c-4f02-a04f-1d98e7e1a9e7" xlink:to="loc_us-gaap_SeveranceCosts1_09c06e64-2819-4d10-8a48-3c1019195cc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e65b8812-c850-4cdd-97c0-b24beba8eaed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_20545a88-860c-4f02-a04f-1d98e7e1a9e7" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e65b8812-c850-4cdd-97c0-b24beba8eaed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_3bfd26ab-38a7-4500-b6b9-b1ca7e9b8b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e65b8812-c850-4cdd-97c0-b24beba8eaed" xlink:to="loc_us-gaap_RestructuringPlanAxis_3bfd26ab-38a7-4500-b6b9-b1ca7e9b8b0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_3bfd26ab-38a7-4500-b6b9-b1ca7e9b8b0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_3bfd26ab-38a7-4500-b6b9-b1ca7e9b8b0a" xlink:to="loc_us-gaap_RestructuringPlanDomain_3bfd26ab-38a7-4500-b6b9-b1ca7e9b8b0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_07c6d3c2-7852-4960-bdb7-5ce6ffe48eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_3bfd26ab-38a7-4500-b6b9-b1ca7e9b8b0a" xlink:to="loc_us-gaap_RestructuringPlanDomain_07c6d3c2-7852-4960-bdb7-5ce6ffe48eff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_COVID19TestManufacturingNetworkRestructuringPlanMember_fdecf0a4-6bd5-407f-a79f-8539947078b5" xlink:href="abt-20220930.xsd#abt_COVID19TestManufacturingNetworkRestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_07c6d3c2-7852-4960-bdb7-5ce6ffe48eff" xlink:to="loc_abt_COVID19TestManufacturingNetworkRestructuringPlanMember_fdecf0a4-6bd5-407f-a79f-8539947078b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember_9a848d6e-e0c6-4154-a7e4-4a3d7bfcbfc9" xlink:href="abt-20220930.xsd#abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_07c6d3c2-7852-4960-bdb7-5ce6ffe48eff" xlink:to="loc_abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember_9a848d6e-e0c6-4154-a7e4-4a3d7bfcbfc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_af03a33d-8f84-4791-ab36-5f799f32e6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e65b8812-c850-4cdd-97c0-b24beba8eaed" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_af03a33d-8f84-4791-ab36-5f799f32e6ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_af03a33d-8f84-4791-ab36-5f799f32e6ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_af03a33d-8f84-4791-ab36-5f799f32e6ac" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_af03a33d-8f84-4791-ab36-5f799f32e6ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4d6f0361-25bf-4691-9ef1-44d1a3a7bbec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_af03a33d-8f84-4791-ab36-5f799f32e6ac" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4d6f0361-25bf-4691-9ef1-44d1a3a7bbec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_FixedAssetWriteDownsMember_303ffafe-d8f2-484e-ba3e-328bdaff5d7b" xlink:href="abt-20220930.xsd#abt_FixedAssetWriteDownsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4d6f0361-25bf-4691-9ef1-44d1a3a7bbec" xlink:to="loc_abt_FixedAssetWriteDownsMember_303ffafe-d8f2-484e-ba3e-328bdaff5d7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_InventoryRelatedChargesMember_6e9d76bd-649b-4587-abfb-7afd0940e89f" xlink:href="abt-20220930.xsd#abt_InventoryRelatedChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4d6f0361-25bf-4691-9ef1-44d1a3a7bbec" xlink:to="loc_abt_InventoryRelatedChargesMember_6e9d76bd-649b-4587-abfb-7afd0940e89f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_OtherExitCostsMember_8528ed9c-534e-4ce4-a421-ad4aead21e45" xlink:href="abt-20220930.xsd#abt_OtherExitCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4d6f0361-25bf-4691-9ef1-44d1a3a7bbec" xlink:to="loc_abt_OtherExitCostsMember_8528ed9c-534e-4ce4-a421-ad4aead21e45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_eca519ab-869d-4974-bbed-bfda700c9864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e65b8812-c850-4cdd-97c0-b24beba8eaed" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_eca519ab-869d-4974-bbed-bfda700c9864" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_eca519ab-869d-4974-bbed-bfda700c9864_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_eca519ab-869d-4974-bbed-bfda700c9864" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_eca519ab-869d-4974-bbed-bfda700c9864_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cca6422d-09ba-4b23-8a2f-125f3797d5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_eca519ab-869d-4974-bbed-bfda700c9864" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cca6422d-09ba-4b23-8a2f-125f3797d5c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_CostOfGoodsAndServicesSoldMember_082ebe0a-c3a7-4d9d-8123-32316396d6d7" xlink:href="abt-20220930.xsd#abt_CostOfGoodsAndServicesSoldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cca6422d-09ba-4b23-8a2f-125f3797d5c2" xlink:to="loc_abt_CostOfGoodsAndServicesSoldMember_082ebe0a-c3a7-4d9d-8123-32316396d6d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_10fb1d85-2a5b-42b2-9c91-d2e2e4c41a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cca6422d-09ba-4b23-8a2f-125f3797d5c2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_10fb1d85-2a5b-42b2-9c91-d2e2e4c41a3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f3cf13cf-d13f-4287-8f16-7a9ef2979009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cca6422d-09ba-4b23-8a2f-125f3797d5c2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f3cf13cf-d13f-4287-8f16-7a9ef2979009" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" xlink:type="extended" id="if3654d4003c04d7f98c0b36ebd540320_RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_644c1e6e-83de-45a3-99fc-5b7bca1e00d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ff17816b-e4cc-4270-a532-85d2e9f6250e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_644c1e6e-83de-45a3-99fc-5b7bca1e00d2" xlink:to="loc_us-gaap_RestructuringCharges_ff17816b-e4cc-4270-a532-85d2e9f6250e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_997a12ce-ef59-4b6a-8f27-40c251986324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_644c1e6e-83de-45a3-99fc-5b7bca1e00d2" xlink:to="loc_us-gaap_PaymentsForRestructuring_997a12ce-ef59-4b6a-8f27-40c251986324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_5dce9d59-b347-4ec2-8b36-5c8a76c13536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_644c1e6e-83de-45a3-99fc-5b7bca1e00d2" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_5dce9d59-b347-4ec2-8b36-5c8a76c13536" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_82a6e2ca-b3e2-4c7c-9dbb-0ebd14f058ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_644c1e6e-83de-45a3-99fc-5b7bca1e00d2" xlink:to="loc_us-gaap_RestructuringReserveRollForward_82a6e2ca-b3e2-4c7c-9dbb-0ebd14f058ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_47b4c750-57dc-4998-bce9-03f9a9a7bee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_82a6e2ca-b3e2-4c7c-9dbb-0ebd14f058ee" xlink:to="loc_us-gaap_RestructuringReserve_47b4c750-57dc-4998-bce9-03f9a9a7bee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments_ceb71459-5b7d-4748-89a7-91a0a0af4eb4" xlink:href="abt-20220930.xsd#abt_RestructuringReservePeriodCashSettledAndOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_82a6e2ca-b3e2-4c7c-9dbb-0ebd14f058ee" xlink:to="loc_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments_ceb71459-5b7d-4748-89a7-91a0a0af4eb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_4a8181d7-d0fd-4ac6-8bc9-cc3efdd9138b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_141583d2-8129-4135-9fd2-44bd3ff019e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_644c1e6e-83de-45a3-99fc-5b7bca1e00d2" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_141583d2-8129-4135-9fd2-44bd3ff019e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_dfe7b334-d27d-4996-9bc0-eecaefb80c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_141583d2-8129-4135-9fd2-44bd3ff019e9" xlink:to="loc_us-gaap_RestructuringPlanAxis_dfe7b334-d27d-4996-9bc0-eecaefb80c3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_dfe7b334-d27d-4996-9bc0-eecaefb80c3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_dfe7b334-d27d-4996-9bc0-eecaefb80c3f" xlink:to="loc_us-gaap_RestructuringPlanDomain_dfe7b334-d27d-4996-9bc0-eecaefb80c3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_1f7c39f7-bb9f-4534-b28d-be843d162260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_dfe7b334-d27d-4996-9bc0-eecaefb80c3f" xlink:to="loc_us-gaap_RestructuringPlanDomain_1f7c39f7-bb9f-4534-b28d-be843d162260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_COVID19TestManufacturingNetworkRestructuringPlanMember_14a89900-6774-46d5-a87e-2a2387057ef5" xlink:href="abt-20220930.xsd#abt_COVID19TestManufacturingNetworkRestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_1f7c39f7-bb9f-4534-b28d-be843d162260" xlink:to="loc_abt_COVID19TestManufacturingNetworkRestructuringPlanMember_14a89900-6774-46d5-a87e-2a2387057ef5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember_c79de3da-6d19-485f-90c6-49ef36290cb7" xlink:href="abt-20220930.xsd#abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_1f7c39f7-bb9f-4534-b28d-be843d162260" xlink:to="loc_abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember_c79de3da-6d19-485f-90c6-49ef36290cb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_d59cad8e-e46c-44b5-85bf-a530a546b187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_141583d2-8129-4135-9fd2-44bd3ff019e9" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_d59cad8e-e46c-44b5-85bf-a530a546b187" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d59cad8e-e46c-44b5-85bf-a530a546b187_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d59cad8e-e46c-44b5-85bf-a530a546b187" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d59cad8e-e46c-44b5-85bf-a530a546b187_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_adfee025-e71f-4766-a626-6579d268162f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d59cad8e-e46c-44b5-85bf-a530a546b187" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_adfee025-e71f-4766-a626-6579d268162f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_InventoryRelatedChargesMember_584ce21a-3b0d-45e8-bdda-4e3c42d2433b" xlink:href="abt-20220930.xsd#abt_InventoryRelatedChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_adfee025-e71f-4766-a626-6579d268162f" xlink:to="loc_abt_InventoryRelatedChargesMember_584ce21a-3b0d-45e8-bdda-4e3c42d2433b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_FixedAssetWriteDownsMember_8805ba8e-1408-4102-8267-ffb616fc9bb6" xlink:href="abt-20220930.xsd#abt_FixedAssetWriteDownsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_adfee025-e71f-4766-a626-6579d268162f" xlink:to="loc_abt_FixedAssetWriteDownsMember_8805ba8e-1408-4102-8267-ffb616fc9bb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_OtherExitCostsMember_173e55d2-229b-4ab2-ad06-9c52ae9e4631" xlink:href="abt-20220930.xsd#abt_OtherExitCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_adfee025-e71f-4766-a626-6579d268162f" xlink:to="loc_abt_OtherExitCostsMember_173e55d2-229b-4ab2-ad06-9c52ae9e4631" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#IncentiveStockProgramNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails" xlink:type="extended" id="i0893219fb16c4acb8e14597df95cd8bb_IncentiveStockProgramNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97bea178-913d-4957-93ce-1af67d160bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c6674042-2e61-458c-b015-bc24181da155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97bea178-913d-4957-93ce-1af67d160bb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c6674042-2e61-458c-b015-bc24181da155" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1a8d9cbf-f809-409d-a457-f71d67878e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97bea178-913d-4957-93ce-1af67d160bb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1a8d9cbf-f809-409d-a457-f71d67878e92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_0e00f7d8-fbb2-4a70-b704-c42885acf549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97bea178-913d-4957-93ce-1af67d160bb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_0e00f7d8-fbb2-4a70-b704-c42885acf549" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8a51a12a-4ca2-49f1-8335-4fcf1df0dbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97bea178-913d-4957-93ce-1af67d160bb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8a51a12a-4ca2-49f1-8335-4fcf1df0dbb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7a616e5c-1e28-4cba-a155-ea607bda7059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97bea178-913d-4957-93ce-1af67d160bb4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7a616e5c-1e28-4cba-a155-ea607bda7059" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5c0bc825-64ac-41ec-8d31-72d9fd47c073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97bea178-913d-4957-93ce-1af67d160bb4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5c0bc825-64ac-41ec-8d31-72d9fd47c073" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df155319-b6ad-4213-b6ff-98be767525cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97bea178-913d-4957-93ce-1af67d160bb4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df155319-b6ad-4213-b6ff-98be767525cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bfb7a94d-1b59-4a86-b5f4-d8b598e1c046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df155319-b6ad-4213-b6ff-98be767525cb" xlink:to="loc_us-gaap_AwardTypeAxis_bfb7a94d-1b59-4a86-b5f4-d8b598e1c046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bfb7a94d-1b59-4a86-b5f4-d8b598e1c046_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bfb7a94d-1b59-4a86-b5f4-d8b598e1c046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bfb7a94d-1b59-4a86-b5f4-d8b598e1c046_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f11cbbe-9f91-49d5-87b9-93910b8ec8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bfb7a94d-1b59-4a86-b5f4-d8b598e1c046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f11cbbe-9f91-49d5-87b9-93910b8ec8e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_af89c9ac-5ba0-4f81-ba47-44561bc84d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f11cbbe-9f91-49d5-87b9-93910b8ec8e4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_af89c9ac-5ba0-4f81-ba47-44561bc84d1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RestrictedStockAwardsMember_7f1776ac-f715-42b1-b445-fb48fe810927" xlink:href="abt-20220930.xsd#abt_RestrictedStockAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f11cbbe-9f91-49d5-87b9-93910b8ec8e4" xlink:to="loc_abt_RestrictedStockAwardsMember_7f1776ac-f715-42b1-b445-fb48fe810927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_125cd644-a2d5-485d-bb9a-a3102b48b5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f11cbbe-9f91-49d5-87b9-93910b8ec8e4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_125cd644-a2d5-485d-bb9a-a3102b48b5bb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/IncentiveStockProgramOptionsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#IncentiveStockProgramOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/IncentiveStockProgramOptionsDetails" xlink:type="extended" id="i2b1cddde9b7242b9880edda782aec5fc_IncentiveStockProgramOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_838a9a1e-48a6-4cba-a5ed-9700d0a150c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_838a9a1e-48a6-4cba-a5ed-9700d0a150c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_169288a3-12a5-4426-bd5d-bedd08d7a763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_169288a3-12a5-4426-bd5d-bedd08d7a763" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_94af5bee-039c-433a-b47b-7f22299f9707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_94af5bee-039c-433a-b47b-7f22299f9707" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ed7db616-fe47-495f-9a04-e7dfa686aa28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ed7db616-fe47-495f-9a04-e7dfa686aa28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1a8c9b24-11ac-406c-994a-bbc448053be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1a8c9b24-11ac-406c-994a-bbc448053be4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c6f627e8-7bf1-4d7f-985d-036d38e7cc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c6f627e8-7bf1-4d7f-985d-036d38e7cc3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6f652d03-26d0-482e-80b9-7656906b04f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6f652d03-26d0-482e-80b9-7656906b04f7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0656571b-28cd-4e56-9a97-1048d7d5c960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0656571b-28cd-4e56-9a97-1048d7d5c960" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b78aed4a-061a-4757-b928-d7d36a3257a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b78aed4a-061a-4757-b928-d7d36a3257a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9725c538-f132-4577-a5ac-7c380974332a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b78aed4a-061a-4757-b928-d7d36a3257a2" xlink:to="loc_us-gaap_AwardTypeAxis_9725c538-f132-4577-a5ac-7c380974332a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9725c538-f132-4577-a5ac-7c380974332a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9725c538-f132-4577-a5ac-7c380974332a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9725c538-f132-4577-a5ac-7c380974332a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ff2528a1-816d-4903-b96e-249e2a0d6c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9725c538-f132-4577-a5ac-7c380974332a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ff2528a1-816d-4903-b96e-249e2a0d6c7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_80e1a4cb-0a00-47a2-8d0f-8b380c6ccbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ff2528a1-816d-4903-b96e-249e2a0d6c7e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_80e1a4cb-0a00-47a2-8d0f-8b380c6ccbed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/DebtandLinesofCreditDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#DebtandLinesofCreditDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/DebtandLinesofCreditDetails" xlink:type="extended" id="i865e314d102148af80bba6e6309e0891_DebtandLinesofCreditDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_82c619fc-5552-4261-b752-974e3ad1deda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_d5a9b25f-5531-44b6-8c3b-94598ffc7d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82c619fc-5552-4261-b752-974e3ad1deda" xlink:to="loc_us-gaap_RepaymentsOfDebt_d5a9b25f-5531-44b6-8c3b-94598ffc7d0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_937d3443-fdf6-4972-8c6f-96087be9c783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82c619fc-5552-4261-b752-974e3ad1deda" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_937d3443-fdf6-4972-8c6f-96087be9c783" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6e24df13-954c-4ced-b6ca-4331b76a27fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82c619fc-5552-4261-b752-974e3ad1deda" xlink:to="loc_us-gaap_DebtInstrumentTable_6e24df13-954c-4ced-b6ca-4331b76a27fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_26abe643-278d-4405-86ee-dbb2c2881fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6e24df13-954c-4ced-b6ca-4331b76a27fe" xlink:to="loc_us-gaap_DebtInstrumentAxis_26abe643-278d-4405-86ee-dbb2c2881fe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_26abe643-278d-4405-86ee-dbb2c2881fe6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_26abe643-278d-4405-86ee-dbb2c2881fe6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_26abe643-278d-4405-86ee-dbb2c2881fe6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_db36b626-31e8-4ac1-9d2b-f7734fdb5187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_26abe643-278d-4405-86ee-dbb2c2881fe6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_db36b626-31e8-4ac1-9d2b-f7734fdb5187" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_A255LongTermNotesDue2022Member_20b561af-4620-4816-a8f7-0937231804bc" xlink:href="abt-20220930.xsd#abt_A255LongTermNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_db36b626-31e8-4ac1-9d2b-f7734fdb5187" xlink:to="loc_abt_A255LongTermNotesDue2022Member_20b561af-4620-4816-a8f7-0937231804bc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails" xlink:type="extended" id="ie5a35c927e424861b8731c04738cafc5_FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_7c572c86-f79a-42a0-be8c-3a680a87f619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_aebef581-ce6f-4c60-9eaa-7ed085ea18ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7c572c86-f79a-42a0-be8c-3a680a87f619" xlink:to="loc_us-gaap_DerivativeNotionalAmount_aebef581-ce6f-4c60-9eaa-7ed085ea18ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_MinimumLengthOfTimeHedgedInCashFlowHedge_831e902e-18eb-4f14-a7aa-4f19b2625827" xlink:href="abt-20220930.xsd#abt_MinimumLengthOfTimeHedgedInCashFlowHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7c572c86-f79a-42a0-be8c-3a680a87f619" xlink:to="loc_abt_MinimumLengthOfTimeHedgedInCashFlowHedge_831e902e-18eb-4f14-a7aa-4f19b2625827" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_b0902bf0-ff88-4d82-99db-51f15ca0b3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7c572c86-f79a-42a0-be8c-3a680a87f619" xlink:to="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_b0902bf0-ff88-4d82-99db-51f15ca0b3f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_3ad9e8b0-8cbd-4161-bc2b-9c98678bb9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7c572c86-f79a-42a0-be8c-3a680a87f619" xlink:to="loc_us-gaap_DebtInstrumentTerm_3ad9e8b0-8cbd-4161-bc2b-9c98678bb9fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a7c453a8-85aa-4d2c-a8b3-fbb1f1395abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7c572c86-f79a-42a0-be8c-3a680a87f619" xlink:to="loc_us-gaap_LongTermDebt_a7c453a8-85aa-4d2c-a8b3-fbb1f1395abf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_fcb242b9-c271-49d1-b7aa-305f54b2da58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7c572c86-f79a-42a0-be8c-3a680a87f619" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_fcb242b9-c271-49d1-b7aa-305f54b2da58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_bba82584-15d7-42c2-ad89-66cb63170bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7c572c86-f79a-42a0-be8c-3a680a87f619" xlink:to="loc_us-gaap_DerivativeTable_bba82584-15d7-42c2-ad89-66cb63170bbd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ea3c1e58-a512-4e3a-8757-f15d151a404a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_bba82584-15d7-42c2-ad89-66cb63170bbd" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ea3c1e58-a512-4e3a-8757-f15d151a404a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ea3c1e58-a512-4e3a-8757-f15d151a404a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ea3c1e58-a512-4e3a-8757-f15d151a404a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ea3c1e58-a512-4e3a-8757-f15d151a404a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4fab381d-d42b-43cc-8211-9194ae987952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ea3c1e58-a512-4e3a-8757-f15d151a404a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4fab381d-d42b-43cc-8211-9194ae987952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_27b3c6c7-9405-4a80-bcac-43513b2e18c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4fab381d-d42b-43cc-8211-9194ae987952" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_27b3c6c7-9405-4a80-bcac-43513b2e18c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b460878e-8552-44a5-bef1-79403867d784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4fab381d-d42b-43cc-8211-9194ae987952" xlink:to="loc_us-gaap_InterestRateSwapMember_b460878e-8552-44a5-bef1-79403867d784" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_142db0c0-7115-471b-85ee-f16bf69b39bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_bba82584-15d7-42c2-ad89-66cb63170bbd" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_142db0c0-7115-471b-85ee-f16bf69b39bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_142db0c0-7115-471b-85ee-f16bf69b39bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_142db0c0-7115-471b-85ee-f16bf69b39bf" xlink:to="loc_us-gaap_HedgingRelationshipDomain_142db0c0-7115-471b-85ee-f16bf69b39bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e4ad1fbd-e86b-4987-aa47-bbdac10f5296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_142db0c0-7115-471b-85ee-f16bf69b39bf" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e4ad1fbd-e86b-4987-aa47-bbdac10f5296" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_9f015e83-425a-44aa-93f4-f77a7b98ff6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e4ad1fbd-e86b-4987-aa47-bbdac10f5296" xlink:to="loc_us-gaap_CashFlowHedgingMember_9f015e83-425a-44aa-93f4-f77a7b98ff6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_201ebf37-288c-4a0e-b4b0-c8d2f6135eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e4ad1fbd-e86b-4987-aa47-bbdac10f5296" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_201ebf37-288c-4a0e-b4b0-c8d2f6135eeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_8d04d342-8ced-4631-8934-9aabc8a77d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e4ad1fbd-e86b-4987-aa47-bbdac10f5296" xlink:to="loc_us-gaap_FairValueHedgingMember_8d04d342-8ced-4631-8934-9aabc8a77d18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a7339e9f-f934-4cc8-987d-b0d219a830de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_bba82584-15d7-42c2-ad89-66cb63170bbd" xlink:to="loc_us-gaap_HedgingDesignationAxis_a7339e9f-f934-4cc8-987d-b0d219a830de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a7339e9f-f934-4cc8-987d-b0d219a830de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_a7339e9f-f934-4cc8-987d-b0d219a830de" xlink:to="loc_us-gaap_HedgingDesignationDomain_a7339e9f-f934-4cc8-987d-b0d219a830de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_5ab47c22-6fd2-4c49-9309-ecec6e90f364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_a7339e9f-f934-4cc8-987d-b0d219a830de" xlink:to="loc_us-gaap_HedgingDesignationDomain_5ab47c22-6fd2-4c49-9309-ecec6e90f364" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_62b96b36-a896-42a8-a413-def97d36aa2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_5ab47c22-6fd2-4c49-9309-ecec6e90f364" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_62b96b36-a896-42a8-a413-def97d36aa2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_30d35990-35f4-4360-94ff-813de5588d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_5ab47c22-6fd2-4c49-9309-ecec6e90f364" xlink:to="loc_us-gaap_NondesignatedMember_30d35990-35f4-4360-94ff-813de5588d8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6e61cdd6-ba4e-4cd0-babc-ee88a0017687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_bba82584-15d7-42c2-ad89-66cb63170bbd" xlink:to="loc_us-gaap_DebtInstrumentAxis_6e61cdd6-ba4e-4cd0-babc-ee88a0017687" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6e61cdd6-ba4e-4cd0-babc-ee88a0017687_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6e61cdd6-ba4e-4cd0-babc-ee88a0017687" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6e61cdd6-ba4e-4cd0-babc-ee88a0017687_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3b03253e-2f62-465e-b7ef-b182630ed12e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6e61cdd6-ba4e-4cd0-babc-ee88a0017687" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3b03253e-2f62-465e-b7ef-b182630ed12e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_YenDenominatedLongTermDebtMember_c9bc2b56-7b24-4f27-8556-a6e0e2bb561b" xlink:href="abt-20220930.xsd#abt_YenDenominatedLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3b03253e-2f62-465e-b7ef-b182630ed12e" xlink:to="loc_abt_YenDenominatedLongTermDebtMember_c9bc2b56-7b24-4f27-8556-a6e0e2bb561b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" xlink:type="extended" id="if5960f48f2fd4d74bb4390f4cdc4ae72_FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_970587b9-576a-42bb-8512-48194323dd99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c0cb0bd7-bfa8-4fdf-85d8-ffffe853b2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_970587b9-576a-42bb-8512-48194323dd99" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c0cb0bd7-bfa8-4fdf-85d8-ffffe853b2b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a789b64a-a82f-4231-b955-95d68fbe024d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_970587b9-576a-42bb-8512-48194323dd99" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a789b64a-a82f-4231-b955-95d68fbe024d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_23ab309f-906d-4494-a8b2-08cd0ab5e6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_970587b9-576a-42bb-8512-48194323dd99" xlink:to="loc_us-gaap_DerivativeTable_23ab309f-906d-4494-a8b2-08cd0ab5e6ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ae75398e-2b72-4bb9-8e1d-bdeb006d93f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_23ab309f-906d-4494-a8b2-08cd0ab5e6ad" xlink:to="loc_us-gaap_HedgingDesignationAxis_ae75398e-2b72-4bb9-8e1d-bdeb006d93f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ae75398e-2b72-4bb9-8e1d-bdeb006d93f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_ae75398e-2b72-4bb9-8e1d-bdeb006d93f0" xlink:to="loc_us-gaap_HedgingDesignationDomain_ae75398e-2b72-4bb9-8e1d-bdeb006d93f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b636f9fc-6378-4aeb-bdfa-3729828eaa07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_ae75398e-2b72-4bb9-8e1d-bdeb006d93f0" xlink:to="loc_us-gaap_HedgingDesignationDomain_b636f9fc-6378-4aeb-bdfa-3729828eaa07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_c5422344-2744-4322-834b-f567ea1aeef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_b636f9fc-6378-4aeb-bdfa-3729828eaa07" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_c5422344-2744-4322-834b-f567ea1aeef1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_bbaf2c21-6e53-4db7-a530-ac1e7cb23e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_b636f9fc-6378-4aeb-bdfa-3729828eaa07" xlink:to="loc_us-gaap_NondesignatedMember_bbaf2c21-6e53-4db7-a530-ac1e7cb23e45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_985956e1-fef3-44f0-aa5f-fd189673f87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_23ab309f-906d-4494-a8b2-08cd0ab5e6ad" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_985956e1-fef3-44f0-aa5f-fd189673f87d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_985956e1-fef3-44f0-aa5f-fd189673f87d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_985956e1-fef3-44f0-aa5f-fd189673f87d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_985956e1-fef3-44f0-aa5f-fd189673f87d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_707dc1c6-551c-4e45-9736-d326e1ffda16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_985956e1-fef3-44f0-aa5f-fd189673f87d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_707dc1c6-551c-4e45-9736-d326e1ffda16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_6e76566a-9678-4312-9d90-b044f83f8bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_707dc1c6-551c-4e45-9736-d326e1ffda16" xlink:to="loc_us-gaap_InterestRateSwapMember_6e76566a-9678-4312-9d90-b044f83f8bed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_d00e5702-8e9a-4623-9663-35824228da71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_707dc1c6-551c-4e45-9736-d326e1ffda16" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_d00e5702-8e9a-4623-9663-35824228da71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtMember_39ecee41-25b0-4b0b-8f86-76619e57cecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_707dc1c6-551c-4e45-9736-d326e1ffda16" xlink:to="loc_us-gaap_DebtMember_39ecee41-25b0-4b0b-8f86-76619e57cecb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_cd07d149-7db1-4984-be9e-b12f00009fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_23ab309f-906d-4494-a8b2-08cd0ab5e6ad" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_cd07d149-7db1-4984-be9e-b12f00009fff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cd07d149-7db1-4984-be9e-b12f00009fff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cd07d149-7db1-4984-be9e-b12f00009fff" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cd07d149-7db1-4984-be9e-b12f00009fff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c44c5a15-9e32-4091-a041-8dd6a556d3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cd07d149-7db1-4984-be9e-b12f00009fff" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c44c5a15-9e32-4091-a041-8dd6a556d3b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DeferredIncomeTaxesAndOtherAssetsMember_0925834b-205a-4972-8087-485cd07b11ae" xlink:href="abt-20220930.xsd#abt_DeferredIncomeTaxesAndOtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c44c5a15-9e32-4091-a041-8dd6a556d3b2" xlink:to="loc_abt_DeferredIncomeTaxesAndOtherAssetsMember_0925834b-205a-4972-8087-485cd07b11ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PrepaidExpensesAndOtherReceivablesMember_db4ffd22-465e-4fde-ac8b-d39ccf1bf484" xlink:href="abt-20220930.xsd#abt_PrepaidExpensesAndOtherReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c44c5a15-9e32-4091-a041-8dd6a556d3b2" xlink:to="loc_abt_PrepaidExpensesAndOtherReceivablesMember_db4ffd22-465e-4fde-ac8b-d39ccf1bf484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember_ba721dfd-8f77-48f5-b17a-8ee32c78c5c3" xlink:href="abt-20220930.xsd#abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c44c5a15-9e32-4091-a041-8dd6a556d3b2" xlink:to="loc_abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember_ba721dfd-8f77-48f5-b17a-8ee32c78c5c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_ef3b5fa6-390c-4d15-aa8e-4527e5ce9281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c44c5a15-9e32-4091-a041-8dd6a556d3b2" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_ef3b5fa6-390c-4d15-aa8e-4527e5ce9281" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_d3907809-80ab-497e-92b9-ff118bbd513c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c44c5a15-9e32-4091-a041-8dd6a556d3b2" xlink:to="loc_us-gaap_LongTermDebtMember_d3907809-80ab-497e-92b9-ff118bbd513c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_dd25c663-c904-49d3-ade2-cb69d0f713c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_23ab309f-906d-4494-a8b2-08cd0ab5e6ad" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_dd25c663-c904-49d3-ade2-cb69d0f713c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_dd25c663-c904-49d3-ade2-cb69d0f713c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_dd25c663-c904-49d3-ade2-cb69d0f713c3" xlink:to="loc_us-gaap_HedgingRelationshipDomain_dd25c663-c904-49d3-ade2-cb69d0f713c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e6e66180-4518-4e5c-b635-4b3c39b5e025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_dd25c663-c904-49d3-ade2-cb69d0f713c3" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e6e66180-4518-4e5c-b635-4b3c39b5e025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_e0e2891e-6729-4b86-9b4b-2c233b9242ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e6e66180-4518-4e5c-b635-4b3c39b5e025" xlink:to="loc_us-gaap_FairValueHedgingMember_e0e2891e-6729-4b86-9b4b-2c233b9242ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_03aa6d2f-6d15-4cc6-b3fa-478c81596d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e6e66180-4518-4e5c-b635-4b3c39b5e025" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_03aa6d2f-6d15-4cc6-b3fa-478c81596d6d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails" xlink:type="extended" id="i98ca266403564726bb7544760bc2724b_FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_3a05dc6d-e012-4065-a957-0bd6a0045677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_a02b85e6-4184-4f57-a98b-7dff735937d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_3a05dc6d-e012-4065-a957-0bd6a0045677" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_a02b85e6-4184-4f57-a98b-7dff735937d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_8ef83310-5a62-488f-85cc-73d9ed12f9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_3a05dc6d-e012-4065-a957-0bd6a0045677" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_8ef83310-5a62-488f-85cc-73d9ed12f9e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2fc7f8db-0b93-4e29-a226-9eb3358de35c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_3a05dc6d-e012-4065-a957-0bd6a0045677" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2fc7f8db-0b93-4e29-a226-9eb3358de35c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_45b3477f-8fe3-47ae-9c06-0a80e2937d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2fc7f8db-0b93-4e29-a226-9eb3358de35c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_45b3477f-8fe3-47ae-9c06-0a80e2937d19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_45b3477f-8fe3-47ae-9c06-0a80e2937d19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_45b3477f-8fe3-47ae-9c06-0a80e2937d19" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_45b3477f-8fe3-47ae-9c06-0a80e2937d19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d7b3a331-cb73-4d31-a96a-10e3d2fbe189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_45b3477f-8fe3-47ae-9c06-0a80e2937d19" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d7b3a331-cb73-4d31-a96a-10e3d2fbe189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_07efd7cc-cd0f-41c3-a0eb-076747abaa3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d7b3a331-cb73-4d31-a96a-10e3d2fbe189" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_07efd7cc-cd0f-41c3-a0eb-076747abaa3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtMember_24eb8ed3-693d-46e6-a522-c626aab2a2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d7b3a331-cb73-4d31-a96a-10e3d2fbe189" xlink:to="loc_us-gaap_DebtMember_24eb8ed3-693d-46e6-a522-c626aab2a2bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_77728b23-dc6c-4822-b301-b10b940e229c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d7b3a331-cb73-4d31-a96a-10e3d2fbe189" xlink:to="loc_us-gaap_InterestRateSwapMember_77728b23-dc6c-4822-b301-b10b940e229c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_812c77dc-e875-420f-b1b1-92e9eaba8f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2fc7f8db-0b93-4e29-a226-9eb3358de35c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_812c77dc-e875-420f-b1b1-92e9eaba8f77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_812c77dc-e875-420f-b1b1-92e9eaba8f77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_812c77dc-e875-420f-b1b1-92e9eaba8f77" xlink:to="loc_us-gaap_HedgingRelationshipDomain_812c77dc-e875-420f-b1b1-92e9eaba8f77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_a887305b-0043-4455-9309-85069584af03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_812c77dc-e875-420f-b1b1-92e9eaba8f77" xlink:to="loc_us-gaap_HedgingRelationshipDomain_a887305b-0043-4455-9309-85069584af03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_94ea5fa0-2ff4-43bd-8901-894a55c7f635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a887305b-0043-4455-9309-85069584af03" xlink:to="loc_us-gaap_CashFlowHedgingMember_94ea5fa0-2ff4-43bd-8901-894a55c7f635" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_8bfbfbba-9e8d-413d-a2f7-1d2992dd3d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a887305b-0043-4455-9309-85069584af03" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_8bfbfbba-9e8d-413d-a2f7-1d2992dd3d3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_44e5d313-9368-4716-ace9-e88041b10821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a887305b-0043-4455-9309-85069584af03" xlink:to="loc_us-gaap_FairValueHedgingMember_44e5d313-9368-4716-ace9-e88041b10821" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_5e048cdf-51f4-4b1b-aa50-42e09124ed0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2fc7f8db-0b93-4e29-a226-9eb3358de35c" xlink:to="loc_us-gaap_HedgingDesignationAxis_5e048cdf-51f4-4b1b-aa50-42e09124ed0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_5e048cdf-51f4-4b1b-aa50-42e09124ed0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_5e048cdf-51f4-4b1b-aa50-42e09124ed0e" xlink:to="loc_us-gaap_HedgingDesignationDomain_5e048cdf-51f4-4b1b-aa50-42e09124ed0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ac2b1a7e-86fb-4f5a-bf06-f26c762a7053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_5e048cdf-51f4-4b1b-aa50-42e09124ed0e" xlink:to="loc_us-gaap_HedgingDesignationDomain_ac2b1a7e-86fb-4f5a-bf06-f26c762a7053" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8b5642fc-3597-4de2-886d-6eb110d857fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_ac2b1a7e-86fb-4f5a-bf06-f26c762a7053" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8b5642fc-3597-4de2-886d-6eb110d857fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e5aa8b0e-5001-47dd-90bf-3f35ebee29d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2fc7f8db-0b93-4e29-a226-9eb3358de35c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e5aa8b0e-5001-47dd-90bf-3f35ebee29d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e5aa8b0e-5001-47dd-90bf-3f35ebee29d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e5aa8b0e-5001-47dd-90bf-3f35ebee29d0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e5aa8b0e-5001-47dd-90bf-3f35ebee29d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a12046df-cc82-4ab7-baae-4f0fddae8723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e5aa8b0e-5001-47dd-90bf-3f35ebee29d0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a12046df-cc82-4ab7-baae-4f0fddae8723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d7991b51-1afb-4a4c-89da-abd76bb6683c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a12046df-cc82-4ab7-baae-4f0fddae8723" xlink:to="loc_us-gaap_CostOfSalesMember_d7991b51-1afb-4a4c-89da-abd76bb6683c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_be3be6b8-4e97-4e82-baee-d023b1fae46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a12046df-cc82-4ab7-baae-4f0fddae8723" xlink:to="loc_us-gaap_InterestExpenseMember_be3be6b8-4e97-4e82-baee-d023b1fae46d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" xlink:type="extended" id="i0cea116cac254c6a8909f72cb68c865c_FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_220e3c87-0538-4625-991b-ee9cab1adc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_621ce7b2-200a-4919-9764-d2c0c465dcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_220e3c87-0538-4625-991b-ee9cab1adc5e" xlink:to="loc_us-gaap_LongTermInvestments_621ce7b2-200a-4919-9764-d2c0c465dcb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_5a934703-abf7-48c5-b9e8-78b3ca1bf448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_220e3c87-0538-4625-991b-ee9cab1adc5e" xlink:to="loc_us-gaap_LongTermDebtFairValue_5a934703-abf7-48c5-b9e8-78b3ca1bf448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue_9c176d4a-0f86-48f9-a3b0-d26e04187ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_220e3c87-0538-4625-991b-ee9cab1adc5e" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue_9c176d4a-0f86-48f9-a3b0-d26e04187ce8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue_ebbb9981-d2ea-4c15-aee3-3cb9e50f142b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_220e3c87-0538-4625-991b-ee9cab1adc5e" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue_ebbb9981-d2ea-4c15-aee3-3cb9e50f142b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_4e112945-b989-4a11-a4e0-eb9861fd6349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_220e3c87-0538-4625-991b-ee9cab1adc5e" xlink:to="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_4e112945-b989-4a11-a4e0-eb9861fd6349" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_7f231fbc-906a-4cbf-bc8c-c3b62334346f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_220e3c87-0538-4625-991b-ee9cab1adc5e" xlink:to="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_7f231fbc-906a-4cbf-bc8c-c3b62334346f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3b05059-4acf-44d5-a503-519e72b3a9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_220e3c87-0538-4625-991b-ee9cab1adc5e" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3b05059-4acf-44d5-a503-519e72b3a9ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_622e1862-2a79-47d1-821c-cae79eca9093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3b05059-4acf-44d5-a503-519e72b3a9ed" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_622e1862-2a79-47d1-821c-cae79eca9093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_622e1862-2a79-47d1-821c-cae79eca9093_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_622e1862-2a79-47d1-821c-cae79eca9093" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_622e1862-2a79-47d1-821c-cae79eca9093_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ab6c138e-7fc3-4157-b0d3-a08c5c846de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_622e1862-2a79-47d1-821c-cae79eca9093" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ab6c138e-7fc3-4157-b0d3-a08c5c846de0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2dc9f884-f1d7-4d2b-a967-9931d7b1087d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ab6c138e-7fc3-4157-b0d3-a08c5c846de0" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2dc9f884-f1d7-4d2b-a967-9931d7b1087d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0efcbabb-fb4c-4297-afe9-f28d520d3ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2dc9f884-f1d7-4d2b-a967-9931d7b1087d" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0efcbabb-fb4c-4297-afe9-f28d520d3ada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_02992794-4972-4419-ab3b-19432ff6cb05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2dc9f884-f1d7-4d2b-a967-9931d7b1087d" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_02992794-4972-4419-ab3b-19432ff6cb05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_317bded1-a18a-48e3-8ca7-83b172d3d979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3b05059-4acf-44d5-a503-519e72b3a9ed" xlink:to="loc_us-gaap_InvestmentTypeAxis_317bded1-a18a-48e3-8ca7-83b172d3d979" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_317bded1-a18a-48e3-8ca7-83b172d3d979_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_317bded1-a18a-48e3-8ca7-83b172d3d979" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_317bded1-a18a-48e3-8ca7-83b172d3d979_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2dc655ae-134c-4d24-9e5a-244fca86de63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_317bded1-a18a-48e3-8ca7-83b172d3d979" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2dc655ae-134c-4d24-9e5a-244fca86de63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_5e314a2d-f305-4819-963c-2d10af3663b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2dc655ae-134c-4d24-9e5a-244fca86de63" xlink:to="loc_us-gaap_EquitySecuritiesMember_5e314a2d-f305-4819-963c-2d10af3663b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAggregatedInvestmentsMember_1b61bb9e-7dc0-4e37-9aad-3940e29828f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAggregatedInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2dc655ae-134c-4d24-9e5a-244fca86de63" xlink:to="loc_us-gaap_OtherAggregatedInvestmentsMember_1b61bb9e-7dc0-4e37-9aad-3940e29828f4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" xlink:type="extended" id="ifddd97b232e84b68909dad43cdb1916d_FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_68d062a1-5c63-44de-8dc9-3e10016d7819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_68d062a1-5c63-44de-8dc9-3e10016d7819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_6bc9e959-a24e-4cab-afea-5cb9672b07e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_6bc9e959-a24e-4cab-afea-5cb9672b07e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue_9ff904f8-1af7-481f-b506-ab9abe5ab6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue_9ff904f8-1af7-481f-b506-ab9abe5ab6ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4422040b-05ca-43d8-8e20-9f21785df4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4422040b-05ca-43d8-8e20-9f21785df4ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_a63dfdae-c936-4df1-985d-f652733392ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_a63dfdae-c936-4df1-985d-f652733392ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_0dba3a9f-98cc-409b-85db-198eaae68f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_0dba3a9f-98cc-409b-85db-198eaae68f07" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue_f8c3aa5b-2759-415f-841f-c65171324994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue_f8c3aa5b-2759-415f-841f-c65171324994" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7925faeb-e6ee-4ac9-91bf-a6d46885e554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7925faeb-e6ee-4ac9-91bf-a6d46885e554" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_29018ad5-8511-4b9d-9814-dd2b1e08ae48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_29018ad5-8511-4b9d-9814-dd2b1e08ae48" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01c5b2b3-7d2c-45d1-b114-73e81186958f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01c5b2b3-7d2c-45d1-b114-73e81186958f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f48b7a6c-3dda-4102-bc84-72fef6723eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01c5b2b3-7d2c-45d1-b114-73e81186958f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f48b7a6c-3dda-4102-bc84-72fef6723eed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f48b7a6c-3dda-4102-bc84-72fef6723eed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f48b7a6c-3dda-4102-bc84-72fef6723eed" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f48b7a6c-3dda-4102-bc84-72fef6723eed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9fb5a273-f822-4af1-b247-e810fd8e69a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f48b7a6c-3dda-4102-bc84-72fef6723eed" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9fb5a273-f822-4af1-b247-e810fd8e69a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1429aa36-7105-4d4f-a387-c076853f79b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9fb5a273-f822-4af1-b247-e810fd8e69a1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1429aa36-7105-4d4f-a387-c076853f79b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c3530428-254c-45b6-a288-d8e9fec959b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01c5b2b3-7d2c-45d1-b114-73e81186958f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c3530428-254c-45b6-a288-d8e9fec959b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3530428-254c-45b6-a288-d8e9fec959b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c3530428-254c-45b6-a288-d8e9fec959b3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3530428-254c-45b6-a288-d8e9fec959b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea5a6dc9-8aaf-4033-9d96-21c8701c5876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c3530428-254c-45b6-a288-d8e9fec959b3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea5a6dc9-8aaf-4033-9d96-21c8701c5876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_79097261-9c5c-424b-983d-383f8815f4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea5a6dc9-8aaf-4033-9d96-21c8701c5876" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_79097261-9c5c-424b-983d-383f8815f4fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c9b59ea6-b77d-497d-ac29-569afa4114ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea5a6dc9-8aaf-4033-9d96-21c8701c5876" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c9b59ea6-b77d-497d-ac29-569afa4114ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d96efdde-8f84-4f0e-a97d-c384c3db3812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea5a6dc9-8aaf-4033-9d96-21c8701c5876" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d96efdde-8f84-4f0e-a97d-c384c3db3812" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#LitigationandEnvironmentalMattersDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" xlink:type="extended" id="i5fac74d3f77146109e7d4da74f124d99_LitigationandEnvironmentalMattersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_2a61f43d-620a-4677-9bb0-43e90aaecb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite_a9c7da50-741f-4b8f-8700-236005df7a70" xlink:href="abt-20220930.xsd#abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2a61f43d-620a-4677-9bb0-43e90aaecb9b" xlink:to="loc_abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite_a9c7da50-741f-4b8f-8700-236005df7a70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites_fc71138c-a30a-4d2f-8b3b-1671cfb3e384" xlink:href="abt-20220930.xsd#abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2a61f43d-620a-4677-9bb0-43e90aaecb9b" xlink:to="loc_abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites_fc71138c-a30a-4d2f-8b3b-1671cfb3e384" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_94fb6af3-a8f7-4572-a7a0-ac502b549f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2a61f43d-620a-4677-9bb0-43e90aaecb9b" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_94fb6af3-a8f7-4572-a7a0-ac502b549f03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_61daae41-de62-4f1e-a79d-a356255347f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2a61f43d-620a-4677-9bb0-43e90aaecb9b" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_61daae41-de62-4f1e-a79d-a356255347f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_03d0aba8-7163-4588-9666-51e06cf3e88a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_2a61f43d-620a-4677-9bb0-43e90aaecb9b" xlink:to="loc_us-gaap_LossContingenciesTable_03d0aba8-7163-4588-9666-51e06cf3e88a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_cc21e359-6ea7-495a-9ecc-bb9480c5a61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_03d0aba8-7163-4588-9666-51e06cf3e88a" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_cc21e359-6ea7-495a-9ecc-bb9480c5a61b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_cc21e359-6ea7-495a-9ecc-bb9480c5a61b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_cc21e359-6ea7-495a-9ecc-bb9480c5a61b" xlink:to="loc_us-gaap_LossContingencyNatureDomain_cc21e359-6ea7-495a-9ecc-bb9480c5a61b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_9c991193-0b15-4c15-9bbd-6a23fd25e3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_cc21e359-6ea7-495a-9ecc-bb9480c5a61b" xlink:to="loc_us-gaap_LossContingencyNatureDomain_9c991193-0b15-4c15-9bbd-6a23fd25e3f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_LegalProceedingsAndEnvironmentalExposuresMember_616d7980-4eed-4f44-ba30-2f63c7c33d21" xlink:href="abt-20220930.xsd#abt_LegalProceedingsAndEnvironmentalExposuresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_9c991193-0b15-4c15-9bbd-6a23fd25e3f4" xlink:to="loc_abt_LegalProceedingsAndEnvironmentalExposuresMember_616d7980-4eed-4f44-ba30-2f63c7c33d21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ce17f583-2096-4d6c-bdb5-c38867cc1e7d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_03d0aba8-7163-4588-9666-51e06cf3e88a" xlink:to="loc_srt_RangeAxis_ce17f583-2096-4d6c-bdb5-c38867cc1e7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ce17f583-2096-4d6c-bdb5-c38867cc1e7d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ce17f583-2096-4d6c-bdb5-c38867cc1e7d" xlink:to="loc_srt_RangeMember_ce17f583-2096-4d6c-bdb5-c38867cc1e7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b647a7b2-ed13-408d-8946-cb0cdcca6a2e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ce17f583-2096-4d6c-bdb5-c38867cc1e7d" xlink:to="loc_srt_RangeMember_b647a7b2-ed13-408d-8946-cb0cdcca6a2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_db8051b2-df3a-46b2-9298-77a4d911a26c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b647a7b2-ed13-408d-8946-cb0cdcca6a2e" xlink:to="loc_srt_MinimumMember_db8051b2-df3a-46b2-9298-77a4d911a26c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_33010a3c-4aa5-4200-940f-83865db3fc3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b647a7b2-ed13-408d-8946-cb0cdcca6a2e" xlink:to="loc_srt_MaximumMember_33010a3c-4aa5-4200-940f-83865db3fc3b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/PostEmploymentBenefitsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#PostEmploymentBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/PostEmploymentBenefitsDetails" xlink:type="extended" id="i777501a3a11a499bbcea947cb73233d8_PostEmploymentBenefitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c43cb219-4e4d-474e-982f-d7ad3777f7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_fd8c8619-90b7-4a72-8ef5-2236cc932592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c43cb219-4e4d-474e-982f-d7ad3777f7e5" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_fd8c8619-90b7-4a72-8ef5-2236cc932592" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_f5afb1a0-4140-4b75-bd3d-184a50c92d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c43cb219-4e4d-474e-982f-d7ad3777f7e5" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_f5afb1a0-4140-4b75-bd3d-184a50c92d3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_cd40ed7a-f9d4-45ba-ba8a-fa6383918a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c43cb219-4e4d-474e-982f-d7ad3777f7e5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_cd40ed7a-f9d4-45ba-ba8a-fa6383918a43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DefinedBenefitPlanNetAmortizationCostsAbstract_be999494-f681-4852-b2d3-65da99e5b81e" xlink:href="abt-20220930.xsd#abt_DefinedBenefitPlanNetAmortizationCostsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c43cb219-4e4d-474e-982f-d7ad3777f7e5" xlink:to="loc_abt_DefinedBenefitPlanNetAmortizationCostsAbstract_be999494-f681-4852-b2d3-65da99e5b81e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_b83690e9-26f0-4783-a385-b5e9cc8bd282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abt_DefinedBenefitPlanNetAmortizationCostsAbstract_be999494-f681-4852-b2d3-65da99e5b81e" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_b83690e9-26f0-4783-a385-b5e9cc8bd282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_099ee666-8271-4e55-994c-2d996b6c673b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abt_DefinedBenefitPlanNetAmortizationCostsAbstract_be999494-f681-4852-b2d3-65da99e5b81e" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_099ee666-8271-4e55-994c-2d996b6c673b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7f9aded9-2108-4470-bf1f-3c61cd07fd36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c43cb219-4e4d-474e-982f-d7ad3777f7e5" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7f9aded9-2108-4470-bf1f-3c61cd07fd36" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d8f1d133-feee-4dcd-95c2-98cb37f24f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c43cb219-4e4d-474e-982f-d7ad3777f7e5" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d8f1d133-feee-4dcd-95c2-98cb37f24f59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_24b50074-ec0a-45b7-a593-a1bda3c9f333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d8f1d133-feee-4dcd-95c2-98cb37f24f59" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_24b50074-ec0a-45b7-a593-a1bda3c9f333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_24b50074-ec0a-45b7-a593-a1bda3c9f333_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_24b50074-ec0a-45b7-a593-a1bda3c9f333" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_24b50074-ec0a-45b7-a593-a1bda3c9f333_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a7a2d70a-1aed-48b7-8fab-077c1336b693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_24b50074-ec0a-45b7-a593-a1bda3c9f333" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a7a2d70a-1aed-48b7-8fab-077c1336b693" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4d7f9f2a-c66e-4627-9ca1-8a68572b680b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_a7a2d70a-1aed-48b7-8fab-077c1336b693" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4d7f9f2a-c66e-4627-9ca1-8a68572b680b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_56a4beac-7400-4142-a250-aa45eb192324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_a7a2d70a-1aed-48b7-8fab-077c1336b693" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_56a4beac-7400-4142-a250-aa45eb192324" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#PostEmploymentBenefitsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails" xlink:type="extended" id="i7c2cc4e313364fe5be43996ba99e7e98_PostEmploymentBenefitsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c53d725e-4578-4cea-9663-033f4077d597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_86bc126b-74da-4d2e-b92a-bb7fec7ed9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c53d725e-4578-4cea-9663-033f4077d597" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_86bc126b-74da-4d2e-b92a-bb7fec7ed9cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2426196f-2b13-468f-8d0e-a585a46b3aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c53d725e-4578-4cea-9663-033f4077d597" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2426196f-2b13-468f-8d0e-a585a46b3aac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_63211d5d-367a-4878-b610-37dbdf6d2ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2426196f-2b13-468f-8d0e-a585a46b3aac" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_63211d5d-367a-4878-b610-37dbdf6d2ab0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_63211d5d-367a-4878-b610-37dbdf6d2ab0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_63211d5d-367a-4878-b610-37dbdf6d2ab0" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_63211d5d-367a-4878-b610-37dbdf6d2ab0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e117f194-ba36-4d2f-82f0-71e6febd5178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_63211d5d-367a-4878-b610-37dbdf6d2ab0" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e117f194-ba36-4d2f-82f0-71e6febd5178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b283465a-5568-4e03-9541-4107f088655a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e117f194-ba36-4d2f-82f0-71e6febd5178" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b283465a-5568-4e03-9541-4107f088655a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_84f8e889-c36e-421f-85ec-51d666d083b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e117f194-ba36-4d2f-82f0-71e6febd5178" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_84f8e889-c36e-421f-85ec-51d666d083b4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/TaxesonEarningsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#TaxesonEarningsDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/TaxesonEarningsDetails" xlink:type="extended" id="i8884c30490a34ea380aae2e303fea546_TaxesonEarningsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems_e27b4c73-9c5e-4e0a-9180-7e228b225561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_ExcessTaxBenefitFromShareBasedCompensation_d7a23b37-377c-4911-b81c-c0f164be22c6" xlink:href="abt-20220930.xsd#abt_ExcessTaxBenefitFromShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems_e27b4c73-9c5e-4e0a-9180-7e228b225561" xlink:to="loc_abt_ExcessTaxBenefitFromShareBasedCompensation_d7a23b37-377c-4911-b81c-c0f164be22c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_7593b582-b925-49d7-b7d9-ea9b3e1eb62a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems_e27b4c73-9c5e-4e0a-9180-7e228b225561" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_7593b582-b925-49d7-b7d9-ea9b3e1eb62a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_3a7823e7-cea0-4f1e-bdda-03e151b0782b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems_e27b4c73-9c5e-4e0a-9180-7e228b225561" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_3a7823e7-cea0-4f1e-bdda-03e151b0782b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable_6b0a9844-015f-479a-a601-99e4b626786f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems_e27b4c73-9c5e-4e0a-9180-7e228b225561" xlink:to="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable_6b0a9844-015f-479a-a601-99e4b626786f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a11790cd-8063-48ad-b858-932d45e887f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable_6b0a9844-015f-479a-a601-99e4b626786f" xlink:to="loc_srt_RangeAxis_a11790cd-8063-48ad-b858-932d45e887f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a11790cd-8063-48ad-b858-932d45e887f2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a11790cd-8063-48ad-b858-932d45e887f2" xlink:to="loc_srt_RangeMember_a11790cd-8063-48ad-b858-932d45e887f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3db87059-a0d1-4889-878d-51e4f6e43011" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a11790cd-8063-48ad-b858-932d45e887f2" xlink:to="loc_srt_RangeMember_3db87059-a0d1-4889-878d-51e4f6e43011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aba2ad94-6631-4a01-ab6d-c19bb7f874e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3db87059-a0d1-4889-878d-51e4f6e43011" xlink:to="loc_srt_MinimumMember_aba2ad94-6631-4a01-ab6d-c19bb7f874e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b5eca630-05e5-4b5f-85d9-81e9663f6f07" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3db87059-a0d1-4889-878d-51e4f6e43011" xlink:to="loc_srt_MaximumMember_b5eca630-05e5-4b5f-85d9-81e9663f6f07" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abbott.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#SegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://www.abbott.com/role/SegmentInformationDetails" xlink:type="extended" id="ie01dadf9420f495ab061dbc91f714da5_SegmentInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9af6e74b-3857-4fcf-bd6c-577266e6303b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9af6e74b-3857-4fcf-bd6c-577266e6303b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f22e8931-9294-49b4-a56b-c1f08e04e1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_us-gaap_OperatingIncomeLoss_f22e8931-9294-49b4-a56b-c1f08e04e1d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_CorporateAndBenefitPlanCosts_f0ae4f43-3a71-48b9-875d-9fd3e1425f3e" xlink:href="abt-20220930.xsd#abt_CorporateAndBenefitPlanCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_abt_CorporateAndBenefitPlanCosts_f0ae4f43-3a71-48b9-875d-9fd3e1425f3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_dcb0b796-ed9b-492d-a2e8-02883a8560b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_dcb0b796-ed9b-492d-a2e8-02883a8560b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9065fb32-3396-41d4-808f-39a98b12a754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9065fb32-3396-41d4-808f-39a98b12a754" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_0ad65082-4348-4ef4-aadc-97ccaa1e1807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_0ad65082-4348-4ef4-aadc-97ccaa1e1807" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_OtherCostAndExpenseOperatingAndNonoperating_2776341f-437d-4be4-a837-e295f6f8d61c" xlink:href="abt-20220930.xsd#abt_OtherCostAndExpenseOperatingAndNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_abt_OtherCostAndExpenseOperatingAndNonoperating_2776341f-437d-4be4-a837-e295f6f8d61c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f24c71e3-5bb2-4c65-b12e-640ee20852c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f24c71e3-5bb2-4c65-b12e-640ee20852c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent_334424f2-d572-47bd-a636-5541fbf946f3" xlink:href="abt-20220930.xsd#abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent_334424f2-d572-47bd-a636-5541fbf946f3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRecallExpense_e2bdf801-9f35-430f-a31d-5b5e7a4dbdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRecallExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_us-gaap_InventoryRecallExpense_e2bdf801-9f35-430f-a31d-5b5e7a4dbdc5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_bc453fd2-50c7-4011-8421-0fe25d752a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_bc453fd2-50c7-4011-8421-0fe25d752a83" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_947a315a-3444-463a-b7d5-e19fe5c0d1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_947a315a-3444-463a-b7d5-e19fe5c0d1a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_ea86d510-c47a-44ab-be33-39731ac8b2bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_947a315a-3444-463a-b7d5-e19fe5c0d1a6" xlink:to="loc_srt_ConsolidationItemsAxis_ea86d510-c47a-44ab-be33-39731ac8b2bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ea86d510-c47a-44ab-be33-39731ac8b2bf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_ea86d510-c47a-44ab-be33-39731ac8b2bf" xlink:to="loc_srt_ConsolidationItemsDomain_ea86d510-c47a-44ab-be33-39731ac8b2bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f38957a0-31d0-4e1a-b9db-bceb974f6a45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_ea86d510-c47a-44ab-be33-39731ac8b2bf" xlink:to="loc_srt_ConsolidationItemsDomain_f38957a0-31d0-4e1a-b9db-bceb974f6a45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_97b67513-b4e7-49a5-8f7c-eddf4b04b088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_f38957a0-31d0-4e1a-b9db-bceb974f6a45" xlink:to="loc_us-gaap_OperatingSegmentsMember_97b67513-b4e7-49a5-8f7c-eddf4b04b088" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_c2f4036b-f552-473a-b004-40f7b41ea803" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_f38957a0-31d0-4e1a-b9db-bceb974f6a45" xlink:to="loc_us-gaap_CorporateNonSegmentMember_c2f4036b-f552-473a-b004-40f7b41ea803" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_8ba7680a-1dd2-4ba5-89cc-f558cca4808f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_f38957a0-31d0-4e1a-b9db-bceb974f6a45" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_8ba7680a-1dd2-4ba5-89cc-f558cca4808f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a5f5c9cd-710a-47dd-8eac-097b93dd91ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_947a315a-3444-463a-b7d5-e19fe5c0d1a6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a5f5c9cd-710a-47dd-8eac-097b93dd91ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a5f5c9cd-710a-47dd-8eac-097b93dd91ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a5f5c9cd-710a-47dd-8eac-097b93dd91ff" xlink:to="loc_us-gaap_SegmentDomain_a5f5c9cd-710a-47dd-8eac-097b93dd91ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_44a62403-9af5-4e54-8a25-9c93f6a4c9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a5f5c9cd-710a-47dd-8eac-097b93dd91ff" xlink:to="loc_us-gaap_SegmentDomain_44a62403-9af5-4e54-8a25-9c93f6a4c9fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_EstablishedPharmaceuticalProductsMember_4e47f182-a2cf-4464-9c78-691ff27c5cc4" xlink:href="abt-20220930.xsd#abt_EstablishedPharmaceuticalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_44a62403-9af5-4e54-8a25-9c93f6a4c9fa" xlink:to="loc_abt_EstablishedPharmaceuticalProductsMember_4e47f182-a2cf-4464-9c78-691ff27c5cc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_NutritionalProductsMember_6621bfab-1f54-4eef-8e40-b6174617cce7" xlink:href="abt-20220930.xsd#abt_NutritionalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_44a62403-9af5-4e54-8a25-9c93f6a4c9fa" xlink:to="loc_abt_NutritionalProductsMember_6621bfab-1f54-4eef-8e40-b6174617cce7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DiagnosticProductsMember_83b2c013-225b-4bd7-b0cf-bfeb401b34a9" xlink:href="abt-20220930.xsd#abt_DiagnosticProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_44a62403-9af5-4e54-8a25-9c93f6a4c9fa" xlink:to="loc_abt_DiagnosticProductsMember_83b2c013-225b-4bd7-b0cf-bfeb401b34a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_MedicalDevicesMember_bc53de43-92d1-4af6-9dd1-6cf9f141886b" xlink:href="abt-20220930.xsd#abt_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_44a62403-9af5-4e54-8a25-9c93f6a4c9fa" xlink:to="loc_abt_MedicalDevicesMember_bc53de43-92d1-4af6-9dd1-6cf9f141886b" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>abt-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:19ee09c1-7a67-41f5-aa0d-f1189dd14b54,g:ff04be54-28ba-406d-b68f-d5381de01f45-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_b4a16800-1a64-4ed6-918c-99b12263ff49_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_097be8f2-b950-4026-8877-99ca9ecb1b69_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_622a92c2-6060-4c3e-820e-29e1c9e1aca8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Investment</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_c06da719-3894-4af3-bf8a-0724ce6e1861_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions/charges to income</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a8d3c96f-3aa5-48ad-ba23-a7c893323d18_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_38c929f0-eddd-4d24-9529-ce7bc9222a6c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of restructuring estimate</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Accrual Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:to="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember_c95d23e7-fc5d-4f51-828c-0eba8504bfa4_terseLabel_en-US" xlink:label="lab_abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies</link:label>
    <link:label id="lab_abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember_label_en-US" xlink:label="lab_abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies [Member]</link:label>
    <link:label id="lab_abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember_documentation_en-US" xlink:label="lab_abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The restructuring plans to streamline operations in order to reduce costs and improve efficiencies in various Abbott businesses including the nutritional, established pharmaceuticals and vascular businesses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember" xlink:href="abt-20220930.xsd#abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember" xlink:to="lab_abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_NeuromodulationMember_cdabb9b7-3216-4891-91ef-55bf5d2d64c0_terseLabel_en-US" xlink:label="lab_abt_NeuromodulationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuromodulation</link:label>
    <link:label id="lab_abt_NeuromodulationMember_label_en-US" xlink:label="lab_abt_NeuromodulationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuromodulation [Member]</link:label>
    <link:label id="lab_abt_NeuromodulationMember_documentation_en-US" xlink:label="lab_abt_NeuromodulationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents the neuromodulation, segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_NeuromodulationMember" xlink:href="abt-20220930.xsd#abt_NeuromodulationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_NeuromodulationMember" xlink:to="lab_abt_NeuromodulationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess_ad1001e0-75e5-4c0c-bb3e-3e4bb65369f8_negatedLabel_en-US" xlink:label="lab_abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of businesses and technologies, net of cash acquired</link:label>
    <link:label id="lab_abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired, And Research and Development in Process</link:label>
    <link:label id="lab_abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess_documentation_en-US" xlink:label="lab_abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase, and research and development assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess" xlink:href="abt-20220930.xsd#abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess" xlink:to="lab_abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_81a09f92-1607-4290-956a-808214575981_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_5eed103b-61e4-447e-96a4-29cd4bb33b43_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_58f90a06-73b5-417e-8095-77c87ba9b855_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_0c3d0b41-9267-4f25-be55-2c2bae89811d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_PediatricNutritionalsMember_933d7d65-5c3b-43a1-9cf8-292fd1bf2c77_terseLabel_en-US" xlink:label="lab_abt_PediatricNutritionalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pediatric Nutritionals</link:label>
    <link:label id="lab_abt_PediatricNutritionalsMember_label_en-US" xlink:label="lab_abt_PediatricNutritionalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pediatric Nutritionals [Member]</link:label>
    <link:label id="lab_abt_PediatricNutritionalsMember_documentation_en-US" xlink:label="lab_abt_PediatricNutritionalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents the pediatric nutritionals, segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PediatricNutritionalsMember" xlink:href="abt-20220930.xsd#abt_PediatricNutritionalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_PediatricNutritionalsMember" xlink:to="lab_abt_PediatricNutritionalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_822151b3-6f4f-4420-beb5-1b52e9bca383_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued balance at beginning of the period</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_43e9cb7c-534c-4656-94c1-6eebe09e073a_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued balance at end of the period</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_ab43db29-f0fd-444e-9eef-cda50ce65044_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories:</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_04d4d4f0-eb94-4405-aace-b705459c8a5a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_cc77015b-7bcb-45dd-bfe4-2931080e064b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3ea0f121-b760-4959-8d9a-d863d7f90f89_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_b13d22b2-274b-4b4a-9b42-c80023fbc2a7_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations_70360eb4-8295-4ecb-96a5-d07575dad726_terseLabel_en-US" xlink:label="lab_abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests&#8217; share of income, business combinations, net of distributions and share repurchases</link:label>
    <link:label id="lab_abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations_label_en-US" xlink:label="lab_abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests Share of Income Net of Distributions and Share Repurchases and Business Combinations</link:label>
    <link:label id="lab_abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations_documentation_en-US" xlink:label="lab_abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represent Noncontrolling Interests' share of income, net of distributions, share repurchases and business combinations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations" xlink:href="abt-20220930.xsd#abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations" xlink:to="lab_abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_37b7c4dd-5ec4-4c3c-a20e-4511b007c734_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_a4122367-bcf7-4613-be55-1361ccac2c23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of derivatives gain (loss) in OCI and earnings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9aaf5d6-ef1e-490f-a890-59c8be95d2c0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_fd3ea467-6242-428e-b6cd-0ed78354a76a_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cost (credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_343f145c-6660-47f4-b174-6ed585714d11_verboseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0494fa71-2d3a-4c89-b0fd-3d163106cafe_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_55a0a6a6-7d41-48af-b40d-3f1712374e8b_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c96af98d-b341-40e3-8f08-18db9eb009f2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_92c71c1a-795a-4a7f-b6da-046d17f9ef56_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_37d6377b-1021-429a-881e-83d3f0ba2d1b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_10d9a263-96a5-440c-bd0f-a76a2893157c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Common Stock Options Having No Dilutive Effect (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_a3311ab5-1376-4d5b-952e-84141b0a920d_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document and Entity Information</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems_eb99ccbb-5805-4957-80d8-d3f2eab3d299_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]</link:label>
    <link:label id="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems_label_en-US" xlink:label="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1cbeb775-e2f8-4eb3-8e66-ada6a0912af8_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service cost (credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_4db89e0e-c5e2-4a6c-8822-d33485f0f6b6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_157bb2d0-7936-4348-a3aa-745e4b6e2a61_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_MolecularMember_48171c82-61e6-42cc-9b18-0cc9bbbd9dff_terseLabel_en-US" xlink:label="lab_abt_MolecularMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular</link:label>
    <link:label id="lab_abt_MolecularMember_label_en-US" xlink:label="lab_abt_MolecularMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molecular [Member]</link:label>
    <link:label id="lab_abt_MolecularMember_documentation_en-US" xlink:label="lab_abt_MolecularMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents the molecular, segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_MolecularMember" xlink:href="abt-20220930.xsd#abt_MolecularMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_MolecularMember" xlink:to="lab_abt_MolecularMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_22c07f7d-4161-4351-b5ae-e69e893af3c5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_630991e0-1c32-4014-bc20-a29f32a893e4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_7fd13060-6d90-43cc-8638-449425cab67a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimation of possible loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_7c754fa5-727f-4013-b06a-acfa844263ae_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares held in treasury, at cost &#8212; Shares: 2022: 242,345,663; 2021: 221,191,228</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_61febc8a-32df-46dc-886a-924aae0cfcec_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative foreign currency translation (loss) adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_dacd1690-c178-47b3-8b34-fc6e94e82763_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net actuarial (losses) and prior service (costs) and credits</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_cfff8d85-5a42-4e82-8dcd-f67a921286c4_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_7ce02b64-d2a6-405c-8f69-5302fa5c2fb1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_d04a66f6-04f3-4ff2-916e-d59aedfaf7f5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1f612c5d-128c-4455-8ce3-6eb11fed5486_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d5298b1a-4828-4639-927a-b4166173b3d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_CostOfGoodsAndServicesSoldMember_32001c8e-782f-4777-a535-9cbf8527d47c_terseLabel_en-US" xlink:label="lab_abt_CostOfGoodsAndServicesSoldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Products Sold</link:label>
    <link:label id="lab_abt_CostOfGoodsAndServicesSoldMember_label_en-US" xlink:label="lab_abt_CostOfGoodsAndServicesSoldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold [Member]</link:label>
    <link:label id="lab_abt_CostOfGoodsAndServicesSoldMember_documentation_en-US" xlink:label="lab_abt_CostOfGoodsAndServicesSoldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_CostOfGoodsAndServicesSoldMember" xlink:href="abt-20220930.xsd#abt_CostOfGoodsAndServicesSoldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_CostOfGoodsAndServicesSoldMember" xlink:to="lab_abt_CostOfGoodsAndServicesSoldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_70167bf5-9455-4086-8628-f9ea5441e5eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate hedge contracts, (payable) position</link:label>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Fair Value Hedge Liability at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:to="lab_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4376e9c1-220b-4268-a34d-b7cac4d35882_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding, weighted-average remaining life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForOtherTaxes_7e02c696-86e3-4b9f-9b30-55e99aa061e4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForOtherTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of cash taxes</link:label>
    <link:label id="lab_us-gaap_PaymentsForOtherTaxes_label_en-US" xlink:label="lab_us-gaap_PaymentsForOtherTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Other Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForOtherTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForOtherTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForOtherTaxes" xlink:to="lab_us-gaap_PaymentsForOtherTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_197c7357-5e8e-4490-993d-e320243b1d2d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8adfb8e4-e8c4-407e-903a-3fd0fba819df_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash From Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_082a3c70-95af-420b-900f-8333bd5e08ee_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_0a450f1c-c72e-4bda-bb30-40daadee62df_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b200ed-7803-4b9a-8751-33efef3b1210_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_c39dc7fb-f448-4a81-9687-b2a068563cd0_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a7c981f7-84bc-436f-9cd8-8c82ddf32500_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow From (Used in) Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8c790f6a-0bec-4c5d-aa8e-525acab82340_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, percentage acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_4f3686f4-96a1-469c-aa34-db1a5ab21fe8_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae123749-fe55-44ee-8494-b54d968fe9b9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_DiabetesCareMember_0d83f5a1-96c4-4054-9290-de04858685ed_terseLabel_en-US" xlink:label="lab_abt_DiabetesCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes Care</link:label>
    <link:label id="lab_abt_DiabetesCareMember_label_en-US" xlink:label="lab_abt_DiabetesCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diabetes Care [Member]</link:label>
    <link:label id="lab_abt_DiabetesCareMember_documentation_en-US" xlink:label="lab_abt_DiabetesCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents the Diabetes Care, segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DiabetesCareMember" xlink:href="abt-20220930.xsd#abt_DiabetesCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_DiabetesCareMember" xlink:to="lab_abt_DiabetesCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_EffectOfCommonAndTreasuryShareTransactions_88f4883e-e873-460e-b099-186f0e55ce11_negatedLabel_en-US" xlink:label="lab_abt_EffectOfCommonAndTreasuryShareTransactions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of common and treasury share transactions</link:label>
    <link:label id="lab_abt_EffectOfCommonAndTreasuryShareTransactions_label_en-US" xlink:label="lab_abt_EffectOfCommonAndTreasuryShareTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Common and Treasury Share Transactions</link:label>
    <link:label id="lab_abt_EffectOfCommonAndTreasuryShareTransactions_documentation_en-US" xlink:label="lab_abt_EffectOfCommonAndTreasuryShareTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the effect on retained earning due to common and treasury stock transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_EffectOfCommonAndTreasuryShareTransactions" xlink:href="abt-20220930.xsd#abt_EffectOfCommonAndTreasuryShareTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_EffectOfCommonAndTreasuryShareTransactions" xlink:to="lab_abt_EffectOfCommonAndTreasuryShareTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_4aac9abb-43c8-4e0e-9dae-98f6e0bb574b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_228179be-262e-474b-be4e-470029d64be2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_38bdb94d-3a45-4934-ba07-68250b2f11ea_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_93938c5d-5f20-42a3-ab5c-3a754d0318b2_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_InventoryRelatedChargesMember_8df86086-3266-473c-9e53-853e2388cc26_terseLabel_en-US" xlink:label="lab_abt_InventoryRelatedChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory- Related Charges</link:label>
    <link:label id="lab_abt_InventoryRelatedChargesMember_label_en-US" xlink:label="lab_abt_InventoryRelatedChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory-related charges [Member]</link:label>
    <link:label id="lab_abt_InventoryRelatedChargesMember_documentation_en-US" xlink:label="lab_abt_InventoryRelatedChargesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to fixed asset inventory related charges .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_InventoryRelatedChargesMember" xlink:href="abt-20220930.xsd#abt_InventoryRelatedChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_InventoryRelatedChargesMember" xlink:to="lab_abt_InventoryRelatedChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_abc20e44-d618-4886-a462-7b521a9e56be_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_2ccb559a-8834-4951-96b2-e701fe102dd9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Lines of Credit</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d014825c-dbf0-4deb-947c-3d97c0453aac_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_StructuralHeartMember_e2af5114-cf1c-4e69-a29c-befa32a39e42_terseLabel_en-US" xlink:label="lab_abt_StructuralHeartMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Structural Heart</link:label>
    <link:label id="lab_abt_StructuralHeartMember_label_en-US" xlink:label="lab_abt_StructuralHeartMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Structural Heart [Member]</link:label>
    <link:label id="lab_abt_StructuralHeartMember_documentation_en-US" xlink:label="lab_abt_StructuralHeartMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents the structural heart, segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_StructuralHeartMember" xlink:href="abt-20220930.xsd#abt_StructuralHeartMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_StructuralHeartMember" xlink:to="lab_abt_StructuralHeartMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_HeartFailureMember_61e75816-a509-4811-9c8e-75c90cb532ca_terseLabel_en-US" xlink:label="lab_abt_HeartFailureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heart Failure</link:label>
    <link:label id="lab_abt_HeartFailureMember_label_en-US" xlink:label="lab_abt_HeartFailureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heart Failure [Member]</link:label>
    <link:label id="lab_abt_HeartFailureMember_documentation_en-US" xlink:label="lab_abt_HeartFailureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents the Heart Failure, segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_HeartFailureMember" xlink:href="abt-20220930.xsd#abt_HeartFailureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_HeartFailureMember" xlink:to="lab_abt_HeartFailureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_RhythmManagementMember_197a6d39-058a-4ae6-868e-5cb1797e278c_terseLabel_en-US" xlink:label="lab_abt_RhythmManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rhythm Management</link:label>
    <link:label id="lab_abt_RhythmManagementMember_label_en-US" xlink:label="lab_abt_RhythmManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rhythm Management [Member]</link:label>
    <link:label id="lab_abt_RhythmManagementMember_documentation_en-US" xlink:label="lab_abt_RhythmManagementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents the rhythm management, segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RhythmManagementMember" xlink:href="abt-20220930.xsd#abt_RhythmManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_RhythmManagementMember" xlink:to="lab_abt_RhythmManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_197a3559-efc1-4dad-8aa5-c71022523c97_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) Recognized in Other Comprehensive Income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_a3006779-7661-40ed-a895-2ab6465abe18_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_e69d8e16-2c73-47f3-a4e5-adbe3e5c34c0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ebe65803-a0f5-4b59-a45a-d9dc6a1871a5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_f4721cf7-2a6a-4a32-8529-294a454989a5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember" xlink:to="lab_us-gaap_OtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_06a0d6dd-423b-4698-aac6-30af31e5855b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_091c9fa5-fc31-444b-9515-1bd6b318d622_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accumulated other comprehensive income (loss), net of taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b813ed6a-f3b2-453a-be9d-7e2f84d24d31_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_9f3600da-ed82-441a-a215-f23399444943_negatedLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts charged off and other deductions</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_69d45719-ddad-4888-b85d-ddc81eef6de6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_KeyEmergingMarketsMember_f426cbcb-21ac-49c1-a0ba-027ef30055bd_terseLabel_en-US" xlink:label="lab_abt_KeyEmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key Emerging Markets</link:label>
    <link:label id="lab_abt_KeyEmergingMarketsMember_label_en-US" xlink:label="lab_abt_KeyEmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key Emerging Markets [Member]</link:label>
    <link:label id="lab_abt_KeyEmergingMarketsMember_documentation_en-US" xlink:label="lab_abt_KeyEmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents the key emerging markets, segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_KeyEmergingMarketsMember" xlink:href="abt-20220930.xsd#abt_KeyEmergingMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_KeyEmergingMarketsMember" xlink:to="lab_abt_KeyEmergingMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_StockIssuedDuringPeriodValueIncentiveStockPrograms_d2fbce00-3eea-44d9-a7d7-a33d9b35479b_terseLabel_en-US" xlink:label="lab_abt_StockIssuedDuringPeriodValueIncentiveStockPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued under incentive stock programs</link:label>
    <link:label id="lab_abt_StockIssuedDuringPeriodValueIncentiveStockPrograms_label_en-US" xlink:label="lab_abt_StockIssuedDuringPeriodValueIncentiveStockPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Incentive Stock Programs</link:label>
    <link:label id="lab_abt_StockIssuedDuringPeriodValueIncentiveStockPrograms_documentation_en-US" xlink:label="lab_abt_StockIssuedDuringPeriodValueIncentiveStockPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Incentive Stock Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_StockIssuedDuringPeriodValueIncentiveStockPrograms" xlink:href="abt-20220930.xsd#abt_StockIssuedDuringPeriodValueIncentiveStockPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_StockIssuedDuringPeriodValueIncentiveStockPrograms" xlink:to="lab_abt_StockIssuedDuringPeriodValueIncentiveStockPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_0f071dde-548d-40bd-8ddf-ba3a5320f2e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems_8c4a4f22-cf64-4a06-a279-e67f2399a38c_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investment Holdings [Line Items]</link:label>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems_label_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investment Holdings [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_b41069f2-963d-4674-a089-95c7d980c26a_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_f957c1d2-bfd9-482e-9e53-b326f4bd7e7d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_400787a6-577a-46d5-8ba8-212a034b7d1f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_0df3607a-dd28-4813-971e-53e3dbe098d3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_f4672d67-20a3-47f3-b9e8-369df3ce09dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_5e1820a0-996e-453a-98f4-6ce60e53af2d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2dee802b-418f-4c0f-925a-71467f650cd7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash From (Used in) Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_5adcb2ca-824a-4b66-a573-460379bac59f_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_InventoryNoNetRealizableValueSold_862557c7-1b4b-4d19-890c-e69d1383d973_terseLabel_en-US" xlink:label="lab_abt_InventoryNoNetRealizableValueSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory sold that was previously estimated to have no net realizable value</link:label>
    <link:label id="lab_abt_InventoryNoNetRealizableValueSold_label_en-US" xlink:label="lab_abt_InventoryNoNetRealizableValueSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory No Net Realizable Value Sold</link:label>
    <link:label id="lab_abt_InventoryNoNetRealizableValueSold_documentation_en-US" xlink:label="lab_abt_InventoryNoNetRealizableValueSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of inventory sold that was previously estimated to have no net realizable value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_InventoryNoNetRealizableValueSold" xlink:href="abt-20220930.xsd#abt_InventoryNoNetRealizableValueSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_InventoryNoNetRealizableValueSold" xlink:to="lab_abt_InventoryNoNetRealizableValueSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_e64676f2-6ccb-43a8-888b-c50f5aac67a4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_4ccbf67c-3fa8-4d59-a2ef-0266b2630f1a_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investment Securities:</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_a5f3e33a-1a63-4c85-833f-c25f983e13f6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries, wages and commissions</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_49034d56-0968-4259-9a5b-489835207961_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_1773be09-1632-4571-b540-809009692d09_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_fb9784cf-843c-4e70-b596-1fa8650655f6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost on projected benefit obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_01e5aaf6-536f-4fd5-a712-5d5850969112_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the amounts and location of certain derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2b8d6d-14a1-4b08-86d5-91a6bce050a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0b3ca088-3490-4a6f-85a3-65d965f396be_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost, recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7b66bdba-c890-4948-bf78-8525700a8788_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable options, weighted-average remaining life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_308ad850-3344-4f76-840d-44c778a57ab0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_68cdea2c-4e04-4c6d-850c-8276ba01f5b1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:to="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_c8dc77cc-7841-4626-94c1-78f77333770f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_StJudeMedicalIncMember_08a463b8-36ec-401d-a1db-45a035b455de_terseLabel_en-US" xlink:label="lab_abt_StJudeMedicalIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">St. Jude Medical</link:label>
    <link:label id="lab_abt_StJudeMedicalIncMember_label_en-US" xlink:label="lab_abt_StJudeMedicalIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">St. Jude Medical, Inc. [Member]</link:label>
    <link:label id="lab_abt_StJudeMedicalIncMember_documentation_en-US" xlink:label="lab_abt_StJudeMedicalIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information relating to acquisition of St. Jude Medical, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_StJudeMedicalIncMember" xlink:href="abt-20220930.xsd#abt_StJudeMedicalIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_StJudeMedicalIncMember" xlink:to="lab_abt_StJudeMedicalIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_944cae43-9a8a-4b2b-b39e-6108725594e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of carrying values and fair values of certain financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_54bb81a9-9c0d-4d35-8777-d456b4a3fcdf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_PrepaidExpenseAndOtherReceivables_80da2c32-cd38-4f7f-9362-b7f60037c4d1_verboseLabel_en-US" xlink:label="lab_abt_PrepaidExpenseAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
    <link:label id="lab_abt_PrepaidExpenseAndOtherReceivables_label_en-US" xlink:label="lab_abt_PrepaidExpenseAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Receivables</link:label>
    <link:label id="lab_abt_PrepaidExpenseAndOtherReceivables_documentation_en-US" xlink:label="lab_abt_PrepaidExpenseAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other receivables that are expected to be realized within one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PrepaidExpenseAndOtherReceivables" xlink:href="abt-20220930.xsd#abt_PrepaidExpenseAndOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_PrepaidExpenseAndOtherReceivables" xlink:to="lab_abt_PrepaidExpenseAndOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_43ac2e2b-98c9-4329-88da-48ff7a864923_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_a052aa83-28b9-4b43-a561-a0b2a7bd4c88_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold</link:label>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_label_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Length of Time Hedged in Cash Flow Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1" xlink:to="lab_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4ae9594b-8412-463a-9f0a-6416a6607b7d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_c542cda6-d468-406d-b069-45f679c64a0e_verboseLabel_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other</link:label>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_label_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:to="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_7d6cceb9-5010-4105-8227-38fd52406be7_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_55e18b0b-f71b-484b-9b43-c853b22d37cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in goodwill due to foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureTextBlockSupplementAbstract_c4e33892-d14b-4677-a648-3ffd203a63de_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureTextBlockSupplementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureTextBlockSupplementAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureTextBlockSupplementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="lab_us-gaap_DisclosureTextBlockSupplementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_e378b686-4f5a-4a39-9192-a16325c4f5c5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Foreign Currency Translation (Loss) Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6e1fe527-1737-4149-823d-9c4f39ce8087_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_YenDenominatedLongTermDebtMember_b3c6817e-8c48-4598-b23b-fcae2e3ddd87_terseLabel_en-US" xlink:label="lab_abt_YenDenominatedLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yen-denominated long-term debt</link:label>
    <link:label id="lab_abt_YenDenominatedLongTermDebtMember_label_en-US" xlink:label="lab_abt_YenDenominatedLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yen-denominated long-term debt [Member]</link:label>
    <link:label id="lab_abt_YenDenominatedLongTermDebtMember_documentation_en-US" xlink:label="lab_abt_YenDenominatedLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to yen denominated Long-term debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_YenDenominatedLongTermDebtMember" xlink:href="abt-20220930.xsd#abt_YenDenominatedLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_YenDenominatedLongTermDebtMember" xlink:to="lab_abt_YenDenominatedLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_3f083273-e2e7-4c26-8f55-68e1519614be_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_52e0e444-4904-48f3-b7ed-d77dc1fbc68f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_de2800fb-7a08-4b2d-96a7-53379ad72394_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d04ac38e-a630-4f82-803c-1fd4635756b1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholders&#8217; Investment</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_66b487e7-3d4c-4a78-97e4-635238794a37_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0ddb96cf-323e-43df-9984-a60d2c3194d0_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsTable_06d690dc-791d-4c9b-974c-1fcfe76b7810_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investment Holdings [Table]</link:label>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsTable_label_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investment Holdings [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_16ccba59-0522-49a5-9ff1-e33e9aabee3b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_7ed589da-d5a7-4525-8990-db39b569d0da_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests in Subsidiaries</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_a059cad2-3496-4bed-8498-fa6121e92420_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4251dc2b-d221-42ea-9e0d-5f5564e5f011_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_6397b5db-16ca-4f0c-8dba-c10ddbce560c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3e15a2ea-c9ea-4828-be6f-e67ea5ecd666_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3cd0c6e9-13cd-470f-b686-7452c3c5088b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_cbbe235a-3f6a-448d-9b0c-b1a6af8f474e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_2a288700-25d1-447f-9042-ba1a059a920e_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_45138906-d54b-4055-9974-eb727b688892_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_30b3cf80-8f74-4f8a-bfcd-112b25d4a861_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_08601894-b5d9-4af9-85e8-3178905a4d70_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares held in treasury (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_e50458a8-5e75-48f8-87a9-bb71ea41f073_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, treasury stock, common (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_346090eb-07a4-4848-a8b8-7824e27c9877_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, treasury stock, common (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_7c24d7f7-bc7a-4f8e-86e4-73a02770f4b0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b364e865-6e17-4661-94a5-1e6f97a159d4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization expense, intangible assets, 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_a6985b30-0e63-4a87-9207-29b4ca444a59_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8dc44061-ffa5-41f2-aac3-a94aff16ac4e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0ead8c49-ce43-43ab-81c6-fdc9cb1d9436_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards granted during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_673c0f22-d453-49f5-82d4-f6fdbbfe6f22_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms_0c115f69-57d6-4f77-a482-7edde9e6c443_terseLabel_en-US" xlink:label="lab_abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued under incentive stock programs (in shares)</link:label>
    <link:label id="lab_abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms_label_en-US" xlink:label="lab_abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Incentive Stock Programs</link:label>
    <link:label id="lab_abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms_documentation_en-US" xlink:label="lab_abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Incentive Stock Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms" xlink:href="abt-20220930.xsd#abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms" xlink:to="lab_abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_PointOfCareMember_0df39e5b-c5ff-4ce4-b622-6af837f4f227_terseLabel_en-US" xlink:label="lab_abt_PointOfCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Point of Care</link:label>
    <link:label id="lab_abt_PointOfCareMember_label_en-US" xlink:label="lab_abt_PointOfCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Point of Care [Member]</link:label>
    <link:label id="lab_abt_PointOfCareMember_documentation_en-US" xlink:label="lab_abt_PointOfCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents the point of care, segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PointOfCareMember" xlink:href="abt-20220930.xsd#abt_PointOfCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_PointOfCareMember" xlink:to="lab_abt_PointOfCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PostemploymentBenefitsDisclosureTextBlock_4ffde2b9-92d1-4b83-909d-b03c1f77735e_terseLabel_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-Employment Benefits</link:label>
    <link:label id="lab_us-gaap_PostemploymentBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d2ecf83f-ed3a-41cc-ab98-0622761fdee8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Earnings</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_aaf5a2b6-7a3f-42e8-a2a0-0b37fcb591bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted during period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_583121d0-8734-4c78-a88b-5848557c1cf1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished products</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_ea6823bc-c948-47f5-a1a7-5583c63708f4_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_ca572002-f972-48c3-ae34-210d35621e62_negatedLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9f07c0d8-58a1-4fbc-80f3-c71d9b77b31b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Earnings Per Common Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_73408f65-1324-49a0-80c0-6e6e37ce3d16_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_16783a31-8ca3-4f26-9c82-bf56f8efec21_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (expense) and Gain (loss) Reclassified into Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_69ddbd18-9d41-4015-a92b-08ab6e2d9b65_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Actuarial (Losses) and Prior Service (Costs) and Credits</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_eacd110a-c8ee-4fd3-ab19-19ac349e94b5_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_51be5b13-a75b-4f9e-8a52-5b8ff8f3eccf_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Abbott Shareholders&#8217; Investment</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c37c1317-c4f1-41be-873b-1e9977d6a54d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of the period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_333022e8-c36f-46be-a106-54a1ad45898b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of the period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_9d5dd7e9-1501-4b56-b6f8-244f32afac23_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Derivatives and Fair Value Measures</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_CorporateAndBenefitPlanCosts_443d02ab-551a-40e4-8fe3-e641592cbb56_negatedLabel_en-US" xlink:label="lab_abt_CorporateAndBenefitPlanCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate functions and benefit plan costs</link:label>
    <link:label id="lab_abt_CorporateAndBenefitPlanCosts_label_en-US" xlink:label="lab_abt_CorporateAndBenefitPlanCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate and Benefit Plan Costs</link:label>
    <link:label id="lab_abt_CorporateAndBenefitPlanCosts_documentation_en-US" xlink:label="lab_abt_CorporateAndBenefitPlanCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The reconciling item from aggregate segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to corporate functions and benefit plan costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_CorporateAndBenefitPlanCosts" xlink:href="abt-20220930.xsd#abt_CorporateAndBenefitPlanCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_CorporateAndBenefitPlanCosts" xlink:to="lab_abt_CorporateAndBenefitPlanCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_06f43eb2-323a-40cc-89ec-41a60979d693_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_2282a7a9-64d6-4e15-8329-7ec9a10220e2_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable_030964e5-4dd1-407b-9401-26b866a0eb57_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table]</link:label>
    <link:label id="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable_label_en-US" xlink:label="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:to="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_2d572702-a578-45e2-9e91-8e4cda253a57_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cbd2e2ad-be25-4342-a0c6-b1537cd53114_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_RestrictedStockAwardsMember_bf098f31-efdc-4c83-bf24-f899e99d0fff_terseLabel_en-US" xlink:label="lab_abt_RestrictedStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Awards</link:label>
    <link:label id="lab_abt_RestrictedStockAwardsMember_label_en-US" xlink:label="lab_abt_RestrictedStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards [Member]</link:label>
    <link:label id="lab_abt_RestrictedStockAwardsMember_documentation_en-US" xlink:label="lab_abt_RestrictedStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RestrictedStockAwardsMember" xlink:href="abt-20220930.xsd#abt_RestrictedStockAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_RestrictedStockAwardsMember" xlink:to="lab_abt_RestrictedStockAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_DeferredIncomeTaxesAndOtherAssetsMember_56994991-1bda-4273-8c47-3618d6e63848_terseLabel_en-US" xlink:label="lab_abt_DeferredIncomeTaxesAndOtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes and other assets</link:label>
    <link:label id="lab_abt_DeferredIncomeTaxesAndOtherAssetsMember_label_en-US" xlink:label="lab_abt_DeferredIncomeTaxesAndOtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes and other assets [Member]</link:label>
    <link:label id="lab_abt_DeferredIncomeTaxesAndOtherAssetsMember_documentation_en-US" xlink:label="lab_abt_DeferredIncomeTaxesAndOtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Deferred Income Taxes and Other Assets line item in the statement of financial position in which the amounts are included.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DeferredIncomeTaxesAndOtherAssetsMember" xlink:href="abt-20220930.xsd#abt_DeferredIncomeTaxesAndOtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_DeferredIncomeTaxesAndOtherAssetsMember" xlink:to="lab_abt_DeferredIncomeTaxesAndOtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_99244dd1-e285-4a3d-ba34-fcd060b5eca9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization expense, intangible assets, 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_0eb91fc3-65c1-4cc8-8c95-08a702839355_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_de69fae7-b7d2-4358-b5c6-89d5d1ed4355_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_59ffd00e-6e20-48ca-b687-2b586d0622d6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_fbfea102-e22c-47a4-9f32-341a8613a5c8_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared on common shares</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedCashFlowStatementsCaptionsLineItems_aeb4117f-7660-42f9-9126-13f1baec9dd3_terseLabel_en-US" xlink:label="lab_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Cash Flow Statements, Captions [Line Items]</link:label>
    <link:label id="lab_srt_CondensedCashFlowStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Cash Flow Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_a31032d1-212e-4e18-ac3c-f93bf9c13745_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_255ef50c-9ff8-4240-bb07-57c285486b4c_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2af49911-133a-4f37-9abf-49a8ddfe42f2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_856f7d21-1f43-4f49-a088-d09f9e455333_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_fbc39db2-c72f-4460-be64-6eb17af29cd4_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_59f32309-d5ea-4331-a584-c45c3b8bb520_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_2fbb495d-a337-4db8-b87e-719c7f292f84_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration related to business combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1e3981ee-61a8-4563-820b-209619af14ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock program, shares reserved for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_cc96e31b-7be5-4a91-b96c-4146d889c2c5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_DiagnosticProductsMember_e1661be3-cdf0-4566-8440-8b69220a2862_terseLabel_en-US" xlink:label="lab_abt_DiagnosticProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Products</link:label>
    <link:label id="lab_abt_DiagnosticProductsMember_label_en-US" xlink:label="lab_abt_DiagnosticProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Products [Member]</link:label>
    <link:label id="lab_abt_DiagnosticProductsMember_documentation_en-US" xlink:label="lab_abt_DiagnosticProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The diagnostics products segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DiagnosticProductsMember" xlink:href="abt-20220930.xsd#abt_DiagnosticProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_DiagnosticProductsMember" xlink:to="lab_abt_DiagnosticProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_63099180-51b0-4eed-9217-238c49a4545b_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c557fa7f-f329-4564-aa9d-4431abd1fbb6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_d01ac352-a4cc-4f0a-83c3-9e7faa8dfe42_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $11 and $36 in 2022 and $18 and $54 in 2021</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_2eafb0a1-3cc0-4b05-937a-d7fa82ecc603_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_39cdb04a-1ce0-49f4-9287-0ea3eeb649d9_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_adba3488-eeff-42c5-ba50-ae7f30dff3e7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Financial Information</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b8570596-c551-4a2f-97b6-066cec9ce4f0_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets related to in-process R&amp;D acquired in a business combination</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2ab189b3-75ec-4504-a98b-0081b2b9df54_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings employed in the business</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4c97d020-176e-4e72-a622-8834a4d393e7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, less allowances of $520 in 2022 and $519 in 2021</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_323bda04-7712-4d08-9709-2c3252b2d2a2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_73d246c7-0970-4a36-967a-fb67dd990c5d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7a06fd92-731b-484e-b09c-4a97b07bc460_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable options, weighted-average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c6517f63-d450-4373-b92a-29948712975e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_35de6860-f7b7-4a7d-a285-96cea22fbec8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow From (Used in) Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e25d476a-d7eb-4b10-9fd3-32eb6494ebd1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_f3b80af8-f721-4e54-bdc3-4715c7920ec2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_ab9555ac-47d9-4d5b-bf6a-7cb50cc525d0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_5f5f5ea5-b2b8-4299-82d1-2f7385d20e8d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_fcd454ca-98e5-4eda-b82f-b003d89ad3a6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amount of amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_476dcab6-7684-44fb-8656-aaa8b971ff19_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_59cac63f-54b8-4463-8618-bc8ee154bd22_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5bd488aa-ab52-4f3e-b7ad-61fbe02596f3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_fc08f534-e4a9-4e18-a55f-105bb897049f_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_MinimumLengthOfTimeHedgedInCashFlowHedge_48f83a82-4216-403c-b49e-3e466e3f6be8_terseLabel_en-US" xlink:label="lab_abt_MinimumLengthOfTimeHedgedInCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold</link:label>
    <link:label id="lab_abt_MinimumLengthOfTimeHedgedInCashFlowHedge_label_en-US" xlink:label="lab_abt_MinimumLengthOfTimeHedgedInCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Length Of Time Hedged In Cash Flow Hedge</link:label>
    <link:label id="lab_abt_MinimumLengthOfTimeHedgedInCashFlowHedge_documentation_en-US" xlink:label="lab_abt_MinimumLengthOfTimeHedgedInCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_MinimumLengthOfTimeHedgedInCashFlowHedge" xlink:href="abt-20220930.xsd#abt_MinimumLengthOfTimeHedgedInCashFlowHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_MinimumLengthOfTimeHedgedInCashFlowHedge" xlink:to="lab_abt_MinimumLengthOfTimeHedgedInCashFlowHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_a12db486-c642-4172-931e-c40ae18018a9_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_35e91f02-d160-4641-aed9-4ee958671707_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bc8adb49-bd33-4bcf-b88f-55056513f612_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4615ebf0-99f4-483c-baeb-dca2d23e69de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock options outstanding and exercisable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_098890e7-75f8-47ab-ba7e-0f513901c679_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating earnings</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_231b7449-140b-435a-acbe-65a4558aa001_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Earnings</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_578e93cc-a551-4879-a25f-fe0ef28a5daf_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f0265478-1b6a-4422-8ccd-95a87b5142ed_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment without readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_69c2250c-fb91-499f-845b-bd6148f0eeac_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_08a30131-1a5b-456d-b6c0-ff580bd588aa_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_29bb4d2a-95ac-4415-85b9-de9098007dca_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_d41a6bb8-bbe3-4069-90e9-ca4c8148a1f1_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember_06e095d9-a42c-44d5-a45b-2794bb404c71_terseLabel_en-US" xlink:label="lab_abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-employment obligations, deferred income taxes and other long-term liabilities</link:label>
    <link:label id="lab_abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember_label_en-US" xlink:label="lab_abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Obligations Deferred Income Taxes And Other Long Term Liabilities [Member]</link:label>
    <link:label id="lab_abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember_documentation_en-US" xlink:label="lab_abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Obligations Deferred Income Taxes And Other Long Term Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember" xlink:href="abt-20220930.xsd#abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember" xlink:to="lab_abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_59bfebed-9b2e-4401-ac54-c1534f47d68f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue_72cde274-4db2-4102-901f-3a5cd1c06a61_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward exchange contracts, (payable) position</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue_2be39fa5-58c4-475e-a0e2-f4dd9fe41429_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Cash Flow Hedge Liability at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_68aa5460-2a40-4ebf-8e88-10a50b868974_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings to net cash from operating activities &#8212;</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_e5246dbc-ae12-4de2-8fb8-93034f9e732a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_33b5ba3d-f280-4058-99d3-32ca4673d116_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on earnings</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_af3d5fb7-489d-41e7-8ba9-d6e64e0a0192_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2342af6d-4c23-4ec7-848c-50cfeb07a4e4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_MedicalDevicesMember_6612de76-a327-4d19-b65f-b17fc6d95624_terseLabel_en-US" xlink:label="lab_abt_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices</link:label>
    <link:label id="lab_abt_MedicalDevicesMember_label_en-US" xlink:label="lab_abt_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices [Member]</link:label>
    <link:label id="lab_abt_MedicalDevicesMember_documentation_en-US" xlink:label="lab_abt_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The medical devices segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_MedicalDevicesMember" xlink:href="abt-20220930.xsd#abt_MedicalDevicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_MedicalDevicesMember" xlink:to="lab_abt_MedicalDevicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_d844bd2e-b198-41d4-9db1-70dc999afa11_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7aa96257-22ce-4df7-a583-e429b5a56464_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c0f58a37-b9c1-4e57-b96a-d3b1b87fccdb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_091ee250-064a-4497-951e-9b9fea72a1ce_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_822ebdaf-5be6-4132-9eaf-7dd04e314a7a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_c8516aed-8803-4bab-a1ae-aae36af2e635_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold, excluding amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_41084d1a-3f46-4e45-a64e-f3045c230dd9_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9d8042bc-05dd-418a-a273-a7d915b633c1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_56aba58e-0c54-4af7-9cd4-51e981691dbc_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_OtherCostAndExpenseOperatingAndNonoperating_678a21b4-b6a2-49fa-bd2b-91b7d04ee2cf_negatedLabel_en-US" xlink:label="lab_abt_OtherCostAndExpenseOperatingAndNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_abt_OtherCostAndExpenseOperatingAndNonoperating_label_en-US" xlink:label="lab_abt_OtherCostAndExpenseOperatingAndNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating and Nonoperating</link:label>
    <link:label id="lab_abt_OtherCostAndExpenseOperatingAndNonoperating_documentation_en-US" xlink:label="lab_abt_OtherCostAndExpenseOperatingAndNonoperating" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The reconciling item from segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to net other income or expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_OtherCostAndExpenseOperatingAndNonoperating" xlink:href="abt-20220930.xsd#abt_OtherCostAndExpenseOperatingAndNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_OtherCostAndExpenseOperatingAndNonoperating" xlink:to="lab_abt_OtherCostAndExpenseOperatingAndNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_668e1b02-44a7-4dfc-9fb9-ac340ebd1f41_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value - Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_7dcc88d8-6f36-498d-a237-b797ae1eb71a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_1718a1b6-28af-4073-b32e-9f6351bfe159_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, without par value Authorized &#8212; 2,400,000,000 shares Issued at stated capital amount &#8212; Shares: 2022: 1,985,919,440; 2021: 1,985,273,421</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_04a4c1df-8052-4d9b-87ce-be9e0c88acb6_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_a55776d1-5695-4636-a35b-b104978c2a6e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_fe807244-1a1d-4fec-bec5-f92c378becc8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_ExcessTaxBenefitFromShareBasedCompensation_07307ba1-b2b8-45d2-9d92-24e46ef8b1b7_terseLabel_en-US" xlink:label="lab_abt_ExcessTaxBenefitFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess tax benefits associated with share-based compensation</link:label>
    <link:label id="lab_abt_ExcessTaxBenefitFromShareBasedCompensation_label_en-US" xlink:label="lab_abt_ExcessTaxBenefitFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation</link:label>
    <link:label id="lab_abt_ExcessTaxBenefitFromShareBasedCompensation_documentation_en-US" xlink:label="lab_abt_ExcessTaxBenefitFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of tax benefits related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_ExcessTaxBenefitFromShareBasedCompensation" xlink:href="abt-20220930.xsd#abt_ExcessTaxBenefitFromShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_ExcessTaxBenefitFromShareBasedCompensation" xlink:to="lab_abt_ExcessTaxBenefitFromShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7f498dc8-1f19-483f-8d76-6c229786beef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets and liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_1b4a6b6c-6d9d-46d6-87e9-8d26fed0bf3f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3b453269-53f5-4c63-bee2-ff0aba7bbcca_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_dbd9c3b1-7fe4-49ef-8932-ce54d192a626_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_3c1989cc-3edf-4dd0-a3b5-42b4348d5934_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease reasonably possible in gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3169a349-5b6f-49ca-bdc9-e88c0a842e4e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Beginning of Year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7343b9de-615e-4b35-b2b9-40470e2abff3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, End of Period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized_c65f5e08-18bb-481b-aa85-6bb8b246ab92_terseLabel_en-US" xlink:label="lab_abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned revenue from cash received during the period</link:label>
    <link:label id="lab_abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized_label_en-US" xlink:label="lab_abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Liability, Change In Unearned Revenue From Cash Received Recognized</link:label>
    <link:label id="lab_abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized_documentation_en-US" xlink:label="lab_abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of revenue recognized arising from contract liability from change in cash received to be satisfied.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized" xlink:href="abt-20220930.xsd#abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized" xlink:to="lab_abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3d23ebe6-a509-419d-9d12-b82e2118d762_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation and Environmental Matters</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9a6a9a88-5cd6-46ef-bea3-ac55fce83774_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_fbe5274e-34d9-45a9-ac4f-18b132360983_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_64cc4d56-b52d-4651-8fdd-5fdfbc07364f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings allocated to common shares</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_ca604036-2e61-4d57-85cd-4006a6a4e33b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_c2d0bdf8-56e4-4b89-8be6-b4fc1e3b1460_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ab6bfb89-5ada-4ddc-b039-b4b500872dbc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2fb0ac67-8ceb-4f96-99bf-1f1fa7f48a2d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_e3bbc75b-1a7a-44d6-acea-936e9b958cdd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments carrying value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_dff5e0cd-e8b2-4afe-a6a2-a6ecea693386_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5b641a77-303e-4b3d-b436-0c481a7affd2_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign exchange (gain) loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_05289a2a-dabd-4c30-b621-9e854afc6bff_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_e94a7027-3d45-47fa-be4e-28ef7ba9c2f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_538e6493-ad15-4778-a604-7f0ceb31f589_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_9dae9372-32e0-4d2a-82cc-6cdedf83ce44_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in intangible assets due to foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e669918b-8a0e-43d1-8ca0-493f4848e902_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0111c278-b748-4e67-ba3c-1ef40ae1a0ea_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_50aa5df1-6cb3-4856-9a8a-3e2b7d88bcef_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash From (Used in) Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_e3d27f00-e561-4be1-bdd2-26c979542c99_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_cadf811f-3c28-4fb0-bc08-eef3bc7d5aa8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes and other assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_180feec8-c681-48c4-95a5-bbc2935021e1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_be917887-21a9-40db-9202-883afb5c5607_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_b9e0d4cf-614e-48a1-83c0-f8ff2d1344ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of segment information - net sales and operating earnings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_8ca4b509-7ee8-4de4-90ba-2dc308185149_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1b31909a-28b7-42fe-bf67-ba800e841666_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c949e232-3e55-44f0-b1e0-90a52e634ebd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_54c7191d-c88c-43e4-bdcf-87f44c4e3ef5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_475c72a5-6efb-45f9-919b-39a2a0895094_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable options, number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_978fb6e5-13d1-491f-b26b-73db301cdaf4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99057298-146a-43c0-b403-a79d9e0190a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding, number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_a4e14140-bc2a-4a6d-a16b-f1730f03e332_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8d4a947a-8ad8-4399-a8d3-9e03f8f01429_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_bd509bf8-cbaf-42d0-bfa4-89fc1b680128_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_806af2e7-c1d8-40fe-b4cd-11f026fb0182_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d22530a1-4621-4969-9b3a-2c46a7501eb5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue_e74e6ef5-4e32-421d-862a-2779d7fe1771_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward exchange contracts, receivable position</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue_084677d3-34c6-4b0e-a2f0-4ddb582fd854_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Cash Flow Hedge Asset at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PostemploymentBenefitsAbstract_278f7c55-9165-4dcf-b7cc-7329e2be9349_terseLabel_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_PostemploymentBenefitsAbstract_label_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:to="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_f089b377-4a4f-4693-8f0a-4520b676dd58_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_8a2b87d4-f7b0-43f9-894a-bff59879f401_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, allowances</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_a9d2d0b0-0088-4a44-902f-d2bdcb569f6c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b21494af-85cd-4d44-a27c-e228badead81_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_83ecf5d6-6977-440c-b0e3-b7a66707f008_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_84a6a0f2-9ef4-48c0-a8ee-c6f21e58d284_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plans</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_61077646-3baf-4c1a-80d9-6b2cc991a64d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_c314a75c-309c-4476-b68a-8e58c103cdbe_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized related to derivatives not designated as hedge</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_d99b294c-ee62-445f-b2e0-4cbd75dca6f1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d5555ba3-5362-493e-adbc-b55af8a2f560_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_1de8d30b-28ad-451c-a85e-99b0f83c6204_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_46f43fd1-257f-41b4-ba7c-711ee0e62850_totalLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3d2f1d4b-fb74-4ec1-9817-932212fdd082_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d57fd7e5-1341-4d06-a6d0-c453b2971e6c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedCashFlowStatementTable_eb391be5-f3b9-4fb1-a8d9-3a647335d85d_terseLabel_en-US" xlink:label="lab_srt_CondensedCashFlowStatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Cash Flow Statement [Table]</link:label>
    <link:label id="lab_srt_CondensedCashFlowStatementTable_label_en-US" xlink:label="lab_srt_CondensedCashFlowStatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Cash Flow Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedCashFlowStatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedCashFlowStatementTable" xlink:to="lab_srt_CondensedCashFlowStatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_d16fc449-6ab7-46b1-999e-28fa7795bd2a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_b58e7fed-eaaf-4166-8ac5-f4444d4b547f_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2711e2c5-659c-49ab-868e-9d9e8a461744_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized related to contract liability balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8a8cabf9-8467-4cdf-9b55-7aaf35a7deb0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_cf800640-d10d-4499-a995-2362eaeec1b7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_16991062-36ab-44aa-b540-0e7934da6459_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $50 and $96 in 2022 and $50 and $98 in 2021</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_fe54bb0c-03d6-4da1-980b-77c153d80b8a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_fa8264aa-de47-4426-aad8-a09d045f0f9f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of the net periodic benefit cost for the entity's major defined benefit plans and post-employment medical and dental benefit plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_adfe7413-c378-4173-9c2c-90edf16fec7a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared on common shares (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bdca25b5-19ab-47df-9f5d-d5354b4f2ace_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected timing of satisfaction period (in months)</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_OtherExitCostsMember_54c29c03-815b-45f3-8ebc-a37e08056392_terseLabel_en-US" xlink:label="lab_abt_OtherExitCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Exit Costs</link:label>
    <link:label id="lab_abt_OtherExitCostsMember_label_en-US" xlink:label="lab_abt_OtherExitCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other exit costs [Member]</link:label>
    <link:label id="lab_abt_OtherExitCostsMember_documentation_en-US" xlink:label="lab_abt_OtherExitCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to fixed asset other exit cost .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_OtherExitCostsMember" xlink:href="abt-20220930.xsd#abt_OtherExitCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_OtherExitCostsMember" xlink:to="lab_abt_OtherExitCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e303677c-4552-40d1-af2b-c2e0b17c1af7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_CoreLaboratoryMember_2fdafedd-73da-4687-91fc-7105269b0e9d_terseLabel_en-US" xlink:label="lab_abt_CoreLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Core Laboratory</link:label>
    <link:label id="lab_abt_CoreLaboratoryMember_label_en-US" xlink:label="lab_abt_CoreLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Core Laboratory [Member]</link:label>
    <link:label id="lab_abt_CoreLaboratoryMember_documentation_en-US" xlink:label="lab_abt_CoreLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents the core laboratory, segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_CoreLaboratoryMember" xlink:href="abt-20220930.xsd#abt_CoreLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_CoreLaboratoryMember" xlink:to="lab_abt_CoreLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_724d1bda-291d-4a95-b036-9201900cb437_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Doubtful Accounts:</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage_1e8c64d2-2637-47a6-985d-4cc9feb2a836_terseLabel_en-US" xlink:label="lab_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of remaining performance obligation expected to be recognized in period</link:label>
    <link:label id="lab_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage_label_en-US" xlink:label="lab_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Remaining Performance Obligation Expected Timing Percentage</link:label>
    <link:label id="lab_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage_documentation_en-US" xlink:label="lab_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of revenue recognized for remaining performance obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage" xlink:href="abt-20220930.xsd#abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage" xlink:to="lab_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_PrepaidExpensesAndOtherReceivablesMember_afcaaede-f861-48c4-9bac-ce84e62b0cbc_terseLabel_en-US" xlink:label="lab_abt_PrepaidExpensesAndOtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
    <link:label id="lab_abt_PrepaidExpensesAndOtherReceivablesMember_label_en-US" xlink:label="lab_abt_PrepaidExpensesAndOtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other receivables [Member]</link:label>
    <link:label id="lab_abt_PrepaidExpensesAndOtherReceivablesMember_documentation_en-US" xlink:label="lab_abt_PrepaidExpensesAndOtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PrepaidExpensesAndOtherReceivablesMember" xlink:href="abt-20220930.xsd#abt_PrepaidExpensesAndOtherReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_PrepaidExpensesAndOtherReceivablesMember" xlink:to="lab_abt_PrepaidExpensesAndOtherReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_COVID19TestManufacturingNetworkRestructuringPlanMember_58db35c4-a236-47cc-afed-6b08c515a8cf_terseLabel_en-US" xlink:label="lab_abt_COVID19TestManufacturingNetworkRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Test Manufacturing Network Restructuring Plan</link:label>
    <link:label id="lab_abt_COVID19TestManufacturingNetworkRestructuringPlanMember_label_en-US" xlink:label="lab_abt_COVID19TestManufacturingNetworkRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Test Manufacturing Network Restructuring Plan [Member]</link:label>
    <link:label id="lab_abt_COVID19TestManufacturingNetworkRestructuringPlanMember_documentation_en-US" xlink:label="lab_abt_COVID19TestManufacturingNetworkRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring plan related to its Diagnostic Products segment to align its manufacturing network for COVID-19 diagnostic tests with recent changes in projected testing demand driven by several factors, including significant reductions in cases in the U.S. and other major developed countries, the accelerated rollout of COVID-19 vaccines globally and recent U.S. health authority guidance on testing for fully vaccinated individuals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_COVID19TestManufacturingNetworkRestructuringPlanMember" xlink:href="abt-20220930.xsd#abt_COVID19TestManufacturingNetworkRestructuringPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_COVID19TestManufacturingNetworkRestructuringPlanMember" xlink:to="lab_abt_COVID19TestManufacturingNetworkRestructuringPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e637ee1c-0835-43a7-a0b7-c2d57c9bb9d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_82eaa713-c675-4e01-a0a8-4f0d686043c2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_79cb8141-8b16-4041-8c71-ed22f3237bb8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ac528217-bb02-4c5c-92e2-10a1c8aef6bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7eee8e42-cd1a-453f-b2bb-34e35d6f1d97_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_ScheduleOfLongTermInvestmentsTableTextBlock_88ba484a-de6f-463c-b3b3-7fe7bce49366_terseLabel_en-US" xlink:label="lab_abt_ScheduleOfLongTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-term investments</link:label>
    <link:label id="lab_abt_ScheduleOfLongTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_abt_ScheduleOfLongTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long Term Investments [Table Text Block]</link:label>
    <link:label id="lab_abt_ScheduleOfLongTermInvestmentsTableTextBlock_documentation_en-US" xlink:label="lab_abt_ScheduleOfLongTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the investments which are intended to be held for an extended period of time (longer than one operating cycle).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_ScheduleOfLongTermInvestmentsTableTextBlock" xlink:href="abt-20220930.xsd#abt_ScheduleOfLongTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_ScheduleOfLongTermInvestmentsTableTextBlock" xlink:to="lab_abt_ScheduleOfLongTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_EstablishedPharmaceuticalProductsMember_43c68ea6-bdf2-4145-8762-7b1b0310777d_terseLabel_en-US" xlink:label="lab_abt_EstablishedPharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Established Pharmaceutical Products</link:label>
    <link:label id="lab_abt_EstablishedPharmaceuticalProductsMember_label_en-US" xlink:label="lab_abt_EstablishedPharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Established Pharmaceutical Products [Member]</link:label>
    <link:label id="lab_abt_EstablishedPharmaceuticalProductsMember_documentation_en-US" xlink:label="lab_abt_EstablishedPharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Established Pharmaceutical Products, segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_EstablishedPharmaceuticalProductsMember" xlink:href="abt-20220930.xsd#abt_EstablishedPharmaceuticalProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_EstablishedPharmaceuticalProductsMember" xlink:to="lab_abt_EstablishedPharmaceuticalProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_6b991d97-832b-4f7d-b9a2-c210abecc085_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_FixedAssetWriteDownsMember_72338e80-6ce6-4b11-a76a-bfdfd62f8958_terseLabel_en-US" xlink:label="lab_abt_FixedAssetWriteDownsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Asset Write-Downs</link:label>
    <link:label id="lab_abt_FixedAssetWriteDownsMember_label_en-US" xlink:label="lab_abt_FixedAssetWriteDownsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed asset write-downs [Member]</link:label>
    <link:label id="lab_abt_FixedAssetWriteDownsMember_documentation_en-US" xlink:label="lab_abt_FixedAssetWriteDownsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to fixed asset write-downs cost .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_FixedAssetWriteDownsMember" xlink:href="abt-20220930.xsd#abt_FixedAssetWriteDownsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_FixedAssetWriteDownsMember" xlink:to="lab_abt_FixedAssetWriteDownsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_df42eef7-1fa4-401a-8e87-c67367cc7aca_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_8351c8e8-bc84-4dc3-8f86-a0064dd7cc7c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_ScheduleOfGoodwillAndIntangibleAssetsTable_6049772e-2238-46bd-b113-02bb5396f3b0_terseLabel_en-US" xlink:label="lab_abt_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill and Intangible Assets [Table]</link:label>
    <link:label id="lab_abt_ScheduleOfGoodwillAndIntangibleAssetsTable_label_en-US" xlink:label="lab_abt_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill and Intangible Assets [Table]</link:label>
    <link:label id="lab_abt_ScheduleOfGoodwillAndIntangibleAssetsTable_documentation_en-US" xlink:label="lab_abt_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:href="abt-20220930.xsd#abt_ScheduleOfGoodwillAndIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:to="lab_abt_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_349f4be1-34e9-47d4-84af-98a04d6e47d2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9ce29103-8245-46ce-8aa6-9b3075575f24_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_333f01e3-df3a-40d9-806d-b581f046eda2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization expense, intangible assets, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_6db5aa7e-169c-41b7-84f5-6afb0ee27a19_terseLabel_en-US" xlink:label="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense from prior year tax positions</link:label>
    <link:label id="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_label_en-US" xlink:label="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Adjustments, Settlements, and Unusual Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:to="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_A255LongTermNotesDue2022Member_a2750472-da1f-4621-adad-52e050f3f7ef_terseLabel_en-US" xlink:label="lab_abt_A255LongTermNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.55% Long-term Notes Due 2022</link:label>
    <link:label id="lab_abt_A255LongTermNotesDue2022Member_label_en-US" xlink:label="lab_abt_A255LongTermNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.55% Long-term Notes Due 2022 [Member]</link:label>
    <link:label id="lab_abt_A255LongTermNotesDue2022Member_documentation_en-US" xlink:label="lab_abt_A255LongTermNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.55% Long-term Notes Due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_A255LongTermNotesDue2022Member" xlink:href="abt-20220930.xsd#abt_A255LongTermNotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_A255LongTermNotesDue2022Member" xlink:to="lab_abt_A255LongTermNotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_54fc81ec-d02b-4a83-aaf2-f51b9eac19fb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Investment</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_29527326-7169-4147-afc6-11f05b4971c1_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_bec2a246-f3dc-4aff-a612-6d57138e8468_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation gain (loss) adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNYS_dc8d92fd-825d-478c-97fb-53cf358c65ce_terseLabel_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK STOCK EXCHANGE, INC.</link:label>
    <link:label id="lab_exch_XNYS_label_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK STOCK EXCHANGE, INC. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNYS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNYS" xlink:to="lab_exch_XNYS" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_f880f54e-0760-4bfc-ac3b-7a64e8de2274_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e02d7dd-72ec-4539-a4f7-952681e5eb05_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_9baffd98-ce24-4e35-9544-fe8220bdf890_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_9c493d9a-60e8-40f1-bb2c-685de7a62fcc_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_2e858582-3db1-4174-b954-55db9d4e3cf5_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges recorded in 2021</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_a1cb2aaa-ac1f-45c8-bbac-829527cddfa4_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_dd4683cb-7ced-4908-8e5c-f8b817de65db_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_NutritionalProductsMember_94ed8f1f-947a-47a9-93f2-0215143b966d_terseLabel_en-US" xlink:label="lab_abt_NutritionalProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nutritional Products</link:label>
    <link:label id="lab_abt_NutritionalProductsMember_label_en-US" xlink:label="lab_abt_NutritionalProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nutritional Products [Member]</link:label>
    <link:label id="lab_abt_NutritionalProductsMember_documentation_en-US" xlink:label="lab_abt_NutritionalProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The nutritional products segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_NutritionalProductsMember" xlink:href="abt-20220930.xsd#abt_NutritionalProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_NutritionalProductsMember" xlink:to="lab_abt_NutritionalProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_60130d8f-3467-4cf8-bc45-e07e5a7ccf01_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from business dispositions</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sales of Business, Affiliate and Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments_c0d93f7e-6bfb-4edb-801a-6e1eb85def38_negatedLabel_en-US" xlink:label="lab_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and other adjustments</link:label>
    <link:label id="lab_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments_label_en-US" xlink:label="lab_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve Period Cash Settled and Other Adjustments</link:label>
    <link:label id="lab_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments_documentation_en-US" xlink:label="lab_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:href="abt-20220930.xsd#abt_RestructuringReservePeriodCashSettledAndOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:to="lab_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_bbe1edd3-7ab4-4705-81b0-099d8ca9995d_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d766ab9c-91fa-4973-8365-44bb2004cb87_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; Investment:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee2ea061-6ce3-4f32-ab9b-6d930da6f278_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_87bd793c-70c2-4b42-aa09-710a583cc145_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_cf591233-37f1-462c-b798-277ec5e1760f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recorded accrual balance for legal proceedings and exposures</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_eb2a2a43-76e7-4d91-9087-df665a974e65_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities in mutual funds held in a rabbi trust</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Held in Employee Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:to="lab_us-gaap_CommonStockSharesHeldInEmployeeTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_55fd8775-83c3-45ef-8165-557921769439_negatedLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_RapidDiagnosticsMember_5545549e-10c8-42fe-bf04-95005a4e5be3_terseLabel_en-US" xlink:label="lab_abt_RapidDiagnosticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rapid Diagnostics</link:label>
    <link:label id="lab_abt_RapidDiagnosticsMember_label_en-US" xlink:label="lab_abt_RapidDiagnosticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rapid Diagnostics [Member]</link:label>
    <link:label id="lab_abt_RapidDiagnosticsMember_documentation_en-US" xlink:label="lab_abt_RapidDiagnosticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents the rapid diagnostics, segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RapidDiagnosticsMember" xlink:href="abt-20220930.xsd#abt_RapidDiagnosticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_RapidDiagnosticsMember" xlink:to="lab_abt_RapidDiagnosticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XCHI_ec21740a-98fa-4441-81fa-17799df51133_terseLabel_en-US" xlink:label="lab_exch_XCHI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHICAGO STOCK EXCHANGE, INC</link:label>
    <link:label id="lab_exch_XCHI_label_en-US" xlink:label="lab_exch_XCHI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NYSE CHICAGO, INC. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XCHI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XCHI" xlink:to="lab_exch_XCHI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_1018cee0-2209-45ab-819c-dc759d6392ec_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ed21ab0a-cc4e-4132-9efd-d7ab9b1277fa_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ae95bfeb-c6de-447f-bd63-2978761f84ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding, weighted-average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_8149a844-b2ad-40de-8b37-353937fde1b6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Derivative Liabilities, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:to="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_79c89d60-d7a4-4367-991c-abdc9e82274b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_30ff8d6c-2374-48e6-b9d8-6ba58ff3d8cb_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, one dollar par value Authorized &#8212; 1,000,000 shares, none issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_88fbfac7-3722-4f80-bc39-66cb61f446cc_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_defdce97-db9e-44ff-8dfe-7ac34dfe90da_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4b879745-568c-45cf-808c-dbffdc6acfeb_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales to External Customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_55b2471e-8e60-4924-a19f-72d721f192cb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost - benefits earned during the period</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue_d09136bb-5f6b-4fe3-ba94-0d114f53c3bf_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Derivative Assets, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:to="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_8e3992c0-27f6-4269-b171-0daee5e5aee0_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_219e1976-d2f1-425b-bf49-57cc3f370c9b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_57c623c0-1504-4e9a-97f8-ca7b4c254d82_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_2e9bc2bf-7c92-4135-897a-5ea8b137f721_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of reductions of goodwill relating to impairments</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_VascularMember_79efd116-e13a-479a-b853-4e0aee356fad_terseLabel_en-US" xlink:label="lab_abt_VascularMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vascular</link:label>
    <link:label id="lab_abt_VascularMember_label_en-US" xlink:label="lab_abt_VascularMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vascular [Member]</link:label>
    <link:label id="lab_abt_VascularMember_documentation_en-US" xlink:label="lab_abt_VascularMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents the vascular products, segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_VascularMember" xlink:href="abt-20220930.xsd#abt_VascularMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_VascularMember" xlink:to="lab_abt_VascularMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7185fcf9-c259-427f-ba78-823d05fe2b8b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Program</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_d2faa807-4a62-41e0-b948-d3493867688a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_e1146a26-17d2-4e04-adc4-ccbb584f6e7d_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_1f75bb5c-fde7-4901-9ea5-6e53e6aa604f_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_716a6fbd-6edb-46d8-8f21-445697b25798_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_f88b8ec9-4d3c-4e72-9eba-cf932d3cc6f7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_7816185d-f707-4678-a0cf-dfb095692d36_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_ContractLiabilitiesRollForward_1eb49cc7-1a4e-40f6-8b82-2f49931be78c_terseLabel_en-US" xlink:label="lab_abt_ContractLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liabilities:</link:label>
    <link:label id="lab_abt_ContractLiabilitiesRollForward_label_en-US" xlink:label="lab_abt_ContractLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liabilities [Roll Forward]</link:label>
    <link:label id="lab_abt_ContractLiabilitiesRollForward_documentation_en-US" xlink:label="lab_abt_ContractLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_ContractLiabilitiesRollForward" xlink:href="abt-20220930.xsd#abt_ContractLiabilitiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_ContractLiabilitiesRollForward" xlink:to="lab_abt_ContractLiabilitiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_a20ce416-3eb5-4ba2-9df4-faae8bc5e5ab_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_2af46368-cabd-47c2-9356-995647456f70_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_ElectrophysiologyMember_28a56807-34cd-473b-b448-6e1b88b14020_terseLabel_en-US" xlink:label="lab_abt_ElectrophysiologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electrophysiology</link:label>
    <link:label id="lab_abt_ElectrophysiologyMember_label_en-US" xlink:label="lab_abt_ElectrophysiologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electrophysiology [Member]</link:label>
    <link:label id="lab_abt_ElectrophysiologyMember_documentation_en-US" xlink:label="lab_abt_ElectrophysiologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents the electrophysiology, segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_ElectrophysiologyMember" xlink:href="abt-20220930.xsd#abt_ElectrophysiologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_ElectrophysiologyMember" xlink:to="lab_abt_ElectrophysiologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_5535c0d4-9392-4f39-b3d0-fc21522a20fd_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net interest expense</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_7b339ee1-d370-47e7-b394-9b678858c742_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial loss, net</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_e4461b2c-d02d-4b54-8a7b-564b78e2958b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Shareholders' Investment</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_4460d580-20a4-4f0e-99d9-bbdd01ffcb22_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_DefinedBenefitPlanNetAmortizationCostsAbstract_e8147385-284b-46ec-82a8-bec3037ba157_terseLabel_en-US" xlink:label="lab_abt_DefinedBenefitPlanNetAmortizationCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization of:</link:label>
    <link:label id="lab_abt_DefinedBenefitPlanNetAmortizationCostsAbstract_label_en-US" xlink:label="lab_abt_DefinedBenefitPlanNetAmortizationCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Net Amortization Costs [Abstract]</link:label>
    <link:label id="lab_abt_DefinedBenefitPlanNetAmortizationCostsAbstract_documentation_en-US" xlink:label="lab_abt_DefinedBenefitPlanNetAmortizationCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DefinedBenefitPlanNetAmortizationCostsAbstract" xlink:href="abt-20220930.xsd#abt_DefinedBenefitPlanNetAmortizationCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_DefinedBenefitPlanNetAmortizationCostsAbstract" xlink:to="lab_abt_DefinedBenefitPlanNetAmortizationCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4f111f2b-1266-46af-ae19-fc977fd57595_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Common Stock Options (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_WalkVascularLLCMember_ee3bd2de-bcef-4af0-87f1-6d225d917595_terseLabel_en-US" xlink:label="lab_abt_WalkVascularLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Walk Vascular</link:label>
    <link:label id="lab_abt_WalkVascularLLCMember_label_en-US" xlink:label="lab_abt_WalkVascularLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Walk Vascular, LLC [Member]</link:label>
    <link:label id="lab_abt_WalkVascularLLCMember_documentation_en-US" xlink:label="lab_abt_WalkVascularLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents information pertaining to its Walk vascular llc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_WalkVascularLLCMember" xlink:href="abt-20220930.xsd#abt_WalkVascularLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_WalkVascularLLCMember" xlink:to="lab_abt_WalkVascularLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_7f10026c-e80e-47ab-ab59-e03b8cce9cfe_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6abd027e-e0e0-42bf-b35b-3464bc64c1b8_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_fa530643-fb3b-4d69-9339-7d301590baf0_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_b7479b83-cff8-41c7-9965-06875e429eaf_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in accumulated other comprehensive income (loss), net of income taxes</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_47dadeb2-f16d-4f09-930b-b857bbe3e3af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent_db262f37-6dee-4de5-a98c-4c326791a1df_terseLabel_en-US" xlink:label="lab_abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual share-based awards recognized in first quarter (as a percent)</link:label>
    <link:label id="lab_abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent_label_en-US" xlink:label="lab_abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Share Based Awards Recognized in First Quarter Percent</link:label>
    <link:label id="lab_abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent_documentation_en-US" xlink:label="lab_abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the annual cost of share-based awards which will typically be recognized in the first quarter.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent" xlink:href="abt-20220930.xsd#abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent" xlink:to="lab_abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_38416d4c-9880-47d2-889b-b8e1d30175a1_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1da93880-e0ef-4715-9810-6fecad23d271_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net of amortization</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c4798e85-c57f-48a8-9cd0-56079e8c058f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted Earnings Per Common Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites_44e3f194-6ea6-471d-8b08-917d1ee2400d_terseLabel_en-US" xlink:label="lab_abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum expected cleanup exposure in aggregate</link:label>
    <link:label id="lab_abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites_label_en-US" xlink:label="lab_abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Range of Possible Loss, Maximum Aggregate Sites</link:label>
    <link:label id="lab_abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites_documentation_en-US" xlink:label="lab_abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated maximum loss, for all sites, from the contingency related to the environmental clean up in the United States and Puerto Rico.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites" xlink:href="abt-20220930.xsd#abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites" xlink:to="lab_abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_f78c15a0-ad3d-4b13-b9b7-f6934e24bd34_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f64b43f9-5513-403d-9762-45149be85cbc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_1b68141d-88d9-4468-9ce3-7039653482fb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_fed80bcc-d99b-4047-9baa-888844a07daa_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_21427a72-98c3-44e4-877d-79f41cba82f2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_050b88c7-e345-4b72-9c70-e67a8567155e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity of allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_20e11cc8-4be4-44e4-b8c0-b65e90c7fa59_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value - Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_LegalProceedingsAndEnvironmentalExposuresMember_6056edc0-c6a9-43aa-901a-454cb972165e_terseLabel_en-US" xlink:label="lab_abt_LegalProceedingsAndEnvironmentalExposuresMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal proceedings and environmental exposures</link:label>
    <link:label id="lab_abt_LegalProceedingsAndEnvironmentalExposuresMember_label_en-US" xlink:label="lab_abt_LegalProceedingsAndEnvironmentalExposuresMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal proceedings and environmental exposures [Member]</link:label>
    <link:label id="lab_abt_LegalProceedingsAndEnvironmentalExposuresMember_documentation_en-US" xlink:label="lab_abt_LegalProceedingsAndEnvironmentalExposuresMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingencies related to legal proceedings and environmental exposures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_LegalProceedingsAndEnvironmentalExposuresMember" xlink:href="abt-20220930.xsd#abt_LegalProceedingsAndEnvironmentalExposuresMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_LegalProceedingsAndEnvironmentalExposuresMember" xlink:to="lab_abt_LegalProceedingsAndEnvironmentalExposuresMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_db423a08-ffa7-4c16-994a-8bfc41834eb2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_c319f7fd-2761-4790-91cf-4c2a885930da_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_6e01435c-22f3-4c9a-b326-811f6b75701b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_d4038a6b-c252-4aa4-9704-2abe64381efb_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_b8b64714-8156-40b2-b0ad-1509beb67d0e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net borrowings (repayments) of short-term debt and other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_23adb403-7c3e-488d-91cb-3a91ca22bbb3_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_4109d224-98ef-4596-83ac-bb27a0aca58e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d5facfa9-1573-4ebd-9086-2d10e6ee94ce_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_c2f3c0b1-9798-4184-bf52-82e27d301098_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate hedge contracts, receivable position</link:label>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Fair Value Hedge Asset at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:to="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_897430c6-4be3-4e25-ab50-81d1a4d4fc2d_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_95e179e0-70fe-469b-b9b0-df3c6c5b7069_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ae4ed145-a8b1-4477-be88-dd62b72e15fd_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_0764a950-67c2-4ff5-9888-90a79945a3fe_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAggregatedInvestmentsMember_096ca653-f47b-4cc6-a8e0-bc3a29560a64_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAggregatedInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAggregatedInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherAggregatedInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Security Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAggregatedInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAggregatedInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAggregatedInvestmentsMember" xlink:to="lab_us-gaap_OtherAggregatedInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_AdultNutritionalsMember_a5d9be61-2176-460f-827e-cccb63d427c7_terseLabel_en-US" xlink:label="lab_abt_AdultNutritionalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adult Nutritionals</link:label>
    <link:label id="lab_abt_AdultNutritionalsMember_label_en-US" xlink:label="lab_abt_AdultNutritionalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adult Nutritionals [Member]</link:label>
    <link:label id="lab_abt_AdultNutritionalsMember_documentation_en-US" xlink:label="lab_abt_AdultNutritionalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents the adult nutritionals, segment of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_AdultNutritionalsMember" xlink:href="abt-20220930.xsd#abt_AdultNutritionalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_AdultNutritionalsMember" xlink:to="lab_abt_AdultNutritionalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_30ed1b11-6eda-448f-8688-63d4db77fcf2_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of hedged long-term debt</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_60620faa-bebf-4295-b87d-124c4e6dac3e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reportable segment included under sales category</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_5360fc24-6cd6-4ef1-b310-32f96877b0ce_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_f642f7ae-7dba-4705-86e3-d46ccd8594c5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization expense, intangible assets, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite_bba87791-dfcf-42f5-bd27-1167cf638b8e_terseLabel_en-US" xlink:label="lab_abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum expected cleanup exposure for individual site</link:label>
    <link:label id="lab_abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite_label_en-US" xlink:label="lab_abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Range of Possible Loss, Maximum Individual Site</link:label>
    <link:label id="lab_abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite_documentation_en-US" xlink:label="lab_abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated maximum loss, per individual site, from the contingency related to the environmental clean up in the United States and Puerto Rico.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite" xlink:href="abt-20220930.xsd#abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite" xlink:to="lab_abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_bb53fcc2-ce91-43ec-906f-3c6facdfc24b_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b0a250ec-afb6-44e0-82f4-cd0e66ac5e9d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Increase (Decrease) in Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_440a6ba8-452c-4f6d-a767-55a9761ae979_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_edf39ed4-a36b-41cd-ab21-032b56ea4198_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restructuring reserve and related cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_998cb95e-b829-4742-93f1-48553c90e955_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of restructuring activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_25540aa4-e496-4bb1-a2e8-b919fb009238_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_26d78c15-8aaa-4038-8844-fd38a1ebe8e5_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (income)</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8080ddc5-7d6c-4b37-9471-d965d27b0092_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_GoodwillAndIntangibleAssetsLineItems_2713281d-20eb-4765-836b-2c347085fe7b_terseLabel_en-US" xlink:label="lab_abt_GoodwillAndIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets [Line Items]</link:label>
    <link:label id="lab_abt_GoodwillAndIntangibleAssetsLineItems_label_en-US" xlink:label="lab_abt_GoodwillAndIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets [Line Items]</link:label>
    <link:label id="lab_abt_GoodwillAndIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_abt_GoodwillAndIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_GoodwillAndIntangibleAssetsLineItems" xlink:href="abt-20220930.xsd#abt_GoodwillAndIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems" xlink:to="lab_abt_GoodwillAndIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70955166-ec9b-4c73-a7fd-f539bf51dd80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_967c2a12-85f6-4383-8f18-a3501262af4e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_bd1d358f-5b32-4668-982e-690e98585483_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities_62e2abb5-1008-4ffc-8747-2a6ed62772dc_verboseLabel_en-US" xlink:label="lab_abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-employment obligations, deferred income taxes and other long-term liabilities</link:label>
    <link:label id="lab_abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities_label_en-US" xlink:label="lab_abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities</link:label>
    <link:label id="lab_abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities_documentation_en-US" xlink:label="lab_abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Post-employment obligations and amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities" xlink:href="abt-20220930.xsd#abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities" xlink:to="lab_abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ee1656ba-7a92-44e3-b27d-86f659aeab7d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_8d0a6a2d-09c3-4385-8aa2-83d3f2d8481c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abt_OtherEmergingMarketsMember_35507461-8683-45f8-b432-4df94745fcd5_terseLabel_en-US" xlink:label="lab_abt_OtherEmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Emerging Markets</link:label>
    <link:label id="lab_abt_OtherEmergingMarketsMember_label_en-US" xlink:label="lab_abt_OtherEmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Emerging Markets [Member]</link:label>
    <link:label id="lab_abt_OtherEmergingMarketsMember_documentation_en-US" xlink:label="lab_abt_OtherEmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Emerging Markets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abt_OtherEmergingMarketsMember" xlink:href="abt-20220930.xsd#abt_OtherEmergingMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abt_OtherEmergingMarketsMember" xlink:to="lab_abt_OtherEmergingMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5078e1cd-047e-4ad7-90c0-3aa3143e7b82_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromInvestments_9eba618c-f7cf-4a68-aea1-16ca946b9099_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales (purchases) of other investment securities, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromInvestments" xlink:to="lab_us-gaap_PaymentsForProceedsFromInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_a2f3495a-d611-409b-96d1-6f1d5be03f34_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtMember_e52c0f64-e216-4285-9419-fae1e858c5b6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtMember_label_en-US" xlink:label="lab_us-gaap_DebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtMember" xlink:to="lab_us-gaap_DebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_58928b57-09d0-4351-8df4-44d99270af3f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow From (Used in) Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRecallExpense_0ed8044f-a3d7-4f61-ad6f-3bfd42629cff_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRecallExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory recall expense</link:label>
    <link:label id="lab_us-gaap_InventoryRecallExpense_label_en-US" xlink:label="lab_us-gaap_InventoryRecallExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Recall Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRecallExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRecallExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRecallExpense" xlink:to="lab_us-gaap_InventoryRecallExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1e7443d2-0bbd-4bed-8752-b6d008ffe86e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_341ce0ce-bf52-4154-8adc-2ff8602b25af_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_316ab18e-1822-425e-be2f-ce9a66ada72e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4449eae7-bb25-488c-960f-d73f826fd7b7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization expense, intangible assets, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_20cd89f3-4ce6-4af5-9240-ecda909e9cd1_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_d1790734-c5a3-4c73-835f-a56f2db38cca_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical and Dental Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>abt-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:19ee09c1-7a67-41f5-aa0d-f1189dd14b54,g:ff04be54-28ba-406d-b68f-d5381de01f45-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.abbott.com/role/Cover" xlink:type="simple" xlink:href="abt-20220930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c0dd323c-c7f4-4b29-b0dd-19913c2929b8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_286a11ea-421e-4a31-b74c-f0dbc4d9a315" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c0dd323c-c7f4-4b29-b0dd-19913c2929b8" xlink:to="loc_dei_DocumentInformationTable_286a11ea-421e-4a31-b74c-f0dbc4d9a315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_77219ae1-9ee0-42f9-96ee-489f182fbec9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_286a11ea-421e-4a31-b74c-f0dbc4d9a315" xlink:to="loc_dei_EntityListingsExchangeAxis_77219ae1-9ee0-42f9-96ee-489f182fbec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_22eecffb-61c9-4fa2-8e54-4dd510ed2761" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_77219ae1-9ee0-42f9-96ee-489f182fbec9" xlink:to="loc_dei_ExchangeDomain_22eecffb-61c9-4fa2-8e54-4dd510ed2761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_164308db-2889-458a-9434-3d0fcd27cf98" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XNYS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_22eecffb-61c9-4fa2-8e54-4dd510ed2761" xlink:to="loc_exch_XNYS_164308db-2889-458a-9434-3d0fcd27cf98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI_f765c30c-63a2-4fd2-9ea7-99ef9e56e0c2" xlink:href="https://xbrl.sec.gov/exch/2022/exch-2022.xsd#exch_XCHI"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_22eecffb-61c9-4fa2-8e54-4dd510ed2761" xlink:to="loc_exch_XCHI_f765c30c-63a2-4fd2-9ea7-99ef9e56e0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_286a11ea-421e-4a31-b74c-f0dbc4d9a315" xlink:to="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_644bb62b-7fd2-4e03-baa1-4a74dc2a8191" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_DocumentType_644bb62b-7fd2-4e03-baa1-4a74dc2a8191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_677759f2-c375-464e-a845-4b5b84f4d49f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_DocumentQuarterlyReport_677759f2-c375-464e-a845-4b5b84f4d49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5f7db9bb-3f6f-4f93-bd9b-3b73835b5820" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_DocumentPeriodEndDate_5f7db9bb-3f6f-4f93-bd9b-3b73835b5820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c2826a80-a59d-4e52-af63-0ffa222969bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_DocumentTransitionReport_c2826a80-a59d-4e52-af63-0ffa222969bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5be6739f-d1f5-4aaf-829d-8d60cc12956d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityFileNumber_5be6739f-d1f5-4aaf-829d-8d60cc12956d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0f45ac9a-dd69-4807-a71e-7cddf8e3e2be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityRegistrantName_0f45ac9a-dd69-4807-a71e-7cddf8e3e2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_515c4463-3e1d-48b6-a831-d9a091475f99" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_515c4463-3e1d-48b6-a831-d9a091475f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_7f6e8308-82c6-4ca9-9f96-faeae1f1da6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityTaxIdentificationNumber_7f6e8308-82c6-4ca9-9f96-faeae1f1da6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e832fda1-446a-4c69-928d-221d2144d2e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityAddressAddressLine1_e832fda1-446a-4c69-928d-221d2144d2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1aa5f367-8724-4aa5-b6f9-0af7d8ab4dd9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityAddressCityOrTown_1aa5f367-8724-4aa5-b6f9-0af7d8ab4dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_29126db9-310b-4af6-b399-3423fe6fc99e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityAddressStateOrProvince_29126db9-310b-4af6-b399-3423fe6fc99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_81175d42-4bc3-4f69-ab6e-53ecb149d5d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityAddressPostalZipCode_81175d42-4bc3-4f69-ab6e-53ecb149d5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c12aac2f-2e0f-4f16-95fa-7c1e3968247c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_CityAreaCode_c12aac2f-2e0f-4f16-95fa-7c1e3968247c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_91744cda-4a80-4a3b-930b-b7ad1d9e2e81" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_LocalPhoneNumber_91744cda-4a80-4a3b-930b-b7ad1d9e2e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8539f332-e300-4f91-8fe3-b77ace5bed39" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_Security12bTitle_8539f332-e300-4f91-8fe3-b77ace5bed39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f591b5cf-2a08-4b27-a049-a02de3116116" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_TradingSymbol_f591b5cf-2a08-4b27-a049-a02de3116116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c25078fe-4e00-4c38-b5cf-df20657edd12" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_SecurityExchangeName_c25078fe-4e00-4c38-b5cf-df20657edd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_cf25a8ef-6ae4-40f3-ab7e-3b140cacf982" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityCurrentReportingStatus_cf25a8ef-6ae4-40f3-ab7e-3b140cacf982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_331614e2-56a1-4268-a4cc-74170bba0541" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityInteractiveDataCurrent_331614e2-56a1-4268-a4cc-74170bba0541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e9c55340-baa3-408d-82d3-7aa28da7e162" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityFilerCategory_e9c55340-baa3-408d-82d3-7aa28da7e162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b9d1b9ed-225d-467c-8185-58a93ad05eca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntitySmallBusiness_b9d1b9ed-225d-467c-8185-58a93ad05eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_982438c8-718e-4258-86bc-2613275605bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityEmergingGrowthCompany_982438c8-718e-4258-86bc-2613275605bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_712de04e-093c-489c-bad5-186d54f3c591" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityShellCompany_712de04e-093c-489c-bad5-186d54f3c591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e18989c7-39a4-4cac-b277-ef93e5be3cca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e18989c7-39a4-4cac-b277-ef93e5be3cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bd796172-e69c-4362-8acc-db0920965a0b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_EntityCentralIndexKey_bd796172-e69c-4362-8acc-db0920965a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_aad51c28-770c-4e7d-8d9f-eaf4e0620f4f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_CurrentFiscalYearEndDate_aad51c28-770c-4e7d-8d9f-eaf4e0620f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_810b3e9b-390e-4442-aa08-0ed3d1c2992e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_DocumentFiscalYearFocus_810b3e9b-390e-4442-aa08-0ed3d1c2992e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c801aaea-f5b6-41cd-a26c-54bac3c23a30" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c801aaea-f5b6-41cd-a26c-54bac3c23a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3fcc319a-19d1-4f09-b8b2-dab41890478b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ba552c81-0957-45c4-a276-c72f4df06bd2" xlink:to="loc_dei_AmendmentFlag_3fcc319a-19d1-4f09-b8b2-dab41890478b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" xlink:type="simple" xlink:href="abt-20220930.xsd#CondensedConsolidatedStatementofEarningsUnaudited"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a4d5beaa-a2e4-4d25-a439-22baeaeef66c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a4d5beaa-a2e4-4d25-a439-22baeaeef66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_63151c2e-67ab-477b-bc75-bbec2b236ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_63151c2e-67ab-477b-bc75-bbec2b236ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9134fb84-d449-4ef0-b7c2-08ba16b7f7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9134fb84-d449-4ef0-b7c2-08ba16b7f7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5d995436-1c6c-4d84-b63f-d3141d205bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5d995436-1c6c-4d84-b63f-d3141d205bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7d2d491c-a9e4-4289-b6d4-8241642d9a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7d2d491c-a9e4-4289-b6d4-8241642d9a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_695cc6f3-0e9d-4b31-8192-4c2f187909b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_CostsAndExpenses_695cc6f3-0e9d-4b31-8192-4c2f187909b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1e55e917-e5ed-4068-8c25-bd247b231f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_OperatingIncomeLoss_1e55e917-e5ed-4068-8c25-bd247b231f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e1fb52cb-c988-41f8-9006-44649a1ee577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_InterestExpense_e1fb52cb-c988-41f8-9006-44649a1ee577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_2b286f49-7571-48e1-8579-d9c9ef3471b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_InvestmentIncomeInterest_2b286f49-7571-48e1-8579-d9c9ef3471b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a5976afa-b2fd-47cd-aeba-5674304106b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a5976afa-b2fd-47cd-aeba-5674304106b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9207eb64-18c0-40e0-9802-ae8ac7f38d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9207eb64-18c0-40e0-9802-ae8ac7f38d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_54d64e6a-d454-4792-a1c4-5f98cb28232d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_54d64e6a-d454-4792-a1c4-5f98cb28232d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e23e08ed-e477-43ed-94c9-7d09c006a9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e23e08ed-e477-43ed-94c9-7d09c006a9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_be6cec88-0d11-4461-b9eb-658ddf0503a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_NetIncomeLoss_be6cec88-0d11-4461-b9eb-658ddf0503a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b7a08023-4171-4456-a712-1d21cbfcb804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_EarningsPerShareBasic_b7a08023-4171-4456-a712-1d21cbfcb804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7cc1e81a-2d0b-40fa-b3d1-ec6bf38d4458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7cc1e81a-2d0b-40fa-b3d1-ec6bf38d4458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dde93e00-50ec-4f40-ace0-dfc33e5a3481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dde93e00-50ec-4f40-ace0-dfc33e5a3481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9491b56c-6ae1-4cb1-abfc-60a37b602b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9491b56c-6ae1-4cb1-abfc-60a37b602b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1cd94075-14c2-4fec-8d77-b6c3e6c761c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1cd94075-14c2-4fec-8d77-b6c3e6c761c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bfde7284-db51-4482-91b1-5d78788c6753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_74c0c8b0-a9e2-4f15-a2b5-87f8671e7416" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bfde7284-db51-4482-91b1-5d78788c6753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="abt-20220930.xsd#CondensedConsolidatedStatementofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3c9e93a6-c62d-43e4-b6a1-e9a3825192b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76ea4334-e564-4860-9048-bfe78c788835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3c9e93a6-c62d-43e4-b6a1-e9a3825192b0" xlink:to="loc_us-gaap_NetIncomeLoss_76ea4334-e564-4860-9048-bfe78c788835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_149865e9-2577-4f71-a09a-e5cfb890b95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3c9e93a6-c62d-43e4-b6a1-e9a3825192b0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_149865e9-2577-4f71-a09a-e5cfb890b95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_5625ba55-5f87-4317-a83b-b51d2e60bc42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3c9e93a6-c62d-43e4-b6a1-e9a3825192b0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_5625ba55-5f87-4317-a83b-b51d2e60bc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_842144d9-213d-4024-b7da-38fcf4328c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3c9e93a6-c62d-43e4-b6a1-e9a3825192b0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_842144d9-213d-4024-b7da-38fcf4328c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7429dbb4-ab65-43d8-854f-a4e68217e1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3c9e93a6-c62d-43e4-b6a1-e9a3825192b0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7429dbb4-ab65-43d8-854f-a4e68217e1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f5815ca9-4890-4a1b-b551-c4be774b49f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3c9e93a6-c62d-43e4-b6a1-e9a3825192b0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f5815ca9-4890-4a1b-b551-c4be774b49f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_031f89b2-c326-42a7-99fa-1646ba8abce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3c9e93a6-c62d-43e4-b6a1-e9a3825192b0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_031f89b2-c326-42a7-99fa-1646ba8abce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_05c578cb-a85c-4393-9960-1d2576dd9988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_031f89b2-c326-42a7-99fa-1646ba8abce8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_05c578cb-a85c-4393-9960-1d2576dd9988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_9bea2f56-7c68-4070-9999-13f0c7dc1535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_031f89b2-c326-42a7-99fa-1646ba8abce8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax_9bea2f56-7c68-4070-9999-13f0c7dc1535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_e81dffc0-c0ce-4691-a79b-df839b881853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_031f89b2-c326-42a7-99fa-1646ba8abce8" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_e81dffc0-c0ce-4691-a79b-df839b881853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_483944b5-3765-4641-8b22-ebc621d4462f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_031f89b2-c326-42a7-99fa-1646ba8abce8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_483944b5-3765-4641-8b22-ebc621d4462f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical" xlink:type="simple" xlink:href="abt-20220930.xsd#CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_51da9720-8ce6-48bb-8091-adf8022af6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_39609b83-c719-4811-9ee1-6609fe495f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_51da9720-8ce6-48bb-8091-adf8022af6cd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_39609b83-c719-4811-9ee1-6609fe495f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_e303f5a2-a302-4c90-808a-ff97a3813df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_51da9720-8ce6-48bb-8091-adf8022af6cd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_e303f5a2-a302-4c90-808a-ff97a3813df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" xlink:type="simple" xlink:href="abt-20220930.xsd#CondensedConsolidatedBalanceSheetUnaudited"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_955b6d3d-b2d3-4995-b1a0-061e26938e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_55971ea6-f8a0-4359-9735-752e1eb93f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_955b6d3d-b2d3-4995-b1a0-061e26938e77" xlink:to="loc_us-gaap_AssetsAbstract_55971ea6-f8a0-4359-9735-752e1eb93f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d9c8e8c6-1d77-4f5a-9a4b-2d80eeab4104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_55971ea6-f8a0-4359-9735-752e1eb93f54" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d9c8e8c6-1d77-4f5a-9a4b-2d80eeab4104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d70b956e-f49e-4f75-b8fb-5dd089c8e432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d9c8e8c6-1d77-4f5a-9a4b-2d80eeab4104" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d70b956e-f49e-4f75-b8fb-5dd089c8e432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_9216ff9a-b20c-42b9-8d0f-5d1227491d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d9c8e8c6-1d77-4f5a-9a4b-2d80eeab4104" xlink:to="loc_us-gaap_ShortTermInvestments_9216ff9a-b20c-42b9-8d0f-5d1227491d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_15f88515-87fc-4fe1-90f6-248a08363e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d9c8e8c6-1d77-4f5a-9a4b-2d80eeab4104" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_15f88515-87fc-4fe1-90f6-248a08363e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_72f9bbb1-ca81-401e-a338-892ff846958f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d9c8e8c6-1d77-4f5a-9a4b-2d80eeab4104" xlink:to="loc_us-gaap_InventoryNetAbstract_72f9bbb1-ca81-401e-a338-892ff846958f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_914b6087-922a-439e-908b-429cc788c37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_72f9bbb1-ca81-401e-a338-892ff846958f" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_914b6087-922a-439e-908b-429cc788c37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c37194f9-cfd2-4f2b-be3b-d5c376cbe64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_72f9bbb1-ca81-401e-a338-892ff846958f" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c37194f9-cfd2-4f2b-be3b-d5c376cbe64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_91de67c4-1a68-4d6e-8503-ba8b579fb522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_72f9bbb1-ca81-401e-a338-892ff846958f" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_91de67c4-1a68-4d6e-8503-ba8b579fb522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_74514b8b-0e8f-4d1d-8955-bc5f4f62ea74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_72f9bbb1-ca81-401e-a338-892ff846958f" xlink:to="loc_us-gaap_InventoryNet_74514b8b-0e8f-4d1d-8955-bc5f4f62ea74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PrepaidExpenseAndOtherReceivables_f1ee298b-b577-4c30-ab5c-1f09b916163b" xlink:href="abt-20220930.xsd#abt_PrepaidExpenseAndOtherReceivables"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d9c8e8c6-1d77-4f5a-9a4b-2d80eeab4104" xlink:to="loc_abt_PrepaidExpenseAndOtherReceivables_f1ee298b-b577-4c30-ab5c-1f09b916163b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_23aeb7ee-23d0-4bd1-9099-b2d217f1efeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d9c8e8c6-1d77-4f5a-9a4b-2d80eeab4104" xlink:to="loc_us-gaap_AssetsCurrent_23aeb7ee-23d0-4bd1-9099-b2d217f1efeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_dfaaf01f-2c98-4b79-866d-af5d82f7b6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_55971ea6-f8a0-4359-9735-752e1eb93f54" xlink:to="loc_us-gaap_LongTermInvestments_dfaaf01f-2c98-4b79-866d-af5d82f7b6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c152ad99-96dc-4def-a369-f5544adad583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_55971ea6-f8a0-4359-9735-752e1eb93f54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c152ad99-96dc-4def-a369-f5544adad583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2eef280f-f1b3-4bdf-820c-8c105803bdff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_55971ea6-f8a0-4359-9735-752e1eb93f54" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2eef280f-f1b3-4bdf-820c-8c105803bdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1692ae32-81c7-493d-8c29-ea74daeb84f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_55971ea6-f8a0-4359-9735-752e1eb93f54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1692ae32-81c7-493d-8c29-ea74daeb84f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d76f855e-8566-49ac-b247-6ee2aa8a45ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_55971ea6-f8a0-4359-9735-752e1eb93f54" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d76f855e-8566-49ac-b247-6ee2aa8a45ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f3b8b39a-ff32-4ffa-a146-ea0036f94edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_55971ea6-f8a0-4359-9735-752e1eb93f54" xlink:to="loc_us-gaap_Goodwill_f3b8b39a-ff32-4ffa-a146-ea0036f94edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_2b41ba34-ab84-458b-8f47-a22f2bf94051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_55971ea6-f8a0-4359-9735-752e1eb93f54" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_2b41ba34-ab84-458b-8f47-a22f2bf94051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_13d9ef24-4bd0-4a1e-9432-9b6ed1b59859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_55971ea6-f8a0-4359-9735-752e1eb93f54" xlink:to="loc_us-gaap_Assets_13d9ef24-4bd0-4a1e-9432-9b6ed1b59859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e617ba4c-6345-459f-8bb8-e00f2812c887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_955b6d3d-b2d3-4995-b1a0-061e26938e77" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e617ba4c-6345-459f-8bb8-e00f2812c887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_eeb96e68-8cab-44e0-ab7d-3ce6c8884c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e617ba4c-6345-459f-8bb8-e00f2812c887" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_eeb96e68-8cab-44e0-ab7d-3ce6c8884c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_596f552a-3dee-438a-8eb1-5940ebdd63f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eeb96e68-8cab-44e0-ab7d-3ce6c8884c59" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_596f552a-3dee-438a-8eb1-5940ebdd63f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ab8d75d3-718d-4d71-a7b8-6d70ff2ac2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eeb96e68-8cab-44e0-ab7d-3ce6c8884c59" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ab8d75d3-718d-4d71-a7b8-6d70ff2ac2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_320ab7bb-4c3b-4c21-9a8e-f9d8882a60eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eeb96e68-8cab-44e0-ab7d-3ce6c8884c59" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_320ab7bb-4c3b-4c21-9a8e-f9d8882a60eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_40319414-a170-4623-9d30-91c2fbbfd658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eeb96e68-8cab-44e0-ab7d-3ce6c8884c59" xlink:to="loc_us-gaap_DividendsPayableCurrent_40319414-a170-4623-9d30-91c2fbbfd658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_77e07dad-9d5a-4e0b-886d-33669dc4130b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eeb96e68-8cab-44e0-ab7d-3ce6c8884c59" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_77e07dad-9d5a-4e0b-886d-33669dc4130b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_4902fe15-ef3b-4d18-8d5c-de5f88d7a747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eeb96e68-8cab-44e0-ab7d-3ce6c8884c59" xlink:to="loc_us-gaap_LongTermDebtCurrent_4902fe15-ef3b-4d18-8d5c-de5f88d7a747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f557d8e0-1020-4539-b194-acb71bf5f710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_eeb96e68-8cab-44e0-ab7d-3ce6c8884c59" xlink:to="loc_us-gaap_LiabilitiesCurrent_f557d8e0-1020-4539-b194-acb71bf5f710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_19890ce6-f6d6-4ab5-85e3-94ebbf882170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e617ba4c-6345-459f-8bb8-e00f2812c887" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_19890ce6-f6d6-4ab5-85e3-94ebbf882170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities_d301ee23-8fa9-47f9-b240-ef9520fdb9ba" xlink:href="abt-20220930.xsd#abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e617ba4c-6345-459f-8bb8-e00f2812c887" xlink:to="loc_abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities_d301ee23-8fa9-47f9-b240-ef9520fdb9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b30da634-036e-4d22-b089-055c26487d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e617ba4c-6345-459f-8bb8-e00f2812c887" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b30da634-036e-4d22-b089-055c26487d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7f1e1258-3f3a-4dcb-be51-d104cb264d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e617ba4c-6345-459f-8bb8-e00f2812c887" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7f1e1258-3f3a-4dcb-be51-d104cb264d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a7040857-00b0-405d-94d0-d979abef0924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7f1e1258-3f3a-4dcb-be51-d104cb264d7f" xlink:to="loc_us-gaap_PreferredStockValue_a7040857-00b0-405d-94d0-d979abef0924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e2ba681b-9358-4c3e-8849-b9bbc7b02f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7f1e1258-3f3a-4dcb-be51-d104cb264d7f" xlink:to="loc_us-gaap_CommonStockValue_e2ba681b-9358-4c3e-8849-b9bbc7b02f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_f44c9909-e7fc-4539-93cf-ea0499aa86ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7f1e1258-3f3a-4dcb-be51-d104cb264d7f" xlink:to="loc_us-gaap_TreasuryStockCommonValue_f44c9909-e7fc-4539-93cf-ea0499aa86ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0e865385-a54a-4446-b43e-1329fbc1d53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7f1e1258-3f3a-4dcb-be51-d104cb264d7f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0e865385-a54a-4446-b43e-1329fbc1d53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_70ab88c1-a576-4acc-9212-95920340b827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7f1e1258-3f3a-4dcb-be51-d104cb264d7f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_70ab88c1-a576-4acc-9212-95920340b827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8ad8560b-6e49-4e39-8702-0c16bfaac5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7f1e1258-3f3a-4dcb-be51-d104cb264d7f" xlink:to="loc_us-gaap_StockholdersEquity_8ad8560b-6e49-4e39-8702-0c16bfaac5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_94524a50-78a7-49eb-9e33-020eaf015a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7f1e1258-3f3a-4dcb-be51-d104cb264d7f" xlink:to="loc_us-gaap_MinorityInterest_94524a50-78a7-49eb-9e33-020eaf015a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_da483c6e-4e9d-4db1-a1cb-405576f79e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7f1e1258-3f3a-4dcb-be51-d104cb264d7f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_da483c6e-4e9d-4db1-a1cb-405576f79e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f71a3421-49a1-4138-93ab-f9be580e89aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e617ba4c-6345-459f-8bb8-e00f2812c887" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f71a3421-49a1-4138-93ab-f9be580e89aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" xlink:type="simple" xlink:href="abt-20220930.xsd#CondensedConsolidatedBalanceSheetUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_db3dacb5-6355-4e55-9ab5-fa53da395bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4435e619-f358-4844-b684-42498d9358c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_db3dacb5-6355-4e55-9ab5-fa53da395bab" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4435e619-f358-4844-b684-42498d9358c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f91cefd8-0bae-4960-8e8d-0f1324632880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_db3dacb5-6355-4e55-9ab5-fa53da395bab" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f91cefd8-0bae-4960-8e8d-0f1324632880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_27a7518d-ea87-465c-bfcf-1565d2fa5c43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_db3dacb5-6355-4e55-9ab5-fa53da395bab" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_27a7518d-ea87-465c-bfcf-1565d2fa5c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_a57e51c1-3f0b-4f5c-aaf2-f8981ab8eb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_db3dacb5-6355-4e55-9ab5-fa53da395bab" xlink:to="loc_us-gaap_PreferredStockSharesIssued_a57e51c1-3f0b-4f5c-aaf2-f8981ab8eb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e7c96d96-d1c3-4efc-be2d-044e9f5ca8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_db3dacb5-6355-4e55-9ab5-fa53da395bab" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e7c96d96-d1c3-4efc-be2d-044e9f5ca8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f951b9ff-e1c1-41f3-bffc-843ba978f53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_db3dacb5-6355-4e55-9ab5-fa53da395bab" xlink:to="loc_us-gaap_CommonStockSharesIssued_f951b9ff-e1c1-41f3-bffc-843ba978f53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_9134856a-dce0-4625-a5a2-5c8f4b10be2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_db3dacb5-6355-4e55-9ab5-fa53da395bab" xlink:to="loc_us-gaap_TreasuryStockCommonShares_9134856a-dce0-4625-a5a2-5c8f4b10be2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" xlink:type="simple" xlink:href="abt-20220930.xsd#CondensedConsolidatedStatementofShareholdersInvestmentUnaudited"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_68e29f33-c4be-4ce8-acd5-76b1ff5a108b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b5ad225e-0602-4052-9e8b-f30f3c72ee23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_68e29f33-c4be-4ce8-acd5-76b1ff5a108b" xlink:to="loc_us-gaap_StatementTable_b5ad225e-0602-4052-9e8b-f30f3c72ee23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f6f19dee-d317-4b32-a94a-d66f3f7fb2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b5ad225e-0602-4052-9e8b-f30f3c72ee23" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f6f19dee-d317-4b32-a94a-d66f3f7fb2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4e98d0bd-443e-4b4e-b2e4-cc23e05b6532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f6f19dee-d317-4b32-a94a-d66f3f7fb2cb" xlink:to="loc_us-gaap_EquityComponentDomain_4e98d0bd-443e-4b4e-b2e4-cc23e05b6532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a48fafc6-2390-4afb-9831-11303bb9e326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4e98d0bd-443e-4b4e-b2e4-cc23e05b6532" xlink:to="loc_us-gaap_CommonStockMember_a48fafc6-2390-4afb-9831-11303bb9e326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_74b1dd2e-645b-4a77-bebb-af35080ef045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4e98d0bd-443e-4b4e-b2e4-cc23e05b6532" xlink:to="loc_us-gaap_TreasuryStockCommonMember_74b1dd2e-645b-4a77-bebb-af35080ef045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_834b4d68-759b-42a4-90f7-410b3e26ead6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4e98d0bd-443e-4b4e-b2e4-cc23e05b6532" xlink:to="loc_us-gaap_RetainedEarningsMember_834b4d68-759b-42a4-90f7-410b3e26ead6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b2d3dfba-a74d-4700-840a-11166152a77d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4e98d0bd-443e-4b4e-b2e4-cc23e05b6532" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b2d3dfba-a74d-4700-840a-11166152a77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_ef455502-be62-4921-8959-203cb49695bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4e98d0bd-443e-4b4e-b2e4-cc23e05b6532" xlink:to="loc_us-gaap_NoncontrollingInterestMember_ef455502-be62-4921-8959-203cb49695bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4f34d4b5-850b-4216-b009-3e48bd25990d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b5ad225e-0602-4052-9e8b-f30f3c72ee23" xlink:to="loc_us-gaap_StatementLineItems_4f34d4b5-850b-4216-b009-3e48bd25990d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4f34d4b5-850b-4216-b009-3e48bd25990d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_775863b7-f66e-4515-9d36-d9acb7876003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_775863b7-f66e-4515-9d36-d9acb7876003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_StockIssuedDuringPeriodValueIncentiveStockPrograms_91445fb7-e6d8-4535-9946-4cc5e9d99328" xlink:href="abt-20220930.xsd#abt_StockIssuedDuringPeriodValueIncentiveStockPrograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_abt_StockIssuedDuringPeriodValueIncentiveStockPrograms_91445fb7-e6d8-4535-9946-4cc5e9d99328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b3a352a3-a132-463d-b44f-65b85bb36a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b3a352a3-a132-463d-b44f-65b85bb36a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_753446ff-db07-4d85-919d-65171be8867f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_753446ff-db07-4d85-919d-65171be8867f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0379fdba-257c-4239-8e47-055cc5bda8df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0379fdba-257c-4239-8e47-055cc5bda8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3e0a5c27-932f-42a0-9272-9f414b9ee4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_us-gaap_NetIncomeLoss_3e0a5c27-932f-42a0-9272-9f414b9ee4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_644910a5-fef8-4e4e-bec3-4e068b746e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_us-gaap_DividendsCommonStockCash_644910a5-fef8-4e4e-bec3-4e068b746e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_EffectOfCommonAndTreasuryShareTransactions_d780634c-71b7-40ae-88f6-f082825e6dc3" xlink:href="abt-20220930.xsd#abt_EffectOfCommonAndTreasuryShareTransactions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_abt_EffectOfCommonAndTreasuryShareTransactions_d780634c-71b7-40ae-88f6-f082825e6dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5110b6e6-aec4-4342-bd4e-e4598e153e59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5110b6e6-aec4-4342-bd4e-e4598e153e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations_caf92269-0cc2-45d6-8739-6122eb4478e2" xlink:href="abt-20220930.xsd#abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations_caf92269-0cc2-45d6-8739-6122eb4478e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_31710976-c6bc-4bd6-9697-a5593b0e63ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35f5f4ac-b5d0-45ae-a03c-96aff34bcfd6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_31710976-c6bc-4bd6-9697-a5593b0e63ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" xlink:type="simple" xlink:href="abt-20220930.xsd#CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a233eef1-63f5-4d80-bf7f-914300648151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9e0fb1a9-cc44-403f-a367-81ee6d8e5229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a233eef1-63f5-4d80-bf7f-914300648151" xlink:to="loc_us-gaap_StatementTable_9e0fb1a9-cc44-403f-a367-81ee6d8e5229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_82c917a2-098a-4bd6-b2a1-3ac65c9527ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9e0fb1a9-cc44-403f-a367-81ee6d8e5229" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_82c917a2-098a-4bd6-b2a1-3ac65c9527ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_62422075-b48f-49ad-8dd9-8061591b9c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_82c917a2-098a-4bd6-b2a1-3ac65c9527ac" xlink:to="loc_us-gaap_EquityComponentDomain_62422075-b48f-49ad-8dd9-8061591b9c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8f2c09ae-312d-4dec-9a22-3948d9870d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62422075-b48f-49ad-8dd9-8061591b9c54" xlink:to="loc_us-gaap_CommonStockMember_8f2c09ae-312d-4dec-9a22-3948d9870d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_b44382ee-a4f6-49a5-9b31-bb7f0c29e3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62422075-b48f-49ad-8dd9-8061591b9c54" xlink:to="loc_us-gaap_TreasuryStockCommonMember_b44382ee-a4f6-49a5-9b31-bb7f0c29e3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_15fd47bf-316b-4b9a-a8fa-b37f85b9d46c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62422075-b48f-49ad-8dd9-8061591b9c54" xlink:to="loc_us-gaap_RetainedEarningsMember_15fd47bf-316b-4b9a-a8fa-b37f85b9d46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4de22e01-5043-4d9f-bada-41f3f4ff54fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9e0fb1a9-cc44-403f-a367-81ee6d8e5229" xlink:to="loc_us-gaap_StatementLineItems_4de22e01-5043-4d9f-bada-41f3f4ff54fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5fe0226-c332-4b4a-a027-1261895bcf1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4de22e01-5043-4d9f-bada-41f3f4ff54fe" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5fe0226-c332-4b4a-a027-1261895bcf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_11bb764e-a847-443c-a89a-ec5324c115be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5fe0226-c332-4b4a-a027-1261895bcf1e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_11bb764e-a847-443c-a89a-ec5324c115be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_624a86e2-5f84-4fa6-848c-0234bf7f8fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5fe0226-c332-4b4a-a027-1261895bcf1e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_624a86e2-5f84-4fa6-848c-0234bf7f8fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms_a24081a9-fea9-4f66-bdd8-faad7889cb68" xlink:href="abt-20220930.xsd#abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5fe0226-c332-4b4a-a027-1261895bcf1e" xlink:to="loc_abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms_a24081a9-fea9-4f66-bdd8-faad7889cb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_bd52658e-bb7e-440d-8d3b-7f7a0f020c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5fe0226-c332-4b4a-a027-1261895bcf1e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_bd52658e-bb7e-440d-8d3b-7f7a0f020c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_fd317d1f-41cd-4938-8f4b-d0a1ac35872a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5fe0226-c332-4b4a-a027-1261895bcf1e" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_fd317d1f-41cd-4938-8f4b-d0a1ac35872a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ba773aef-53cf-49b8-8317-68846bf702aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5fe0226-c332-4b4a-a027-1261895bcf1e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ba773aef-53cf-49b8-8317-68846bf702aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_1f9f7dfc-b142-4223-8ff5-05f14162c9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5fe0226-c332-4b4a-a027-1261895bcf1e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_1f9f7dfc-b142-4223-8ff5-05f14162c9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" xlink:type="simple" xlink:href="abt-20220930.xsd#CondensedConsolidatedStatementofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_aa560aee-6657-43b4-b0e3-02d72030e87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_739b0fb8-4370-4d73-a3ef-48d3b3a16791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa560aee-6657-43b4-b0e3-02d72030e87c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_739b0fb8-4370-4d73-a3ef-48d3b3a16791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eba52cfb-d0b5-4963-8f56-4cd6a61fd186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_739b0fb8-4370-4d73-a3ef-48d3b3a16791" xlink:to="loc_us-gaap_NetIncomeLoss_eba52cfb-d0b5-4963-8f56-4cd6a61fd186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a93c22f4-6fd3-4162-b8c4-a3cecd82a2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_739b0fb8-4370-4d73-a3ef-48d3b3a16791" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a93c22f4-6fd3-4162-b8c4-a3cecd82a2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ffa66e86-9102-41d9-85af-7d436e6638ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a93c22f4-6fd3-4162-b8c4-a3cecd82a2f5" xlink:to="loc_us-gaap_Depreciation_ffa66e86-9102-41d9-85af-7d436e6638ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_59506ddc-6e6f-45d7-913f-aa9fc077f093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a93c22f4-6fd3-4162-b8c4-a3cecd82a2f5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_59506ddc-6e6f-45d7-913f-aa9fc077f093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9363ae10-4980-4110-a18c-565aa3df6cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a93c22f4-6fd3-4162-b8c4-a3cecd82a2f5" xlink:to="loc_us-gaap_ShareBasedCompensation_9363ae10-4980-4110-a18c-565aa3df6cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fec9260e-e217-4250-8c54-002b918b6d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_739b0fb8-4370-4d73-a3ef-48d3b3a16791" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fec9260e-e217-4250-8c54-002b918b6d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6ac33113-930e-4d3c-a20d-3786fe19dcce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_739b0fb8-4370-4d73-a3ef-48d3b3a16791" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6ac33113-930e-4d3c-a20d-3786fe19dcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5ba44c44-1dcd-4991-9fcb-8326bf6f4393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_739b0fb8-4370-4d73-a3ef-48d3b3a16791" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5ba44c44-1dcd-4991-9fcb-8326bf6f4393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7104673f-cad3-4468-8660-67419ca99be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_739b0fb8-4370-4d73-a3ef-48d3b3a16791" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7104673f-cad3-4468-8660-67419ca99be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f68ad950-9e2b-4169-b553-b63d1fca75dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa560aee-6657-43b4-b0e3-02d72030e87c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f68ad950-9e2b-4169-b553-b63d1fca75dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7b116ab1-ecb4-4bec-819a-1244441e529e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f68ad950-9e2b-4169-b553-b63d1fca75dc" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7b116ab1-ecb4-4bec-819a-1244441e529e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess_eccc3eec-b3a2-46c5-b5d1-64b0484b47d6" xlink:href="abt-20220930.xsd#abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f68ad950-9e2b-4169-b553-b63d1fca75dc" xlink:to="loc_abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess_eccc3eec-b3a2-46c5-b5d1-64b0484b47d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_f0c765ab-7eee-405c-b985-875c4c556e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f68ad950-9e2b-4169-b553-b63d1fca75dc" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_f0c765ab-7eee-405c-b985-875c4c556e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_d1099de2-fbfd-4b28-b4fe-79b79e7dfba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f68ad950-9e2b-4169-b553-b63d1fca75dc" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments_d1099de2-fbfd-4b28-b4fe-79b79e7dfba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_df2e17c0-5e47-4b1c-b6de-1b294aa6ba45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f68ad950-9e2b-4169-b553-b63d1fca75dc" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_df2e17c0-5e47-4b1c-b6de-1b294aa6ba45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cd146288-3575-4a13-89fe-ba83f1f34964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f68ad950-9e2b-4169-b553-b63d1fca75dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cd146288-3575-4a13-89fe-ba83f1f34964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_495977a4-a534-4df6-a6f3-9ef3bcdf48df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa560aee-6657-43b4-b0e3-02d72030e87c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_495977a4-a534-4df6-a6f3-9ef3bcdf48df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_7cc3a394-8361-4949-b653-2f611c2f9c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_495977a4-a534-4df6-a6f3-9ef3bcdf48df" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_7cc3a394-8361-4949-b653-2f611c2f9c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d0a5d74d-7427-4935-bc4f-9e83ee58cd64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_495977a4-a534-4df6-a6f3-9ef3bcdf48df" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d0a5d74d-7427-4935-bc4f-9e83ee58cd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_e5adb457-351b-4ab7-a0ee-cb0bfb3e9289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_495977a4-a534-4df6-a6f3-9ef3bcdf48df" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_e5adb457-351b-4ab7-a0ee-cb0bfb3e9289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_223822aa-7448-4629-8d62-8a8d002652aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_495977a4-a534-4df6-a6f3-9ef3bcdf48df" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_223822aa-7448-4629-8d62-8a8d002652aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_53f57e30-eb34-4b84-8bfc-fb6037f0ea2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_495977a4-a534-4df6-a6f3-9ef3bcdf48df" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_53f57e30-eb34-4b84-8bfc-fb6037f0ea2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_b1228f1e-cdf6-4f20-9664-e89536c775f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_495977a4-a534-4df6-a6f3-9ef3bcdf48df" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_b1228f1e-cdf6-4f20-9664-e89536c775f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b481f804-3541-4d65-bfef-998310aca564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_495977a4-a534-4df6-a6f3-9ef3bcdf48df" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b481f804-3541-4d65-bfef-998310aca564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7ae0ad4c-0f79-4428-b836-bfd73e56657c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa560aee-6657-43b4-b0e3-02d72030e87c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7ae0ad4c-0f79-4428-b836-bfd73e56657c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d72a64fc-aa63-4912-b6bc-46fa8f44e126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa560aee-6657-43b4-b0e3-02d72030e87c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d72a64fc-aa63-4912-b6bc-46fa8f44e126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_38e00a11-5619-4c51-9fb2-860cdf9cb423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa560aee-6657-43b4-b0e3-02d72030e87c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_38e00a11-5619-4c51-9fb2-860cdf9cb423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b50dfb24-eeeb-494f-b586-f3febe44661e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa560aee-6657-43b4-b0e3-02d72030e87c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b50dfb24-eeeb-494f-b586-f3febe44661e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/BasisofPresentation" xlink:type="simple" xlink:href="abt-20220930.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4d97286-2878-4733-9dbe-71752b31ac1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_e636b04e-584a-4c86-93c9-79f3f8f1dc08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4d97286-2878-4733-9dbe-71752b31ac1a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_e636b04e-584a-4c86-93c9-79f3f8f1dc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/Revenue" xlink:type="simple" xlink:href="abt-20220930.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5ebac859-97b2-44c4-b083-3325375280ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_21b1e229-1a20-4a5b-b28b-d2fa3c57b631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5ebac859-97b2-44c4-b083-3325375280ba" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_21b1e229-1a20-4a5b-b28b-d2fa3c57b631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/SupplementalFinancialInformation" xlink:type="simple" xlink:href="abt-20220930.xsd#SupplementalFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/SupplementalFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract_d632ce69-6dd7-4c9d-b7ad-4efa1d8ae572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_cd402277-b1ed-4265-86f6-4c7b56114ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_d632ce69-6dd7-4c9d-b7ad-4efa1d8ae572" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_cd402277-b1ed-4265-86f6-4c7b56114ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="abt-20220930.xsd#ChangesinAccumulatedOtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_d2496bc0-7b9a-481b-bc84-03b7fad5e530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_ed6b7ff1-a785-4a2e-9bc4-87ea188f1ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_d2496bc0-7b9a-481b-bc84-03b7fad5e530" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_ed6b7ff1-a785-4a2e-9bc4-87ea188f1ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="abt-20220930.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c72ac159-3451-478e-9ffd-546d69f1c583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_b5ff6868-b25e-4405-a563-2d9f3420deff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c72ac159-3451-478e-9ffd-546d69f1c583" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_b5ff6868-b25e-4405-a563-2d9f3420deff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/RestructuringPlans" xlink:type="simple" xlink:href="abt-20220930.xsd#RestructuringPlans"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/RestructuringPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0c654d62-a1d4-40b3-aee5-3b39f9304a50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1fe8b2f0-d7dc-45d7-bf29-a24a56ac7f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0c654d62-a1d4-40b3-aee5-3b39f9304a50" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1fe8b2f0-d7dc-45d7-bf29-a24a56ac7f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/IncentiveStockProgram" xlink:type="simple" xlink:href="abt-20220930.xsd#IncentiveStockProgram"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/IncentiveStockProgram" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_75e3d6c8-d957-434d-92f2-3f5076eed318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_acc060fb-146d-4220-858d-6d26a7dbd771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_75e3d6c8-d957-434d-92f2-3f5076eed318" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_acc060fb-146d-4220-858d-6d26a7dbd771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/DebtandLinesofCredit" xlink:type="simple" xlink:href="abt-20220930.xsd#DebtandLinesofCredit"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/DebtandLinesofCredit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_16daa44c-328d-4181-a5e8-930c01d2e573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_5da05198-c785-4d0f-b84a-f91d8c204568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_16daa44c-328d-4181-a5e8-930c01d2e573" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_5da05198-c785-4d0f-b84a-f91d8c204568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures" xlink:type="simple" xlink:href="abt-20220930.xsd#FinancialInstrumentsDerivativesandFairValueMeasures"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e5f7dc08-965d-46ea-a23c-4ac729c20136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_6e5b1ae7-19b7-415d-9e3e-dc2dfc824180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e5f7dc08-965d-46ea-a23c-4ac729c20136" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_6e5b1ae7-19b7-415d-9e3e-dc2dfc824180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/LitigationandEnvironmentalMatters" xlink:type="simple" xlink:href="abt-20220930.xsd#LitigationandEnvironmentalMatters"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/LitigationandEnvironmentalMatters" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5abdbf4d-fc51-4d05-989d-4242449873ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_24c6f5c5-3e5f-4448-bc66-d23df0d3ec15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5abdbf4d-fc51-4d05-989d-4242449873ce" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_24c6f5c5-3e5f-4448-bc66-d23df0d3ec15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/PostEmploymentBenefits" xlink:type="simple" xlink:href="abt-20220930.xsd#PostEmploymentBenefits"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/PostEmploymentBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_dce3e939-c6a3-472d-882e-7cb47ee5e55a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsDisclosureTextBlock_abddca76-9c9d-4448-90a8-613862b06160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_dce3e939-c6a3-472d-882e-7cb47ee5e55a" xlink:to="loc_us-gaap_PostemploymentBenefitsDisclosureTextBlock_abddca76-9c9d-4448-90a8-613862b06160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/TaxesonEarnings" xlink:type="simple" xlink:href="abt-20220930.xsd#TaxesonEarnings"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/TaxesonEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_19bb4ff9-00bd-430d-9135-06d4a489e37c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_cc6c2b3d-cc8e-43e0-b1aa-8327a243fa34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_19bb4ff9-00bd-430d-9135-06d4a489e37c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_cc6c2b3d-cc8e-43e0-b1aa-8327a243fa34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/SegmentInformation" xlink:type="simple" xlink:href="abt-20220930.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_218ce03f-19b7-4e65-baf9-18023a59fae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_69e8cc64-4b8e-439a-8e7e-0d963a85f432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_218ce03f-19b7-4e65-baf9-18023a59fae5" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_69e8cc64-4b8e-439a-8e7e-0d963a85f432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/RevenueTables" xlink:type="simple" xlink:href="abt-20220930.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6fcf0e53-fc66-4c04-a8e3-4e5c6508ccfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_a4f2c1ac-ade8-44c5-bbc1-cdf9be87dea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6fcf0e53-fc66-4c04-a8e3-4e5c6508ccfb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_a4f2c1ac-ade8-44c5-bbc1-cdf9be87dea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_1e9b3be2-cdb8-44d5-85b5-6f6a61474bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6fcf0e53-fc66-4c04-a8e3-4e5c6508ccfb" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_1e9b3be2-cdb8-44d5-85b5-6f6a61474bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/SupplementalFinancialInformationTables" xlink:type="simple" xlink:href="abt-20220930.xsd#SupplementalFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/SupplementalFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract_3b188d95-004c-4f39-adc6-88ef3c579666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_e5b057fc-c997-475f-8b32-53962eb360ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_3b188d95-004c-4f39-adc6-88ef3c579666" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_e5b057fc-c997-475f-8b32-53962eb360ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_ScheduleOfLongTermInvestmentsTableTextBlock_b2e9a0ef-d447-49ed-a7e0-2bf067304755" xlink:href="abt-20220930.xsd#abt_ScheduleOfLongTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_3b188d95-004c-4f39-adc6-88ef3c579666" xlink:to="loc_abt_ScheduleOfLongTermInvestmentsTableTextBlock_b2e9a0ef-d447-49ed-a7e0-2bf067304755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="abt-20220930.xsd#ChangesinAccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_ba295fbd-1f51-4200-8be7-513d22092beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e8dee74a-c703-4348-b708-732f6bbca109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_ba295fbd-1f51-4200-8be7-513d22092beb" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e8dee74a-c703-4348-b708-732f6bbca109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/RestructuringPlansTables" xlink:type="simple" xlink:href="abt-20220930.xsd#RestructuringPlansTables"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/RestructuringPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5b918c91-8bc3-4880-8a48-07314e2720b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_9964ceb9-9242-4115-ae86-4686804bc651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5b918c91-8bc3-4880-8a48-07314e2720b5" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_9964ceb9-9242-4115-ae86-4686804bc651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_a305db74-a174-4e4e-b943-58a3344258b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5b918c91-8bc3-4880-8a48-07314e2720b5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_a305db74-a174-4e4e-b943-58a3344258b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/IncentiveStockProgramTables" xlink:type="simple" xlink:href="abt-20220930.xsd#IncentiveStockProgramTables"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/IncentiveStockProgramTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51e30e8d-7007-4fe6-b059-2da2bb9d5d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_25ec2a1b-e90d-43a3-a4f5-4eeaf59749df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51e30e8d-7007-4fe6-b059-2da2bb9d5d2b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_25ec2a1b-e90d-43a3-a4f5-4eeaf59749df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" xlink:type="simple" xlink:href="abt-20220930.xsd#FinancialInstrumentsDerivativesandFairValueMeasuresTables"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_eff0b605-3b84-48f3-ae5c-96f43c77131c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_24fbfdbd-0392-40de-aa6b-612207e07abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_eff0b605-3b84-48f3-ae5c-96f43c77131c" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_24fbfdbd-0392-40de-aa6b-612207e07abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_c4bdcc90-1779-40b4-a728-f7f5e1702691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_eff0b605-3b84-48f3-ae5c-96f43c77131c" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_c4bdcc90-1779-40b4-a728-f7f5e1702691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_56041e63-6922-4567-a820-2bd27b60664b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_eff0b605-3b84-48f3-ae5c-96f43c77131c" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_56041e63-6922-4567-a820-2bd27b60664b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_fd09fcb0-57e3-4a77-898d-287b4ea92063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_eff0b605-3b84-48f3-ae5c-96f43c77131c" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_fd09fcb0-57e3-4a77-898d-287b4ea92063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/PostEmploymentBenefitsTables" xlink:type="simple" xlink:href="abt-20220930.xsd#PostEmploymentBenefitsTables"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/PostEmploymentBenefitsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_0bf2e897-2427-4711-923c-da0f61096b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_ea5d7542-d5d1-40aa-985a-066cff8092b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_0bf2e897-2427-4711-923c-da0f61096b79" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_ea5d7542-d5d1-40aa-985a-066cff8092b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="abt-20220930.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_eb6197b7-b359-4e40-bb2f-191337f57cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_70c93d46-5282-4e06-9fb8-a0c7af14e614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_eb6197b7-b359-4e40-bb2f-191337f57cca" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_70c93d46-5282-4e06-9fb8-a0c7af14e614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b7823c06-1d6a-4f71-a735-9d43753ef3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9cce46a8-0dcb-4104-80a1-57517cfc3ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b7823c06-1d6a-4f71-a735-9d43753ef3bc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9cce46a8-0dcb-4104-80a1-57517cfc3ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_03bcde9d-58b0-472f-9c38-61d9f3eace3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9cce46a8-0dcb-4104-80a1-57517cfc3ba2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_03bcde9d-58b0-472f-9c38-61d9f3eace3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_cd2bae6c-058a-4adf-b7b5-1ba3344dd553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9cce46a8-0dcb-4104-80a1-57517cfc3ba2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_cd2bae6c-058a-4adf-b7b5-1ba3344dd553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_76274abd-02d0-4c49-b081-c09bae002cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cd2bae6c-058a-4adf-b7b5-1ba3344dd553" xlink:to="loc_us-gaap_SegmentDomain_76274abd-02d0-4c49-b081-c09bae002cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DiagnosticProductsMember_813721f7-6d0c-40ea-9d8b-9de6a196c338" xlink:href="abt-20220930.xsd#abt_DiagnosticProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_76274abd-02d0-4c49-b081-c09bae002cb7" xlink:to="loc_abt_DiagnosticProductsMember_813721f7-6d0c-40ea-9d8b-9de6a196c338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_MedicalDevicesMember_ca5010cf-6b85-4303-92c3-4a12e581a54e" xlink:href="abt-20220930.xsd#abt_MedicalDevicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_76274abd-02d0-4c49-b081-c09bae002cb7" xlink:to="loc_abt_MedicalDevicesMember_ca5010cf-6b85-4303-92c3-4a12e581a54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_9cce46a8-0dcb-4104-80a1-57517cfc3ba2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_e75b4008-fea7-49a5-b728-e91b1afc15ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:to="loc_us-gaap_NumberOfReportableSegments_e75b4008-fea7-49a5-b728-e91b1afc15ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_0e0f4fda-a1e8-464a-b653-a01007bcd7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_0e0f4fda-a1e8-464a-b653-a01007bcd7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage_72864081-f835-41dc-804f-99678717e965" xlink:href="abt-20220930.xsd#abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:to="loc_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage_72864081-f835-41dc-804f-99678717e965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_84e790a9-51ea-4205-a352-2632218ef110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_61c57c61-7a5f-4d29-ac25-2e30c82bb924" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_84e790a9-51ea-4205-a352-2632218ef110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/RevenueNarrativeDetails_1" xlink:type="simple" xlink:href="abt-20220930.xsd#RevenueNarrativeDetails_1"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/RevenueNarrativeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.abbott.com/role/RevenueSegmentsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#RevenueSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/RevenueSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_43e90fd9-a8c7-47ac-a364-972a48c9daf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cfbc05d0-42ec-42ac-b610-9f0256c543ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_43e90fd9-a8c7-47ac-a364-972a48c9daf2" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cfbc05d0-42ec-42ac-b610-9f0256c543ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_00fddbf8-9e3a-4bd3-87ec-99220933d24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cfbc05d0-42ec-42ac-b610-9f0256c543ef" xlink:to="loc_us-gaap_SubsegmentsAxis_00fddbf8-9e3a-4bd3-87ec-99220933d24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_00fddbf8-9e3a-4bd3-87ec-99220933d24d" xlink:to="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_KeyEmergingMarketsMember_9534f6f5-635b-46b2-9286-ea48799a4484" xlink:href="abt-20220930.xsd#abt_KeyEmergingMarketsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_KeyEmergingMarketsMember_9534f6f5-635b-46b2-9286-ea48799a4484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_OtherEmergingMarketsMember_a203d1fc-2cbc-4c6c-bcad-5fc656abcf94" xlink:href="abt-20220930.xsd#abt_OtherEmergingMarketsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_OtherEmergingMarketsMember_a203d1fc-2cbc-4c6c-bcad-5fc656abcf94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PediatricNutritionalsMember_59dc21e0-c7f7-42e9-8f8b-8d0bd234ec6d" xlink:href="abt-20220930.xsd#abt_PediatricNutritionalsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_PediatricNutritionalsMember_59dc21e0-c7f7-42e9-8f8b-8d0bd234ec6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_AdultNutritionalsMember_e419d872-6e9c-4d8a-b405-03297c95a883" xlink:href="abt-20220930.xsd#abt_AdultNutritionalsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_AdultNutritionalsMember_e419d872-6e9c-4d8a-b405-03297c95a883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_CoreLaboratoryMember_b2825a79-c212-4afb-b527-10a50aa4714b" xlink:href="abt-20220930.xsd#abt_CoreLaboratoryMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_CoreLaboratoryMember_b2825a79-c212-4afb-b527-10a50aa4714b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_MolecularMember_57bb6763-f164-4465-acc5-6a42f37af4b9" xlink:href="abt-20220930.xsd#abt_MolecularMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_MolecularMember_57bb6763-f164-4465-acc5-6a42f37af4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PointOfCareMember_ff757bfc-8c95-4815-b198-b4982031b13e" xlink:href="abt-20220930.xsd#abt_PointOfCareMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_PointOfCareMember_ff757bfc-8c95-4815-b198-b4982031b13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RapidDiagnosticsMember_12567dbf-2efe-4d79-9f83-f36a7e997c94" xlink:href="abt-20220930.xsd#abt_RapidDiagnosticsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_RapidDiagnosticsMember_12567dbf-2efe-4d79-9f83-f36a7e997c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RhythmManagementMember_83600d2d-c1de-4cf2-8a27-c0acd7eec718" xlink:href="abt-20220930.xsd#abt_RhythmManagementMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_RhythmManagementMember_83600d2d-c1de-4cf2-8a27-c0acd7eec718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_ElectrophysiologyMember_6280fcd2-80f6-43a6-9dbc-893e21c7daf3" xlink:href="abt-20220930.xsd#abt_ElectrophysiologyMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_ElectrophysiologyMember_6280fcd2-80f6-43a6-9dbc-893e21c7daf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_HeartFailureMember_82295b6e-9773-4405-81e6-ebb1346d2f41" xlink:href="abt-20220930.xsd#abt_HeartFailureMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_HeartFailureMember_82295b6e-9773-4405-81e6-ebb1346d2f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_VascularMember_907fd424-2ccb-4a03-a1b5-798a87bbd1ab" xlink:href="abt-20220930.xsd#abt_VascularMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_VascularMember_907fd424-2ccb-4a03-a1b5-798a87bbd1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_StructuralHeartMember_b3c0756b-f9e3-46b0-a750-022b0c779aed" xlink:href="abt-20220930.xsd#abt_StructuralHeartMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_StructuralHeartMember_b3c0756b-f9e3-46b0-a750-022b0c779aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_NeuromodulationMember_ccc57ba2-afcb-4606-9ae2-81e8751bfb73" xlink:href="abt-20220930.xsd#abt_NeuromodulationMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_NeuromodulationMember_ccc57ba2-afcb-4606-9ae2-81e8751bfb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DiabetesCareMember_43cbe98b-2c11-4272-bdbd-4d5ad0a78f28" xlink:href="abt-20220930.xsd#abt_DiabetesCareMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_205c7b93-b2e6-4de3-856c-e18037951f5a" xlink:to="loc_abt_DiabetesCareMember_43cbe98b-2c11-4272-bdbd-4d5ad0a78f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_012841c0-9fe8-4f89-b4b7-f45c103d5a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cfbc05d0-42ec-42ac-b610-9f0256c543ef" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_012841c0-9fe8-4f89-b4b7-f45c103d5a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9fa057cf-fc2d-42f6-b804-76520efa50da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_012841c0-9fe8-4f89-b4b7-f45c103d5a78" xlink:to="loc_us-gaap_SegmentDomain_9fa057cf-fc2d-42f6-b804-76520efa50da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_EstablishedPharmaceuticalProductsMember_87267824-2e63-438e-810c-2249a3bd2975" xlink:href="abt-20220930.xsd#abt_EstablishedPharmaceuticalProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9fa057cf-fc2d-42f6-b804-76520efa50da" xlink:to="loc_abt_EstablishedPharmaceuticalProductsMember_87267824-2e63-438e-810c-2249a3bd2975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_NutritionalProductsMember_b0d9ed9f-53f7-4333-b8ef-33e9d20f3054" xlink:href="abt-20220930.xsd#abt_NutritionalProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9fa057cf-fc2d-42f6-b804-76520efa50da" xlink:to="loc_abt_NutritionalProductsMember_b0d9ed9f-53f7-4333-b8ef-33e9d20f3054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DiagnosticProductsMember_d5ac2c3b-7ae1-4067-b7df-6d4924a74cba" xlink:href="abt-20220930.xsd#abt_DiagnosticProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9fa057cf-fc2d-42f6-b804-76520efa50da" xlink:to="loc_abt_DiagnosticProductsMember_d5ac2c3b-7ae1-4067-b7df-6d4924a74cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_MedicalDevicesMember_c7a4ed16-c949-48b8-802e-7218643d00f9" xlink:href="abt-20220930.xsd#abt_MedicalDevicesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9fa057cf-fc2d-42f6-b804-76520efa50da" xlink:to="loc_abt_MedicalDevicesMember_c7a4ed16-c949-48b8-802e-7218643d00f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bb40e5eb-adfc-4ab4-973c-b1834a51e21d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cfbc05d0-42ec-42ac-b610-9f0256c543ef" xlink:to="loc_srt_StatementGeographicalAxis_bb40e5eb-adfc-4ab4-973c-b1834a51e21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3eacea21-c8f3-42a2-bf0e-f723d1274f78" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_bb40e5eb-adfc-4ab4-973c-b1834a51e21d" xlink:to="loc_srt_SegmentGeographicalDomain_3eacea21-c8f3-42a2-bf0e-f723d1274f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1bf2cfd4-8846-41b0-93d8-670dc5368b7e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3eacea21-c8f3-42a2-bf0e-f723d1274f78" xlink:to="loc_country_US_1bf2cfd4-8846-41b0-93d8-670dc5368b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_001d6f3a-eadc-4eb7-b0ba-e90105aa91ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3eacea21-c8f3-42a2-bf0e-f723d1274f78" xlink:to="loc_us-gaap_NonUsMember_001d6f3a-eadc-4eb7-b0ba-e90105aa91ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a3d2bc63-051a-404d-a1e4-b96afbfef148" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cfbc05d0-42ec-42ac-b610-9f0256c543ef" xlink:to="loc_srt_ConsolidationItemsAxis_a3d2bc63-051a-404d-a1e4-b96afbfef148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1d42c65e-c5ce-49d8-85c3-02e23dfa22d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_a3d2bc63-051a-404d-a1e4-b96afbfef148" xlink:to="loc_srt_ConsolidationItemsDomain_1d42c65e-c5ce-49d8-85c3-02e23dfa22d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_1a752890-eb7e-4b82-8964-b0ddacc8e621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_1d42c65e-c5ce-49d8-85c3-02e23dfa22d1" xlink:to="loc_us-gaap_OperatingSegmentsMember_1a752890-eb7e-4b82-8964-b0ddacc8e621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_f4502b8c-f306-4345-be65-f7ea84a80bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_1d42c65e-c5ce-49d8-85c3-02e23dfa22d1" xlink:to="loc_us-gaap_CorporateNonSegmentMember_f4502b8c-f306-4345-be65-f7ea84a80bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5310fc32-2a10-4c3f-a6e3-c92a6769ce83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cfbc05d0-42ec-42ac-b610-9f0256c543ef" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_5310fc32-2a10-4c3f-a6e3-c92a6769ce83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6c16fca9-7c89-4306-9a0d-0d15ad935264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5310fc32-2a10-4c3f-a6e3-c92a6769ce83" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6c16fca9-7c89-4306-9a0d-0d15ad935264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/RevenueOtherContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#RevenueOtherContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/RevenueOtherContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0f3f2fde-7869-4a34-88d4-32c54051c54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_ContractLiabilitiesRollForward_9888a775-f051-43b0-8511-3b9c7020162b" xlink:href="abt-20220930.xsd#abt_ContractLiabilitiesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0f3f2fde-7869-4a34-88d4-32c54051c54e" xlink:to="loc_abt_ContractLiabilitiesRollForward_9888a775-f051-43b0-8511-3b9c7020162b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c7aa9a34-3d99-4d60-8033-919267389e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_ContractLiabilitiesRollForward_9888a775-f051-43b0-8511-3b9c7020162b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c7aa9a34-3d99-4d60-8033-919267389e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized_7115445d-5059-4502-9cae-4f22e51c7598" xlink:href="abt-20220930.xsd#abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_ContractLiabilitiesRollForward_9888a775-f051-43b0-8511-3b9c7020162b" xlink:to="loc_abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized_7115445d-5059-4502-9cae-4f22e51c7598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_276c4939-ef4d-4b62-9206-3e758e667123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_ContractLiabilitiesRollForward_9888a775-f051-43b0-8511-3b9c7020162b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_276c4939-ef4d-4b62-9206-3e758e667123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_65afad02-35a3-4841-b908-9dd45a8885d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_ContractLiabilitiesRollForward_9888a775-f051-43b0-8511-3b9c7020162b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_65afad02-35a3-4841-b908-9dd45a8885d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#SupplementalFinancialInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract_89bc3a4c-dc07-4dc8-ae4e-e0eb8883df82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementTable_81e512a2-d984-4f81-9229-d898b1a25676" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedCashFlowStatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_89bc3a4c-dc07-4dc8-ae4e-e0eb8883df82" xlink:to="loc_srt_CondensedCashFlowStatementTable_81e512a2-d984-4f81-9229-d898b1a25676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_0e9732d0-8fc5-4ce2-9246-77c0d11b70e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementTable_81e512a2-d984-4f81-9229-d898b1a25676" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_0e9732d0-8fc5-4ce2-9246-77c0d11b70e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_03df9faa-13e7-45d7-847c-e0087a5b168c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_0e9732d0-8fc5-4ce2-9246-77c0d11b70e7" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_03df9faa-13e7-45d7-847c-e0087a5b168c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_3125b154-c096-424a-920d-679620f3b6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_03df9faa-13e7-45d7-847c-e0087a5b168c" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_3125b154-c096-424a-920d-679620f3b6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0f0e1c02-d9ba-4bf5-ae70-7877738396ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementTable_81e512a2-d984-4f81-9229-d898b1a25676" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0f0e1c02-d9ba-4bf5-ae70-7877738396ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e6dc49ba-d945-4edd-8567-7f0bd6544fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0f0e1c02-d9ba-4bf5-ae70-7877738396ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e6dc49ba-d945-4edd-8567-7f0bd6544fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_StJudeMedicalIncMember_7c05919d-f130-4076-bba8-57a01bf09183" xlink:href="abt-20220930.xsd#abt_StJudeMedicalIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e6dc49ba-d945-4edd-8567-7f0bd6544fd8" xlink:to="loc_abt_StJudeMedicalIncMember_7c05919d-f130-4076-bba8-57a01bf09183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_WalkVascularLLCMember_2c1366c1-784d-4d0a-bce6-98ee33bf2767" xlink:href="abt-20220930.xsd#abt_WalkVascularLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e6dc49ba-d945-4edd-8567-7f0bd6544fd8" xlink:to="loc_abt_WalkVascularLLCMember_2c1366c1-784d-4d0a-bce6-98ee33bf2767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_326d421a-f09b-4bc0-96e6-bebdf2cd4ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementTable_81e512a2-d984-4f81-9229-d898b1a25676" xlink:to="loc_us-gaap_InvestmentTypeAxis_326d421a-f09b-4bc0-96e6-bebdf2cd4ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_aa064449-1544-41aa-a638-cb9dd1f364e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_326d421a-f09b-4bc0-96e6-bebdf2cd4ec2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_aa064449-1544-41aa-a638-cb9dd1f364e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_e1d1e880-3a43-41a1-a002-fd0b6c040f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_aa064449-1544-41aa-a638-cb9dd1f364e1" xlink:to="loc_us-gaap_EquitySecuritiesMember_e1d1e880-3a43-41a1-a002-fd0b6c040f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementTable_81e512a2-d984-4f81-9229-d898b1a25676" xlink:to="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_61b11c6f-52a2-4907-983f-156099bcc48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_61b11c6f-52a2-4907-983f-156099bcc48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_0fc9d0cd-196f-48dd-8c24-fd6b9428a285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_0fc9d0cd-196f-48dd-8c24-fd6b9428a285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForOtherTaxes_97ffe7c2-d2e7-4ca9-8a23-06e66ca54288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForOtherTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:to="loc_us-gaap_PaymentsForOtherTaxes_97ffe7c2-d2e7-4ca9-8a23-06e66ca54288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_514f75de-d99a-4191-adba-872a7c911092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesHeldInEmployeeTrust"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:to="loc_us-gaap_CommonStockSharesHeldInEmployeeTrust_514f75de-d99a-4191-adba-872a7c911092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ae3e9502-efb9-43cd-8fe5-e509169c1ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:to="loc_us-gaap_EquityMethodInvestments_ae3e9502-efb9-43cd-8fe5-e509169c1ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_8fbec2a3-5e98-4270-a168-f38db7f9188c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_8fbec2a3-5e98-4270-a168-f38db7f9188c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9c15e868-f63c-4940-8aae-bae9666e2438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_5f547ae5-a570-45cd-aaf8-60829e971855" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9c15e868-f63c-4940-8aae-bae9666e2438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract_1aea7aba-991b-482b-b3bd-5a2c2aef37d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c21457be-4adb-46ee-b3b2-03dcf2f524de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_1aea7aba-991b-482b-b3bd-5a2c2aef37d9" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c21457be-4adb-46ee-b3b2-03dcf2f524de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2b18e785-1f5a-41e3-b399-7940c64e46f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c21457be-4adb-46ee-b3b2-03dcf2f524de" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_2b18e785-1f5a-41e3-b399-7940c64e46f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_0b0f79c4-0e1b-4a74-a22a-daaed741ddd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c21457be-4adb-46ee-b3b2-03dcf2f524de" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_0b0f79c4-0e1b-4a74-a22a-daaed741ddd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_364680a0-7b80-4a25-a324-c8ddbba3a183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c21457be-4adb-46ee-b3b2-03dcf2f524de" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_364680a0-7b80-4a25-a324-c8ddbba3a183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_331f0823-4756-43e6-a205-c9661bac6ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c21457be-4adb-46ee-b3b2-03dcf2f524de" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_331f0823-4756-43e6-a205-c9661bac6ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#SupplementalFinancialInformationInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract_f07f990e-1964-4930-be8e-20d234242af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable_4f79d144-7a53-4bc4-a9d6-10efb6784eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_f07f990e-1964-4930-be8e-20d234242af5" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsTable_4f79d144-7a53-4bc4-a9d6-10efb6784eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_083b5fed-f077-4c5f-9e5b-4d3812b0069a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_4f79d144-7a53-4bc4-a9d6-10efb6784eb9" xlink:to="loc_us-gaap_InvestmentTypeAxis_083b5fed-f077-4c5f-9e5b-4d3812b0069a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_60a1515a-9bd2-4edb-9f2a-ff3c9760ba3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_083b5fed-f077-4c5f-9e5b-4d3812b0069a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_60a1515a-9bd2-4edb-9f2a-ff3c9760ba3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_d253d62d-f1da-4d30-a62d-f1d51508c178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_60a1515a-9bd2-4edb-9f2a-ff3c9760ba3a" xlink:to="loc_us-gaap_EquitySecuritiesMember_d253d62d-f1da-4d30-a62d-f1d51508c178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_765892bb-9c36-4095-bbb1-e9b774a6fc17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_60a1515a-9bd2-4edb-9f2a-ff3c9760ba3a" xlink:to="loc_us-gaap_OtherInvestmentsMember_765892bb-9c36-4095-bbb1-e9b774a6fc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_29ccedf8-fafa-485a-8c78-1c1832633360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_4f79d144-7a53-4bc4-a9d6-10efb6784eb9" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_29ccedf8-fafa-485a-8c78-1c1832633360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_d097fb14-6df9-4533-88a8-50430e44c957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_29ccedf8-fafa-485a-8c78-1c1832633360" xlink:to="loc_us-gaap_LongTermInvestments_d097fb14-6df9-4533-88a8-50430e44c957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#ChangesinAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_1a630df0-79c4-4b46-9b64-b05caacc7795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8c8f9b07-f342-4ced-a150-6f104857dc24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_1a630df0-79c4-4b46-9b64-b05caacc7795" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8c8f9b07-f342-4ced-a150-6f104857dc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d021139c-0b6c-4b5c-abec-1c9c2f7aea2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8c8f9b07-f342-4ced-a150-6f104857dc24" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d021139c-0b6c-4b5c-abec-1c9c2f7aea2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bd0d784c-fbba-4ec0-a411-ca4d841b756d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d021139c-0b6c-4b5c-abec-1c9c2f7aea2a" xlink:to="loc_us-gaap_EquityComponentDomain_bd0d784c-fbba-4ec0-a411-ca4d841b756d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_ebb52b0e-1a24-43e2-bac9-45a7bc67388d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bd0d784c-fbba-4ec0-a411-ca4d841b756d" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_ebb52b0e-1a24-43e2-bac9-45a7bc67388d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_30cfff46-5e70-4dbf-a774-bebeaa8a5ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bd0d784c-fbba-4ec0-a411-ca4d841b756d" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_30cfff46-5e70-4dbf-a774-bebeaa8a5ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_55bd64e5-d6de-44d7-a322-c22dd167c7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bd0d784c-fbba-4ec0-a411-ca4d841b756d" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_55bd64e5-d6de-44d7-a322-c22dd167c7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_354a3a42-1c94-4435-a821-d2454f05728d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8c8f9b07-f342-4ced-a150-6f104857dc24" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_354a3a42-1c94-4435-a821-d2454f05728d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_caf859fe-d8bd-4ed8-a35d-ad538543e6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_354a3a42-1c94-4435-a821-d2454f05728d" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_caf859fe-d8bd-4ed8-a35d-ad538543e6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1cdc32e9-48fa-4208-a2e4-962d6506b9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_caf859fe-d8bd-4ed8-a35d-ad538543e6b7" xlink:to="loc_us-gaap_StockholdersEquity_1cdc32e9-48fa-4208-a2e4-962d6506b9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_02b5c076-dfa5-4c47-97dd-710596af57c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_caf859fe-d8bd-4ed8-a35d-ad538543e6b7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_02b5c076-dfa5-4c47-97dd-710596af57c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_77e1c574-a3e4-401a-a43e-9871467016d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_caf859fe-d8bd-4ed8-a35d-ad538543e6b7" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_77e1c574-a3e4-401a-a43e-9871467016d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2a739ba9-d544-44bb-939b-f8bacd46747a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_caf859fe-d8bd-4ed8-a35d-ad538543e6b7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2a739ba9-d544-44bb-939b-f8bacd46747a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1c18fedf-bbdd-4fc9-974b-2283683c4e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_caf859fe-d8bd-4ed8-a35d-ad538543e6b7" xlink:to="loc_us-gaap_StockholdersEquity_1c18fedf-bbdd-4fc9-974b-2283683c4e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#GoodwillandIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_13335adf-d5aa-493a-aa28-c5a72796ec77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_ScheduleOfGoodwillAndIntangibleAssetsTable_3a6dd95c-e097-4ed4-909e-c987b6d04494" xlink:href="abt-20220930.xsd#abt_ScheduleOfGoodwillAndIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_13335adf-d5aa-493a-aa28-c5a72796ec77" xlink:to="loc_abt_ScheduleOfGoodwillAndIntangibleAssetsTable_3a6dd95c-e097-4ed4-909e-c987b6d04494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d210362a-11b1-4e34-87e3-8300e1e3f142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_ScheduleOfGoodwillAndIntangibleAssetsTable_3a6dd95c-e097-4ed4-909e-c987b6d04494" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d210362a-11b1-4e34-87e3-8300e1e3f142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d98e3013-c2f9-42d2-8745-8162f87526ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d210362a-11b1-4e34-87e3-8300e1e3f142" xlink:to="loc_us-gaap_SegmentDomain_d98e3013-c2f9-42d2-8745-8162f87526ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_EstablishedPharmaceuticalProductsMember_e14aeddf-3a68-484f-83aa-26fb4ec4f052" xlink:href="abt-20220930.xsd#abt_EstablishedPharmaceuticalProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d98e3013-c2f9-42d2-8745-8162f87526ca" xlink:to="loc_abt_EstablishedPharmaceuticalProductsMember_e14aeddf-3a68-484f-83aa-26fb4ec4f052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_NutritionalProductsMember_db69ce08-30da-4b0f-9148-f0468980395b" xlink:href="abt-20220930.xsd#abt_NutritionalProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d98e3013-c2f9-42d2-8745-8162f87526ca" xlink:to="loc_abt_NutritionalProductsMember_db69ce08-30da-4b0f-9148-f0468980395b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DiagnosticProductsMember_d5fd036d-41e1-46d2-b129-32fc8a098156" xlink:href="abt-20220930.xsd#abt_DiagnosticProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d98e3013-c2f9-42d2-8745-8162f87526ca" xlink:to="loc_abt_DiagnosticProductsMember_d5fd036d-41e1-46d2-b129-32fc8a098156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_MedicalDevicesMember_6d3941f3-c89c-4c4f-86c9-962da3414f24" xlink:href="abt-20220930.xsd#abt_MedicalDevicesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d98e3013-c2f9-42d2-8745-8162f87526ca" xlink:to="loc_abt_MedicalDevicesMember_6d3941f3-c89c-4c4f-86c9-962da3414f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:href="abt-20220930.xsd#abt_GoodwillAndIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_ScheduleOfGoodwillAndIntangibleAssetsTable_3a6dd95c-e097-4ed4-909e-c987b6d04494" xlink:to="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_afc1c6f2-803b-4160-8127-3278300f4f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_Goodwill_afc1c6f2-803b-4160-8127-3278300f4f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_4c6300d8-41fb-43fd-a645-878960e68a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_4c6300d8-41fb-43fd-a645-878960e68a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4dd28b9f-50c7-46c9-a9d2-eb4dbfeb8afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4dd28b9f-50c7-46c9-a9d2-eb4dbfeb8afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f5db1b96-ea49-46f1-8b82-d03f4c90ec3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f5db1b96-ea49-46f1-8b82-d03f4c90ec3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_598b7434-4162-4675-932d-e6db807d6573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_598b7434-4162-4675-932d-e6db807d6573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_9b4d6cd6-01db-4cb8-be27-d149c88da2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_9b4d6cd6-01db-4cb8-be27-d149c88da2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b42b79f3-02bf-40ab-966e-b7a9ab98375b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b42b79f3-02bf-40ab-966e-b7a9ab98375b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_98d15663-0b31-471a-a22d-032b6e267549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_98d15663-0b31-471a-a22d-032b6e267549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2a9da0e5-ba1d-485d-8121-ea8a1c804cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2a9da0e5-ba1d-485d-8121-ea8a1c804cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8f659890-2002-4ee1-8bee-0e3da799abc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8f659890-2002-4ee1-8bee-0e3da799abc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4b7e6c7f-cf8a-4fa1-a9f9-94613c66ab45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4b7e6c7f-cf8a-4fa1-a9f9-94613c66ab45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a4ade7aa-6bf0-415c-bacd-bbd8dee4fd68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a4ade7aa-6bf0-415c-bacd-bbd8dee4fd68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3d8db3d2-9b84-4e3a-9afe-b5109542260c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_GoodwillAndIntangibleAssetsLineItems_ca7c4b67-e85b-41a9-a577-695e870d8e61" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3d8db3d2-9b84-4e3a-9afe-b5109542260c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/RestructuringPlansNarrativeDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#RestructuringPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/RestructuringPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_63e40ba3-a61b-4626-871c-7fd31cef9619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e65b8812-c850-4cdd-97c0-b24beba8eaed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_63e40ba3-a61b-4626-871c-7fd31cef9619" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e65b8812-c850-4cdd-97c0-b24beba8eaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_3bfd26ab-38a7-4500-b6b9-b1ca7e9b8b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e65b8812-c850-4cdd-97c0-b24beba8eaed" xlink:to="loc_us-gaap_RestructuringPlanAxis_3bfd26ab-38a7-4500-b6b9-b1ca7e9b8b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_07c6d3c2-7852-4960-bdb7-5ce6ffe48eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_3bfd26ab-38a7-4500-b6b9-b1ca7e9b8b0a" xlink:to="loc_us-gaap_RestructuringPlanDomain_07c6d3c2-7852-4960-bdb7-5ce6ffe48eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_COVID19TestManufacturingNetworkRestructuringPlanMember_fdecf0a4-6bd5-407f-a79f-8539947078b5" xlink:href="abt-20220930.xsd#abt_COVID19TestManufacturingNetworkRestructuringPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_07c6d3c2-7852-4960-bdb7-5ce6ffe48eff" xlink:to="loc_abt_COVID19TestManufacturingNetworkRestructuringPlanMember_fdecf0a4-6bd5-407f-a79f-8539947078b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember_9a848d6e-e0c6-4154-a7e4-4a3d7bfcbfc9" xlink:href="abt-20220930.xsd#abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_07c6d3c2-7852-4960-bdb7-5ce6ffe48eff" xlink:to="loc_abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember_9a848d6e-e0c6-4154-a7e4-4a3d7bfcbfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_af03a33d-8f84-4791-ab36-5f799f32e6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e65b8812-c850-4cdd-97c0-b24beba8eaed" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_af03a33d-8f84-4791-ab36-5f799f32e6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4d6f0361-25bf-4691-9ef1-44d1a3a7bbec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_af03a33d-8f84-4791-ab36-5f799f32e6ac" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4d6f0361-25bf-4691-9ef1-44d1a3a7bbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_FixedAssetWriteDownsMember_303ffafe-d8f2-484e-ba3e-328bdaff5d7b" xlink:href="abt-20220930.xsd#abt_FixedAssetWriteDownsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4d6f0361-25bf-4691-9ef1-44d1a3a7bbec" xlink:to="loc_abt_FixedAssetWriteDownsMember_303ffafe-d8f2-484e-ba3e-328bdaff5d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_InventoryRelatedChargesMember_6e9d76bd-649b-4587-abfb-7afd0940e89f" xlink:href="abt-20220930.xsd#abt_InventoryRelatedChargesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4d6f0361-25bf-4691-9ef1-44d1a3a7bbec" xlink:to="loc_abt_InventoryRelatedChargesMember_6e9d76bd-649b-4587-abfb-7afd0940e89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_OtherExitCostsMember_8528ed9c-534e-4ce4-a421-ad4aead21e45" xlink:href="abt-20220930.xsd#abt_OtherExitCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4d6f0361-25bf-4691-9ef1-44d1a3a7bbec" xlink:to="loc_abt_OtherExitCostsMember_8528ed9c-534e-4ce4-a421-ad4aead21e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_eca519ab-869d-4974-bbed-bfda700c9864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e65b8812-c850-4cdd-97c0-b24beba8eaed" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_eca519ab-869d-4974-bbed-bfda700c9864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cca6422d-09ba-4b23-8a2f-125f3797d5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_eca519ab-869d-4974-bbed-bfda700c9864" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cca6422d-09ba-4b23-8a2f-125f3797d5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_CostOfGoodsAndServicesSoldMember_082ebe0a-c3a7-4d9d-8123-32316396d6d7" xlink:href="abt-20220930.xsd#abt_CostOfGoodsAndServicesSoldMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cca6422d-09ba-4b23-8a2f-125f3797d5c2" xlink:to="loc_abt_CostOfGoodsAndServicesSoldMember_082ebe0a-c3a7-4d9d-8123-32316396d6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_10fb1d85-2a5b-42b2-9c91-d2e2e4c41a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cca6422d-09ba-4b23-8a2f-125f3797d5c2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_10fb1d85-2a5b-42b2-9c91-d2e2e4c41a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f3cf13cf-d13f-4287-8f16-7a9ef2979009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cca6422d-09ba-4b23-8a2f-125f3797d5c2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f3cf13cf-d13f-4287-8f16-7a9ef2979009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_20545a88-860c-4f02-a04f-1d98e7e1a9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e65b8812-c850-4cdd-97c0-b24beba8eaed" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_20545a88-860c-4f02-a04f-1d98e7e1a9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_5430328b-a0ed-4ca7-bfe5-d276997febf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_20545a88-860c-4f02-a04f-1d98e7e1a9e7" xlink:to="loc_us-gaap_RestructuringCharges_5430328b-a0ed-4ca7-bfe5-d276997febf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_InventoryNoNetRealizableValueSold_2071e326-7ad9-4c6e-8123-68d648cb86e7" xlink:href="abt-20220930.xsd#abt_InventoryNoNetRealizableValueSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_20545a88-860c-4f02-a04f-1d98e7e1a9e7" xlink:to="loc_abt_InventoryNoNetRealizableValueSold_2071e326-7ad9-4c6e-8123-68d648cb86e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_183e3ae9-a2ce-4526-bd9b-ee1b2a5dc052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_20545a88-860c-4f02-a04f-1d98e7e1a9e7" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_183e3ae9-a2ce-4526-bd9b-ee1b2a5dc052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_09c06e64-2819-4d10-8a48-3c1019195cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_20545a88-860c-4f02-a04f-1d98e7e1a9e7" xlink:to="loc_us-gaap_SeveranceCosts1_09c06e64-2819-4d10-8a48-3c1019195cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b7e1e633-a9a9-4c9f-bc7b-9f3fd87ef31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_141583d2-8129-4135-9fd2-44bd3ff019e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b7e1e633-a9a9-4c9f-bc7b-9f3fd87ef31c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_141583d2-8129-4135-9fd2-44bd3ff019e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_dfe7b334-d27d-4996-9bc0-eecaefb80c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_141583d2-8129-4135-9fd2-44bd3ff019e9" xlink:to="loc_us-gaap_RestructuringPlanAxis_dfe7b334-d27d-4996-9bc0-eecaefb80c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_1f7c39f7-bb9f-4534-b28d-be843d162260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_dfe7b334-d27d-4996-9bc0-eecaefb80c3f" xlink:to="loc_us-gaap_RestructuringPlanDomain_1f7c39f7-bb9f-4534-b28d-be843d162260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_COVID19TestManufacturingNetworkRestructuringPlanMember_14a89900-6774-46d5-a87e-2a2387057ef5" xlink:href="abt-20220930.xsd#abt_COVID19TestManufacturingNetworkRestructuringPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_1f7c39f7-bb9f-4534-b28d-be843d162260" xlink:to="loc_abt_COVID19TestManufacturingNetworkRestructuringPlanMember_14a89900-6774-46d5-a87e-2a2387057ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember_c79de3da-6d19-485f-90c6-49ef36290cb7" xlink:href="abt-20220930.xsd#abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_1f7c39f7-bb9f-4534-b28d-be843d162260" xlink:to="loc_abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember_c79de3da-6d19-485f-90c6-49ef36290cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_d59cad8e-e46c-44b5-85bf-a530a546b187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_141583d2-8129-4135-9fd2-44bd3ff019e9" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_d59cad8e-e46c-44b5-85bf-a530a546b187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_adfee025-e71f-4766-a626-6579d268162f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d59cad8e-e46c-44b5-85bf-a530a546b187" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_adfee025-e71f-4766-a626-6579d268162f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_InventoryRelatedChargesMember_584ce21a-3b0d-45e8-bdda-4e3c42d2433b" xlink:href="abt-20220930.xsd#abt_InventoryRelatedChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_adfee025-e71f-4766-a626-6579d268162f" xlink:to="loc_abt_InventoryRelatedChargesMember_584ce21a-3b0d-45e8-bdda-4e3c42d2433b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_FixedAssetWriteDownsMember_8805ba8e-1408-4102-8267-ffb616fc9bb6" xlink:href="abt-20220930.xsd#abt_FixedAssetWriteDownsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_adfee025-e71f-4766-a626-6579d268162f" xlink:to="loc_abt_FixedAssetWriteDownsMember_8805ba8e-1408-4102-8267-ffb616fc9bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_OtherExitCostsMember_173e55d2-229b-4ab2-ad06-9c52ae9e4631" xlink:href="abt-20220930.xsd#abt_OtherExitCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_adfee025-e71f-4766-a626-6579d268162f" xlink:to="loc_abt_OtherExitCostsMember_173e55d2-229b-4ab2-ad06-9c52ae9e4631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_644c1e6e-83de-45a3-99fc-5b7bca1e00d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_141583d2-8129-4135-9fd2-44bd3ff019e9" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_644c1e6e-83de-45a3-99fc-5b7bca1e00d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ff17816b-e4cc-4270-a532-85d2e9f6250e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_644c1e6e-83de-45a3-99fc-5b7bca1e00d2" xlink:to="loc_us-gaap_RestructuringCharges_ff17816b-e4cc-4270-a532-85d2e9f6250e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_997a12ce-ef59-4b6a-8f27-40c251986324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_644c1e6e-83de-45a3-99fc-5b7bca1e00d2" xlink:to="loc_us-gaap_PaymentsForRestructuring_997a12ce-ef59-4b6a-8f27-40c251986324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_5dce9d59-b347-4ec2-8b36-5c8a76c13536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_644c1e6e-83de-45a3-99fc-5b7bca1e00d2" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_5dce9d59-b347-4ec2-8b36-5c8a76c13536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_82a6e2ca-b3e2-4c7c-9dbb-0ebd14f058ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_644c1e6e-83de-45a3-99fc-5b7bca1e00d2" xlink:to="loc_us-gaap_RestructuringReserveRollForward_82a6e2ca-b3e2-4c7c-9dbb-0ebd14f058ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_47b4c750-57dc-4998-bce9-03f9a9a7bee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_82a6e2ca-b3e2-4c7c-9dbb-0ebd14f058ee" xlink:to="loc_us-gaap_RestructuringReserve_47b4c750-57dc-4998-bce9-03f9a9a7bee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments_ceb71459-5b7d-4748-89a7-91a0a0af4eb4" xlink:href="abt-20220930.xsd#abt_RestructuringReservePeriodCashSettledAndOtherAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_82a6e2ca-b3e2-4c7c-9dbb-0ebd14f058ee" xlink:to="loc_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments_ceb71459-5b7d-4748-89a7-91a0a0af4eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_4a8181d7-d0fd-4ac6-8bc9-cc3efdd9138b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_82a6e2ca-b3e2-4c7c-9dbb-0ebd14f058ee" xlink:to="loc_us-gaap_RestructuringReserve_4a8181d7-d0fd-4ac6-8bc9-cc3efdd9138b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#IncentiveStockProgramNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9352303-6c4f-4171-8b6d-908444b6b881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df155319-b6ad-4213-b6ff-98be767525cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9352303-6c4f-4171-8b6d-908444b6b881" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df155319-b6ad-4213-b6ff-98be767525cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bfb7a94d-1b59-4a86-b5f4-d8b598e1c046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df155319-b6ad-4213-b6ff-98be767525cb" xlink:to="loc_us-gaap_AwardTypeAxis_bfb7a94d-1b59-4a86-b5f4-d8b598e1c046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f11cbbe-9f91-49d5-87b9-93910b8ec8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bfb7a94d-1b59-4a86-b5f4-d8b598e1c046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f11cbbe-9f91-49d5-87b9-93910b8ec8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_af89c9ac-5ba0-4f81-ba47-44561bc84d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f11cbbe-9f91-49d5-87b9-93910b8ec8e4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_af89c9ac-5ba0-4f81-ba47-44561bc84d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_RestrictedStockAwardsMember_7f1776ac-f715-42b1-b445-fb48fe810927" xlink:href="abt-20220930.xsd#abt_RestrictedStockAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f11cbbe-9f91-49d5-87b9-93910b8ec8e4" xlink:to="loc_abt_RestrictedStockAwardsMember_7f1776ac-f715-42b1-b445-fb48fe810927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_125cd644-a2d5-485d-bb9a-a3102b48b5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f11cbbe-9f91-49d5-87b9-93910b8ec8e4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_125cd644-a2d5-485d-bb9a-a3102b48b5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97bea178-913d-4957-93ce-1af67d160bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df155319-b6ad-4213-b6ff-98be767525cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97bea178-913d-4957-93ce-1af67d160bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c6674042-2e61-458c-b015-bc24181da155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97bea178-913d-4957-93ce-1af67d160bb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c6674042-2e61-458c-b015-bc24181da155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1a8d9cbf-f809-409d-a457-f71d67878e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97bea178-913d-4957-93ce-1af67d160bb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1a8d9cbf-f809-409d-a457-f71d67878e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_0e00f7d8-fbb2-4a70-b704-c42885acf549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97bea178-913d-4957-93ce-1af67d160bb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_0e00f7d8-fbb2-4a70-b704-c42885acf549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8a51a12a-4ca2-49f1-8335-4fcf1df0dbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97bea178-913d-4957-93ce-1af67d160bb4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8a51a12a-4ca2-49f1-8335-4fcf1df0dbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7a616e5c-1e28-4cba-a155-ea607bda7059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97bea178-913d-4957-93ce-1af67d160bb4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7a616e5c-1e28-4cba-a155-ea607bda7059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5c0bc825-64ac-41ec-8d31-72d9fd47c073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97bea178-913d-4957-93ce-1af67d160bb4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5c0bc825-64ac-41ec-8d31-72d9fd47c073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/IncentiveStockProgramOptionsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#IncentiveStockProgramOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/IncentiveStockProgramOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a26ae87-d40f-4b98-b15a-f0d95d563205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b78aed4a-061a-4757-b928-d7d36a3257a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a26ae87-d40f-4b98-b15a-f0d95d563205" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b78aed4a-061a-4757-b928-d7d36a3257a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9725c538-f132-4577-a5ac-7c380974332a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b78aed4a-061a-4757-b928-d7d36a3257a2" xlink:to="loc_us-gaap_AwardTypeAxis_9725c538-f132-4577-a5ac-7c380974332a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ff2528a1-816d-4903-b96e-249e2a0d6c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9725c538-f132-4577-a5ac-7c380974332a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ff2528a1-816d-4903-b96e-249e2a0d6c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_80e1a4cb-0a00-47a2-8d0f-8b380c6ccbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ff2528a1-816d-4903-b96e-249e2a0d6c7e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_80e1a4cb-0a00-47a2-8d0f-8b380c6ccbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b78aed4a-061a-4757-b928-d7d36a3257a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_838a9a1e-48a6-4cba-a5ed-9700d0a150c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_838a9a1e-48a6-4cba-a5ed-9700d0a150c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_169288a3-12a5-4426-bd5d-bedd08d7a763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_169288a3-12a5-4426-bd5d-bedd08d7a763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_94af5bee-039c-433a-b47b-7f22299f9707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_94af5bee-039c-433a-b47b-7f22299f9707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ed7db616-fe47-495f-9a04-e7dfa686aa28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ed7db616-fe47-495f-9a04-e7dfa686aa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1a8c9b24-11ac-406c-994a-bbc448053be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1a8c9b24-11ac-406c-994a-bbc448053be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c6f627e8-7bf1-4d7f-985d-036d38e7cc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c6f627e8-7bf1-4d7f-985d-036d38e7cc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6f652d03-26d0-482e-80b9-7656906b04f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6f652d03-26d0-482e-80b9-7656906b04f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0656571b-28cd-4e56-9a97-1048d7d5c960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfa90bde-dd74-4260-ac45-5bf60b937e0a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0656571b-28cd-4e56-9a97-1048d7d5c960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/DebtandLinesofCreditDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#DebtandLinesofCreditDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/DebtandLinesofCreditDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b73e954b-b78a-481b-802a-f0b73fd4ce6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6e24df13-954c-4ced-b6ca-4331b76a27fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b73e954b-b78a-481b-802a-f0b73fd4ce6c" xlink:to="loc_us-gaap_DebtInstrumentTable_6e24df13-954c-4ced-b6ca-4331b76a27fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_26abe643-278d-4405-86ee-dbb2c2881fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6e24df13-954c-4ced-b6ca-4331b76a27fe" xlink:to="loc_us-gaap_DebtInstrumentAxis_26abe643-278d-4405-86ee-dbb2c2881fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_db36b626-31e8-4ac1-9d2b-f7734fdb5187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_26abe643-278d-4405-86ee-dbb2c2881fe6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_db36b626-31e8-4ac1-9d2b-f7734fdb5187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_A255LongTermNotesDue2022Member_20b561af-4620-4816-a8f7-0937231804bc" xlink:href="abt-20220930.xsd#abt_A255LongTermNotesDue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_db36b626-31e8-4ac1-9d2b-f7734fdb5187" xlink:to="loc_abt_A255LongTermNotesDue2022Member_20b561af-4620-4816-a8f7-0937231804bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_82c619fc-5552-4261-b752-974e3ad1deda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6e24df13-954c-4ced-b6ca-4331b76a27fe" xlink:to="loc_us-gaap_DebtInstrumentLineItems_82c619fc-5552-4261-b752-974e3ad1deda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_d5a9b25f-5531-44b6-8c3b-94598ffc7d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82c619fc-5552-4261-b752-974e3ad1deda" xlink:to="loc_us-gaap_RepaymentsOfDebt_d5a9b25f-5531-44b6-8c3b-94598ffc7d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_937d3443-fdf6-4972-8c6f-96087be9c783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82c619fc-5552-4261-b752-974e3ad1deda" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_937d3443-fdf6-4972-8c6f-96087be9c783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d06a29ba-2a79-4633-ac2c-d391334a5c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_bba82584-15d7-42c2-ad89-66cb63170bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d06a29ba-2a79-4633-ac2c-d391334a5c53" xlink:to="loc_us-gaap_DerivativeTable_bba82584-15d7-42c2-ad89-66cb63170bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ea3c1e58-a512-4e3a-8757-f15d151a404a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_bba82584-15d7-42c2-ad89-66cb63170bbd" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ea3c1e58-a512-4e3a-8757-f15d151a404a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4fab381d-d42b-43cc-8211-9194ae987952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ea3c1e58-a512-4e3a-8757-f15d151a404a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4fab381d-d42b-43cc-8211-9194ae987952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_27b3c6c7-9405-4a80-bcac-43513b2e18c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4fab381d-d42b-43cc-8211-9194ae987952" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_27b3c6c7-9405-4a80-bcac-43513b2e18c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b460878e-8552-44a5-bef1-79403867d784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4fab381d-d42b-43cc-8211-9194ae987952" xlink:to="loc_us-gaap_InterestRateSwapMember_b460878e-8552-44a5-bef1-79403867d784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_142db0c0-7115-471b-85ee-f16bf69b39bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_bba82584-15d7-42c2-ad89-66cb63170bbd" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_142db0c0-7115-471b-85ee-f16bf69b39bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e4ad1fbd-e86b-4987-aa47-bbdac10f5296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_142db0c0-7115-471b-85ee-f16bf69b39bf" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e4ad1fbd-e86b-4987-aa47-bbdac10f5296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_9f015e83-425a-44aa-93f4-f77a7b98ff6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e4ad1fbd-e86b-4987-aa47-bbdac10f5296" xlink:to="loc_us-gaap_CashFlowHedgingMember_9f015e83-425a-44aa-93f4-f77a7b98ff6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_201ebf37-288c-4a0e-b4b0-c8d2f6135eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e4ad1fbd-e86b-4987-aa47-bbdac10f5296" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_201ebf37-288c-4a0e-b4b0-c8d2f6135eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_8d04d342-8ced-4631-8934-9aabc8a77d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e4ad1fbd-e86b-4987-aa47-bbdac10f5296" xlink:to="loc_us-gaap_FairValueHedgingMember_8d04d342-8ced-4631-8934-9aabc8a77d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a7339e9f-f934-4cc8-987d-b0d219a830de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_bba82584-15d7-42c2-ad89-66cb63170bbd" xlink:to="loc_us-gaap_HedgingDesignationAxis_a7339e9f-f934-4cc8-987d-b0d219a830de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_5ab47c22-6fd2-4c49-9309-ecec6e90f364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_a7339e9f-f934-4cc8-987d-b0d219a830de" xlink:to="loc_us-gaap_HedgingDesignationDomain_5ab47c22-6fd2-4c49-9309-ecec6e90f364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_62b96b36-a896-42a8-a413-def97d36aa2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_5ab47c22-6fd2-4c49-9309-ecec6e90f364" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_62b96b36-a896-42a8-a413-def97d36aa2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_30d35990-35f4-4360-94ff-813de5588d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_5ab47c22-6fd2-4c49-9309-ecec6e90f364" xlink:to="loc_us-gaap_NondesignatedMember_30d35990-35f4-4360-94ff-813de5588d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6e61cdd6-ba4e-4cd0-babc-ee88a0017687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_bba82584-15d7-42c2-ad89-66cb63170bbd" xlink:to="loc_us-gaap_DebtInstrumentAxis_6e61cdd6-ba4e-4cd0-babc-ee88a0017687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3b03253e-2f62-465e-b7ef-b182630ed12e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6e61cdd6-ba4e-4cd0-babc-ee88a0017687" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3b03253e-2f62-465e-b7ef-b182630ed12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_YenDenominatedLongTermDebtMember_c9bc2b56-7b24-4f27-8556-a6e0e2bb561b" xlink:href="abt-20220930.xsd#abt_YenDenominatedLongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3b03253e-2f62-465e-b7ef-b182630ed12e" xlink:to="loc_abt_YenDenominatedLongTermDebtMember_c9bc2b56-7b24-4f27-8556-a6e0e2bb561b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_7c572c86-f79a-42a0-be8c-3a680a87f619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_bba82584-15d7-42c2-ad89-66cb63170bbd" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_7c572c86-f79a-42a0-be8c-3a680a87f619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_aebef581-ce6f-4c60-9eaa-7ed085ea18ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7c572c86-f79a-42a0-be8c-3a680a87f619" xlink:to="loc_us-gaap_DerivativeNotionalAmount_aebef581-ce6f-4c60-9eaa-7ed085ea18ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_MinimumLengthOfTimeHedgedInCashFlowHedge_831e902e-18eb-4f14-a7aa-4f19b2625827" xlink:href="abt-20220930.xsd#abt_MinimumLengthOfTimeHedgedInCashFlowHedge"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7c572c86-f79a-42a0-be8c-3a680a87f619" xlink:to="loc_abt_MinimumLengthOfTimeHedgedInCashFlowHedge_831e902e-18eb-4f14-a7aa-4f19b2625827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_b0902bf0-ff88-4d82-99db-51f15ca0b3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7c572c86-f79a-42a0-be8c-3a680a87f619" xlink:to="loc_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1_b0902bf0-ff88-4d82-99db-51f15ca0b3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_3ad9e8b0-8cbd-4161-bc2b-9c98678bb9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7c572c86-f79a-42a0-be8c-3a680a87f619" xlink:to="loc_us-gaap_DebtInstrumentTerm_3ad9e8b0-8cbd-4161-bc2b-9c98678bb9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a7c453a8-85aa-4d2c-a8b3-fbb1f1395abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7c572c86-f79a-42a0-be8c-3a680a87f619" xlink:to="loc_us-gaap_LongTermDebt_a7c453a8-85aa-4d2c-a8b3-fbb1f1395abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_fcb242b9-c271-49d1-b7aa-305f54b2da58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7c572c86-f79a-42a0-be8c-3a680a87f619" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_fcb242b9-c271-49d1-b7aa-305f54b2da58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_562a0951-19f2-4b41-839f-20a3345d55c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_23ab309f-906d-4494-a8b2-08cd0ab5e6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_562a0951-19f2-4b41-839f-20a3345d55c0" xlink:to="loc_us-gaap_DerivativeTable_23ab309f-906d-4494-a8b2-08cd0ab5e6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ae75398e-2b72-4bb9-8e1d-bdeb006d93f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_23ab309f-906d-4494-a8b2-08cd0ab5e6ad" xlink:to="loc_us-gaap_HedgingDesignationAxis_ae75398e-2b72-4bb9-8e1d-bdeb006d93f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b636f9fc-6378-4aeb-bdfa-3729828eaa07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_ae75398e-2b72-4bb9-8e1d-bdeb006d93f0" xlink:to="loc_us-gaap_HedgingDesignationDomain_b636f9fc-6378-4aeb-bdfa-3729828eaa07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_c5422344-2744-4322-834b-f567ea1aeef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_b636f9fc-6378-4aeb-bdfa-3729828eaa07" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_c5422344-2744-4322-834b-f567ea1aeef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_bbaf2c21-6e53-4db7-a530-ac1e7cb23e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_b636f9fc-6378-4aeb-bdfa-3729828eaa07" xlink:to="loc_us-gaap_NondesignatedMember_bbaf2c21-6e53-4db7-a530-ac1e7cb23e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_985956e1-fef3-44f0-aa5f-fd189673f87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_23ab309f-906d-4494-a8b2-08cd0ab5e6ad" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_985956e1-fef3-44f0-aa5f-fd189673f87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_707dc1c6-551c-4e45-9736-d326e1ffda16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_985956e1-fef3-44f0-aa5f-fd189673f87d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_707dc1c6-551c-4e45-9736-d326e1ffda16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_6e76566a-9678-4312-9d90-b044f83f8bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_707dc1c6-551c-4e45-9736-d326e1ffda16" xlink:to="loc_us-gaap_InterestRateSwapMember_6e76566a-9678-4312-9d90-b044f83f8bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_d00e5702-8e9a-4623-9663-35824228da71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_707dc1c6-551c-4e45-9736-d326e1ffda16" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_d00e5702-8e9a-4623-9663-35824228da71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtMember_39ecee41-25b0-4b0b-8f86-76619e57cecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_707dc1c6-551c-4e45-9736-d326e1ffda16" xlink:to="loc_us-gaap_DebtMember_39ecee41-25b0-4b0b-8f86-76619e57cecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_cd07d149-7db1-4984-be9e-b12f00009fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_23ab309f-906d-4494-a8b2-08cd0ab5e6ad" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_cd07d149-7db1-4984-be9e-b12f00009fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c44c5a15-9e32-4091-a041-8dd6a556d3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cd07d149-7db1-4984-be9e-b12f00009fff" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c44c5a15-9e32-4091-a041-8dd6a556d3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DeferredIncomeTaxesAndOtherAssetsMember_0925834b-205a-4972-8087-485cd07b11ae" xlink:href="abt-20220930.xsd#abt_DeferredIncomeTaxesAndOtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c44c5a15-9e32-4091-a041-8dd6a556d3b2" xlink:to="loc_abt_DeferredIncomeTaxesAndOtherAssetsMember_0925834b-205a-4972-8087-485cd07b11ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PrepaidExpensesAndOtherReceivablesMember_db4ffd22-465e-4fde-ac8b-d39ccf1bf484" xlink:href="abt-20220930.xsd#abt_PrepaidExpensesAndOtherReceivablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c44c5a15-9e32-4091-a041-8dd6a556d3b2" xlink:to="loc_abt_PrepaidExpensesAndOtherReceivablesMember_db4ffd22-465e-4fde-ac8b-d39ccf1bf484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember_ba721dfd-8f77-48f5-b17a-8ee32c78c5c3" xlink:href="abt-20220930.xsd#abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c44c5a15-9e32-4091-a041-8dd6a556d3b2" xlink:to="loc_abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember_ba721dfd-8f77-48f5-b17a-8ee32c78c5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_ef3b5fa6-390c-4d15-aa8e-4527e5ce9281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c44c5a15-9e32-4091-a041-8dd6a556d3b2" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_ef3b5fa6-390c-4d15-aa8e-4527e5ce9281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_d3907809-80ab-497e-92b9-ff118bbd513c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c44c5a15-9e32-4091-a041-8dd6a556d3b2" xlink:to="loc_us-gaap_LongTermDebtMember_d3907809-80ab-497e-92b9-ff118bbd513c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_dd25c663-c904-49d3-ade2-cb69d0f713c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_23ab309f-906d-4494-a8b2-08cd0ab5e6ad" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_dd25c663-c904-49d3-ade2-cb69d0f713c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e6e66180-4518-4e5c-b635-4b3c39b5e025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_dd25c663-c904-49d3-ade2-cb69d0f713c3" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e6e66180-4518-4e5c-b635-4b3c39b5e025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_e0e2891e-6729-4b86-9b4b-2c233b9242ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e6e66180-4518-4e5c-b635-4b3c39b5e025" xlink:to="loc_us-gaap_FairValueHedgingMember_e0e2891e-6729-4b86-9b4b-2c233b9242ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_03aa6d2f-6d15-4cc6-b3fa-478c81596d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e6e66180-4518-4e5c-b635-4b3c39b5e025" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_03aa6d2f-6d15-4cc6-b3fa-478c81596d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_970587b9-576a-42bb-8512-48194323dd99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_23ab309f-906d-4494-a8b2-08cd0ab5e6ad" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_970587b9-576a-42bb-8512-48194323dd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c0cb0bd7-bfa8-4fdf-85d8-ffffe853b2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_970587b9-576a-42bb-8512-48194323dd99" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c0cb0bd7-bfa8-4fdf-85d8-ffffe853b2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a789b64a-a82f-4231-b955-95d68fbe024d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_970587b9-576a-42bb-8512-48194323dd99" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a789b64a-a82f-4231-b955-95d68fbe024d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b2abb3dd-f505-4f13-be8b-6e9559524d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2fc7f8db-0b93-4e29-a226-9eb3358de35c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b2abb3dd-f505-4f13-be8b-6e9559524d8a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2fc7f8db-0b93-4e29-a226-9eb3358de35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_45b3477f-8fe3-47ae-9c06-0a80e2937d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2fc7f8db-0b93-4e29-a226-9eb3358de35c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_45b3477f-8fe3-47ae-9c06-0a80e2937d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d7b3a331-cb73-4d31-a96a-10e3d2fbe189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_45b3477f-8fe3-47ae-9c06-0a80e2937d19" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d7b3a331-cb73-4d31-a96a-10e3d2fbe189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_07efd7cc-cd0f-41c3-a0eb-076747abaa3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d7b3a331-cb73-4d31-a96a-10e3d2fbe189" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_07efd7cc-cd0f-41c3-a0eb-076747abaa3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtMember_24eb8ed3-693d-46e6-a522-c626aab2a2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d7b3a331-cb73-4d31-a96a-10e3d2fbe189" xlink:to="loc_us-gaap_DebtMember_24eb8ed3-693d-46e6-a522-c626aab2a2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_77728b23-dc6c-4822-b301-b10b940e229c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d7b3a331-cb73-4d31-a96a-10e3d2fbe189" xlink:to="loc_us-gaap_InterestRateSwapMember_77728b23-dc6c-4822-b301-b10b940e229c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_812c77dc-e875-420f-b1b1-92e9eaba8f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2fc7f8db-0b93-4e29-a226-9eb3358de35c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_812c77dc-e875-420f-b1b1-92e9eaba8f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_a887305b-0043-4455-9309-85069584af03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_812c77dc-e875-420f-b1b1-92e9eaba8f77" xlink:to="loc_us-gaap_HedgingRelationshipDomain_a887305b-0043-4455-9309-85069584af03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_94ea5fa0-2ff4-43bd-8901-894a55c7f635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a887305b-0043-4455-9309-85069584af03" xlink:to="loc_us-gaap_CashFlowHedgingMember_94ea5fa0-2ff4-43bd-8901-894a55c7f635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_8bfbfbba-9e8d-413d-a2f7-1d2992dd3d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a887305b-0043-4455-9309-85069584af03" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_8bfbfbba-9e8d-413d-a2f7-1d2992dd3d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_44e5d313-9368-4716-ace9-e88041b10821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a887305b-0043-4455-9309-85069584af03" xlink:to="loc_us-gaap_FairValueHedgingMember_44e5d313-9368-4716-ace9-e88041b10821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_5e048cdf-51f4-4b1b-aa50-42e09124ed0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2fc7f8db-0b93-4e29-a226-9eb3358de35c" xlink:to="loc_us-gaap_HedgingDesignationAxis_5e048cdf-51f4-4b1b-aa50-42e09124ed0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ac2b1a7e-86fb-4f5a-bf06-f26c762a7053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_5e048cdf-51f4-4b1b-aa50-42e09124ed0e" xlink:to="loc_us-gaap_HedgingDesignationDomain_ac2b1a7e-86fb-4f5a-bf06-f26c762a7053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8b5642fc-3597-4de2-886d-6eb110d857fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_ac2b1a7e-86fb-4f5a-bf06-f26c762a7053" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8b5642fc-3597-4de2-886d-6eb110d857fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e5aa8b0e-5001-47dd-90bf-3f35ebee29d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2fc7f8db-0b93-4e29-a226-9eb3358de35c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e5aa8b0e-5001-47dd-90bf-3f35ebee29d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a12046df-cc82-4ab7-baae-4f0fddae8723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e5aa8b0e-5001-47dd-90bf-3f35ebee29d0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a12046df-cc82-4ab7-baae-4f0fddae8723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d7991b51-1afb-4a4c-89da-abd76bb6683c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a12046df-cc82-4ab7-baae-4f0fddae8723" xlink:to="loc_us-gaap_CostOfSalesMember_d7991b51-1afb-4a4c-89da-abd76bb6683c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_be3be6b8-4e97-4e82-baee-d023b1fae46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a12046df-cc82-4ab7-baae-4f0fddae8723" xlink:to="loc_us-gaap_InterestExpenseMember_be3be6b8-4e97-4e82-baee-d023b1fae46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_3a05dc6d-e012-4065-a957-0bd6a0045677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2fc7f8db-0b93-4e29-a226-9eb3358de35c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_3a05dc6d-e012-4065-a957-0bd6a0045677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_a02b85e6-4184-4f57-a98b-7dff735937d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_3a05dc6d-e012-4065-a957-0bd6a0045677" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_a02b85e6-4184-4f57-a98b-7dff735937d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_8ef83310-5a62-488f-85cc-73d9ed12f9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_3a05dc6d-e012-4065-a957-0bd6a0045677" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_8ef83310-5a62-488f-85cc-73d9ed12f9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_850664a0-0055-4974-b350-9dabf4f6f617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3b05059-4acf-44d5-a503-519e72b3a9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_850664a0-0055-4974-b350-9dabf4f6f617" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3b05059-4acf-44d5-a503-519e72b3a9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_622e1862-2a79-47d1-821c-cae79eca9093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3b05059-4acf-44d5-a503-519e72b3a9ed" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_622e1862-2a79-47d1-821c-cae79eca9093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ab6c138e-7fc3-4157-b0d3-a08c5c846de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_622e1862-2a79-47d1-821c-cae79eca9093" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ab6c138e-7fc3-4157-b0d3-a08c5c846de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2dc9f884-f1d7-4d2b-a967-9931d7b1087d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ab6c138e-7fc3-4157-b0d3-a08c5c846de0" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2dc9f884-f1d7-4d2b-a967-9931d7b1087d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0efcbabb-fb4c-4297-afe9-f28d520d3ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2dc9f884-f1d7-4d2b-a967-9931d7b1087d" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0efcbabb-fb4c-4297-afe9-f28d520d3ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_02992794-4972-4419-ab3b-19432ff6cb05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2dc9f884-f1d7-4d2b-a967-9931d7b1087d" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_02992794-4972-4419-ab3b-19432ff6cb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_317bded1-a18a-48e3-8ca7-83b172d3d979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3b05059-4acf-44d5-a503-519e72b3a9ed" xlink:to="loc_us-gaap_InvestmentTypeAxis_317bded1-a18a-48e3-8ca7-83b172d3d979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2dc655ae-134c-4d24-9e5a-244fca86de63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_317bded1-a18a-48e3-8ca7-83b172d3d979" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2dc655ae-134c-4d24-9e5a-244fca86de63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_5e314a2d-f305-4819-963c-2d10af3663b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2dc655ae-134c-4d24-9e5a-244fca86de63" xlink:to="loc_us-gaap_EquitySecuritiesMember_5e314a2d-f305-4819-963c-2d10af3663b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAggregatedInvestmentsMember_1b61bb9e-7dc0-4e37-9aad-3940e29828f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAggregatedInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2dc655ae-134c-4d24-9e5a-244fca86de63" xlink:to="loc_us-gaap_OtherAggregatedInvestmentsMember_1b61bb9e-7dc0-4e37-9aad-3940e29828f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_220e3c87-0538-4625-991b-ee9cab1adc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d3b05059-4acf-44d5-a503-519e72b3a9ed" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_220e3c87-0538-4625-991b-ee9cab1adc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_621ce7b2-200a-4919-9764-d2c0c465dcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_220e3c87-0538-4625-991b-ee9cab1adc5e" xlink:to="loc_us-gaap_LongTermInvestments_621ce7b2-200a-4919-9764-d2c0c465dcb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_5a934703-abf7-48c5-b9e8-78b3ca1bf448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_220e3c87-0538-4625-991b-ee9cab1adc5e" xlink:to="loc_us-gaap_LongTermDebtFairValue_5a934703-abf7-48c5-b9e8-78b3ca1bf448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue_9c176d4a-0f86-48f9-a3b0-d26e04187ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_220e3c87-0538-4625-991b-ee9cab1adc5e" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue_9c176d4a-0f86-48f9-a3b0-d26e04187ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue_ebbb9981-d2ea-4c15-aee3-3cb9e50f142b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_220e3c87-0538-4625-991b-ee9cab1adc5e" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue_ebbb9981-d2ea-4c15-aee3-3cb9e50f142b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_4e112945-b989-4a11-a4e0-eb9861fd6349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_220e3c87-0538-4625-991b-ee9cab1adc5e" xlink:to="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_4e112945-b989-4a11-a4e0-eb9861fd6349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_7f231fbc-906a-4cbf-bc8c-c3b62334346f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_220e3c87-0538-4625-991b-ee9cab1adc5e" xlink:to="loc_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue_7f231fbc-906a-4cbf-bc8c-c3b62334346f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_262dfe20-522d-4f26-93e9-6ef9df3a1781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01c5b2b3-7d2c-45d1-b114-73e81186958f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_262dfe20-522d-4f26-93e9-6ef9df3a1781" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01c5b2b3-7d2c-45d1-b114-73e81186958f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f48b7a6c-3dda-4102-bc84-72fef6723eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01c5b2b3-7d2c-45d1-b114-73e81186958f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f48b7a6c-3dda-4102-bc84-72fef6723eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9fb5a273-f822-4af1-b247-e810fd8e69a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f48b7a6c-3dda-4102-bc84-72fef6723eed" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9fb5a273-f822-4af1-b247-e810fd8e69a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1429aa36-7105-4d4f-a387-c076853f79b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9fb5a273-f822-4af1-b247-e810fd8e69a1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1429aa36-7105-4d4f-a387-c076853f79b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c3530428-254c-45b6-a288-d8e9fec959b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01c5b2b3-7d2c-45d1-b114-73e81186958f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c3530428-254c-45b6-a288-d8e9fec959b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea5a6dc9-8aaf-4033-9d96-21c8701c5876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c3530428-254c-45b6-a288-d8e9fec959b3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea5a6dc9-8aaf-4033-9d96-21c8701c5876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_79097261-9c5c-424b-983d-383f8815f4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea5a6dc9-8aaf-4033-9d96-21c8701c5876" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_79097261-9c5c-424b-983d-383f8815f4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c9b59ea6-b77d-497d-ac29-569afa4114ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea5a6dc9-8aaf-4033-9d96-21c8701c5876" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c9b59ea6-b77d-497d-ac29-569afa4114ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d96efdde-8f84-4f0e-a97d-c384c3db3812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea5a6dc9-8aaf-4033-9d96-21c8701c5876" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d96efdde-8f84-4f0e-a97d-c384c3db3812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01c5b2b3-7d2c-45d1-b114-73e81186958f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_68d062a1-5c63-44de-8dc9-3e10016d7819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_68d062a1-5c63-44de-8dc9-3e10016d7819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_6bc9e959-a24e-4cab-afea-5cb9672b07e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_6bc9e959-a24e-4cab-afea-5cb9672b07e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue_9ff904f8-1af7-481f-b506-ab9abe5ab6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue_9ff904f8-1af7-481f-b506-ab9abe5ab6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4422040b-05ca-43d8-8e20-9f21785df4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4422040b-05ca-43d8-8e20-9f21785df4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_a63dfdae-c936-4df1-985d-f652733392ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_a63dfdae-c936-4df1-985d-f652733392ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_0dba3a9f-98cc-409b-85db-198eaae68f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_0dba3a9f-98cc-409b-85db-198eaae68f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue_f8c3aa5b-2759-415f-841f-c65171324994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue_f8c3aa5b-2759-415f-841f-c65171324994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7925faeb-e6ee-4ac9-91bf-a6d46885e554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7925faeb-e6ee-4ac9-91bf-a6d46885e554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_29018ad5-8511-4b9d-9814-dd2b1e08ae48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9d3d0ad-1ece-4beb-a165-df20edf8fda3" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_29018ad5-8511-4b9d-9814-dd2b1e08ae48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#LitigationandEnvironmentalMattersDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_64fbbc50-42f9-4d84-988b-d992256d8f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_03d0aba8-7163-4588-9666-51e06cf3e88a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_64fbbc50-42f9-4d84-988b-d992256d8f3f" xlink:to="loc_us-gaap_LossContingenciesTable_03d0aba8-7163-4588-9666-51e06cf3e88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_cc21e359-6ea7-495a-9ecc-bb9480c5a61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_03d0aba8-7163-4588-9666-51e06cf3e88a" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_cc21e359-6ea7-495a-9ecc-bb9480c5a61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_9c991193-0b15-4c15-9bbd-6a23fd25e3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_cc21e359-6ea7-495a-9ecc-bb9480c5a61b" xlink:to="loc_us-gaap_LossContingencyNatureDomain_9c991193-0b15-4c15-9bbd-6a23fd25e3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_LegalProceedingsAndEnvironmentalExposuresMember_616d7980-4eed-4f44-ba30-2f63c7c33d21" xlink:href="abt-20220930.xsd#abt_LegalProceedingsAndEnvironmentalExposuresMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_9c991193-0b15-4c15-9bbd-6a23fd25e3f4" xlink:to="loc_abt_LegalProceedingsAndEnvironmentalExposuresMember_616d7980-4eed-4f44-ba30-2f63c7c33d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ce17f583-2096-4d6c-bdb5-c38867cc1e7d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_03d0aba8-7163-4588-9666-51e06cf3e88a" xlink:to="loc_srt_RangeAxis_ce17f583-2096-4d6c-bdb5-c38867cc1e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b647a7b2-ed13-408d-8946-cb0cdcca6a2e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ce17f583-2096-4d6c-bdb5-c38867cc1e7d" xlink:to="loc_srt_RangeMember_b647a7b2-ed13-408d-8946-cb0cdcca6a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_db8051b2-df3a-46b2-9298-77a4d911a26c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b647a7b2-ed13-408d-8946-cb0cdcca6a2e" xlink:to="loc_srt_MinimumMember_db8051b2-df3a-46b2-9298-77a4d911a26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_33010a3c-4aa5-4200-940f-83865db3fc3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b647a7b2-ed13-408d-8946-cb0cdcca6a2e" xlink:to="loc_srt_MaximumMember_33010a3c-4aa5-4200-940f-83865db3fc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_2a61f43d-620a-4677-9bb0-43e90aaecb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_03d0aba8-7163-4588-9666-51e06cf3e88a" xlink:to="loc_us-gaap_LossContingenciesLineItems_2a61f43d-620a-4677-9bb0-43e90aaecb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite_a9c7da50-741f-4b8f-8700-236005df7a70" xlink:href="abt-20220930.xsd#abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2a61f43d-620a-4677-9bb0-43e90aaecb9b" xlink:to="loc_abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite_a9c7da50-741f-4b8f-8700-236005df7a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites_fc71138c-a30a-4d2f-8b3b-1671cfb3e384" xlink:href="abt-20220930.xsd#abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2a61f43d-620a-4677-9bb0-43e90aaecb9b" xlink:to="loc_abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites_fc71138c-a30a-4d2f-8b3b-1671cfb3e384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_94fb6af3-a8f7-4572-a7a0-ac502b549f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2a61f43d-620a-4677-9bb0-43e90aaecb9b" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_94fb6af3-a8f7-4572-a7a0-ac502b549f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_61daae41-de62-4f1e-a79d-a356255347f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2a61f43d-620a-4677-9bb0-43e90aaecb9b" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_61daae41-de62-4f1e-a79d-a356255347f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/PostEmploymentBenefitsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#PostEmploymentBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/PostEmploymentBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_31cea315-4381-4334-814a-d9f006254455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d8f1d133-feee-4dcd-95c2-98cb37f24f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_31cea315-4381-4334-814a-d9f006254455" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d8f1d133-feee-4dcd-95c2-98cb37f24f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_24b50074-ec0a-45b7-a593-a1bda3c9f333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d8f1d133-feee-4dcd-95c2-98cb37f24f59" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_24b50074-ec0a-45b7-a593-a1bda3c9f333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a7a2d70a-1aed-48b7-8fab-077c1336b693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_24b50074-ec0a-45b7-a593-a1bda3c9f333" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a7a2d70a-1aed-48b7-8fab-077c1336b693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4d7f9f2a-c66e-4627-9ca1-8a68572b680b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_a7a2d70a-1aed-48b7-8fab-077c1336b693" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4d7f9f2a-c66e-4627-9ca1-8a68572b680b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_56a4beac-7400-4142-a250-aa45eb192324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_a7a2d70a-1aed-48b7-8fab-077c1336b693" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_56a4beac-7400-4142-a250-aa45eb192324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c43cb219-4e4d-474e-982f-d7ad3777f7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d8f1d133-feee-4dcd-95c2-98cb37f24f59" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c43cb219-4e4d-474e-982f-d7ad3777f7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_fd8c8619-90b7-4a72-8ef5-2236cc932592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c43cb219-4e4d-474e-982f-d7ad3777f7e5" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_fd8c8619-90b7-4a72-8ef5-2236cc932592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_f5afb1a0-4140-4b75-bd3d-184a50c92d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c43cb219-4e4d-474e-982f-d7ad3777f7e5" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_f5afb1a0-4140-4b75-bd3d-184a50c92d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_cd40ed7a-f9d4-45ba-ba8a-fa6383918a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c43cb219-4e4d-474e-982f-d7ad3777f7e5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_cd40ed7a-f9d4-45ba-ba8a-fa6383918a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DefinedBenefitPlanNetAmortizationCostsAbstract_be999494-f681-4852-b2d3-65da99e5b81e" xlink:href="abt-20220930.xsd#abt_DefinedBenefitPlanNetAmortizationCostsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c43cb219-4e4d-474e-982f-d7ad3777f7e5" xlink:to="loc_abt_DefinedBenefitPlanNetAmortizationCostsAbstract_be999494-f681-4852-b2d3-65da99e5b81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_b83690e9-26f0-4783-a385-b5e9cc8bd282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_DefinedBenefitPlanNetAmortizationCostsAbstract_be999494-f681-4852-b2d3-65da99e5b81e" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_b83690e9-26f0-4783-a385-b5e9cc8bd282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_099ee666-8271-4e55-994c-2d996b6c673b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abt_DefinedBenefitPlanNetAmortizationCostsAbstract_be999494-f681-4852-b2d3-65da99e5b81e" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_099ee666-8271-4e55-994c-2d996b6c673b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7f9aded9-2108-4470-bf1f-3c61cd07fd36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c43cb219-4e4d-474e-982f-d7ad3777f7e5" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7f9aded9-2108-4470-bf1f-3c61cd07fd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#PostEmploymentBenefitsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_9a9152e0-faf9-4d36-8fa3-a6a8a43980ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2426196f-2b13-468f-8d0e-a585a46b3aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_9a9152e0-faf9-4d36-8fa3-a6a8a43980ef" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2426196f-2b13-468f-8d0e-a585a46b3aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_63211d5d-367a-4878-b610-37dbdf6d2ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2426196f-2b13-468f-8d0e-a585a46b3aac" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_63211d5d-367a-4878-b610-37dbdf6d2ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e117f194-ba36-4d2f-82f0-71e6febd5178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_63211d5d-367a-4878-b610-37dbdf6d2ab0" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e117f194-ba36-4d2f-82f0-71e6febd5178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b283465a-5568-4e03-9541-4107f088655a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e117f194-ba36-4d2f-82f0-71e6febd5178" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b283465a-5568-4e03-9541-4107f088655a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_84f8e889-c36e-421f-85ec-51d666d083b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e117f194-ba36-4d2f-82f0-71e6febd5178" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_84f8e889-c36e-421f-85ec-51d666d083b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c53d725e-4578-4cea-9663-033f4077d597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_2426196f-2b13-468f-8d0e-a585a46b3aac" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c53d725e-4578-4cea-9663-033f4077d597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_86bc126b-74da-4d2e-b92a-bb7fec7ed9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c53d725e-4578-4cea-9663-033f4077d597" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_86bc126b-74da-4d2e-b92a-bb7fec7ed9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/TaxesonEarningsDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#TaxesonEarningsDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/TaxesonEarningsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d1d1cd32-29db-4b8c-866a-898f1b913907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable_6b0a9844-015f-479a-a601-99e4b626786f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d1d1cd32-29db-4b8c-866a-898f1b913907" xlink:to="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable_6b0a9844-015f-479a-a601-99e4b626786f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a11790cd-8063-48ad-b858-932d45e887f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable_6b0a9844-015f-479a-a601-99e4b626786f" xlink:to="loc_srt_RangeAxis_a11790cd-8063-48ad-b858-932d45e887f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3db87059-a0d1-4889-878d-51e4f6e43011" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a11790cd-8063-48ad-b858-932d45e887f2" xlink:to="loc_srt_RangeMember_3db87059-a0d1-4889-878d-51e4f6e43011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aba2ad94-6631-4a01-ab6d-c19bb7f874e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3db87059-a0d1-4889-878d-51e4f6e43011" xlink:to="loc_srt_MinimumMember_aba2ad94-6631-4a01-ab6d-c19bb7f874e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b5eca630-05e5-4b5f-85d9-81e9663f6f07" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3db87059-a0d1-4889-878d-51e4f6e43011" xlink:to="loc_srt_MaximumMember_b5eca630-05e5-4b5f-85d9-81e9663f6f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems_e27b4c73-9c5e-4e0a-9180-7e228b225561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable_6b0a9844-015f-479a-a601-99e4b626786f" xlink:to="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems_e27b4c73-9c5e-4e0a-9180-7e228b225561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_ExcessTaxBenefitFromShareBasedCompensation_d7a23b37-377c-4911-b81c-c0f164be22c6" xlink:href="abt-20220930.xsd#abt_ExcessTaxBenefitFromShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems_e27b4c73-9c5e-4e0a-9180-7e228b225561" xlink:to="loc_abt_ExcessTaxBenefitFromShareBasedCompensation_d7a23b37-377c-4911-b81c-c0f164be22c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_7593b582-b925-49d7-b7d9-ea9b3e1eb62a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems_e27b4c73-9c5e-4e0a-9180-7e228b225561" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_7593b582-b925-49d7-b7d9-ea9b3e1eb62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_3a7823e7-cea0-4f1e-bdda-03e151b0782b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems_e27b4c73-9c5e-4e0a-9180-7e228b225561" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_3a7823e7-cea0-4f1e-bdda-03e151b0782b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abbott.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="abt-20220930.xsd#SegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.abbott.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5365470f-b394-4322-b918-1d5170b9efac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_947a315a-3444-463a-b7d5-e19fe5c0d1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5365470f-b394-4322-b918-1d5170b9efac" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_947a315a-3444-463a-b7d5-e19fe5c0d1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_ea86d510-c47a-44ab-be33-39731ac8b2bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_947a315a-3444-463a-b7d5-e19fe5c0d1a6" xlink:to="loc_srt_ConsolidationItemsAxis_ea86d510-c47a-44ab-be33-39731ac8b2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f38957a0-31d0-4e1a-b9db-bceb974f6a45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_ea86d510-c47a-44ab-be33-39731ac8b2bf" xlink:to="loc_srt_ConsolidationItemsDomain_f38957a0-31d0-4e1a-b9db-bceb974f6a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_97b67513-b4e7-49a5-8f7c-eddf4b04b088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_f38957a0-31d0-4e1a-b9db-bceb974f6a45" xlink:to="loc_us-gaap_OperatingSegmentsMember_97b67513-b4e7-49a5-8f7c-eddf4b04b088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_c2f4036b-f552-473a-b004-40f7b41ea803" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_f38957a0-31d0-4e1a-b9db-bceb974f6a45" xlink:to="loc_us-gaap_CorporateNonSegmentMember_c2f4036b-f552-473a-b004-40f7b41ea803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_8ba7680a-1dd2-4ba5-89cc-f558cca4808f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_f38957a0-31d0-4e1a-b9db-bceb974f6a45" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_8ba7680a-1dd2-4ba5-89cc-f558cca4808f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a5f5c9cd-710a-47dd-8eac-097b93dd91ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_947a315a-3444-463a-b7d5-e19fe5c0d1a6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a5f5c9cd-710a-47dd-8eac-097b93dd91ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_44a62403-9af5-4e54-8a25-9c93f6a4c9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a5f5c9cd-710a-47dd-8eac-097b93dd91ff" xlink:to="loc_us-gaap_SegmentDomain_44a62403-9af5-4e54-8a25-9c93f6a4c9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_EstablishedPharmaceuticalProductsMember_4e47f182-a2cf-4464-9c78-691ff27c5cc4" xlink:href="abt-20220930.xsd#abt_EstablishedPharmaceuticalProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_44a62403-9af5-4e54-8a25-9c93f6a4c9fa" xlink:to="loc_abt_EstablishedPharmaceuticalProductsMember_4e47f182-a2cf-4464-9c78-691ff27c5cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_NutritionalProductsMember_6621bfab-1f54-4eef-8e40-b6174617cce7" xlink:href="abt-20220930.xsd#abt_NutritionalProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_44a62403-9af5-4e54-8a25-9c93f6a4c9fa" xlink:to="loc_abt_NutritionalProductsMember_6621bfab-1f54-4eef-8e40-b6174617cce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_DiagnosticProductsMember_83b2c013-225b-4bd7-b0cf-bfeb401b34a9" xlink:href="abt-20220930.xsd#abt_DiagnosticProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_44a62403-9af5-4e54-8a25-9c93f6a4c9fa" xlink:to="loc_abt_DiagnosticProductsMember_83b2c013-225b-4bd7-b0cf-bfeb401b34a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_MedicalDevicesMember_bc53de43-92d1-4af6-9dd1-6cf9f141886b" xlink:href="abt-20220930.xsd#abt_MedicalDevicesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_44a62403-9af5-4e54-8a25-9c93f6a4c9fa" xlink:to="loc_abt_MedicalDevicesMember_bc53de43-92d1-4af6-9dd1-6cf9f141886b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_947a315a-3444-463a-b7d5-e19fe5c0d1a6" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9af6e74b-3857-4fcf-bd6c-577266e6303b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9af6e74b-3857-4fcf-bd6c-577266e6303b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f22e8931-9294-49b4-a56b-c1f08e04e1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_us-gaap_OperatingIncomeLoss_f22e8931-9294-49b4-a56b-c1f08e04e1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_CorporateAndBenefitPlanCosts_f0ae4f43-3a71-48b9-875d-9fd3e1425f3e" xlink:href="abt-20220930.xsd#abt_CorporateAndBenefitPlanCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_abt_CorporateAndBenefitPlanCosts_f0ae4f43-3a71-48b9-875d-9fd3e1425f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_dcb0b796-ed9b-492d-a2e8-02883a8560b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_dcb0b796-ed9b-492d-a2e8-02883a8560b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9065fb32-3396-41d4-808f-39a98b12a754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9065fb32-3396-41d4-808f-39a98b12a754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_0ad65082-4348-4ef4-aadc-97ccaa1e1807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_0ad65082-4348-4ef4-aadc-97ccaa1e1807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_OtherCostAndExpenseOperatingAndNonoperating_2776341f-437d-4be4-a837-e295f6f8d61c" xlink:href="abt-20220930.xsd#abt_OtherCostAndExpenseOperatingAndNonoperating"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_abt_OtherCostAndExpenseOperatingAndNonoperating_2776341f-437d-4be4-a837-e295f6f8d61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f24c71e3-5bb2-4c65-b12e-640ee20852c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f24c71e3-5bb2-4c65-b12e-640ee20852c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent_334424f2-d572-47bd-a636-5541fbf946f3" xlink:href="abt-20220930.xsd#abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent_334424f2-d572-47bd-a636-5541fbf946f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRecallExpense_e2bdf801-9f35-430f-a31d-5b5e7a4dbdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRecallExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_us-gaap_InventoryRecallExpense_e2bdf801-9f35-430f-a31d-5b5e7a4dbdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_bc453fd2-50c7-4011-8421-0fe25d752a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2603cdb4-e11b-4fde-a7b4-f452475410dc" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_bc453fd2-50c7-4011-8421-0fe25d752a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454849365360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-2189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABBOTT LABORATORIES<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-0698440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Abbott Park Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Abbott Park<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60064-6400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">667-6100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">1,743,573,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000001800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNYS', window );">NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, Without Par Value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XCHI', window );">CHICAGO STOCK EXCHANGE, INC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, Without Par Value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">CHX<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNYS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNYS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XCHI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XCHI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454849560240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Earnings (Unaudited) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 10,410<span></span>
</td>
<td class="nump">$ 10,928<span></span>
</td>
<td class="nump">$ 33,562<span></span>
</td>
<td class="nump">$ 31,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold, excluding amortization of intangible assets</a></td>
<td class="nump">4,629<span></span>
</td>
<td class="nump">4,423<span></span>
</td>
<td class="nump">14,549<span></span>
</td>
<td class="nump">13,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">520<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
<td class="nump">1,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">782<span></span>
</td>
<td class="nump">672<span></span>
</td>
<td class="nump">2,163<span></span>
</td>
<td class="nump">1,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,731<span></span>
</td>
<td class="nump">2,767<span></span>
</td>
<td class="nump">8,275<span></span>
</td>
<td class="nump">8,276<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating cost and expenses</a></td>
<td class="nump">8,640<span></span>
</td>
<td class="nump">8,382<span></span>
</td>
<td class="nump">26,504<span></span>
</td>
<td class="nump">25,560<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating earnings</a></td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">2,546<span></span>
</td>
<td class="nump">7,058<span></span>
</td>
<td class="nump">6,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest (income)</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Net foreign exchange (gain) loss</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(93)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="num">(253)<span></span>
</td>
<td class="num">(214)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before taxes</a></td>
<td class="nump">1,758<span></span>
</td>
<td class="nump">2,493<span></span>
</td>
<td class="nump">6,986<span></span>
</td>
<td class="nump">5,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on earnings</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
<td class="nump">802<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Earnings</a></td>
<td class="nump">$ 1,435<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="nump">$ 5,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic Earnings Per Common Share (in dollars per share)</a></td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 1.18<span></span>
</td>
<td class="nump">$ 3.35<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted Earnings Per Common Share (in dollars per share)</a></td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="nump">$ 3.32<span></span>
</td>
<td class="nump">$ 2.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)</a></td>
<td class="nump">1,752,968<span></span>
</td>
<td class="nump">1,774,516<span></span>
</td>
<td class="nump">1,756,209<span></span>
</td>
<td class="nump">1,776,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive Common Stock Options (in shares)</a></td>
<td class="nump">10,685<span></span>
</td>
<td class="nump">14,483<span></span>
</td>
<td class="nump">11,638<span></span>
</td>
<td class="nump">14,407<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)</a></td>
<td class="nump">1,763,653<span></span>
</td>
<td class="nump">1,788,999<span></span>
</td>
<td class="nump">1,767,847<span></span>
</td>
<td class="nump">1,791,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding Common Stock Options Having No Dilutive Effect (in shares)</a></td>
<td class="nump">5,445<span></span>
</td>
<td class="nump">2,740<span></span>
</td>
<td class="nump">2,655<span></span>
</td>
<td class="nump">2,694<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454940637968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 1,435<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="nump">$ 5,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation gain (loss) adjustments</a></td>
<td class="num">(1,008)<span></span>
</td>
<td class="num">(391)<span></span>
</td>
<td class="num">(1,429)<span></span>
</td>
<td class="num">(762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $11 and $36 in 2022 and $18 and $54 in 2021</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent', window );">Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $50 and $96 in 2022 and $50 and $98 in 2021</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(739)<span></span>
</td>
<td class="num">(174)<span></span>
</td>
<td class="num">(1,071)<span></span>
</td>
<td class="num">(294)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Income</a></td>
<td class="nump">696<span></span>
</td>
<td class="nump">$ 1,926<span></span>
</td>
<td class="nump">4,829<span></span>
</td>
<td class="nump">$ 4,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Cumulative foreign currency translation (loss) adjustments</a></td>
<td class="num">(7,268)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,268)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,839)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax', window );">Net actuarial (losses) and prior service (costs) and credits</a></td>
<td class="num">(2,498)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,498)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,670)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax', window );">Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other</a></td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">$ (9,445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,374)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594809&amp;loc=SL116692626-108610<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454846201680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax', window );">Other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454849619520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,594<span></span>
</td>
<td class="nump">$ 9,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables, less allowances of $520 in 2022 and $519 in 2021</a></td>
<td class="nump">6,408<span></span>
</td>
<td class="nump">6,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventories:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished products</a></td>
<td class="nump">3,407<span></span>
</td>
<td class="nump">3,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">726<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Materials</a></td>
<td class="nump">1,601<span></span>
</td>
<td class="nump">1,382<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">5,734<span></span>
</td>
<td class="nump">5,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_PrepaidExpenseAndOtherReceivables', window );">Prepaid expenses and other receivables</a></td>
<td class="nump">2,796<span></span>
</td>
<td class="nump">2,346<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">24,845<span></span>
</td>
<td class="nump">24,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments</a></td>
<td class="nump">764<span></span>
</td>
<td class="nump">816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">19,306<span></span>
</td>
<td class="nump">19,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="nump">10,617<span></span>
</td>
<td class="nump">10,405<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net property and equipment</a></td>
<td class="nump">8,689<span></span>
</td>
<td class="nump">8,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of amortization</a></td>
<td class="nump">10,850<span></span>
</td>
<td class="nump">12,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">22,284<span></span>
</td>
<td class="nump">23,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent', window );">Deferred income taxes and other assets</a></td>
<td class="nump">5,369<span></span>
</td>
<td class="nump">5,212<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">72,801<span></span>
</td>
<td class="nump">75,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable</a></td>
<td class="nump">4,133<span></span>
</td>
<td class="nump">4,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Salaries, wages and commissions</a></td>
<td class="nump">1,426<span></span>
</td>
<td class="nump">1,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">5,475<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">820<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">754<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">13,365<span></span>
</td>
<td class="nump">13,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">15,297<span></span>
</td>
<td class="nump">17,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities', window );">Post-employment obligations, deferred income taxes and other long-term liabilities</a></td>
<td class="nump">8,255<span></span>
</td>
<td class="nump">8,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders&#8217; Investment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred shares, one dollar par value Authorized &#8212; 1,000,000 shares, none issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, without par value Authorized &#8212; 2,400,000,000 shares Issued at stated capital amount &#8212; Shares: 2022: 1,985,919,440; 2021: 1,985,273,421</a></td>
<td class="nump">24,560<span></span>
</td>
<td class="nump">24,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Common shares held in treasury, at cost &#8212; Shares: 2022: 242,345,663; 2021: 221,191,228</a></td>
<td class="num">(14,555)<span></span>
</td>
<td class="num">(11,822)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Earnings employed in the business</a></td>
<td class="nump">35,115<span></span>
</td>
<td class="nump">31,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(9,445)<span></span>
</td>
<td class="num">(8,374)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Abbott Shareholders&#8217; Investment</a></td>
<td class="nump">35,675<span></span>
</td>
<td class="nump">35,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling Interests in Subsidiaries</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Shareholders&#8217; Investment</a></td>
<td class="nump">35,884<span></span>
</td>
<td class="nump">36,024<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders' Investment</a></td>
<td class="nump">$ 72,801<span></span>
</td>
<td class="nump">$ 75,196<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Post-employment obligations and amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_PrepaidExpenseAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other receivables that are expected to be realized within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_PrepaidExpenseAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454844701520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Trade receivables, allowances</a></td>
<td class="nump">$ 520<span></span>
</td>
<td class="nump">$ 519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value (in dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, authorized (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized (in shares)</a></td>
<td class="nump">2,400,000,000<span></span>
</td>
<td class="nump">2,400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued (in shares)</a></td>
<td class="nump">1,985,919,440<span></span>
</td>
<td class="nump">1,985,273,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Common shares held in treasury (in shares)</a></td>
<td class="nump">242,345,663<span></span>
</td>
<td class="nump">221,191,228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454845862960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Shareholders' Investment (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 1,435<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="nump">$ 5,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(739)<span></span>
</td>
<td class="num">(174)<span></span>
</td>
<td class="num">(1,071)<span></span>
</td>
<td class="num">(294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">35,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">24,429<span></span>
</td>
<td class="nump">24,153<span></span>
</td>
<td class="nump">24,470<span></span>
</td>
<td class="nump">24,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_StockIssuedDuringPeriodValueIncentiveStockPrograms', window );">Issued under incentive stock programs</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock awards</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(518)<span></span>
</td>
<td class="num">(487)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">24,560<span></span>
</td>
<td class="nump">24,285<span></span>
</td>
<td class="nump">24,560<span></span>
</td>
<td class="nump">24,285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock, Common</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(13,720)<span></span>
</td>
<td class="num">(10,340)<span></span>
</td>
<td class="num">(11,822)<span></span>
</td>
<td class="num">(10,042)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_StockIssuedDuringPeriodValueIncentiveStockPrograms', window );">Issued under incentive stock programs</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchased</a></td>
<td class="num">(866)<span></span>
</td>
<td class="num">(685)<span></span>
</td>
<td class="num">(2,994)<span></span>
</td>
<td class="num">(1,222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(14,555)<span></span>
</td>
<td class="num">(10,999)<span></span>
</td>
<td class="num">(14,555)<span></span>
</td>
<td class="num">(10,999)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">34,487<span></span>
</td>
<td class="nump">29,053<span></span>
</td>
<td class="nump">31,528<span></span>
</td>
<td class="nump">27,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="nump">5,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared on common shares</a></td>
<td class="num">(822)<span></span>
</td>
<td class="num">(799)<span></span>
</td>
<td class="num">(2,475)<span></span>
</td>
<td class="num">(2,403)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_EffectOfCommonAndTreasuryShareTransactions', window );">Effect of common and treasury share transactions</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">35,115<span></span>
</td>
<td class="nump">30,376<span></span>
</td>
<td class="nump">35,115<span></span>
</td>
<td class="nump">30,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(8,706)<span></span>
</td>
<td class="num">(9,066)<span></span>
</td>
<td class="num">(8,374)<span></span>
</td>
<td class="num">(8,946)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(739)<span></span>
</td>
<td class="num">(174)<span></span>
</td>
<td class="num">(1,071)<span></span>
</td>
<td class="num">(294)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(9,445)<span></span>
</td>
<td class="num">(9,240)<span></span>
</td>
<td class="num">(9,445)<span></span>
</td>
<td class="num">(9,240)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations', window );">Noncontrolling Interests&#8217; share of income, business combinations, net of distributions and share repurchases</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_EffectOfCommonAndTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the effect on retained earning due to common and treasury stock transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_EffectOfCommonAndTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represent Noncontrolling Interests' share of income, net of distributions, share repurchases and business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_StockIssuedDuringPeriodValueIncentiveStockPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Incentive Stock Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_StockIssuedDuringPeriodValueIncentiveStockPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454849394320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, common (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,191,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, common (in shares)</a></td>
<td class="nump">242,345,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,345,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="nump">1,985,676,735<span></span>
</td>
<td class="nump">1,982,553,488<span></span>
</td>
<td class="nump">1,985,273,421<span></span>
</td>
<td class="nump">1,981,156,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms', window );">Issued under incentive stock programs (in shares)</a></td>
<td class="nump">242,705<span></span>
</td>
<td class="nump">550,366<span></span>
</td>
<td class="nump">646,019<span></span>
</td>
<td class="nump">1,946,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares)</a></td>
<td class="nump">1,985,919,440<span></span>
</td>
<td class="nump">1,983,103,854<span></span>
</td>
<td class="nump">1,985,919,440<span></span>
</td>
<td class="nump">1,983,103,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock, Common</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, common (in shares)</a></td>
<td class="nump">234,456,992<span></span>
</td>
<td class="nump">209,736,139<span></span>
</td>
<td class="nump">221,191,228<span></span>
</td>
<td class="nump">209,926,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms', window );">Issued under incentive stock programs (in shares)</a></td>
<td class="nump">528,436<span></span>
</td>
<td class="nump">545,860<span></span>
</td>
<td class="nump">4,808,575<span></span>
</td>
<td class="nump">5,524,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchased (in shares)</a></td>
<td class="nump">8,417,107<span></span>
</td>
<td class="nump">5,626,606<span></span>
</td>
<td class="nump">25,963,010<span></span>
</td>
<td class="nump">10,414,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, common (in shares)</a></td>
<td class="nump">242,345,663<span></span>
</td>
<td class="nump">214,816,885<span></span>
</td>
<td class="nump">242,345,663<span></span>
</td>
<td class="nump">214,816,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared on common shares (in dollars per share)</a></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Incentive Stock Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454843385792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flow From (Used in) Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="nump">$ 5,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings to net cash from operating activities &#8212;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">943<span></span>
</td>
<td class="nump">1,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1,517<span></span>
</td>
<td class="nump">1,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="num">(409)<span></span>
</td>
<td class="num">(194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(1,224)<span></span>
</td>
<td class="num">(471)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other, net</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(140)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash From Operating Activities</a></td>
<td class="nump">7,255<span></span>
</td>
<td class="nump">7,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flow From (Used in) Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisitions of property and equipment</a></td>
<td class="num">(1,167)<span></span>
</td>
<td class="num">(1,271)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess', window );">Acquisitions of businesses and technologies, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Proceeds from business dispositions</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Sales (purchases) of other investment securities, net</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash From (Used in) Investing Activities</a></td>
<td class="num">(1,108)<span></span>
</td>
<td class="num">(1,337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flow From (Used in) Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt', window );">Net borrowings (repayments) of short-term debt and other</a></td>
<td class="nump">37<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(753)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of common shares</a></td>
<td class="num">(3,110)<span></span>
</td>
<td class="num">(1,325)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid</a></td>
<td class="num">(2,486)<span></span>
</td>
<td class="num">(2,404)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash From (Used in) Financing Activities</a></td>
<td class="num">(6,179)<span></span>
</td>
<td class="num">(3,608)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(173)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Increase (Decrease) in Cash and Cash Equivalents</a></td>
<td class="num">(205)<span></span>
</td>
<td class="nump">2,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents, Beginning of Year</a></td>
<td class="nump">9,799<span></span>
</td>
<td class="nump">6,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents, End of Period</a></td>
<td class="nump">$ 9,594<span></span>
</td>
<td class="nump">$ 9,302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase, and research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454938455152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 1 &#8212; Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454850461760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 2 &#8212; Revenue</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott&#8217;s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide detail by sales category:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products &#8212; </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,795&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,108&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics &#8212; </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,671&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,965&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,410&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,560&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,515&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,515&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,518&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,642&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,628&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,624&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,252&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,951&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,743&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,430&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,173&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,937&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,923&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,639&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,787&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $3.9 billion in the Diagnostics segment and approximately $433 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 60 percent of these remaining performance obligations over the next 24 months, approximately 16 percent over the subsequent 12 months and the remainder thereafter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Contract Assets and Liabilities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott&#8217;s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott&#8217;s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the contract liabilities during the period are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue from cash received during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized related to contract liability balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454846809328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Supplemental Financial Information</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 3 &#8212; Supplemental Financial Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended September&#160;30, 2022 and 2021 were $1.429 billion and $2.092 billion, respectively, and for the nine months ended September&#160;30, 2022 and 2021 were $5.876 billion and $5.061 billion, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first nine months of 2022 includes $362 million of pension contributions and the payment of cash taxes of approximately $987 million. The first nine months of 2021 includes $366 million of pension contributions and the payment of cash taxes of approximately $990 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity for the first nine months of 2022 related to the allowance for doubtful accounts as of September&#160;30, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for Doubtful Accounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions/charges to income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged off and other deductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term investments as of September&#160;30, 2022 and December&#160;31, 2021 are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Abbott&#8217;s long-term investments as of September&#160;30, 2022 versus the balance as of December&#160;31, 2021 primarily relates to a decrease in the value of investments held in a rabbi trust and the impact of equity method investment losses partially offset by an investment in long-term time deposits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott&#8217;s equity securities as of September&#160;30, 2022, include $285 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott also holds certain investments as of September&#160;30, 2022 with a carrying value of $228 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $83 million that do not have a readily determinable fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2021, Abbott acquired 100 percent of Walk Vascular, LLC (Walk Vascular), a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots. The purchase price, the allocation of acquired assets and liabilities, and the revenue and net income contributed by Walk Vascular since the date of acquisition are not material to Abbott&#8217;s condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454846879520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in Accumulated Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Changes in Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 4 &#8212; Changes In Accumulated Other Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow<br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,260)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,230)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,554)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,738)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,268)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,621)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,498)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,660)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow <br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,839)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,859)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,670)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,871)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(762)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(762)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,268)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,621)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,498)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,660)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 11 for additional details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454846895488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 5 &#8212; Goodwill and Intangible Assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of goodwill reported was $22.3 billion at September&#160;30, 2022 and $23.2 billion at December&#160;31, 2021. Foreign currency translation adjustments decreased goodwill by approximately $946 million in the first nine months of 2022. The amount of goodwill related to reportable segments at September&#160;30, 2022 was $2.6 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.5 billion for the Diagnostic Products segment, and $15.9 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first nine months of 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross amount of amortizable intangible assets, primarily product rights and technology, was $26.9 billion and $27.7 billion as of September&#160;30, 2022 and December&#160;31, 2021, respectively. Accumulated amortization was $16.9 billion and $15.9 billion as of September&#160;30, 2022 and  December&#160;31, 2021, respectively. Foreign currency translation adjustments decreased intangible assets by $250 million in the first nine months of 2022. Abbott&#8217;s estimated annual amortization expense for intangible assets is approximately $2.1 billion in 2022, $2.0 billion in 2023, $1.9 billion in 2024, $1.7 billion in 2025 and $1.6 billion in 2026.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, which relate to in-process R&amp;D (IPR&amp;D) acquired in a business combination, were approximately $807 million as of September&#160;30, 2022 and $919 million as of December&#160;31, 2021. In the third quarter of 2022, $111 million of impairment charges were recorded on the Research and development line of the Condensed Consolidated Statement of Earnings related to certain IPR&amp;D intangible assets associated with the Medical Devices business segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454850292480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Plans</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 6 &#8212; Restructuring Plans </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2021, Abbott management approved a restructuring plan related to its Diagnostic Products segment to align its manufacturing network for COVID-19 diagnostic tests with changes in the second quarter in projected testing demand driven by several factors, including significant reductions in cases in the U.S. and other major developed countries, the accelerated rollout of COVID-19 vaccines globally and the U.S. health authority&#8217;s updated guidance on testing for fully vaccinated individuals. In the second quarter of 2021, Abbott recorded charges of $499 million under this plan in Cost of products sold. The charge recognized in the second quarter of 2021 included fixed asset write-downs of $80 million, inventory-related charges of $248 million, and other exit costs, which included contract cancellations and employee-related costs of $171 million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second half of 2021, as the Delta and Omicron variants of COVID-19 spread and the number of new COVID-19 cases increased significantly, particularly in the U.S., demand for rapid COVID-19 tests increased significantly. As a result, in the second half of 2021, Abbott sold approximately $181 million of inventory that was previously estimated to have no net realizable value under the second quarter of 2021 restructuring action. In addition, the estimate of other exit costs was reduced by a net $58 million as Abbott fulfilled its purchase obligations under certain contracts for which a liability was recorded in the second quarter of 2021 or Abbott settled with the counterparty in the second half of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity related to this restructuring action and the status of the related accruals as of September&#160;30, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inventory-<br/>Related<br/>Charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Asset<br/>Write-Downs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Exit<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges recorded in 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in Abbott&#8217;s diagnostic, established pharmaceutical, and nutritional businesses. In 2022 and 2021, Abbott management approved plans to streamline operations in its medical devices segment. Abbott recorded employees-related severance and other charges of approximately $12 million in the first nine months of 2022 of which approximately $5&#160;million was recorded in Cost of products sold, approximately $2 million was recorded in Research and development, and approximately $5&#160;million was recorded in Selling, general and administrative expense.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity for these restructurings:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges recorded in 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges recorded in 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454847734320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Incentive Stock Program<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Incentive Stock Program</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 7 &#8212; Incentive Stock Program</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first nine months of 2022, Abbott granted 2,634,647 stock options, 514,205 restricted stock awards and 5,427,697 restricted stock units under its incentive stock program. At September&#160;30, 2022, approximately 87 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at September&#160;30, 2022 is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,048,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,310,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total unrecognized share-based compensation cost at September&#160;30, 2022 amounted to approximately $600 million which is expected to be recognized over the next three years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454850407520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Lines of Credit<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt and Lines of Credit</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 8 &#8212; Debt and Lines of Credit</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454850466608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments, Derivatives and Fair Value Measures<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Financial Instruments, Derivatives and Fair Value Measures</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 9 &#8212; Financial Instruments, Derivatives and Fair Value Measures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.9 billion at September&#160;30, 2022 and $8.6 billion at December&#160;31, 2021, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of September&#160;30, 2022 will be included in Cost of products sold at the time the products are sold, generally through the next <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNjQ1_49b14940-1788-44d4-b632-7d72eb48a1c0">twelve</span> to eighteen months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At September&#160;30, 2022 and December&#160;31, 2021, Abbott held the gross notional amounts of $10.3 billion and $12.2 billion, respectively, of such foreign currency forward exchange contracts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott has designated a yen-denominated, 5-year term loan of approximately $413 million and $521 million as of September&#160;30, 2022 and December&#160;31, 2021, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott is a party to interest rate hedge contracts with notional values totaling approximately $2.9 billion at September&#160;30, 2022 and December&#160;31, 2021 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts and location of certain derivative financial instruments as of September&#160;30, 2022 and December&#160;31, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dec. 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dec. 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Post-employment obligations, deferred income taxes and other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Others not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September&#160;30, 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain (loss) Recognized in Other <br/>Comprehensive Income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (expense) and Gain (loss)<br/>Reclassified into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Losses of $27 million and $18 million were recognized in the three months ended September&#160;30, 2022 and 2021, respectively, related to foreign currency forward exchange contracts not designated as a hedge. Gains of $225 million and $15 million were recognized in the nine months ended September&#160;30, 2022 and 2021, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values and fair values of certain financial instruments as of September&#160;30, 2022 and December&#160;31, 2021 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investment Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,414)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,821)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Forward Exchange Contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Hedge Contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the debt was determined based on significant other observable inputs, including current interest rates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding<br/>Balances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,201&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,196&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454850331760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation and Environmental Matters<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Litigation and Environmental Matters</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 10 &#8212; Litigation and Environmental Matters</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.</span></div>Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $40 million to $50 million. The recorded accrual balance at September&#160;30, 2022 for these proceedings and exposures was approximately $45 million. This accrual represents management&#8217;s best estimate of probable loss, as defined by FASB ASC No. 450, &#8220;Contingencies.&#8221; Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott&#8217;s financial position, cash flows, or results of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454846899968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-Employment Benefits<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsDisclosureTextBlock', window );">Post-Employment Benefits</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 11 &#8212; Post-Employment Benefits</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three and nine months ended September&#160;30 for Abbott&#8217;s major defined benefit plans and post-employment medical and dental benefit plans is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical and Dental Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine  Months <br/>Ended Sept. 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine  Months <br/>Ended Sept. 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost - benefits earned during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost on projected benefit obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(633)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amortization of:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial loss, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cost (credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first nine months of 2022 and 2021, $362 million and $366 million, respectively, were contributed to defined benefit plans. In the first nine months of 2022 and 2021, $28 million</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$26&#160;million, respectively</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span> were contributed to the post-employment medical and dental plans.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for postemployment benefits, which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6410195&amp;loc=d3e80090-111668<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454846762224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Earnings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Taxes on Earnings</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 12 &#8212; Taxes on Earnings</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2022 and 2021, taxes on earnings include approximately $36 million and $97 million, respectively, in excess tax benefits associated with share-based compensation. In the first nine months of 2022, taxes on earnings also include approximately $20 million of tax expense as the result of the resolution of various tax positions related to prior years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax authorities in various jurisdictions regularly review Abbott&#8217;s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $75 million to $100 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454850326976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 13 &#8212; Segment Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott&#8217;s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott&#8217;s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians&#8217; offices and government agencies throughout the world.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott&#8217;s reportable segments are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Established Pharmaceutical Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; International sales of a broad line of branded generic pharmaceutical products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nutritional Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Worldwide sales of a broad line of adult and pediatric nutritional products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diagnostic Products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physician offices and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Devices</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbott&#8217;s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment&#8217;s assets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Sales to External Customers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended Sept. 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended Sept. 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Established Pharmaceutical Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nutritional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Reportable Segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate functions and benefit plan costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (a) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,884&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. </span></div></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other, net for the three and nine months ended September&#160;30, 2022 includes $10 million and $172 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment and $111 million of charges related to the impairment of IPR&amp;D intangible assets.  Other, net for the three and nine months ended September&#160;30, 2022 and 2021 also includes integration costs associated with the acquisition of Alere and restructuring charges. Restructuring charges in 2021 include Abbott&#8217;s restructuring plan for its COVID-19 test manufacturing network. Other, net for the nine months ended September&#160;30, 2021 also includes costs related to certain litigation.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454846862240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of reportable segment included under sales category</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide detail by sales category:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products &#8212; </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,795&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,108&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics &#8212; </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,671&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,965&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,410&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,560&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Established Pharmaceutical Products &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Key Emerging Markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,515&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,515&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nutritionals &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pediatric Nutritionals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adult Nutritionals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,518&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,642&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,628&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,624&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,252&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Core Laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Molecular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rapid Diagnostics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,951&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,743&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,430&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,173&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Management</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Electrophysiology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Failure</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vascular</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Structural Heart</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuromodulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diabetes Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,937&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,923&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,639&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,787&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of changes in contract liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the contract liabilities during the period are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue from cash received during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized related to contract liability balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454846796816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Summary of activity of allowance for doubtful accounts</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity for the first nine months of 2022 related to the allowance for doubtful accounts as of September&#160;30, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for Doubtful Accounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions/charges to income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged off and other deductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_ScheduleOfLongTermInvestmentsTableTextBlock', window );">Schedule of long-term investments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term investments as of September&#160;30, 2022 and December&#160;31, 2021 are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_ScheduleOfLongTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the investments which are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_ScheduleOfLongTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454850297200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of accumulated other comprehensive income (loss), net of taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow<br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,260)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,230)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,554)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,738)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,008)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,268)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,621)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,498)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,660)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Foreign<br/>Currency Translation<br/>(Loss) Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Actuarial (Losses) and<br/>Prior Service (Costs) and<br/>Credits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Gains (Losses)<br/>on Derivative Instruments<br/>Designated as Cash Flow <br/>Hedges and Other</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,839)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,859)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,670)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,871)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(762)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(762)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,268)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,621)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,498)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,660)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454846796816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of restructuring reserve and related cost</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity related to this restructuring action and the status of the related accruals as of September&#160;30, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inventory-<br/>Related<br/>Charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Asset<br/>Write-Downs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Exit<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges recorded in 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of restructuring activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the activity for these restructurings:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges recorded in 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges recorded in 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454850292480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Incentive Stock Program (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock options outstanding and exercisable</a></td>
<td class="text">Information regarding the number of options outstanding and exercisable at September&#160;30, 2022 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,048,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,310,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454849610576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments, Derivatives and Fair Value Measures (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of the amounts and location of certain derivative financial instruments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts and location of certain derivative financial instruments as of September&#160;30, 2022 and December&#160;31, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value - Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dec. 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dec. 31,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Post-employment obligations, deferred income taxes and other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Others not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Schedule of derivatives gain (loss) in OCI and earnings</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September&#160;30, 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain (loss) Recognized in Other <br/>Comprehensive Income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (expense) and Gain (loss)<br/>Reclassified into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt designated as a hedge of net investment in a foreign subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps designated as fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of carrying values and fair values of certain financial instruments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values and fair values of certain financial instruments as of September&#160;30, 2022 and December&#160;31, 2021 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Investment Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,414)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,821)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Forward Exchange Contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Hedge Contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable position</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Payable) position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding<br/>Balances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted<br/>Prices in<br/>Active<br/>Markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,201&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,196&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap derivative financial instruments </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of hedged long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration related to business combinations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454847734320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-Employment Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Schedule of components of the net periodic benefit cost for the entity's major defined benefit plans and post-employment medical and dental benefit plans</a></td>
<td class="text">Net cost recognized for the three and nine months ended September&#160;30 for Abbott&#8217;s major defined benefit plans and post-employment medical and dental benefit plans is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical and Dental Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine  Months <br/>Ended Sept. 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine  Months <br/>Ended Sept. 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost - benefits earned during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost on projected benefit obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(633)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amortization of:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial loss, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cost (credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454846879520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment information - net sales and operating earnings</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Sales to External Customers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended Sept. 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months <br/>Ended Sept. 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>Ended Sept. 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Established Pharmaceutical Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nutritional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Reportable Segments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate functions and benefit plan costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (a) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,533)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,884&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. </span></div></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other, net for the three and nine months ended September&#160;30, 2022 includes $10 million and $172 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment and $111 million of charges related to the impairment of IPR&amp;D intangible assets.  Other, net for the three and nine months ended September&#160;30, 2022 and 2021 also includes integration costs associated with the acquisition of Alere and restructuring charges. Restructuring charges in 2021 include Abbott&#8217;s restructuring plan for its COVID-19 test manufacturing network. Other, net for the nine months ended September&#160;30, 2021 also includes costs related to certain litigation.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454844020416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>segment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember', window );">Diagnostic Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligations</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligations</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage', window );">Percentage of remaining performance obligation expected to be recognized in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Expected timing of satisfaction period (in months)</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-10-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage', window );">Percentage of remaining performance obligation expected to be recognized in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Expected timing of satisfaction period (in months)</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of revenue recognized for remaining performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-10-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-10-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454838091792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Segments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 10,410<span></span>
</td>
<td class="nump">$ 10,928<span></span>
</td>
<td class="nump">$ 33,562<span></span>
</td>
<td class="nump">$ 31,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">10,407<span></span>
</td>
<td class="nump">10,917<span></span>
</td>
<td class="nump">33,554<span></span>
</td>
<td class="nump">31,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">4,094<span></span>
</td>
<td class="nump">4,368<span></span>
</td>
<td class="nump">13,923<span></span>
</td>
<td class="nump">11,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">6,316<span></span>
</td>
<td class="nump">6,560<span></span>
</td>
<td class="nump">19,639<span></span>
</td>
<td class="nump">19,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_EstablishedPharmaceuticalProductsMember', window );">Established Pharmaceutical Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,326<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
<td class="nump">3,696<span></span>
</td>
<td class="nump">3,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_EstablishedPharmaceuticalProductsMember', window );">Established Pharmaceutical Products | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_EstablishedPharmaceuticalProductsMember', window );">Established Pharmaceutical Products | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,326<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
<td class="nump">3,696<span></span>
</td>
<td class="nump">3,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_NutritionalProductsMember', window );">Nutritional Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,795<span></span>
</td>
<td class="nump">2,108<span></span>
</td>
<td class="nump">5,642<span></span>
</td>
<td class="nump">6,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_NutritionalProductsMember', window );">Nutritional Products | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">686<span></span>
</td>
<td class="nump">919<span></span>
</td>
<td class="nump">2,124<span></span>
</td>
<td class="nump">2,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_NutritionalProductsMember', window );">Nutritional Products | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">1,189<span></span>
</td>
<td class="nump">3,518<span></span>
</td>
<td class="nump">3,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember', window );">Diagnostic Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">3,671<span></span>
</td>
<td class="nump">3,912<span></span>
</td>
<td class="nump">13,279<span></span>
</td>
<td class="nump">11,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember', window );">Diagnostic Products | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,741<span></span>
</td>
<td class="nump">1,947<span></span>
</td>
<td class="nump">6,951<span></span>
</td>
<td class="nump">4,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember', window );">Diagnostic Products | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,930<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
<td class="nump">6,328<span></span>
</td>
<td class="nump">6,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember', window );">Medical Devices | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">3,615<span></span>
</td>
<td class="nump">3,632<span></span>
</td>
<td class="nump">10,937<span></span>
</td>
<td class="nump">10,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember', window );">Medical Devices | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,664<span></span>
</td>
<td class="nump">1,496<span></span>
</td>
<td class="nump">4,840<span></span>
</td>
<td class="nump">4,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember', window );">Medical Devices | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,951<span></span>
</td>
<td class="nump">2,136<span></span>
</td>
<td class="nump">6,097<span></span>
</td>
<td class="nump">6,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_KeyEmergingMarketsMember', window );">Key Emerging Markets | Established Pharmaceutical Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">993<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="nump">2,826<span></span>
</td>
<td class="nump">2,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_KeyEmergingMarketsMember', window );">Key Emerging Markets | Established Pharmaceutical Products | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_KeyEmergingMarketsMember', window );">Key Emerging Markets | Established Pharmaceutical Products | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">993<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="nump">2,826<span></span>
</td>
<td class="nump">2,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_OtherEmergingMarketsMember', window );">Other Emerging Markets | Established Pharmaceutical Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">870<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_OtherEmergingMarketsMember', window );">Other Emerging Markets | Established Pharmaceutical Products | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_OtherEmergingMarketsMember', window );">Other Emerging Markets | Established Pharmaceutical Products | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">870<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_PediatricNutritionalsMember', window );">Pediatric Nutritionals | Nutritional Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">827<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">2,599<span></span>
</td>
<td class="nump">3,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_PediatricNutritionalsMember', window );">Pediatric Nutritionals | Nutritional Products | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
<td class="nump">1,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_PediatricNutritionalsMember', window );">Pediatric Nutritionals | Nutritional Products | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">470<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">1,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_AdultNutritionalsMember', window );">Adult Nutritionals | Nutritional Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">968<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
<td class="nump">3,043<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_AdultNutritionalsMember', window );">Adult Nutritionals | Nutritional Products | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="nump">1,016<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_AdultNutritionalsMember', window );">Adult Nutritionals | Nutritional Products | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">639<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="nump">2,027<span></span>
</td>
<td class="nump">1,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_CoreLaboratoryMember', window );">Core Laboratory | Diagnostic Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,219<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">3,624<span></span>
</td>
<td class="nump">3,780<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_CoreLaboratoryMember', window );">Core Laboratory | Diagnostic Products | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="nump">836<span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_CoreLaboratoryMember', window );">Core Laboratory | Diagnostic Products | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">938<span></span>
</td>
<td class="nump">1,001<span></span>
</td>
<td class="nump">2,788<span></span>
</td>
<td class="nump">2,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_MolecularMember', window );">Molecular | Diagnostic Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="nump">815<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_MolecularMember', window );">Molecular | Diagnostic Products | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_MolecularMember', window );">Molecular | Diagnostic Products | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">507<span></span>
</td>
<td class="nump">651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_PointOfCareMember', window );">Point of Care | Diagnostic Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_PointOfCareMember', window );">Point of Care | Diagnostic Products | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_PointOfCareMember', window );">Point of Care | Diagnostic Products | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_RapidDiagnosticsMember', window );">Rapid Diagnostics | Diagnostic Products | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">2,142<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
<td class="nump">8,446<span></span>
</td>
<td class="nump">5,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_RapidDiagnosticsMember', window );">Rapid Diagnostics | Diagnostic Products | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,303<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
<td class="nump">5,523<span></span>
</td>
<td class="nump">3,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_RapidDiagnosticsMember', window );">Rapid Diagnostics | Diagnostic Products | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">839<span></span>
</td>
<td class="nump">746<span></span>
</td>
<td class="nump">2,923<span></span>
</td>
<td class="nump">2,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_RhythmManagementMember', window );">Rhythm Management | Medical Devices | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">571<span></span>
</td>
<td class="nump">1,605<span></span>
</td>
<td class="nump">1,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_RhythmManagementMember', window );">Rhythm Management | Medical Devices | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">775<span></span>
</td>
<td class="nump">776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_RhythmManagementMember', window );">Rhythm Management | Medical Devices | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="nump">830<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_ElectrophysiologyMember', window );">Electrophysiology | Medical Devices | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="nump">1,440<span></span>
</td>
<td class="nump">1,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_ElectrophysiologyMember', window );">Electrophysiology | Medical Devices | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">667<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_ElectrophysiologyMember', window );">Electrophysiology | Medical Devices | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">773<span></span>
</td>
<td class="nump">823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_HeartFailureMember', window );">Heart Failure | Medical Devices | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="nump">690<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_HeartFailureMember', window );">Heart Failure | Medical Devices | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">523<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_HeartFailureMember', window );">Heart Failure | Medical Devices | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_VascularMember', window );">Vascular | Medical Devices | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">606<span></span>
</td>
<td class="nump">644<span></span>
</td>
<td class="nump">1,878<span></span>
</td>
<td class="nump">1,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_VascularMember', window );">Vascular | Medical Devices | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_VascularMember', window );">Vascular | Medical Devices | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="nump">1,228<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_StructuralHeartMember', window );">Structural Heart | Medical Devices | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="nump">1,271<span></span>
</td>
<td class="nump">1,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_StructuralHeartMember', window );">Structural Heart | Medical Devices | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">604<span></span>
</td>
<td class="nump">537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_StructuralHeartMember', window );">Structural Heart | Medical Devices | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">667<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_NeuromodulationMember', window );">Neuromodulation | Medical Devices | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="nump">568<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_NeuromodulationMember', window );">Neuromodulation | Medical Devices | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_NeuromodulationMember', window );">Neuromodulation | Medical Devices | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_DiabetesCareMember', window );">Diabetes Care | Medical Devices | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">1,167<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">3,485<span></span>
</td>
<td class="nump">3,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_DiabetesCareMember', window );">Diabetes Care | Medical Devices | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
<td class="nump">865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=abt_DiabetesCareMember', window );">Diabetes Care | Medical Devices | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 744<span></span>
</td>
<td class="nump">$ 798<span></span>
</td>
<td class="nump">$ 2,320<span></span>
</td>
<td class="nump">$ 2,292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=abt_EstablishedPharmaceuticalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=abt_EstablishedPharmaceuticalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=abt_NutritionalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=abt_NutritionalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=abt_KeyEmergingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=abt_KeyEmergingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=abt_OtherEmergingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=abt_OtherEmergingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=abt_PediatricNutritionalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=abt_PediatricNutritionalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=abt_AdultNutritionalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=abt_AdultNutritionalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=abt_CoreLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=abt_CoreLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=abt_MolecularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=abt_MolecularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=abt_PointOfCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=abt_PointOfCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=abt_RapidDiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=abt_RapidDiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=abt_RhythmManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=abt_RhythmManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=abt_ElectrophysiologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=abt_ElectrophysiologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=abt_HeartFailureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=abt_HeartFailureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=abt_VascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=abt_VascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=abt_StructuralHeartMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=abt_StructuralHeartMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=abt_NeuromodulationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=abt_NeuromodulationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=abt_DiabetesCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=abt_DiabetesCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454846057632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Other Contract Assets and Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_ContractLiabilitiesRollForward', window );"><strong>Contract Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized', window );">Unearned revenue from cash received during the period</a></td>
<td class="nump">466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized related to contract liability balance</a></td>
<td class="num">(508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_ContractLiabilitiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_ContractLiabilitiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in cash received to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454836724784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedCashFlowStatementsCaptionsLineItems', window );"><strong>Condensed Cash Flow Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net earnings allocated to common shares</a></td>
<td class="nump">$ 1,429<span></span>
</td>
<td class="nump">$ 2,092<span></span>
</td>
<td class="nump">$ 5,876<span></span>
</td>
<td class="nump">$ 5,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForOtherTaxes', window );">Payment of cash taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">987<span></span>
</td>
<td class="nump">$ 990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments carrying value</a></td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investment without readily determinable fair value</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abt_StJudeMedicalIncMember', window );">St. Jude Medical | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedCashFlowStatementsCaptionsLineItems', window );"><strong>Condensed Cash Flow Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesHeldInEmployeeTrust', window );">Securities in mutual funds held in a rabbi trust</a></td>
<td class="nump">$ 285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abt_WalkVascularLLCMember', window );">Walk Vascular</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedCashFlowStatementsCaptionsLineItems', window );"><strong>Condensed Cash Flow Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, percentage acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedCashFlowStatementsCaptionsLineItems', window );"><strong>Condensed Cash Flow Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Pension contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
<td class="nump">$ 366<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedCashFlowStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedCashFlowStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesHeldInEmployeeTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesHeldInEmployeeTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForOtherTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for taxes classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForOtherTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abt_StJudeMedicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abt_StJudeMedicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abt_WalkVascularLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abt_WalkVascularLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454843830848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information - Allowance for Doubtful Accounts (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Allowance for Doubtful Accounts:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provisions/charges to income</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Amounts charged off and other deductions</a></td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454848523872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Financial Information - Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments</a></td>
<td class="nump">$ 764<span></span>
</td>
<td class="nump">$ 816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments</a></td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfInvestmentHoldingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfInvestmentHoldingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454841069808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Changes in accumulated other comprehensive income (loss), net of income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">$ (739)<span></span>
</td>
<td class="num">$ (174)<span></span>
</td>
<td class="num">(1,071)<span></span>
</td>
<td class="num">$ (294)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">End of the period</a></td>
<td class="nump">35,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Cumulative Foreign Currency Translation (Loss) Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Changes in accumulated other comprehensive income (loss), net of income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning of the period</a></td>
<td class="num">(6,260)<span></span>
</td>
<td class="num">(5,230)<span></span>
</td>
<td class="num">(5,839)<span></span>
</td>
<td class="num">(4,859)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(1,008)<span></span>
</td>
<td class="num">(391)<span></span>
</td>
<td class="num">(1,429)<span></span>
</td>
<td class="num">(762)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1,008)<span></span>
</td>
<td class="num">(391)<span></span>
</td>
<td class="num">(1,429)<span></span>
</td>
<td class="num">(762)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">End of the period</a></td>
<td class="num">(7,268)<span></span>
</td>
<td class="num">(5,621)<span></span>
</td>
<td class="num">(7,268)<span></span>
</td>
<td class="num">(5,621)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Net Actuarial (Losses) and Prior Service (Costs) and Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Changes in accumulated other comprehensive income (loss), net of income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning of the period</a></td>
<td class="num">(2,554)<span></span>
</td>
<td class="num">(3,738)<span></span>
</td>
<td class="num">(2,670)<span></span>
</td>
<td class="num">(3,871)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">End of the period</a></td>
<td class="num">(2,498)<span></span>
</td>
<td class="num">(3,660)<span></span>
</td>
<td class="num">(2,498)<span></span>
</td>
<td class="num">(3,660)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Changes in accumulated other comprehensive income (loss), net of income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning of the period</a></td>
<td class="nump">108<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="num">(216)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income</a></td>
<td class="num">(65)<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">End of the period</a></td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454841231456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 22,284<span></span>
</td>
<td class="nump">$ 22,284<span></span>
</td>
<td class="nump">$ 23,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Decrease in goodwill due to foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Amount of reductions of goodwill relating to impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross amount of amortizable intangible assets</a></td>
<td class="nump">26,900<span></span>
</td>
<td class="nump">26,900<span></span>
</td>
<td class="nump">27,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization of intangible assets</a></td>
<td class="nump">16,900<span></span>
</td>
<td class="nump">16,900<span></span>
</td>
<td class="nump">15,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss', window );">Decrease in intangible assets due to foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Estimated annual amortization expense, intangible assets, 2022</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated annual amortization expense, intangible assets, 2023</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated annual amortization expense, intangible assets, 2024</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated annual amortization expense, intangible assets, 2025</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated annual amortization expense, intangible assets, 2026</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets related to in-process R&amp;D acquired in a business combination</a></td>
<td class="nump">807<span></span>
</td>
<td class="nump">807<span></span>
</td>
<td class="nump">$ 919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_EstablishedPharmaceuticalProductsMember', window );">Established Pharmaceutical Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_NutritionalProductsMember', window );">Nutritional Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember', window );">Diagnostic Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">15,900<span></span>
</td>
<td class="nump">15,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_GoodwillAndIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill and Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_GoodwillAndIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=abt_EstablishedPharmaceuticalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=abt_EstablishedPharmaceuticalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=abt_NutritionalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=abt_NutritionalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454848444640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abt_COVID19TestManufacturingNetworkRestructuringPlanMember', window );">COVID-19 Test Manufacturing Network Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_InventoryNoNetRealizableValueSold', window );">Inventory sold that was previously estimated to have no net realizable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abt_COVID19TestManufacturingNetworkRestructuringPlanMember', window );">COVID-19 Test Manufacturing Network Restructuring Plan | Fixed Asset Write-Downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abt_COVID19TestManufacturingNetworkRestructuringPlanMember', window );">COVID-19 Test Manufacturing Network Restructuring Plan | Inventory- Related Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abt_COVID19TestManufacturingNetworkRestructuringPlanMember', window );">COVID-19 Test Manufacturing Network Restructuring Plan | Other Exit Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Reduction of restructuring estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember', window );">Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember', window );">Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies | Cost of Products Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember', window );">Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember', window );">Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies | Selling, General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_InventoryNoNetRealizableValueSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory sold that was previously estimated to have no net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_InventoryNoNetRealizableValueSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=abt_COVID19TestManufacturingNetworkRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=abt_COVID19TestManufacturingNetworkRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=abt_FixedAssetWriteDownsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=abt_FixedAssetWriteDownsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=abt_InventoryRelatedChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=abt_InventoryRelatedChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=abt_OtherExitCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=abt_OtherExitCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=abt_CostOfGoodsAndServicesSoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=abt_CostOfGoodsAndServicesSoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454837962816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Plans - Streamline of Operations and Improve Efficiencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abt_COVID19TestManufacturingNetworkRestructuringPlanMember', window );">COVID-19 Test Manufacturing Network Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges recorded in 2021</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Other non-cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance at beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments', window );">Payments and other adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance at end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abt_COVID19TestManufacturingNetworkRestructuringPlanMember', window );">COVID-19 Test Manufacturing Network Restructuring Plan | Inventory- Related Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges recorded in 2021</a></td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Other non-cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance at beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments', window );">Payments and other adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance at end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abt_COVID19TestManufacturingNetworkRestructuringPlanMember', window );">COVID-19 Test Manufacturing Network Restructuring Plan | Fixed Asset Write-Downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges recorded in 2021</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Other non-cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance at beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments', window );">Payments and other adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance at end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abt_COVID19TestManufacturingNetworkRestructuringPlanMember', window );">COVID-19 Test Manufacturing Network Restructuring Plan | Other Exit Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges recorded in 2021</a></td>
<td class="nump">$ 171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Other non-cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance at beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments', window );">Payments and other adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance at end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember', window );">Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges recorded in 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance at beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments', window );">Payments and other adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued balance at end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_RestructuringReservePeriodCashSettledAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_RestructuringReservePeriodCashSettledAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveSettledWithoutCash2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the reserve for full or partial settlement through consideration other than cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveSettledWithoutCash2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=abt_COVID19TestManufacturingNetworkRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=abt_COVID19TestManufacturingNetworkRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=abt_InventoryRelatedChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=abt_InventoryRelatedChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=abt_FixedAssetWriteDownsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=abt_FixedAssetWriteDownsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=abt_OtherExitCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=abt_OtherExitCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454846139232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Incentive Stock Program - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Incentive stock program, shares reserved for future grants (in shares)</a></td>
<td class="nump">87,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost | $</a></td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Total unrecognized compensation cost, recognition period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted during the period (in shares)</a></td>
<td class="nump">2,634,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=abt_RestrictedStockAwardsMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards granted during the period (in shares)</a></td>
<td class="nump">514,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Restricted stock units granted during period (in shares)</a></td>
<td class="nump">5,427,697<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abt_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abt_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454846136640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Incentive Stock Program - Options (Details) - Share-based Payment Arrangement, Option<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding, number of shares | shares</a></td>
<td class="nump">29,048,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable options, number of shares | shares</a></td>
<td class="nump">23,310,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Stock options outstanding, weighted-average remaining life</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable options, weighted-average remaining life</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options outstanding, weighted-average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 70.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable options, weighted-average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 59.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding | $</a></td>
<td class="nump">$ 901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of options exercisable | $</a></td>
<td class="nump">$ 890<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454846802880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Lines of Credit (Details) - 2.55% Long-term Notes Due 2022<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 15, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate percentage</a></td>
<td class="nump">2.55%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abt_A255LongTermNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abt_A255LongTermNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454843395136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Designated as Hedging Instrument | Yen-denominated long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Gain (loss) recognized related to derivatives not designated as hedge</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward | Cash Flow Hedging | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_MinimumLengthOfTimeHedgedInCashFlowHedge', window );">Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1', window );">Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Fair Value Hedging | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_MinimumLengthOfTimeHedgedInCashFlowHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_MinimumLengthOfTimeHedgedInCashFlowHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abt_YenDenominatedLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abt_YenDenominatedLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454843324704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">$ 908<span></span>
</td>
<td class="nump">$ 379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">786<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Interest Rate Swap | Deferred income taxes and other assets | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Interest Rate Swap | Post-employment obligations, deferred income taxes and other long-term liabilities | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Foreign Exchange Forward | Prepaid expenses and other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">760<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Foreign Exchange Forward | Other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Debt | Long-term debt | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Foreign Exchange Forward | Prepaid expenses and other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value - Assets</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Foreign Exchange Forward | Other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair Value - Liabilities</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=abt_DeferredIncomeTaxesAndOtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=abt_DeferredIncomeTaxesAndOtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=abt_PrepaidExpensesAndOtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=abt_PrepaidExpensesAndOtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_DebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_DebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454849221376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details) - Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward | Cash Flow Hedging | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Gain (loss) Recognized in Other Comprehensive Income (loss)</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">$ 442<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Income (expense) and Gain (loss) Reclassified into Income</a></td>
<td class="nump">79<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_DebtMember', window );">Debt | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Gain (loss) Recognized in Other Comprehensive Income (loss)</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Fair Value Hedging | Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Income (expense) and Gain (loss) Reclassified into Income</a></td>
<td class="num">$ (85)<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (253)<span></span>
</td>
<td class="num">$ (81)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_DebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_DebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454841226032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term Investment Securities:</a></td>
<td class="nump">$ 764<span></span>
</td>
<td class="nump">$ 816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term Investment Securities:</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total Long-term Debt</a></td>
<td class="num">(16,414)<span></span>
</td>
<td class="num">(18,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue', window );">Foreign currency forward exchange contracts, receivable position</a></td>
<td class="nump">908<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue', window );">Foreign currency forward exchange contracts, (payable) position</a></td>
<td class="num">(207)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue', window );">Interest rate hedge contracts, receivable position</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue', window );">Interest rate hedge contracts, (payable) position</a></td>
<td class="num">(166)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term Investment Securities:</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term Investment Securities:</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total Long-term Debt</a></td>
<td class="num">(15,821)<span></span>
</td>
<td class="num">(21,152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue', window );">Foreign currency forward exchange contracts, receivable position</a></td>
<td class="nump">908<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue', window );">Foreign currency forward exchange contracts, (payable) position</a></td>
<td class="num">(207)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue', window );">Interest rate hedge contracts, receivable position</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue', window );">Interest rate hedge contracts, (payable) position</a></td>
<td class="num">(166)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term Investment Securities:</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term Investment Securities:</a></td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative assets designated as cash flow hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateFairValueHedgeAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all derivative liabilities designated as interest rate fair value hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherAggregatedInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherAggregatedInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454843967840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) - Fair Value, Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">$ 293<span></span>
</td>
<td class="nump">$ 402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue', window );">Foreign currency forward exchange contracts</a></td>
<td class="nump">908<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">1,201<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Fair value of hedged long-term debt</a></td>
<td class="nump">2,685<span></span>
</td>
<td class="nump">2,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest rate swap derivative financial instruments</a></td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue', window );">Foreign currency forward exchange contracts</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration related to business combinations</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">3,196<span></span>
</td>
<td class="nump">3,153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue', window );">Foreign currency forward exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Fair value of hedged long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest rate swap derivative financial instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue', window );">Foreign currency forward exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration related to business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue', window );">Foreign currency forward exchange contracts</a></td>
<td class="nump">908<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">908<span></span>
</td>
<td class="nump">379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Fair value of hedged long-term debt</a></td>
<td class="nump">2,685<span></span>
</td>
<td class="nump">2,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest rate swap derivative financial instruments</a></td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue', window );">Foreign currency forward exchange contracts</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration related to business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">3,058<span></span>
</td>
<td class="nump">3,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap derivative financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue', window );">Foreign currency forward exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Fair value of hedged long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest rate swap derivative financial instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue', window );">Foreign currency forward exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration related to business combinations</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative assets designated as cash flow hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateDerivativeAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateDerivativeAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateDerivativeLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454848435280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Litigation and Environmental Matters (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite', window );">Maximum expected cleanup exposure for individual site</a></td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites', window );">Maximum expected cleanup exposure in aggregate</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=abt_LegalProceedingsAndEnvironmentalExposuresMember', window );">Legal proceedings and environmental exposures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Recorded accrual balance for legal proceedings and exposures</a></td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=abt_LegalProceedingsAndEnvironmentalExposuresMember', window );">Legal proceedings and environmental exposures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimation of possible loss</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=abt_LegalProceedingsAndEnvironmentalExposuresMember', window );">Legal proceedings and environmental exposures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimation of possible loss</a></td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated maximum loss, for all sites, from the contingency related to the environmental clean up in the United States and Puerto Rico.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated maximum loss, per individual site, from the contingency related to the environmental clean up in the United States and Puerto Rico.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=abt_LegalProceedingsAndEnvironmentalExposuresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=abt_LegalProceedingsAndEnvironmentalExposuresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454843402864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-Employment Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost - benefits earned during the period</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 282<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost on projected benefit obligations</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(231)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
<td class="num">(701)<span></span>
</td>
<td class="num">(633)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_DefinedBenefitPlanNetAmortizationCostsAbstract', window );"><strong>Net amortization of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Actuarial loss, net</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Prior service cost (credit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net cost (credit)</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Medical and Dental Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost - benefits earned during the period</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost on projected benefit obligations</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_DefinedBenefitPlanNetAmortizationCostsAbstract', window );"><strong>Net amortization of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Actuarial loss, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Prior service cost (credit)</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net cost (credit)</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_DefinedBenefitPlanNetAmortizationCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_DefinedBenefitPlanNetAmortizationCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454847600576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-Employment Benefits - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Defined Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">$ 362<span></span>
</td>
<td class="nump">$ 366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Medical and Dental Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454848435472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Earnings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems', window );"><strong>Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_ExcessTaxBenefitFromShareBasedCompensation', window );">Excess tax benefits associated with share-based compensation</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions', window );">Tax expense from prior year tax positions</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems', window );"><strong>Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease reasonably possible in gross unrecognized tax benefits</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems', window );"><strong>Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease reasonably possible in gross unrecognized tax benefits</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_ExcessTaxBenefitFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefits related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_ExcessTaxBenefitFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126928070&amp;loc=d3e28511-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126928070&amp;loc=d3e28446-109314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140454844813760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Sales to External Customers</a></td>
<td class="nump">$ 10,410<span></span>
</td>
<td class="nump">$ 10,928<span></span>
</td>
<td class="nump">$ 33,562<span></span>
</td>
<td class="nump">$ 31,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Earnings</a></td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">2,546<span></span>
</td>
<td class="nump">7,058<span></span>
</td>
<td class="nump">6,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="num">(498)<span></span>
</td>
<td class="num">(520)<span></span>
</td>
<td class="num">(1,517)<span></span>
</td>
<td class="num">(1,533)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before taxes</a></td>
<td class="nump">$ 1,758<span></span>
</td>
<td class="nump">$ 2,493<span></span>
</td>
<td class="nump">$ 6,986<span></span>
</td>
<td class="nump">$ 5,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent', window );">Annual share-based awards recognized in first quarter (as a percent)</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_NutritionalProductsMember', window );">Nutritional Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRecallExpense', window );">Inventory recall expense</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Sales to External Customers</a></td>
<td class="nump">10,407<span></span>
</td>
<td class="nump">$ 10,917<span></span>
</td>
<td class="nump">33,554<span></span>
</td>
<td class="nump">$ 31,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Earnings</a></td>
<td class="nump">2,791<span></span>
</td>
<td class="nump">3,536<span></span>
</td>
<td class="nump">10,284<span></span>
</td>
<td class="nump">9,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Established Pharmaceutical Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Sales to External Customers</a></td>
<td class="nump">1,326<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
<td class="nump">3,696<span></span>
</td>
<td class="nump">3,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Earnings</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="nump">682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Nutritional Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Sales to External Customers</a></td>
<td class="nump">1,795<span></span>
</td>
<td class="nump">2,108<span></span>
</td>
<td class="nump">5,642<span></span>
</td>
<td class="nump">6,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Earnings</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="nump">1,388<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Diagnostic Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Sales to External Customers</a></td>
<td class="nump">3,671<span></span>
</td>
<td class="nump">3,912<span></span>
</td>
<td class="nump">13,279<span></span>
</td>
<td class="nump">11,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Earnings</a></td>
<td class="nump">1,352<span></span>
</td>
<td class="nump">1,652<span></span>
</td>
<td class="nump">5,631<span></span>
</td>
<td class="nump">4,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Sales to External Customers</a></td>
<td class="nump">3,615<span></span>
</td>
<td class="nump">3,632<span></span>
</td>
<td class="nump">10,937<span></span>
</td>
<td class="nump">10,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Earnings</a></td>
<td class="nump">1,039<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">3,272<span></span>
</td>
<td class="nump">3,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Sales to External Customers</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_CorporateAndBenefitPlanCosts', window );">Corporate functions and benefit plan costs</a></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
<td class="num">(352)<span></span>
</td>
<td class="num">(450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Net interest expense</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="num">(309)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="num">(570)<span></span>
</td>
<td class="num">(534)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="num">(498)<span></span>
</td>
<td class="num">(520)<span></span>
</td>
<td class="num">(1,517)<span></span>
</td>
<td class="num">(1,533)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abt_OtherCostAndExpenseOperatingAndNonoperating', window );">Other, net</a></td>
<td class="num">$ (211)<span></span>
</td>
<td class="num">$ (82)<span></span>
</td>
<td class="num">$ (550)<span></span>
</td>
<td class="num">$ (1,103)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the annual cost of share-based awards which will typically be recognized in the first quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_CorporateAndBenefitPlanCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reconciling item from aggregate segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to corporate functions and benefit plan costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_CorporateAndBenefitPlanCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abt_OtherCostAndExpenseOperatingAndNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reconciling item from segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to net other income or expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abt_OtherCostAndExpenseOperatingAndNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRecallExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the amount charged against earnings comprised of the costs to announce and effect a recall of defective merchandise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRecallExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=abt_NutritionalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=abt_NutritionalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=abt_EstablishedPharmaceuticalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=abt_EstablishedPharmaceuticalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>abt-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:abt="http://www.abbott.com/20220930"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:exch="http://xbrl.sec.gov/exch/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="abt-20220930.xsd" xlink:type="simple"/>
    <context id="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icaa425fa3d3747d6ad2878dffdb267d0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XCHI</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i59773e96f1294946be35567fa420b29a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iec9d7c7b895f4b01a5849a89d5bca911_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i161741e7e8f046ff9a2cc29b1a64a357_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife5c2b9c51b24905939dfe6b3d3e4056_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i318af3e554204da2b38e2945f4629296_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9f1d1e1ca3304ec8bafbf0a80a96bd80_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib7b8a9dc239044a6b1a2b862dd61b7fc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i29242515a9cd41d3929b65fa4ab2da75_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0ec2d32ee1c543f89872966939398c80_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i13853862ec4e4a8f9dd87d9d1f5a0eba_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i84388393a8aa4ea4ad5e48e8c7f24e44_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2f2db6dc6a8f4d8d97404a772b976d3d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5a2381935eb3479c8272fe544f91e498_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib0384842a3a44e638930735a2b593396_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iee53b5e2f57b467bafb6a07b010ce7b8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibdd95633e0b74ebebb2ef9d790e7e133_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id6cd17f6345343d188d64dda2acbc2ba_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib605aa77a1694292a23c576b3cbe9f51_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6675c4a62c704c83b04414e2e96f9f15_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9a9d779acbe44e3bacba61c64c39e891_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iffc3d7b1f7924f49a467f9de89cf4580_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i93502cdb071b40d78c7d41a2b5166b24_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3efcbced2c284e42846b07cbce02af0f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i42f5fd859ca5425389497f80eb2c653e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i76df37ef10134753b1301a961c801516_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib49fbe36bbba46d5a960a042585a8ca3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id1445a4f41614df3b5934c37b319c6c4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iff7c2622a69b432d86720be37f7e2a16_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0ef7377540aa4e4c823d715421f8fd87_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3d04e8e8dc804bc79e6cf5d8fac6d42b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7057ecd5f0c1428ba00d5cc5b5ed8119_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib97d8339fa5a4a14be94890cbc7535a3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i088ce8132a864ce3a40176de183626a8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1504c2dad3014570b5b401bc387b8c52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d042e1363a74135b1ff431769cbdd3c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2633c881b0854a9387e79c0bf0e90227_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i00352c2d1368429694fe5d87533d4a96_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5cfae92185d549208e196b57add32000_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida0d59058b594e578193e429a2f6c056_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b724be0df7a469ba9c898710b2dbf1a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie6098fe1fbe54bc9a82cd2c345421c2c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i852ddcd4489e42389a31b5f021e6e092_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa7c44803cf240068637223e01d8287e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibdca6cdd2c3846f6ad4787b16fed5ea4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic5e6626a450843eba3abf231608db97f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib0d9d6801c8c4803a0622083412ac492_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f3f735442774afcb720cdb3ae2b9822_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id78baae4639244558d7fbe8dde9cdbaa_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icc6ae1cd7a5648a9876bfd212f13b5fa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifc59d11b30d140339de2cf7f2ac54561_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide6a9cde9eec42f099b747ac02363030_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ide40706d122541aa80614540c148de08_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i621d2ad3316543a1886bf830d26e3ffa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3397ef3061f44f36bc9ca7c33654a5de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8bf57bd89e8649de9b14b6f40f63d3b6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifdd6935a04684767a7df321fc7d8e04b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i20dea8b9fbad40a38c94c202b5a06584_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i553b1f411dac4315b9a061214928d19f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4fd8b94ecb894e8195d49738629f7663_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iab868753d235445d83b1848d574f0930_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9377afb46605449ba04338e3aed6ebac_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifb9ead876d79497b81d1a4e75fa4b045_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idb241d31511748689ba74aba957986b9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if08d89d55ab546df94df4e9acd51d621_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i392c359c05c842bdbf2ea56e22942b96_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7a2976080c494443a4931b79f76745ad_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i356b34bf48444864bd8276a14a0a84e4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1992bffa64a74127b5f3ce81b21991bf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic22fc4ec43f24128aae74e88776149f8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id1e67684e5e949128a2dec705cc5342d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7f479639da464db4b609d3fa8cba57e3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9d8adee8e3b749c59dcd592b973fe816_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifffc59617b4841e6842d4164adb3ad90_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i938d14e18c764f7591831cee2b53ef86_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic3d4661d9eae4662a6bc7af372b39a7f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0270bd857761409ca80dff389f4005fb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5684517b411b4be6b66e253acbe21100_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i94a3d528fe5c493698dcfd7f6cdbd624_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic4c46ec7babe4d8d98a3a5f521e8605a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1ce87a21a2074f99b7e3a9096bf4bc2c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3981790b8e294829b7fce3da94293b1a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idee15a5bd7a94f2a92b34458fffd592d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia5d4fcd289e94e72b4495606b599fffc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id8fe4e7fed8d4ca39d192d7298446b1b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i56ce1b628bc24fbba472f845695459c7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i262c247a794c4eefad4c4426111eda88_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3d37f71b97414ca0a196529d4e6c3728_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia8fa29318db7448c942a75e199de1be5_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i248ff18b88c14ec0b9b3fa1462dc670e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i84b6259abeb9432c9b1f4f981322d6e2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i45f3203f3fae46e1ae8028fc5a27e29c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia256be207eb1438f97b1a7c44dda87d3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia5dcca58e8964d269d6d18f5bae1e53d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i40d8bf57ab5544cf81d04120e139dabf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia86213c5d496444e8758ca35cdaeb05c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2c1f5c24bb5841378c451a90d43000f2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3b897bac92554d069fad477918947757_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9b4a4864d2ff4c4e8574e011f96d543b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8377a58ea461458c9ebd573507a2eb81_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8800ac73633d482e852c78a6b3b8d03d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9cda9249440a4ababf23d348f31db81e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iec3890031ec84733b487409a7fff947e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i29f47d268de74c4bb30f8f0125aeccc5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i30e9486b2c674fe99294020e754c817f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6366c00282d04fa5a78abdb1ee423aed_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i79d29b0d89e645e0bcb31189ca823228_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i20ea475fdf0c48e98e083f8dff8056a9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i003dbc498c9a441d89cc0b04ebbd771a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i975d74cca0954d4da1bd068770b41605_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7d047d8dfd414c5d869bcd80fcd41acd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i737b2378d74d4e7492bfe82a019bb4ab_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i769d3ce030b942ae9d850540e53df223_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ida0bffdbe968459c98f06e252484ccc3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id63c448a841840358193db0fad40f4c5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic56a546e33244e07a2c5e1ab9ecb4292_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6fee55729a8c4e7185f644e1bfe2485b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2140596e31a1496bafdd0b9ee4a2e6a6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i09ee6e9676f048f79f0471399c05b638_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id19d1f5e16084839a8c193bc0d1b0b6b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idd6b40c44ce54ba1bde4642cb23e69f6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie4186212e28d4b569b09c70bbface083_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id659a1190f7b4070a747d070536ed33b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib6480973800e4bb4b9ae80722ce16e59_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1d61af67909049b9a444fc24e14717ea_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if890618fe578485fa3a4db43677fe34e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i34397dbe2fe94c6295a14a8d146a8e33_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1f8368e30efc48f7b56ba92dc4adc061_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i928d6fe7e0df441780768f564d2effcd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4f24ca1db60e4a9da9ffd86e0dd87fe7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i822021d7a9e249bab1fe800a9aedfb9b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8ab1d9822ff84b4480b3cd3b8cc641bf_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if718f850e60e4378916dbadb60c282ad_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7e82029ad78c409e9753b65d01cfa2d5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iedef7300876e4675ba5cd753aef79d39_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3d1631e3346a480c9d5b5659e244276e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i77aac3496d504b269d56bad2b76e5104_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i780ba98a53b04c0abf1fcfadfe606d7f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic59cae3887574b7b9d34a8c5fd1fb0b6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i228ab2341a2243eeb1c80b00645ce995_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2294cc5729724ad4beb4eca7c9cdd070_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ide82ac8a034040ebbe46d3d3b8e71a00_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1dc02637faf8456f8e9ffb0ddcae89e6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie4030aeb71c94f9bbc3b600344c1518a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i921fd3c95d3b4f22ad34e4bc60148ba2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3145c2c6bd974f55ac9749bc3df087bf_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4b5c721c4b474f6ea1f090bb7b8e4fd0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i35e0589ff3084f539d0a76d845294702_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i34e8d657434743fe827a4089fc230ba9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i08e9a03bf16d46ea811c32e2fd25a006_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i570d7e8aa51741029b8421acbd7e89ee_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i35c10ac918394db8b1c3491c2981f0e5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9d04f4545b8b43d7bcd56adb5418487d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3a32eb2db2de4ba4b33ad343ddc6021a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1583d120070b4c648cbb100c9764e0a7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i683987d035904d219c421b72bf0f8f88_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9a64fbf194cd46d1a5f071cd845567da_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9adf53e54b3447a88875f2f71694d649_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ica898e019d964049bedef258b5226f95_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1c4b4059d40945188d652327f054645d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8056ef31a802430fa929e0598584b1c7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia16e81903f114d79b6e640358306f75a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1005eed0e87a4f6ca75ca475d4fb2b94_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i351b1476da8947a8a63c6a3ff672aee0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iff8daa2d825a48a298a1cc610189cf7c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9a811c943c8c43aa93ad41f1bdcb253d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i91226d7ee83f4e5298c5a54390a1eccc_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i10e8ad512c2f4a09873c90ec51a3e052_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9911c8668779460c87a6b1bfc290914f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id2c236dcb265432793429913b3061d27_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id73b999e6aee402da9f298dad7a6ac0b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i069f4c6f209746c789a3cc531b1374c1_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8e1452c0c5d145a29227070d32c787ac_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i93831c5392ae4927b11006f81f940e3c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if0a7f44a74844847a52a461dc905dc00_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1ef09987de6c4adeb7fa5bf0cf0c7704_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf27976a942a4fc19586a8236e981bc0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1349d737be5b4ef59e79e923b2ac2288_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i453afdd41ffd4a8f9d41a110816ebc00_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8b9d6f53ba814d1b95c967e665c217ea_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iada0437a2d644f70bb7d16cf91f31b89_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8cade4bab8cd43e19b63a86b43643ef5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i361870a0e2f94355b13e0b60175a2edb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i134a99d86b0243888efe2cec770050b5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i690d3ee447044de5b2a11910dd16abaf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i31f2c0a0ad5d4d44bb78b1dc657ab16d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:KeyEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i554353f0dd4640f1b215201bed46099d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifec2214696a74f5fa73835f5d611690a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id6e6c2d98d8f46038f546582021c6a94_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id9a4321960004899b56bca3a97bccffd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i102907d306274282b184801c40f69f97_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iad208ef1d3254acaa72d25a179cf7d24_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:OtherEmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i92e9ca2b2e18494baca77d7365fc681a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i40287ad92f234638a3f0573ebae44eca_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i88535b01ff934a65be5cc199bcb770b6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icecdc6a5fc1c478c8f0fdbb2c241e43e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i708d2529d4054b78a3b367c21aaa1820_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0c90b3c1db944b208e77b4076259563c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia34a1de062a34934a0a112436ec8d560_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1345044a56d74824ac553b8f40f2c74d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic52e79d5447c4977917c82e49b86fb4e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5e840f2b6e62404898af58c0cbc62fbf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7a8d70dcf5384658960d5b5ea48dfbb7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i43915f754bb04fb5a0040abb37d51123_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PediatricNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i41d6039c97b64dbc820635198caf3dc4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i258f0ca4a6f44bcd94d893ebab9cc9c1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1e3063d3a8aa47c784ad799aceff5e06_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iea4b8d31930d4018a5338e7cf5435676_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i176c1169defa4bb381f30ee2fe87a5d3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie585e82674e94179ab887b7f775c682b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:AdultNutritionalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie623ae8b28ba4c44b6fec7b856d08e06_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i35395fcaaf34451c9cbfa534d8d7ce9a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i30091a5d3bab43efa63d14e4a226925c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib1596bb0bf8f43fd80c7d6d3d9119a9b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i248be60308a146df85a86a26a0fc60f8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i151bd5c29f3c46848ec98ccbecda7c02_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0b056141550548c3be6dd5b036db3ff1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1e31728b4def4db89b236907c78b2797_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia75bb1a2605e4d8ea6e25aa3afb20121_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifaa33587aec14e3c92b0c60d0a771555_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i62abea3acfae48e8890da0175c0339ac_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if933b85d1d764e94956ab214e194e081_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:CoreLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0d65665918964adeb3fff6362875e715_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i381802cbd03a48bf88e11eee86e25b7f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id56510d8ef1842c0ae332b5fed72a26a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i775838a7944846a986221b63ebbe9b64_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iba87ee33146849a291c62b0745bb5f5d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2d36392cd74f4d26a9d42617161eafaf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:MolecularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7a75adec61da4340b39d6915dcb31f11_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if9cf76723706485f8673bd279ede2bf5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic3769aaf2e984527ab4d6cd5c5790c6a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3d0f4ef4f7424767974f102dbe69d978_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2ea63032d5234ccd932e6fd8c70cf960_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i390a22555acc4884934c9d58d45d11d2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:PointOfCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i49197e2409e34e65a96c75e9f85a6de5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6b4a4436b7e3437ebd0171fc877d29e3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i43eff708b8824e8da4d9838d6a4f5e3f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1103a7e9b8c9470d9eb268366aaf62b7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0287b1ef094c4fad8318d6eca7385301_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2e49e1388c1b47c883e46629b8e2b191_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RapidDiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i59bf5ff82ae5408b905d3c438eb99949_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib084a5804053469ab97816e5c1ee7359_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i72d0903dbdb14905994e7b293b54456f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4974eb5146784a269db4203e8c6fa7e6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i66b90b7445ea43d9b419aa50bb82b8e5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibc14a44dcf1344559829bf251b14704d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i00bbc05a48e34b0895b143638542cf98_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icd4ab9bd729548cdbc214c561241cdc1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id965fbb08df843a7b71062949bd75de8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9f23fb6c9b6b40f996df1df9c7d4d1b0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i59ade9da924b40b8b3b22b5c8d7085b2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i63931e4da08749c89fc6a8bd235b4ef4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:RhythmManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3d48c3bb559c4a829632103b69a3a872_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i79f1f89cdf584d59a1701cdbbeead083_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if86c316bd32140fcb1db26b35d96f19a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9da5f32878ef4ff2bb7b73e8340888d3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i85330517d5a14b5eb736122a3a5bcebc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i899221de84bb4f4da22a481ff4200823_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9f3b2c7957554d658f3db970c6d6b430_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iec90285d812f4f068310c71aedbc8afa_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i152ee6da621e4956b226578681a95301_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2e8d82e7deaf4edbb04c1b33ba231943_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iadf482c8b62342cabd96a8f08883e08f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibdfc6bf7155d4385a0a3ab7ed7d09c3a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:HeartFailureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia12ba51821814d288ee081fbaa8ce473_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i74fa6dbf7cce4f75b02f642d1f599489_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0df3bfdd84f14f64ba3f84ad0dc9a807_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1935bf7c22124130bed4e1a214f63308_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iedb59d3d7f814dd5a908dfbd889da9d7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iabd1755cc8654a2692d559c24619a01b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:VascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6f0c0e2be49847eda32a1bc8f4a3d0a4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i603417b878634bc7b3c6c7e28e82df50_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i30de540bbd614a38a4d9b0e11618a079_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i46266d118c974a5aa2d9e68681b6b922_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1ebd6bf1d71d4400b4815379954178a3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9b829deb2ae74f13a56fe33a45c6e829_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:StructuralHeartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie6e1e30c4e804011b00a91294e5115f6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4463afae1e5544929d49ae0a34367c96_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia3476fa0ac234ff2842cfecc49b3e986_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if64d98f713314bb9833a430722b4386d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9857ddf749154af092177a27b3317c19_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i18e9f36c179f44e3bfaec15ee0847c98_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:NeuromodulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3859aeb3184c430cad30ee39666a826e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6cd2a1a447c34980acee85e3b68e0919_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i37249fb3b9b7438bae34cc8f3ddc38da_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i82e117f9b22f4ad18dde00710f85564b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0deea721100d42d2aa599ecbc0b6ee95_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i47b80c5b0ee9422a85373b6736cab652_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">abt:DiabetesCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i08308c9f9c6a446496b0ba98a0a5fa36_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie6041fbdff4649fb80901f2a88fc9805_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i165fe1c62d6e440d91dc4abc8a0dee83_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i417cf26f3afb43a3a54f1bb81556fdd8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i25afbf02cb5a452089cc6973c24865ab_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i81462640315a4b09a820a1f604b6aa3d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic909cb81fa33496693b9dc997788164a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iee4f114b62e84287ad7fc6130c023ad9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic07c5110a61643c2a55c992dde280072_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i07c1d47dd14647d0964914f96057eefe_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3382e3eaaaa846039edbe767cda3d3e8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0b228ed718b140b2a339fb6308161ea7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i99c7716e33994105b40cddd5474333b2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i69cecf5a94a046b59d942b45947a7002_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibf4171e1cd304992aba32032b32e09ae_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i991a1bda2a6e4464a4b0a7be66e27ead_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id035b12c3f014d2bafdba8da0f64bb42_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:DiagnosticProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i62bee42564544f0d9b3280c51a9cc02c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0c7dafe2cfba49daa19fb3f0283b449f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i20fe539eb4a74b7492123682cd84ae45_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i22df9ace730b4d42bc4be5744f0a1bad_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6aa796dac9664691b74441abe1256b0d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i06b3500e4f5c4314a3d8cf6b4089c98e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1d0dbddbfdc84cd0ab7a31f5e8fdf16e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7c97d1edcfa444cb20aa7be67ab0d50_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5fa4384e8a504eeda1c27de655e4e9d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b879570db6940ef8d990b6465f15c41_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abt:StJudeMedicalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3f5a2e21895448f88c750459f871dbf2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abt:WalkVascularLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i495e1acb6ab646e1be98f86d888adf7c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i11d15dbdba194d4ea258e34ec953d6bd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i415827a77ac0453d839b9593bd2f924c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if1fe447f6ae64a75be725ca40d0bc9da_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i964adde7ff6b4fdc8165d93476caeb82_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie15dbca7371a44c29034f90ed736efd2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icd59cc26c1dd433798bec018b3ccbb28_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1aa011bcd53148e7baa700ba02afe7ec_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i17e4add20e234af2a1a931e4e20817bf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9696538c691b42caac0b357c13f12bac_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7e0af11ae9ab4bbcacc64379488edc44_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2e81d4049c794423a14e1d1c1af22cc7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i427e7206d73746e6898e10c2092b8bbc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i967b4d49862b4a9c90ab0df452b406c3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i819bcaf6924348468ba7ae6973f92309_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i95867ab5ff4a46c2b64acfbbad20d613_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i23ed49d742db4ba5b2f23508085a61cb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia4466aaca90a4878b4208479546c953a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i874ac07585e34b5781c671c1bc0b74c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6cdf5c348d5b4b53b9a6c86bb4a3e3c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e549a342ce24de7b2b4542ffdabcbee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7de505469f274ea4a34eb536d8434973_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c966c996c54468f969135a6a97d474a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic6e9ff01f8fd42f38aa515217549336f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idaba0b25f7ac490d965f16df9dcbf02c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9341a3223163491aafcd6fe2d673a55a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if502b2d6402f4818a6bd6e4dd318d573_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iede3d406d2714638aca592a7412cf559_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i65f21a35a5f64266baecf8e128ca0727_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2212cc9951e446de85154e63b59c05bc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4be71fc1af9b4576bbbec0f3973e74bc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:EstablishedPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8d3eeb93a75a4a2cbd31ad08fd494ee9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id2602c6bfcec4afcb539d839ccd375bd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib718c9002df547a9bb6009289d5ab871_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i73865c3e534643d5ab15aa1266d200db_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:FixedAssetWriteDownsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i32e1a3f5ab2a404ca01cc18696529902_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:InventoryRelatedChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i36df938cc26341c18a1b3e9570bcec52_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:OtherExitCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i53e8568bc39d4cb19a2c23541737716d_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i527c49b1d22240058f22784151a891f3_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:OtherExitCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic5061818384c4b19aae354446d336fd1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:InventoryRelatedChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7c70ec7c6d944192a4c8aaf8042cb9f6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:FixedAssetWriteDownsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3d67be86a0834dfeb506f82b11589377_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:OtherExitCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icd32e0ec232449a093586b6ac423eb4f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib1b41672050b4f62a5208c5e716d43f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:InventoryRelatedChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i901a35e981d14756b34a5adff1083cf4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:FixedAssetWriteDownsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7235f22a8e74924b42a859bb232635a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:OtherExitCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifda673e60ee8405ea4371f6fba8fc86f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d18df850f834757a75a53bf2cdc1ca9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:InventoryRelatedChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1eef48e6721d4174ad61b0c4bacfd4ef_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:FixedAssetWriteDownsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9dfe1081e2a7492d8113f7b5208ba611_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:OtherExitCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0e0db81ff25a4a54b0211447d6b1257a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic210a4881e7a4bfc8506d1330434b1b9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:InventoryRelatedChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia8624555d304424fb6b08adc08120a68_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:FixedAssetWriteDownsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3ba1fc8cda234a89b835a4e348ba3cef_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abt:OtherExitCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i562dbdedf98e492987bde41c83f41e48_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:COVID19TestManufacturingNetworkRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4794a110deb7433cbee3148cdeb358b8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibabb70918fa246128ee74b2f2f3ccaf0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abt:CostOfGoodsAndServicesSoldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i83f541eac1144e6bba42b451c74c7720_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie2df776b1f8948a8af5d5968a2f003d9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0d232a4fb6cb42509c44225cb0f739e3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i025aec3dc4f441b783d28fd3085d2f29_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id22fc873c34b4c30b31390c7c0722eab_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">abt:RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3d7dd7f42af3454e98ea0cd9e0de9533_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ief8174a37ce742efb72aee7ec66f0b45_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abt:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4e93f70390524d65aa024c34612f8203_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i33f19560992c435a88092f47daf02b5b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib0b29ca98ef14de0a3be8cd36653449b_D20220315-20220315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abt:A255LongTermNotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-15</startDate>
            <endDate>2022-03-15</endDate>
        </period>
    </context>
    <context id="icb2e6dec32fd457dab072263060d0e7f_I20220315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abt:A255LongTermNotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-15</instant>
        </period>
    </context>
    <context id="i76a875a71c9d425d9d761f5b9b84a5e2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iaf6d0188932d469bac5c2cf700f6c5e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75c98c84b66f4cfa973544e07e3a54c4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7768645f0e3548ef8fa07c72bb1ea50a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib70687d909df4adf951907f9e4120aa4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i362cc950c402435b85ccd22cc23f812e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abt:YenDenominatedLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i549e4e2eae714c2daeb70c21f201d001_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abt:YenDenominatedLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie414f701cbf142b7b9b601b415e450e9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abt:YenDenominatedLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3273ef5ba89846a6b3579791ad4114a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abt:YenDenominatedLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37b05ec060e14d3a94f524f71c4a509a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7159ef591665413e9beeecc68ac31d2d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec45d80b0bae4c32b4f36d6967676878_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abt:DeferredIncomeTaxesAndOtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie3c67e54492a410491b80a24aa671e4c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abt:DeferredIncomeTaxesAndOtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b9ef5b827994c42a6595f4e0c623688_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abt:PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0ec5a2619fbe4414981ad28228a6b87f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abt:PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9cb408ff61494ac1a4b289c86d1de300_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abt:PrepaidExpensesAndOtherReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iea63a66bbec848d5af23efa2feb1ab3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abt:PrepaidExpensesAndOtherReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia26c1f62062f4ea0a07843e03153843d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic0dc5c19ed38405a941c3edfc0d6963e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4cdc399d14e84bc6a02151fe08ebeac0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abt:PrepaidExpensesAndOtherReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i65c2fb65db7845fb87663d6e762d2d63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abt:PrepaidExpensesAndOtherReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2505f0c40f0d485cb42f96d4df9ad116_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2e3df89ca5cd458499f4fddc42ea907e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea1dfa89210b49259cbcc86f33bc5af3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifd9937735c2340e2a5e5e7ccb99a641e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5397677ab93a49019eae8c9a0bb21d79_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7dcc53ef71a34fb88566cf49ebd25f9f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie72837af6cc147a5874155b6990bf8c9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i65ae9ecf6fd5486287c43691fc391e33_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3506a1ed3b6c452f90c9f839466ac4e4_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie5be187d8164445380ced526aa943a0c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7cdf77deb3954cceb710b7273d79ecc6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaf6360515a084a56b0e124d0c9a4b858_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:DebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7a8804aef7ab405a9bd7994c3c7fc41c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6840ccb5da6c4ad4bda53b49c4cd3231_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6afdc8cb667a4638a732ba5f45eb54ba_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i091abb1e8fe94a55b833b101e4414fe1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i88b7ee098ae642899deeab2cddde1c6d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1277200202a84547aa376e37e03fd635_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia237ff4511bb4929b3bba3623e099990_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8cd680e248c64638be6c598cf72ebfad_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7e53ec310eb54a098325e121ff28338f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4dcc8e7c28ee4309824c37c0f1ba79d8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i301f40be6d6f4ebb92077078845bdb8c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa54db95946a4086a4914e1aa90c5af3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedd4976f99c842058ae43f0aefe27d73_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9db10f8a54af4a0aaa440b1f3206a5d2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i44e6cf7c4a144759b6e10215356df268_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i199db302b74f4397862dc61ac1c91c79_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i132737fb549d49b2af4b792fb9883efb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic595c192e42f4320bb74ffe5f79848fa_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if9130097464e4c8abfc4ebc47a8bf3db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic386176ec45b4cb29e70f8de930f1a01_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie6d54ddc609d499383aafcf6ba76dd93_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib18fc392e579454d8f85e5dc41070311_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1f2a644ac84481c931d626da6d56b5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1940cafbfda44622acb910b14b1f0a51_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie698bf737c3e45f2bb1ceb02130904bb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">abt:LegalProceedingsAndEnvironmentalExposuresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia383194c19ba4900ae6daf189c3fb80d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">abt:LegalProceedingsAndEnvironmentalExposuresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id0f82983e37f491aa82bf6e3c57ef4d8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">abt:LegalProceedingsAndEnvironmentalExposuresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic55e17708b144d149c97d0b172bd426e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idf9e8de48606409d948398115c9f7699_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i40386c7e28f341b4ae443602056c8368_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i229532fb1b884a2b865d6f39735f6e86_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib6b147cc106249baa28781e370ab66ec_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iae69ef505e864efdaa37bebaf468436c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i08ff00d9980745d3b2b0e1c3d2eefd08_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1099be209597485a9a6ade72499f0853_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7c3c6424ac1343408381b0dd7b44aae4_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2a9d35abc82344dd90c2c98e1ecdaa09_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8bf83d91e28e4b25a1e93ffb4e5cc448_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1d7ba7ecde044f91a11577ec17c7a3cd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibc718d211ed24b9d86b6822747cccf0f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic04e27180eea452fabf297f6b5a3fb8f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4d59739e470d42f5ae66f7d538c62253_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib6f6799cbf824e39b44c30362ca2098b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i54d09e1c87b34a10a7dd79336679c8d9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8f4b8383f4d6400996c6ee0273a48d8f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:NutritionalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia6ddcd9bbd2f4feaa5056904c8dc104b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000001800</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">abt:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>abt:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80L2ZyYWc6Njc0NDY0Y2U0NDY4NGIzOWEyNWE5NGNjNzM3OTI2ZTcvdGFibGU6NWViMjRkY2Y3ZmUyNGMyOWIzYjkxNDU1NTc3Yjc1Y2EvdGFibGVyYW5nZTo1ZWIyNGRjZjdmZTI0YzI5YjNiOTE0NTU1NzdiNzVjYV8yLTEtMS0xLTE3ODY4_4eaaeac8-85b2-496d-a419-aae9524859d5">0000001800</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80L2ZyYWc6Njc0NDY0Y2U0NDY4NGIzOWEyNWE5NGNjNzM3OTI2ZTcvdGFibGU6NWViMjRkY2Y3ZmUyNGMyOWIzYjkxNDU1NTc3Yjc1Y2EvdGFibGVyYW5nZTo1ZWIyNGRjZjdmZTI0YzI5YjNiOTE0NTU1NzdiNzVjYV8zLTEtMS0xLTE3ODY4_3f2f8326-f4c1-4f18-ac5a-874377f2cd8b">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80L2ZyYWc6Njc0NDY0Y2U0NDY4NGIzOWEyNWE5NGNjNzM3OTI2ZTcvdGFibGU6NWViMjRkY2Y3ZmUyNGMyOWIzYjkxNDU1NTc3Yjc1Y2EvdGFibGVyYW5nZTo1ZWIyNGRjZjdmZTI0YzI5YjNiOTE0NTU1NzdiNzVjYV80LTEtMS0xLTE3ODY4_50dc7d2f-10b5-4a11-a1b2-8c9678e65b0c">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80L2ZyYWc6Njc0NDY0Y2U0NDY4NGIzOWEyNWE5NGNjNzM3OTI2ZTcvdGFibGU6NWViMjRkY2Y3ZmUyNGMyOWIzYjkxNDU1NTc3Yjc1Y2EvdGFibGVyYW5nZTo1ZWIyNGRjZjdmZTI0YzI5YjNiOTE0NTU1NzdiNzVjYV81LTEtMS0xLTE3ODY4_3019bba2-3873-4692-bdb7-29c5f761543d">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80L2ZyYWc6Njc0NDY0Y2U0NDY4NGIzOWEyNWE5NGNjNzM3OTI2ZTcvdGFibGU6NWViMjRkY2Y3ZmUyNGMyOWIzYjkxNDU1NTc3Yjc1Y2EvdGFibGVyYW5nZTo1ZWIyNGRjZjdmZTI0YzI5YjNiOTE0NTU1NzdiNzVjYV82LTEtMS0xLTE3ODY4_743c084b-6ded-4bb7-be40-ae0abd05f679">false</dei:AmendmentFlag>
    <abt:MinimumLengthOfTimeHedgedInCashFlowHedge
      contextRef="i75c98c84b66f4cfa973544e07e3a54c4_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNjQ1_49b14940-1788-44d4-b632-7d72eb48a1c0">P12M</abt:MinimumLengthOfTimeHedgedInCashFlowHedge>
    <dei:DocumentType
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xODM4_a76e7008-2061-4ad1-8399-c6a8f097cf57">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6YzE3Mzk0ZmY5NzBiNDMzY2FmMTA0YmQ4YWVkMjQ1NGYvdGFibGVyYW5nZTpjMTczOTRmZjk3MGI0MzNjYWYxMDRiZDhhZWQyNDU0Zl8wLTAtMS0xLTE3ODY4_5857281c-c04b-4ec2-b76b-cb9f84bd8806">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xMzM_49d38512-ad89-4c81-9947-7c731f02515c">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6MmQ0Y2ZjMWRjZmE1NGI5ZGI1Y2VlMDI3ZmYxNDBhZDEvdGFibGVyYW5nZToyZDRjZmMxZGNmYTU0YjlkYjVjZWUwMjdmZjE0MGFkMV8wLTAtMS0xLTE3ODY4_3301bc90-8960-4e69-8723-a9ec6ec3531c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xODQz_99072e9e-5dc1-4add-83ff-49b96cd25ae6">1-2189</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xODQ0_365133b9-000a-4f3b-ab96-2366cc62f21b">ABBOTT LABORATORIES</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6NWY3N2FkNTZiMGQ4NDkwM2FjYWY1YmE3MTcwMDUzNTQvdGFibGVyYW5nZTo1Zjc3YWQ1NmIwZDg0OTAzYWNhZjViYTcxNzAwNTM1NF8wLTAtMS0xLTE3ODY4L3RleHRyZWdpb246ZTgwMjQ1MzUxMGI1NDQ1ZGFiOTIxMWFhMDIxNTk1ZTRfNw_2c1f3eee-522e-429c-ab00-e687085fe4a0">IL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6NWY3N2FkNTZiMGQ4NDkwM2FjYWY1YmE3MTcwMDUzNTQvdGFibGVyYW5nZTo1Zjc3YWQ1NmIwZDg0OTAzYWNhZjViYTcxNzAwNTM1NF8xLTEtMS0xLTE3ODY4_0ec025b1-6419-4087-96ac-78c3d4f3c23b">36-0698440</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8yMzk_337c1930-de71-45cd-ad9d-b7c646a4ef1f">100 Abbott Park Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8yNDI_4b132994-4ad9-405f-8b36-a70c26710c72">Abbott Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8yNDY_7d0d7546-d3b0-4248-87be-4ecb0d606121">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8yNDk_2564abbf-c8a3-4c5b-8631-b9a64938ae81">60064-6400</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xODM5_a020ab5a-4771-4ae8-90a2-82918f7ebfe3">224</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xODQw_0381a5bc-e517-45a1-bd1f-ee07f3fc5744">667-6100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="icaa425fa3d3747d6ad2878dffdb267d0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6YzY1NWVjNzUzMzI4NGYxNGIyZWU2MDE2NjEyNWRhOGIvdGFibGVyYW5nZTpjNjU1ZWM3NTMzMjg0ZjE0YjJlZTYwMTY2MTI1ZGE4Yl8yLTAtMS0xLTE3ODY4_ad449f61-9f17-435f-b6b4-4b2fcdee62fd">Common Shares, Without Par Value</dei:Security12bTitle>
    <dei:Security12bTitle
      contextRef="i59773e96f1294946be35567fa420b29a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6YzY1NWVjNzUzMzI4NGYxNGIyZWU2MDE2NjEyNWRhOGIvdGFibGVyYW5nZTpjNjU1ZWM3NTMzMjg0ZjE0YjJlZTYwMTY2MTI1ZGE4Yl8yLTAtMS0xLTE3ODY4_bf84ae93-3535-443c-94fd-66d248573588">Common Shares, Without Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icaa425fa3d3747d6ad2878dffdb267d0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6YzY1NWVjNzUzMzI4NGYxNGIyZWU2MDE2NjEyNWRhOGIvdGFibGVyYW5nZTpjNjU1ZWM3NTMzMjg0ZjE0YjJlZTYwMTY2MTI1ZGE4Yl8yLTEtMS0xLTE3ODY4_54b68d94-6492-406b-9cc6-48f25b94a44b">ABT</dei:TradingSymbol>
    <dei:TradingSymbol
      contextRef="i59773e96f1294946be35567fa420b29a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6YzY1NWVjNzUzMzI4NGYxNGIyZWU2MDE2NjEyNWRhOGIvdGFibGVyYW5nZTpjNjU1ZWM3NTMzMjg0ZjE0YjJlZTYwMTY2MTI1ZGE4Yl8yLTEtMS0xLTE3ODY4_a1536d56-69aa-40ab-8ab2-676151642bff">ABT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i59773e96f1294946be35567fa420b29a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6YzY1NWVjNzUzMzI4NGYxNGIyZWU2MDE2NjEyNWRhOGIvdGFibGVyYW5nZTpjNjU1ZWM3NTMzMjg0ZjE0YjJlZTYwMTY2MTI1ZGE4Yl8yLTItMS0xLTE3ODY4L3RleHRyZWdpb246MmVlNzRhYWZlYmM2NDc2M2IzNzUyZTY1NjUyNTM5OThfNQ_072e4e22-4c38-4fa3-b411-69892dc8e034">NYSE</dei:SecurityExchangeName>
    <dei:SecurityExchangeName
      contextRef="icaa425fa3d3747d6ad2878dffdb267d0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6YzY1NWVjNzUzMzI4NGYxNGIyZWU2MDE2NjEyNWRhOGIvdGFibGVyYW5nZTpjNjU1ZWM3NTMzMjg0ZjE0YjJlZTYwMTY2MTI1ZGE4Yl8yLTItMS0xLTE3ODY4L3RleHRyZWdpb246MmVlNzRhYWZlYmM2NDc2M2IzNzUyZTY1NjUyNTM5OThfOA_fb450a8b-021e-4b33-b55f-0a9e093f3c19">CHX</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xODQ1_5960b6ee-e8fe-4bef-8693-245a055a921e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xODQx_4915dd4c-f090-4281-a712-a9ffa7ceb3e5">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6N2Y2Yzg3NTQyZWY0NGUyNjkyMjQwMTBjYjJlOGU3ZGUvdGFibGVyYW5nZTo3ZjZjODc1NDJlZjQ0ZTI2OTIyNDAxMGNiMmU4ZTdkZV8wLTAtMS0xLTE3ODY4L3RleHRyZWdpb246MGQxM2NmMjNhMzczNDU5MzhjM2NiMjc1YmE2YzVhYjJfNA_b5fac75f-b1f9-4c94-94b0-732ef06ebcbf">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6N2Y2Yzg3NTQyZWY0NGUyNjkyMjQwMTBjYjJlOGU3ZGUvdGFibGVyYW5nZTo3ZjZjODc1NDJlZjQ0ZTI2OTIyNDAxMGNiMmU4ZTdkZV8yLTEtMS0xLTE3ODY4_7fbb2507-18f2-449c-b008-42d6b8377fd7">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGFibGU6N2Y2Yzg3NTQyZWY0NGUyNjkyMjQwMTBjYjJlOGU3ZGUvdGFibGVyYW5nZTo3ZjZjODc1NDJlZjQ0ZTI2OTIyNDAxMGNiMmU4ZTdkZV80LTEtMS0xLTE3ODY4_6ce0fed0-6970-4c06-b3e0-27a41b600eaf">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xODQy_a4ba5941-3e45-419d-a46b-786fa4b45144">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xL2ZyYWc6M2U5NjFjMTU0ZWZhNDNiZDk2NjEyNDM2OTY4N2M3MzgvdGV4dHJlZ2lvbjozZTk2MWMxNTRlZmE0M2JkOTY2MTI0MzY5Njg3YzczOF8xMDk5NTExNjI5Nzc5_549533f1-8001-4da9-b4a8-1cfb61fb1b4b"
      unitRef="shares">1743573777</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMy0xLTEtMS0xNzg2OA_49817899-a5f0-4509-aa25-f0d11bd7b323"
      unitRef="usd">10410000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMy0zLTEtMS0xNzg2OA_5058b4c4-c5d4-43fb-b01d-3fb569148c64"
      unitRef="usd">10928000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMy01LTEtMS0xNzg2OA_51d45413-ad19-4e9d-ac2a-a53f21c6673c"
      unitRef="usd">33562000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMy03LTEtMS0xNzg2OA_60d34563-72ce-4541-b8a9-069922686196"
      unitRef="usd">31607000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNS0xLTEtMS0xNzg2OA_966defd9-3d41-4857-87ce-04c495fd306c"
      unitRef="usd">4629000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNS0zLTEtMS0xNzg2OA_74f7facf-0c1d-4ad5-939b-d90ae48ea14c"
      unitRef="usd">4423000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNS01LTEtMS0xNzg2OA_ed88e7e9-5d17-41d3-97aa-611b3f6af9a7"
      unitRef="usd">14549000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNS03LTEtMS0xNzg2OA_12eda92f-da41-4dbd-94cf-d0290a435aed"
      unitRef="usd">13771000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNi0xLTEtMS0xNzg2OA_51d4e935-6924-454d-b778-09b027569f7c"
      unitRef="usd">498000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNi0zLTEtMS0xNzg2OA_48797f2c-57d5-433f-a716-c3cf0d651c7e"
      unitRef="usd">520000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNi01LTEtMS0xNzg2OA_9dad01b7-b275-4fd4-9312-c84fd11a5a7d"
      unitRef="usd">1517000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNi03LTEtMS0xNzg2OA_b2285418-eaed-4fb6-a683-c4843b5a4d71"
      unitRef="usd">1533000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNy0xLTEtMS0xNzg2OA_2b4ba563-a1d1-459a-9cde-616e7e9ec5de"
      unitRef="usd">782000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNy0zLTEtMS0xNzg2OA_0b94913b-9dde-413c-bf3c-9608a27128fd"
      unitRef="usd">672000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNy01LTEtMS0xNzg2OA_c31c7e0b-7c08-4c4b-b4aa-af20a58906db"
      unitRef="usd">2163000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfNy03LTEtMS0xNzg2OA_5277ef0b-70d6-4bc3-ba44-2ee2d8396e52"
      unitRef="usd">1980000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfOC0xLTEtMS0xNzg2OA_7a0d6fc9-6008-4e79-915a-6614145d0310"
      unitRef="usd">2731000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfOC0zLTEtMS0xNzg2OA_dc03f945-2fd5-4852-af02-d2022558537c"
      unitRef="usd">2767000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfOC01LTEtMS0xNzg2OA_1c912b19-669c-48cf-aba4-6f7e6dda85d9"
      unitRef="usd">8275000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfOC03LTEtMS0xNzg2OA_322ac259-3c1f-44a9-a3b7-65d03a3bfcd8"
      unitRef="usd">8276000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfOS0xLTEtMS0xNzg2OA_bc463ef4-3ce2-41d0-8884-be0328338632"
      unitRef="usd">8640000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfOS0zLTEtMS0xNzg2OA_378968aa-f5d7-46ea-b5b2-6f79bfbc5f96"
      unitRef="usd">8382000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfOS01LTEtMS0xNzg2OA_7a3edf77-6500-45b2-83dd-d703ccf2889c"
      unitRef="usd">26504000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfOS03LTEtMS0xNzg2OA_ff1d159d-3db3-4e4c-b867-eae584eca6ca"
      unitRef="usd">25560000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTEtMS0xLTEtMTc4Njg_d52bb521-062b-440b-9ebd-d037a851cd1b"
      unitRef="usd">1770000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTEtMy0xLTEtMTc4Njg_5e3cf824-7427-4dcd-9f39-63a0b479bcd8"
      unitRef="usd">2546000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTEtNS0xLTEtMTc4Njg_0c42c9ea-f875-4957-b4be-06b38b48ea43"
      unitRef="usd">7058000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTEtNy0xLTEtMTc4Njg_573cd700-ee16-4fe6-9c6e-1da772a9ecae"
      unitRef="usd">6047000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTMtMS0xLTEtMTc4Njg_76559864-0878-4b51-995b-c35a0d37995e"
      unitRef="usd">141000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTMtMy0xLTEtMTc4Njg_039e3441-a430-4857-8990-3fd8c1ea5c28"
      unitRef="usd">133000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTMtNS0xLTEtMTc4Njg_0f1338f5-a714-4439-8be6-08b0ae94868a"
      unitRef="usd">404000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTMtNy0xLTEtMTc4Njg_31d33abd-d6f4-4c7b-b4ee-349e16bc82a0"
      unitRef="usd">402000000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTQtMS0xLTEtMTc4Njg_f502b2f5-0343-44a7-a8f4-0a842a68ff81"
      unitRef="usd">55000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTQtMy0xLTEtMTc4Njg_d113d973-6db4-4d91-b45e-47b5ef0a313f"
      unitRef="usd">10000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTQtNS0xLTEtMTc4Njg_9bea4115-0add-4ab9-9eec-4a453cc4939b"
      unitRef="usd">95000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTQtNy0xLTEtMTc4Njg_b6e539f7-026d-44f7-8295-5abf55e45ff5"
      unitRef="usd">32000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTUtMS0xLTEtMTc4Njg_a954bbdd-927f-4d41-a099-327c4b7e7a9b"
      unitRef="usd">-19000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTUtMy0xLTEtMTc4Njg_e0a67c57-d7b3-4795-945d-c09ba1ba7868"
      unitRef="usd">-4000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTUtNS0xLTEtMTc4Njg_0f5e84ec-dd9b-42b9-a12c-d7035c4bfbc5"
      unitRef="usd">-16000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTUtNy0xLTEtMTc4Njg_4040741e-23dd-473c-89f3-a3144b0854eb"
      unitRef="usd">-7000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTYtMS0xLTEtMTc4Njg_860ea2cb-76c8-4214-a507-7483ca68f020"
      unitRef="usd">93000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTYtMy0xLTEtMTc4Njg_23048a92-70ec-49e3-8db0-99d9d7592761"
      unitRef="usd">74000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTYtNS0xLTEtMTc4Njg_caeab90c-0574-46fd-a789-e78996d7a2ef"
      unitRef="usd">253000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTYtNy0xLTEtMTc4Njg_57778ecc-16dd-4f53-b11b-a4df5e6b880f"
      unitRef="usd">214000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTctMS0xLTEtMTc4Njg_c1c6bc20-53d4-487e-9782-b4fed5bd1b4d"
      unitRef="usd">1758000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTctMy0xLTEtMTc4Njg_a9307866-040f-4555-988d-54c59af21fee"
      unitRef="usd">2493000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTctNS0xLTEtMTc4Njg_18ea6bf4-a99c-4f2b-a357-9bd0694bafc2"
      unitRef="usd">6986000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTctNy0xLTEtMTc4Njg_9fe227ba-38a9-4646-9766-19ee97a5e0f1"
      unitRef="usd">5884000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTgtMS0xLTEtMTc4Njg_32b50073-b948-451c-a63f-e28d2904dec2"
      unitRef="usd">323000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTgtMy0xLTEtMTc4Njg_5972ad36-c7a0-4c61-a7ea-0a95b75f40e2"
      unitRef="usd">393000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTgtNS0xLTEtMTc4Njg_961fb605-d3a4-471e-a3a3-2509d9e1fa64"
      unitRef="usd">1086000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTgtNy0xLTEtMTc4Njg_a84c8da7-e762-44d7-9f45-af2d3fc19285"
      unitRef="usd">802000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTktMS0xLTEtMTc4Njg_3631ef4b-b3a2-49e6-9943-4cac2bc61023"
      unitRef="usd">1435000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTktMy0xLTEtMTc4Njg_61369dd7-0c34-42b1-a71d-9e35712f6a45"
      unitRef="usd">2100000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTktNS0xLTEtMTc4Njg_c6c175ee-8dfa-4234-a006-3255854b0d27"
      unitRef="usd">5900000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMTktNy0xLTEtMTc4Njg_2c8b6e52-9063-4a11-b360-d6a5848dd74f"
      unitRef="usd">5082000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjEtMS0xLTEtMTc4Njg_958fb907-a53c-4d31-9375-be5cd9c4faf2"
      unitRef="usdPerShare">0.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjEtMy0xLTEtMTc4Njg_b7f00a63-1adb-4b6e-8b3a-53b09afffe96"
      unitRef="usdPerShare">1.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjEtNS0xLTEtMTc4Njg_0dbb7573-4d96-4805-ae39-2f307adb3519"
      unitRef="usdPerShare">3.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjEtNy0xLTEtMTc4Njg_bd120ff5-f8f8-4d01-baad-dce56b202be8"
      unitRef="usdPerShare">2.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjMtMS0xLTEtMTc4Njg_c031830f-320b-457e-b1be-5de86fb8e0b2"
      unitRef="usdPerShare">0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjMtMy0xLTEtMTc4Njg_f8632043-bf35-4189-97bd-a5f26a6e2f4d"
      unitRef="usdPerShare">1.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjMtNS0xLTEtMTc4Njg_b9029f4f-cc2a-406c-be0d-59f51a2a80f4"
      unitRef="usdPerShare">3.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjMtNy0xLTEtMTc4Njg_1b04ee2b-9d3e-4663-ade9-1e25f31b58c5"
      unitRef="usdPerShare">2.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjUtMS0xLTEtMTc4Njg_66a6aa95-9001-49d9-b21c-467c4efe0677"
      unitRef="shares">1752968000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjUtMy0xLTEtMTc4Njg_b88f1766-ac45-49a2-8cda-739e354e65a3"
      unitRef="shares">1774516000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjUtNS0xLTEtMTc4Njg_a3b15a8c-bef8-46a3-968a-53db15ea985b"
      unitRef="shares">1756209000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjUtNy0xLTEtMTc4Njg_4afd2373-f512-4c5f-9d28-9ca0e770a3e2"
      unitRef="shares">1776870000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjYtMS0xLTEtMTc4Njg_9be962a7-4cac-4676-bcd3-d74ad723442f"
      unitRef="shares">10685000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjYtMy0xLTEtMTc4Njg_ddf13721-f302-42e3-8c0f-79a08d95868d"
      unitRef="shares">14483000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjYtNS0xLTEtMTc4Njg_01f0e8b4-8c9c-4ac6-9670-1556ace0bd54"
      unitRef="shares">11638000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjYtNy0xLTEtMTc4Njg_cde29cb8-e546-47d3-a734-2e38ac9d2bec"
      unitRef="shares">14407000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjctMS0xLTEtMTc4Njg_eb216da7-4c66-4742-bd70-6c0ebf3cc6c3"
      unitRef="shares">1763653000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjctMy0xLTEtMTc4Njg_df389df9-125a-4a23-a855-bd6a25ed7962"
      unitRef="shares">1788999000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjctNS0xLTEtMTc4Njg_88e753c6-99b6-4786-a59e-c34ccd3e62a7"
      unitRef="shares">1767847000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjctNy0xLTEtMTc4Njg_06fd953d-171b-438d-8796-f8b86392c2c3"
      unitRef="shares">1791277000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjktMS0xLTEtMTc4Njg_7bba17bf-1a2b-4aaf-94d5-7f90ab2f6a7b"
      unitRef="shares">5445000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjktMy0xLTEtMTc4Njg_e90d9069-1681-44b6-85c6-a98a8e2c3cff"
      unitRef="shares">2740000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjktNS0xLTEtMTc4Njg_5ddfe742-b308-4063-a3bc-123da50a78ac"
      unitRef="shares">2655000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xNi9mcmFnOmE3ZGVkN2UyOTcwMjQyN2Y5MzQwZmNjYzJjMjE4NDFlL3RhYmxlOjRmYjkyZGIxMDg2OTRlMzE4MmYwYmM0YWNmZThlNjFmL3RhYmxlcmFuZ2U6NGZiOTJkYjEwODY5NGUzMTgyZjBiYzRhY2ZlOGU2MWZfMjktNy0xLTEtMTc4Njg_f22eff5c-6f99-4807-b72f-f365448762a9"
      unitRef="shares">2694000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NetIncomeLoss
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfMy0xLTEtMS0xNzg2OA_474eae53-a05e-4ada-9d08-c19e28217d4e"
      unitRef="usd">1435000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfMy0zLTEtMS0xNzg2OA_6cf096ff-017c-4b31-bd54-e585bc59bc36"
      unitRef="usd">2100000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfMy01LTEtMS0xNzg2OA_857d5921-ce3c-4a90-aba5-c1c8452230a5"
      unitRef="usd">5900000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfMy03LTEtMS0xNzg2OA_5d83e1f2-82a8-4a3f-8a32-d9d55b7ebc9b"
      unitRef="usd">5082000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNC0xLTEtMS0xNzg2OA_c9117d24-1350-4ec7-b17e-b9061ddda273"
      unitRef="usd">-1008000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNC0zLTEtMS0xNzg2OA_f8073a6b-5d42-4049-a010-fdee92d68395"
      unitRef="usd">-391000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNC01LTEtMS0xNzg2OA_9ae8832c-6a94-4633-9d6b-f83b021a7504"
      unitRef="usd">-1429000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNC03LTEtMS0xNzg2OA_d76ac2de-09dd-42d9-952c-3431c69c69cc"
      unitRef="usd">-762000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNS0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjllZGM1NjMzZjUxZjRjM2M5ZDJkYTYyMzQwYmU0NzIxXzEyNw_f433843b-f6a9-4f7b-9fdf-c26cd3e13058"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNS0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjllZGM1NjMzZjUxZjRjM2M5ZDJkYTYyMzQwYmU0NzIxXzEzNA_a78c5a3d-1524-41a7-aa5d-b4f038270897"
      unitRef="usd">-36000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNS0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjllZGM1NjMzZjUxZjRjM2M5ZDJkYTYyMzQwYmU0NzIxXzE0Nw_5ef35f83-e0ba-45aa-a8e4-a552f4a10d53"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNS0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjllZGM1NjMzZjUxZjRjM2M5ZDJkYTYyMzQwYmU0NzIxXzE1NA_211ac1e9-b4de-4a69-b0ec-1580a26bff9e"
      unitRef="usd">-54000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNS0xLTEtMS0xNzg2OA_42234238-203c-4c36-886e-a2cb75e1e9be"
      unitRef="usd">-56000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNS0zLTEtMS0xNzg2OA_3d7008a0-b88e-414f-8fe6-ea7778e28472"
      unitRef="usd">-78000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNS01LTEtMS0xNzg2OA_830086fd-7cc6-4f73-98ac-08a0627b5cfc"
      unitRef="usd">-172000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNS03LTEtMS0xNzg2OA_2a1d6623-3b67-4792-90d4-2bf683e33fba"
      unitRef="usd">-211000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNi0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOmUyNzU2OTBhYTRlZTRmMDliYzY1YjU0NmQ1Y2E2ZDA3XzEwOA_07d16fad-c0f5-4024-b5e7-5291a760b984"
      unitRef="usd">50000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNi0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOmUyNzU2OTBhYTRlZTRmMDliYzY1YjU0NmQ1Y2E2ZDA3XzExNQ_f6c50bfe-88d7-40a5-85b2-703a2fb22576"
      unitRef="usd">96000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNi0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOmUyNzU2OTBhYTRlZTRmMDliYzY1YjU0NmQ1Y2E2ZDA3XzEyOA_d4d2eb94-bff7-4676-9450-45c4e78cfa53"
      unitRef="usd">50000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNi0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOmUyNzU2OTBhYTRlZTRmMDliYzY1YjU0NmQ1Y2E2ZDA3XzEzNQ_7ae5bcd7-4089-45bd-a1dd-bc70a204e408"
      unitRef="usd">98000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNi0xLTEtMS0xNzg2OA_0f3102d7-a24b-4158-a598-520c598dd4b2"
      unitRef="usd">213000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNi0zLTEtMS0xNzg2OA_4d0d2c14-2d99-4a3e-9623-7f2e3256bb23"
      unitRef="usd">139000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNi01LTEtMS0xNzg2OA_90a1cab1-afe6-423a-a724-8897d37ec605"
      unitRef="usd">186000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNi03LTEtMS0xNzg2OA_8b71d0cd-2726-44c0-bc17-183aac498591"
      unitRef="usd">257000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNy0xLTEtMS0xNzg2OA_3492d2bf-6908-410a-953c-cf21fc84b29e"
      unitRef="usd">-739000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNy0zLTEtMS0xNzg2OA_f378625f-92a5-49dc-9e2e-c48ec6cba283"
      unitRef="usd">-174000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNy01LTEtMS0xNzg2OA_15c3654c-14e5-4e47-b082-165be16b3d46"
      unitRef="usd">-1071000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfNy03LTEtMS0xNzg2OA_42c40118-fa0b-4e33-b2e2-71b4dbda6ac2"
      unitRef="usd">-294000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfOC0xLTEtMS0xNzg2OA_d77243d3-26b7-4057-834f-645a7a110835"
      unitRef="usd">696000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfOC0zLTEtMS0xNzg2OA_3901b267-153a-4cd1-ba88-b87902bcfcbe"
      unitRef="usd">1926000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfOC01LTEtMS0xNzg2OA_a119c32b-5e62-4d4e-8fea-b1f2e3ab879d"
      unitRef="usd">4829000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjk1NTVlMDhkMWQzMTRkN2E4ZTAzNGQ3ZTczMGM4ZjgzL3RhYmxlcmFuZ2U6OTU1NWUwOGQxZDMxNGQ3YThlMDM0ZDdlNzMwYzhmODNfOC03LTEtMS0xNzg2OA_e5bd0429-a92e-40c2-be13-d5aa3028b0ad"
      unitRef="usd">4788000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjBhZTI2MzM2ZWJhMjQzMzg4MTU3ZWNmMzQzZmU2MzQ3L3RhYmxlcmFuZ2U6MGFlMjYzMzZlYmEyNDMzODgxNTdlY2YzNDNmZTYzNDdfMi0xLTEtMS0xNzg2OA_75d15e2d-af7e-4913-aa06-9da99984496c"
      unitRef="usd">-7268000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjBhZTI2MzM2ZWJhMjQzMzg4MTU3ZWNmMzQzZmU2MzQ3L3RhYmxlcmFuZ2U6MGFlMjYzMzZlYmEyNDMzODgxNTdlY2YzNDNmZTYzNDdfMi0zLTEtMS0xNzg2OA_7c13eb3b-738e-4c1e-bda0-e3e1c721d991"
      unitRef="usd">-5839000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjBhZTI2MzM2ZWJhMjQzMzg4MTU3ZWNmMzQzZmU2MzQ3L3RhYmxlcmFuZ2U6MGFlMjYzMzZlYmEyNDMzODgxNTdlY2YzNDNmZTYzNDdfMy0xLTEtMS0xNzg2OA_7b804ca0-206a-402a-9a14-eda7992be1c7"
      unitRef="usd">2498000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjBhZTI2MzM2ZWJhMjQzMzg4MTU3ZWNmMzQzZmU2MzQ3L3RhYmxlcmFuZ2U6MGFlMjYzMzZlYmEyNDMzODgxNTdlY2YzNDNmZTYzNDdfMy0zLTEtMS0xNzg2OA_47703934-c08c-48d3-bcc0-39f97348a61f"
      unitRef="usd">2670000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjBhZTI2MzM2ZWJhMjQzMzg4MTU3ZWNmMzQzZmU2MzQ3L3RhYmxlcmFuZ2U6MGFlMjYzMzZlYmEyNDMzODgxNTdlY2YzNDNmZTYzNDdfNC0xLTEtMS0xNzg2OA_53df0870-a224-4709-962e-d2e34056e509"
      unitRef="usd">321000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjBhZTI2MzM2ZWJhMjQzMzg4MTU3ZWNmMzQzZmU2MzQ3L3RhYmxlcmFuZ2U6MGFlMjYzMzZlYmEyNDMzODgxNTdlY2YzNDNmZTYzNDdfNC0zLTEtMS0xNzg2OA_dacdf6a1-bbea-41ac-9edd-a0c25f3c063b"
      unitRef="usd">135000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjBhZTI2MzM2ZWJhMjQzMzg4MTU3ZWNmMzQzZmU2MzQ3L3RhYmxlcmFuZ2U6MGFlMjYzMzZlYmEyNDMzODgxNTdlY2YzNDNmZTYzNDdfNS0xLTEtMS0xNzg2OA_26c09a41-6e8d-4105-8dd6-aba3e6c2e586"
      unitRef="usd">-9445000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8xOS9mcmFnOjAzZjRhNzg5NTk3OTRlMWNhYzRkZDNhMDMzMTZjMDY0L3RhYmxlOjBhZTI2MzM2ZWJhMjQzMzg4MTU3ZWNmMzQzZmU2MzQ3L3RhYmxlcmFuZ2U6MGFlMjYzMzZlYmEyNDMzODgxNTdlY2YzNDNmZTYzNDdfNS0zLTEtMS0xNzg2OA_e0155b9a-7930-452c-9d60-2cb9ccf51677"
      unitRef="usd">-8374000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMy0xLTEtMS0xNzg2OA_8ca40d68-0b67-4d03-b8f6-ad74081318d2"
      unitRef="usd">9594000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMy0zLTEtMS0xNzg2OA_8feb9c7e-0d92-4f1f-9b44-fe383f1352aa"
      unitRef="usd">9799000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNC0xLTEtMS0xNzg2OA_d449e088-ec4f-4400-b123-e7406637670c"
      unitRef="usd">313000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNC0zLTEtMS0xNzg2OA_3ba6af97-c6bc-4070-a016-6ecbfa8792fb"
      unitRef="usd">450000000</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNS0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjQ1NmMyMWQ4NTRiYjRkYzViNDY2MTgxNmQ5YTU0MzZlXzQy_9a4486da-ea0e-4ea9-ac13-e5e8c9cc2ef6"
      unitRef="usd">520000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNS0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjQ1NmMyMWQ4NTRiYjRkYzViNDY2MTgxNmQ5YTU0MzZlXzU1_3f961409-3e62-4da4-abae-5892388a3653"
      unitRef="usd">519000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNS0xLTEtMS0xNzg2OA_34939715-de69-4200-a62c-5ee22b3e2551"
      unitRef="usd">6408000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNS0zLTEtMS0xNzg2OA_0a05389a-933d-4a81-9474-c5c94736ade3"
      unitRef="usd">6487000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNy0xLTEtMS0xNzg2OA_0f3fd6ad-cb55-4338-81ec-9047a2fd8c4e"
      unitRef="usd">3407000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNy0zLTEtMS0xNzg2OA_8b88250c-076b-445c-9fca-9b9985a23738"
      unitRef="usd">3081000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfOC0xLTEtMS0xNzg2OA_5d1f1f51-1dc8-48f0-8d42-c82ccafd63f5"
      unitRef="usd">726000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfOC0zLTEtMS0xNzg2OA_f434799e-e78d-49f6-a75a-702416e4a350"
      unitRef="usd">694000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfOS0xLTEtMS0xNzg2OA_76daf8bb-8244-4db1-a106-e2776bf20cbf"
      unitRef="usd">1601000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfOS0zLTEtMS0xNzg2OA_698ad899-9616-44ef-a7d4-3166637fff2f"
      unitRef="usd">1382000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTAtMS0xLTEtMTc4Njg_39dc3d16-bd24-45dc-a9f8-f66a420870b8"
      unitRef="usd">5734000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTAtMy0xLTEtMTc4Njg_bfa79450-2504-440a-b86d-4ba154359ab4"
      unitRef="usd">5157000000</us-gaap:InventoryNet>
    <abt:PrepaidExpenseAndOtherReceivables
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTEtMS0xLTEtMTc4Njg_79db51bc-fc93-4b01-9f29-cbaef2496297"
      unitRef="usd">2796000000</abt:PrepaidExpenseAndOtherReceivables>
    <abt:PrepaidExpenseAndOtherReceivables
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTEtMy0xLTEtMTc4Njg_dcc9768f-af12-49e7-aa24-5b67ad59d2da"
      unitRef="usd">2346000000</abt:PrepaidExpenseAndOtherReceivables>
    <us-gaap:AssetsCurrent
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTItMS0xLTEtMTc4Njg_198de426-59dc-4a9c-8ca2-2f1b5e177ec9"
      unitRef="usd">24845000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTItMy0xLTEtMTc4Njg_e5c1078c-90d2-4cb6-8e75-1f6d4a72d904"
      unitRef="usd">24239000000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTMtMS0xLTEtMTc4Njg_e1bada71-9221-4fc1-b002-8b8acd6f30ed"
      unitRef="usd">764000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTMtMy0xLTEtMTc4Njg_0faf52d1-a2f1-4820-a9e3-1ebf73b5999f"
      unitRef="usd">816000000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTQtMS0xLTEtMTc4Njg_458d2cac-7994-4ac4-bc1c-135cbde9e058"
      unitRef="usd">19306000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTQtMy0xLTEtMTc4Njg_026fc982-c751-4c1a-815b-eb3d38dcdcc5"
      unitRef="usd">19364000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTUtMS0xLTEtMTc4Njg_66672224-38af-46be-94a4-e6f06abce2fe"
      unitRef="usd">10617000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTUtMy0xLTEtMTc4Njg_e4e1c57a-e512-472b-add4-8c3d8e7cd931"
      unitRef="usd">10405000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTYtMS0xLTEtMTc4Njg_6da7023d-9e0a-4052-88cf-64f5873da71f"
      unitRef="usd">8689000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTYtMy0xLTEtMTc4Njg_299ab2d7-8c2a-40b7-9d75-2eca7400c72b"
      unitRef="usd">8959000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTctMS0xLTEtMTc4Njg_54317994-6057-4afb-af05-51bab68d341e"
      unitRef="usd">10850000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTctMy0xLTEtMTc4Njg_064d5715-e3f1-4b6a-b475-a5e147220a58"
      unitRef="usd">12739000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTgtMS0xLTEtMTc4Njg_f461add4-7565-4884-905b-d703f17776a8"
      unitRef="usd">22284000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTgtMy0xLTEtMTc4Njg_1f796c19-2510-4ea2-86c2-1fa5e2f8e400"
      unitRef="usd">23231000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTktMS0xLTEtMTc4Njg_3f7d25fc-5e46-43a0-8afa-03177ac82291"
      unitRef="usd">5369000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMTktMy0xLTEtMTc4Njg_3b954258-8fb5-49e4-8906-994d9b76f59a"
      unitRef="usd">5212000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjAtMS0xLTEtMTc4Njg_70de742e-2fd1-4a62-b77b-f5d0532fb633"
      unitRef="usd">72801000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjAtMy0xLTEtMTc4Njg_e984481f-997b-4b49-9d1f-0cb4fdd7b2f8"
      unitRef="usd">75196000000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjMtMS0xLTEtMTc4Njg_6b8ff413-803f-40e4-9b5f-5db975f33787"
      unitRef="usd">4133000000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjMtMy0xLTEtMTc4Njg_c62df9b7-7d65-4e65-87d7-83fc28aba03a"
      unitRef="usd">4408000000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjQtMS0xLTEtMTc4Njg_dae186f0-5673-4b7e-b858-66f845083e06"
      unitRef="usd">1426000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjQtMy0xLTEtMTc4Njg_cead212e-0203-4d13-a53b-da655ccc2d4e"
      unitRef="usd">1625000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjUtMS0xLTEtMTc4Njg_6c13b28b-5002-491e-bd82-a829d722ef4d"
      unitRef="usd">5475000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjUtMy0xLTEtMTc4Njg_24b22644-11cb-426a-b67e-f2f8cb3fbfba"
      unitRef="usd">5181000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjYtMS0xLTEtMTc4Njg_fa4971e3-4923-4b1f-98c0-c56dcef19971"
      unitRef="usd">820000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjYtMy0xLTEtMTc4Njg_36391678-46f0-4186-8323-04832b06e82a"
      unitRef="usd">831000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjctMS0xLTEtMTc4Njg_b6f7b9b2-4dbc-4011-b25e-3940e80e0a8d"
      unitRef="usd">394000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjctMy0xLTEtMTc4Njg_6b5521c1-6a78-4a4b-ba91-55c974d8b41c"
      unitRef="usd">306000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjgtMS0xLTEtMTc4Njg_28a5806e-7522-4406-8c33-0058eac4d582"
      unitRef="usd">1117000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjgtMy0xLTEtMTc4Njg_129119a1-ca70-4a2c-8846-8d24b7cc011b"
      unitRef="usd">754000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjktMS0xLTEtMTc4Njg_eb1ff2e2-6955-44d4-bbf6-e665539faa94"
      unitRef="usd">13365000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMjktMy0xLTEtMTc4Njg_72287aa3-3073-41a0-a710-b52fd026613f"
      unitRef="usd">13105000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzAtMS0xLTEtMTc4Njg_08d4f424-c183-429b-8fbd-558c9050120b"
      unitRef="usd">15297000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzAtMy0xLTEtMTc4Njg_cbaa39f2-2624-487d-ae04-99efff69e5ec"
      unitRef="usd">17296000000</us-gaap:LongTermDebtNoncurrent>
    <abt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzEtMS0xLTEtMTc4Njg_e29c760f-4f75-4690-b5e9-1dc562b97b2a"
      unitRef="usd">8255000000</abt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities>
    <abt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzEtMy0xLTEtMTc4Njg_a01819c8-cf4d-4ff3-9889-8a28e4051259"
      unitRef="usd">8771000000</abt:PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzItMS0xLTEtMTc4Njg_4ef6a919-1140-4b29-a869-50ff0c9fcbba"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzItMy0xLTEtMTc4Njg_ed5584b7-10d3-4b53-b677-30711f66a1cb"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjphODkxY2E2NDdkMDY0ZGQ4OTYxYmI0NjhiMDFlODUyMl8yMg_0f3bddc8-761a-4e8b-8642-6cd264f15e7c"
      unitRef="usdPerShare">1</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjphODkxY2E2NDdkMDY0ZGQ4OTYxYmI0NjhiMDFlODUyMl8yMg_7cd87e62-fe1b-4109-9eb5-3206a5576df1"
      unitRef="usdPerShare">1</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjphODkxY2E2NDdkMDY0ZGQ4OTYxYmI0NjhiMDFlODUyMl81NQ_1ef806f3-3894-47ce-99dd-6e5002ab5d37"
      unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjphODkxY2E2NDdkMDY0ZGQ4OTYxYmI0NjhiMDFlODUyMl81NQ_bfa4dccd-1ddf-44a2-a1bc-7beede1e2449"
      unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjphODkxY2E2NDdkMDY0ZGQ4OTYxYmI0NjhiMDFlODUyMl82Ng_9546d799-01da-42c1-aa73-e75d9712e44b"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjphODkxY2E2NDdkMDY0ZGQ4OTYxYmI0NjhiMDFlODUyMl82Ng_d7ba7593-321d-4750-a9fb-3a884c304bcf"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzQtMS0xLTEtMTc4Njg_8198e645-0e13-435d-95f4-7bc1d39f7476"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzQtMy0xLTEtMTc4Njg_2065becb-1c5b-452e-b1bb-e513595a8da4"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzUtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjozNjYyNWVkNTcxYjg0N2I2YWZmODljNWQwZDNjYzg0ZF81MA_83594fa4-7162-4989-a5e0-45e1a2ae7b7f"
      unitRef="shares">2400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzUtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjozNjYyNWVkNTcxYjg0N2I2YWZmODljNWQwZDNjYzg0ZF81MA_f021d291-2c95-4174-bd2b-0725729c60b7"
      unitRef="shares">2400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzUtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjozNjYyNWVkNTcxYjg0N2I2YWZmODljNWQwZDNjYzg0ZF8xMDc_1c9ac0b6-f505-4916-8017-7873c4097b93"
      unitRef="shares">1985919440</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzUtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjozNjYyNWVkNTcxYjg0N2I2YWZmODljNWQwZDNjYzg0ZF8xMTU_24b241c6-1203-4466-a584-b2bf5a5cf452"
      unitRef="shares">1985273421</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzUtMS0xLTEtMTc4Njg_db785a41-fe91-4f4f-b083-2f8012d68404"
      unitRef="usd">24560000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzUtMy0xLTEtMTc4Njg_86067153-9fab-4185-9158-089f13bbb92e"
      unitRef="usd">24470000000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzYtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo2YjdkMDcxM2RiMzM0MzMzYTNiN2ZkYTQxZDI4Mzk1M181OA_3c11e0e5-3cb2-4dbc-af16-7cabf392dcb2"
      unitRef="shares">242345663</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzYtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo2YjdkMDcxM2RiMzM0MzMzYTNiN2ZkYTQxZDI4Mzk1M182Ng_197ad5ec-2e04-4374-901a-dcce8ee8899f"
      unitRef="shares">221191228</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzYtMS0xLTEtMTc4Njg_befac003-8371-4b9f-b43e-e7b0ca6efec7"
      unitRef="usd">14555000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzYtMy0xLTEtMTc4Njg_7e112bf9-e8df-434e-a9ae-348d02e9ed3f"
      unitRef="usd">11822000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzctMS0xLTEtMTc4Njg_3f5883a0-8b30-4c6a-ae7c-65910eb2f407"
      unitRef="usd">35115000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzctMy0xLTEtMTc4Njg_7a2cc1ce-40e8-4e20-bc04-55c59988f59c"
      unitRef="usd">31528000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzgtMS0xLTEtMTc4Njg_4474c2ca-4998-4cb7-8429-fece122be42d"
      unitRef="usd">-9445000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzgtMy0xLTEtMTc4Njg_0f28d5c3-bc4d-4c8a-a66b-27563350b833"
      unitRef="usd">-8374000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzktMS0xLTEtMTc4Njg_b5fadf41-2122-4dd8-a15c-39acf7aa7e69"
      unitRef="usd">35675000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfMzktMy0xLTEtMTc4Njg_d8f6badc-9d1e-4fc0-b4d1-07c53cbcb0b4"
      unitRef="usd">35802000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNDAtMS0xLTEtMTc4Njg_cd131c6e-fc08-4925-b60e-04f9c35d6d8d"
      unitRef="usd">209000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNDAtMy0xLTEtMTc4Njg_47d5584f-de67-4109-84e6-4eff2892c8e1"
      unitRef="usd">222000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNDEtMS0xLTEtMTc4Njg_1e5778e5-4ebd-4660-9824-2a6a3fcabf04"
      unitRef="usd">35884000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNDEtMy0xLTEtMTc4Njg_4bfeba8b-4469-44d5-9392-1dfdab833fa0"
      unitRef="usd">36024000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNDItMS0xLTEtMTc4Njg_4c4573ca-e233-40fe-b372-eedc7b78cc03"
      unitRef="usd">72801000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yMi9mcmFnOmNkOWU1Y2Y2MzZkODQwNDZiNDQ4ODM4MjMyYzVjZDE2L3RhYmxlOjg1NDY3NmI1Y2QzNzRmNGM4NzViZmU5NzkwYjFjMTg0L3RhYmxlcmFuZ2U6ODU0Njc2YjVjZDM3NGY0Yzg3NWJmZTk3OTBiMWMxODRfNDItMy0xLTEtMTc4Njg_2ba76cd8-a5ab-40b2-b7c2-827920bbef91"
      unitRef="usd">75196000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ife5c2b9c51b24905939dfe6b3d3e4056_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNC0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOmRhMzA4MDZiNzYyZDQyZmViODQwYzgyZDQxOGEyNWJjXzE2_c3544a26-aa31-4fb4-b015-87f9c447b35d"
      unitRef="shares">1985676735</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i318af3e554204da2b38e2945f4629296_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNC0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOmRhMzA4MDZiNzYyZDQyZmViODQwYzgyZDQxOGEyNWJjXzI0_3225348d-a590-47b5-8ab3-294ab0c7696b"
      unitRef="shares">1982553488</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife5c2b9c51b24905939dfe6b3d3e4056_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNC0xLTEtMS0xNzg2OA_ea9b0a97-0834-493e-b8cb-a7ebc8cbe4f2"
      unitRef="usd">24429000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i318af3e554204da2b38e2945f4629296_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNC0zLTEtMS0xNzg2OA_809032c9-7792-40d7-9a18-724c89caa62c"
      unitRef="usd">24153000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms
      contextRef="i9f1d1e1ca3304ec8bafbf0a80a96bd80_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNi0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOmQ1N2VmY2Y3Yjg1MjQzN2M4OGM1OWYwZGM4ZWNiZGI4XzE2_fbea0a0a-bff4-4bb4-9f63-831953ac34eb"
      unitRef="shares">242705</abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms>
    <abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms
      contextRef="ib7b8a9dc239044a6b1a2b862dd61b7fc_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNi0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOmQ1N2VmY2Y3Yjg1MjQzN2M4OGM1OWYwZGM4ZWNiZGI4XzI0_c63e234a-eccf-4fcb-86ec-f0906a067ba9"
      unitRef="shares">550366</abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms>
    <abt:StockIssuedDuringPeriodValueIncentiveStockPrograms
      contextRef="i9f1d1e1ca3304ec8bafbf0a80a96bd80_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNi0xLTEtMS0xNzg2OA_dd75419a-b911-4f7d-92cd-3d490ca46949"
      unitRef="usd">12000000</abt:StockIssuedDuringPeriodValueIncentiveStockPrograms>
    <abt:StockIssuedDuringPeriodValueIncentiveStockPrograms
      contextRef="ib7b8a9dc239044a6b1a2b862dd61b7fc_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNi0zLTEtMS0xNzg2OA_f3e4fb6c-b68f-4acc-b9e1-283c91f8d5cb"
      unitRef="usd">26000000</abt:StockIssuedDuringPeriodValueIncentiveStockPrograms>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9f1d1e1ca3304ec8bafbf0a80a96bd80_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNy0xLTEtMS0xNzg2OA_72af38b6-107e-402a-ba7e-3f7725a3f29c"
      unitRef="usd">123000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib7b8a9dc239044a6b1a2b862dd61b7fc_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfNy0zLTEtMS0xNzg2OA_d8ad1755-87b3-4403-be72-2965d8f013d0"
      unitRef="usd">113000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i9f1d1e1ca3304ec8bafbf0a80a96bd80_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfOC0xLTEtMS0xNzg2OA_4695e62d-97c2-476d-9984-083e43f4c1c9"
      unitRef="usd">-4000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ib7b8a9dc239044a6b1a2b862dd61b7fc_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfOC0zLTEtMS0xNzg2OA_8471320e-36d0-48d4-8738-1ae43a91406c"
      unitRef="usd">-7000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i29242515a9cd41d3929b65fa4ab2da75_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTAtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo0MzhiYWM1NmIzZjA0OWIzODBhZDBkNjdiYzkxNjM3M18xNg_e31590f7-fcd9-4106-8dd5-ff818409a7a6"
      unitRef="shares">1985919440</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0ec2d32ee1c543f89872966939398c80_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTAtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo0MzhiYWM1NmIzZjA0OWIzODBhZDBkNjdiYzkxNjM3M18yNA_e4c065aa-5d92-4ba0-a895-7f27c2e9465f"
      unitRef="shares">1983103854</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i29242515a9cd41d3929b65fa4ab2da75_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTAtMS0xLTEtMTc4Njg_55d26d71-91ec-4219-851e-44bcdad46292"
      unitRef="usd">24560000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ec2d32ee1c543f89872966939398c80_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTAtMy0xLTEtMTc4Njg_0c7b1cdf-cfa0-4d88-8d33-2aaf599f032f"
      unitRef="usd">24285000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i13853862ec4e4a8f9dd87d9d1f5a0eba_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjpjNWRkY2VmNjI1OTk0YjFhOWIxZDc1YjA0YTM3MzVkMV8xNg_27a4cc9a-98a9-4fcc-b68d-a0efa1e31120"
      unitRef="shares">234456992</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i84388393a8aa4ea4ad5e48e8c7f24e44_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjpjNWRkY2VmNjI1OTk0YjFhOWIxZDc1YjA0YTM3MzVkMV8yNA_3deb2dfa-40de-40ff-bd72-d59271250832"
      unitRef="shares">209736139</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i13853862ec4e4a8f9dd87d9d1f5a0eba_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTQtMS0xLTEtMTc4Njg_8a9bd000-22b5-456e-b31d-9a8ddd482b8f"
      unitRef="usd">-13720000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i84388393a8aa4ea4ad5e48e8c7f24e44_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTQtMy0xLTEtMTc4Njg_f9798284-2656-4d9d-b2a0-06c2d4901b68"
      unitRef="usd">-10340000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms
      contextRef="i2f2db6dc6a8f4d8d97404a772b976d3d_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTYtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo0MmFlZjYzMGMyZWE0MDkxYTRlNjgzNDVlNzk4OGJhZF8xNg_d4aa52b9-8efa-4f33-988a-8ab697c94806"
      unitRef="shares">528436</abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms>
    <abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms
      contextRef="i5a2381935eb3479c8272fe544f91e498_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTYtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo0MmFlZjYzMGMyZWE0MDkxYTRlNjgzNDVlNzk4OGJhZF8yNA_2ef8cd08-ec9d-44fd-aa1b-7dbe3ecf8a86"
      unitRef="shares">545860</abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms>
    <abt:StockIssuedDuringPeriodValueIncentiveStockPrograms
      contextRef="i2f2db6dc6a8f4d8d97404a772b976d3d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTYtMS0xLTEtMTc4Njg_731044c9-109d-4e41-b694-7beb21170582"
      unitRef="usd">31000000</abt:StockIssuedDuringPeriodValueIncentiveStockPrograms>
    <abt:StockIssuedDuringPeriodValueIncentiveStockPrograms
      contextRef="i5a2381935eb3479c8272fe544f91e498_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTYtMy0xLTEtMTc4Njg_7f4ed89c-ed96-468c-a7e5-54f822348245"
      unitRef="usd">26000000</abt:StockIssuedDuringPeriodValueIncentiveStockPrograms>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i2f2db6dc6a8f4d8d97404a772b976d3d_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTgtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo4OWQ4ZGZiNWJkOGE0YTRkYWNjODBmMjE4NjdmZWFlYV8xNg_f85cf389-ece5-47ca-85b0-26aea016e755"
      unitRef="shares">8417107</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i5a2381935eb3479c8272fe544f91e498_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTgtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo4OWQ4ZGZiNWJkOGE0YTRkYWNjODBmMjE4NjdmZWFlYV8yNA_64636b03-9435-4070-8a2c-0e4f15c98f66"
      unitRef="shares">5626606</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2f2db6dc6a8f4d8d97404a772b976d3d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTgtMS0xLTEtMTc4Njg_d28b0078-b9b6-4d90-ace0-f5e80abfd346"
      unitRef="usd">866000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i5a2381935eb3479c8272fe544f91e498_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMTgtMy0xLTEtMTc4Njg_a3935753-e90f-43b2-bd70-15e1e0118bf5"
      unitRef="usd">685000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ib0384842a3a44e638930735a2b593396_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjAtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo3NzFjMzY1MzNlMDk0YTJjOWJiMDZiZDc0MmI4MzIxM18xNg_9dad3c23-1cf4-4d45-b3c8-78ecbfab80e8"
      unitRef="shares">242345663</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="iee53b5e2f57b467bafb6a07b010ce7b8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjAtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo3NzFjMzY1MzNlMDk0YTJjOWJiMDZiZDc0MmI4MzIxM18yNA_92921201-7737-435f-aafb-1b7f2c8f2eeb"
      unitRef="shares">214816885</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib0384842a3a44e638930735a2b593396_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjAtMS0xLTEtMTc4Njg_67c5d400-e3c5-46c1-ba60-d430fc4ca387"
      unitRef="usd">-14555000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee53b5e2f57b467bafb6a07b010ce7b8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjAtMy0xLTEtMTc4Njg_aa994c2e-8223-401d-a19c-fe5f5e3f6b44"
      unitRef="usd">-10999000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibdd95633e0b74ebebb2ef9d790e7e133_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjMtMS0xLTEtMTc4Njg_7a14676f-4105-4cca-8248-b55242e29eb6"
      unitRef="usd">34487000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id6cd17f6345343d188d64dda2acbc2ba_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjMtMy0xLTEtMTc4Njg_094cba70-5799-4181-a998-f7442c717bd9"
      unitRef="usd">29053000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ib605aa77a1694292a23c576b3cbe9f51_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjQtMS0xLTEtMTc4Njg_8ccab4bc-47ee-4d50-a3c9-00955a82e1b5"
      unitRef="usd">1435000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6675c4a62c704c83b04414e2e96f9f15_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjQtMy0xLTEtMTc4Njg_e46ed3de-7406-473a-8e8f-e63189be4090"
      unitRef="usd">2100000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ib605aa77a1694292a23c576b3cbe9f51_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjUtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjozNDBiZmYyYzA3ZDU0MjNkYTM4N2YzMjNkMzBlNDk1Nl82Mg_69cfc095-206a-43f2-8b36-2457d50c8d4f"
      unitRef="usdPerShare">0.47</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i6675c4a62c704c83b04414e2e96f9f15_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjUtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjozNDBiZmYyYzA3ZDU0MjNkYTM4N2YzMjNkMzBlNDk1Nl83MA_abba3b85-ae3f-46bf-a7c3-9a4875fb706e"
      unitRef="usdPerShare">0.45</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ib605aa77a1694292a23c576b3cbe9f51_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjUtMS0xLTEtMTc4Njg_c6648017-eb68-48ac-9b80-12addd22c9c1"
      unitRef="usd">822000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i6675c4a62c704c83b04414e2e96f9f15_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjUtMy0xLTEtMTc4Njg_2de65509-e8f2-4dcd-a19c-b7ffaefc6dbf"
      unitRef="usd">799000000</us-gaap:DividendsCommonStockCash>
    <abt:EffectOfCommonAndTreasuryShareTransactions
      contextRef="ib605aa77a1694292a23c576b3cbe9f51_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjYtMS0xLTEtMTc4Njg_35e1403e-9b52-4204-a69f-b12b471ef056"
      unitRef="usd">-15000000</abt:EffectOfCommonAndTreasuryShareTransactions>
    <abt:EffectOfCommonAndTreasuryShareTransactions
      contextRef="i6675c4a62c704c83b04414e2e96f9f15_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjYtMy0xLTEtMTc4Njg_493024be-c33c-4844-9062-eeaca0e1467f"
      unitRef="usd">-22000000</abt:EffectOfCommonAndTreasuryShareTransactions>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a9d779acbe44e3bacba61c64c39e891_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjctMS0xLTEtMTc4Njg_14871c43-eca9-4619-a4ba-8d95981cc40c"
      unitRef="usd">35115000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iffc3d7b1f7924f49a467f9de89cf4580_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMjctMy0xLTEtMTc4Njg_0686338e-b6bc-4e79-90a7-028b6c373461"
      unitRef="usd">30376000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93502cdb071b40d78c7d41a2b5166b24_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzAtMS0xLTEtMTc4Njg_41b14495-0e60-4b3f-accd-a839b290aa2b"
      unitRef="usd">-8706000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3efcbced2c284e42846b07cbce02af0f_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzAtMy0xLTEtMTc4Njg_eb4b7a59-7e57-4bb1-b2d1-b9079a8fcdce"
      unitRef="usd">-9066000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i42f5fd859ca5425389497f80eb2c653e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzEtMS0xLTEtMTc4Njg_cb2dfe7a-2064-4ffd-aa51-3f891b3696f7"
      unitRef="usd">-739000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i76df37ef10134753b1301a961c801516_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzEtMy0xLTEtMTc4Njg_dc93273b-9a47-4b92-926f-63e364f733a1"
      unitRef="usd">-174000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib49fbe36bbba46d5a960a042585a8ca3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzItMS0xLTEtMTc4Njg_0af2916f-bde3-48a9-8c7d-3a33aa32d638"
      unitRef="usd">-9445000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id1445a4f41614df3b5934c37b319c6c4_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzItMy0xLTEtMTc4Njg_ead29812-166d-4109-8e36-379477bb9035"
      unitRef="usd">-9240000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff7c2622a69b432d86720be37f7e2a16_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzUtMS0xLTEtMTc4Njg_08e21d85-8ce6-4364-a908-0ea4644c7ade"
      unitRef="usd">226000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ef7377540aa4e4c823d715421f8fd87_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzUtMy0xLTEtMTc4Njg_ede74b68-4feb-46b8-bff1-e336b5f84db5"
      unitRef="usd">229000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <abt:NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations
      contextRef="i3d04e8e8dc804bc79e6cf5d8fac6d42b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzYtMS0xLTEtMTc4Njg_eb35ebea-ca6c-45bd-9cc4-accb75ba9109"
      unitRef="usd">-17000000</abt:NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations>
    <abt:NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations
      contextRef="i7057ecd5f0c1428ba00d5cc5b5ed8119_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzYtMy0xLTEtMTc4Njg_ff7f053d-1bac-48b5-a852-6e8afbe7b688"
      unitRef="usd">-13000000</abt:NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib97d8339fa5a4a14be94890cbc7535a3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzctMS0xLTEtMTc4Njg_ab61259a-ffaa-4b8e-a39c-75474e89fd0f"
      unitRef="usd">209000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i088ce8132a864ce3a40176de183626a8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOjMwMjgzMzZlZTA3ZDRlNmRiNzYwYTRkMDBlZmNkZTQ5L3RhYmxlcmFuZ2U6MzAyODMzNmVlMDdkNGU2ZGI3NjBhNGQwMGVmY2RlNDlfMzctMy0xLTEtMTc4Njg_02270554-8968-4642-84b0-921e93104baa"
      unitRef="usd">216000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1504c2dad3014570b5b401bc387b8c52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNC0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjgzZDEzM2I3OWE4MjRkNGRhOTYzOGRjOTk2MzhhNTZlXzE2_b52df573-2713-4943-be72-ffa5ed6f912e"
      unitRef="shares">1985273421</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6d042e1363a74135b1ff431769cbdd3c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNC0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjgzZDEzM2I3OWE4MjRkNGRhOTYzOGRjOTk2MzhhNTZlXzI0_d19ebfce-f588-4aaa-b9a2-3fa31b6e6626"
      unitRef="shares">1981156896</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1504c2dad3014570b5b401bc387b8c52_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNC0xLTEtMS0xNzg2OA_f2ffaede-9dfc-4c61-884d-30038e803563"
      unitRef="usd">24470000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d042e1363a74135b1ff431769cbdd3c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNC0zLTEtMS0xNzg2OA_5f0f0531-6b9a-49bb-9169-68b12d5e5322"
      unitRef="usd">24145000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms
      contextRef="i2633c881b0854a9387e79c0bf0e90227_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNi0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjg2YjAxNzMwNjA4YjQyZTY5MWE1NGIyNzZmY2MyOWUwXzE2_50282b56-cee6-479e-a025-11324d1ad2aa"
      unitRef="shares">646019</abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms>
    <abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms
      contextRef="i00352c2d1368429694fe5d87533d4a96_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNi0wLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjg2YjAxNzMwNjA4YjQyZTY5MWE1NGIyNzZmY2MyOWUwXzI0_069ec46e-edb1-49bf-b1c9-49ed09f1da21"
      unitRef="shares">1946958</abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms>
    <abt:StockIssuedDuringPeriodValueIncentiveStockPrograms
      contextRef="i2633c881b0854a9387e79c0bf0e90227_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNi0xLTEtMS0xNzg2OA_dc6672c3-7b15-49a3-ac40-5b960f39bb1a"
      unitRef="usd">36000000</abt:StockIssuedDuringPeriodValueIncentiveStockPrograms>
    <abt:StockIssuedDuringPeriodValueIncentiveStockPrograms
      contextRef="i00352c2d1368429694fe5d87533d4a96_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNi0zLTEtMS0xNzg2OA_96d9f9bf-c735-40ee-8e90-825f0cc8849e"
      unitRef="usd">91000000</abt:StockIssuedDuringPeriodValueIncentiveStockPrograms>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2633c881b0854a9387e79c0bf0e90227_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNy0xLTEtMS0xNzg2OA_760aa257-167f-46e7-adc1-7ab37d6b06f9"
      unitRef="usd">572000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i00352c2d1368429694fe5d87533d4a96_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfNy0zLTEtMS0xNzg2OA_89556791-65d0-4402-b638-6586fad00616"
      unitRef="usd">536000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i2633c881b0854a9387e79c0bf0e90227_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfOC0xLTEtMS0xNzg2OA_ca2dbf99-105d-4c0e-8186-acc0e5ff1c70"
      unitRef="usd">-518000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i00352c2d1368429694fe5d87533d4a96_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfOC0zLTEtMS0xNzg2OA_e08e11dc-aac4-4103-9b2e-b1839d4cd7d5"
      unitRef="usd">-487000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i29242515a9cd41d3929b65fa4ab2da75_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTAtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjowNDRjOWQ5NzdmMmM0MzQwOGViNmIzN2Y4NDJmMzc4OV8xNg_48d388f6-37cf-4b6e-85c1-4d3ed3800f1c"
      unitRef="shares">1985919440</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0ec2d32ee1c543f89872966939398c80_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTAtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjowNDRjOWQ5NzdmMmM0MzQwOGViNmIzN2Y4NDJmMzc4OV8yNA_3b730d55-1ee9-48a8-8783-d85166d569ad"
      unitRef="shares">1983103854</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i29242515a9cd41d3929b65fa4ab2da75_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTAtMS0xLTEtMTc4Njg_bb140e5a-3359-4ee4-986c-d67139648fca"
      unitRef="usd">24560000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ec2d32ee1c543f89872966939398c80_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTAtMy0xLTEtMTc4Njg_71167d38-f7c8-4e7d-b353-b682714dad07"
      unitRef="usd">24285000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i5cfae92185d549208e196b57add32000_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjpjNzVjZWRkZDY3Yzk0ZWJjYmU4M2QwYjYwYzY4ZWY1ZV8xNg_29059a4f-1179-4d8d-82ba-50f2a4b14b7c"
      unitRef="shares">221191228</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ida0d59058b594e578193e429a2f6c056_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTQtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjpjNzVjZWRkZDY3Yzk0ZWJjYmU4M2QwYjYwYzY4ZWY1ZV8yNA_14ce9ee6-3f0f-4372-b461-2b56f24a3761"
      unitRef="shares">209926622</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5cfae92185d549208e196b57add32000_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTQtMS0xLTEtMTc4Njg_8fcea808-2b56-42bd-a310-048e69970b6f"
      unitRef="usd">-11822000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ida0d59058b594e578193e429a2f6c056_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTQtMy0xLTEtMTc4Njg_2324f878-5d05-4f84-ac3c-a0a63f096b99"
      unitRef="usd">-10042000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms
      contextRef="i4b724be0df7a469ba9c898710b2dbf1a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTYtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjozNmRkMmVkODMxZjk0NjIyOTZjNGY1ZjdmYzNiNzVjY18xNg_e1e62711-d4e4-490e-9bd3-4e4e28653e93"
      unitRef="shares">4808575</abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms>
    <abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms
      contextRef="ie6098fe1fbe54bc9a82cd2c345421c2c_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTYtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjozNmRkMmVkODMxZjk0NjIyOTZjNGY1ZjdmYzNiNzVjY18yNA_8e5c7a06-736c-42be-a02a-490e0e88a04e"
      unitRef="shares">5524291</abt:StockIssuedDuringPeriodSharesIncentiveStockPrograms>
    <abt:StockIssuedDuringPeriodValueIncentiveStockPrograms
      contextRef="i4b724be0df7a469ba9c898710b2dbf1a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTYtMS0xLTEtMTc4Njg_ae3bcfda-fc82-43bc-913d-6041c1fa106e"
      unitRef="usd">261000000</abt:StockIssuedDuringPeriodValueIncentiveStockPrograms>
    <abt:StockIssuedDuringPeriodValueIncentiveStockPrograms
      contextRef="ie6098fe1fbe54bc9a82cd2c345421c2c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTYtMy0xLTEtMTc4Njg_fa988edc-104c-4813-bea0-d9f594778b78"
      unitRef="usd">265000000</abt:StockIssuedDuringPeriodValueIncentiveStockPrograms>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i4b724be0df7a469ba9c898710b2dbf1a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTgtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjpkNzM5ZDA4NDAyNGQ0NTBkOTdjNjZhYWRmNzM2MzdmZl8xNg_a686b9ff-1260-40ea-812c-e37562557eab"
      unitRef="shares">25963010</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ie6098fe1fbe54bc9a82cd2c345421c2c_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTgtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjpkNzM5ZDA4NDAyNGQ0NTBkOTdjNjZhYWRmNzM2MzdmZl8yNA_7b5a74d6-b80b-4d70-a2e1-115b9947ef56"
      unitRef="shares">10414554</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4b724be0df7a469ba9c898710b2dbf1a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTgtMS0xLTEtMTc4Njg_0b5fc02f-f5e6-48e7-ae1c-fcc970d0b4ca"
      unitRef="usd">2994000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie6098fe1fbe54bc9a82cd2c345421c2c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMTgtMy0xLTEtMTc4Njg_b5c47529-839d-4681-bba1-4c4de9aeadda"
      unitRef="usd">1222000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ib0384842a3a44e638930735a2b593396_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjAtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo0NGQ3NjlkZWY3Nzk0ZjFiOGJjMmQ1MGJkYzhiZDU0OV8xNg_ed5aa859-20fd-4e9c-97d7-0ada103c67db"
      unitRef="shares">242345663</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="iee53b5e2f57b467bafb6a07b010ce7b8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjAtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo0NGQ3NjlkZWY3Nzk0ZjFiOGJjMmQ1MGJkYzhiZDU0OV8yNA_38de9d19-baba-489e-a025-5f4b9db91627"
      unitRef="shares">214816885</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib0384842a3a44e638930735a2b593396_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjAtMS0xLTEtMTc4Njg_feb7b622-521c-4319-8bc2-aafd63d3af83"
      unitRef="usd">-14555000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee53b5e2f57b467bafb6a07b010ce7b8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjAtMy0xLTEtMTc4Njg_e4e70d61-2fe7-43e9-a1e6-365b12eb1c92"
      unitRef="usd">-10999000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i852ddcd4489e42389a31b5f021e6e092_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjMtMS0xLTEtMTc4Njg_a886ccd4-b499-4736-b774-26d03defa574"
      unitRef="usd">31528000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa7c44803cf240068637223e01d8287e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjMtMy0xLTEtMTc4Njg_03f8240b-e193-4114-b7ea-a478686b4cab"
      unitRef="usd">27627000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ibdca6cdd2c3846f6ad4787b16fed5ea4_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjQtMS0xLTEtMTc4Njg_83a94f44-e0bc-4781-8a2a-343395852cdd"
      unitRef="usd">5900000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic5e6626a450843eba3abf231608db97f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjQtMy0xLTEtMTc4Njg_1ab3d214-c8dd-4361-a2dd-b909259cd4a4"
      unitRef="usd">5082000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ibdca6cdd2c3846f6ad4787b16fed5ea4_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjUtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo4NzQ2OGJmMzU3ODY0NTdkYWE0NmRhOThjMGMyNmZlMF82Mg_96040555-4396-4362-a07a-d6e32632aece"
      unitRef="usdPerShare">1.41</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ic5e6626a450843eba3abf231608db97f_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjUtMC0xLTEtMTc4NjgvdGV4dHJlZ2lvbjo4NzQ2OGJmMzU3ODY0NTdkYWE0NmRhOThjMGMyNmZlMF83MA_a4676b99-7d8c-4cc8-827f-956e41884e30"
      unitRef="usdPerShare">1.35</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ibdca6cdd2c3846f6ad4787b16fed5ea4_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjUtMS0xLTEtMTc4Njg_2b362754-4f35-4692-87fb-a11af5174dc6"
      unitRef="usd">2475000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ic5e6626a450843eba3abf231608db97f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjUtMy0xLTEtMTc4Njg_91bc6deb-8bb3-4be7-95bb-a20cfbcccfc4"
      unitRef="usd">2403000000</us-gaap:DividendsCommonStockCash>
    <abt:EffectOfCommonAndTreasuryShareTransactions
      contextRef="ibdca6cdd2c3846f6ad4787b16fed5ea4_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjYtMS0xLTEtMTc4Njg_9561be56-fd44-48d0-b433-f95a7d9a30bf"
      unitRef="usd">-162000000</abt:EffectOfCommonAndTreasuryShareTransactions>
    <abt:EffectOfCommonAndTreasuryShareTransactions
      contextRef="ic5e6626a450843eba3abf231608db97f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjYtMy0xLTEtMTc4Njg_444ca5d7-8534-4abb-b1b8-cc7f601fa63b"
      unitRef="usd">-70000000</abt:EffectOfCommonAndTreasuryShareTransactions>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a9d779acbe44e3bacba61c64c39e891_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjctMS0xLTEtMTc4Njg_fa327c4c-c4c3-4fe3-a51f-8c508faabada"
      unitRef="usd">35115000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iffc3d7b1f7924f49a467f9de89cf4580_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMjctMy0xLTEtMTc4Njg_0c4ec2c3-1dc4-4aaa-bd7d-4d8900a7807d"
      unitRef="usd">30376000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib0d9d6801c8c4803a0622083412ac492_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzAtMS0xLTEtMTc4Njg_2b561326-c132-46c9-ad87-c8cce103032b"
      unitRef="usd">-8374000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f3f735442774afcb720cdb3ae2b9822_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzAtMy0xLTEtMTc4Njg_b12353e3-f384-4441-8fa0-2970e3a2ba24"
      unitRef="usd">-8946000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id78baae4639244558d7fbe8dde9cdbaa_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzEtMS0xLTEtMTc4Njg_244e34e1-7ccf-4fda-9641-9eb47dfe2c15"
      unitRef="usd">-1071000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icc6ae1cd7a5648a9876bfd212f13b5fa_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzEtMy0xLTEtMTc4Njg_454643f2-9cd4-4ab4-90c2-1ba850209a31"
      unitRef="usd">-294000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib49fbe36bbba46d5a960a042585a8ca3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzItMS0xLTEtMTc4Njg_b756ea53-9e44-4344-b44d-fa7e4ac5b387"
      unitRef="usd">-9445000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id1445a4f41614df3b5934c37b319c6c4_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzItMy0xLTEtMTc4Njg_3cd33ab3-a6cd-4951-a0a3-1322c951ba60"
      unitRef="usd">-9240000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc59d11b30d140339de2cf7f2ac54561_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzUtMS0xLTEtMTc4Njg_0c38ab25-84a8-4f0d-bb3b-5fc000f38266"
      unitRef="usd">222000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide6a9cde9eec42f099b747ac02363030_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzUtMy0xLTEtMTc4Njg_4d5442fe-dce8-41c9-9b94-c57ec5f18dde"
      unitRef="usd">219000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <abt:NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations
      contextRef="ide40706d122541aa80614540c148de08_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzYtMS0xLTEtMTc4Njg_7b47d5c8-8953-48e3-8f4e-e413d70f38a4"
      unitRef="usd">-13000000</abt:NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations>
    <abt:NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations
      contextRef="i621d2ad3316543a1886bf830d26e3ffa_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzYtMy0xLTEtMTc4Njg_5078d9ad-1668-4b97-827c-0203beaec2de"
      unitRef="usd">-3000000</abt:NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib97d8339fa5a4a14be94890cbc7535a3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzctMS0xLTEtMTc4Njg_1272dea1-9783-4d70-b8ed-7e91a865a458"
      unitRef="usd">209000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i088ce8132a864ce3a40176de183626a8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yNS9mcmFnOjM2MmU5YjY5ZmMxZTQ1MDI5MTE5NTEwYzc2ZDllMGEwL3RhYmxlOmJmMWYxMWI3ZmVjNDQwOWY4OGQ3YmE4YjA4ZTIyZjdjL3RhYmxlcmFuZ2U6YmYxZjExYjdmZWM0NDA5Zjg4ZDdiYThiMDhlMjJmN2NfMzctMy0xLTEtMTc4Njg_049f2f4e-83fc-4508-bd79-6a0ac22ccdc4"
      unitRef="usd">216000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMy0xLTEtMS0xNzg2OA_a718c7f8-2c27-4c03-8ac4-c5eebfea04cd"
      unitRef="usd">5900000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMy0zLTEtMS0xNzg2OA_52ec0393-e073-4d57-867a-46f03a50023a"
      unitRef="usd">5082000000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfNS0xLTEtMS0xNzg2OA_b742def5-dcf2-4353-8495-2ddcc2f2a342"
      unitRef="usd">943000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfNS0zLTEtMS0xNzg2OA_d31a461c-f0dd-4ee2-88f4-92276c7a17c4"
      unitRef="usd">1122000000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfNi0xLTEtMS0xNzg2OA_210464e3-0519-4680-b97d-f78e07c5f146"
      unitRef="usd">1517000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfNi0zLTEtMS0xNzg2OA_bf0ed8c1-61eb-4bbb-8f4c-6228de9a1c92"
      unitRef="usd">1533000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfNy0xLTEtMS0xNzg2OA_7587a0d1-96a8-4b38-84ef-964c86175285"
      unitRef="usd">570000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfNy0zLTEtMS0xNzg2OA_c31f131a-d5ca-49ad-8d4f-dfec0f9fba7f"
      unitRef="usd">534000000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfOC0xLTEtMS0xNzg2OA_0b1f4599-4746-4f0a-9afe-0a325c8864f4"
      unitRef="usd">409000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfOC0zLTEtMS0xNzg2OA_04b0853d-7645-4588-a17d-562f1f2c278e"
      unitRef="usd">194000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfOS0xLTEtMS0xNzg2OA_efde2801-a2d0-42ca-816b-3014f1739033"
      unitRef="usd">1224000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfOS0zLTEtMS0xNzg2OA_bed51d9b-4b75-4c4a-a4e8-8455c8b5aa2b"
      unitRef="usd">471000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTAtMS0xLTEtMTc4Njg_60d6d3cb-dbad-494f-aebe-39f692de9130"
      unitRef="usd">42000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTAtMy0xLTEtMTc4Njg_6b4b6f46-9d4b-4293-9b12-72b7f51af577"
      unitRef="usd">140000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTEtMS0xLTEtMTc4Njg_2dabf650-56a5-493b-96ed-818ce964b896"
      unitRef="usd">7255000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTEtMy0xLTEtMTc4Njg_7bb1a78d-4372-484f-a08c-295188a279ac"
      unitRef="usd">7466000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTQtMS0xLTEtMTc4Njg_a396b801-c7a7-4460-82ff-4f405ffa410d"
      unitRef="usd">1167000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTQtMy0xLTEtMTc4Njg_2a6aff8e-5a90-40a2-9136-fe18c7f88666"
      unitRef="usd">1271000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <abt:PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTUtMS0xLTEtMTc4Njg_8cf94476-b693-4a69-8916-e8d210f8dc46"
      unitRef="usd">0</abt:PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess>
    <abt:PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTUtMy0xLTEtMTc4Njg_1eca013f-17fa-4a99-8a49-127494ed7453"
      unitRef="usd">187000000</abt:PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTYtMS0xLTEtMTc4Njg_aabc5b93-ab88-4572-bc9c-51b7dd04c2a5"
      unitRef="usd">48000000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTYtMy0xLTEtMTc4Njg_7d3236ee-c4be-43fb-821a-dd20161efd37"
      unitRef="usd">134000000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTctMS0xLTEtMTc4Njg_437fd13b-3d39-4b36-ab69-e96202cc7169"
      unitRef="usd">3000000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTctMy0xLTEtMTc4Njg_382a4633-0ae4-4089-bd60-47cfef63a443"
      unitRef="usd">27000000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTgtMS0xLTEtMTc4Njg_890cda09-f5ef-49a5-ab6a-5219f31b7025"
      unitRef="usd">-14000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTgtMy0xLTEtMTc4Njg_f30dac6a-95f7-409b-9f9b-c4c8c5220888"
      unitRef="usd">-14000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTktMS0xLTEtMTc4Njg_e0a99a8d-05d5-451b-8f2e-21f6c0d6a044"
      unitRef="usd">-1108000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMTktMy0xLTEtMTc4Njg_b9380a71-799a-4132-b8a4-3655f5726491"
      unitRef="usd">-1337000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjItMS0xLTEtMTc4Njg_4ef3e32a-5298-4acc-bf86-a0bda8752ecb"
      unitRef="usd">37000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjItMy0xLTEtMTc4Njg_199813ab-bb7a-4776-a591-c70beef4c111"
      unitRef="usd">-7000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjMtMS0xLTEtMTc4Njg_045be4ee-ee5f-444e-b9b3-1d2b5b4fac39"
      unitRef="usd">7000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjMtMy0xLTEtMTc4Njg_5a383ef5-238f-41ca-9cd9-cc56ca1fd697"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjQtMS0xLTEtMTc4Njg_d987c2f0-ff09-4ccb-80fc-c579e3eb191f"
      unitRef="usd">753000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjQtMy0xLTEtMTc4Njg_58612a58-acab-4b87-a0af-cc0a338148ab"
      unitRef="usd">45000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjUtMS0xLTEtMTc4Njg_26004153-2167-4e82-abb6-497a3008f057"
      unitRef="usd">3110000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjUtMy0xLTEtMTc4Njg_c354a32f-e3f6-4889-b29d-da9a07e5ab21"
      unitRef="usd">1325000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjYtMS0xLTEtMTc4Njg_6f0181f6-5da3-473b-a263-a4f6d727ff84"
      unitRef="usd">126000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjYtMy0xLTEtMTc4Njg_59e824cc-6148-4714-977f-fac4df9a237d"
      unitRef="usd">173000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjctMS0xLTEtMTc4Njg_cc81d62a-2f2b-49f4-8408-0699d40c3f4f"
      unitRef="usd">2486000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjctMy0xLTEtMTc4Njg_400d31b3-c49b-42c7-9066-8a76008f9c03"
      unitRef="usd">2404000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjgtMS0xLTEtMTc4Njg_3b99f8d2-6efd-4980-bf01-2c7153057e7b"
      unitRef="usd">-6179000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMjgtMy0xLTEtMTc4Njg_48c0b96c-39f3-4845-a6c0-c35ecc46952a"
      unitRef="usd">-3608000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMzAtMS0xLTEtMTc4Njg_4b8e365c-05ea-4867-ae3a-2b4f8efabed2"
      unitRef="usd">-173000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMzAtMy0xLTEtMTc4Njg_8ca79bc7-1f31-4174-91ed-5f19b4456b40"
      unitRef="usd">-57000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMzItMS0xLTEtMTc4Njg_2cb80018-0b69-4b10-80f7-127950f69a3f"
      unitRef="usd">-205000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMzItMy0xLTEtMTc4Njg_21aead67-01f9-4e1e-abd9-3b4ca4c5b875"
      unitRef="usd">2464000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMzMtMS0xLTEtMTc4Njg_c8f6eb45-937c-4de8-9aa6-d54d94bdc49e"
      unitRef="usd">9799000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3397ef3061f44f36bc9ca7c33654a5de_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMzMtMy0xLTEtMTc4Njg_c3f5e17a-7035-45a4-9995-702da542054f"
      unitRef="usd">6838000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMzQtMS0xLTEtMTc4Njg_df0aed94-a880-4749-b171-f7b8ac982359"
      unitRef="usd">9594000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8bf57bd89e8649de9b14b6f40f63d3b6_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8yOC9mcmFnOjM2NmQ4MjE5ODNjMzQyYTE5OGU0ZjA3YmMzZTgxZjRjL3RhYmxlOmM5ZDJmYzk5OWRmZjRmZGZiNjc3MDNlZWJmYmNhZTFhL3RhYmxlcmFuZ2U6YzlkMmZjOTk5ZGZmNGZkZmI2NzcwM2VlYmZiY2FlMWFfMzQtMy0xLTEtMTc4Njg_60f6b06c-59ae-441c-9196-d9352c39a121"
      unitRef="usd">9302000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNC9mcmFnOjNmNjgyM2FhZDI5NzRjZTg4OWFlM2E3MTcxMDYxYmRkL3RleHRyZWdpb246M2Y2ODIzYWFkMjk3NGNlODg5YWUzYTcxNzEwNjFiZGRfODE3_5e506e19-5489-4b82-8a9a-426a651baed9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 1 &#x2014; Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RleHRyZWdpb246YmIwM2Q2NjdkMjQ2NGY4Yzg2MTExOGYyZmJiMDAzNDNfMzM4_3baaf0c4-7e31-43c7-a98c-d17b5063b1c4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 2 &#x2014; Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Abbott&#x2019;s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide detail by sales category:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Established Pharmaceutical Products &#x2014; &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Key Emerging Markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nutritionals &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pediatric Nutritionals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Adult Nutritionals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diagnostics &#x2014; &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Core Laboratory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Molecular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Point of Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rapid Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical Devices &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rhythm Management&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Electrophysiology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Heart Failure&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Structural Heart&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Neuromodulation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diabetes Care &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Established Pharmaceutical Products &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Key Emerging Markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nutritionals &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pediatric Nutritionals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Adult Nutritionals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diagnostics &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Core Laboratory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Molecular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Point of Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rapid Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical Devices &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rhythm Management&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Electrophysiology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Heart Failure&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Structural Heart&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Neuromodulation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diabetes Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Remaining Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $3.9 billion in the Diagnostics segment and approximately $433 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 60 percent of these remaining performance obligations over the next 24 months, approximately 16 percent over the subsequent 12 months and the remainder thereafter.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Contract Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott&#x2019;s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott&#x2019;s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the contract liabilities during the period are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unearned revenue from cash received during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized related to contract liability balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RleHRyZWdpb246YmIwM2Q2NjdkMjQ2NGY4Yzg2MTExOGYyZmJiMDAzNDNfMTU2_9ff8148d-c840-4e56-a462-d45331374e70"
      unitRef="segment">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RleHRyZWdpb246YmIwM2Q2NjdkMjQ2NGY4Yzg2MTExOGYyZmJiMDAzNDNfMTU2_b5e986b8-0a0a-4b04-a393-f937aeeadd1b"
      unitRef="segment">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RleHRyZWdpb246YmIwM2Q2NjdkMjQ2NGY4Yzg2MTExOGYyZmJiMDAzNDNfMTU2_ccfb94bb-d305-4b74-afd1-f9bedee29362"
      unitRef="segment">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RleHRyZWdpb246YmIwM2Q2NjdkMjQ2NGY4Yzg2MTExOGYyZmJiMDAzNDNfMTU2_d435c934-c0c4-47f7-bc53-8826f82c28c7"
      unitRef="segment">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RleHRyZWdpb246YmIwM2Q2NjdkMjQ2NGY4Yzg2MTExOGYyZmJiMDAzNDNfMzM5_6ac5f4c7-197c-4d3c-adb3-8eba5f39144c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide detail by sales category:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Established Pharmaceutical Products &#x2014; &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Key Emerging Markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nutritionals &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pediatric Nutritionals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Adult Nutritionals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diagnostics &#x2014; &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Core Laboratory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Molecular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Point of Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rapid Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical Devices &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rhythm Management&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Electrophysiology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Heart Failure&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Structural Heart&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Neuromodulation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diabetes Care &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Established Pharmaceutical Products &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Key Emerging Markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nutritionals &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pediatric Nutritionals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Adult Nutritionals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diagnostics &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Core Laboratory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Molecular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Point of Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rapid Diagnostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical Devices &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rhythm Management&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Electrophysiology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Heart Failure&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Structural Heart&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Neuromodulation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diabetes Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifdd6935a04684767a7df321fc7d8e04b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMy0yLTEtMS0xNzg2OA_0a4310c1-94f9-4194-9bd6-a31ff3c8099e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20dea8b9fbad40a38c94c202b5a06584_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMy00LTEtMS0xNzg2OA_967baf65-d730-477b-abde-9d78843e8801"
      unitRef="usd">993000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i553b1f411dac4315b9a061214928d19f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMy02LTEtMS0xNzg2OA_5d27bdf8-212f-4f3a-8f33-68cbd0980c84"
      unitRef="usd">993000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fd8b94ecb894e8195d49738629f7663_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMy04LTEtMS0xNzg2OA_ca008849-7c3d-48d8-84e8-820fb413260b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab868753d235445d83b1848d574f0930_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMy0xMC0xLTEtMTc4Njg_aece119e-e9d9-4780-a321-fbc7fb821ffb"
      unitRef="usd">936000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9377afb46605449ba04338e3aed6ebac_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMy0xMi0xLTEtMTc4Njg_902785c1-2405-47c4-b821-d0ea8d28d6cc"
      unitRef="usd">936000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb9ead876d79497b81d1a4e75fa4b045_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNC0yLTEtMS0xNzg2OA_cb710407-cd42-46aa-bce6-dcdb0794ea33"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb241d31511748689ba74aba957986b9_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNC00LTEtMS0xNzg2OA_0bad085b-abe6-49ce-b877-e5de38b1d2ed"
      unitRef="usd">333000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if08d89d55ab546df94df4e9acd51d621_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNC02LTEtMS0xNzg2OA_5bc1a5e9-5cd3-488a-89ac-fc07c5379d3d"
      unitRef="usd">333000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i392c359c05c842bdbf2ea56e22942b96_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNC04LTEtMS0xNzg2OA_7a8f02fc-0215-4717-ac6d-f259229f428b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a2976080c494443a4931b79f76745ad_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNC0xMC0xLTEtMTc4Njg_6e9107eb-6468-4cdd-a903-bbea1a3a4586"
      unitRef="usd">329000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i356b34bf48444864bd8276a14a0a84e4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNC0xMi0xLTEtMTc4Njg_4e6189b7-0874-420c-9598-2b224811b886"
      unitRef="usd">329000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1992bffa64a74127b5f3ce81b21991bf_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNS0yLTEtMS0xNzg2OA_a1975d79-6845-41cc-913a-951978f5c2d9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic22fc4ec43f24128aae74e88776149f8_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNS00LTEtMS0xNzg2OA_0f9e2c05-703d-4227-a34b-0116b4fc426c"
      unitRef="usd">1326000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1e67684e5e949128a2dec705cc5342d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNS02LTEtMS0xNzg2OA_a50b8d9d-0778-45db-b833-ee1afa7d4a2c"
      unitRef="usd">1326000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f479639da464db4b609d3fa8cba57e3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNS04LTEtMS0xNzg2OA_efa85bf5-6864-4117-bf74-b3c8203e4fcb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d8adee8e3b749c59dcd592b973fe816_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNS0xMC0xLTEtMTc4Njg_068d57d6-9beb-4a3e-bd8f-13bfcbab2c50"
      unitRef="usd">1265000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifffc59617b4841e6842d4164adb3ad90_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNS0xMi0xLTEtMTc4Njg_6fc02f61-4821-4ba5-afb4-c372554d1a7b"
      unitRef="usd">1265000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i938d14e18c764f7591831cee2b53ef86_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNy0yLTEtMS0xNzg2OA_2ed4e506-1899-4dde-ac59-060dd8862dd3"
      unitRef="usd">357000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3d4661d9eae4662a6bc7af372b39a7f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNy00LTEtMS0xNzg2OA_31e81c28-4b01-4e34-a427-5ceb4228bd98"
      unitRef="usd">470000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0270bd857761409ca80dff389f4005fb_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNy02LTEtMS0xNzg2OA_2878eb71-0747-41eb-ac1b-47756ece22ad"
      unitRef="usd">827000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5684517b411b4be6b66e253acbe21100_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNy04LTEtMS0xNzg2OA_621d9ee0-89e1-4c91-bfbd-e37045a155d9"
      unitRef="usd">586000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94a3d528fe5c493698dcfd7f6cdbd624_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNy0xMC0xLTEtMTc4Njg_eaf5e971-b976-42fc-b3cd-1fc18bb52319"
      unitRef="usd">514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4c46ec7babe4d8d98a3a5f521e8605a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfNy0xMi0xLTEtMTc4Njg_f6b46338-558e-4906-9551-337be9ed437e"
      unitRef="usd">1100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ce87a21a2074f99b7e3a9096bf4bc2c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOC0yLTEtMS0xNzg2OA_db2e9d92-d751-4594-9234-d5215e777901"
      unitRef="usd">329000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3981790b8e294829b7fce3da94293b1a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOC00LTEtMS0xNzg2OA_a9e532ce-58f3-4a99-8331-7eb814928e68"
      unitRef="usd">639000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idee15a5bd7a94f2a92b34458fffd592d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOC02LTEtMS0xNzg2OA_380ff371-28a2-42ad-b083-c3c98ec9eb31"
      unitRef="usd">968000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5d4fcd289e94e72b4495606b599fffc_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOC04LTEtMS0xNzg2OA_122f8f01-592b-4486-a8cf-78e5994f0d88"
      unitRef="usd">333000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8fe4e7fed8d4ca39d192d7298446b1b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOC0xMC0xLTEtMTc4Njg_ad1768f4-ef07-4059-8beb-9b5535ab314e"
      unitRef="usd">675000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56ce1b628bc24fbba472f845695459c7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOC0xMi0xLTEtMTc4Njg_a87e1661-b57b-4010-b9ff-6a92d4a7894b"
      unitRef="usd">1008000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i262c247a794c4eefad4c4426111eda88_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOS0yLTEtMS0xNzg2OA_7398b2f7-24b0-4996-bb08-e13b62af0d30"
      unitRef="usd">686000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d37f71b97414ca0a196529d4e6c3728_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOS00LTEtMS0xNzg2OA_8bdaa4ec-38bf-48ba-a93f-c0d023c63497"
      unitRef="usd">1109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8fa29318db7448c942a75e199de1be5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOS02LTEtMS0xNzg2OA_cddb7d0b-3f19-4519-9374-80e6d1216eca"
      unitRef="usd">1795000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i248ff18b88c14ec0b9b3fa1462dc670e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOS04LTEtMS0xNzg2OA_5365df2e-4a8f-4503-834c-52c1fa860d10"
      unitRef="usd">919000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84b6259abeb9432c9b1f4f981322d6e2_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOS0xMC0xLTEtMTc4Njg_63be25d1-ba87-4ebc-b1f1-b3fb082f7240"
      unitRef="usd">1189000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45f3203f3fae46e1ae8028fc5a27e29c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfOS0xMi0xLTEtMTc4Njg_a562c333-735d-4a5e-9d87-b0b67b9ff3e9"
      unitRef="usd">2108000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia256be207eb1438f97b1a7c44dda87d3_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTEtMi0xLTEtMTc4Njg_001142f8-f371-4b67-9a82-cb445970fb2f"
      unitRef="usd">281000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5dcca58e8964d269d6d18f5bae1e53d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTEtNC0xLTEtMTc4Njg_88feb6f2-6777-4750-b9e2-c35bbabd34c8"
      unitRef="usd">938000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40d8bf57ab5544cf81d04120e139dabf_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTEtNi0xLTEtMTc4Njg_550df209-dc8f-4373-8dd2-ed2d5a344398"
      unitRef="usd">1219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia86213c5d496444e8758ca35cdaeb05c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTEtOC0xLTEtMTc4Njg_58f8a886-94f3-40f3-90fe-e0a39794f6bf"
      unitRef="usd">291000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c1f5c24bb5841378c451a90d43000f2_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTEtMTAtMS0xLTE3ODY4_c8f05de4-2b52-467d-891d-22342c185ae1"
      unitRef="usd">1001000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b897bac92554d069fad477918947757_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTEtMTItMS0xLTE3ODY4_1c98b451-08d2-49ff-bc12-0531a8f5802d"
      unitRef="usd">1292000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b4a4864d2ff4c4e8574e011f96d543b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTItMi0xLTEtMTc4Njg_08df279f-24b9-4aa2-a04d-bea243c815e0"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8377a58ea461458c9ebd573507a2eb81_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTItNC0xLTEtMTc4Njg_b2756997-3dc6-492d-87e0-54f84707f582"
      unitRef="usd">118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8800ac73633d482e852c78a6b3b8d03d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTItNi0xLTEtMTc4Njg_3fe2b8c9-446b-4a00-a9b0-1b79229bbb05"
      unitRef="usd">183000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cda9249440a4ababf23d348f31db81e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTItOC0xLTEtMTc4Njg_a6e9cdc6-c14d-4b06-a957-9c9ff857e111"
      unitRef="usd">162000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec3890031ec84733b487409a7fff947e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTItMTAtMS0xLTE3ODY4_3cf6a3d8-6029-4f66-a083-add89851afd1"
      unitRef="usd">183000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29f47d268de74c4bb30f8f0125aeccc5_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTItMTItMS0xLTE3ODY4_c067eb4a-de68-4f39-96bd-f2264c54cdd1"
      unitRef="usd">345000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30e9486b2c674fe99294020e754c817f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTMtMi0xLTEtMTc4Njg_115e9e74-c553-44c9-b941-f4a99f081f24"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6366c00282d04fa5a78abdb1ee423aed_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTMtNC0xLTEtMTc4Njg_ce3d67c2-a224-4a98-ad59-542006ace06f"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79d29b0d89e645e0bcb31189ca823228_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTMtNi0xLTEtMTc4Njg_5afabfec-9505-4db7-a5a1-9808ac31a93f"
      unitRef="usd">127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20ea475fdf0c48e98e083f8dff8056a9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTMtOC0xLTEtMTc4Njg_3f472c2c-662b-45a5-bbc1-fef340a4a03a"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i003dbc498c9a441d89cc0b04ebbd771a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTMtMTAtMS0xLTE3ODY4_e1e6c113-5214-4aa6-bf22-74d34ed5cb61"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i975d74cca0954d4da1bd068770b41605_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTMtMTItMS0xLTE3ODY4_533cee79-79b6-47d5-93d5-e7f6b4da73a6"
      unitRef="usd">135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d047d8dfd414c5d869bcd80fcd41acd_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTQtMi0xLTEtMTc4Njg_a84aea8d-0121-4db3-a80d-f42d0db4f2d2"
      unitRef="usd">1303000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i737b2378d74d4e7492bfe82a019bb4ab_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTQtNC0xLTEtMTc4Njg_723b6fa6-aad5-47fd-9dad-3b091a3e0b2b"
      unitRef="usd">839000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i769d3ce030b942ae9d850540e53df223_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTQtNi0xLTEtMTc4Njg_095a180b-785f-4067-b2c1-24e62010b1dd"
      unitRef="usd">2142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida0bffdbe968459c98f06e252484ccc3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTQtOC0xLTEtMTc4Njg_ebe5039f-4e88-4d97-87d8-7067058bd2af"
      unitRef="usd">1394000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id63c448a841840358193db0fad40f4c5_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTQtMTAtMS0xLTE3ODY4_c226428b-1d71-4031-81c5-61f95a1625c6"
      unitRef="usd">746000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic56a546e33244e07a2c5e1ab9ecb4292_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTQtMTItMS0xLTE3ODY4_c6ee7cab-99ca-4eb9-b13c-d9e74233f73c"
      unitRef="usd">2140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fee55729a8c4e7185f644e1bfe2485b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTUtMi0xLTEtMTc4Njg_34d8bc76-71a8-413f-8e18-97935c100527"
      unitRef="usd">1741000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2140596e31a1496bafdd0b9ee4a2e6a6_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTUtNC0xLTEtMTc4Njg_3839b917-e978-4652-b3d0-e4ab6dbe31b8"
      unitRef="usd">1930000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09ee6e9676f048f79f0471399c05b638_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTUtNi0xLTEtMTc4Njg_6f3b89f7-40c4-4d70-a245-5b9cc668f2d5"
      unitRef="usd">3671000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id19d1f5e16084839a8c193bc0d1b0b6b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTUtOC0xLTEtMTc4Njg_37a6e0b1-1ea3-46e4-91e5-e1cef7290f9c"
      unitRef="usd">1947000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd6b40c44ce54ba1bde4642cb23e69f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTUtMTAtMS0xLTE3ODY4_9e4a41a7-2dcb-416c-854d-9260f42fc654"
      unitRef="usd">1965000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4186212e28d4b569b09c70bbface083_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTUtMTItMS0xLTE3ODY4_ba997ff6-db82-432b-b93f-c378ace4e075"
      unitRef="usd">3912000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id659a1190f7b4070a747d070536ed33b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTctMi0xLTEtMTc4Njg_52d405ec-1844-477b-9081-81ca9d4c3b32"
      unitRef="usd">263000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6480973800e4bb4b9ae80722ce16e59_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTctNC0xLTEtMTc4Njg_91282d40-3260-4601-882b-aefa1d7ff438"
      unitRef="usd">270000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d61af67909049b9a444fc24e14717ea_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTctNi0xLTEtMTc4Njg_4df21009-782d-4386-9c9f-95c72ffe4e56"
      unitRef="usd">533000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if890618fe578485fa3a4db43677fe34e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTctOC0xLTEtMTc4Njg_103220cf-14ab-4010-ae13-38ceb0afd660"
      unitRef="usd">266000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34397dbe2fe94c6295a14a8d146a8e33_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTctMTAtMS0xLTE3ODY4_62a570fc-a918-44d6-bd29-86b1662a5acb"
      unitRef="usd">305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f8368e30efc48f7b56ba92dc4adc061_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTctMTItMS0xLTE3ODY4_22bc5eb7-5db0-4bbe-b73a-cc65d621e3a6"
      unitRef="usd">571000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i928d6fe7e0df441780768f564d2effcd_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTgtMi0xLTEtMTc4Njg_32837afa-b19f-4fce-bd38-440d2a1167ef"
      unitRef="usd">225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f24ca1db60e4a9da9ffd86e0dd87fe7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTgtNC0xLTEtMTc4Njg_4861537d-1b91-4792-b047-60a64cddcf52"
      unitRef="usd">244000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i822021d7a9e249bab1fe800a9aedfb9b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTgtNi0xLTEtMTc4Njg_1b760cd7-1415-4b63-9b3a-6880b57d58b4"
      unitRef="usd">469000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ab1d9822ff84b4480b3cd3b8cc641bf_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTgtOC0xLTEtMTc4Njg_e28117b8-916d-4c46-bb28-a865dac4b7d2"
      unitRef="usd">192000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if718f850e60e4378916dbadb60c282ad_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTgtMTAtMS0xLTE3ODY4_194c7c3b-f66b-4696-a0e6-a23b674cba15"
      unitRef="usd">293000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e82029ad78c409e9753b65d01cfa2d5_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTgtMTItMS0xLTE3ODY4_db565a59-2ae6-458b-8253-141631b13eaa"
      unitRef="usd">485000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedef7300876e4675ba5cd753aef79d39_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTktMi0xLTEtMTc4Njg_04714945-70d4-4b68-b5fa-d315e51a05dd"
      unitRef="usd">177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d1631e3346a480c9d5b5659e244276e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTktNC0xLTEtMTc4Njg_f301d0bc-81e1-4d83-b5ad-0f71fe55ef7e"
      unitRef="usd">51000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77aac3496d504b269d56bad2b76e5104_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTktNi0xLTEtMTc4Njg_ec26dc55-284b-4500-adc3-72290ba5afbc"
      unitRef="usd">228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i780ba98a53b04c0abf1fcfadfe606d7f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTktOC0xLTEtMTc4Njg_8919f931-9041-4974-8016-89125fe97100"
      unitRef="usd">170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic59cae3887574b7b9d34a8c5fd1fb0b6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTktMTAtMS0xLTE3ODY4_d253d750-4ca7-4b0c-876a-d7ca306ac623"
      unitRef="usd">59000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i228ab2341a2243eeb1c80b00645ce995_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMTktMTItMS0xLTE3ODY4_7a82a5fd-2722-4cd5-805e-403bf59e150e"
      unitRef="usd">229000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2294cc5729724ad4beb4eca7c9cdd070_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjAtMi0xLTEtMTc4Njg_fa9f201c-35df-4cd4-a8ea-7b07e344ab5f"
      unitRef="usd">213000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide82ac8a034040ebbe46d3d3b8e71a00_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjAtNC0xLTEtMTc4Njg_0af31bb5-5ea3-4d1f-b3ce-8653be910c41"
      unitRef="usd">393000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dc02637faf8456f8e9ffb0ddcae89e6_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjAtNi0xLTEtMTc4Njg_47c73f0b-2d6a-4816-b040-dca1c27ab440"
      unitRef="usd">606000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4030aeb71c94f9bbc3b600344c1518a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjAtOC0xLTEtMTc4Njg_09e4d74b-ab9f-4dab-aedd-36126f9a403e"
      unitRef="usd">219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i921fd3c95d3b4f22ad34e4bc60148ba2_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjAtMTAtMS0xLTE3ODY4_18fefe00-ae6c-4236-923f-7252c95bd749"
      unitRef="usd">425000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3145c2c6bd974f55ac9749bc3df087bf_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjAtMTItMS0xLTE3ODY4_8ff52f0d-4e53-4fae-a1dc-55a4d25eeb9e"
      unitRef="usd">644000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b5c721c4b474f6ea1f090bb7b8e4fd0_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjEtMi0xLTEtMTc4Njg_88255012-e5a9-427a-9c0d-b0babd3e5be2"
      unitRef="usd">207000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35e0589ff3084f539d0a76d845294702_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjEtNC0xLTEtMTc4Njg_90e1a0c0-dd4b-4c3c-bdc6-84ef5888e88b"
      unitRef="usd">213000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34e8d657434743fe827a4089fc230ba9_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjEtNi0xLTEtMTc4Njg_a1f29af1-78af-42b7-b0dc-77d25b0a7402"
      unitRef="usd">420000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08e9a03bf16d46ea811c32e2fd25a006_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjEtOC0xLTEtMTc4Njg_e1470a0b-f7c9-4471-b491-71457cac78ba"
      unitRef="usd">177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i570d7e8aa51741029b8421acbd7e89ee_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjEtMTAtMS0xLTE3ODY4_12e579ac-4af5-446f-be7d-9ddfecbf792e"
      unitRef="usd">215000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35c10ac918394db8b1c3491c2981f0e5_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjEtMTItMS0xLTE3ODY4_be36c51d-e6ef-4c20-a213-65399506d484"
      unitRef="usd">392000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d04f4545b8b43d7bcd56adb5418487d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjItMi0xLTEtMTc4Njg_26cab113-85df-4a1d-bf65-26bd3e6d4b02"
      unitRef="usd">156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a32eb2db2de4ba4b33ad343ddc6021a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjItNC0xLTEtMTc4Njg_316fe859-eb8a-4a61-8828-165b52e39598"
      unitRef="usd">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1583d120070b4c648cbb100c9764e0a7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjItNi0xLTEtMTc4Njg_65141c81-b0c0-4c3c-a01b-c56509403832"
      unitRef="usd">192000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i683987d035904d219c421b72bf0f8f88_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjItOC0xLTEtMTc4Njg_9de02406-9a48-4ed6-8488-8afb006f7d07"
      unitRef="usd">149000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a64fbf194cd46d1a5f071cd845567da_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjItMTAtMS0xLTE3ODY4_2df1db48-ec21-4310-9955-30c5cdc82cf5"
      unitRef="usd">41000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9adf53e54b3447a88875f2f71694d649_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjItMTItMS0xLTE3ODY4_d8f2697b-1059-4bfd-9495-e87676fbb282"
      unitRef="usd">190000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica898e019d964049bedef258b5226f95_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjMtMi0xLTEtMTc4Njg_62903bf4-3181-4549-8c3b-be9f1afb518b"
      unitRef="usd">423000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c4b4059d40945188d652327f054645d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjMtNC0xLTEtMTc4Njg_85170a7d-4c90-4c3e-9533-65e9e00bd998"
      unitRef="usd">744000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8056ef31a802430fa929e0598584b1c7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjMtNi0xLTEtMTc4Njg_261d8f2e-e9ee-462d-bb83-0f50ad614518"
      unitRef="usd">1167000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia16e81903f114d79b6e640358306f75a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjMtOC0xLTEtMTc4Njg_c20c084a-14c0-4af3-a018-b50dcc955b4f"
      unitRef="usd">323000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1005eed0e87a4f6ca75ca475d4fb2b94_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjMtMTAtMS0xLTE3ODY4_f5eaf19e-92e1-4ded-9e9d-01946468a8e1"
      unitRef="usd">798000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i351b1476da8947a8a63c6a3ff672aee0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjMtMTItMS0xLTE3ODY4_4f370366-d051-449e-8217-41aa4ab6b0d5"
      unitRef="usd">1121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff8daa2d825a48a298a1cc610189cf7c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjQtMi0xLTEtMTc4Njg_e6b64cd1-eeed-4d53-960e-0abe8b454192"
      unitRef="usd">1664000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a811c943c8c43aa93ad41f1bdcb253d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjQtNC0xLTEtMTc4Njg_179e342d-0197-4371-b837-ed98db35a3c0"
      unitRef="usd">1951000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91226d7ee83f4e5298c5a54390a1eccc_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjQtNi0xLTEtMTc4Njg_c68690c0-32f4-44ad-8f79-161a5fa44423"
      unitRef="usd">3615000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10e8ad512c2f4a09873c90ec51a3e052_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjQtOC0xLTEtMTc4Njg_80473528-f9dc-43d6-8986-87c29312e76c"
      unitRef="usd">1496000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9911c8668779460c87a6b1bfc290914f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjQtMTAtMS0xLTE3ODY4_1c54badc-4603-47a6-8deb-6343f28c412c"
      unitRef="usd">2136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2c236dcb265432793429913b3061d27_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjQtMTItMS0xLTE3ODY4_24458ee6-5b26-4ca0-8b51-4a2f6e446b4b"
      unitRef="usd">3632000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id73b999e6aee402da9f298dad7a6ac0b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjYtMi0xLTEtMTc4Njg_4abc7ede-ccad-47e3-ba05-8f088e27d4c4"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i069f4c6f209746c789a3cc531b1374c1_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjYtNC0xLTEtMTc4Njg_8bc5dcd5-be2f-45b4-9232-d7ed569ec3fd"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e1452c0c5d145a29227070d32c787ac_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjYtNi0xLTEtMTc4Njg_a9d96adf-5df0-497b-acc6-e9b623200f8f"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93831c5392ae4927b11006f81f940e3c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjYtOC0xLTEtMTc4Njg_23b420bc-690a-4339-a672-f3fbee40b9ef"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0a7f44a74844847a52a461dc905dc00_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjYtMTAtMS0xLTE3ODY4_2f367a89-824c-4e6f-a2d6-be2b23e8de2e"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ef09987de6c4adeb7fa5bf0cf0c7704_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjYtMTItMS0xLTE3ODY4_17a627f7-a6c9-4e76-816a-3d81fefac64e"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf27976a942a4fc19586a8236e981bc0_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjgtMi0xLTEtMTc4Njg_c9ce204e-19d3-49a8-a80c-f0ef3b5dc00a"
      unitRef="usd">4094000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1349d737be5b4ef59e79e923b2ac2288_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjgtNC0xLTEtMTc4Njg_b7c38778-ce23-45c5-8964-a6298d598192"
      unitRef="usd">6316000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjgtNi0xLTEtMTc4Njg_bc8e12a1-5b6f-4670-8446-950181c7f4a5"
      unitRef="usd">10410000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i453afdd41ffd4a8f9d41a110816ebc00_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjgtOC0xLTEtMTc4Njg_a2a46355-51c6-409a-8ed0-66683a93e465"
      unitRef="usd">4368000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b9d6f53ba814d1b95c967e665c217ea_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjgtMTAtMS0xLTE3ODY4_9b1e1384-d02f-45a5-a287-8f5a9229514c"
      unitRef="usd">6560000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl8zNy9mcmFnOmJiMDNkNjY3ZDI0NjRmOGM4NjExMThmMmZiYjAwMzQzL3RhYmxlOmQ2ZDljYzdjNGU1ZTRhMmRhY2E5NGRiYzUzMTBmZmI1L3RhYmxlcmFuZ2U6ZDZkOWNjN2M0ZTVlNGEyZGFjYTk0ZGJjNTMxMGZmYjVfMjgtMTItMS0xLTE3ODY4_20d541f3-119b-4ef7-ae1f-7a8a07fec024"
      unitRef="usd">10928000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iada0437a2d644f70bb7d16cf91f31b89_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMy0yLTEtMS0xNzg2OA_cf4063c3-edb7-4318-9706-827d901d5e35"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cade4bab8cd43e19b63a86b43643ef5_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMy00LTEtMS0xNzg2OA_c1d64034-1c52-4f40-b874-b31cbf60da35"
      unitRef="usd">2826000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i361870a0e2f94355b13e0b60175a2edb_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMy02LTEtMS0xNzg2OA_aecd10e5-352a-445c-966b-0546396f2555"
      unitRef="usd">2826000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i134a99d86b0243888efe2cec770050b5_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMy04LTEtMS0xNzg2OA_88fe2cef-a07c-43b9-9085-1e9c765ab64e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i690d3ee447044de5b2a11910dd16abaf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMy0xMC0xLTEtMTc4Njg_ea47a617-b03c-4723-b313-0af787a8f677"
      unitRef="usd">2672000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31f2c0a0ad5d4d44bb78b1dc657ab16d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMy0xMi0xLTEtMTc4Njg_b8eaf661-5c70-4524-8878-31ff54d53448"
      unitRef="usd">2672000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i554353f0dd4640f1b215201bed46099d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNC0yLTEtMS0xNzg2OA_2cdd0814-c2a2-42f7-b90d-18852d666c0d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifec2214696a74f5fa73835f5d611690a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNC00LTEtMS0xNzg2OA_56164637-9812-44b7-9cf5-05abc36ad937"
      unitRef="usd">870000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6e6c2d98d8f46038f546582021c6a94_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNC02LTEtMS0xNzg2OA_3e6d46c9-9119-421a-b981-8cb9d9f4b58d"
      unitRef="usd">870000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9a4321960004899b56bca3a97bccffd_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNC04LTEtMS0xNzg2OA_66e49c82-b68a-4ac5-bed9-8801d7cb16e6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i102907d306274282b184801c40f69f97_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNC0xMC0xLTEtMTc4Njg_47004d0d-f1b0-4d2b-a0f6-0e7b67e4a1fe"
      unitRef="usd">843000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad208ef1d3254acaa72d25a179cf7d24_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNC0xMi0xLTEtMTc4Njg_d2015de1-4349-412b-82ff-40c0a93446fc"
      unitRef="usd">843000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92e9ca2b2e18494baca77d7365fc681a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNS0yLTEtMS0xNzg2OA_4140014a-1a91-44c5-92fd-c87467dda91e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40287ad92f234638a3f0573ebae44eca_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNS00LTEtMS0xNzg2OA_3793fff3-8490-4f23-9aeb-f5e75e110793"
      unitRef="usd">3696000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88535b01ff934a65be5cc199bcb770b6_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNS02LTEtMS0xNzg2OA_6d028957-46fc-4d81-809e-2ffbe2fba5ca"
      unitRef="usd">3696000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icecdc6a5fc1c478c8f0fdbb2c241e43e_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNS04LTEtMS0xNzg2OA_bc130e99-455e-4b0b-8291-b6920250bdb6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i708d2529d4054b78a3b367c21aaa1820_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNS0xMC0xLTEtMTc4Njg_d970fcde-0647-4ed3-9c1c-7ffd9ca54650"
      unitRef="usd">3515000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c90b3c1db944b208e77b4076259563c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNS0xMi0xLTEtMTc4Njg_d82e851e-ebf9-4d99-8125-8a00018e4fe8"
      unitRef="usd">3515000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia34a1de062a34934a0a112436ec8d560_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNy0yLTEtMS0xNzg2OA_f15bec24-172f-48cb-931e-cb80cc39e9a1"
      unitRef="usd">1108000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1345044a56d74824ac553b8f40f2c74d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNy00LTEtMS0xNzg2OA_d8107eab-3b75-4a63-8928-e721a19f5b6e"
      unitRef="usd">1491000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic52e79d5447c4977917c82e49b86fb4e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNy02LTEtMS0xNzg2OA_422ac4bb-5311-41b1-bf5e-8c2702dfe20e"
      unitRef="usd">2599000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e840f2b6e62404898af58c0cbc62fbf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNy04LTEtMS0xNzg2OA_1fd0e72b-ccfa-4415-950e-e6b7d7ff350f"
      unitRef="usd">1622000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a8d70dcf5384658960d5b5ea48dfbb7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNy0xMC0xLTEtMTc4Njg_94c0ce47-1ac9-499b-8350-190412152844"
      unitRef="usd">1637000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43915f754bb04fb5a0040abb37d51123_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfNy0xMi0xLTEtMTc4Njg_cf844cfb-8046-4314-b8af-372d25486c14"
      unitRef="usd">3259000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41d6039c97b64dbc820635198caf3dc4_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOC0yLTEtMS0xNzg2OA_270eb083-c825-4615-90ce-42c15f3843bf"
      unitRef="usd">1016000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i258f0ca4a6f44bcd94d893ebab9cc9c1_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOC00LTEtMS0xNzg2OA_d3bb9ef9-688a-4599-bf58-bff4536749b8"
      unitRef="usd">2027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e3063d3a8aa47c784ad799aceff5e06_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOC02LTEtMS0xNzg2OA_ee8414f1-080b-4fb6-b837-68ec81876d7a"
      unitRef="usd">3043000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea4b8d31930d4018a5338e7cf5435676_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOC04LTEtMS0xNzg2OA_8ef3db9f-9263-4612-b08f-039b638c2e4a"
      unitRef="usd">1006000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i176c1169defa4bb381f30ee2fe87a5d3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOC0xMC0xLTEtMTc4Njg_3a1a0ef7-1173-48d9-b589-48d13722381e"
      unitRef="usd">1987000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie585e82674e94179ab887b7f775c682b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOC0xMi0xLTEtMTc4Njg_a89e81b3-4e27-4048-b359-553ea49b5b1e"
      unitRef="usd">2993000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie623ae8b28ba4c44b6fec7b856d08e06_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOS0yLTEtMS0xNzg2OA_4e083b7a-b8ba-4fcb-acde-e926bb9b78a7"
      unitRef="usd">2124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35395fcaaf34451c9cbfa534d8d7ce9a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOS00LTEtMS0xNzg2OA_4b71e7bf-7325-471e-9d63-9405945ca7df"
      unitRef="usd">3518000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30091a5d3bab43efa63d14e4a226925c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOS02LTEtMS0xNzg2OA_074e6269-1e9a-4529-80ad-f860c3ccda2b"
      unitRef="usd">5642000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1596bb0bf8f43fd80c7d6d3d9119a9b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOS04LTEtMS0xNzg2OA_f289dd5d-4a4d-452c-8675-84613b588401"
      unitRef="usd">2628000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i248be60308a146df85a86a26a0fc60f8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOS0xMC0xLTEtMTc4Njg_ee1cef3d-e301-45d6-a0e4-d7f4c7f12874"
      unitRef="usd">3624000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i151bd5c29f3c46848ec98ccbecda7c02_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfOS0xMi0xLTEtMTc4Njg_aa04e518-6503-4539-b873-a1f2037832fa"
      unitRef="usd">6252000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b056141550548c3be6dd5b036db3ff1_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTEtMi0xLTEtMTc4Njg_5fae7b43-afef-4547-9e21-327e0c8156c9"
      unitRef="usd">836000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e31728b4def4db89b236907c78b2797_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTEtNC0xLTEtMTc4Njg_c442d5a0-05cb-471c-9c90-ae9555b25f53"
      unitRef="usd">2788000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia75bb1a2605e4d8ea6e25aa3afb20121_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTEtNi0xLTEtMTc4Njg_23ed9262-45ac-4266-8a45-0c40518c9284"
      unitRef="usd">3624000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifaa33587aec14e3c92b0c60d0a771555_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTEtOC0xLTEtMTc4Njg_28bc5e6e-3821-4603-9c4e-766b3c66c479"
      unitRef="usd">845000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62abea3acfae48e8890da0175c0339ac_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTEtMTAtMS0xLTE3ODY4_53de4401-d389-4fe7-a8b9-48b830622231"
      unitRef="usd">2935000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if933b85d1d764e94956ab214e194e081_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTEtMTItMS0xLTE3ODY4_9268f000-57bf-4fcc-ba6e-b2e2196ab1b3"
      unitRef="usd">3780000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d65665918964adeb3fff6362875e715_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTItMi0xLTEtMTc4Njg_566f8691-e0db-44a8-a573-298a5c475d50"
      unitRef="usd">308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i381802cbd03a48bf88e11eee86e25b7f_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTItNC0xLTEtMTc4Njg_a8c0c4f3-0244-4c8f-bd6b-79ba136b5303"
      unitRef="usd">507000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id56510d8ef1842c0ae332b5fed72a26a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTItNi0xLTEtMTc4Njg_1d26800a-372a-4756-be9c-a75e2cd39f90"
      unitRef="usd">815000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i775838a7944846a986221b63ebbe9b64_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTItOC0xLTEtMTc4Njg_e15d1511-37bf-450e-88c7-b7ca9d6c9aa6"
      unitRef="usd">431000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba87ee33146849a291c62b0745bb5f5d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTItMTAtMS0xLTE3ODY4_8cd71789-893f-4945-b6ad-3aae1ec56519"
      unitRef="usd">651000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d36392cd74f4d26a9d42617161eafaf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTItMTItMS0xLTE3ODY4_cb903f2d-350f-4322-b2dd-41a55f1a0230"
      unitRef="usd">1082000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a75adec61da4340b39d6915dcb31f11_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTMtMi0xLTEtMTc4Njg_6c14a42e-4a64-4494-aa12-61496badd37c"
      unitRef="usd">284000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9cf76723706485f8673bd279ede2bf5_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTMtNC0xLTEtMTc4Njg_d2988916-9e11-4442-9ed3-2bf0b4216274"
      unitRef="usd">110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3769aaf2e984527ab4d6cd5c5790c6a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTMtNi0xLTEtMTc4Njg_e2a2ad7a-184c-48d2-a95d-e02eb1433caa"
      unitRef="usd">394000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d0f4ef4f7424767974f102dbe69d978_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTMtOC0xLTEtMTc4Njg_2b0eb344-7216-4906-afb7-ee0f7fe86b5b"
      unitRef="usd">289000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ea63032d5234ccd932e6fd8c70cf960_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTMtMTAtMS0xLTE3ODY4_c5b5ff2a-3836-4d28-97e3-c85a4e926192"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i390a22555acc4884934c9d58d45d11d2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTMtMTItMS0xLTE3ODY4_459f3207-9750-43e5-be0d-8202b1281035"
      unitRef="usd">401000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49197e2409e34e65a96c75e9f85a6de5_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTQtMi0xLTEtMTc4Njg_4195af59-0ef8-4b91-b445-0b97490607f5"
      unitRef="usd">5523000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b4a4436b7e3437ebd0171fc877d29e3_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTQtNC0xLTEtMTc4Njg_cf959004-43c9-469e-bfb0-75a7ac2cd95c"
      unitRef="usd">2923000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43eff708b8824e8da4d9838d6a4f5e3f_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTQtNi0xLTEtMTc4Njg_02f69c43-4f05-4a9e-bd46-842267749772"
      unitRef="usd">8446000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1103a7e9b8c9470d9eb268366aaf62b7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTQtOC0xLTEtMTc4Njg_042880f9-5f5c-4917-b353-64c446209e5a"
      unitRef="usd">3178000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0287b1ef094c4fad8318d6eca7385301_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTQtMTAtMS0xLTE3ODY4_a0384696-59ea-42f6-8be7-f85d6722a7e3"
      unitRef="usd">2732000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e49e1388c1b47c883e46629b8e2b191_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTQtMTItMS0xLTE3ODY4_84603913-2be8-4907-bda4-96ff9e43edcf"
      unitRef="usd">5910000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59bf5ff82ae5408b905d3c438eb99949_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTUtMi0xLTEtMTc4Njg_f3905c34-64eb-4b3b-8562-db4b88d3b228"
      unitRef="usd">6951000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib084a5804053469ab97816e5c1ee7359_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTUtNC0xLTEtMTc4Njg_86713266-80e5-46c4-a56f-755c48810297"
      unitRef="usd">6328000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72d0903dbdb14905994e7b293b54456f_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTUtNi0xLTEtMTc4Njg_64d2d88c-85ad-4943-9d16-69e0a90fd5c8"
      unitRef="usd">13279000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4974eb5146784a269db4203e8c6fa7e6_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTUtOC0xLTEtMTc4Njg_22ff5069-d1f1-40a8-9bd3-63bc5c2e9e2d"
      unitRef="usd">4743000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66b90b7445ea43d9b419aa50bb82b8e5_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTUtMTAtMS0xLTE3ODY4_d4427878-724f-4089-86c2-a65ba8aca210"
      unitRef="usd">6430000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc14a44dcf1344559829bf251b14704d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTUtMTItMS0xLTE3ODY4_40dc305d-94b0-48ea-986b-ca28eb135325"
      unitRef="usd">11173000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00bbc05a48e34b0895b143638542cf98_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTctMi0xLTEtMTc4Njg_28c2a2ec-6f2d-48cd-95f6-fba6ff664a91"
      unitRef="usd">775000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd4ab9bd729548cdbc214c561241cdc1_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTctNC0xLTEtMTc4Njg_d63c575c-3d6b-4e46-bd82-3bb9f45d0a09"
      unitRef="usd">830000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id965fbb08df843a7b71062949bd75de8_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTctNi0xLTEtMTc4Njg_22acd5a7-70b9-42c3-b8b6-fe0c63e076f2"
      unitRef="usd">1605000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f23fb6c9b6b40f996df1df9c7d4d1b0_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTctOC0xLTEtMTc4Njg_53a1f51b-e0d0-4c35-931c-c1b475429d94"
      unitRef="usd">776000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59ade9da924b40b8b3b22b5c8d7085b2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTctMTAtMS0xLTE3ODY4_cb59a83d-76da-4554-9912-e95edbeec4c2"
      unitRef="usd">881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63931e4da08749c89fc6a8bd235b4ef4_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTctMTItMS0xLTE3ODY4_92e52cba-65c3-46d8-ac87-352bbca3fa21"
      unitRef="usd">1657000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d48c3bb559c4a829632103b69a3a872_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTgtMi0xLTEtMTc4Njg_d257d1a4-b706-4930-b504-c702104d25ce"
      unitRef="usd">667000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79f1f89cdf584d59a1701cdbbeead083_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTgtNC0xLTEtMTc4Njg_cde8ea4e-43ab-4d04-b175-2a46ad694322"
      unitRef="usd">773000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if86c316bd32140fcb1db26b35d96f19a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTgtNi0xLTEtMTc4Njg_72f4a2bb-c5da-48a4-9e6d-6fd20de1b0b5"
      unitRef="usd">1440000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9da5f32878ef4ff2bb7b73e8340888d3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTgtOC0xLTEtMTc4Njg_afc66f88-03ec-4bf9-a6f0-3cf05a922970"
      unitRef="usd">580000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85330517d5a14b5eb736122a3a5bcebc_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTgtMTAtMS0xLTE3ODY4_11980195-2bde-4000-afe5-ff8e096c7b49"
      unitRef="usd">823000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i899221de84bb4f4da22a481ff4200823_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTgtMTItMS0xLTE3ODY4_430389b6-56a6-41cb-9336-edf2b482b409"
      unitRef="usd">1403000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f3b2c7957554d658f3db970c6d6b430_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTktMi0xLTEtMTc4Njg_6b180882-aab6-41ab-bfed-adb80c2f631b"
      unitRef="usd">523000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec90285d812f4f068310c71aedbc8afa_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTktNC0xLTEtMTc4Njg_d6f6004b-2537-4e5f-b72e-ba6541c29d2b"
      unitRef="usd">167000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i152ee6da621e4956b226578681a95301_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTktNi0xLTEtMTc4Njg_f9af8c34-3d96-4b0b-aaf8-6a95a7e5c2d8"
      unitRef="usd">690000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e8d82e7deaf4edbb04c1b33ba231943_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTktOC0xLTEtMTc4Njg_dccea81b-b117-4e33-bd17-d3ac79502059"
      unitRef="usd">483000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iadf482c8b62342cabd96a8f08883e08f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTktMTAtMS0xLTE3ODY4_792f0246-1376-453a-a551-c90b9422261b"
      unitRef="usd">167000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibdfc6bf7155d4385a0a3ab7ed7d09c3a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMTktMTItMS0xLTE3ODY4_88148155-f14d-4a7a-a7e4-806a0f5882e5"
      unitRef="usd">650000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia12ba51821814d288ee081fbaa8ce473_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjAtMi0xLTEtMTc4Njg_71932dd6-5bc8-49ca-85f5-668b159aedab"
      unitRef="usd">650000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74fa6dbf7cce4f75b02f642d1f599489_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjAtNC0xLTEtMTc4Njg_ed3a6ec8-44c7-4cc9-9d34-d3c63323f2ca"
      unitRef="usd">1228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0df3bfdd84f14f64ba3f84ad0dc9a807_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjAtNi0xLTEtMTc4Njg_f6a6593b-003b-47b1-a79f-31067cc31ba5"
      unitRef="usd">1878000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1935bf7c22124130bed4e1a214f63308_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjAtOC0xLTEtMTc4Njg_ba3b9676-fcdf-4ece-85d9-f67af0d6c185"
      unitRef="usd">684000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedb59d3d7f814dd5a908dfbd889da9d7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjAtMTAtMS0xLTE3ODY4_cad11e36-61e9-482d-8a66-797b5827afc4"
      unitRef="usd">1292000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabd1755cc8654a2692d559c24619a01b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjAtMTItMS0xLTE3ODY4_0247d6d0-03df-47ac-a324-174c74f2e95a"
      unitRef="usd">1976000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f0c0e2be49847eda32a1bc8f4a3d0a4_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjEtMi0xLTEtMTc4Njg_32781e36-cb80-4314-862e-02802cf9fdf6"
      unitRef="usd">604000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i603417b878634bc7b3c6c7e28e82df50_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjEtNC0xLTEtMTc4Njg_f189bfbc-7ea9-41d8-8413-db417e116328"
      unitRef="usd">667000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30de540bbd614a38a4d9b0e11618a079_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjEtNi0xLTEtMTc4Njg_d2a8dbba-ec1b-4308-9419-9801a406158d"
      unitRef="usd">1271000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46266d118c974a5aa2d9e68681b6b922_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjEtOC0xLTEtMTc4Njg_c97e79cd-514e-4549-ae65-3947de93aa7a"
      unitRef="usd">537000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ebd6bf1d71d4400b4815379954178a3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjEtMTAtMS0xLTE3ODY4_459040fd-7605-4b20-ad32-b23243a32a21"
      unitRef="usd">654000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b829deb2ae74f13a56fe33a45c6e829_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjEtMTItMS0xLTE3ODY4_5074636b-5b10-4728-ae02-65f26e5c1db7"
      unitRef="usd">1191000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6e1e30c4e804011b00a91294e5115f6_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjItMi0xLTEtMTc4Njg_90aff5ad-9310-40d4-a1f6-c9924495847f"
      unitRef="usd">456000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4463afae1e5544929d49ae0a34367c96_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjItNC0xLTEtMTc4Njg_1859794f-0043-4cae-8ba7-309b2d4e3482"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3476fa0ac234ff2842cfecc49b3e986_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjItNi0xLTEtMTc4Njg_20d2c6c7-21d4-4ad7-9de0-f9f1e34f6f2a"
      unitRef="usd">568000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if64d98f713314bb9833a430722b4386d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjItOC0xLTEtMTc4Njg_497293d4-d128-41f8-a926-eaa867b6514f"
      unitRef="usd">460000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9857ddf749154af092177a27b3317c19_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjItMTAtMS0xLTE3ODY4_dc75ca70-24ca-4771-bb52-d7ad0eedcfe3"
      unitRef="usd">124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18e9f36c179f44e3bfaec15ee0847c98_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjItMTItMS0xLTE3ODY4_c19dd138-c821-4c95-ac53-c6667ec106d5"
      unitRef="usd">584000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3859aeb3184c430cad30ee39666a826e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjMtMi0xLTEtMTc4Njg_19772cc9-61fe-42f6-8220-65a081eda951"
      unitRef="usd">1165000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cd2a1a447c34980acee85e3b68e0919_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjMtNC0xLTEtMTc4Njg_5b5e52d4-d912-4168-9624-d4d47cd11d63"
      unitRef="usd">2320000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37249fb3b9b7438bae34cc8f3ddc38da_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjMtNi0xLTEtMTc4Njg_5a0dc391-3b33-4701-8b4f-9562e0a84811"
      unitRef="usd">3485000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82e117f9b22f4ad18dde00710f85564b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjMtOC0xLTEtMTc4Njg_4db6ac6d-5123-4a8d-9352-ed1c3fb07dab"
      unitRef="usd">865000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0deea721100d42d2aa599ecbc0b6ee95_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjMtMTAtMS0xLTE3ODY4_ba6bc13d-00e7-460a-96f2-3282cbd57e2c"
      unitRef="usd">2292000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47b80c5b0ee9422a85373b6736cab652_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjMtMTItMS0xLTE3ODY4_598ec29f-e745-4bc6-a54e-ec8466a49bf8"
      unitRef="usd">3157000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08308c9f9c6a446496b0ba98a0a5fa36_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjQtMi0xLTEtMTc4Njg_0d1645bf-7f5e-45ad-880e-10b2247bbdd8"
      unitRef="usd">4840000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6041fbdff4649fb80901f2a88fc9805_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjQtNC0xLTEtMTc4Njg_ffa851d9-5533-424e-9182-1b90b275a878"
      unitRef="usd">6097000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i165fe1c62d6e440d91dc4abc8a0dee83_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjQtNi0xLTEtMTc4Njg_f5914f95-2609-4cbf-a3ba-de8f96788fbc"
      unitRef="usd">10937000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i417cf26f3afb43a3a54f1bb81556fdd8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjQtOC0xLTEtMTc4Njg_ce3b653d-6155-4dae-8780-01869691f32a"
      unitRef="usd">4385000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25afbf02cb5a452089cc6973c24865ab_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjQtMTAtMS0xLTE3ODY4_b2167b6b-b820-43bc-bbc4-a9ebaaab70b5"
      unitRef="usd">6233000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81462640315a4b09a820a1f604b6aa3d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjQtMTItMS0xLTE3ODY4_78bed76c-7e0b-42d4-a9fe-d21e1b16b923"
      unitRef="usd">10618000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic909cb81fa33496693b9dc997788164a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjYtMi0xLTEtMTc4Njg_82b898ef-3fb6-4e73-8cc8-3d6e4b17b373"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee4f114b62e84287ad7fc6130c023ad9_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjYtNC0xLTEtMTc4Njg_991c7fd7-f8c4-40fa-aa3c-167ab3ecf8ca"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic07c5110a61643c2a55c992dde280072_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjYtNi0xLTEtMTc4Njg_3090397a-eafe-4c15-af28-20b0daee11dc"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07c1d47dd14647d0964914f96057eefe_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjYtOC0xLTEtMTc4Njg_81816501-4dbb-44a3-a928-650f5dc85d9e"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3382e3eaaaa846039edbe767cda3d3e8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjYtMTAtMS0xLTE3ODY4_3a6a4acc-f76f-4bbe-a590-96c47b84e663"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b228ed718b140b2a339fb6308161ea7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjYtMTItMS0xLTE3ODY4_c1d9ebff-3c1f-4076-bedb-a75050c3931f"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99c7716e33994105b40cddd5474333b2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjgtMi0xLTEtMTc4Njg_787e6ae7-4c60-431e-ae66-9065fbdd2c18"
      unitRef="usd">13923000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69cecf5a94a046b59d942b45947a7002_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjgtNC0xLTEtMTc4Njg_db576f7f-7c66-42ab-9d4a-edc29f6ff752"
      unitRef="usd">19639000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjgtNi0xLTEtMTc4Njg_7df016d0-a3e5-4633-91a0-e039ae0188cc"
      unitRef="usd">33562000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf4171e1cd304992aba32032b32e09ae_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjgtOC0xLTEtMTc4Njg_80e7c619-7276-49b9-8a91-6c995e810615"
      unitRef="usd">11787000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i991a1bda2a6e4464a4b0a7be66e27ead_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjgtMTAtMS0xLTE3ODY4_c7fcc1c6-95ff-45e0-b786-ce15a2cfb597"
      unitRef="usd">19820000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmJiNzY0Yjg3NTcxYjQ0NTU4ODFlZWY0NWQ4ODY3YmJmL3RhYmxlcmFuZ2U6YmI3NjRiODc1NzFiNDQ1NTg4MWVlZjQ1ZDg4NjdiYmZfMjgtMTItMS0xLTE3ODY4_fe071a48-3818-40bf-83a8-c302d34486ab"
      unitRef="usd">31607000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="id035b12c3f014d2bafdba8da0f64bb42_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RleHRyZWdpb246NTk4ZmI2NzViZjI0NDFkNGIyNmU1NDAxODY3ZjA0MjRfMjE2_c163c48e-ae8a-4e4c-ad91-bf8d2273cd84"
      unitRef="usd">3900000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i62bee42564544f0d9b3280c51a9cc02c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RleHRyZWdpb246NTk4ZmI2NzViZjI0NDFkNGIyNmU1NDAxODY3ZjA0MjRfMjY0_38900cec-1a85-469e-8554-bad076659224"
      unitRef="usd">433000000</us-gaap:RevenueRemainingPerformanceObligation>
    <abt:RevenueRemainingPerformanceObligationExpectedTimingPercentage
      contextRef="i0c7dafe2cfba49daa19fb3f0283b449f_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RleHRyZWdpb246NTk4ZmI2NzViZjI0NDFkNGIyNmU1NDAxODY3ZjA0MjRfMzUy_2896d2e3-134c-4dd8-9c56-edec2d5f1b23"
      unitRef="number">0.60</abt:RevenueRemainingPerformanceObligationExpectedTimingPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i20fe539eb4a74b7492123682cd84ae45_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RleHRyZWdpb246NTk4ZmI2NzViZjI0NDFkNGIyNmU1NDAxODY3ZjA0MjRfNDEy_bdf2e747-1b03-423f-9dae-434b2d29bfbc">P24M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <abt:RevenueRemainingPerformanceObligationExpectedTimingPercentage
      contextRef="i22df9ace730b4d42bc4be5744f0a1bad_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RleHRyZWdpb246NTk4ZmI2NzViZjI0NDFkNGIyNmU1NDAxODY3ZjA0MjRfNDMw_ec2d6411-b881-4ab1-b351-d713f1d2f162"
      unitRef="number">0.16</abt:RevenueRemainingPerformanceObligationExpectedTimingPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i6aa796dac9664691b74441abe1256b0d_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RleHRyZWdpb246NTk4ZmI2NzViZjI0NDFkNGIyNmU1NDAxODY3ZjA0MjRfNDUz_16bc1452-0e8b-4828-ab61-6f03c0cf2a46">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RleHRyZWdpb246NTk4ZmI2NzViZjI0NDFkNGIyNmU1NDAxODY3ZjA0MjRfMTg3OQ_6f927f22-fed9-4686-a382-6c2aabbe19da">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the contract liabilities during the period are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unearned revenue from cash received during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized related to contract liability balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmVlOTUxMzI1ZTQ0NDQyYzRhOWU5ZTE0MWVlODM0YzIwL3RhYmxlcmFuZ2U6ZWU5NTEzMjVlNDQ0NDJjNGE5ZTllMTQxZWU4MzRjMjBfMi0yLTEtMS0xNzg2OA_b9cc1ffa-842e-47b4-b093-a198dde4e01a"
      unitRef="usd">520000000</us-gaap:ContractWithCustomerLiability>
    <abt:ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmVlOTUxMzI1ZTQ0NDQyYzRhOWU5ZTE0MWVlODM0YzIwL3RhYmxlcmFuZ2U6ZWU5NTEzMjVlNDQ0NDJjNGE5ZTllMTQxZWU4MzRjMjBfMy0yLTEtMS0xNzg2OA_be99e087-87b8-4321-915a-93e819be7ec0"
      unitRef="usd">466000000</abt:ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmVlOTUxMzI1ZTQ0NDQyYzRhOWU5ZTE0MWVlODM0YzIwL3RhYmxlcmFuZ2U6ZWU5NTEzMjVlNDQ0NDJjNGE5ZTllMTQxZWU4MzRjMjBfNC0yLTEtMS0xNzg2OA_07438b7a-3e82-4abe-959a-db0f1b9cf3f8"
      unitRef="usd">508000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80MC9mcmFnOjU5OGZiNjc1YmYyNDQxZDRiMjZlNTQwMTg2N2YwNDI0L3RhYmxlOmVlOTUxMzI1ZTQ0NDQyYzRhOWU5ZTE0MWVlODM0YzIwL3RhYmxlcmFuZ2U6ZWU5NTEzMjVlNDQ0NDJjNGE5ZTllMTQxZWU4MzRjMjBfNS0yLTEtMS0xNzg2OA_a67b1a71-4cb6-44b0-8401-dbd687230e05"
      unitRef="usd">478000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfMjYxOQ_d020f982-eae9-4666-b372-f190ed8c88ae">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 3 &#x2014; Supplemental Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended September&#160;30, 2022 and 2021 were $1.429 billion and $2.092 billion, respectively, and for the nine months ended September&#160;30, 2022 and 2021 were $5.876 billion and $5.061 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first nine months of 2022 includes $362 million of pension contributions and the payment of cash taxes of approximately $987 million. The first nine months of 2021 includes $366 million of pension contributions and the payment of cash taxes of approximately $990 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the activity for the first nine months of 2022 related to the allowance for doubtful accounts as of September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for Doubtful Accounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions/charges to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts charged off and other deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of long-term investments as of September&#160;30, 2022 and December&#160;31, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decrease in Abbott&#x2019;s long-term investments as of September&#160;30, 2022 versus the balance as of December&#160;31, 2021 primarily relates to a decrease in the value of investments held in a rabbi trust and the impact of equity method investment losses partially offset by an investment in long-term time deposits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Abbott&#x2019;s equity securities as of September&#160;30, 2022, include $285 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Abbott also holds certain investments as of September&#160;30, 2022 with a carrying value of $228 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $83 million that do not have a readily determinable fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2021, Abbott acquired 100 percent of Walk Vascular, LLC (Walk Vascular), a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots. The purchase price, the allocation of acquired assets and liabilities, and the revenue and net income contributed by Walk Vascular since the date of acquisition are not material to Abbott&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfNDA5_7f167e19-6fd6-457f-b92c-c96f8576520a"
      unitRef="usd">1429000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfNDE2_4d5122b2-0e88-44bf-b06c-2c86ea7abbe3"
      unitRef="usd">2092000000.000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfNDc3_775f9915-38c2-45c1-bd8f-6faa9c5d5d3a"
      unitRef="usd">5876000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfNDg0_82db709c-e95e-4904-af0e-fb730409342c"
      unitRef="usd">5061000000.000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfNjQ1_278b8bcf-e920-491c-9794-6cb07b8fd9dc"
      unitRef="usd">362000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:PaymentsForOtherTaxes
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfNzIw_220dd95c-8eac-4f4e-956f-50d8fd62c2d4"
      unitRef="usd">987000000</us-gaap:PaymentsForOtherTaxes>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfNzU5_bd9c3f60-2dd0-44be-98a5-d4da3d8ec241"
      unitRef="usd">366000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:PaymentsForOtherTaxes
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfODM0_cd8f7848-8951-4b8f-b5d6-e66fdaa6862e"
      unitRef="usd">990000000</us-gaap:PaymentsForOtherTaxes>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfMjYyMA_c8444ec8-24aa-482c-b3ab-1f28d1554806">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the activity for the first nine months of 2022 related to the allowance for doubtful accounts as of September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for Doubtful Accounts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions/charges to income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts charged off and other deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOjNmMjliZWM2Nzg2NjRkNWNiYTRhYTA0NGNhN2M5NjZkL3RhYmxlcmFuZ2U6M2YyOWJlYzY3ODY2NGQ1Y2JhNGFhMDQ0Y2E3Yzk2NmRfMi0yLTEtMS0xNzg2OA_4eee6650-5408-4ebb-a84e-2591a2454d93"
      unitRef="usd">313000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOjNmMjliZWM2Nzg2NjRkNWNiYTRhYTA0NGNhN2M5NjZkL3RhYmxlcmFuZ2U6M2YyOWJlYzY3ODY2NGQ1Y2JhNGFhMDQ0Y2E3Yzk2NmRfMy0yLTEtMS0xNzg2OA_e9fe7f72-422c-4d94-a354-4bd2582f87a3"
      unitRef="usd">10000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOjNmMjliZWM2Nzg2NjRkNWNiYTRhYTA0NGNhN2M5NjZkL3RhYmxlcmFuZ2U6M2YyOWJlYzY3ODY2NGQ1Y2JhNGFhMDQ0Y2E3Yzk2NmRfNC0yLTEtMS0xNzg2OA_9e2d7a12-9ffc-4945-a9f3-7370048b4f23"
      unitRef="usd">49000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOjNmMjliZWM2Nzg2NjRkNWNiYTRhYTA0NGNhN2M5NjZkL3RhYmxlcmFuZ2U6M2YyOWJlYzY3ODY2NGQ1Y2JhNGFhMDQ0Y2E3Yzk2NmRfNS0yLTEtMS0xNzg2OA_c3d3225a-8fd7-4bff-8b96-51c8f7d71fc8"
      unitRef="usd">274000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <abt:ScheduleOfLongTermInvestmentsTableTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfMjYyMQ_ec5b701b-2b47-4a87-b6aa-895c6b0b6c8d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of long-term investments as of September&#160;30, 2022 and December&#160;31, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</abt:ScheduleOfLongTermInvestmentsTableTextBlock>
    <us-gaap:LongTermInvestments
      contextRef="i06b3500e4f5c4314a3d8cf6b4089c98e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOmE3N2U5ZDc3NzlmMDQ2MGJhNTVlOWE0ZGQwNmIzZDQ0L3RhYmxlcmFuZ2U6YTc3ZTlkNzc3OWYwNDYwYmE1NWU5YTRkZDA2YjNkNDRfMi0yLTEtMS0xNzg2OA_b8366d7e-acc8-4f7b-94d9-841c7c2b25f9"
      unitRef="usd">604000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i1d0dbddbfdc84cd0ab7a31f5e8fdf16e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOmE3N2U5ZDc3NzlmMDQ2MGJhNTVlOWE0ZGQwNmIzZDQ0L3RhYmxlcmFuZ2U6YTc3ZTlkNzc3OWYwNDYwYmE1NWU5YTRkZDA2YjNkNDRfMi00LTEtMS0xNzg2OA_86e215eb-f687-4739-a755-b6fb1fdad660"
      unitRef="usd">748000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ie7c97d1edcfa444cb20aa7be67ab0d50_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOmE3N2U5ZDc3NzlmMDQ2MGJhNTVlOWE0ZGQwNmIzZDQ0L3RhYmxlcmFuZ2U6YTc3ZTlkNzc3OWYwNDYwYmE1NWU5YTRkZDA2YjNkNDRfMy0yLTEtMS0xNzg2OA_e3516eaa-18d1-4fec-8abf-11cd80ea4f22"
      unitRef="usd">160000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i5fa4384e8a504eeda1c27de655e4e9d5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOmE3N2U5ZDc3NzlmMDQ2MGJhNTVlOWE0ZGQwNmIzZDQ0L3RhYmxlcmFuZ2U6YTc3ZTlkNzc3OWYwNDYwYmE1NWU5YTRkZDA2YjNkNDRfMy00LTEtMS0xNzg2OA_8d64141f-ab76-4ce0-beff-f92032fbc89a"
      unitRef="usd">68000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOmE3N2U5ZDc3NzlmMDQ2MGJhNTVlOWE0ZGQwNmIzZDQ0L3RhYmxlcmFuZ2U6YTc3ZTlkNzc3OWYwNDYwYmE1NWU5YTRkZDA2YjNkNDRfNC0yLTEtMS0xNzg2OA_3012285c-739a-48e0-818f-d107ad7ed1ee"
      unitRef="usd">764000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RhYmxlOmE3N2U5ZDc3NzlmMDQ2MGJhNTVlOWE0ZGQwNmIzZDQ0L3RhYmxlcmFuZ2U6YTc3ZTlkNzc3OWYwNDYwYmE1NWU5YTRkZDA2YjNkNDRfNC00LTEtMS0xNzg2OA_93a66f02-78d6-42f9-a7f9-8b8c3ed66a70"
      unitRef="usd">816000000</us-gaap:LongTermInvestments>
    <us-gaap:CommonStockSharesHeldInEmployeeTrust
      contextRef="i3b879570db6940ef8d990b6465f15c41_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfMTk0OQ_0fd4e1fc-88a4-4802-84a2-2f3f1ae1c1db"
      unitRef="usd">285000000</us-gaap:CommonStockSharesHeldInEmployeeTrust>
    <us-gaap:EquityMethodInvestments
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfMjQzMw_60a4b336-2159-40d4-9425-2a63d7444af0"
      unitRef="usd">228000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfMjU2NQ_19017287-1837-4c0e-b853-492911bf73ab"
      unitRef="usd">83000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i3f5a2e21895448f88c750459f871dbf2_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80My9mcmFnOjkyZGI0NTg5ZTRjMDRlYTE5YjAxYWJjYzc5MjQ1MWQwL3RleHRyZWdpb246OTJkYjQ1ODllNGMwNGVhMTliMDFhYmNjNzkyNDUxZDBfMTA5OTUxMTYzMTkxMg_3386aac9-caf5-46b6-b0e5-591932c865e9"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RleHRyZWdpb246OTBiODVhZTJhNTRiNDM5Nzg3ZTRjZGEyOWY5MmVkZThfMzI4_ea9eb664-e529-42c3-b8e2-f53aa9e520d4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 4 &#x2014; Changes In Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Foreign&lt;br/&gt;Currency Translation&lt;br/&gt;(Loss) Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Actuarial (Losses) and&lt;br/&gt;Prior Service (Costs) and&lt;br/&gt;Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Gains (Losses)&lt;br/&gt;on Derivative Instruments&lt;br/&gt;Designated as Cash Flow&lt;br/&gt;Hedges and Other&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,738)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Foreign&lt;br/&gt;Currency Translation&lt;br/&gt;(Loss) Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Actuarial (Losses) and&lt;br/&gt;Prior Service (Costs) and&lt;br/&gt;Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Gains (Losses)&lt;br/&gt;on Derivative Instruments&lt;br/&gt;Designated as Cash Flow &lt;br/&gt;Hedges and Other&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(762)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(762)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 11 for additional details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RleHRyZWdpb246OTBiODVhZTJhNTRiNDM5Nzg3ZTRjZGEyOWY5MmVkZThfMzI5_1f4ac7ee-ff5b-48d5-8b24-a189d9b85dd6">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Foreign&lt;br/&gt;Currency Translation&lt;br/&gt;(Loss) Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Actuarial (Losses) and&lt;br/&gt;Prior Service (Costs) and&lt;br/&gt;Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Gains (Losses)&lt;br/&gt;on Derivative Instruments&lt;br/&gt;Designated as Cash Flow&lt;br/&gt;Hedges and Other&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,738)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Foreign&lt;br/&gt;Currency Translation&lt;br/&gt;(Loss) Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Actuarial (Losses) and&lt;br/&gt;Prior Service (Costs) and&lt;br/&gt;Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Gains (Losses)&lt;br/&gt;on Derivative Instruments&lt;br/&gt;Designated as Cash Flow &lt;br/&gt;Hedges and Other&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(762)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(762)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i495e1acb6ab646e1be98f86d888adf7c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfMy0yLTEtMS0xNzg2OA_944bc75c-0416-4b66-8f65-9d2d29cf25c0"
      unitRef="usd">-6260000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i11d15dbdba194d4ea258e34ec953d6bd_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfMy00LTEtMS0xNzg2OA_6b3422dc-c5b5-4536-b852-d67fd1df40e4"
      unitRef="usd">-5230000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i415827a77ac0453d839b9593bd2f924c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfMy02LTEtMS0xNzg2OA_75c8881e-0dcc-44c8-a39e-968a3b496902"
      unitRef="usd">-2554000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if1fe447f6ae64a75be725ca40d0bc9da_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfMy04LTEtMS0xNzg2OA_19a14b12-7bad-44e6-9659-07b21c1e158e"
      unitRef="usd">-3738000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i964adde7ff6b4fdc8165d93476caeb82_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfMy0xMC0xLTEtMTc4Njg_cd05e8ed-0ff0-4688-a31d-ff4c67c1432a"
      unitRef="usd">108000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie15dbca7371a44c29034f90ed736efd2_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfMy0xMi0xLTEtMTc4Njg_8782d622-5d62-4d2b-ba7e-212159b78356"
      unitRef="usd">-98000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="icd59cc26c1dd433798bec018b3ccbb28_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNC0yLTEtMS0xNzg2OA_bc7b122d-d99e-4305-8392-d653c3103e24"
      unitRef="usd">-1008000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i1aa011bcd53148e7baa700ba02afe7ec_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNC00LTEtMS0xNzg2OA_13f6dba0-f9d1-4be4-9d90-2d65aca823c6"
      unitRef="usd">-391000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i17e4add20e234af2a1a931e4e20817bf_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNC02LTEtMS0xNzg2OA_70611886-8063-4a2e-9837-f02263d027dd"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i9696538c691b42caac0b357c13f12bac_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNC04LTEtMS0xNzg2OA_4df67708-f62a-4178-9395-e7c3c15df21a"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7e0af11ae9ab4bbcacc64379488edc44_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNC0xMC0xLTEtMTc4Njg_c853acd4-e95f-4b41-abf8-9a692eb52819"
      unitRef="usd">278000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2e81d4049c794423a14e1d1c1af22cc7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNC0xMi0xLTEtMTc4Njg_12ac57e7-1d89-48fc-8a59-180da44fb8b5"
      unitRef="usd">70000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="icd59cc26c1dd433798bec018b3ccbb28_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNS0yLTEtMS0xNzg2OA_d26695ef-d7cb-4ea3-b801-819684fe7773"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i1aa011bcd53148e7baa700ba02afe7ec_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNS00LTEtMS0xNzg2OA_b967fd0e-a1a2-4300-8481-b679eeb78815"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i17e4add20e234af2a1a931e4e20817bf_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNS02LTEtMS0xNzg2OA_cecb695a-6a3f-45f6-ac32-57d9b9e515bd"
      unitRef="usd">-41000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9696538c691b42caac0b357c13f12bac_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNS04LTEtMS0xNzg2OA_8cc5f078-acce-4d03-9a48-406e16fb7e3e"
      unitRef="usd">-62000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7e0af11ae9ab4bbcacc64379488edc44_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNS0xMC0xLTEtMTc4Njg_c47627b3-0f92-4e1a-abfe-359ec3f68b52"
      unitRef="usd">65000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2e81d4049c794423a14e1d1c1af22cc7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNS0xMi0xLTEtMTc4Njg_7f2b4d25-fbc5-49b1-a70d-e8b49422bc76"
      unitRef="usd">-69000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icd59cc26c1dd433798bec018b3ccbb28_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNi0yLTEtMS0xNzg2OA_46a6e248-333f-4be4-9cc7-15c3056a7c3c"
      unitRef="usd">-1008000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1aa011bcd53148e7baa700ba02afe7ec_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNi00LTEtMS0xNzg2OA_be555c3e-f9d4-420e-af74-b45ebf322c79"
      unitRef="usd">-391000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i17e4add20e234af2a1a931e4e20817bf_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNi02LTEtMS0xNzg2OA_48468a9d-21ad-4388-94ac-afe1b8e9cb78"
      unitRef="usd">56000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9696538c691b42caac0b357c13f12bac_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNi04LTEtMS0xNzg2OA_a27187a6-5220-4868-babb-955383f28d9f"
      unitRef="usd">78000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7e0af11ae9ab4bbcacc64379488edc44_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNi0xMC0xLTEtMTc4Njg_8447eb5a-4cce-4e52-b909-abf8f9df2b34"
      unitRef="usd">213000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2e81d4049c794423a14e1d1c1af22cc7_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNi0xMi0xLTEtMTc4Njg_27796e6f-212f-47ca-bd91-ea50c188db19"
      unitRef="usd">139000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i427e7206d73746e6898e10c2092b8bbc_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNy0yLTEtMS0xNzg2OA_8d697180-bad7-4216-a9c1-a1e6298926e8"
      unitRef="usd">-7268000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i967b4d49862b4a9c90ab0df452b406c3_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNy00LTEtMS0xNzg2OA_c07af5ee-1d29-466e-8096-e8e53b03a395"
      unitRef="usd">-5621000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i819bcaf6924348468ba7ae6973f92309_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNy02LTEtMS0xNzg2OA_42f596c3-b5ca-4b9d-aa70-151e0b229fa8"
      unitRef="usd">-2498000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i95867ab5ff4a46c2b64acfbbad20d613_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNy04LTEtMS0xNzg2OA_117de8c2-61af-4923-8334-9636982daf84"
      unitRef="usd">-3660000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i23ed49d742db4ba5b2f23508085a61cb_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNy0xMC0xLTEtMTc4Njg_f338971c-27c9-4c5d-bceb-93c056d2735f"
      unitRef="usd">321000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia4466aaca90a4878b4208479546c953a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmM3MTM5N2JmNGQ1MjQxZDU5NDI0YTMxYzQxODBlNzM2L3RhYmxlcmFuZ2U6YzcxMzk3YmY0ZDUyNDFkNTk0MjRhMzFjNDE4MGU3MzZfNy0xMi0xLTEtMTc4Njg_9b90d0f8-6375-470c-9d5a-ce060d0eef9e"
      unitRef="usd">41000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i874ac07585e34b5781c671c1bc0b74c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfMy0yLTEtMS0xNzg2OA_cd6496e9-f33f-450f-90b6-72bc2e91f788"
      unitRef="usd">-5839000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6cdf5c348d5b4b53b9a6c86bb4a3e3c6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfMy00LTEtMS0xNzg2OA_238708dc-65a2-41cc-bc06-f27057150c3a"
      unitRef="usd">-4859000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e549a342ce24de7b2b4542ffdabcbee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfMy02LTEtMS0xNzg2OA_dfe19359-3673-4f37-935f-b4e0112bb2a7"
      unitRef="usd">-2670000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7de505469f274ea4a34eb536d8434973_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfMy04LTEtMS0xNzg2OA_4ff1a730-0b3d-4789-a10b-a197538e5d01"
      unitRef="usd">-3871000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c966c996c54468f969135a6a97d474a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfMy0xMC0xLTEtMTc4Njg_000316c0-59de-46bb-913b-617f2e027c72"
      unitRef="usd">135000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic6e9ff01f8fd42f38aa515217549336f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfMy0xMi0xLTEtMTc4Njg_7a1cbb41-1bf9-4a7c-b042-af356e44f71f"
      unitRef="usd">-216000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="idaba0b25f7ac490d965f16df9dcbf02c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNC0yLTEtMS0xNzg2OA_7d6f966a-044a-48ce-b6e8-3e13157ec25c"
      unitRef="usd">-1429000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i9341a3223163491aafcd6fe2d673a55a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNC00LTEtMS0xNzg2OA_0d5a4a95-4a44-4bc9-8be3-52166e687891"
      unitRef="usd">-762000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if502b2d6402f4818a6bd6e4dd318d573_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNC02LTEtMS0xNzg2OA_0e3fe1d4-86c9-4b06-bd23-f07ac971f1c0"
      unitRef="usd">45000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="iede3d406d2714638aca592a7412cf559_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNC04LTEtMS0xNzg2OA_736ff874-153f-4eda-82b1-82e3f6c5eb59"
      unitRef="usd">26000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i65f21a35a5f64266baecf8e128ca0727_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNC0xMC0xLTEtMTc4Njg_b780efa6-8375-4170-98a4-82cf9a47e713"
      unitRef="usd">289000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2212cc9951e446de85154e63b59c05bc_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNC0xMi0xLTEtMTc4Njg_8101cc24-6fc6-423e-8fa3-d9cf1d8d812e"
      unitRef="usd">138000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="idaba0b25f7ac490d965f16df9dcbf02c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNS0yLTEtMS0xNzg2OA_750fdd57-5cdd-4085-8df0-b301893b4feb"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9341a3223163491aafcd6fe2d673a55a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNS00LTEtMS0xNzg2OA_f3658d13-52ca-406c-8b11-ccc8ad4692df"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if502b2d6402f4818a6bd6e4dd318d573_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNS02LTEtMS0xNzg2OA_7b37f394-e6fb-4ac7-bda4-25f088554699"
      unitRef="usd">-127000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="iede3d406d2714638aca592a7412cf559_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNS04LTEtMS0xNzg2OA_686cb904-a70c-439b-9bd3-1962838b817a"
      unitRef="usd">-185000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i65f21a35a5f64266baecf8e128ca0727_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNS0xMC0xLTEtMTc4Njg_9259907c-6f65-4073-af73-d5487f7489b7"
      unitRef="usd">103000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2212cc9951e446de85154e63b59c05bc_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNS0xMi0xLTEtMTc4Njg_00f1aa9e-1b24-4473-bfd7-e397e53ed7d8"
      unitRef="usd">-119000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="idaba0b25f7ac490d965f16df9dcbf02c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNi0yLTEtMS0xNzg2OA_65274006-b28f-4cb1-ac85-c3abf1991f45"
      unitRef="usd">-1429000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9341a3223163491aafcd6fe2d673a55a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNi00LTEtMS0xNzg2OA_4c3fb4cf-4b77-40aa-847e-f26707b93531"
      unitRef="usd">-762000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if502b2d6402f4818a6bd6e4dd318d573_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNi02LTEtMS0xNzg2OA_dd3b6dd9-a5a0-4681-801b-6b1ad3f14323"
      unitRef="usd">172000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iede3d406d2714638aca592a7412cf559_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNi04LTEtMS0xNzg2OA_cc0ae5a9-4d1d-4de3-b01b-d7a235c14240"
      unitRef="usd">211000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i65f21a35a5f64266baecf8e128ca0727_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNi0xMC0xLTEtMTc4Njg_ada4bf9b-0053-43be-aaf9-fa419721c171"
      unitRef="usd">186000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2212cc9951e446de85154e63b59c05bc_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNi0xMi0xLTEtMTc4Njg_50a8bfe0-6876-42b9-8b62-c43bd330e378"
      unitRef="usd">257000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i427e7206d73746e6898e10c2092b8bbc_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNy0yLTEtMS0xNzg2OA_e06108e6-1bf0-4c09-b459-2707052acad4"
      unitRef="usd">-7268000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i967b4d49862b4a9c90ab0df452b406c3_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNy00LTEtMS0xNzg2OA_e1523175-aa44-475d-bb8a-9c674df1d07b"
      unitRef="usd">-5621000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i819bcaf6924348468ba7ae6973f92309_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNy02LTEtMS0xNzg2OA_fc3a811a-5dfa-41c0-a16f-bb67c3fcc163"
      unitRef="usd">-2498000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i95867ab5ff4a46c2b64acfbbad20d613_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNy04LTEtMS0xNzg2OA_a87f2903-f37f-4f70-90c6-52d263d78fed"
      unitRef="usd">-3660000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i23ed49d742db4ba5b2f23508085a61cb_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNy0xMC0xLTEtMTc4Njg_8c8b5a7c-b0e8-4084-9d74-87e97556453d"
      unitRef="usd">321000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia4466aaca90a4878b4208479546c953a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80Ni9mcmFnOjkwYjg1YWUyYTU0YjQzOTc4N2U0Y2RhMjlmOTJlZGU4L3RhYmxlOmU3NzkzMzk4YWM1YjQ2YmNhNWI5YjQ2YTU5Zjg5Zjg4L3RhYmxlcmFuZ2U6ZTc3OTMzOThhYzViNDZiY2E1YjliNDZhNTlmODlmODhfNy0xMi0xLTEtMTc4Njg_596228f8-9898-4946-8283-4263ceefe0e0"
      unitRef="usd">41000000</us-gaap:StockholdersEquity>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfMTEwNA_6e7a4b90-9c95-4b67-8a47-2ccfac0ced47">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 5 &#x2014; Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total amount of goodwill reported was $22.3 billion at September&#160;30, 2022 and $23.2 billion at December&#160;31, 2021. Foreign currency translation adjustments decreased goodwill by approximately $946 million in the first nine months of 2022. The amount of goodwill related to reportable segments at September&#160;30, 2022 was $2.6 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.5 billion for the Diagnostic Products segment, and $15.9 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first nine months of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross amount of amortizable intangible assets, primarily product rights and technology, was $26.9 billion and $27.7 billion as of September&#160;30, 2022 and December&#160;31, 2021, respectively. Accumulated amortization was $16.9 billion and $15.9 billion as of September&#160;30, 2022 and  December&#160;31, 2021, respectively. Foreign currency translation adjustments decreased intangible assets by $250 million in the first nine months of 2022. Abbott&#x2019;s estimated annual amortization expense for intangible assets is approximately $2.1 billion in 2022, $2.0 billion in 2023, $1.9 billion in 2024, $1.7 billion in 2025 and $1.6 billion in 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets, which relate to in-process R&amp;amp;D (IPR&amp;amp;D) acquired in a business combination, were approximately $807 million as of September&#160;30, 2022 and $919 million as of December&#160;31, 2021. In the third quarter of 2022, $111 million of impairment charges were recorded on the Research and development line of the Condensed Consolidated Statement of Earnings related to certain IPR&amp;amp;D intangible assets associated with the Medical Devices business segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNTE_07ee8472-abbc-43aa-a2fa-a4fd0c80669f"
      unitRef="usd">22300000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNjQ_3750c554-ec61-4297-9ceb-a06538de4b1c"
      unitRef="usd">23200000000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfMTQ0_e8487b72-b2b8-448e-9f40-45bb237cee6b"
      unitRef="usd">-946000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i4be71fc1af9b4576bbbec0f3973e74bc_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfMjQx_4d9ab0ce-c517-4467-b223-a508020cab1a"
      unitRef="usd">2600000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8d3eeb93a75a4a2cbd31ad08fd494ee9_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfMjk3_d02bdf54-060c-490a-b8a6-fdab58103a2e"
      unitRef="usd">286000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id035b12c3f014d2bafdba8da0f64bb42_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfMzM4_25d412ad-a7a7-44ce-97e6-5839110ef176"
      unitRef="usd">3500000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i62bee42564544f0d9b3280c51a9cc02c_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfMzgy_66887fae-9cf5-4eb7-92ea-73184b6e40d2"
      unitRef="usd">15900000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNDI4_a1185aac-9a0a-4746-8165-1ea8fd2aa0d5"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNjA0_5bf81dfa-e0e5-43ad-9514-1bb7e342e9d1"
      unitRef="usd">26900000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNjEx_c29141aa-f735-4e6e-9403-f2e61e862bd8"
      unitRef="usd">27700000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNjc0_b44e55aa-51cd-420d-9ea1-4f73f07d49c9"
      unitRef="usd">16900000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNjgx_470649d6-aa41-401f-a30f-fe22274187a4"
      unitRef="usd">15900000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNzgx_00ed8de0-fc85-47f4-af4c-2e3e408e0fe0"
      unitRef="usd">-250000000</us-gaap:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfOTAw_7662b1c2-4a7a-40d4-8109-6a4b2479323d"
      unitRef="usd">2100000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfOTEw_4a4bc219-6ca5-4837-bf70-41e8a7eadbe1"
      unitRef="usd">2000000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfOTIw_2eb61dd3-d38e-4197-81ad-c505889da09b"
      unitRef="usd">1900000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfOTMw_1e246181-c983-4ba3-9908-d06db636b389"
      unitRef="usd">1700000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfOTQz_e06eb8f5-2931-4a50-ae7b-6bbc51178786"
      unitRef="usd">1600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfMTA4NA_cc138054-ce7f-412c-915f-ac7c097cb5f8"
      unitRef="usd">807000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNTQ5NzU1ODE2NzA1_190759e6-d3e1-4f11-ba53-f58212c12e46"
      unitRef="usd">919000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="id2602c6bfcec4afcb539d839ccd375bd_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl80OS9mcmFnOmNkZTIyOWVhMjNlNDRmZTE5ZmU1Y2RmZDNhYTUyODE5L3RleHRyZWdpb246Y2RlMjI5ZWEyM2U0NGZlMTlmZTVjZGZkM2FhNTI4MTlfNTQ5NzU1ODE2NzYw_8ee0209a-c604-4a75-922f-b7e420d58fb4"
      unitRef="usd">111000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfMjIwNQ_3b7cd385-825b-4fc2-8a17-b06e92fed488">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 6 &#x2014; Restructuring Plans &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 27, 2021, Abbott management approved a restructuring plan related to its Diagnostic Products segment to align its manufacturing network for COVID-19 diagnostic tests with changes in the second quarter in projected testing demand driven by several factors, including significant reductions in cases in the U.S. and other major developed countries, the accelerated rollout of COVID-19 vaccines globally and the U.S. health authority&#x2019;s updated guidance on testing for fully vaccinated individuals. In the second quarter of 2021, Abbott recorded charges of $499 million under this plan in Cost of products sold. The charge recognized in the second quarter of 2021 included fixed asset write-downs of $80 million, inventory-related charges of $248 million, and other exit costs, which included contract cancellations and employee-related costs of $171 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second half of 2021, as the Delta and Omicron variants of COVID-19 spread and the number of new COVID-19 cases increased significantly, particularly in the U.S., demand for rapid COVID-19 tests increased significantly. As a result, in the second half of 2021, Abbott sold approximately $181 million of inventory that was previously estimated to have no net realizable value under the second quarter of 2021 restructuring action. In addition, the estimate of other exit costs was reduced by a net $58 million as Abbott fulfilled its purchase obligations under certain contracts for which a liability was recorded in the second quarter of 2021 or Abbott settled with the counterparty in the second half of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the activity related to this restructuring action and the status of the related accruals as of September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inventory-&lt;br/&gt;Related&lt;br/&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fixed Asset&lt;br/&gt;Write-Downs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Exit&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges recorded in 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in Abbott&#x2019;s diagnostic, established pharmaceutical, and nutritional businesses. In 2022 and 2021, Abbott management approved plans to streamline operations in its medical devices segment. Abbott recorded employees-related severance and other charges of approximately $12 million in the first nine months of 2022 of which approximately $5&#160;million was recorded in Cost of products sold, approximately $2 million was recorded in Research and development, and approximately $5&#160;million was recorded in Selling, general and administrative expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the activity for these restructurings:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges recorded in 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges recorded in 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="ib718c9002df547a9bb6009289d5ab871_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfNTY4_f2dbab42-f604-42e7-9304-5c53a03a3bee"
      unitRef="usd">499000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i73865c3e534643d5ab15aa1266d200db_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfNjkz_97c67cf5-f5da-4130-80ec-beb198ea0e1d"
      unitRef="usd">80000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i32e1a3f5ab2a404ca01cc18696529902_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfNzI2_50e83982-b910-4bfe-bcca-bb8639aa661c"
      unitRef="usd">248000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i36df938cc26341c18a1b3e9570bcec52_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfODIw_21fb5400-d061-46cd-a5f5-e21862bf5e38"
      unitRef="usd">171000000</us-gaap:RestructuringCharges>
    <abt:InventoryNoNetRealizableValueSold
      contextRef="i53e8568bc39d4cb19a2c23541737716d_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfMTExMA_588d2af8-fee1-47e6-9ce0-ca108512834e"
      unitRef="usd">181000000</abt:InventoryNoNetRealizableValueSold>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="i527c49b1d22240058f22784151a891f3_D20210701-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfMTMwOA_7ba68bd0-89fa-4ca4-9638-6d6f304c968c"
      unitRef="usd">58000000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfMjIwNg_f6622cdf-705d-4e59-982a-006516c2e1f3">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the activity related to this restructuring action and the status of the related accruals as of September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inventory-&lt;br/&gt;Related&lt;br/&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fixed Asset&lt;br/&gt;Write-Downs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Exit&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges recorded in 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="ic5061818384c4b19aae354446d336fd1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMS0yLTEtMS0xNzg2OA_dbf1d7bf-42f4-4010-832f-6456d2f3906e"
      unitRef="usd">248000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i7c70ec7c6d944192a4c8aaf8042cb9f6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMS00LTEtMS0xNzg2OA_c7101023-61b3-49c2-b594-2516a3defcaa"
      unitRef="usd">80000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i3d67be86a0834dfeb506f82b11589377_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMS02LTEtMS0xNzg2OA_3fe043c7-615b-408e-8952-e5c208f4d390"
      unitRef="usd">113000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="icd32e0ec232449a093586b6ac423eb4f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMS04LTEtMS0xNzg2OA_56b89738-04a3-4b78-aeda-1b1b22c5f690"
      unitRef="usd">441000000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="ic5061818384c4b19aae354446d336fd1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMi0yLTEtMS0xNzg2OA_a6cb6480-0950-4275-b9bb-479b5c874082"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i7c70ec7c6d944192a4c8aaf8042cb9f6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMi00LTEtMS0xNzg2OA_b99ee32c-6f2b-4e3a-b3f7-6d76b5ff46e0"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i3d67be86a0834dfeb506f82b11589377_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMi02LTEtMS0xNzg2OA_b01a3f9a-6573-4bf6-910a-d65fc7bbd29e"
      unitRef="usd">90000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="icd32e0ec232449a093586b6ac423eb4f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMi04LTEtMS0xNzg2OA_15ac5427-6e0e-4543-ad77-cefefa1f860d"
      unitRef="usd">90000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="ic5061818384c4b19aae354446d336fd1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMy0yLTEtMS0xNzg2OA_d85658fc-f1c6-49f7-90f6-e69463b22def"
      unitRef="usd">248000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i7c70ec7c6d944192a4c8aaf8042cb9f6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMy00LTEtMS0xNzg2OA_70c03f43-7867-472e-b960-d37869990a54"
      unitRef="usd">80000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i3d67be86a0834dfeb506f82b11589377_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMy02LTEtMS0xNzg2OA_4b845dc7-70dc-436f-9782-7b8c7b2adb73"
      unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="icd32e0ec232449a093586b6ac423eb4f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfMy04LTEtMS0xNzg2OA_345935cf-baa9-45fa-9f8e-d5502bb2ef35"
      unitRef="usd">328000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserve
      contextRef="ib1b41672050b4f62a5208c5e716d43f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNC0yLTEtMS0xNzg2OA_909c6a74-8e99-49b7-9165-119f85c998ef"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i901a35e981d14756b34a5adff1083cf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNC00LTEtMS0xNzg2OA_8201df6c-c1ba-4de2-8c66-8cb658d61329"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ie7235f22a8e74924b42a859bb232635a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNC02LTEtMS0xNzg2OA_70a0aeb0-f00c-43a3-99ab-da3ff86b1aa9"
      unitRef="usd">23000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ifda673e60ee8405ea4371f6fba8fc86f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNC04LTEtMS0xNzg2OA_b9cecad7-8b79-4dd6-8618-5aeba357b79b"
      unitRef="usd">23000000</us-gaap:RestructuringReserve>
    <abt:RestructuringReservePeriodCashSettledAndOtherAdjustments
      contextRef="i8d18df850f834757a75a53bf2cdc1ca9_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNS0yLTEtMS0xNzg2OA_a65a4fa2-48e3-4206-a264-b3f6b6d24b8c"
      unitRef="usd">0</abt:RestructuringReservePeriodCashSettledAndOtherAdjustments>
    <abt:RestructuringReservePeriodCashSettledAndOtherAdjustments
      contextRef="i1eef48e6721d4174ad61b0c4bacfd4ef_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNS00LTEtMS0xNzg2OA_2203da1d-f654-4a0e-ae38-3bcb32ab77b2"
      unitRef="usd">0</abt:RestructuringReservePeriodCashSettledAndOtherAdjustments>
    <abt:RestructuringReservePeriodCashSettledAndOtherAdjustments
      contextRef="i9dfe1081e2a7492d8113f7b5208ba611_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNS02LTEtMS0xNzg2OA_948ae90c-8d93-409c-8eab-ff57800550ba"
      unitRef="usd">10000000</abt:RestructuringReservePeriodCashSettledAndOtherAdjustments>
    <abt:RestructuringReservePeriodCashSettledAndOtherAdjustments
      contextRef="i0e0db81ff25a4a54b0211447d6b1257a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNS04LTEtMS0xNzg2OA_4f2c1a23-9b8a-443c-9832-c01c89d8825a"
      unitRef="usd">10000000</abt:RestructuringReservePeriodCashSettledAndOtherAdjustments>
    <us-gaap:RestructuringReserve
      contextRef="ic210a4881e7a4bfc8506d1330434b1b9_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNi0yLTEtMS0xNzg2OA_0d6967d0-6c09-4e79-9ffd-2712341bb62b"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ia8624555d304424fb6b08adc08120a68_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNi00LTEtMS0xNzg2OA_b6c2bd80-0174-4734-ab66-3b1000ff6d17"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i3ba1fc8cda234a89b835a4e348ba3cef_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNi02LTEtMS0xNzg2OA_46e71149-cfaf-4ddc-b93f-557dd40e76b5"
      unitRef="usd">13000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i562dbdedf98e492987bde41c83f41e48_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjYxMzNkNGJlMjJmZTQyNzVhYzY4YjQ5NjQ2MjdmZDJmL3RhYmxlcmFuZ2U6NjEzM2Q0YmUyMmZlNDI3NWFjNjhiNDk2NDYyN2ZkMmZfNi04LTEtMS0xNzg2OA_9960eae0-0e99-4fc2-90af-4c2abce64781"
      unitRef="usd">13000000</us-gaap:RestructuringReserve>
    <us-gaap:SeveranceCosts1
      contextRef="i4794a110deb7433cbee3148cdeb358b8_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfOTg5NTYwNDY1Mjk4NA_ffa08c3f-99e1-4a98-b4e0-ba126b3acf1d"
      unitRef="usd">12000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="ibabb70918fa246128ee74b2f2f3ccaf0_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfOTg5NTYwNDY1MzAxNA_86108081-beea-4a46-8620-9f1f29735960"
      unitRef="usd">5000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i83f541eac1144e6bba42b451c74c7720_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfOTg5NTYwNDY1MzAzMg_3527cafc-5145-4099-8c7c-7f499d606dd2"
      unitRef="usd">2000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="ie2df776b1f8948a8af5d5968a2f003d9_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfOTg5NTYwNDY1MzA0OA_05fd476a-2d26-4c88-8bf6-340d90c91cc3"
      unitRef="usd">5000000</us-gaap:SeveranceCosts1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RleHRyZWdpb246ODFhNjU5Njg2ODk3NGYwMGI3YWM2YjRkMjgwZGNjZDlfMjIwNw_49910d3c-ddac-4805-b60f-350a93aa43de">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the activity for these restructurings:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges recorded in 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges recorded in 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="i0d232a4fb6cb42509c44225cb0f739e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjMwOTY2ZGMxYjZhOTRlZjY4NzIwOTViNmZlZWMyZTZmL3RhYmxlcmFuZ2U6MzA5NjZkYzFiNmE5NGVmNjg3MjA5NWI2ZmVlYzJlNmZfMS0yLTEtMS0yNzY1OQ_fa98b45d-51db-4946-8a59-8165f0d6640e"
      unitRef="usd">68000000</us-gaap:RestructuringCharges>
    <abt:RestructuringReservePeriodCashSettledAndOtherAdjustments
      contextRef="i0d232a4fb6cb42509c44225cb0f739e3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjMwOTY2ZGMxYjZhOTRlZjY4NzIwOTViNmZlZWMyZTZmL3RhYmxlcmFuZ2U6MzA5NjZkYzFiNmE5NGVmNjg3MjA5NWI2ZmVlYzJlNmZfMi0yLTEtMS0yNzcxNQ_65f86033-6a53-40de-ad10-7937f9f52a5f"
      unitRef="usd">7000000</abt:RestructuringReservePeriodCashSettledAndOtherAdjustments>
    <us-gaap:RestructuringReserve
      contextRef="i025aec3dc4f441b783d28fd3085d2f29_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjMwOTY2ZGMxYjZhOTRlZjY4NzIwOTViNmZlZWMyZTZmL3RhYmxlcmFuZ2U6MzA5NjZkYzFiNmE5NGVmNjg3MjA5NWI2ZmVlYzJlNmZfMy0yLTEtMS0xNzg2OA_e82889b3-d731-4388-af33-7556d6d15189"
      unitRef="usd">61000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i4794a110deb7433cbee3148cdeb358b8_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjMwOTY2ZGMxYjZhOTRlZjY4NzIwOTViNmZlZWMyZTZmL3RhYmxlcmFuZ2U6MzA5NjZkYzFiNmE5NGVmNjg3MjA5NWI2ZmVlYzJlNmZfNC0yLTEtMS0yNjg3OA_c60d44d3-e2ed-4476-8621-a6d8bdcad120"
      unitRef="usd">12000000</us-gaap:RestructuringCharges>
    <abt:RestructuringReservePeriodCashSettledAndOtherAdjustments
      contextRef="i4794a110deb7433cbee3148cdeb358b8_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjMwOTY2ZGMxYjZhOTRlZjY4NzIwOTViNmZlZWMyZTZmL3RhYmxlcmFuZ2U6MzA5NjZkYzFiNmE5NGVmNjg3MjA5NWI2ZmVlYzJlNmZfNC0yLTEtMS0xNzg2OA_e2140fa3-2f0d-4e48-abf1-da919018726c"
      unitRef="usd">39000000</abt:RestructuringReservePeriodCashSettledAndOtherAdjustments>
    <us-gaap:RestructuringReserve
      contextRef="id22fc873c34b4c30b31390c7c0722eab_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81Mi9mcmFnOjgxYTY1OTY4Njg5NzRmMDBiN2FjNmI0ZDI4MGRjY2Q5L3RhYmxlOjMwOTY2ZGMxYjZhOTRlZjY4NzIwOTViNmZlZWMyZTZmL3RhYmxlcmFuZ2U6MzA5NjZkYzFiNmE5NGVmNjg3MjA5NWI2ZmVlYzJlNmZfNS0yLTEtMS0xNzg2OA_d981e049-6fd9-466c-81de-8f5d7fb60125"
      unitRef="usd">34000000</us-gaap:RestructuringReserve>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RleHRyZWdpb246YmY1NDc1ZDM5Njk2NGVmNzk1NTk3Y2Y4Yzc3OTc5MTJfNDY1_2c6c7651-f5bf-48fc-84a7-f833c076dc25">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 7 &#x2014; Incentive Stock Program&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first nine months of 2022, Abbott granted 2,634,647 stock options, 514,205 restricted stock awards and 5,427,697 restricted stock units under its incentive stock program. At September&#160;30, 2022, approximately 87 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at September&#160;30, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,048,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,310,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining life &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total unrecognized share-based compensation cost at September&#160;30, 2022 amounted to approximately $600 million which is expected to be recognized over the next three years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3d7dd7f42af3454e98ea0cd9e0de9533_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RleHRyZWdpb246YmY1NDc1ZDM5Njk2NGVmNzk1NTk3Y2Y4Yzc3OTc5MTJfNTQ_6afeeb84-1603-4253-8e6f-c26ab7a824e4"
      unitRef="shares">2634647</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ief8174a37ce742efb72aee7ec66f0b45_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RleHRyZWdpb246YmY1NDc1ZDM5Njk2NGVmNzk1NTk3Y2Y4Yzc3OTc5MTJfNzI_80d44d5c-0324-41b5-899a-609dfc33001c"
      unitRef="shares">514205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="i4e93f70390524d65aa024c34612f8203_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RleHRyZWdpb246YmY1NDc1ZDM5Njk2NGVmNzk1NTk3Y2Y4Yzc3OTc5MTJfMTAz_4e3ab1d9-5688-4a1d-99ad-27d0f604243f"
      unitRef="shares">5427697</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RleHRyZWdpb246YmY1NDc1ZDM5Njk2NGVmNzk1NTk3Y2Y4Yzc3OTc5MTJfMTg1_c7f6a31a-26fe-4366-a65d-d576801e035d"
      unitRef="shares">87000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RleHRyZWdpb246YmY1NDc1ZDM5Njk2NGVmNzk1NTk3Y2Y4Yzc3OTc5MTJfNDY3_e7809869-80a1-475d-9ad2-763d00ad1d60">Information regarding the number of options outstanding and exercisable at September&#160;30, 2022 is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,048,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,310,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining life &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i33f19560992c435a88092f47daf02b5b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RhYmxlOjBkMzg2NTI1YzZiNTQzNWM4NzJhODg2NmVlZjY4MjQ4L3RhYmxlcmFuZ2U6MGQzODY1MjVjNmI1NDM1Yzg3MmE4ODY2ZWVmNjgyNDhfMS0yLTEtMS0xNzg2OA_1e689900-db55-470e-9151-3a6b4cd0d08c"
      unitRef="shares">29048449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i33f19560992c435a88092f47daf02b5b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RhYmxlOjBkMzg2NTI1YzZiNTQzNWM4NzJhODg2NmVlZjY4MjQ4L3RhYmxlcmFuZ2U6MGQzODY1MjVjNmI1NDM1Yzg3MmE4ODY2ZWVmNjgyNDhfMS00LTEtMS0xNzg2OA_e98c0418-2ca3-4745-a83b-c755a1623187"
      unitRef="shares">23310464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3d7dd7f42af3454e98ea0cd9e0de9533_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RhYmxlOjBkMzg2NTI1YzZiNTQzNWM4NzJhODg2NmVlZjY4MjQ4L3RhYmxlcmFuZ2U6MGQzODY1MjVjNmI1NDM1Yzg3MmE4ODY2ZWVmNjgyNDhfMi0yLTEtMS0xNzg2OA_b69de965-d5dd-4fc0-85a7-c1aeed52f07c">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i3d7dd7f42af3454e98ea0cd9e0de9533_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RhYmxlOjBkMzg2NTI1YzZiNTQzNWM4NzJhODg2NmVlZjY4MjQ4L3RhYmxlcmFuZ2U6MGQzODY1MjVjNmI1NDM1Yzg3MmE4ODY2ZWVmNjgyNDhfMi00LTEtMS0xNzg2OA_4ad87d20-7a1d-466b-828f-b026812c0a20">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i33f19560992c435a88092f47daf02b5b_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RhYmxlOjBkMzg2NTI1YzZiNTQzNWM4NzJhODg2NmVlZjY4MjQ4L3RhYmxlcmFuZ2U6MGQzODY1MjVjNmI1NDM1Yzg3MmE4ODY2ZWVmNjgyNDhfMy0yLTEtMS0xNzg2OA_9c2c4457-1dd6-4913-a2b9-466e17dcea1f"
      unitRef="usdPerShare">70.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i33f19560992c435a88092f47daf02b5b_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RhYmxlOjBkMzg2NTI1YzZiNTQzNWM4NzJhODg2NmVlZjY4MjQ4L3RhYmxlcmFuZ2U6MGQzODY1MjVjNmI1NDM1Yzg3MmE4ODY2ZWVmNjgyNDhfMy00LTEtMS0xNzg2OA_2a17f461-43db-4fd0-8a93-24e705446e54"
      unitRef="usdPerShare">59.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i33f19560992c435a88092f47daf02b5b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RhYmxlOjBkMzg2NTI1YzZiNTQzNWM4NzJhODg2NmVlZjY4MjQ4L3RhYmxlcmFuZ2U6MGQzODY1MjVjNmI1NDM1Yzg3MmE4ODY2ZWVmNjgyNDhfNC0yLTEtMS0xNzg2OA_90fd3ea0-3854-4f6c-9223-ec60e77ff698"
      unitRef="usd">901000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i33f19560992c435a88092f47daf02b5b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RhYmxlOjBkMzg2NTI1YzZiNTQzNWM4NzJhODg2NmVlZjY4MjQ4L3RhYmxlcmFuZ2U6MGQzODY1MjVjNmI1NDM1Yzg3MmE4ODY2ZWVmNjgyNDhfNC00LTEtMS0xNzg2OA_c51df1a2-aa96-49d7-ac38-f061032aee5e"
      unitRef="usd">890000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RleHRyZWdpb246YmY1NDc1ZDM5Njk2NGVmNzk1NTk3Y2Y4Yzc3OTc5MTJfNDEw_82a23fae-d721-4d3b-9bf5-760568923940"
      unitRef="usd">600000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81NS9mcmFnOmJmNTQ3NWQzOTY5NjRlZjc5NTU5N2NmOGM3Nzk3OTEyL3RleHRyZWdpb246YmY1NDc1ZDM5Njk2NGVmNzk1NTk3Y2Y4Yzc3OTc5MTJfNDYy_d55b60b8-1cb3-41d1-b96c-248318471a24">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81OC9mcmFnOmFiMmYzYmZiNjE5NDQyMzBhM2RiZmNjOTJhNDRlMjA4L3RleHRyZWdpb246YWIyZjNiZmI2MTk0NDIzMGEzZGJmY2M5MmE0NGUyMDhfOTY_f46e6c5d-c13a-4fc5-9acb-ffc907a7850c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 8 &#x2014; Debt and Lines of Credit&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:RepaymentsOfDebt
      contextRef="ib0b29ca98ef14de0a3be8cd36653449b_D20220315-20220315"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81OC9mcmFnOmFiMmYzYmZiNjE5NDQyMzBhM2RiZmNjOTJhNDRlMjA4L3RleHRyZWdpb246YWIyZjNiZmI2MTk0NDIzMGEzZGJmY2M5MmE0NGUyMDhfMzQ_8c6dc8b0-278b-43f4-be12-f12485f06fcb"
      unitRef="usd">750000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icb2e6dec32fd457dab072263060d0e7f_I20220315"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl81OC9mcmFnOmFiMmYzYmZiNjE5NDQyMzBhM2RiZmNjOTJhNDRlMjA4L3RleHRyZWdpb246YWIyZjNiZmI2MTk0NDIzMGEzZGJmY2M5MmE0NGUyMDhfNzM_38f89095-728a-4037-97d4-992251c68d8e"
      unitRef="number">0.0255</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNDUwMA_9824efbf-b0e5-454b-a1e7-b22f286f7f63">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 9 &#x2014; Financial Instruments, Derivatives and Fair Value Measures&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.9 billion at September&#160;30, 2022 and $8.6 billion at December&#160;31, 2021, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of September&#160;30, 2022 will be included in Cost of products sold at the time the products are sold, generally through the next &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNjQ1_49b14940-1788-44d4-b632-7d72eb48a1c0"&gt;twelve&lt;/span&gt; to eighteen months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At September&#160;30, 2022 and December&#160;31, 2021, Abbott held the gross notional amounts of $10.3 billion and $12.2 billion, respectively, of such foreign currency forward exchange contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Abbott has designated a yen-denominated, 5-year term loan of approximately $413 million and $521 million as of September&#160;30, 2022 and December&#160;31, 2021, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Abbott is a party to interest rate hedge contracts with notional values totaling approximately $2.9 billion at September&#160;30, 2022 and December&#160;31, 2021 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts and location of certain derivative financial instruments as of September&#160;30, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value - Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value - Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dec. 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dec. 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income taxes and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Post-employment obligations, deferred income taxes and other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Others not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt designated as a hedge of net investment in a foreign subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gain (loss) Recognized in Other &lt;br/&gt;Comprehensive Income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income (expense) and Gain (loss)&lt;br/&gt;Reclassified into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;Ended September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months&lt;br/&gt;Ended September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;Ended September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months&lt;br/&gt;Ended September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt designated as a hedge of net investment in a foreign subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Losses of $27 million and $18 million were recognized in the three months ended September&#160;30, 2022 and 2021, respectively, related to foreign currency forward exchange contracts not designated as a hedge. Gains of $225 million and $15 million were recognized in the nine months ended September&#160;30, 2022 and 2021, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values and fair values of certain financial instruments as of September&#160;30, 2022 and December&#160;31, 2021 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Investment Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign Currency Forward Exchange Contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivable position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Payable) position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Rate Hedge Contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivable position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Payable) position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the debt was determined based on significant other observable inputs, including current interest rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basis of Fair Value Measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;br/&gt;Balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of hedged long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration related to business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap derivative financial instruments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of hedged long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration related to business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i76a875a71c9d425d9d761f5b9b84a5e2_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMzM1_0ca8ddac-fe26-48a4-914e-511b12beb027"
      unitRef="usd">7900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iaf6d0188932d469bac5c2cf700f6c5e3_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMzQ4_ed3a2088-4ef2-41d0-afe7-a1db5258fe0d"
      unitRef="usd">8600000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:MaximumLengthOfTimeHedgedInCashFlowHedge1
      contextRef="i75c98c84b66f4cfa973544e07e3a54c4_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNjUx_02f143c0-f435-4599-8e99-d5e84c8c7855">P18M</us-gaap:MaximumLengthOfTimeHedgedInCashFlowHedge1>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7768645f0e3548ef8fa07c72bb1ea50a_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMTM2Ng_0423c1e6-262a-4234-917d-6dc7649cc28f"
      unitRef="usd">10300000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib70687d909df4adf951907f9e4120aa4_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMTM3Mw_cc8f3c89-6fba-4e11-aa97-7cfb3e1d6d73"
      unitRef="usd">12200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="i362cc950c402435b85ccd22cc23f812e_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMTQ4Ng_4e7326ae-3a2f-4823-a283-d196255adafa">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="i549e4e2eae714c2daeb70c21f201d001_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMTQ4Ng_59ca2b57-5df0-48f6-823d-092a8df1defa">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LongTermDebt
      contextRef="ie414f701cbf142b7b9b601b415e450e9_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMTUyMQ_6b4933b0-b883-43fc-9e71-8599f4891d44"
      unitRef="usd">413000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3273ef5ba89846a6b3579791ad4114a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMTUyOA_e91f18e2-7165-48af-92ce-7d83ebedfb66"
      unitRef="usd">521000000</us-gaap:LongTermDebt>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i37b05ec060e14d3a94f524f71c4a509a_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMTg2NQ_211b09f5-62be-4ad2-a36c-e8d02d2ab366"
      unitRef="usd">2900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7159ef591665413e9beeecc68ac31d2d_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMTg2NQ_d0157d99-7f63-4106-8731-afd30c94d550"
      unitRef="usd">2900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNDUwMg_762ace3e-ce0e-47f4-8cde-cd0dea7bc108">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts and location of certain derivative financial instruments as of September&#160;30, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value - Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value - Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dec. 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dec. 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swaps designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income taxes and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Post-employment obligations, deferred income taxes and other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Others not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt designated as a hedge of net investment in a foreign subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="iec45d80b0bae4c32b4f36d6967676878_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfMi0yLTEtMS0xNzg2OA_f9736537-d8e0-4b58-9ac0-bd0d955ecace"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ie3c67e54492a410491b80a24aa671e4c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfMi00LTEtMS0xNzg2OA_d7936b8f-36c9-4a9d-8b3c-b825028553e7"
      unitRef="usd">87000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i5b9ef5b827994c42a6595f4e0c623688_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfMi04LTEtMS0xNzg2OA_2a05c395-068e-4b3d-8c6d-347753a71b26"
      unitRef="usd">166000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i0ec5a2619fbe4414981ad28228a6b87f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfMi0xMC0xLTEtMTc4Njg_662e62d4-95b0-4a03-bbd7-b10377b63936"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i9cb408ff61494ac1a4b289c86d1de300_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNC0yLTEtMS0xNzg2OA_bb8b8546-88e2-411a-9de5-fd50447f35a0"
      unitRef="usd">760000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="iea63a66bbec848d5af23efa2feb1ab3c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNC00LTEtMS0xNzg2OA_8d84cf2c-4d02-4dfb-a051-e13e46f637f5"
      unitRef="usd">222000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ia26c1f62062f4ea0a07843e03153843d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNC04LTEtMS0xNzg2OA_8549a0bd-97ba-4075-ba47-be065b39fbbb"
      unitRef="usd">66000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ic0dc5c19ed38405a941c3edfc0d6963e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNC0xMC0xLTEtMTc4Njg_334855e1-e0f0-42e6-ae98-e0ea2eeac7bb"
      unitRef="usd">65000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i4cdc399d14e84bc6a02151fe08ebeac0_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNS0yLTEtMS0xNzg2OA_b8c27caa-36e2-459c-8867-659e201990aa"
      unitRef="usd">148000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i65c2fb65db7845fb87663d6e762d2d63_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNS00LTEtMS0xNzg2OA_18d56a54-d4f9-4ed0-968b-02cc91f71616"
      unitRef="usd">70000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i2505f0c40f0d485cb42f96d4df9ad116_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNS04LTEtMS0xNzg2OA_d61232b5-7bc7-4698-b971-703898948028"
      unitRef="usd">141000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i2e3df89ca5cd458499f4fddc42ea907e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNS0xMC0xLTEtMTc4Njg_90ccac65-065b-4195-9dc2-e8ff1272e41a"
      unitRef="usd">32000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="iea1dfa89210b49259cbcc86f33bc5af3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNi04LTEtMS0xNzg2OA_2a502eb3-ee08-4a1e-a17d-00322b007334"
      unitRef="usd">413000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ifd9937735c2340e2a5e5e7ccb99a641e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNi0xMC0xLTEtMTc4Njg_613e6304-1090-4494-ad6d-d2242febc781"
      unitRef="usd">521000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNy0yLTEtMS0xNzg2OA_6ec5d7f1-f440-4b25-9424-ae79b6b5bd15"
      unitRef="usd">908000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNy00LTEtMS0xNzg2OA_50e12d63-e838-40a6-ac29-e477c7844ce4"
      unitRef="usd">379000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNy04LTEtMS0xNzg2OA_68a76a80-f17f-4091-bc04-3ccd57233053"
      unitRef="usd">786000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i161741e7e8f046ff9a2cc29b1a64a357_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjM0ODdhOGQ4M2Y0YjRhM2JiMzU3ZDQyYjc3ZTdlMTZiL3RhYmxlcmFuZ2U6MzQ4N2E4ZDgzZjRiNGEzYmIzNTdkNDJiNzdlN2UxNmJfNy0xMC0xLTEtMTc4Njg_57180693-0d3e-4841-a08e-54aebbd86159"
      unitRef="usd">618000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNDUwNA_6e2db637-0359-424c-87cc-60110f96cb66">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended September&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gain (loss) Recognized in Other &lt;br/&gt;Comprehensive Income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income (expense) and Gain (loss)&lt;br/&gt;Reclassified into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;Ended September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months&lt;br/&gt;Ended September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;Ended September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months&lt;br/&gt;Ended September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt designated as a hedge of net investment in a foreign subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps designated as fair value hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i5397677ab93a49019eae8c9a0bb21d79_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfMy0yLTEtMS0xNzg2OA_e92909c7-6dd1-4b9a-88de-4a6fa7be2dab"
      unitRef="usd">350000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i7dcc53ef71a34fb88566cf49ebd25f9f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfMy00LTEtMS0xNzg2OA_f3b24a7f-08d1-4287-81f6-94ab3d4c0d7b"
      unitRef="usd">96000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie72837af6cc147a5874155b6990bf8c9_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfMy02LTEtMS0xNzg2OA_ca720148-1741-4c5e-bbb9-14ff314bd1b9"
      unitRef="usd">442000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i65ae9ecf6fd5486287c43691fc391e33_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfMy04LTEtMS0xNzg2OA_bdfc3271-d5fc-4c69-911d-939a7060ef3a"
      unitRef="usd">142000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i5397677ab93a49019eae8c9a0bb21d79_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfMy0xMC0xLTEtMTc4Njg_11c68bfe-eb9c-4d3e-9413-aa1d32edf4ec"
      unitRef="usd">79000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i7dcc53ef71a34fb88566cf49ebd25f9f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfMy0xMi0xLTEtMTc4Njg_42dee4a1-4a52-4817-8834-70ae823528fc"
      unitRef="usd">-92000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="ie72837af6cc147a5874155b6990bf8c9_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfMy0xNC0xLTEtMTc4Njg_d6b4582f-8f25-4a2d-8b92-1c2dbbf3c84c"
      unitRef="usd">149000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i65ae9ecf6fd5486287c43691fc391e33_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfMy0xNi0xLTEtMTc4Njg_31fd5eb2-1134-4ae8-abd3-3d5413f21b60"
      unitRef="usd">-207000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3506a1ed3b6c452f90c9f839466ac4e4_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfNC0yLTEtMS0xNzg2OA_23f3e974-8b6a-4396-ac39-3363a33b6266"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie5be187d8164445380ced526aa943a0c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfNC00LTEtMS0xNzg2OA_1fda8a80-11fc-4cae-9945-3c8802372fb7"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i7cdf77deb3954cceb710b7273d79ecc6_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfNC02LTEtMS0xNzg2OA_dcd1d91b-b7b0-4a94-820c-9432aa47f9cf"
      unitRef="usd">108000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="iaf6360515a084a56b0e124d0c9a4b858_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfNC04LTEtMS0xNzg2OA_74ba8d62-927e-48b4-ab82-26da5c9fa5b2"
      unitRef="usd">41000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i7a8804aef7ab405a9bd7994c3c7fc41c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfNS0xMC0xLTEtMTc4Njg_66dfe6c2-db7f-407d-895d-7280b0114b37"
      unitRef="usd">-85000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i6840ccb5da6c4ad4bda53b49c4cd3231_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfNS0xMi0xLTEtMTc4Njg_88d00a2e-e9bd-4ec8-9c63-4496e02e6825"
      unitRef="usd">-14000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i6afdc8cb667a4638a732ba5f45eb54ba_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfNS0xNC0xLTEtMTc4Njg_763cc9f5-53f2-435c-aca3-1a4f297c70ed"
      unitRef="usd">-253000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="i091abb1e8fe94a55b833b101e4414fe1_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOmRhNjk4ODhiZWFlMzQyYzk5YWM1Y2QxNDQxNGM4YjA4L3RhYmxlcmFuZ2U6ZGE2OTg4OGJlYWUzNDJjOTlhYzVjZDE0NDE0YzhiMDhfNS0xNi0xLTEtMTc4Njg_c6db9d57-baf1-4b71-95c5-3ac8071a2d4b"
      unitRef="usd">-81000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i88b7ee098ae642899deeab2cddde1c6d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMjc5OQ_ce95c530-ffd7-4bea-a192-e4ac9dd40e5b"
      unitRef="usd">-27000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i1277200202a84547aa376e37e03fd635_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMjgwNw_6ae2c396-58a7-43a0-9a19-2ec63c52007b"
      unitRef="usd">-18000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ia237ff4511bb4929b3bba3623e099990_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMjk2NA_cea73ada-a6a6-4512-93af-36ef04e113f2"
      unitRef="usd">225000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i8cd680e248c64638be6c598cf72ebfad_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfMjk3Mg_e2901a4d-1be2-43eb-89aa-b80a72750acc"
      unitRef="usd">15000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNDUwNQ_ecdd286a-487e-4e1a-8f94-36f1fc0c73c8">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values and fair values of certain financial instruments as of September&#160;30, 2022 and December&#160;31, 2021 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Investment Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign Currency Forward Exchange Contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivable position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Payable) position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Rate Hedge Contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivable position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Payable) position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:LongTermInvestments
      contextRef="i7e53ec310eb54a098325e121ff28338f_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMy0yLTEtMS0xNzg2OA_979345e9-ac79-4268-b1ed-5418ff3deff8"
      unitRef="usd">604000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i4dcc8e7c28ee4309824c37c0f1ba79d8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMy00LTEtMS0xNzg2OA_b02fd853-ff84-4aac-9a2a-6fd60f316a1c"
      unitRef="usd">604000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i301f40be6d6f4ebb92077078845bdb8c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMy02LTEtMS0xNzg2OA_8326a942-c9f7-464a-8ed8-f1e6d480453b"
      unitRef="usd">748000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="iaa54db95946a4086a4914e1aa90c5af3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMy04LTEtMS0xNzg2OA_d4c3f37c-699b-4788-85cf-ca2e4d937c90"
      unitRef="usd">748000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="iedd4976f99c842058ae43f0aefe27d73_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNC0yLTEtMS0xNzg2OA_4e19e6de-42f5-4a41-b4a6-f965f880f4d8"
      unitRef="usd">160000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i9db10f8a54af4a0aaa440b1f3206a5d2_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNC00LTEtMS0xNzg2OA_954bca80-633f-41e5-ba0e-900343959542"
      unitRef="usd">160000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i44e6cf7c4a144759b6e10215356df268_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNC02LTEtMS0xNzg2OA_5e700b8e-b680-40f4-8ba6-2b1b9031a762"
      unitRef="usd">68000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i199db302b74f4397862dc61ac1c91c79_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNC04LTEtMS0xNzg2OA_db363419-3c90-4085-9516-84674682dce8"
      unitRef="usd">68000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermDebtFairValue
      contextRef="i132737fb549d49b2af4b792fb9883efb_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNS0yLTEtMS0xNzg2OA_7314c2d3-07c8-4dc1-89f2-73438d3e4ff9"
      unitRef="usd">16414000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ic595c192e42f4320bb74ffe5f79848fa_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNS00LTEtMS0xNzg2OA_41da45f2-65f9-4a68-b7f3-d6930460b29d"
      unitRef="usd">15821000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="if9130097464e4c8abfc4ebc47a8bf3db_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNS02LTEtMS0xNzg2OA_aa09955a-d58e-4921-a6f0-b06b44f5c4da"
      unitRef="usd">18050000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ic386176ec45b4cb29e70f8de930f1a01_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNS04LTEtMS0xNzg2OA_12fb5b7e-112d-4084-8279-943229b5d10b"
      unitRef="usd">21152000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue
      contextRef="i132737fb549d49b2af4b792fb9883efb_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNy0yLTEtMS0xNzg2OA_6647ecd8-0f14-4ce1-9648-182ef0b6ac67"
      unitRef="usd">908000000</us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue
      contextRef="ic595c192e42f4320bb74ffe5f79848fa_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNy00LTEtMS0xNzg2OA_568e7834-2009-4479-a824-1e894ad9a22e"
      unitRef="usd">908000000</us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue
      contextRef="if9130097464e4c8abfc4ebc47a8bf3db_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNy02LTEtMS0xNzg2OA_ed9ceb41-1af8-421b-841e-d1377f05e907"
      unitRef="usd">292000000</us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue
      contextRef="ic386176ec45b4cb29e70f8de930f1a01_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfNy04LTEtMS0xNzg2OA_a6375119-0616-4c0e-a131-b344c0c54db6"
      unitRef="usd">292000000</us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue
      contextRef="i132737fb549d49b2af4b792fb9883efb_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfOC0yLTEtMS0xNzg2OA_cdee36a8-ea31-4461-b49f-79b76c58d5ed"
      unitRef="usd">207000000</us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue
      contextRef="ic595c192e42f4320bb74ffe5f79848fa_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfOC00LTEtMS0xNzg2OA_ab532618-35e2-44f2-9a05-08debc9f00bd"
      unitRef="usd">207000000</us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue
      contextRef="if9130097464e4c8abfc4ebc47a8bf3db_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfOC02LTEtMS0xNzg2OA_ac3ab9f2-f4bf-4f97-b07b-4df601cb15da"
      unitRef="usd">97000000</us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue
      contextRef="ic386176ec45b4cb29e70f8de930f1a01_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfOC04LTEtMS0xNzg2OA_2ddc6747-d93e-4c53-8e51-69679736b05a"
      unitRef="usd">97000000</us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="i132737fb549d49b2af4b792fb9883efb_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMTAtMi0xLTEtMTc4Njg_90021c49-c519-4b29-988e-a19a81f1e216"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="ic595c192e42f4320bb74ffe5f79848fa_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMTAtNC0xLTEtMTc4Njg_1353256f-537e-4956-8777-8da34a10b4d4"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="if9130097464e4c8abfc4ebc47a8bf3db_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMTAtNi0xLTEtMTc4Njg_658bdcb9-331b-4e34-b8be-bc4b4b609a53"
      unitRef="usd">87000000</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue
      contextRef="ic386176ec45b4cb29e70f8de930f1a01_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMTAtOC0xLTEtMTc4Njg_02ca14f9-a2ac-47e5-a4ad-6f1512c59ee5"
      unitRef="usd">87000000</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="i132737fb549d49b2af4b792fb9883efb_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMTEtMi0xLTEtMTc4Njg_fccd85f4-eab5-4c53-b098-b82f2956a246"
      unitRef="usd">166000000</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="ic595c192e42f4320bb74ffe5f79848fa_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMTEtNC0xLTEtMTc4Njg_48e9d8c8-2e30-4a33-8e99-90cdecc5ac03"
      unitRef="usd">166000000</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="if9130097464e4c8abfc4ebc47a8bf3db_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMTEtNi0xLTEtMTc4Njg_c6879b36-0a30-4621-8e1d-c7da383febbe"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue
      contextRef="ic386176ec45b4cb29e70f8de930f1a01_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjcyNDcwODNiNWQzNjRjZDg4NjU4NWNmZDAyYTk0YWM3L3RhYmxlcmFuZ2U6NzI0NzA4M2I1ZDM2NGNkODg2NTg1Y2ZkMDJhOTRhYzdfMTEtOC0xLTEtMTc4Njg_b80b2dde-5afa-40c4-a778-fc210330cdf5"
      unitRef="usd">0</us-gaap:InterestRateFairValueHedgeLiabilityAtFairValue>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RleHRyZWdpb246NDNiMGI4MWUyYjZhNDdiNThiNzJlZDRmMWZhODg5OTVfNDUwNg_8d8eeb61-ac78-4efe-aae6-e916505d896f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basis of Fair Value Measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;br/&gt;Balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of hedged long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration related to business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap derivative financial instruments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of hedged long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration related to business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie6d54ddc609d499383aafcf6ba76dd93_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMy0yLTEtMS0xNzg2OA_1584614e-e303-4931-b8b6-639ec566cf7d"
      unitRef="usd">293000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMy00LTEtMS0xNzg2OA_6597639d-b9f9-4569-894c-7a03f1fe2a7d"
      unitRef="usd">293000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMy02LTEtMS0xNzg2OA_204e7b95-978c-4c73-aa36-57288f23402b"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib18fc392e579454d8f85e5dc41070311_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMy04LTEtMS0xNzg2OA_12b39101-8c39-4867-ad73-2b050688ce3a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue
      contextRef="ie6d54ddc609d499383aafcf6ba76dd93_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNC0yLTEtMS0xNzg2OA_354a0dfb-79c8-4c47-893c-510e1e70a16e"
      unitRef="usd">908000000</us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue
      contextRef="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNC00LTEtMS0xNzg2OA_e7535746-ecef-48d6-9200-97f7a9f07b32"
      unitRef="usd">0</us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue
      contextRef="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNC02LTEtMS0xNzg2OA_accc8894-dd45-43c4-8a8c-241788e6f3cc"
      unitRef="usd">908000000</us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue
      contextRef="ib18fc392e579454d8f85e5dc41070311_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNC04LTEtMS0xNzg2OA_39318e31-73f9-443c-a35a-3785e7991f0d"
      unitRef="usd">0</us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie6d54ddc609d499383aafcf6ba76dd93_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNS0yLTEtMS0xNzg2OA_a42b3775-5ce0-4898-bfea-1fcf2ea14183"
      unitRef="usd">1201000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNS00LTEtMS0xNzg2OA_b26651be-2ed7-4edf-ad5f-8297322b7e86"
      unitRef="usd">293000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNS02LTEtMS0xNzg2OA_dd448843-1525-47e2-ae2c-5e6ada244e17"
      unitRef="usd">908000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib18fc392e579454d8f85e5dc41070311_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNS04LTEtMS0xNzg2OA_0f6ecb4a-ac91-4d32-b51b-515f04ef33fa"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ie6d54ddc609d499383aafcf6ba76dd93_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNy0yLTEtMS0xNzg2OA_89dd9ddf-bf40-47a2-96dc-d7de7183739f"
      unitRef="usd">2685000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNy00LTEtMS0xNzg2OA_caba650b-a22b-44da-a47a-9cb2af1d0dc1"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNy02LTEtMS0xNzg2OA_bfe415e8-8870-4ac1-9c5e-e57b40405444"
      unitRef="usd">2685000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ib18fc392e579454d8f85e5dc41070311_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfNy04LTEtMS0xNzg2OA_80c7d717-daab-4a58-a621-d7c95157c3c7"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="ie6d54ddc609d499383aafcf6ba76dd93_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfOC0yLTEtMS0xNzg2OA_f3400582-7715-4faf-9fe5-f2400afd2781"
      unitRef="usd">166000000</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfOC00LTEtMS0xNzg2OA_adb4c54f-b6bf-4357-86fd-43b31838366a"
      unitRef="usd">0</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfOC02LTEtMS0xNzg2OA_cc9ef0f0-654d-4038-9a29-e489bf81b851"
      unitRef="usd">166000000</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue
      contextRef="ib18fc392e579454d8f85e5dc41070311_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfOC04LTEtMS0xNzg2OA_1bce38b0-6adc-41d6-b2b0-633019ba6c3f"
      unitRef="usd">0</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue
      contextRef="ie6d54ddc609d499383aafcf6ba76dd93_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfOS0yLTEtMS0xNzg2OA_97b2ab11-0be3-40b3-8d1f-91dcaccb3c41"
      unitRef="usd">207000000</us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue
      contextRef="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfOS00LTEtMS0xNzg2OA_27543035-6ede-4f22-9e98-b0e46873e793"
      unitRef="usd">0</us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue
      contextRef="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfOS02LTEtMS0xNzg2OA_57207b7c-7e3c-4ea2-9dba-2bede82e75d1"
      unitRef="usd">207000000</us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue
      contextRef="ib18fc392e579454d8f85e5dc41070311_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfOS04LTEtMS0xNzg2OA_20f4b16d-67fb-4ec9-adef-4f8e91729935"
      unitRef="usd">0</us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie6d54ddc609d499383aafcf6ba76dd93_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTAtMi0xLTEtMTc4Njg_ba3c3dea-da45-4be3-bba6-850231cea4f6"
      unitRef="usd">138000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTAtNC0xLTEtMTc4Njg_e19c04f1-819b-43ab-8343-e0381465f3c2"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTAtNi0xLTEtMTc4Njg_8582f2f8-05ed-46aa-9350-e4020995fa7d"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib18fc392e579454d8f85e5dc41070311_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTAtOC0xLTEtMTc4Njg_3cabe06a-7625-4eb4-890c-ffb5bee41f6c"
      unitRef="usd">138000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie6d54ddc609d499383aafcf6ba76dd93_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTEtMi0xLTEtMTc4Njg_733e8cf7-718c-4d6f-b953-b6c02a5a8f21"
      unitRef="usd">3196000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i00a588a59f6f4a5e9c790ca23d8148f5_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTEtNC0xLTEtMTc4Njg_79f30c6c-944e-4613-8c0c-6bf3243ab857"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="icf368d99e4494ef6a68d26d9ff45b5a0_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTEtNi0xLTEtMTc4Njg_110ac013-8157-43da-8abf-e5dce55b6e79"
      unitRef="usd">3058000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib18fc392e579454d8f85e5dc41070311_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTEtOC0xLTEtMTc4Njg_eac23811-0335-49bb-9d8d-d1d8e6221e7c"
      unitRef="usd">138000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTQtMi0xLTEtMTc4Njg_ac4844be-feaa-4534-9dbb-78627f8848e0"
      unitRef="usd">402000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie1f2a644ac84481c931d626da6d56b5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTQtNC0xLTEtMTc4Njg_64526c17-9f2e-4485-b65a-d3bb7a804c63"
      unitRef="usd">402000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1940cafbfda44622acb910b14b1f0a51_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTQtNi0xLTEtMTc4Njg_7069d389-5867-468a-b16e-3f3de5a77d1e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTQtOC0xLTEtMTc4Njg_e1ba0974-0db0-4aef-a5de-e2de3cfebc6f"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTUtMi0xLTEtMTc4Njg_151a30db-c439-436d-851f-f92826cd19af"
      unitRef="usd">87000000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="ie1f2a644ac84481c931d626da6d56b5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTUtNC0xLTEtMTc4Njg_9e283e62-019d-4249-bb83-300073a02549"
      unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="i1940cafbfda44622acb910b14b1f0a51_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTUtNi0xLTEtMTc4Njg_a12a7c2b-91a9-4803-a3ae-7d303f901dff"
      unitRef="usd">87000000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue
      contextRef="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTUtOC0xLTEtMTc4Njg_f0f62fde-118b-4b0f-8400-2e7484131e80"
      unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue
      contextRef="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTYtMi0xLTEtMTc4Njg_2bba3449-baac-4406-aa03-dd1511587757"
      unitRef="usd">292000000</us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue
      contextRef="ie1f2a644ac84481c931d626da6d56b5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTYtNC0xLTEtMTc4Njg_a35637c9-cfc8-4bc2-a418-949e2f54eb88"
      unitRef="usd">0</us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue
      contextRef="i1940cafbfda44622acb910b14b1f0a51_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTYtNi0xLTEtMTc4Njg_1de3c0b9-41ea-45ca-b7cf-010ceafe6da2"
      unitRef="usd">292000000</us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue
      contextRef="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTYtOC0xLTEtMTc4Njg_3ea1b56e-1a50-4a03-8385-c445c3ca018a"
      unitRef="usd">0</us-gaap:ForeignCurrencyCashFlowHedgeAssetAtFairValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTctMi0xLTEtMTc4Njg_6496efc1-e181-4582-a26c-a27da080f2d2"
      unitRef="usd">781000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie1f2a644ac84481c931d626da6d56b5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTctNC0xLTEtMTc4Njg_36902231-4973-4cc4-a15d-b5a7e44b5d17"
      unitRef="usd">402000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1940cafbfda44622acb910b14b1f0a51_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTctNi0xLTEtMTc4Njg_ce98f844-d7cf-45bb-9958-5c1b20316de7"
      unitRef="usd">379000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTctOC0xLTEtMTc4Njg_642081ef-6ad6-4791-b885-ae3e284e838c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTktMi0xLTEtMTc4Njg_f7f93d42-c04f-42e1-ab82-a832f65873d7"
      unitRef="usd">2926000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ie1f2a644ac84481c931d626da6d56b5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTktNC0xLTEtMTc4Njg_7bf58050-0900-46dc-90b7-b8d1211e5c7a"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i1940cafbfda44622acb910b14b1f0a51_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTktNi0xLTEtMTc4Njg_803460f1-912d-4d49-b28f-a67c4935121b"
      unitRef="usd">2926000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMTktOC0xLTEtMTc4Njg_47408d7c-3629-4d44-af54-d0793197f1ee"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue
      contextRef="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjAtMi0xLTEtMTc4Njg_afce6ec9-9481-4faa-a397-5eadc005733d"
      unitRef="usd">97000000</us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue
      contextRef="ie1f2a644ac84481c931d626da6d56b5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjAtNC0xLTEtMTc4Njg_e0248c14-3b73-4194-ae50-14e1cb29e12a"
      unitRef="usd">0</us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue
      contextRef="i1940cafbfda44622acb910b14b1f0a51_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjAtNi0xLTEtMTc4Njg_ca381ca4-e602-445b-8830-3fe3eeb716ba"
      unitRef="usd">97000000</us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue
      contextRef="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjAtOC0xLTEtMTc4Njg_26f2cc04-38b8-45d5-91b5-31b9a89af585"
      unitRef="usd">0</us-gaap:ForeignCurrencyCashFlowHedgeLiabilityAtFairValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjEtMi0xLTEtMTc4Njg_515a00d8-b416-4a3a-92c5-0f0cb29c8119"
      unitRef="usd">130000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie1f2a644ac84481c931d626da6d56b5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjEtNC0xLTEtMTc4Njg_1ecd262f-d1b0-40ac-9a6a-925e6cb245f1"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1940cafbfda44622acb910b14b1f0a51_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjEtNi0xLTEtMTc4Njg_3aadd2b8-adbc-485c-b630-5c3a1305c283"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjEtOC0xLTEtMTc4Njg_e8b74d68-85e6-4112-b60a-8527ada59ccf"
      unitRef="usd">130000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia5cf799d49c74fec9ef3403ffaddf5e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjItMi0xLTEtMTc4Njg_2e41e4db-f9e7-404a-9ce1-35f598d97a31"
      unitRef="usd">3153000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie1f2a644ac84481c931d626da6d56b5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjItNC0xLTEtMTc4Njg_a364a90f-62dd-4ceb-bebb-f1e6012ecf18"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1940cafbfda44622acb910b14b1f0a51_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjItNi0xLTEtMTc4Njg_094c095b-df8f-42d2-b158-e83decb83301"
      unitRef="usd">3023000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0e2aedd62cbf42c89131acc69f8b5d74_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82MS9mcmFnOjQzYjBiODFlMmI2YTQ3YjU4YjcyZWQ0ZjFmYTg4OTk1L3RhYmxlOjkwYTczYWIzN2E5ZDRkMGQ5ZTU3MWYwNTM1YzBiY2MyL3RhYmxlcmFuZ2U6OTBhNzNhYjM3YTlkNGQwZDllNTcxZjA1MzVjMGJjYzJfMjItOC0xLTEtMTc4Njg_c540460a-8b70-46ff-a6e0-d0c5fa6e90af"
      unitRef="usd">130000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82NC9mcmFnOjhlNjExZjg0NjVmMjQzNDg4NmJhMDgwNDJiZGU0MDA3L3RleHRyZWdpb246OGU2MTFmODQ2NWYyNDM0ODg2YmEwODA0MmJkZTQwMDdfMTM0Mg_dad30976-381d-46b2-8968-ff6b730e4a9a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 10 &#x2014; Litigation and Environmental Matters&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.&lt;/span&gt;&lt;/div&gt;Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $40 million to $50 million. The recorded accrual balance at September&#160;30, 2022 for these proceedings and exposures was approximately $45 million. This accrual represents management&#x2019;s best estimate of probable loss, as defined by FASB ASC No. 450, &#x201c;Contingencies.&#x201d; Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott&#x2019;s financial position, cash flows, or results of operations.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <abt:LossContingencyRangeOfPossibleLossMaximumIndividualSite
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82NC9mcmFnOjhlNjExZjg0NjVmMjQzNDg4NmJhMDgwNDJiZGU0MDA3L3RleHRyZWdpb246OGU2MTFmODQ2NWYyNDM0ODg2YmEwODA0MmJkZTQwMDdfNDgw_766c7957-64ec-4138-bc4c-6d1abe95bd1b"
      unitRef="usd">4000000</abt:LossContingencyRangeOfPossibleLossMaximumIndividualSite>
    <abt:LossContingencyRangeOfPossibleLossMaximumAggregateSites
      contextRef="iec9d7c7b895f4b01a5849a89d5bca911_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82NC9mcmFnOjhlNjExZjg0NjVmMjQzNDg4NmJhMDgwNDJiZGU0MDA3L3RleHRyZWdpb246OGU2MTFmODQ2NWYyNDM0ODg2YmEwODA0MmJkZTQwMDdfNTQ1_ffacafed-c4d3-40ee-85fe-a66dc388545f"
      unitRef="usd">10000000</abt:LossContingencyRangeOfPossibleLossMaximumAggregateSites>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ie698bf737c3e45f2bb1ceb02130904bb_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82NC9mcmFnOjhlNjExZjg0NjVmMjQzNDg4NmJhMDgwNDJiZGU0MDA3L3RleHRyZWdpb246OGU2MTFmODQ2NWYyNDM0ODg2YmEwODA0MmJkZTQwMDdfNzM3_f093a3c5-79ad-4305-a46e-03b961426551"
      unitRef="usd">40000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ia383194c19ba4900ae6daf189c3fb80d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82NC9mcmFnOjhlNjExZjg0NjVmMjQzNDg4NmJhMDgwNDJiZGU0MDA3L3RleHRyZWdpb246OGU2MTFmODQ2NWYyNDM0ODg2YmEwODA0MmJkZTQwMDdfNzQz_c8b642e7-6c88-489b-9f23-74230f10e100"
      unitRef="usd">50000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="id0f82983e37f491aa82bf6e3c57ef4d8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82NC9mcmFnOjhlNjExZjg0NjVmMjQzNDg4NmJhMDgwNDJiZGU0MDA3L3RleHRyZWdpb246OGU2MTFmODQ2NWYyNDM0ODg2YmEwODA0MmJkZTQwMDdfODM2_c40d2066-6137-469f-b8ed-e8f534d54d13"
      unitRef="usd">45000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:PostemploymentBenefitsDisclosureTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RleHRyZWdpb246OTJiNTcyNDg0MzBkNDdiN2E0ZWVhNDIzY2FhYWE5NTJfOTE1_24eaf328-44c7-497e-b15f-be22b0d32f22">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 11 &#x2014; Post-Employment Benefits&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three and nine months ended September&#160;30 for Abbott&#x2019;s major defined benefit plans and post-employment medical and dental benefit plans is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medical and Dental Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;Ended Sept. 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine  Months &lt;br/&gt;Ended Sept. 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;Ended Sept. 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine  Months &lt;br/&gt;Ended Sept. 30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost - benefits earned during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost on projected benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net amortization of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actuarial loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first nine months of 2022 and 2021, $362 million and $366 million, respectively, were contributed to defined benefit plans. In the first nine months of 2022 and 2021, $28 million&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$26&#160;million, respectively&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt; were contributed to the post-employment medical and dental plans.</us-gaap:PostemploymentBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RleHRyZWdpb246OTJiNTcyNDg0MzBkNDdiN2E0ZWVhNDIzY2FhYWE5NTJfOTE2_53a8ff76-bd1a-4d2f-bead-14dd64b377b7">Net cost recognized for the three and nine months ended September&#160;30 for Abbott&#x2019;s major defined benefit plans and post-employment medical and dental benefit plans is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Defined Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medical and Dental Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;Ended Sept. 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine  Months &lt;br/&gt;Ended Sept. 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;Ended Sept. 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine  Months &lt;br/&gt;Ended Sept. 30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost - benefits earned during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost on projected benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net amortization of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actuarial loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ic55e17708b144d149c97d0b172bd426e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfMy0yLTEtMS0xNzg2OA_e16afc75-965e-48a3-b580-7ed77e8cfe7e"
      unitRef="usd">92000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="idf9e8de48606409d948398115c9f7699_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfMy00LTEtMS0xNzg2OA_cdd1d51d-a631-49d7-99d8-5422a338d214"
      unitRef="usd">98000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfMy02LTEtMS0xNzg2OA_71a9edfd-7f31-4cd5-a594-67da3a5d98e8"
      unitRef="usd">282000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfMy04LTEtMS0xNzg2OA_ad3b512c-3ab6-449a-960d-4e6d93b2408d"
      unitRef="usd">294000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i40386c7e28f341b4ae443602056c8368_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfMy0xMC0xLTEtMTc4Njg_22563f56-dd80-4ef1-be66-2363defd7386"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i229532fb1b884a2b865d6f39735f6e86_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfMy0xMi0xLTEtMTc4Njg_8ecc15b3-ef37-476b-8bcc-335745f0cdb9"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib6b147cc106249baa28781e370ab66ec_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfMy0xNC0xLTEtMTc4Njg_95be01a1-4eb0-45de-a691-06c090be4de6"
      unitRef="usd">38000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iae69ef505e864efdaa37bebaf468436c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfMy0xNi0xLTEtMTc4Njg_095552d1-376f-4941-bd81-6c5189d022b3"
      unitRef="usd">42000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ic55e17708b144d149c97d0b172bd426e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNC0yLTEtMS0xNzg2OA_3d7a6886-117e-4529-b6d1-e7cc4c3fc2d0"
      unitRef="usd">74000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="idf9e8de48606409d948398115c9f7699_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNC00LTEtMS0xNzg2OA_f8a4085e-66fc-4068-b120-fe65e4719818"
      unitRef="usd">62000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNC02LTEtMS0xNzg2OA_43b29e20-834c-4b26-8588-9fce26e24318"
      unitRef="usd">225000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNC04LTEtMS0xNzg2OA_4cb07d5f-f2ff-4a08-99e6-1c656643cde7"
      unitRef="usd">186000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i40386c7e28f341b4ae443602056c8368_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNC0xMC0xLTEtMTc4Njg_59fcb263-1d5b-4afd-b61e-8cc702ffc38b"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i229532fb1b884a2b865d6f39735f6e86_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNC0xMi0xLTEtMTc4Njg_b13a332d-55c9-48ef-9de0-99d3383e2a3e"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib6b147cc106249baa28781e370ab66ec_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNC0xNC0xLTEtMTc4Njg_f0dc5e30-4d60-444e-8a30-8b4e61954606"
      unitRef="usd">27000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iae69ef505e864efdaa37bebaf468436c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNC0xNi0xLTEtMTc4Njg_483cc596-de19-460c-ad95-c51139fcfe1f"
      unitRef="usd">25000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ic55e17708b144d149c97d0b172bd426e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNS0yLTEtMS0xNzg2OA_92560eee-404e-469d-ae10-e83db73e8c79"
      unitRef="usd">231000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="idf9e8de48606409d948398115c9f7699_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNS00LTEtMS0xNzg2OA_fe01d452-66d5-4ec8-807d-af5ab4bb942f"
      unitRef="usd">211000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNS02LTEtMS0xNzg2OA_578fe312-08d9-4b79-b268-ef3968e900cb"
      unitRef="usd">701000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNS04LTEtMS0xNzg2OA_481cbf3e-5d6b-4e7b-8232-7445693851f4"
      unitRef="usd">633000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i40386c7e28f341b4ae443602056c8368_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNS0xMC0xLTEtMTc4Njg_9731951a-f1af-4675-b838-2ab20c5ccf2d"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i229532fb1b884a2b865d6f39735f6e86_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNS0xMi0xLTEtMTc4Njg_96d9fad2-62b9-44e6-a184-34ce61a3066b"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ib6b147cc106249baa28781e370ab66ec_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNS0xNC0xLTEtMTc4Njg_1c16a4c3-e6f8-4f9a-8f2b-7dd46366db2d"
      unitRef="usd">23000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="iae69ef505e864efdaa37bebaf468436c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNS0xNi0xLTEtMTc4Njg_ad31b2fd-bbba-4cd2-915b-2be559276eec"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ic55e17708b144d149c97d0b172bd426e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNy0yLTEtMS0xNzg2OA_3c7fcfa2-f1ae-47a1-a960-dbfe4a0f19e8"
      unitRef="usd">-58000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="idf9e8de48606409d948398115c9f7699_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNy00LTEtMS0xNzg2OA_e7025aab-b549-49b1-b76c-ad030dd3f05b"
      unitRef="usd">-79000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNy02LTEtMS0xNzg2OA_48663cf5-4e84-4904-a6ca-d825213eb8c4"
      unitRef="usd">-174000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNy04LTEtMS0xNzg2OA_ad7882a5-06d7-4692-8241-75d42186511d"
      unitRef="usd">-238000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i40386c7e28f341b4ae443602056c8368_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNy0xMC0xLTEtMTc4Njg_27b33682-b6fb-4222-b097-ed00171deb6b"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i229532fb1b884a2b865d6f39735f6e86_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNy0xMi0xLTEtMTc4Njg_d546f8e7-b47e-4497-a164-1261681a426a"
      unitRef="usd">-7000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ib6b147cc106249baa28781e370ab66ec_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNy0xNC0xLTEtMTc4Njg_733e1629-bd15-488a-a69c-620a517f7537"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="iae69ef505e864efdaa37bebaf468436c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfNy0xNi0xLTEtMTc4Njg_cba9386f-c68a-4d46-a839-13262dffe85a"
      unitRef="usd">-21000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ic55e17708b144d149c97d0b172bd426e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOC0yLTEtMS0xNzg2OA_400e7f3f-d618-4f6f-a603-e3383824ec7a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="idf9e8de48606409d948398115c9f7699_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOC00LTEtMS0xNzg2OA_5f357e32-196c-49a3-a8e0-51f52907d50d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOC02LTEtMS0xNzg2OA_1f6ffde2-b590-4c4b-a08a-1f736d059e89"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOC04LTEtMS0xNzg2OA_d53601c1-6662-4a84-a7ba-b11981120afe"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i40386c7e28f341b4ae443602056c8368_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOC0xMC0xLTEtMTc4Njg_c2b76e73-263d-402d-96ef-eac522a2d557"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i229532fb1b884a2b865d6f39735f6e86_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOC0xMi0xLTEtMTc4Njg_af68c7cf-a82c-496d-a241-02a9a5153725"
      unitRef="usd">-7000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ib6b147cc106249baa28781e370ab66ec_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOC0xNC0xLTEtMTc4Njg_d5485541-3b73-45fb-b042-763fdcc4b2f3"
      unitRef="usd">-18000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="iae69ef505e864efdaa37bebaf468436c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOC0xNi0xLTEtMTc4Njg_9126d4eb-8bb5-435b-b84a-4d0d3e3aa134"
      unitRef="usd">-21000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ic55e17708b144d149c97d0b172bd426e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOS0yLTEtMS0xNzg2OA_4167aeed-8c71-4a40-82e8-362572e639d7"
      unitRef="usd">-7000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="idf9e8de48606409d948398115c9f7699_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOS00LTEtMS0xNzg2OA_ec21e0da-f40d-46f3-91e9-6ce1e0cb0c40"
      unitRef="usd">28000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOS02LTEtMS0xNzg2OA_ee283dad-3476-4234-b8d1-d4f22590bf45"
      unitRef="usd">-19000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOS04LTEtMS0xNzg2OA_6fdd7254-c63f-4085-983e-c742e86ce5da"
      unitRef="usd">86000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i40386c7e28f341b4ae443602056c8368_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOS0xMC0xLTEtMTc4Njg_8ffdf535-b0fc-4169-a525-ae311d8d9f6d"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i229532fb1b884a2b865d6f39735f6e86_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOS0xMi0xLTEtMTc4Njg_28113fbf-a985-4ae3-b130-76ad769db34b"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ib6b147cc106249baa28781e370ab66ec_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOS0xNC0xLTEtMTc4Njg_3e8915e5-33c1-4173-962d-d90955992481"
      unitRef="usd">32000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="iae69ef505e864efdaa37bebaf468436c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RhYmxlOjY0YTVjMDYwYmZjMjRmMTc5YmU5NDRlZjc0Y2M4MjJmL3RhYmxlcmFuZ2U6NjRhNWMwNjBiZmMyNGYxNzliZTk0NGVmNzRjYzgyMmZfOS0xNi0xLTEtMTc4Njg_e9847635-8b5f-447d-bf1a-674ee7e80b8e"
      unitRef="usd">47000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RleHRyZWdpb246OTJiNTcyNDg0MzBkNDdiN2E0ZWVhNDIzY2FhYWE5NTJfNjQ1_192fa17f-2dac-4750-a6e0-d2c3f7c340c1"
      unitRef="usd">362000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ifecc5784ac09438d9d59e7670e0d2eb9_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RleHRyZWdpb246OTJiNTcyNDg0MzBkNDdiN2E0ZWVhNDIzY2FhYWE5NTJfNjUy_652e7c62-ede7-45fb-9d4b-44b5ce468ce5"
      unitRef="usd">366000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ib6b147cc106249baa28781e370ab66ec_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RleHRyZWdpb246OTJiNTcyNDg0MzBkNDdiN2E0ZWVhNDIzY2FhYWE5NTJfNzQz_3b8dbc9e-68cd-41ad-a006-f2874065cd84"
      unitRef="usd">28000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="iae69ef505e864efdaa37bebaf468436c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl82Ny9mcmFnOjkyYjU3MjQ4NDMwZDQ3YjdhNGVlYTQyM2NhYWFhOTUyL3RleHRyZWdpb246OTJiNTcyNDg0MzBkNDdiN2E0ZWVhNDIzY2FhYWE5NTJfMTA5OTUxMTYyODkxMA_27705bf1-f7ae-4c25-ba06-cecc6f3e1066"
      unitRef="usd">26000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83MC9mcmFnOjEzMDU0ZmU5OTYwZDQ3YzA5ZjQ0OTEwZTY2NGMwMmFjL3RleHRyZWdpb246MTMwNTRmZTk5NjBkNDdjMDlmNDQ5MTBlNjY0YzAyYWNfODIz_74a64e60-a69b-45da-adc5-41148de8f7ea">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 12 &#x2014; Taxes on Earnings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2022 and 2021, taxes on earnings include approximately $36 million and $97 million, respectively, in excess tax benefits associated with share-based compensation. In the first nine months of 2022, taxes on earnings also include approximately $20 million of tax expense as the result of the resolution of various tax positions related to prior years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax authorities in various jurisdictions regularly review Abbott&#x2019;s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $75 million to $100 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <abt:ExcessTaxBenefitFromShareBasedCompensation
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83MC9mcmFnOjEzMDU0ZmU5OTYwZDQ3YzA5ZjQ0OTEwZTY2NGMwMmFjL3RleHRyZWdpb246MTMwNTRmZTk5NjBkNDdjMDlmNDQ5MTBlNjY0YzAyYWNfMTk3_d242ed21-8120-45ce-9474-69bf072082ae"
      unitRef="usd">36000000</abt:ExcessTaxBenefitFromShareBasedCompensation>
    <abt:ExcessTaxBenefitFromShareBasedCompensation
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83MC9mcmFnOjEzMDU0ZmU5OTYwZDQ3YzA5ZjQ0OTEwZTY2NGMwMmFjL3RleHRyZWdpb246MTMwNTRmZTk5NjBkNDdjMDlmNDQ5MTBlNjY0YzAyYWNfMjA0_0c0b812e-a64a-415f-805b-c90a55ebbdad"
      unitRef="usd">97000000</abt:ExcessTaxBenefitFromShareBasedCompensation>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83MC9mcmFnOjEzMDU0ZmU5OTYwZDQ3YzA5ZjQ0OTEwZTY2NGMwMmFjL3RleHRyZWdpb246MTMwNTRmZTk5NjBkNDdjMDlmNDQ5MTBlNjY0YzAyYWNfMzYy_7dd57035-9b28-4355-bc23-819145a949ab"
      unitRef="usd">20000000</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i08ff00d9980745d3b2b0e1c3d2eefd08_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83MC9mcmFnOjEzMDU0ZmU5OTYwZDQ3YzA5ZjQ0OTEwZTY2NGMwMmFjL3RleHRyZWdpb246MTMwNTRmZTk5NjBkNDdjMDlmNDQ5MTBlNjY0YzAyYWNfNjgz_17fe4e04-d386-4bbc-95b5-21a09c62076a"
      unitRef="usd">75000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i1099be209597485a9a6ade72499f0853_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83MC9mcmFnOjEzMDU0ZmU5OTYwZDQ3YzA5ZjQ0OTEwZTY2NGMwMmFjL3RleHRyZWdpb246MTMwNTRmZTk5NjBkNDdjMDlmNDQ5MTBlNjY0YzAyYWNfNjg5_c5b7ff7c-6399-4a03-a518-41bb5acacdc9"
      unitRef="usd">100000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83My9mcmFnOmQ1NjNmMDFlZmY1YzRlM2I4YjBiZWI2M2QwOWYxYTA2L3RleHRyZWdpb246ZDU2M2YwMWVmZjVjNGUzYjhiMGJlYjYzZDA5ZjFhMDZfMjA4NA_2c8c995f-3493-4eec-aef3-f76aab765fc2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 13 &#x2014; Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Abbott&#x2019;s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott&#x2019;s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians&#x2019; offices and government agencies throughout the world.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Abbott&#x2019;s reportable segments are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Established Pharmaceutical Products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; International sales of a broad line of branded generic pharmaceutical products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nutritional Products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Worldwide sales of a broad line of adult and pediatric nutritional products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Diagnostic Products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physician offices and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medical Devices&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Abbott&#x2019;s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment&#x2019;s assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Sales to External Customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Earnings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months &lt;br/&gt;Ended Sept. 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months&lt;br/&gt;Ended Sept. 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months &lt;br/&gt;Ended Sept. 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months&lt;br/&gt;Ended Sept. 30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Established Pharmaceutical Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nutritional Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostic Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Reportable Segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate functions and benefit plan costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net interest expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation (a) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:93.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:93.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other, net for the three and nine months ended September&#160;30, 2022 includes $10 million and $172 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment and $111 million of charges related to the impairment of IPR&amp;amp;D intangible assets.  Other, net for the three and nine months ended September&#160;30, 2022 and 2021 also includes integration costs associated with the acquisition of Alere and restructuring charges. Restructuring charges in 2021 include Abbott&#x2019;s restructuring plan for its COVID-19 test manufacturing network. Other, net for the nine months ended September&#160;30, 2021 also includes costs related to certain litigation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RleHRyZWdpb246NGExNmViMDI2MmIyNDNmZWFkZDE3NGMyNDZiOTcwZWNfMzE2_c317704a-ed0e-411d-bfac-6cf3da721d9c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Sales to External Customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Earnings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months &lt;br/&gt;Ended Sept. 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months&lt;br/&gt;Ended Sept. 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months &lt;br/&gt;Ended Sept. 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months&lt;br/&gt;Ended Sept. 30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Established Pharmaceutical Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nutritional Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diagnostic Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Reportable Segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate functions and benefit plan costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net interest expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation (a) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings before taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:93.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:93.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other, net for the three and nine months ended September&#160;30, 2022 includes $10 million and $172 million, respectively, of charges related to a voluntary recall within the Nutritional Products segment and $111 million of charges related to the impairment of IPR&amp;amp;D intangible assets.  Other, net for the three and nine months ended September&#160;30, 2022 and 2021 also includes integration costs associated with the acquisition of Alere and restructuring charges. Restructuring charges in 2021 include Abbott&#x2019;s restructuring plan for its COVID-19 test manufacturing network. Other, net for the nine months ended September&#160;30, 2021 also includes costs related to certain litigation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1e67684e5e949128a2dec705cc5342d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMy0yLTEtMS0xNzg2OA_999c96a2-3e3b-4af1-b5fa-63bfa0c8bfc4"
      unitRef="usd">1326000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifffc59617b4841e6842d4164adb3ad90_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMy00LTEtMS0xNzg2OA_75f1c065-982e-4bef-99cd-16ec29feb13b"
      unitRef="usd">1265000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88535b01ff934a65be5cc199bcb770b6_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMy02LTEtMS0xNzg2OA_9c92c2cb-27bb-421e-b2f2-9f74c9670003"
      unitRef="usd">3696000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c90b3c1db944b208e77b4076259563c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMy04LTEtMS0xNzg2OA_7f339e9d-43b2-46fa-9971-6d1666b3979e"
      unitRef="usd">3515000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="id1e67684e5e949128a2dec705cc5342d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMy0xMC0xLTEtMTc4Njg_52ef2795-ab3f-4556-8b39-f21e15b163d2"
      unitRef="usd">331000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifffc59617b4841e6842d4164adb3ad90_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMy0xMi0xLTEtMTc4Njg_5281416f-8c9f-460d-8db5-e2a4dd03a455"
      unitRef="usd">293000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i88535b01ff934a65be5cc199bcb770b6_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMy0xNC0xLTEtMTc4Njg_2d0051b7-cc23-4746-941b-10f34f8cf8cd"
      unitRef="usd">831000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0c90b3c1db944b208e77b4076259563c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMy0xNi0xLTEtMTc4Njg_6c4c3913-ef08-46c9-aced-a1ecb7b71f78"
      unitRef="usd">682000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8fa29318db7448c942a75e199de1be5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNC0yLTEtMS0xNzg2OA_77a5ad93-5fa2-45bb-96f3-473f7d43cf31"
      unitRef="usd">1795000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45f3203f3fae46e1ae8028fc5a27e29c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNC00LTEtMS0xNzg2OA_8538ec58-949f-47e7-8554-046542f53a8b"
      unitRef="usd">2108000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30091a5d3bab43efa63d14e4a226925c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNC02LTEtMS0xNzg2OA_ac37f9d4-3c3b-4b64-b218-28954c86e0b0"
      unitRef="usd">5642000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i151bd5c29f3c46848ec98ccbecda7c02_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNC04LTEtMS0xNzg2OA_4b72d31a-0494-4eb0-913b-587eeafd30c4"
      unitRef="usd">6252000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia8fa29318db7448c942a75e199de1be5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNC0xMC0xLTEtMTc4Njg_004a9898-f158-4238-8f16-38ffcf026bc0"
      unitRef="usd">69000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i45f3203f3fae46e1ae8028fc5a27e29c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNC0xMi0xLTEtMTc4Njg_f978efc5-133e-4e12-ba7d-ef4519a0b9a9"
      unitRef="usd">431000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i30091a5d3bab43efa63d14e4a226925c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNC0xNC0xLTEtMTc4Njg_c1f1fcc6-0d2a-47ec-bea9-8217864a0857"
      unitRef="usd">550000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i151bd5c29f3c46848ec98ccbecda7c02_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNC0xNi0xLTEtMTc4Njg_59e05929-493b-47d0-b33e-92b206f3e022"
      unitRef="usd">1388000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09ee6e9676f048f79f0471399c05b638_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNS0yLTEtMS0xNzg2OA_7e76fdc2-42af-49f4-bbec-59608496899f"
      unitRef="usd">3671000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4186212e28d4b569b09c70bbface083_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNS00LTEtMS0xNzg2OA_3ab29e52-ad87-4bcf-ac2b-e48cdd554d04"
      unitRef="usd">3912000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72d0903dbdb14905994e7b293b54456f_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNS02LTEtMS0xNzg2OA_043219ea-6f87-4b6a-a5a7-bdf4ea0682e2"
      unitRef="usd">13279000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc14a44dcf1344559829bf251b14704d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNS04LTEtMS0xNzg2OA_dd18498d-016f-48fb-843e-2709e7c5938c"
      unitRef="usd">11173000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i09ee6e9676f048f79f0471399c05b638_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNS0xMC0xLTEtMTc4Njg_b831577d-868e-4e58-9aef-84d3b658b6f5"
      unitRef="usd">1352000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie4186212e28d4b569b09c70bbface083_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNS0xMi0xLTEtMTc4Njg_7925ab87-e4f5-48d8-9f99-018964ef2ac0"
      unitRef="usd">1652000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i72d0903dbdb14905994e7b293b54456f_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNS0xNC0xLTEtMTc4Njg_3e5fea1c-3c72-49c3-9139-40adf33a77e8"
      unitRef="usd">5631000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibc14a44dcf1344559829bf251b14704d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNS0xNi0xLTEtMTc4Njg_10a50345-1824-496a-8c2e-5a5f8bf3ffcb"
      unitRef="usd">4429000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91226d7ee83f4e5298c5a54390a1eccc_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNi0yLTEtMS0xNzg2OA_71d587c9-f53e-4112-ab60-d0c011166db8"
      unitRef="usd">3615000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2c236dcb265432793429913b3061d27_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNi00LTEtMS0xNzg2OA_02566a9f-537c-43a5-b502-c4d6b03294b8"
      unitRef="usd">3632000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i165fe1c62d6e440d91dc4abc8a0dee83_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNi02LTEtMS0xNzg2OA_70f54183-57f8-4128-ae29-1e94eb6cfc65"
      unitRef="usd">10937000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81462640315a4b09a820a1f604b6aa3d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNi04LTEtMS0xNzg2OA_cf03a6a5-c3cb-4f96-b8af-6aa818b25eec"
      unitRef="usd">10618000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i91226d7ee83f4e5298c5a54390a1eccc_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNi0xMC0xLTEtMTc4Njg_b24cdc6f-63bc-4925-be45-45f170272686"
      unitRef="usd">1039000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id2c236dcb265432793429913b3061d27_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNi0xMi0xLTEtMTc4Njg_83be29da-99ce-428a-85b4-474babde478f"
      unitRef="usd">1160000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i165fe1c62d6e440d91dc4abc8a0dee83_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNi0xNC0xLTEtMTc4Njg_308e7d52-803f-4179-9af4-542775440e72"
      unitRef="usd">3272000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i81462640315a4b09a820a1f604b6aa3d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNi0xNi0xLTEtMTc4Njg_206666a9-44f8-4695-8245-6b0d912b435c"
      unitRef="usd">3375000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c3c6424ac1343408381b0dd7b44aae4_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNy0yLTEtMS0xNzg2OA_c379dcdf-2258-4995-9626-812a806c5313"
      unitRef="usd">10407000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a9d35abc82344dd90c2c98e1ecdaa09_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNy00LTEtMS0xNzg2OA_0d7f72bb-cb44-4b37-9bf6-5b44893c1a94"
      unitRef="usd">10917000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bf83d91e28e4b25a1e93ffb4e5cc448_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNy02LTEtMS0xNzg2OA_e109b470-01a8-40f6-a8e1-7e10f281d6c1"
      unitRef="usd">33554000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d7ba7ecde044f91a11577ec17c7a3cd_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNy04LTEtMS0xNzg2OA_031ca468-f6c7-4c9e-ab0e-c7da40dc607f"
      unitRef="usd">31558000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7c3c6424ac1343408381b0dd7b44aae4_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNy0xMC0xLTEtMTc4Njg_7938ca18-64c0-40f5-9f17-a42d54d27a3f"
      unitRef="usd">2791000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2a9d35abc82344dd90c2c98e1ecdaa09_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNy0xMi0xLTEtMTc4Njg_cf9312a6-8f48-4b38-b810-2b3072444383"
      unitRef="usd">3536000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8bf83d91e28e4b25a1e93ffb4e5cc448_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNy0xNC0xLTEtMTc4Njg_e6760a8f-8a14-4776-b7a1-86037672583d"
      unitRef="usd">10284000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1d7ba7ecde044f91a11577ec17c7a3cd_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfNy0xNi0xLTEtMTc4Njg_193886b3-04e9-4213-807f-b217a5f1bd71"
      unitRef="usd">9874000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e1452c0c5d145a29227070d32c787ac_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfOC0yLTEtMS0xNzg2OA_56d87460-501f-47c7-94f3-98bf7ed1c715"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ef09987de6c4adeb7fa5bf0cf0c7704_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfOC00LTEtMS0xNzg2OA_dde92c43-064c-440d-a3e6-35378a33d78e"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic07c5110a61643c2a55c992dde280072_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfOC02LTEtMS0xNzg2OA_1cb4dc00-6da8-4fbb-a049-f8a5f49e5229"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b228ed718b140b2a339fb6308161ea7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfOC04LTEtMS0xNzg2OA_3ebf086b-9fac-49a2-84d7-998076e4c1f2"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfOS0yLTEtMS0xNzg2OA_d5951474-7f6d-4a2a-b358-dfea7b3346f7"
      unitRef="usd">10410000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfOS00LTEtMS0xNzg2OA_ee24a45a-12ed-4181-8d28-fbb78504da99"
      unitRef="usd">10928000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfOS02LTEtMS0xNzg2OA_33301128-70aa-41ee-aa96-937338b86b13"
      unitRef="usd">33562000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfOS04LTEtMS0xNzg2OA_3c77164c-dcdd-49f0-8b85-4aa8b30d92df"
      unitRef="usd">31607000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <abt:CorporateAndBenefitPlanCosts
      contextRef="ibc718d211ed24b9d86b6822747cccf0f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTAtMTAtMS0xLTE3ODY4_a877e2ef-dead-491b-beec-ca05bcd6a0a9"
      unitRef="usd">115000000</abt:CorporateAndBenefitPlanCosts>
    <abt:CorporateAndBenefitPlanCosts
      contextRef="ic04e27180eea452fabf297f6b5a3fb8f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTAtMTItMS0xLTE3ODY4_02bfdd2c-c885-4acf-a08f-9fdcba360e71"
      unitRef="usd">204000000</abt:CorporateAndBenefitPlanCosts>
    <abt:CorporateAndBenefitPlanCosts
      contextRef="i4d59739e470d42f5ae66f7d538c62253_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTAtMTQtMS0xLTE3ODY4_95144a41-22d5-4ff9-a4de-e71f2b943085"
      unitRef="usd">352000000</abt:CorporateAndBenefitPlanCosts>
    <abt:CorporateAndBenefitPlanCosts
      contextRef="ib6f6799cbf824e39b44c30362ca2098b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTAtMTYtMS0xLTE3ODY4_25d97049-df70-4788-8ded-3ff306b82ae7"
      unitRef="usd">450000000</abt:CorporateAndBenefitPlanCosts>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="ibc718d211ed24b9d86b6822747cccf0f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTEtMTAtMS0xLTE3ODY4_73efda72-b3d3-41c7-a0aa-2d4233d40fb2"
      unitRef="usd">-86000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="ic04e27180eea452fabf297f6b5a3fb8f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTEtMTItMS0xLTE3ODY4_36016094-0723-44b6-bfd0-f5b0a92e9fee"
      unitRef="usd">-123000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i4d59739e470d42f5ae66f7d538c62253_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTEtMTQtMS0xLTE3ODY4_c345b7b9-a7a7-4faa-8f31-f7411bae993c"
      unitRef="usd">-309000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="ib6f6799cbf824e39b44c30362ca2098b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTEtMTYtMS0xLTE3ODY4_9080d11c-b0b9-4eeb-a91c-6554213859b3"
      unitRef="usd">-370000000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibc718d211ed24b9d86b6822747cccf0f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTItMTAtMS0xLTE3ODY4_21f22d88-cd80-49af-8930-23b96d02e86b"
      unitRef="usd">123000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic04e27180eea452fabf297f6b5a3fb8f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTItMTItMS0xLTE3ODY4_1972467b-9927-4bbb-b8b9-6759a95502fa"
      unitRef="usd">114000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4d59739e470d42f5ae66f7d538c62253_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTItMTQtMS0xLTE3ODY4_6d7c6809-c400-48c8-89d9-1acfb4263aff"
      unitRef="usd">570000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib6f6799cbf824e39b44c30362ca2098b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTItMTYtMS0xLTE3ODY4_4754e483-111b-4f19-878e-ac024c511754"
      unitRef="usd">534000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ibc718d211ed24b9d86b6822747cccf0f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTMtMTAtMS0xLTE3ODY4_055ecd91-691a-45fc-a608-c1622d97a21f"
      unitRef="usd">498000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic04e27180eea452fabf297f6b5a3fb8f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTMtMTItMS0xLTE3ODY4_71020c2c-f996-43a2-868b-ed0d76aa020e"
      unitRef="usd">520000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4d59739e470d42f5ae66f7d538c62253_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTMtMTQtMS0xLTE3ODY4_be29b632-2d69-4185-9256-17f3196ea070"
      unitRef="usd">1517000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib6f6799cbf824e39b44c30362ca2098b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTMtMTYtMS0xLTE3ODY4_0a2f8044-a298-4058-a631-e62dc0cb6cad"
      unitRef="usd">1533000000</us-gaap:AmortizationOfIntangibleAssets>
    <abt:OtherCostAndExpenseOperatingAndNonoperating
      contextRef="ibc718d211ed24b9d86b6822747cccf0f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTQtMTAtMS0xLTE3ODY4_65999f9f-4312-45c0-8fef-9fb4092771fa"
      unitRef="usd">211000000</abt:OtherCostAndExpenseOperatingAndNonoperating>
    <abt:OtherCostAndExpenseOperatingAndNonoperating
      contextRef="ic04e27180eea452fabf297f6b5a3fb8f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTQtMTItMS0xLTE3ODY4_db86feef-d1d9-4bc6-acbe-97a6c272a940"
      unitRef="usd">82000000</abt:OtherCostAndExpenseOperatingAndNonoperating>
    <abt:OtherCostAndExpenseOperatingAndNonoperating
      contextRef="i4d59739e470d42f5ae66f7d538c62253_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTQtMTQtMS0xLTE3ODY4_f38ed3ac-65dd-453d-9f63-b6a96939474c"
      unitRef="usd">550000000</abt:OtherCostAndExpenseOperatingAndNonoperating>
    <abt:OtherCostAndExpenseOperatingAndNonoperating
      contextRef="ib6f6799cbf824e39b44c30362ca2098b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTQtMTYtMS0xLTE3ODY4_240b1afe-06a6-4bb9-86e7-9e9928bf3129"
      unitRef="usd">1103000000</abt:OtherCostAndExpenseOperatingAndNonoperating>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTUtMTAtMS0xLTE3ODY4_c2c21baf-4041-43e3-8016-adb0d1bf5721"
      unitRef="usd">1758000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTUtMTItMS0xLTE3ODY4_e313164a-7008-4fed-95b9-d12c6f6fbbd5"
      unitRef="usd">2493000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTUtMTQtMS0xLTE3ODY4_f8224e30-abfd-4578-b9eb-1550cc3332d8"
      unitRef="usd">6986000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjFlMmFhMmFhMmIxMTQ2NjY5NTNmMmI0YzdiNjk4OGVkL3RhYmxlcmFuZ2U6MWUyYWEyYWEyYjExNDY2Njk1M2YyYjRjN2I2OTg4ZWRfMTUtMTYtMS0xLTE3ODY4_c2e77fb8-78f9-4b86-a678-2570a3862a57"
      unitRef="usd">5884000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent
      contextRef="i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjg2N2JlYmEyMGY3ODQ1ZGZiNTg3NjFjOTI2MzNlMjRhL3RhYmxlcmFuZ2U6ODY3YmViYTIwZjc4NDVkZmI1ODc2MWM5MjYzM2UyNGFfMC0xLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjllZjAxMjQxN2Y5NzQ4OWY5MTRjOWIxYjkzYTRmMTUzXzE4_01288e8b-a187-411c-ac13-2606c6b6efdb"
      unitRef="number">0.45</abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent>
    <abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent
      contextRef="icb97bf5d56f04592aa6d0bed5e0628f6_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjg2N2JlYmEyMGY3ODQ1ZGZiNTg3NjFjOTI2MzNlMjRhL3RhYmxlcmFuZ2U6ODY3YmViYTIwZjc4NDVkZmI1ODc2MWM5MjYzM2UyNGFfMC0xLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjllZjAxMjQxN2Y5NzQ4OWY5MTRjOWIxYjkzYTRmMTUzXzE4_15b1a722-f342-4081-b060-85b68772b223"
      unitRef="number">0.45</abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent>
    <abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent
      contextRef="iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjg2N2JlYmEyMGY3ODQ1ZGZiNTg3NjFjOTI2MzNlMjRhL3RhYmxlcmFuZ2U6ODY3YmViYTIwZjc4NDVkZmI1ODc2MWM5MjYzM2UyNGFfMC0xLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjllZjAxMjQxN2Y5NzQ4OWY5MTRjOWIxYjkzYTRmMTUzXzE4_169d0f28-897a-4e9b-81bc-319b436960ec"
      unitRef="number">0.45</abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent>
    <abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent
      contextRef="i939d41060f2d43fbbb7520d4797a0aec_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjg2N2JlYmEyMGY3ODQ1ZGZiNTg3NjFjOTI2MzNlMjRhL3RhYmxlcmFuZ2U6ODY3YmViYTIwZjc4NDVkZmI1ODc2MWM5MjYzM2UyNGFfMC0xLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjllZjAxMjQxN2Y5NzQ4OWY5MTRjOWIxYjkzYTRmMTUzXzE4_f623c41d-878e-4f51-8779-4d78af4d0b2d"
      unitRef="number">0.45</abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent>
    <us-gaap:InventoryRecallExpense
      contextRef="i54d09e1c87b34a10a7dd79336679c8d9_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjcyNmMzZTg2ZTlkYTQ0ZDViZTIyMGIyYmIxN2QzN2FjL3RhYmxlcmFuZ2U6NzI2YzNlODZlOWRhNDRkNWJlMjIwYjJiYjE3ZDM3YWNfMC0xLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjk1NzIwOTQ1ODliNzRjNDM4NmQ3Yzk3Mzg0Njk5MzlmXzUx_f8e3dd7a-79c3-4d25-83de-446d10a06a47"
      unitRef="usd">10000000</us-gaap:InventoryRecallExpense>
    <us-gaap:InventoryRecallExpense
      contextRef="i8f4b8383f4d6400996c6ee0273a48d8f_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjcyNmMzZTg2ZTlkYTQ0ZDViZTIyMGIyYmIxN2QzN2FjL3RhYmxlcmFuZ2U6NzI2YzNlODZlOWRhNDRkNWJlMjIwYjJiYjE3ZDM3YWNfMC0xLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjk1NzIwOTQ1ODliNzRjNDM4NmQ3Yzk3Mzg0Njk5MzlmXzU4_8bbb58e3-815d-407a-8388-43242adb725c"
      unitRef="usd">172000000</us-gaap:InventoryRecallExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="id2602c6bfcec4afcb539d839ccd375bd_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjcyNmMzZTg2ZTlkYTQ0ZDViZTIyMGIyYmIxN2QzN2FjL3RhYmxlcmFuZ2U6NzI2YzNlODZlOWRhNDRkNWJlMjIwYjJiYjE3ZDM3YWNfMC0xLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjk1NzIwOTQ1ODliNzRjNDM4NmQ3Yzk3Mzg0Njk5MzlmXzU0OTc1NTgxNDU1MQ_2c3e4efa-4636-4468-a218-ad24db7bb081"
      unitRef="usd">111000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ia6ddcd9bbd2f4feaa5056904c8dc104b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIwZmY5ODA4ZmU3NjRmZGVhMTk1ODkzMjQzNzJmOTZiL3NlYzpiMGZmOTgwOGZlNzY0ZmRlYTE5NTg5MzI0MzcyZjk2Yl83Ni9mcmFnOjRhMTZlYjAyNjJiMjQzZmVhZGQxNzRjMjQ2Yjk3MGVjL3RhYmxlOjcyNmMzZTg2ZTlkYTQ0ZDViZTIyMGIyYmIxN2QzN2FjL3RhYmxlcmFuZ2U6NzI2YzNlODZlOWRhNDRkNWJlMjIwYjJiYjE3ZDM3YWNfMC0xLTEtMS0xNzg2OC90ZXh0cmVnaW9uOjk1NzIwOTQ1ODliNzRjNDM4NmQ3Yzk3Mzg0Njk5MzlmXzU0OTc1NTgxNDU1MQ_b4961fb9-2454-4765-adb0-8155f55478bb"
      unitRef="usd">111000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MD(;ZH1MF]"9"90UH/Y72W$^L@^:5%?T"4$L#!!0    ( ,> 856N&R^!RP<
M  DA   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULK5IM;^,V$OXKA+OH
M[0+.6B3UYFQB()NT=P%VVZ"^O7ZF)<8F*HLN2=N;_OH.9<>RS9>DAWQ((ME#
MZIGA<)YGJ%QMI?I#+S@WZ/NR:?7U8&',ZG(TTM6"+YG^*%>\A6\>I5HR [=J
M/M(KQ5G=#5HV(Y(D^6C)1#N87'6?/:C)E5R;1K3\02&]7BZ9>OK,&[F]'N#!
M\P>_B?G"V ]&DZL5F_,I-]]6#PKN1H=9:K'DK1:R18H_7@]N\.5MV@WH+/XG
M^%8?72/KRDS*/^S-?7T]2"PBWO#*V"D8_-GP6]XT=B; \>=^TL'AF7;@\?7S
M[#]WSH,S,Z;YK6Q^%[597 _* :KY(ULWYC>Y_0_?.Y39^2K9Z.XWVNYMDP&J
MUMK(Y7XP(%B*=O>7?=\'XF@ 3@,#R'X >>T NA] .T=WR#JW[IAADRLEMTA9
M:YC-7G2QZ4:#-Z*URS@U"KX5,,Y,;F5;PZ+P&L&5EHVHF8&;SZQA;<71M$NE
M]]]:MJX%?/$!7:!OTSOT_MT'] Z)%GT530/+H:]&!M#8.4?5_LF?=T\F@2=/
M^>HCHLD0D800S_#;^/ [7L%PW W'I\-'$(-#(,@A$*2;CX8"L5:*MP;=:,V-
MOO3YLYL@]4]@]]NE7K&*7P]@0VFN-GPP^?$'G">??-Z]T60GOM*#KS0V^^26
MZ05B;8TJ>\'_7(L-:\!Y[RKNILJ[J6Q1V$S&V3B]&FV.O?$8%>/QP>@$97I
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M@5T7)?()X6&2)/;G,+*U0X&J@0N]<7,Y^)Q;HB:G'O8<3>,<;;,:JO4SR*T
M3]8F[AL9ICO?COQ#]YUGMN'5IFLG*[82ML)"AP.JZC"X2RGH/.TQZ26$:5QF
MPS$>#T$@?>J.2I\_A/9EF/I/3JFK DB:Y4Z\?&9I$8I9KQ9H7"V<Q PM>&,K
M&S**,[U63X>F/^ R2<F0IMDPS^FSPX3@(1[C(71/7G==37&!T\PM?#X[7))
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M$YG'"$=!!S)2(R,O$G&I2Y;&?$+D14Q:8"8DCIN0/5;1>-P!N591_),R:H>
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M57XN*$^,+-P;]Y4T1N;N<,MHRI0U@/MK*<WAQ#Z@^FBS^ ]02P,$%     @
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M@.L?IG[C;1,?@Z"XK>.RXN*A"P;\/5R!PR8$&/\[6'\#4$L#!!0    ( ,>
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M& R;D%CH F_]*4QO+A[ /IB8^% *AHT@-(%0<!\"NM/ W,OC?NH&1]QW,GD
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M)^38L&KK[F IS%3C7C<2)*-I +ZO%/:&H4$+3)?R%_\#4$L#!!0    ( ,>
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M>>-$62.EAJROLN&1X!5$.("560AW5,JMFH=AU3?IGR!R'O*8'(@3C-1E/]B
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M3<;.KLB)-M!$B*%&:SBGC13E(3CL:MB%R9WUX=-U59?V&:D.=,F&9SKX<2\
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MXJ<%-7'4SH#.UTK9P\(Y:'X+T]]02P,$%     @ QX!A50%^1*]/!P  (!<
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MMD/-?]HO86V7]P]O?V@V3VT-+F9?-DVS>3S\^% O[NKM7M#^_=?-ICG^83_
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M 6IG0.<KI>QAX0C:7TOV&U!+ P04    " #'@&%5_,MQH<8$  "9&0  &0
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M@.)!\32_Z%YQI7B<-[=0<Q.A!>#]FG/U\J -5%]CIO\ 4$L#!!0    ( ,>
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M:"&K;U65Q0,!'\J4%@2\_H-R_@:\CHG 62Y_G8$O=S%X_>H->%71?,SR7)8
MOQP+.;_*RCAMYW+3S 7MF8L+/M)2K#A(RCF9:\;'YO%3P_BQC,LV..@Y.#?(
M2'A'UN? ==X"Y""DF4]T_'"H<^?[K"<OMMX+AKNM%+?F<P]7"MZI%%I72MJK
ME*RME+RJE+>@E.L=73R?%?B):(NC,3_1FZ\6S N^QBFY&DE+G+ ',IK]^@OT
MG=]TF;%)%MLD2RR1]7(XV>9P8F*?W9!E5I99N:SR(1,'UH1E5'>KW1B)3LV&
M3;*X(?-KLFH??)BY7NC(.^1A-\R63/;"[&W#[!G#_.G0/:$+N#=PZRQPIWVO
M(@T(!I,^*&Y 7@_D!% )D(8*33NJGN/^UG'?Z+A<> ]7EC^8GNOY@:=X:C1T
M:LD<93*Q9+(7N6 ;N< 8N:A94*M*D0)(RIL21!O&2)E^ W\Q7/+JHA16[>Y[
M/?]7:@,IV(1V*37:.O7FM4D6VR1++)'U$A9N$Q;^W.TPM)E#FV2Q3;+$$EDO
MA]-M#J>VML/I<$WUD>\HBY8&Y2%70<4Z5*@N]8D&-0F]J7Z!ADZG]YWOVYO
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MTGS]TM$W'^-\Q&Q9*9R<+*0IYSR0&6'-]RW-@:#K^@..>RH$+>J?*X+GA%4
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M;]BSNF;+QLD8C+2M%Y=B_EKL;,.(]K#;;$2_,J(/&O%%SGF*$I&T Y;-F^P
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M<\ZF/,T;J,]G0LB7@SQ!]4C>^']02P,$%     @ QX!A53%L8WZ, P  !@T
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M8VU=5)?N:J!X82^Z&Z[TM=F^IOI#!879H->WG*NG@3'0?/HL/@-02P,$%
M  @ QX!A58K.Z$%P P  /PH  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N
M>&ULK9;;;N,V$(9?9:!=% F06 ?+I]06$"=;-$"#&FNDO2CV@I;&,A&*U)*T
M'0-]^)*4K*B-[&)W<V.3%&?F^X>GF>Z%?%8;1 TO!>-JYFVT+F]\7Z4;+(CJ
MB1*Y^;(6LB#:=&7NJU(BR9Q1P?PH"(9^02CWDJD;6\AD*K::48X+"6I;%$0>
MYLC$?N:%WG'@,\TWV@[XR;0D.2Y1/Y4+:7I^XR6C!7)%!0>)ZYEW&][,0V?@
M9OQ!<:]:;;!25D(\V\Y#-O,"2X0,4VU=$/.WPSMDS'HR'%]KIUX3TQJVVT?O
MOSCQ1LR**+P3[$^:Z<W,&WN0X9ILF?XL]K]B+6A@_:6"*?<+^WINX$&Z55H4
MM;$A*"BO_LE+G8B607S*(*H-(L==!7*4]T239"K%'J2=;;S9AI/JK T<Y795
MEEJ:K]38Z>2!I\AM8F"I1?H,"RER20JXAM]+FS8%%_>H"67JTHPM-T3BM<U"
M!@MR,*NCX59*PG.T[:O:"#Z"#\K.54 Y/'&JU949-.U'RIAU._6UH;<,?EJ3
MSBO2Z 3I!!X%UQL%GWB&V;_M?:.ZD1X=I<^CLPZ76/:@'UQ!%$01/"WOX>+C
M91N]^CL3J=\DN>\B]4]%<FF;N[3=B<*<*$5<GEJY@]4!VO.:].Z)S."OWXQ+
M>-!8J"]=J:OBQ]WQ[<F^425)<>:9HZM0[M!+?OH0#H.?SZB+&W7Q.>])M7%$
MO5W,R5>:\(SR_ KXMEBA!+$^IO3OSJ16&JHH Q?%7B:[))H$\3B.)U-_U\$W
M:/@&9_D^O:!,J2(KAD?*;R0;O"7K]\,@'L;=9,.&;/B]F=N[ZP2S:[)#::Y'
M<P/:.]9\ T;7V$5Y/M8 #DBD@AB*ZAA%,63D<&Y[CQH9HV]/\'<(.!\EK@6,
MC@*&_\<_;OC'[[8,6&E%*"5-$2[,E98)QBQ8:?:3VT.79C.]7B-=2BN>46M#
MC8)>%'7OIDDC8_(.R_ ^ B9O! PFO>&)@QH&KX]1<%;";9Y+S(E&\U1H2<W;
MG\*.L"W:@]JQ0):S\R6IP@Q;?),@/$'7>BK#'Z?#UBJ<H@O?T(TGP7_H_-:;
M7J#,7>6B(!5;KJOGO1EMJJ/;JB9XG5Z55H]$YH86&*Z-:= ;F9M,5M5*U=&B
M=!7"2FA3;[CFQE1X*.T$\WTMA#YV;("F9DS^ 5!+ P04    " #'@&%5U)H&
MD#X"  "]!   &0   'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q]5&%/VS 0
M_2NGC$T@C29-&]A8&FE0H56""8'8/DS[X";7UL*Q,_O:PK_?V0E1-Y5^27SV
MO7?OQ7?)M\8^N14BP7.MM)M$*Z+F(HY=N<):N(%I4//)PMA:$(=V&;O&HJ@"
MJ%9QFB1G<2VDCHH\[-W9(C=K4E+CG06WKFMA7RY1F>TD&D:O&_=RN2*_$1=Y
M(Y;X@/38W%F.XIZEDC5J)XT&BXM)]'5X<3GV^2'AA\2MVUF#=S(WYLD'LVH2
M)5X0*BS),PA^;? *E?)$+.-/QQGU)3UP=_W*?AV\LY>Y<'AEU$]9T6H2?8J@
MPH58*[HWVV_8^<D\7VF4"T_8=KE)!.7:D:D[,"NHI6[?XKG[#CN -'T#D':
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MJ04  /(F   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;,6:;6_;-A"
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MJ(]R=WJTN]%B98Y''H36HC"7&= 49.F SQ="Z*>;,D%]AC?_!U!+ P04
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MTVMR?'3R',;% )HH@B:*H,+M[8M":DVNI#!,9" 2!II\'^,9<FL@US_:B-:
M_79 ^RU<Z((F,')0[!K4$ISX_3L_]#YVT.TU='M=Z/&$KEE>Y@36!8H34I)P
MH*(L[ .I2P4$/S?,=,J6+"VQ$)H9: NB=A-6;NSWMXS[D;ML8=9OF/7_DQG6
MGV:9 A1-*Z4:?[!#R??:.0T:3H-.3F/TQ4FA9 *08H%UI51XIM0MO59-=L*_
MLM1A0SX\M#+#-Z [;.@..W-]#XE4*=:=)HFRRIM13D52"Y*W%Z(K]<,7:N@/
MVM5PUC \.YP:R&^\K(15=!NY3D>O3/1Y$\;YH75Q_@9T?>^I3WB=>;_1AN5U
MHY!S@OG5;,:!<%RT]@'O9>7WW /^3J_R#UO[^C9KY=?IZ;79?.I7_L$;EO\6
M'<M_:EE^=\_ZU_J_;$V#O^OO[HPM=@2<4)4QH?&>F:.1=SI$]:AZJJHW1A;5
M)#.3!N>B:KG 2124/8#OYU*:[<8.1\UL&_\!4$L#!!0    ( ,> 854U5OMP
M[P0  #$:   9    >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;+5977.C-A3]
M*QJZTTEF-@$)_%G;,[%AIYEI=CR;V>U#IP\*R#9=0%22XVQ_?<6'L9%D-NG2
MEP3PN4<Z]TJ7 \P.E'WE.T($>$F3C,^MG1#YU+9YN",IYK<T)YG\94-9BH4\
M95N;YXS@J Q*$QLYSM!.<9Q9BUEY;<T6,[H729R1-0-\GZ:8?5N2A![F%K2.
M%S[%VYTH+MB+68ZWY)&(S_F:R3.[88GBE&0\IAE@9#.W[N T0$X14"*^Q.3
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M,2YX;6RU5FUOVC 0_BM65DVMM#8AH< ZB%2@U2J-"15U^S#M@TD.8M6Q,]M
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M*%!VK5G!5ZZ_*EH#F'H75Z=5)=:?!)_+DOG)/SOA>$@WO&BA-'^PV:!49C;
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M8$])DF19& $L["!), 2>1AS!'( '#$D2=PX>G$?QYIR*M[^=C'\#4$L#!!0
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MQ^R3$ML'#ZC#'&B*V2<EML_0>B.8/D-,S#XIL7V&,5?. *^D"-?H&2:@C%A
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M_ZEW+J==RM>>[S4^_S^I+N=[T_7QE^7WR=&K<L$YP&_[QR]02P,$%     @
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M/@%02P$"% ,4    " #'@&%5!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,> 855#@ZC>[@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( ,> 85697)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ QX!A582YB=^G!0  SQD  !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( ,> 855&D\\_: 8  #<;   8              " @>H-  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #'@&%5K^+#ND0%  "S&
M&               @(&(%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ QX!A59# TJX. P  <0D  !@              ("! AH  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( ,> 856N&R^!RP<
M  DA   8              " @48=  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " #'@&%5RK9I8Q\#  ","0  &               @(%'
M)0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ QX!A5;H@
M+^:,!P  $2\  !@              ("!G"@  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( ,> 856G\,M#+04  $P<   8
M  " @5XP  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #'
M@&%5$H W4TH&  # &0  &               @('!-0  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ QX!A5=O8VFNE P  *0@  !D
M         ("!03P  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " #'@&%5T $M5LX)  "@%P  &0              @($=0   >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ,> 857X\,?"R0<  $<3
M   9              " @2)*  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ QX!A56_H<'$1!   WPH  !D              ("!(E(
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #'@&%5+I1A
M&)@$  #("P  &0              @(%J5@  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( ,> 85604%ILE08  .<0   9
M  " @3E;  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
MQX!A54E04[*= P  Q@<  !D              ("!!6(  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " #'@&%52H*>E58"   P!0  &0
M            @('990  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( ,> 854756DY" L  , C   9              " @69H  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ QX!A52(N_] K P
M*@<  !D              ("!I7,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " #'@&%5+_TLKG,$  !2"@  &0              @($'
M=P  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,> 857(
M:LQEHP,  !X(   9              " @;%[  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ QX!A5>NA*M'#"   )A4  !D
M     ("!BW\  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,> 854!;45ZU (  "(&   9              "
M@5R:  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ QX!A
M50%^1*]/!P  (!<  !D              ("!9YT  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " #'@&%5.KY:$9T#   X"   &0
M        @('MI   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( ,> 857F+:H5X@4  .@,   9              " @<&H  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ QX!A532%RQ^:!   /!\
M !D              ("!VJX  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " #'@&%5]E/F/B 6  "[%@$ &0              @(&KLP
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( ,> 856+P""K
MH (  &8&   9              " @0+*  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ QX!A5?S+<:'&!   F1D  !D
M ("!V<P  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #'
M@&%5%XD/$)8"  !;!@  &0              @('6T0  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( ,> 856EXG2CM (  "@*   9
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M970T,"YX;6Q02P$"% ,4    " #'@&%5,6QC?HP#   &#0  &0
M    @('F\   >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M ,> 856*SNA!< ,  #\*   9              " @:GT  !X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ QX!A5=2:!I ^ @  O00  !D
M             ("!4/@  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    " #'@&%5=.[6Q:D%  #R)@  &0              @('%^@  >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( ,> 854LQT_XH@0
M ($:   9              " @:4  0!X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ QX!A57.LX],X!   SQ,  !D              ("!
M?@4! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #'@&%5
MU'(UAP<%  #*'P  &0              @('M"0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( ,> 857'(*IX-@8  -HE   9
M      " @2L/ 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ QX!A54N?[#\% P  YPH  !D              ("!F!4! 'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #'@&%5-5;[<.\$   Q&@
M&0              @('4& $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( ,> 854M1G&4P@(  $X)   9              " @?H= 0!X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ QX!A5;MC_^Y:
M P  ZPP  !D              ("!\R ! 'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6Q02P$"% ,4    " #'@&%55N 0#3T(  #\.@  &0
M@(&$) $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( ,>
M854<Q0^@'@,  $@1   -              "  ?@L 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ QX!A59>*NQS     $P(   L              ( !03 !
M %]R96QS+RYR96QS4$L! A0#%     @ QX!A52\?B0@\!   ?R,   \
M         ( !*C$! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,> 855\
M?ND;U $  ,8?   :              "  9,U 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,> 854J9-*FR@$  )L?   3
M      "  9\W 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     ] #T HA
' )HY 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>473</ContextCount>
  <ElementCount>258</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>79</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Statement of Earnings (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited</Role>
      <ShortName>Condensed Consolidated Statement of Earnings (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statement of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Balance Sheet (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheet (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited</Role>
      <ShortName>Condensed Consolidated Statement of Shareholders' Investment (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statement of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Supplemental Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/SupplementalFinancialInformation</Role>
      <ShortName>Supplemental Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Changes in Accumulated Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Restructuring Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/RestructuringPlans</Role>
      <ShortName>Restructuring Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Incentive Stock Program</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/IncentiveStockProgram</Role>
      <ShortName>Incentive Stock Program</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Debt and Lines of Credit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/DebtandLinesofCredit</Role>
      <ShortName>Debt and Lines of Credit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures</Role>
      <ShortName>Financial Instruments, Derivatives and Fair Value Measures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Litigation and Environmental Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/LitigationandEnvironmentalMatters</Role>
      <ShortName>Litigation and Environmental Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Post-Employment Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/PostEmploymentBenefits</Role>
      <ShortName>Post-Employment Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Taxes on Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/TaxesonEarnings</Role>
      <ShortName>Taxes on Earnings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbott.com/role/Revenue</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Supplemental Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/SupplementalFinancialInformationTables</Role>
      <ShortName>Supplemental Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbott.com/role/SupplementalFinancialInformation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Changes in Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Restructuring Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/RestructuringPlansTables</Role>
      <ShortName>Restructuring Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbott.com/role/RestructuringPlans</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Incentive Stock Program (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/IncentiveStockProgramTables</Role>
      <ShortName>Incentive Stock Program (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbott.com/role/IncentiveStockProgram</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables</Role>
      <ShortName>Financial Instruments, Derivatives and Fair Value Measures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Post-Employment Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/PostEmploymentBenefitsTables</Role>
      <ShortName>Post-Employment Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbott.com/role/PostEmploymentBenefits</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abbott.com/role/SegmentInformation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Revenue - Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/RevenueSegmentsDetails</Role>
      <ShortName>Revenue - Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Revenue - Other Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/RevenueOtherContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Revenue - Other Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Supplemental Financial Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails</Role>
      <ShortName>Supplemental Financial Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails</Role>
      <ShortName>Supplemental Financial Information - Allowance for Doubtful Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Supplemental Financial Information - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails</Role>
      <ShortName>Supplemental Financial Information - Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Changes in Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbott.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Restructuring Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/RestructuringPlansNarrativeDetails</Role>
      <ShortName>Restructuring Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Restructuring Plans - Streamline of Operations and Improve Efficiencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails</Role>
      <ShortName>Restructuring Plans - Streamline of Operations and Improve Efficiencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Incentive Stock Program - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails</Role>
      <ShortName>Incentive Stock Program - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Incentive Stock Program - Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/IncentiveStockProgramOptionsDetails</Role>
      <ShortName>Incentive Stock Program - Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Debt and Lines of Credit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/DebtandLinesofCreditDetails</Role>
      <ShortName>Debt and Lines of Credit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbott.com/role/DebtandLinesofCredit</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails</Role>
      <ShortName>Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails</Role>
      <ShortName>Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails</Role>
      <ShortName>Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails</Role>
      <ShortName>Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails</Role>
      <ShortName>Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Litigation and Environmental Matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails</Role>
      <ShortName>Litigation and Environmental Matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbott.com/role/LitigationandEnvironmentalMatters</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Post-Employment Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/PostEmploymentBenefitsDetails</Role>
      <ShortName>Post-Employment Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbott.com/role/PostEmploymentBenefitsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Post-Employment Benefits - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails</Role>
      <ShortName>Post-Employment Benefits - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Taxes on Earnings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/TaxesonEarningsDetails</Role>
      <ShortName>Taxes on Earnings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbott.com/role/TaxesonEarnings</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="abt-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbott.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abbott.com/role/SegmentInformationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: abt:MinimumLengthOfTimeHedgedInCashFlowHedge -  abt-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="abt-20220930.htm">abt-20220930.htm</File>
    <File>abt-20220930.xsd</File>
    <File>abt-20220930_cal.xml</File>
    <File>abt-20220930_def.xml</File>
    <File>abt-20220930_lab.xml</File>
    <File>abt-20220930_pre.xml</File>
    <File>q3202210qex311.htm</File>
    <File>q3202210qex312.htm</File>
    <File>q3202210qex321.htm</File>
    <File>q3202210qex322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1046">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="32">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>71
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "abt-20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 473,
   "dts": {
    "calculationLink": {
     "local": [
      "abt-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "abt-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "abt-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abt-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abt-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abt-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd"
     ]
    }
   },
   "elementCount": 454,
   "entityCount": 1,
   "hidden": {
    "http://www.abbott.com/20220930": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 6
   },
   "keyCustom": 19,
   "keyStandard": 239,
   "memberCustom": 34,
   "memberStandard": 45,
   "nsprefix": "abt",
   "nsuri": "http://www.abbott.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://www.abbott.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Basis of Presentation",
     "role": "http://www.abbott.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Revenue",
     "role": "http://www.abbott.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Supplemental Financial Information",
     "role": "http://www.abbott.com/role/SupplementalFinancialInformation",
     "shortName": "Supplemental Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss)",
     "role": "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLoss",
     "shortName": "Changes in Accumulated Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.abbott.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Restructuring Plans",
     "role": "http://www.abbott.com/role/RestructuringPlans",
     "shortName": "Restructuring Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Incentive Stock Program",
     "role": "http://www.abbott.com/role/IncentiveStockProgram",
     "shortName": "Incentive Stock Program",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Debt and Lines of Credit",
     "role": "http://www.abbott.com/role/DebtandLinesofCredit",
     "shortName": "Debt and Lines of Credit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures",
     "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures",
     "shortName": "Financial Instruments, Derivatives and Fair Value Measures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Litigation and Environmental Matters",
     "role": "http://www.abbott.com/role/LitigationandEnvironmentalMatters",
     "shortName": "Litigation and Environmental Matters",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Statement of Earnings (Unaudited)",
     "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited",
     "shortName": "Condensed Consolidated Statement of Earnings (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Post-Employment Benefits",
     "role": "http://www.abbott.com/role/PostEmploymentBenefits",
     "shortName": "Post-Employment Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Taxes on Earnings",
     "role": "http://www.abbott.com/role/TaxesonEarnings",
     "shortName": "Taxes on Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Segment Information",
     "role": "http://www.abbott.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Revenue (Tables)",
     "role": "http://www.abbott.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Supplemental Financial Information (Tables)",
     "role": "http://www.abbott.com/role/SupplementalFinancialInformationTables",
     "shortName": "Supplemental Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ComprehensiveIncomeNoteTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Changes in Accumulated Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ComprehensiveIncomeNoteTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Restructuring Plans (Tables)",
     "role": "http://www.abbott.com/role/RestructuringPlansTables",
     "shortName": "Restructuring Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Incentive Stock Program (Tables)",
     "role": "http://www.abbott.com/role/IncentiveStockProgramTables",
     "shortName": "Incentive Stock Program (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables)",
     "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables",
     "shortName": "Financial Instruments, Derivatives and Fair Value Measures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Post-Employment Benefits (Tables)",
     "role": "http://www.abbott.com/role/PostEmploymentBenefitsTables",
     "shortName": "Post-Employment Benefits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited)",
     "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited",
     "shortName": "Condensed Consolidated Statement of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Segment Information (Tables)",
     "role": "http://www.abbott.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "us-gaap:NumberOfReportableSegments",
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Revenue - Narrative (Details)",
     "role": "http://www.abbott.com/role/RevenueNarrativeDetails",
     "shortName": "Revenue - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "us-gaap:NumberOfReportableSegments",
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Revenue - Segments (Details)",
     "role": "http://www.abbott.com/role/RevenueSegmentsDetails",
     "shortName": "Revenue - Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "ibf27976a942a4fc19586a8236e981bc0_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i161741e7e8f046ff9a2cc29b1a64a357_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Revenue - Other Contract Assets and Liabilities (Details)",
     "role": "http://www.abbott.com/role/RevenueOtherContractAssetsandLiabilitiesDetails",
     "shortName": "Revenue - Other Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i161741e7e8f046ff9a2cc29b1a64a357_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Supplemental Financial Information - Narrative (Details)",
     "role": "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails",
     "shortName": "Supplemental Financial Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i161741e7e8f046ff9a2cc29b1a64a357_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details)",
     "role": "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails",
     "shortName": "Supplemental Financial Information - Allowance for Doubtful Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i161741e7e8f046ff9a2cc29b1a64a357_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "abt:ScheduleOfLongTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Supplemental Financial Information - Investments (Details)",
     "role": "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails",
     "shortName": "Supplemental Financial Information - Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "abt:ScheduleOfLongTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "ie7c97d1edcfa444cb20aa7be67ab0d50_I20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i161741e7e8f046ff9a2cc29b1a64a357_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Changes in Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:ComprehensiveIncomeNoteTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i495e1acb6ab646e1be98f86d888adf7c_I20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Goodwill and Intangible Assets (Details)",
     "role": "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "ib718c9002df547a9bb6009289d5ab871_D20210401-20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Restructuring Plans - Narrative (Details)",
     "role": "http://www.abbott.com/role/RestructuringPlansNarrativeDetails",
     "shortName": "Restructuring Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i53e8568bc39d4cb19a2c23541737716d_D20210701-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "abt:InventoryNoNetRealizableValueSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical)",
     "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical",
     "shortName": "Condensed Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "ib718c9002df547a9bb6009289d5ab871_D20210401-20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Restructuring Plans - Streamline of Operations and Improve Efficiencies (Details)",
     "role": "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails",
     "shortName": "Restructuring Plans - Streamline of Operations and Improve Efficiencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "icd32e0ec232449a093586b6ac423eb4f_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRestructuring",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Incentive Stock Program - Narrative (Details)",
     "role": "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails",
     "shortName": "Incentive Stock Program - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i33f19560992c435a88092f47daf02b5b_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Incentive Stock Program - Options (Details)",
     "role": "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails",
     "shortName": "Incentive Stock Program - Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i33f19560992c435a88092f47daf02b5b_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "ib0b29ca98ef14de0a3be8cd36653449b_D20220315-20220315",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Debt and Lines of Credit (Details)",
     "role": "http://www.abbott.com/role/DebtandLinesofCreditDetails",
     "shortName": "Debt and Lines of Credit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "ib0b29ca98ef14de0a3be8cd36653449b_D20220315-20220315",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i362cc950c402435b85ccd22cc23f812e_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details)",
     "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails",
     "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i362cc950c402435b85ccd22cc23f812e_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details)",
     "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails",
     "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i5397677ab93a49019eae8c9a0bb21d79_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details)",
     "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails",
     "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i5397677ab93a49019eae8c9a0bb21d79_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "abt:ScheduleOfLongTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details)",
     "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails",
     "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i132737fb549d49b2af4b792fb9883efb_I20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "ie6d54ddc609d499383aafcf6ba76dd93_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details)",
     "role": "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails",
     "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "ie6d54ddc609d499383aafcf6ba76dd93_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "abt:LossContingencyRangeOfPossibleLossMaximumIndividualSite",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Litigation and Environmental Matters (Details)",
     "role": "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails",
     "shortName": "Litigation and Environmental Matters (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "abt:LossContingencyRangeOfPossibleLossMaximumIndividualSite",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Balance Sheet (Unaudited)",
     "role": "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited",
     "shortName": "Condensed Consolidated Balance Sheet (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "ic55e17708b144d149c97d0b172bd426e_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Post-Employment Benefits (Details)",
     "role": "http://www.abbott.com/role/PostEmploymentBenefitsDetails",
     "shortName": "Post-Employment Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "ic55e17708b144d149c97d0b172bd426e_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "ifec682ce169c4d6ea37dc9e5838ba9d2_D20220101-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Post-Employment Benefits - Narrative (Details)",
     "role": "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails",
     "shortName": "Post-Employment Benefits - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "ib6b147cc106249baa28781e370ab66ec_D20220101-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "abt:ExcessTaxBenefitFromShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Taxes on Earnings (Details)",
     "role": "http://www.abbott.com/role/TaxesonEarningsDetails",
     "shortName": "Taxes on Earnings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "abt:ExcessTaxBenefitFromShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Segment Information (Details)",
     "role": "http://www.abbott.com/role/SegmentInformationDetails",
     "shortName": "Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent",
       "abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iaa80179ef7464cbc8f6a2239534d28e2_D20220701-20220930",
      "decimals": "2",
      "lang": "en-US",
      "name": "abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical)",
     "role": "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheet (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "iec9d7c7b895f4b01a5849a89d5bca911_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i161741e7e8f046ff9a2cc29b1a64a357_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited)",
     "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited",
     "shortName": "Condensed Consolidated Statement of Shareholders' Investment (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "ife5c2b9c51b24905939dfe6b3d3e4056_I20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i161741e7e8f046ff9a2cc29b1a64a357_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockCommonShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical)",
     "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical",
     "shortName": "Condensed Consolidated Statement of Shareholders' Investment (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "ife5c2b9c51b24905939dfe6b3d3e4056_I20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)",
     "role": "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statement of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abt-20220930.htm",
      "contextRef": "i11883cdfd9db483ab65f38ddd5c10bcf_D20220101-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 79,
   "tag": {
    "abt_A255LongTermNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.55% Long-term Notes Due 2022",
        "label": "2.55% Long-term Notes Due 2022 [Member]",
        "terseLabel": "2.55% Long-term Notes Due 2022"
       }
      }
     },
     "localname": "A255LongTermNotesDue2022Member",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/DebtandLinesofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_AdultNutritionalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the adult nutritionals, segment of the entity.",
        "label": "Adult Nutritionals [Member]",
        "terseLabel": "Adult Nutritionals"
       }
      }
     },
     "localname": "AdultNutritionalsMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the annual cost of share-based awards which will typically be recognized in the first quarter.",
        "label": "Annual Share Based Awards Recognized in First Quarter Percent",
        "terseLabel": "Annual share-based awards recognized in first quarter (as a percent)"
       }
      }
     },
     "localname": "AnnualShareBasedAwardsRecognizedInFirstQuarterPercent",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abt_COVID19TestManufacturingNetworkRestructuringPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring plan related to its Diagnostic Products segment to align its manufacturing network for COVID-19 diagnostic tests with recent changes in projected testing demand driven by several factors, including significant reductions in cases in the U.S. and other major developed countries, the accelerated rollout of COVID-19 vaccines globally and recent U.S. health authority guidance on testing for fully vaccinated individuals.",
        "label": "COVID-19 Test Manufacturing Network Restructuring Plan [Member]",
        "terseLabel": "COVID-19 Test Manufacturing Network Restructuring Plan"
       }
      }
     },
     "localname": "COVID19TestManufacturingNetworkRestructuringPlanMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails",
      "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_ContractLiabilitiesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Liabilities",
        "label": "Contract Liabilities [Roll Forward]",
        "terseLabel": "Contract Liabilities:"
       }
      }
     },
     "localname": "ContractLiabilitiesRollForward",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueOtherContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized arising from contract liability from change in cash received to be satisfied.",
        "label": "Contract With Customer Liability, Change In Unearned Revenue From Cash Received Recognized",
        "terseLabel": "Unearned revenue from cash received during the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueOtherContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abt_CoreLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the core laboratory, segment of the entity.",
        "label": "Core Laboratory [Member]",
        "terseLabel": "Core Laboratory"
       }
      }
     },
     "localname": "CoreLaboratoryMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_CorporateAndBenefitPlanCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbott.com/role/SegmentInformationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reconciling item from aggregate segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to corporate functions and benefit plan costs.",
        "label": "Corporate and Benefit Plan Costs",
        "negatedLabel": "Corporate functions and benefit plan costs"
       }
      }
     },
     "localname": "CorporateAndBenefitPlanCosts",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abt_CostOfGoodsAndServicesSoldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of Goods and Services Sold",
        "label": "Cost of Goods and Services Sold [Member]",
        "terseLabel": "Cost of Products Sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_DeferredIncomeTaxesAndOtherAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Deferred Income Taxes and Other Assets line item in the statement of financial position in which the amounts are included.",
        "label": "Deferred income taxes and other assets [Member]",
        "terseLabel": "Deferred income taxes and other assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherAssetsMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_DefinedBenefitPlanNetAmortizationCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Defined Benefit Plan Net Amortization Costs [Abstract]",
        "terseLabel": "Net amortization of:"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetAmortizationCostsAbstract",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abt_DiabetesCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the Diabetes Care, segment of the entity.",
        "label": "Diabetes Care [Member]",
        "terseLabel": "Diabetes Care"
       }
      }
     },
     "localname": "DiabetesCareMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_DiagnosticProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The diagnostics products segment of the entity.",
        "label": "Diagnostic Products [Member]",
        "terseLabel": "Diagnostic Products"
       }
      }
     },
     "localname": "DiagnosticProductsMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails",
      "http://www.abbott.com/role/RevenueNarrativeDetails",
      "http://www.abbott.com/role/RevenueSegmentsDetails",
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_EffectOfCommonAndTreasuryShareTransactions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the effect on retained earning due to common and treasury stock transactions.",
        "label": "Effect of Common and Treasury Share Transactions",
        "negatedLabel": "Effect of common and treasury share transactions"
       }
      }
     },
     "localname": "EffectOfCommonAndTreasuryShareTransactions",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abt_ElectrophysiologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the electrophysiology, segment of the entity.",
        "label": "Electrophysiology [Member]",
        "terseLabel": "Electrophysiology"
       }
      }
     },
     "localname": "ElectrophysiologyMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_EstablishedPharmaceuticalProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Established Pharmaceutical Products, segment of the entity.",
        "label": "Established Pharmaceutical Products [Member]",
        "terseLabel": "Established Pharmaceutical Products"
       }
      }
     },
     "localname": "EstablishedPharmaceuticalProductsMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails",
      "http://www.abbott.com/role/RevenueSegmentsDetails",
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_ExcessTaxBenefitFromShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefits related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.",
        "label": "Excess Tax Benefit from Share-based Compensation",
        "terseLabel": "Excess tax benefits associated with share-based compensation"
       }
      }
     },
     "localname": "ExcessTaxBenefitFromShareBasedCompensation",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/TaxesonEarningsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abt_FixedAssetWriteDownsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to fixed asset write-downs cost .",
        "label": "Fixed asset write-downs [Member]",
        "terseLabel": "Fixed Asset Write-Downs"
       }
      }
     },
     "localname": "FixedAssetWriteDownsMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails",
      "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_GoodwillAndIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and Intangible Assets",
        "label": "Goodwill and Intangible Assets [Line Items]",
        "terseLabel": "Goodwill and Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsLineItems",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abt_HeartFailureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the Heart Failure, segment of the entity.",
        "label": "Heart Failure [Member]",
        "terseLabel": "Heart Failure"
       }
      }
     },
     "localname": "HeartFailureMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_InventoryNoNetRealizableValueSold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory sold that was previously estimated to have no net realizable value.",
        "label": "Inventory No Net Realizable Value Sold",
        "terseLabel": "Inventory sold that was previously estimated to have no net realizable value"
       }
      }
     },
     "localname": "InventoryNoNetRealizableValueSold",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abt_InventoryRelatedChargesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to fixed asset inventory related charges .",
        "label": "Inventory-related charges [Member]",
        "terseLabel": "Inventory- Related Charges"
       }
      }
     },
     "localname": "InventoryRelatedChargesMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails",
      "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_KeyEmergingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the key emerging markets, segment of the entity.",
        "label": "Key Emerging Markets [Member]",
        "terseLabel": "Key Emerging Markets"
       }
      }
     },
     "localname": "KeyEmergingMarketsMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_LegalProceedingsAndEnvironmentalExposuresMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss contingencies related to legal proceedings and environmental exposures.",
        "label": "Legal proceedings and environmental exposures [Member]",
        "terseLabel": "Legal proceedings and environmental exposures"
       }
      }
     },
     "localname": "LegalProceedingsAndEnvironmentalExposuresMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated maximum loss, for all sites, from the contingency related to the environmental clean up in the United States and Puerto Rico.",
        "label": "Loss Contingency Range of Possible Loss, Maximum Aggregate Sites",
        "terseLabel": "Maximum expected cleanup exposure in aggregate"
       }
      }
     },
     "localname": "LossContingencyRangeOfPossibleLossMaximumAggregateSites",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated maximum loss, per individual site, from the contingency related to the environmental clean up in the United States and Puerto Rico.",
        "label": "Loss Contingency Range of Possible Loss, Maximum Individual Site",
        "terseLabel": "Maximum expected cleanup exposure for individual site"
       }
      }
     },
     "localname": "LossContingencyRangeOfPossibleLossMaximumIndividualSite",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abt_MedicalDevicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The medical devices segment of the entity.",
        "label": "Medical Devices [Member]",
        "terseLabel": "Medical Devices"
       }
      }
     },
     "localname": "MedicalDevicesMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails",
      "http://www.abbott.com/role/RevenueNarrativeDetails",
      "http://www.abbott.com/role/RevenueSegmentsDetails",
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_MinimumLengthOfTimeHedgedInCashFlowHedge": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Minimum Length Of Time Hedged In Cash Flow Hedge",
        "terseLabel": "Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold"
       }
      }
     },
     "localname": "MinimumLengthOfTimeHedgedInCashFlowHedge",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "abt_MolecularMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the molecular, segment of the entity.",
        "label": "Molecular [Member]",
        "terseLabel": "Molecular"
       }
      }
     },
     "localname": "MolecularMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_NeuromodulationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the neuromodulation, segment of the entity.",
        "label": "Neuromodulation [Member]",
        "terseLabel": "Neuromodulation"
       }
      }
     },
     "localname": "NeuromodulationMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represent Noncontrolling Interests' share of income, net of distributions, share repurchases and business combinations.",
        "label": "Noncontrolling Interests Share of Income Net of Distributions and Share Repurchases and Business Combinations",
        "terseLabel": "Noncontrolling Interests\u2019 share of income, business combinations, net of distributions and share repurchases"
       }
      }
     },
     "localname": "NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abt_NutritionalProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The nutritional products segment of the entity.",
        "label": "Nutritional Products [Member]",
        "terseLabel": "Nutritional Products"
       }
      }
     },
     "localname": "NutritionalProductsMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails",
      "http://www.abbott.com/role/RevenueSegmentsDetails",
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_OtherCostAndExpenseOperatingAndNonoperating": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbott.com/role/SegmentInformationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reconciling item from segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to net other income or expenses.",
        "label": "Other Cost and Expense, Operating and Nonoperating",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperatingAndNonoperating",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abt_OtherEmergingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Emerging Markets",
        "label": "Other Emerging Markets [Member]",
        "terseLabel": "Other Emerging Markets"
       }
      }
     },
     "localname": "OtherEmergingMarketsMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_OtherExitCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to fixed asset other exit cost .",
        "label": "Other exit costs [Member]",
        "terseLabel": "Other Exit Costs"
       }
      }
     },
     "localname": "OtherExitCostsMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails",
      "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase, and research and development assets.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired, And Research and Development in Process",
        "negatedLabel": "Acquisitions of businesses and technologies, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abt_PediatricNutritionalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the pediatric nutritionals, segment of the entity.",
        "label": "Pediatric Nutritionals [Member]",
        "terseLabel": "Pediatric Nutritionals"
       }
      }
     },
     "localname": "PediatricNutritionalsMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_PointOfCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the point of care, segment of the entity.",
        "label": "Point of Care [Member]",
        "terseLabel": "Point of Care"
       }
      }
     },
     "localname": "PointOfCareMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Post-employment obligations and amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer.",
        "label": "Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities",
        "verboseLabel": "Post-employment obligations, deferred income taxes and other long-term liabilities"
       }
      }
     },
     "localname": "PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abt_PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Postemployment Obligations Deferred Income Taxes And Other Long Term Liabilities",
        "label": "Postemployment Obligations Deferred Income Taxes And Other Long Term Liabilities [Member]",
        "terseLabel": "Post-employment obligations, deferred income taxes and other long-term liabilities"
       }
      }
     },
     "localname": "PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_PrepaidExpenseAndOtherReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other receivables that are expected to be realized within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Receivables",
        "verboseLabel": "Prepaid expenses and other receivables"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherReceivables",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abt_PrepaidExpensesAndOtherReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other receivables.",
        "label": "Prepaid expenses and other receivables [Member]",
        "terseLabel": "Prepaid expenses and other receivables"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherReceivablesMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_RapidDiagnosticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the rapid diagnostics, segment of the entity.",
        "label": "Rapid Diagnostics [Member]",
        "terseLabel": "Rapid Diagnostics"
       }
      }
     },
     "localname": "RapidDiagnosticsMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_RestrictedStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock awards.",
        "label": "Restricted stock awards [Member]",
        "terseLabel": "Restricted Stock Awards"
       }
      }
     },
     "localname": "RestrictedStockAwardsMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The restructuring plans to streamline operations in order to reduce costs and improve efficiencies in various Abbott businesses including the nutritional, established pharmaceuticals and vascular businesses.",
        "label": "Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies [Member]",
        "terseLabel": "Restructuring Plan 2021, Streamline of Operations and Improve Efficiencies"
       }
      }
     },
     "localname": "RestructuringPlan2021StreamlineOfOperationsAndImproveEfficienciesMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails",
      "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_RestructuringReservePeriodCashSettledAndOtherAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period.",
        "label": "Restructuring Reserve Period Cash Settled and Other Adjustments",
        "negatedLabel": "Payments and other adjustments"
       }
      }
     },
     "localname": "RestructuringReservePeriodCashSettledAndOtherAdjustments",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abt_RevenueRemainingPerformanceObligationExpectedTimingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of revenue recognized for remaining performance obligations.",
        "label": "Revenue Remaining Performance Obligation Expected Timing Percentage",
        "terseLabel": "Percentage of remaining performance obligation expected to be recognized in period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingPercentage",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abt_RhythmManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the rhythm management, segment of the entity.",
        "label": "Rhythm Management [Member]",
        "terseLabel": "Rhythm Management"
       }
      }
     },
     "localname": "RhythmManagementMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_ScheduleOfGoodwillAndIntangibleAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Goodwill and Intangible Assets",
        "label": "Schedule of Goodwill and Intangible Assets [Table]",
        "terseLabel": "Schedule of Goodwill and Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillAndIntangibleAssetsTable",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abt_ScheduleOfLongTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the investments which are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Schedule of Long Term Investments [Table Text Block]",
        "terseLabel": "Schedule of long-term investments"
       }
      }
     },
     "localname": "ScheduleOfLongTermInvestmentsTableTextBlock",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abt_StJudeMedicalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to acquisition of St. Jude Medical, Inc.",
        "label": "St. Jude Medical, Inc. [Member]",
        "terseLabel": "St. Jude Medical"
       }
      }
     },
     "localname": "StJudeMedicalIncMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_StockIssuedDuringPeriodSharesIncentiveStockPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Incentive Stock Programs",
        "label": "Stock Issued During Period, Shares, Incentive Stock Programs",
        "terseLabel": "Issued under incentive stock programs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIncentiveStockPrograms",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "abt_StockIssuedDuringPeriodValueIncentiveStockPrograms": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Incentive Stock Programs",
        "label": "Stock Issued During Period, Value, Incentive Stock Programs",
        "terseLabel": "Issued under incentive stock programs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIncentiveStockPrograms",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abt_StructuralHeartMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the structural heart, segment of the entity.",
        "label": "Structural Heart [Member]",
        "terseLabel": "Structural Heart"
       }
      }
     },
     "localname": "StructuralHeartMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_VascularMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the vascular products, segment of the entity.",
        "label": "Vascular [Member]",
        "terseLabel": "Vascular"
       }
      }
     },
     "localname": "VascularMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_WalkVascularLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents information pertaining to its Walk vascular llc.",
        "label": "Walk Vascular, LLC [Member]",
        "terseLabel": "Walk Vascular"
       }
      }
     },
     "localname": "WalkVascularLLCMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abt_YenDenominatedLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to yen denominated Long-term debt.",
        "label": "Yen-denominated long-term debt [Member]",
        "terseLabel": "Yen-denominated long-term debt"
       }
      }
     },
     "localname": "YenDenominatedLongTermDebtMember",
     "nsuri": "http://www.abbott.com/20220930",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document and Entity Information"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsExchangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Listings, Exchange [Axis]",
        "terseLabel": "Entity Listings, Exchange [Axis]"
       }
      }
     },
     "localname": "EntityListingsExchangeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_ExchangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
        "label": "Exchange [Domain]",
        "terseLabel": "Exchange [Domain]"
       }
      }
     },
     "localname": "ExchangeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exch_XCHI": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NYSE CHICAGO, INC. [Member]",
        "terseLabel": "CHICAGO STOCK EXCHANGE, INC"
       }
      }
     },
     "localname": "XCHI",
     "nsuri": "http://xbrl.sec.gov/exch/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "exch_XNYS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK STOCK EXCHANGE, INC. [Member]",
        "terseLabel": "NEW YORK STOCK EXCHANGE, INC."
       }
      }
     },
     "localname": "XNYS",
     "nsuri": "http://xbrl.sec.gov/exch/2022",
     "presentation": [
      "http://www.abbott.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CondensedCashFlowStatementTable": {
     "auth_ref": [
      "r105",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Cash Flow Statement [Table]",
        "terseLabel": "Condensed Cash Flow Statement [Table]"
       }
      }
     },
     "localname": "CondensedCashFlowStatementTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CondensedCashFlowStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Cash Flow Statements, Captions [Line Items]",
        "terseLabel": "Condensed Cash Flow Statements, Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedCashFlowStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r105",
      "r140",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r160",
      "r164",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r257",
      "r259",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails",
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r105",
      "r140",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r160",
      "r164",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r257",
      "r259",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails",
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r241",
      "r243",
      "r244",
      "r245",
      "r267",
      "r299",
      "r402",
      "r407",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r574",
      "r618",
      "r620",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails",
      "http://www.abbott.com/role/TaxesonEarningsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r241",
      "r243",
      "r244",
      "r245",
      "r267",
      "r299",
      "r402",
      "r407",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r574",
      "r618",
      "r620",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails",
      "http://www.abbott.com/role/TaxesonEarningsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r217",
      "r241",
      "r243",
      "r244",
      "r245",
      "r267",
      "r299",
      "r354",
      "r402",
      "r407",
      "r438",
      "r439",
      "r440",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r574",
      "r618",
      "r620",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails",
      "http://www.abbott.com/role/TaxesonEarningsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r217",
      "r241",
      "r243",
      "r244",
      "r245",
      "r267",
      "r299",
      "r354",
      "r402",
      "r407",
      "r438",
      "r439",
      "r440",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r574",
      "r618",
      "r620",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails",
      "http://www.abbott.com/role/TaxesonEarningsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r168",
      "r169",
      "r321",
      "r325",
      "r619",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r168",
      "r169",
      "r321",
      "r325",
      "r619",
      "r643",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "Changes in accumulated other comprehensive income (loss), net of income taxes"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r10",
      "r37"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Summary of activity of allowance for doubtful accounts"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r173",
      "r174"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Trade receivables, less allowances of $520 in 2022 and $519 in 2021"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r21",
      "r582",
      "r603"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r53",
      "r59",
      "r66",
      "r67",
      "r68",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Net Actuarial (Losses) and Prior Service (Costs) and Credits"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r15",
      "r213"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r59",
      "r66",
      "r67",
      "r68",
      "r69",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": {
     "auth_ref": [
      "r54",
      "r59",
      "r374"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax",
        "negatedLabel": "Net actuarial (losses) and prior service (costs) and credits"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r50",
      "r56",
      "r58",
      "r59",
      "r537"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "terseLabel": "Cumulative foreign currency translation (loss) adjustments"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r56",
      "r58",
      "r59",
      "r605",
      "r625",
      "r626"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      },
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "totalLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r66",
      "r67",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r55",
      "r59",
      "r66",
      "r67",
      "r68",
      "r106",
      "r107",
      "r108",
      "r486",
      "r560",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r51",
      "r59",
      "r66",
      "r67",
      "r68",
      "r486",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Cumulative Foreign Currency Translation (Loss) Adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Supplemental Financial Information"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net earnings to net cash from operating activities \u2014"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://www.abbott.com/role/SegmentInformationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "negatedLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r30",
      "r175",
      "r182",
      "r183",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r30",
      "r175",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Trade receivables, allowances"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "negatedLabel": "Amounts charged off and other deductions"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r96",
      "r203",
      "r206"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.abbott.com/role/SegmentInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "negatedLabel": "Amortization of intangible assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited",
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Outstanding Common Stock Options Having No Dilutive Effect (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax",
        "verboseLabel": "Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other"
       }
      }
     },
     "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r18",
      "r102",
      "r148",
      "r155",
      "r162",
      "r180",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r260",
      "r262",
      "r263",
      "r483",
      "r487",
      "r541",
      "r561",
      "r563",
      "r580",
      "r602"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r36",
      "r102",
      "r180",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r260",
      "r262",
      "r263",
      "r483",
      "r487",
      "r541",
      "r561",
      "r563"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r527"
     ],
     "calculation": {
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails",
      "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r500",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r398",
      "r403",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r398",
      "r403",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Business acquisition, percentage acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r475",
      "r476",
      "r477"
     ],
     "calculation": {
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "verboseLabel": "Contingent consideration related to business combinations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r5",
      "r11",
      "r98"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r92",
      "r98",
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and Cash Equivalents, End of Period",
        "periodStartLabel": "Cash and Cash Equivalents, Beginning of Year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r92",
      "r546"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net Increase (Decrease) in Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r43",
      "r588",
      "r610"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r246",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Litigation and Environmental Matters"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/LitigationandEnvironmentalMatters"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared on common shares (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r106",
      "r107",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common shares, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesHeldInEmployeeTrust": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.",
        "label": "Common Stock, Shares Held in Employee Trust",
        "terseLabel": "Securities in mutual funds held in a rabbi trust"
       }
      }
     },
     "localname": "CommonStockSharesHeldInEmployeeTrust",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r24",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r24",
      "r563"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common shares, without par value Authorized \u2014 2,400,000,000 shares Issued at stated capital amount \u2014 Shares: 2022: 1,985,919,440; 2021: 1,985,273,421"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r62",
      "r64",
      "r65",
      "r74",
      "r592",
      "r613"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r73",
      "r83",
      "r591",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Changes in Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of changes in contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r308",
      "r309",
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueOtherContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Revenue recognized related to contract liability balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueOtherContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r164",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails",
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r78",
      "r576"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold, excluding amortization of intangible assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "verboseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating cost and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r281",
      "r288",
      "r289",
      "r291",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt and Lines of Credit"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/DebtandLinesofCredit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r21",
      "r22",
      "r101",
      "r105",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r293",
      "r294",
      "r295",
      "r296",
      "r558",
      "r581",
      "r583",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/DebtandLinesofCreditDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/DebtandLinesofCreditDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/DebtandLinesofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r42",
      "r101",
      "r105",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r293",
      "r294",
      "r295",
      "r296",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/DebtandLinesofCreditDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r42",
      "r101",
      "r105",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r301",
      "r302",
      "r303",
      "r304",
      "r555",
      "r556",
      "r558",
      "r559",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/DebtandLinesofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation to pay money on demand or on fixed or determinable dates.",
        "label": "Debt [Member]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Decrease reasonably possible in gross unrecognized tax benefits"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/TaxesonEarningsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Deferred Income Taxes and Other Assets, Noncurrent",
        "terseLabel": "Deferred income taxes and other assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r332",
      "r369",
      "r388",
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedTerseLabel": "Actuarial loss, net"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r332",
      "r370",
      "r389",
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "verboseLabel": "Prior service cost (credit)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r347",
      "r355",
      "r356",
      "r392",
      "r394",
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Company contributions",
        "verboseLabel": "Pension contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails",
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails",
      "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r332",
      "r368",
      "r387",
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r332",
      "r336",
      "r367",
      "r386",
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost on projected benefit obligations"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r365",
      "r384",
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net cost (credit)"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r334",
      "r366",
      "r385",
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost - benefits earned during the period"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r96",
      "r211"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r503",
      "r573"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Fair Value - Assets"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r503",
      "r573"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Fair Value - Liabilities"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r48",
      "r501",
      "r504",
      "r509",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r522",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Financial Instruments, Derivatives and Fair Value Measures"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r498",
      "r501",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r498",
      "r501",
      "r509",
      "r513",
      "r514",
      "r518",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r508",
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Gain (loss) recognized related to derivatives not designated as hedge"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r492",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r491",
      "r493",
      "r494",
      "r498",
      "r499",
      "r506",
      "r509",
      "r516",
      "r517",
      "r520",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of reportable segment included under sales category"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r411",
      "r412",
      "r443",
      "r444",
      "r446",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Incentive Stock Program"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgram"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block Supplement [Abstract]",
        "terseLabel": "Disclosure Text Block Supplement [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockSupplementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedLabel": "Cash dividends declared on common shares"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r75",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r119",
      "r122",
      "r128",
      "r129",
      "r130",
      "r132",
      "r133",
      "r524",
      "r525",
      "r593",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic Earnings Per Common Share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r75",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r122",
      "r128",
      "r129",
      "r130",
      "r132",
      "r133",
      "r524",
      "r525",
      "r593",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted Earnings Per Common Share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r546"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Salaries, wages and commissions"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Total unrecognized compensation cost, recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails",
      "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r66",
      "r67",
      "r68",
      "r106",
      "r107",
      "r108",
      "r110",
      "r116",
      "r118",
      "r134",
      "r181",
      "r300",
      "r305",
      "r449",
      "r450",
      "r451",
      "r462",
      "r463",
      "r523",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r560",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r12",
      "r149",
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity method investments carrying value"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r7",
      "r20",
      "r535"
     ],
     "calculation": {
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r177",
      "r600",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails",
      "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails",
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investment without readily determinable fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r279",
      "r293",
      "r294",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r527",
      "r528",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r527",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r527",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Schedule of carrying values and fair values of certain financial instruments"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r279",
      "r293",
      "r294",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r394",
      "r528",
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r279",
      "r293",
      "r294",
      "r527",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r527",
      "r528",
      "r529",
      "r530",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r279",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r279",
      "r355",
      "r356",
      "r361",
      "r394",
      "r528",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r279",
      "r293",
      "r294",
      "r355",
      "r356",
      "r361",
      "r394",
      "r528",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r279",
      "r293",
      "r294",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r394",
      "r528",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r279",
      "r293",
      "r294",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r394",
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r531",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r17",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated amortization of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated annual amortization expense, intangible assets, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Estimated annual amortization expense, intangible assets, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Estimated annual amortization expense, intangible assets, 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Estimated annual amortization expense, intangible assets, 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Estimated annual amortization expense, intangible assets, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Decrease in intangible assets due to foreign currency translation adjustments"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r205",
      "r577"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross amount of amortizable intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets designated as cash flow hedging instruments.",
        "label": "Foreign Currency Cash Flow Hedge Asset at Fair Value",
        "terseLabel": "Foreign currency forward exchange contracts, receivable position",
        "verboseLabel": "Foreign currency forward exchange contracts"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeAssetAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments.",
        "label": "Foreign Currency Cash Flow Hedge Liability at Fair Value",
        "negatedLabel": "Foreign currency forward exchange contracts, (payable) position",
        "verboseLabel": "Foreign currency forward exchange contracts"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r545"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Net foreign exchange (gain) loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign Exchange Forward"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r16",
      "r189",
      "r191",
      "r198",
      "r201",
      "r563",
      "r579"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited",
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Decrease in goodwill due to foreign currency translation adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r96",
      "r190",
      "r195",
      "r200",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Amount of reductions of goodwill relating to impairments"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedge": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability hedged in fair value hedging relationship.",
        "label": "Hedged Liability, Fair Value Hedge",
        "terseLabel": "Fair value of hedged long-term debt"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r498",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r96",
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "terseLabel": "Impairment of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails",
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r71",
      "r148",
      "r154",
      "r158",
      "r161",
      "r164",
      "r578",
      "r589",
      "r596",
      "r615"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.abbott.com/role/SegmentInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Earnings before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited",
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r215",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails",
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails",
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r103",
      "r457",
      "r460",
      "r461",
      "r464",
      "r466",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Taxes on Earnings"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/TaxesonEarnings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r117",
      "r118",
      "r146",
      "r456",
      "r465",
      "r467",
      "r616"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Taxes on earnings"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Investment"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r130",
      "r410"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Dilutive Common Stock Options (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived intangible assets related to in-process R&amp;D acquired in a business combination"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r202",
      "r204"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net of amortization"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r70",
      "r142",
      "r554",
      "r557",
      "r595"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r594"
     ],
     "calculation": {
      "http://www.abbott.com/role/SegmentInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Net interest expense"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateDerivativeAssetsAtFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.",
        "label": "Interest Rate Derivative Assets, at Fair Value",
        "terseLabel": "Interest rate swap derivative financial instruments"
       }
      }
     },
     "localname": "InterestRateDerivativeAssetsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.",
        "label": "Interest Rate Derivative Liabilities, at Fair Value",
        "terseLabel": "Interest rate swap derivative financial instruments"
       }
      }
     },
     "localname": "InterestRateDerivativeLiabilitiesAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateFairValueHedgeAssetAtFairValue": {
     "auth_ref": [
      "r504"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments.",
        "label": "Interest Rate Fair Value Hedge Asset at Fair Value",
        "terseLabel": "Interest rate hedge contracts, receivable position"
       }
      }
     },
     "localname": "InterestRateFairValueHedgeAssetAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue": {
     "auth_ref": [
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all derivative liabilities designated as interest rate fair value hedging instruments.",
        "label": "Interest Rate Fair Value Hedge Liability at Fair Value",
        "negatedTerseLabel": "Interest rate hedge contracts, (payable) position"
       }
      }
     },
     "localname": "InterestRateFairValueHedgeLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r31",
      "r188"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r6",
      "r34",
      "r563"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "terseLabel": "Inventories:"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r33",
      "r188"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRecallExpense": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the amount charged against earnings comprised of the costs to announce and effect a recall of defective merchandise.",
        "label": "Inventory Recall Expense",
        "terseLabel": "Inventory recall expense"
       }
      }
     },
     "localname": "InventoryRecallExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r32",
      "r188"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r81",
      "r141"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest (income)"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails",
      "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails",
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails",
      "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails",
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r102",
      "r180",
      "r541",
      "r563",
      "r585",
      "r608"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Shareholders' Investment"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders\u2019 Investment"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r40",
      "r102",
      "r180",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255",
      "r256",
      "r258",
      "r260",
      "r262",
      "r263",
      "r484",
      "r487",
      "r488",
      "r541",
      "r561",
      "r562",
      "r563"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r527"
     ],
     "calculation": {
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresBasesofMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r22",
      "r278",
      "r292",
      "r293",
      "r294",
      "r583",
      "r604"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "negatedLabel": "Total Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-Term Debt [Member]",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Investments",
        "verboseLabel": "Long-term Investment Securities:"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails",
      "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r238",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Recorded accrual balance for legal proceedings and exposures"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r241",
      "r243",
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Estimation of possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/LitigationandEnvironmentalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Segment Reconciling Items"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maximum Length of Time Hedged in Cash Flow Hedge",
        "terseLabel": "Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold"
       }
      }
     },
     "localname": "MaximumLengthOfTimeHedgedInCashFlowHedge1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r46",
      "r102",
      "r180",
      "r249",
      "r254",
      "r255",
      "r256",
      "r262",
      "r263",
      "r541",
      "r584",
      "r607"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "verboseLabel": "Noncontrolling Interests in Subsidiaries"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "Allowance for Doubtful Accounts:"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash From (Used in) Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flow From (Used in) Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash From (Used in) Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flow From (Used in) Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r92",
      "r94",
      "r97"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash From Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flow From (Used in) Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r3",
      "r60",
      "r63",
      "r68",
      "r72",
      "r97",
      "r102",
      "r109",
      "r111",
      "r112",
      "r113",
      "r114",
      "r117",
      "r118",
      "r126",
      "r148",
      "r154",
      "r158",
      "r161",
      "r164",
      "r180",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255",
      "r256",
      "r258",
      "r260",
      "r262",
      "r263",
      "r525",
      "r541",
      "r590",
      "r611"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net earnings",
        "totalLabel": "Net Earnings"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r119",
      "r120",
      "r127",
      "r130",
      "r148",
      "r154",
      "r158",
      "r161",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net earnings allocated to common shares"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r305",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresContractsDetails",
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresLocationofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r148",
      "r154",
      "r158",
      "r161",
      "r164"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.abbott.com/role/SegmentInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating Earnings",
        "totalLabel": "Operating earnings"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited",
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails",
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r4",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAggregatedInvestmentsMember": {
     "auth_ref": [
      "r628",
      "r631",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other investments in debt and equity securities and other forms of securities that provide ownership interests.",
        "label": "Other Security Investments [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAggregatedInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r54",
      "r56",
      "r481",
      "r485"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent",
        "negatedLabel": "Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $11 and $36 in 2022 and $18 and $54 in 2021"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r481",
      "r482",
      "r485"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation gain (loss) adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r59",
      "r66",
      "r67",
      "r69",
      "r547",
      "r549",
      "r553"
     ],
     "calculation": {
      "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent",
        "terseLabel": "Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $50 and $96 in 2022 and $50 and $98 in 2021"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "terseLabel": "Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r52",
      "r56",
      "r502",
      "r507",
      "r519"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Gain (loss) Recognized in Other Comprehensive Income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r61",
      "r64",
      "r481",
      "r482",
      "r485"
     ],
     "calculation": {
      "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnaudited",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
     "auth_ref": [
      "r54",
      "r57",
      "r481"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
        "negatedTerseLabel": "Other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofComprehensiveIncomeUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other investments.",
        "label": "Other Investments [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r328",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Medical and Dental Plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails",
      "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForOtherTaxes": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for taxes classified as other.",
        "label": "Payments for Other Taxes",
        "terseLabel": "Payment of cash taxes"
       }
      }
     },
     "localname": "PaymentsForOtherTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.",
        "label": "Payments for (Proceeds from) Investments",
        "negatedLabel": "Sales (purchases) of other investment securities, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r84",
      "r86"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchases of common shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r91",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Acquisitions of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r327",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r403",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Defined Benefit Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails",
      "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails",
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresCarryingValueandFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Postemployment Benefits [Abstract]",
        "terseLabel": "Postemployment Benefits [Abstract]"
       }
      }
     },
     "localname": "PostemploymentBenefitsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PostemploymentBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for postemployment benefits, which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.",
        "label": "Postemployment Benefits Disclosure [Text Block]",
        "terseLabel": "Post-Employment Benefits"
       }
      }
     },
     "localname": "PostemploymentBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/PostEmploymentBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred shares, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred shares, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r23",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred shares, issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r23",
      "r563"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred shares, one dollar par value Authorized \u2014 1,000,000 shares, none issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from (Repayments of) Short-Term Debt",
        "verboseLabel": "Net borrowings (repayments) of short-term debt and other"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Proceeds from Sales of Business, Affiliate and Productive Assets",
        "terseLabel": "Proceeds from business dispositions"
       }
      }
     },
     "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r87",
      "r448"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r14",
      "r212"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r214",
      "r563",
      "r597",
      "r609"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Net property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r76",
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provisions/charges to income"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": {
     "auth_ref": [
      "r59",
      "r66",
      "r67",
      "r547",
      "r551",
      "r553"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax",
        "terseLabel": "Income (expense) and Gain (loss) Reclassified into Income"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresGainorLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r59",
      "r66",
      "r67",
      "r69",
      "r547",
      "r551",
      "r553"
     ],
     "calculation": {
      "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedLabel": "Amounts reclassified from accumulated other comprehensive income"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "verboseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/DebtandLinesofCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r453",
      "r575",
      "r656"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r219",
      "r221",
      "r224",
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring Plans"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r96",
      "r218",
      "r227",
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges",
        "verboseLabel": "Restructuring charges recorded in 2021"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails",
      "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r220",
      "r221",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails",
      "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails",
      "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails",
      "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails",
      "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r221",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Accrued balance at end of the period",
        "periodStartLabel": "Accrued balance at beginning of the period"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveAccrualAdjustment1": {
     "auth_ref": [
      "r221",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.",
        "label": "Restructuring Reserve, Accrual Adjustment",
        "terseLabel": "Reduction of restructuring estimate"
       }
      }
     },
     "localname": "RestructuringReserveAccrualAdjustment1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserveSettledWithoutCash2": {
     "auth_ref": [
      "r221",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.",
        "label": "Restructuring Reserve, Settled without Cash",
        "negatedTerseLabel": "Other non-cash"
       }
      }
     },
     "localname": "RestructuringReserveSettledWithoutCash2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r305",
      "r563",
      "r606",
      "r624",
      "r626"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Earnings employed in the business"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r106",
      "r107",
      "r108",
      "r110",
      "r116",
      "r118",
      "r181",
      "r449",
      "r450",
      "r451",
      "r462",
      "r463",
      "r523",
      "r621",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r327",
      "r328",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails",
      "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails",
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r327",
      "r328",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails",
      "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails",
      "http://www.abbott.com/role/SupplementalFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r139",
      "r140",
      "r153",
      "r159",
      "r160",
      "r167",
      "r168",
      "r171",
      "r320",
      "r321",
      "r576"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net sales",
        "verboseLabel": "Net Sales to External Customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited",
      "http://www.abbott.com/role/RevenueSegmentsDetails",
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r324",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Expected timing of satisfaction period (in months)"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r59",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of accumulated other comprehensive income (loss), net of taxes"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r383",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/PostEmploymentBenefitsDetails",
      "http://www.abbott.com/role/PostEmploymentBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r501",
      "r509",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Schedule of derivatives gain (loss) in OCI and earnings"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of the amounts and location of certain derivative financial instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/FinancialInstrumentsDerivativesandFairValueMeasuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Schedule of components of the net periodic benefit cost for the entity's major defined benefit plans and post-employment medical and dental benefit plans"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/PostEmploymentBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r223",
      "r230",
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails",
      "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r225",
      "r226",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of restructuring activity"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r221",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of restructuring reserve and related cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r148",
      "r151",
      "r157",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails",
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r148",
      "r151",
      "r157",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of segment information - net sales and operating earnings"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r408",
      "r409",
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails",
      "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r415",
      "r431",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock options outstanding and exercisable"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r135",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r171",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r223",
      "r232",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails",
      "http://www.abbott.com/role/RevenueNarrativeDetails",
      "http://www.abbott.com/role/RevenueSegmentsDetails",
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r135",
      "r137",
      "r138",
      "r148",
      "r152",
      "r158",
      "r162",
      "r163",
      "r164",
      "r165",
      "r167",
      "r170",
      "r171",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails",
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock awards granted during the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails",
      "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "terseLabel": "Restricted stock units granted during period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Incentive stock program, shares reserved for future grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable options, number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable options, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock options granted during the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Stock options outstanding, number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Stock options outstanding, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramNarrativeDetails",
      "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic value of options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable options, weighted-average remaining life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Stock options outstanding, weighted-average remaining life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/IncentiveStockProgramOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r35",
      "r586",
      "r587",
      "r601"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]",
        "terseLabel": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]"
       }
      }
     },
     "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/TaxesonEarningsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return for which the resultant tax benefit has not been recognized in the financial statements because it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.",
        "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table]",
        "terseLabel": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table]"
       }
      }
     },
     "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/TaxesonEarningsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r2",
      "r135",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r153",
      "r154",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r171",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r216",
      "r223",
      "r232",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/GoodwillandIntangibleAssetsDetails",
      "http://www.abbott.com/role/RevenueNarrativeDetails",
      "http://www.abbott.com/role/RevenueSegmentsDetails",
      "http://www.abbott.com/role/SegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r44",
      "r66",
      "r67",
      "r68",
      "r106",
      "r107",
      "r108",
      "r110",
      "r116",
      "r118",
      "r134",
      "r181",
      "r300",
      "r305",
      "r449",
      "r450",
      "r451",
      "r462",
      "r463",
      "r523",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r560",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r134",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r300",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r23",
      "r24",
      "r305",
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r27",
      "r28",
      "r102",
      "r176",
      "r180",
      "r541",
      "r563"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "End of the period",
        "periodStartLabel": "Beginning of the period",
        "totalLabel": "Total Abbott Shareholders\u2019 Investment"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/ChangesinAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r67",
      "r102",
      "r106",
      "r107",
      "r108",
      "r110",
      "r116",
      "r180",
      "r181",
      "r305",
      "r449",
      "r450",
      "r451",
      "r462",
      "r463",
      "r479",
      "r480",
      "r489",
      "r523",
      "r541",
      "r547",
      "r548",
      "r553",
      "r560",
      "r622",
      "r623"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Shareholders\u2019 Investment"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Shareholders\u2019 Investment:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RevenueSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SummaryOfInvestmentHoldingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Summary of Investment Holdings [Line Items]",
        "terseLabel": "Summary of Investment Holdings [Line Items]"
       }
      }
     },
     "localname": "SummaryOfInvestmentHoldingsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfInvestmentHoldingsTable": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The summary of investment holding table is used for any listing of investment in a summary form. Table lists the 50 largest investments and any other investment the value of which exceeded 1 percent of net asset value of the registrant as of the close of the period.",
        "label": "Summary of Investment Holdings [Table]",
        "terseLabel": "Summary of Investment Holdings [Table]"
       }
      }
     },
     "localname": "SummaryOfInvestmentHoldingsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/SupplementalFinancialInformationInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": {
     "auth_ref": [
      "r454",
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.",
        "label": "Tax Adjustments, Settlements, and Unusual Provisions",
        "terseLabel": "Tax expense from prior year tax positions"
       }
      }
     },
     "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/TaxesonEarningsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock, Common"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "periodEndLabel": "Ending balance, treasury stock, common (in shares)",
        "periodStartLabel": "Beginning balance, treasury stock, common (in shares)",
        "terseLabel": "Common shares held in treasury (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnauditedParenthetical",
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r45",
      "r306",
      "r307"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedLabel": "Common shares held in treasury, at cost \u2014 Shares: 2022: 242,345,663; 2021: 221,191,228"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedBalanceSheetUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r24",
      "r300",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Purchased (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r300",
      "r305",
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Purchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofShareholdersInvestmentUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r220",
      "r221",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/RestructuringPlansNarrativeDetails",
      "http://www.abbott.com/role/RestructuringPlansStreamlineofOperationsandImproveEfficienciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r121",
      "r130"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r119",
      "r130"
     ],
     "calculation": {
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abbott.com/role/CondensedConsolidatedStatementofEarningsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410195&loc=d3e80090-111668"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28511-109314"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28446-109314"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5283-111683"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r657": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r658": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r659": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r660": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r661": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r662": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0001628280-22-027550-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-027550-xbrl.zip
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MWC#J==KXUOEVVPW\V>94Z/"QT?;.L=[N(>O##UXPKE_AI[./M3]S<-0O^_1
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MC=KGZG0C9Y>HZT3R&2%@Z&I#4LD<A0U;\LO3C==OJ/E%8\XE"5 .4AQ(C>P
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M6BP*LR,)D'E:E3B]Z)%'G!* M.K5@0_._%1O88B222L_]LVGUQQ\E*FI3@8
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MB'S/KTB3#Q(:D,-:HJ S29ZBN31"78HU.N]!943$'IQKSK44A.RD%LKLN4E
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M$11?* 5Z2@PT7[-CEM$.HUU23'D6N4C4.>*C@R<P;#!W"Q#3S_5!+^&50 %
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M#.[+6Z]W3EJO-T]W/WZ@S?6-\7<_;N]OO=Z<2AUO'7P@NQ^;K-5NPCOLX9R
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MB,PAXUSL?,UV'!YW1]4E6T=Q/+3"'8O!'5D;*"WD4<CCA@D)%[NP?*7*S!F
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M3-R/I[_]5AW_]OOWY[_=I_[OB2?GWMU^NQ/'3?3Q_=FY.563W\)W,^>[Z8)
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M'.W#7)SLT W:6@^?F^OPSJ]AW.V=DYW#37C.?J>Y_JH+SSQMYG?>^X03<R&
MT:XDL8A'[9"6G"+I Y4\$1&5__FB>HV.W2W*4W3L">J8\D&K*"E*D3C$"3;(
M1"<0HUA:(90,B2RM]GOQBO5\XA>-T.]V[:!Q!/__DN7?6#L>[?<'0*"A42V$
M],_K&7%,F0^CJ)56#K^-[F:QAZ*A#ZZAI/7N$XE)8YD88MIPQ)6/R)@0D(RY
M%8YU(C#U$Q:\4J_FM,@6O5H@O7+)\N!]0"2$A#BW%%GB/%(NQA!)I)R;7.H
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M':%RU_OA/D$$;;"'/B/1MK%]X(NCGB 0$D<2MN'7WZPM@;$$-@(!6U Q,QY
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MO\V5A)^,YCGI)'*6N"?>K*S>I35$"6#4V+ 7P#B*8=?"L&>2+[@BC&+P(&3
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M$ZUYA$F&I<9^EOTP?P'23<-:]>-B<V44+=J?NC"C2Z:5MZ7"RQ9J8E.N%76
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M[]@NC!3^<!1[HV$C!P)A[!VPDKT!O'1L!U70<+3?&7Y_WXL?]>LO/8O)D+B
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M7QCK\1@60Z<*]#\SG<#'9,N7'WO9?N;8?MKO9_BP4YR&F 0*/E'$F0 ^S(U
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M]V+$TVG>QF@"D(M@XH#1*P7V*TPN4L4.UB_WA "CKTE%ZK-*N/HQR;LS')X
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M-QO9:UVVV_CM0\^>A [,RN]7@6CUS_C/;O#'%19U0VSE%]@ZYB+MDR,8KU]
M%LR/C'5KL&=[G;,*2[XO.?@%F.H_@SB$1UW]NI4NUN#W)9C3([O]X<D@;L.8
M_NI61<V/R4[/VA?LM'T$K.^T15_O[ZYOBO;9NP-@HWSK$S!$NL& %7YKK>]\
MVSEZ=PA,LQO__>YT]U,X=I3+%MVA6^N;9SN?7A^V#@Y9^TV[N[6^)W8^?3C;
M@<^USS:^M@]>=W;?O$M;ZQOLLX@"RT@,$ESG'!1-D;:Y]2.55@KBLF._THA
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MZO23C,%;:0S:>;#OQ]_\8]P5'KS/L=>O_4& 7>LB[(J?&P!L?Z"?34JYF4!
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M()9U6FHE6*!,<"Z"!EJE87$+Q5.&IX=!K(),\R#3M]:K'R6G;/21$!-1-,&
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MI=R86W%"E1.)^:B)H_ *<0^4&%O\G[OCW?N9,P=+C!)!&20U!_^'^-Q:C%G
M/'A!)^%I,(M.0:M'?\:""W?%!4_!<>;1<Y8HX(*V-BH>M59*$FZ2?GA<J&GC
MP64!AYE#C&0B]3CW\<[YJ90J9('@(DR(=!SFGDJ_LDJ:C"XJWZ) P]. AD"B
M5+"E1!$--QD;*-BDPL)[P3@-!1J6#!JFST6LP$X'$Q!62B,N@D-.,X9B)#99
M%;BE!1H*-%P5[DQ<&<E,L%SRX+B3V 26K/;."A5+0<L2H<+T:4J$:10N"? F
M) =O@BCDDN+(,:\I9A$XP\(+6@HN/ U<,$';$*..S"ENO##!!V&H,^K_L_?N
M/W8=Q[GHOT+,.?<B!V [7=U5U57VQ0"&Y>#XG$BV8SN!\DM0U0^)#B4*%)E8
M^>MO]TAVY#U^D)[-X=J;;<C#X3P6U]Z]OJ^^>N?1!=Y#EG5+A@>1P[T<2>35
M!-0XJ'</:+D';S("9)^\8)XJQ:49$M/FALT-WZ^D&F,2 D-Q%)RNA4P7 H%Q
M[6:PIH_44K:YX8S<<))VX5%C&@P!5SL'3BD85K-.J+DD(FQ@Q2^)&\[4]''D
ME,SW5N+\81[G^Q['^1?>OL/QWY]^;/<[=BGOV%&NL4]NOV./^IQ^0*-9?]';
M,WNU5K!]W]J][SJ$J];ZFJ4!=I"Z]FL74I ,\VE,3KD/X=TU<30Y?W]L:>H-
M.T4.(*H!6^O!I@,7(L?61#BUEF]N,Y4#M6EO')^Y.B W9(:FW?K\)!E[+3:F
M/^=9K>QQ>@?$\6D!0(8N4).L)<O3*^\9@V$J@6IW3$F\J=S<8HD;QU>+XYA*
M]"9T5]43M9K$-D86'?/2-!YIO/C&\=O@^#1;GZ1(]P(A%BP!H?NTQ^!K;"]Q
MKSTE:S>WDK8]OEX<TZKP7!%T $?O[,P]4;;J/<&\VNY..!Z.3_/KG):>ZC&(
M]FF/JT+PX2WT7"*2 =&JUB4YTOBCC>,S^\=HN5&2T:FB9E9I=;0RN#9OG':7
MT0%Q?"\5WFU0UVF070L'7 W(GFL+,"J(.Z4,"\B &\A7"^2*%:?X*F[>L<ET
MI2P;#4K3Z>)(MI/:%X?RDZ3V8$?.60*1]( :.2@1A)R+=^T-<^DKJ3T?G0/A
M_ .:5_CC]OKYJX>']G>#]!LV$M8NQ1)8FG[H4/72LVE4]H%>4]VAA(.1VL_O
M#RELGM9(Z!1:F4R&M#:2I8QA2E*@7DK1M??G6/W1&\=G'G2@ O.<77I2E#1Q
M/&K/S1239@?;.#X>CD]#^Z:=<JH]D(P<T%2#Y RA=)>[E4>=Y>:6\\;Q]>*X
M]0YDY*U,Z(YDFCPCS@=BC%5Z_TA=>AO';X/CT]!^ECA&+O.$Q%+ 9"UXE!QJ
MKBJ]:O>\]O"Q;!Q?+8Z-&H[:DFA7["4YHA)'=E)=I?,[)'@\')^&]B&E(6.>
MT.IY"FM^5#"I(Q3I\Q1QQ":R!XU>-XZ;C#[Q.WJ3AM6R-IA6N"051';PC>/C
MX?C^YJ0&A65@Z".6@)&FL%[];NI$F6R:8^Q36)<'][%L(!\6R,2U@W,2KPF'
MNV&9[([$2DA:RP[M7QS*3T+[)J4#,P2G,LUUA!A\:JW TXEJ:$44[_K58CR2
M\-Z# G>;[CNDO<1I\EVQHEAQ/K0V50QB8@#HS>21!H)M9GMS9KL_$+!D%4^C
MA(0> ZIR<(\2.N1IT&SZ(?/0;OEL)4:[1?\ZL)];+J. :T&8ODLT4*:D#3NO
M'NX]#/#2B.$T82#>S+#7D,5'0'$+IGF$&EM,N7)&+=\6,SPX9;"IX:JHP618
MT@S2O"!*54Q6J(-JFUY2?P\["S<U/(@:3G,0M<V3;=%#'J !:7[07#!([-P@
M ?=JBQJ*7L;PCDT-C^8QH(P!XB(5IFV)KIZ' 7)JE4OL.^)Y//2?9BXH,[61
M>L!)]!/],0?)6 .E"L.$8X/I,2AL6;"Q_WWL"TZ'DM2\NV).51T&#A7(*37N
M:0=)+XP8[B]%RMX3-0AN4@)VKV&>\?QK'AXEC9+P;N ?R.:&S0W?YP:DD5/,
M8XJ!CMS!NL0DHY*ETI,^4D7#YH8S<L-I H4XU9QS*)G:E [4@[;)$AZ=RTJE
MY*XWM^DI/#R!\BC<\ $,_/OHF7WVY8NOY^W\8=[?DZ,,J+H$_CO62*_]CEWJ
M-?;)[7=L#_Q[-Z?PDQ<O^Y-_M*D5[-6+E]^\[T*"JQ;YEHBG@[C6Y@)F&5H<
MK%3$UJ:_V/(N%SB8CO]XZ?<3'1\C *8AX:X) :=X#VJ20G5$TA*'IS%UO,"!
M.IPWD,_>?U"KD711QI98&S>006X=.N7=1W1$(']R$JP3&=UYI,"EE("%5D5C
MGT#.Y&[>,E:YN=5\+G=\ _EX0,;8Q <5<R+$.@1:1$BQP]K7]3XV_>ZPVP-1
M?F*NB6(;\^!"JRM9ETL.TEH*O:5&EA'SFN@)3]/9TG4;Y\?#N0DGR)4:3H.-
MV*605,M4FW6/M!L&CPCEGY\8;)(A)L)!<77PQ_E!X^BA1\M:YA?9E_+6K;RO
M%\BKQ()J0G<2A%RD(H%I;)CG+8Z=0[\XE'_\ZQ_?%==,I.>??_0I_MNTTY%:
MQY"<4D N+8A""REEG,<O-)VL;SN--M"O%^C91<M\Z7JW#2VRKN::4A1$UQ#G
MW5%X@4#_V1\#':J*3_H.4:8@Q]5-Z!52B)3!9)#$U.ZDN:8# ?T#FA;X\8OG
MO;Y^;B_WD,!W.=_8T5!6''&,U48H5+!'@*'<"//>-W \,OO9_:R M)&*CM5%
MJ '-4K"(+7BWA+D*4%]=A'L&PO7B6'(I*R=@R( D:Q)5HY(I%DMKQMS&\0%Q
M?)H4\%2(54O(K?+4)&DZ'Z7'0#@$2RQ3E:2I2>!(0PXVD,\,9(G1:LF<<T-)
MTR"G6L38IT_2XL[N'1/()P8YCYY\DG!8DZ2F08XQF'H,X$534G>/-($L>[S8
M]0)9:S--J(C1T-Q\I-PRRLC0ID'>S79'!/)IU-^XSW.<QKC"U-/HD2>0J02M
M.L;TE3K "@?R@V,$&\B'!7*O633&#+U.%9:SHQ2,:ZGF&(IE _F(0+X7V,]U
ML.4F@6.:=GGP1/*:W#N?7%$AL-%@F^3K1G+2@:4EEM8+5G3/\6X*;"+KM5;:
M2#XDDD\B]S5RZ8X66F>92,X:E+V%D1)C):QM(3GCD<)='U!-_R]>//ORU9,7
MX\E/[&7?%?WO,DL9NZ*PI\H%1U=-BC'%7B8&!/;.[P/2V<?W8O< U'6:HU")
M<D"L&EP1PEA+0D84& EO;@^5A-PX/B^..3/7&).D%G$861'SYM [IFQ]A_R.
MB./3V/U:R<2EIF IX=KP(].U( V$*4:VVB./J4K.-9)KX_AX."[:DGJ<_F1G
MI!Z]>@80K28II\<:RKEQ_'8X/BW9MV$^>@U*D0(V+V$R,@25*%8SK"F<-[>0
MR@;RU0)Y:FC#0J.-6%&Z2H^2A[0Q)!*;[CC! 8%\&KK/ TNJJ0;FM>*'C()[
MG<*ZCWR7DHEYC<D\U#+@#>3S CG&W+RB2E5#A&F9:XT>L;NW4N"1EGYO(+^=
MAWP:NN_0N0+D0 F6M#8./E(*!5O&WJ@ZPY;65PUD+=0*UFI1"1LV V^1I93H
M.,]X1^Z/">23R#WE7'LO&HHZ!RR-@N;YH9?!/@^U9.-ID@^%Y ^HXOZ?[*MG
M[<GWYL[MROMW&2UH<2)@.A5MK?"@)JQ>F\11YQ>L/E+4;_<8G8OO?GDOM&^"
MUDU:B)!@A1)R,(DM#$PM-L>1VBKG?9KC+CJX8ISGXBD7F?JE82^HR4>79!'4
M'6UWV!P1RJ?1_9*R\YB.A]G4*UA&"]JLA>Q1P7*/GOSF5O*#QWAL(!\7R*QM
MZM>8HZ^=.EV;4"2,:^;6=$<?:8#>-MAG1/EI'YV2@40/16@$C%R"ISJ/$SNG
M"-&AM;LIV;CK?:\7Y\VBC]&\*\O:'ZPR(O=$"05KK7DW_U\:SD]3 ]T[Q:P3
MXEUD"G,M0:8K%LI$?"3QEFS<"7/%C?/KQ3GGBBC32P/!F$E <_.X1GW$@;L:
M^)!0OC^P9U7])O$ ;4W$C1F"0*7 ,)8UYT25;VX+/GB#[D;R89%<B8V0>\X)
ML:^6]TH=S+57QZ1[+M<%PORTZ)][+]4\J%9;RZTT..0:VJJ=33F/DNNWTOS!
M^?SCE?T?.6GPZQ>O[/G[+O/_0/=V\>B=J"0UJ=@+3*^5)P&"CSZ=%7JDT.+F
MO7/QWF_NI1 R-O%:.!2PZ:E 'D$Z2-"BF>I\8"C=K0$O>*YQA'NGWW5P0YJ6
MD'1J(C! 9;?16IR*J*.ESL:;&RZ-&TYS$EFRND()7<OD!J84/+<8Y@D[-Y\G
M[W?#Q>?);F[8W/#]LLA) ]R5"X^(,HK./PKD*:TC.>=':E38W'!&;CC1#3S6
M"-M1 L:* 5N)P1)2(-=:F66D1C>W^2F7K1LV-_Q15!2TP: ^GP'!:6&F:P&:
MO<8&:UFL[UC*I7'#O<:(8MRC0X!N>>J&CD&A4^A0^YC.9!Q:[W0#GJO':7/#
ME7!#8U\&!6LG]%6#W9$Q54^YLP[>W'!IW' OG:+3>T"P$E*K'A"X!B%L01/'
M@6E4)KPCAX=/$][D<%7DT!'6GJ/4DS1T8O6HM43WL9K?99=-7" YG"1AW%3+
M&!R:2PJ8DP?7/$+-1>8AK]3;G5>A<*YQ)>^6',[4VW'D],S'O:T[>?)1_X]G
M=5[U__T?,C%ZF,77E\"!QUH5OM^Q2[W&/KG]CCWJ<_H!#1W\I\^_>?7Y%T\^
MMB_ML_Y%__+5^ZY(N&JIWYC4 #2.XC@5O14L;?Y)F7O+>VG0 =5\O5=:0*EA
MI%X#"&+ 4CQHE+OJ2=.&-7M.-[>)']R;N,<J'!;(SBA12Y88.[JCJW6)):7:
M@3OI!O(!@7Q:!S"];5E8#CEQ#,CSL$2F:VY]&+3IKV.6">2R!QU=+Y"A,=C@
MHE$CJJ]I1SAJP@Y8H'3;0#XBD$\L,K:1YLEK*!//8:*6[_:,!*5:TA@=._'-
M+>5MD:\7R$,T,LCH5 2%AF7#YIBYE-$S[F4C1P3R:88=8IX<6T< - \8(4YC
M##EDJ=VCC<8<E[1^<$_2!O)A@9PQ:VG>T^B*E=-J1D.3!L@F/3]2.FP#^>U\
MY--T.">C$D<-IB !L7'PEC0(._#ZIE6_N<WQ2!/+-I+/K*V'9)Z0C7W452WK
MQ&Z:6D5K=1KKC>1#(ODD=YV25^I> C6?7K)[#UZRA5J9&B?H=[,'Z6SUL ?*
M3U]" /^GSWM]]?+%5Y]_\_6S^2]^]LV>/?@NQZDF:3QZZ;$-1"@2"\L@QI;F
M:W^LV8.;TMZ"TCZ[WQN8)!<;%AS6*)-1)Z.UO%1*;,D N/0QO8QTI#UH&\CG
M!3*.A-6@.<>.ILUTC"8\<=VD3(!O(!\0R*<!?!0&RJ4%<(6 15/PB"5P-%[;
M#.N@E8G#/8SH>H$L:?D.K9CVA.KF,+K$:&J]#=>=4C\DD$]W^7GA6%L)@$#3
MQ^ <U*>/P2+1J302QYM;Y#TE](J!/*';=,)Y#$%'G">?:\LNT]%$\+&C!0<$
M\KT!@4D BDM0X!:P(@?W),&$J5E%+W>3NQ^^E7,#^;! '@5D",6^I'4NLAX%
MMZ6T:Y)D;0/Y@$"^%\ 'Q5IJ]C"8/4S3R\'FD09; [T+5C>@J:UU3^"_7B27
M+A.A:JU(Q:A="\W#IQ:A#DMM#_H\)I)/ OC-B<E(0[*)7YQ:.DBBO+0V9W#(
MW6R*:SE2N.L#JL#_W]U>OGKR#_;L^>N7?5??O\M&V]9'R3%*X8Y<R(VFSTG9
MYI>UY5VT>SPZ^_=[P?LU< D5*938<(4*)#@-"RT#=0*+M%8-0-EKAJ\7R+DM
MR]5S1C:46+71LG$K HAI@GL#^8! /@W>CQRA1:]!H*\E7Y(GD*V%./W'T8DF
M*?>;6SI26<'&\9G]BV)6,RHWBNB))X[9K26?&":(N'%\1!R?&.1>$[=*%)+@
M6A<>8[!6<R@I:9P2RX:O >-)-I"O%\@R3UK%*'O$&LT'C#JLC<Z16]FQ^R,"
M^31V+PHZ-$/0B-,@:\$@$3C,KR<:7<M\+):RWNUPUPOD2EJM9Y%"!;WX=(O1
MI-)H,-84RPWD P+Y7NR^)<JM4 Q8K4P?.4Z177CZR*5:CFR54Y[2^L'9] WD
MPP)YZBWSE!$L)<R].]1IHV-DI-I5=^C^F$ ^"=T7DV23?$.::GJBN=$TR=37
MMBX?I!TH]J6MCX3D#ZCV_I_MZ_KZN;W<)??OE,D4:UW+>DI":^C=L4^[5K6V
M-3MG!PF.QF2__?&]J/TP'2E"#9G:6$2&P:1;*!Y+SXCFM$KN85<37"^06Y_&
MK(K%C!%C=^_(+:\*OU[ X@;R$8%\&K6/-C*X4Z"[&?C3+0R>:P_"E+TKQ(IP
M<YMW6= 5 QE:C8ES&38$B8=T'<-C:]6Z:'^D#5D;R&\'Y-.9.:66/**'U-@"
M"O#JG8EA'B+45,P1X\TMQ[W^]WJ!W*<?&:U[@:HXU+UFYSCM,U8@$-M!@@,"
M^31L'[5C*^C!?'6S-EL#[%H+F2'Q4)MGO&($L'MGKA?(FF"T7)6FFL:1DK6,
M';UR!!2W1]KCO8'\=C[RO9)[&7WTE3_O7 .FS$%3'J$D2O-L?:)<;VYQ]Z5?
M,9(S(-54V9L6'$16YY\Z#7,;4<KN@CLHDD_B]C(&I1%;P$[32Q[6@TVO*<SS
MQ):H=]=ID_E0C>D?4,G]KUZ]?%U?O7YISY_<5=_OJOMW.6G#UQ16J.@X&8V[
MP8@:W8M+Q]%VV.]XC/;3>_%[D404(85.IE.:% M:)[]Y=/.6.WE?DS;BKKJ_
M7B!GZI%$Q\A1IC3)VJ(5;H*4%$M,&\@'!/*]F?>Q@\4:0VNK6K?F&KQ5#H)]
MD(AT$3]+(FX#^;A QBZ-J6">%CF/+I/.,4YDUY17'>\&\A&!?&*1IXQ*:@-"
M$1O3(GN9QGBZ&*5,!\/79J&85K!@5^M>+Y"C=+55"@;<<"IK :@Y]33F(V Q
M[FK=(P+YWL@<F.+)HH=1ZI366" XZL0U()5JM8C;;FB];B!3B:UT,2,H"#&I
M"R:PZNNKVO?RBB,"^7[\/G4J:C6@#9I(YA&\EQ:TM=&KCZ+I+A.W9]Y?+Y(S
M58A6%20K-A>'U> *-:G B'W7W1\3R:?[VGOF2M!"Y[[*55,,-GWBP)15*4ZU
M);BJW,ZUK7W7W;\5'C_IKR<<7K37SVV]Z;O\_EV6%K2( PEI<AGF5KPV8FM.
M"()2]L3[XQ':S^Z%[Q-7<Y@$)G?E]S:9S0=32+R"]Y/.? 4+@':QW_4".5M.
MW5.;_W5T0\]YE0GEUBI/);(W71X1R*?A^PP\NI"&[F(3R'RWLE8",#FEGI54
MIC#9.+Y>' -);I#B1*IC993J/B]2M3#V:'MSQ2%Q?&*0F0"A"@1?N;B[-)Q%
M\%")*2K&+'G/R;YR(+-DG0(Z9M*(+8%63. E^8A#AL@.%1P0R*?1>VT])HP<
MU% "]K92Z2)!;*QI"V.>;YE QEU]?[U 5F,</M;$](;<P&C$ G55QA"7MMMH
MC@CD>]'[U 8TGR#N-4' ##&H$H4<*]56)=5!-[?XX'F4&\@'!G(;E#M-WQBQ
MF*PQ6".- JS8&'4#^9! /IUW+R.Q%@\0IZ.,/EI05 I="A<>:Q_-G;9^<&7,
M+K[_6_#XT3/S_FI>[B?VLC_9I??O<IJ?B4J/H$T9(ZJO"?B)Q"FMUE#:H8+#
M\=G']V+WG'25>&'((%.7$&J0M9?'NPZ87@;!JMC%M"MVKQ?(=]TSTYHUC(KS
MP%?Y;LJIC$C(2#L)=T0@G\;NA:!$*VLMGM[%_'I0RJNHH&N/T9NNV'UY>%/@
M!O)A@2R1N(\,)C%ACL,TS;,G%1)TJ(\4O!\O7GYAK^;M_.[5#[]\_45H+UZ%
M[_Z1C?*W1?F]5#LL!Z2'">H>D%,+[I)#'!2M,2SZGM['4^!=T'N].#?@+M/%
MS , 6U'G/A5X)LDK)DP[)'A$*)_&]FN*-0I: %Q).AMY)>G6OJG8:E4BQW%S
MF[?ROF(@SU^@WEOL4@P'5RM4#0LU')Y<<0/Y@$"^%]L?U&V 3L&=[G9-]1:T
M:PL1=/I/+"8=IO36O:/F>I&<"1RP<#/1%=PWSI4MC\$E6>_Q<9"\I?<Y87X2
M^<>12\S,H46:,,<)>$E0 H(9FK/'1G?:.QUIJ]R9"O>/'//_]8M7]OQ]E^G[
MBY>MOPRO7GSUPW547[]X_JP]62_]NGEO#&EFJ4DB0[&D8E KPU2R6D>I.^1P
M6;SWRWL9@L[.6!N$/I7J5#>4@W+L(9IW<20$70G/I\SGFC?V9E"ZH+*&#Y0;
M]&YD@&*N4C&;:;:&,,!;];5#:G/#I7'#:=(!BO:,Z<[5F4(HK^D"DDOH3:5Y
M)LMU+?5[J@]?M+NYX;JX 5+B5GJ7/+#3U V5C#!K-.BU;MUP>=QPHALJ"^OJ
M/\AIX'27K 4910/P*F$U1%QK O-3?OC$@LT-5\4-$+M8(TAU/CD654JN&GLE
ML-PC/=*\\<T-Y^.&>\N (Y9,2<+05J=N6'T-*O-#J4DSI%ZX+MV >JY>P\T-
MU\$-JM.E$&8I19%CE6+LX&,^-U$!'VF"^>:&,\8;[@TZJH1NBQ<XYH#S@(.T
M[H$SYI&F*SD-P\UM>@IG:T3>Y' =Y-"F8LB\H@L\78E4=/JFDS"RY\C04MGD
M<'GD<)*$28@DO7.@><AK WD,XBL=8VEP1V1'O_,J\KF:F]\M.7R7GOG]77SW
MY/,=\L^=H]W7V-?8U_C+U_@ TJ4_?_5YWTO%WZD.*=E5M;/UCC&UM9Y:I5F;
M6M9J]-U0<3BI\>F]O">:U]);#[5:FVY(S\$M4I 117HJ#>N:TGB@-L\-XS,/
M0&<=6'E,@!;D6D0MUTH9''+!"H^?HQC/?M=;^*_^\L6&]UO"^UZ_E%=JM5'P
MGD9 <ESK$%-H$_/$VFL>[6:"61*D'VV07RW(I0-2JG$^#?,32YI2F9!N.4W
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MO?$VR:OD-4U=JR5/?2H3Q?GV6"FM9*916>"1@H+;"7DXW_WJ7N ?83X>@!;
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M52RQ:??$DIG-!B<ON\SPTG!^FCJ(F$3BT$"#:IA^6EE+9'/@M3R3)W-W6CG
MIU!VS^WUXCPF*0Y]1)W'/JQ)AFG,>[62A7+<8T(N#N?W,@L6LTRYSH&T6\!I
MWH-X+V$(-2XI39K_=E)G/E(Y\0;ZN;.$J!VR2 7'4D5R1^8T#7Q/#KJ!?H%
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M;BK@45ZQWNJ#@(32D(SU43'L>.#4>>ZB4/F(LL0-[6,UD#PAA6R?'62XD)R
M(*,U0=PZ^,0$04$1EDB@B<@<%2)O )(1.O0&KA?_.\C?W801TEH%X&6]D1+.
M2 (PP3FQ+A*08!P.-4;\1 KX?'% <ELP+BC"43O$-=7(.DF03)AY[!.U7 (%
MT&LPHI1=\_97YTBHB*$;;>K'[MK=U<GGHH;NEH?G=4?F:1>PI0MOA65)+2#(
M226S!WB3SU]8I$/@EMX?P!^]P4DV/_2R!.B'IJY>XZSH'X%LV"Y.!B>-TT'7
M']G>E1>M@BC8C[#J ?3,;M>V^^<-4$5A3EEPO#*D2=461,6B,^C!\'J=5F@
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MV01_@N!:)<6U<0IX'+.'AZC7[+V$)_D"'!WU2;Z$;%Y,)]0E8JV)B#C*$>?
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MX]?MX\.S_??-X_W-'*.X==;\<,"< N32 FDJ'$"OITA;HI #D=G0% /7NH+
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MJO>GF$A#4J#]DJ1S (VV200@9FUIPIB%V\<QUQ1S?XK!V>,E4N!*6D0#E2"
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MSPS4&L<-LH.]U77CZ!1S(W)MP3P2'I$@Q!'JHL-4 4]:F]W5K]R8)UT5/ .
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MJJ/806=LX.J55)9)ZKT1V'-,@5 Y+;P/%%ZC+&E"XS5W8$^C?/G@[9*>NWT
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MW.BOTS_G%IZIT5H8REWAGJ72DR0IEC3Q:+'%2G,6<T\E!K^$LIGPL-@WO9D
M#,58[ (R*I<8Q4H@9[E"+F(I'#/).;>ROK"]A*6#OF>MK!X'+SPQ,8!N8F$-
M)Y[%D.!U:22+BP^9%V6=1UEG0N.,<2U$!&J"<X%-&B6RT6CX,UH:H_6JUM;9
M?FI/1%N?$%'9'*5V>-\;QG O@>IECB+5LU&7IY_*![]%$OAU(WQ7F8 +IO-I
MF0#N@V?&!,*CYLY+"X O2(I81P=X4B)*#P;_GV8C2MI3Y:U%3.:(DC >:2T5
MDL)$BHDQV-J5=<+U;>'_"A"Y$_@OFGH-397"T^2D" X\*I&<5E*R(*.2-- @
M+^O-5C3U'C1U.J)$=!#2"HX"3P;Q&# R4CN$<Z< DA211*ZLJUN'?I=54>=G
M*$O+3.XPH%1@[QJP1P46*??62#B \^,=SX41 P_)V$"(+ &EAX6^Z8!2D&""
MJ!-(.:\0E^"=.J,(4IAIHPW7F.I,4F9+PS\1['O>VAI92-IX*WS@0O/<\B&%
MX#F-UF!5(DH/K*TS$26#O;=>YF1RX1 G1B 3/$51IT2HHI$3\"G8K;>^EE5;
MGQ!3N:.(TA6QP,>5^KA15U<_%UTZTSEDMFN(G>T7<E0V#N>:\G&2]A.)/I?U
M6>[U>4*[ YT_;(&:N\O-(B%9;2C!CALJC'?>:YD8<U[8Q(I+^9 D]:(#CP+3
MZ!B*$6O$+8G(YKZW&#-*'<:*L4LZRCT18'O6VIJ",4PI)CQE'$<0ABBB\MX9
M8R4GQ:5\8&V=/;]'6)0,<T2PP8ASPY$-,J! *<_YKUYI<G%SP">BKD^(A_Q]
M<I0N-V)::&K"79S:^=5UXX.1XWKV#(0E=(>Y.GY]./+Y'1-?Y+0\"6,3O0G*
M*Z=S!0R'B<TQ3*"*03AO#2$E'>*A#,W13#J$C%X$E0A*G.?B;U0@PRD8FZB,
MDTZX0,3*NL&+2H=8A)8\9,RS@&,!QUN!(Y%$ >%642?,94K&4N^I<01XN&5"
ME0R4AP/'Z0P4@2/)64$H:@8^,[8265@K%+D"^Z8Y]Q%\9J9F>[ ^3W!<EGL4
MD"X@_1@8; F7W!"HIX.;4ELEK<8H$94 J U!SF..F/=!*,H8%FQE7>E;G\!Z
M(D!= +( Y&-@L04@;PB0,_%DH8C&TC"$ XN(:TZ0Q3HBP6UT+FA)A%E9EZ3X
M^8LL7?1'W0%T?=(]^%QCWG%CT=&T7M@L^.&:^+ZSK<[?W?YES7QCKZ[:V/'/
MNHUO,T?/:'"2*829,(A3[I%6WB.)"<')2.^D?#)M? $.?@ 4YX2NDZ2N:U3
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MHAB#%%C-!5?6,B4C4Q&S%"03-P\I%TFY(TG9/6P>[D@;J<^'XH2V("G,8F1
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M,,.(CHP@Q?)>"F@TLDQ8Q!2LJ3*&)!R6T1H_IP)Q6]V!;5>CLUL/D31SO5S
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ML>@XTD"[4$I.N!@Y2=(O&_5^?D6YSV3QE,K<I6+:HPBDG)'94I[[3E']S4Q
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M,-B;!!;.7#7V#?'I)=:!)S@<7'[)F0'ZF%V ^[>V1,"8B)Z:TS,_]T[J;A^
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M=3ZD/D7L)$D4.F$")B-+I.(D\L+(I<P-:!+Y\>? V>L>FG%29X4$(6'H"IF
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MEE9I(UNGC7_4H",P],04?93J/R-P2;0-W!][AG(<&&A>IM\P5*7V%W.AVA>
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M[[IJRZV3.\LZ/M^J:'#N[%??!EX/?DNE]Z,69#Q,./@C!-R4@#%P6QCE@:?
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M'A?-N?XM'<,MHKD=-V'!P;B#MBW&P=@,=MIQ*@_F9!@L;3,/&1?0;-&L85S
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M0[)+JD%+EO,D5?)A"I]/VOTB4>L!Q%+5\/"$VJ=DSQ:(P@7>N)T "T"E+!%
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M?6\5%;)HK*!ZM5W]]+Q!!,=L-!V880%[<2?[7I&#-&Y_RT8"L6D > L QB6
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M \2=<9T]TV&?*>,MQ9K]7,(GHD6T%NZ ?BS-ZUUC\EUEU>GS-I&]NG/L)^,
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M^.3@L B'),]:/:;)H@9+;LF'91'O>$R3ZSM=N:ZQF!Q4=FU0^C%%5!N[B:"
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MP<?-$\&$N/S;_D?N$9E/'&PP%A0O&D)@&0KGSN?,5=3J_Q[\6 I3$;4"X6(
MQ4R&:%R!K*7C&1DO2H\?NNQ6__RQ_A?#@$](N-4P_OC3TX^;S=&/SY[]\<<?
M/WR._?*'=7_P3# FGYV^^^G)VS]?>?\?<GPW]]X_&W][]M:AN^Z-]+'\V7_]
M[=</Z2,>!NA6PR:L4GW T/TXC"_^NDYA,^K\F[B>W/B.^A.<O@WJ2\ %2/[#
MYR$__<N?GCS9JJ-?+_$]EB?UZ]_?_W+AD2'&]6;S0UH?/JN_?O9RO<JX&C#3
M-\-ZV>5JY \;^K]:?5U>AWY%W!C^O@K'N:/?D5#C0S9?CO"GIT-W>+3$T]<^
M]EA^>AKB!JKQF9>L(OL_]W_&LZ_"I+!,Q\M1=[_2SR=/JMBGE L_;Y ^8*O5
M4RC+=;KPIF6UZ;H__<MEB+@<7UT<#W 0PM'B[1'V!'UU\ N-L4/\=3T,BR*]
MLRDHR,IR4(I[<$(3M:4BLINL@K 7%5K%'$C.D0PE#'%DQ,DSGE55/\/E9CA]
M953^J/A;8&Q5_'#)WN,G7!WC&YH"2,.;/J3-/VAF>'D\;.@)_>O/:7E<)Y7G
MPX#T+_\>/B\TXTIF3, Y4Z "1@@Q.QK9RGH9$]J4&DO^ )@7-7..?L_[]&3=
M9^QIWGSZY ^LL]S)%+K%'/ITA9<7!_#).YX-QX>'XV<"4>_P]._K?-J6/YOU
M?JVV90])N2N]7JZ'S?!\E5]_/JJC>%CDQ*RPA=:-2 (KYC*XK /P)'3(Q<7H
M2F/N7,9P%V*(K\2 [XH9.RF\F=E_P\UY>7S2FI"#E861KQ L^&QHX2M.*1(V
M1=[:YA< ["K-UT\Z'7#=ZIA,=F([6IA>8%GWN'T?C34<7G^F04E<ZE:A__(+
M,6#X;4V_I:&Z7BY':V^PQV&S<,P'%;D$[:4#A4Z ,XC K>':&68*MIY+)Q1G
M3G/NPSEX>4S-Q?[-AN<9T)-9X@6NL'2;18A,B^0\Q!P,*$(&0<H,S/)8K(@J
M)34)&:] F=4<W9I)NRF^&0O^,2H/\W,*(\,!_G9\&+%_6UYUR^/J8W\,1-"W
MQYL: U5?8L$C16RV>$#C-#D07($/H8!3PF .(4F>&[/CGA GTLB5Y[P(0Y<6
M9&RC/"VJ/H5*! KA7):%?A0AE5*$CF8_^K@>X)PFXRFY=GF036?%EA-P/P:P
M8?ER?7BX7FW!/=]L^BX>;T)<XN_K\34"B?E=^%+?_+SOP^I@_+MAH;003FH%
MF*, %0/Y=;'.2L+ID *6[%L[5;NCON>T_B]#R3W;N[&C,(WG8[*I+@X%H"(F
M$D@9$DA&0"$D"T+9;%HO)WOS?-MDF)053)+=(2"K)B^!&#<F6A&5#"D3$_>=
M87K<960N?+P\OG>U7L,!NY7FQ+]<T(R5A$\*'.?D6/)$+B9W"7)P6CH6DRKM
M/?H+$&;ER<^5/[N8K2%W/A&$NMILQ?\J&=<Q6!] .ZQH1(*H;28Z.Y?1*RD3
M:TZBZ['<A4WRWWPR:F+'9JQZ0QKH#E8OC_L>5^G+[^32#"%5]?P<NE75WE9+
M-47M(A.II *9&9):&@.!E032H;(:N33<-R;:/>#=A7OJWYQ[4UF[&1W?;CYB
M3X*O+Z[8IQ,O*E&4S ZL]8XP):0A(NA'K83*,? 26T]UMR.Z"^GTOSGI&MIT
MNHTO8X70! .T-@P4DB?HD+Q#X3 @=]QR'O>Z\?4PF=Z6G]?K7#_U _:?NH3#
MA_4R+S!$65 STFPB9]<8!XZY ")YE(P+5OP4TEV/9DX1RTX\N&YSKX$!FI'\
M^>&ZWW3_.^KA;:&Q'%8'75QBW7;># N7)(\)JVR)!IY5%IQE$;Q"9"6+*))H
M3(K;$<TI_=24& T-T8P<[W% ^IB/).,K_(3+]5%U24\G9::Y],E+\(QAW?>B
M^3X5A$2XG(P\2-<Z>7XKH#D%%DVIT<X,S9CQ <>U_V=<T7J])&#/\V&WZH9-
M7;T_G:W;)E&XHJP (Y.LZS:A1"6!8F"=$UHC S:FR-V0S2D0:,J5"0QSB31_
M?G999[_2S].4/+Y<'Q[U^)'>0MBW+N&4U8^W/F[Z0LB[2]NJ)K)ZW=<\M<8'
MOR'Y*10 O*O+$HV+"_L<[P+%AIM%,()S1NN1UY5%R0GP/!N0V1J&V=H<PA2A
MUL,A-XD]KWG\S4$S#<'QIY/I)?_W\3:Q<Q?]FAB$<X%!YNAIE*(&GZ.#0G.Z
MYHYBHM3:)=^K@'/R\O<Y%JZ-?F?)JK9)FVM$?(6E6V$^J:)YMR29[B=-H>@(
MC5-@ZSJII.#@C<O .!9NN,AL;V-D5UEFM<\RQ_&P5[),3OVJR9=A^/AFN?[C
MKY@/\#2_^KQLL'^/:1F&H2O=]K1*'?$DW,D0%H8SK0-$3/5,#B\04E80I8I)
M2^:8:1V6MY=B3O':'-F^)WXTS)=>$>%4=8OH@DQ"6."H'>D'"8ORM626\" 3
M3KO6F]BWP)ER1-^%+5'98JROV9M<"_J9A\"9@R"C+IYHA+JU-IKZS8^=CVW#
ML_N,P]96G>B8!N>>RUIJ4+!.0\)8B-9%""PZ1"<BYWI_QS0>.SL[#4T>KO%V
M2?N4C@^K9C'?A;0+8X32O!A(2B"H6GWH1$9(.NN,AA8$TWI+])X0]Z21ZP*J
MFT(H<A:94RD)$-+3(NI* &>S "F5511"\9Q:ES),(,:<9NXI>7ME/^61&;'O
MP7XI-JJ_'IW"\6_>K8=-CYMN6\$\!DYG0N62JDM(HF"NATJY!1?JZ942I9 Y
M<*T>B>8/%6E6<?0,.;\7JK3C_SIU5T*AEULY2:P+05$%263C6F@)A2M:VU6)
MX(J)$+-+*G'F36Z]YW1/B',*?/=*SPDMN>]-JA=A6?N*?/B(N&F^)77]AT^T
M 74'21IM-WW8K-,_/ZZ71/#A]?\<=YLO1+!MEX-KXZJ;ZLS0<F^YA%SG'N6R
M!.>8@6)H5I(&:5IJW;6C#?*=-]VOH%A$IKU0S@%R:6DX&@X^20<:.5/:1$-A
MR.2ZF).+^0@<N[(%OYN9FBV<?^M6ZWY4P(E0/A2CBO'@6> 4JTJ$D&I/I\"8
M,E['B+PQ62YCF%."8 94V<E$[8IYKA*6)9D22QIT2;3,V^ AR.0@26LE2T&Y
MYCTMOC6OW%^N=P0,*:[+XT?_O[ \Q@5/FG-C5:VJK+4U%,R%E'WM9A95\(HQ
MT[IDX1H8\YXQ[V7]RY3>5>DMMR/J*=VO*+*.6GC.((A(D[#F"B)7"B3/52;M
MK&Y]6O4RAGE/?SO9?2=U-S/Z[SV&X;C_,N+80MJB,3S80,*!51B)@D)3+,$<
MN&B5=,%;65IGQF_"<L_P;]KT1&,6--%_P_KE3:B9CM,.@^>"W9H#2=UF4930
M&(,E6G**,8,@8>L2SHQ+F28J*X5L7L3\+51SJDYM3)#&)GFT+14>25BF(GA=
M6TGHXHG/CC G)2QY<>3$M0Y"=]I2>=QC9XU)-*6QFI[%7M%;OA",1>#28ZC'
M-QBCQ=#593%K!,P^LH+(N&A=L'/^^<UD>5-KR3]B'@\PC?JMAQ/Z3S@LA#!D
M.>>!C&?KGBJ"CSH"JN*2DCZ+T+X-WC=AS<G3?C CKCL>WM(<[3E?FTW_LGK7
MKQ,.EX$YDY/(!K*L1]B5M10,D#N 41C-%.8HVS>-^2:L.7GF[7G2R!SM>?(^
M_/$WFL;[+BPOX4HZ&Y510Q3D-2H*&,"+E,#&G&1@1G,W&4UN1#6GG9OV+&EC
MC&8D^;4+L5MVFP['H[)770CIK?8Y,Q":%8HI%(43GM9V^JDX$YU*L77_M&]A
M:BCSMB1AL_""6:-= BV3)RFM("D=F99%RY5/+#<OG;R*8D[+:%->7!X,.QJ@
M'?G7JX/?L3]\A7%3$\\G6#A:+4MTX),B+-9FB'PL/"M.FQ"\DJW3E]<CF=-Z
M.2TA=C?$SJ0(<;.H=1FO#X^6Z[&OX-NX[ ZV#3M>G>1;S[7L.*WE.,5^3D&+
M:(QPTHX=A&H/1,+L,-0]"R64MI&CN^2F7]FS;@AG3@OJ)#1Z+-,U3:-W8QE<
MQ;;M&'. JU0!B82",R36>U,!L02>.04F:2PZH*6H?H*,^@UPYI0UFW1*:F62
M"3<0'[23&EV,Z&EY3;6'E$J$G?BMP%IR/Z.13,O6GLX4A1V/FVJ;E'F/8.AV
M&=ZQD<JI4U=8<3D+!"8U!XIM"OB("A+77 FK)+K6^T$7 .P\+8>A]@.I7ZHA
M/H7E.!UL7H:^_T*Z/MF#*X4S7:7T*M5V@9+B-FX@2"6U)\=5-,^UW G8G,*)
MA_/BRKS<W";M9NB/-#RK/_&UL^2P,,93Z(X!I,):8E(LA, ]%&9]09Z+CJV7
M[^MPS"F4:$>&G37><FMK?4Q/?X\)B90T,?^&FU,1E9$A&VU!F?$DE*.(IM:H
M>9V=-")*3*US*+?AF5,\T(X+S2PPS>94I,".PED%(FM1/8(,H0@&Q4H,UG,O
MFA>1WKPY];A^>SN;/UC#;;(%/1Z%[K2EU&E0^95_P\(JI;QP#*)T!"D+#3$4
M7K>+,M.(FEW>P+X^#_"M!\W)-][=NNUUV]B_)?<^Z"2<AF E Z5%!!<4!QU4
MM,9QGV/SXR_7=&;<U3\7.;&,G**4Y$K-JD5285:@4\PV>ZY2:=YX\F;_? X>
MZKTL>V4%>K!RFV>TS_M#47L*.[V%K$T],E^[6D9=ZF'JK&4Q]/O65KX&QOP<
MT)ULO:NBFUG\75_;.6^^U$.$F]K@D(*BHY,#M0OM0Y#&1C!)$@=]UN"L3!"M
M4,9:[L@E:EZ(?3.>^3F>.W&@F>I;7FMRH:,M 3F[X[:6K_S1+9>+R!A/(AJ@
M%=F/>RG@-$I@2CMF$+D(K5O*W@77_#S4G<C1W!3-2'+V=%L7(:80,":*C*0E
M=GJC0 IDW+,B@VB=GKN/L??KL.YD[ >IM)E!;]GA.N'>URW5+#F7I1#CE"8I
MC100&:%,5A3+5;#$O,8VOP>\N]#"?#^TF,HP4U3_G+JML@230])@>:: K=8U
M^I <2![(B4E*T8RUYTJ8AV?CWH4OXQY)'S*>":@\YSE%PJ%K5V9!$:D) 6PV
MA6<*'&7S*QAN@3.G$&A'-MR4D-O5",W8OBT/0'R/8U7[->)J'Z,R/H*LI?)*
M)P8N:0T:!:NG(@QGK5VC;X*:4^#4F"%M#=*VERBQMS^^%E,FHLJBZNTX2H&*
M-05EI ::LGF)47 LDS3DOA'1G,*JQ@QI:(IV[E;WJ<NXRJ<3VRF8Y*5!R06%
M_Y@I_#<$)A.LH-$6E<F5YZU/_M\ 94ZA5&-"M%!^RTV_2LQS[MW9O)5<T,5J
MR(56-95S .^JG)@D+73)EN9W<MP(9DZQ5GL7HX$!)JDG/MMY#,FD4H]^1&=
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MS-AZWR*M9Z!38DX+QV,$;G0W8^J^T8^&]0;"7<%Z@XNL&A^;O"07_&0\^3K
MD(Q1FM?$%'+&N,_,RZR8 Y ^@T-A6RSQ&X,>#<>[BW(%M0UNKSZ<P]G9SQ=3
MFMZ4YA:RB 'K':G)3%N7F!?>,.,A*,C<8&H1?;@QZ-%0N[LH5Z2 -+BB>G6.
MDQ,Z//XZ&?\Q.WTY/O\$HZ\#.B*T\LDS)SR9#])XYFU,3%JAI#.6F]CM!N.>
MP8^&ZNZB74%YIUNJI0J>XMG9)1PGR-+G&FF**C'M0Z)M)ALFO,U&%Y5,QSS,
MNV,>#<$["W(%KYWNK9;VX/C\O$:QQ^E?'TYA@M-W%[-:;E']O0$*'PB38RJ
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M&.0(S#L)+@4A>&C= 7X37$>J)\TIZ>%I@5?_?3&<??T-9Z=C@O89I[.Y( :
M"@/Y#0Q+K)WZ:-Z^D!C0\"!L2")!ZRUD#90C58X6@F]X*7L3U@=,%S6G"J>U
MI>/X8O8[0AZ>?25W B?GY'"09?4:AI-_P-D%OCBO4:.!+Q&3!,4,!E^SYSD#
M83UYG3Y'5X+PS0W?G<$>M4[U35[#=@27P"_S=U\DFL%TN'QZ9?F$T+ORC_$B
M+D+X:9TL?FN">4"KP:"O,*U*9,)K3D<N((N P5J+4M_N]MU9Y79#>J3ZM@?:
M&C92N%\TBPB;%VA$]0=S\+KFC L6I PL^^"C@-H_P/9Z@;&7;JY[49+6XGXL
MG5M_QQEI<?U2]0L_TK^UJ#8@,:C:V=V79,C\Q]J=3EOF7.)9B.@XMGYJ8C62
M?0>TF_-\I\]T9WGWX'C?1759';0!KIYJL-9A.DPY5@O>'E2%#D+?JU*H7$(!
M8$+5NP&3'?/:)8:<>P<FDJG5VC;>KS(\4*BU5UW80M9]W,@M1%)!36]>(R[#
M<4I( F%T??C#DJFM@2;-,[,NV%J3$FUIK0L/83K$ Y$MV+M]+]=2]#U<^:\P
MEQ?+H' 4B=?3,=9VQX7L+"0[RWGGG/(JV-O-,?IP8X[1=F@A\1[N:E?!6CA'
MWY;!!@![LB(>!'<8<Z()E1NH1W<>>CA4'@:*-B==,>:@Z2C%&H>BE<%<X3%;
MHW7)>[@*V8>B/&!J'$9/MA%_XTK3#[/_^R+CL@;OS2@MSSHRH4P0(;,B%+GL
MW%D6(WAF'' 1"P]BH]['J[^^?X.A,07CIO)K7 +^3SC[UV5'KU]_?;D$))-0
MUB9!&JMK3QH.+":T+'A$I6*1SKH-"%WY\6/BL[OT>MC KR(\WYP?)6W64@ C
M78JT(=5&%98018RYR)0UIM:QV+LHCLW@ZRCG'@*L-Q&]I)F>C"?#_[G>+FP3
MA#T9>P^C.XRUUY7'>]6B&0F];Q0KD0)PJ[4.C#Q96A^"G&6PRK,40\ZB**NQ
M==K\H=3D 5MO_UJRC>Q[T([; =[+5QM$%N@]9PJTJJ@$ TZF;LD\VL0U+SXV
MUHC52/9O1[3F[(&(^@X"7VL<[C&E_EJ"27])]2L&Z3VM_J&)W4JL5Y&#K6]0
M\F2T"\GSQ"&["$+;0#\\F%B_8KRNK\"=G\/DZ[MR]>6_C<_JNZG7PJ\RI(2Y
M>%:@D._J#3"?G&<BD1,BK5+*\L;K>Q-<77>S7\>CDX\X.;^>_I1Y<"4*S6PN
M@6FC%/.^NEU<*XY:IV!:AU%7P#A$8]/&>G![)^LJ[![NP^^9\\(3T,6%+&C3
M=F!4/<PU@Y M$QQ+M.3)X>UG9/K4^_T^M-NW/C05_F/)S5AA$'*OHBF8R2!T
M-2W;%!:POA^8E1<R<FY#Z\:8AW>S^R'Y85][&V$?QGG:!.%W7WLK'K?WHG8A
MX3#J8CD((VA?#3'+>@D962B2O,NB4B S,H+J=_=XS+YVSUJRC>SWYVMG:52V
MLL8%,M2I<O(F%S\26.Z3:-Z&_0GYVEMQMIFOO8W >S!2YQ5>UXSFR_"0-3[(
M2--+RC+-@V$Q1L$P1.<TV$*P&JO!:B1'IP8-!+Z/+@8O3V%T@M/AZ$5*%^?U
M_0_,<^@OQ^>?)GA:M]7/>%61O/N]RZXC=;Y\:3+%6S<P4GI5E 1?G-0*9!3>
M<7)B%-I4^U$,=AVTVRK?<+ KUTL933JL)?E:H;[?J0P#+P7+4AM=N''2M\[9
MVA9CUYWOQ;N7;U[,%E7/BU+Z]S"A%?D69^_*1_CR^_CL[/5X\@=,\B!!\284
M<DI\?3 %LV>@3&:0C?*U+YF-K;?#+>#M?X_L59]N[YA]$=7'E<^U-@R+\WX@
M4DZJOA:N?;W$D)P02=0LT"%O#;<QY-;YL'=1'$!#^B+MSO,UG23>1SNP>Q;$
MSUC&$SJ#TQE,I\,R3'.K8GHIE &7T:2:BY,+U(QQ[5AP.3,GN*G=T8QKGC31
M >[Q:M6^..PA^?8VL-<DQ VVZY<7DRK(]S@9CO.WN3B'(AFG27*T@#07P( D
MQX)W0EO'A<VM];$E_N-5T(.QW$,*T7V+[1+C^]H[EHA;(=J!!*="A,#R/ "N
MJQ-%?\&*CY R34"[UI=8'2$?KU[ND\L>VD.LM":$+Y@+N>.TB>N2 FWG.K+J
MZ5FODD;9/#C]@/W6F_^W3%!,OH3('2N*#'9-WBL#83BS17#MC<M)ZL/X?GL-
M4>[7Q^F+H,<2NOR6!+M0Z#J_\0@OW[++7 JA0F(UOXAI,J 8?2)52299'"#(
MYL_[W0?H4 '-_M1@W:N?G>GH+33Q#=,R87X34#V%-E<".O KH-V)6QF?:"'U
MO:E$S#P[KQ,KL18]8>)DN K!$NCLM8C.V-:WE'M4A4U?!]V3)FPC[!XTX-K6
M^'$"H^GB1?(7^?^[6 12+E-78S0R<F0")!W""B4CR[%F?X&+R3KE^[RXO@?9
M_FW^!C2NMU):<=##)>PUE'<;G4[OH%4\E5*T9:;62^H<"P-'SG#$B  >3(3F
M=_M;(3PRS6G-2;][S5]IYDOG];*>ZV^83W#AKR[A&A.SU6A8MAG)\L^./&8I
M69(R9V%=<KA16ZW=5&@3B$>F0\U967L1VS"D_M?Q./\Q/".%SV]&,QB=#,F*
M?S&=8I>JA0T^VCE0OBWP6S%QBQH0G3+<<YT\AQ*LB)Q'KD3220XV^/[NU<:7
M'W]Q]^-7KGL"EW2TCJ&O"5X"0FT%YY@-!KWCV:,5#Q"QZ5A=]Z;+,0904NWO
M+IGGJF*VG'DA'5/2><5YT46UMG0NQ][?;M(+@[<WEIU$VH/A<HGC]7B"PY/1
MXK(^?;UF:EWN>P.=+ '*GD 60JH*^?Y6&^:=#Y:C]1!:W]%MCNY(U:,Q+3W8
M+9=(WYQ_@N&DVE,+5#E+'^L[\3PYIBV9XA"R9!BK98710_.67*N1'*EB=!!W
M#P'@UU6H^.OP,]Z9]E\G%5\Q.8H8+$.H3Y?;(IBO[V9EKHI.@6-JGO3]$*8C
M4XRF%/00<;T'WS4C^\5Y#=0M$E\')OCHM*H%QE828F=84#(SM#EZ[K(U3NU/
M:=:@?#YJU(*F'N*G]R#>X/0,M$':E"WC(I.L4O3D\)/YE84.R?L,,K:N\^\$
M^/FH6V/R>FBQ?]]:N;9 7GWY5'OS_(Y5W#3RN_)Z.$UP]E\(DT'4,KI0ZH.$
ML3#-(;)@+;+H($ ,7CFS1_W;%/;ST<)>B&S8@7^W*;S%+[./?^#99_QM/)J=
MTDKR61A;W\>-2C#M:CJ6I#V<*QDM2MK3=>NR\&Z(G[4&=J+OKO*Y_2I?72X?
M_Q@/)'DHP-&P""+74OM<;SX$V:<>1*KW=F6//L%ZH,]:U78AZZZ&^0-H&*D,
M#GRQ9)X&3JK :]4<5J<'D7%4&5R@G3FU+BW=$>IW+=N:L+MZ%O:O9Z_'%Y.!
MCJX6VQ66B@>F2VU>%4I@05NADK40=>OW1'=#^NRU;&NZ5ER9=KYT?S-:2GXU
M]%=?TME%[2AR%230D-$!,!L+)QF95+,;<LT/]AE1EVQ;;V/;8CPRS>J5HA4Z
MU;WSQK<+X=J:YB;:J\F<U<G<!:\(8U19LA!K?UA4P (4<EZ,X,%H*2UO?5O?
M!>^QZ=J^J%NA=SM?_<_[?*=3S!=G^*[<(Z-%XK "FW,P]=61X&J!AV:!!V0I
M>!=MYEK?#AZN[IV^\8A]I^SWJAD]"O?1)>=?MBW_L/CN,I54"JZL!"9$%%6K
M-?,.%:LA<12HBM"MBP#O!;3OY/P^%6!=6GYG(GJ(+B^Q7":&;P"FIW3\&T .
MG(;?G:C;*M!9ROU3'SPJ+A1+LO;5E'3@>5>S'(25Q3LC;6I>K=,_Y9NFV_?-
M^!;";?S4RJMI+<8<3FFK>W\*DW-(>#&KSX:\GXSS19I=M8?6@#D71EN=9]KK
M0O,D:UO:$C6F6NLF-[ ?-ASN ,UJ=R=DW*\T&[_$\O9B-IG+\@ZH'&U(R#U3
MO'8EB[RP(+1GA6OK@^<JW Z%K:1X[0!/E=0V$FN\;G\9PLEH/"7ENHW)E$S;
M4B9+%VE7LC3+*&1@2I;D@0<OC-V Q77??ZHD-I%7P\RMBFGY0-,O^'F8OO4&
MM%D%+0I-T(=46XG0UE#3R6HG&U!:Z'*[$GLE?ZN^_52YZRRGM>E4#3/]?\<I
MN6UI=C$9CD[F%2YO83*!V? S[I[IO\%'.V?Z;PO\=J:_X+9 =8!BT&AS+>T0
M4$L^DLX@PF"#[W?M?G-M@)>TQLE-H[_#R6>\N@60W&@#WI.2<%*7PB4#3CHC
MJE(Z%!!Z>,O\85S=._]<'X-,CA.<#HQ67$D?:89(^UH"QV*I-3'2V1!<P5A:
MER:MPG&()W@;:\+=%CP=Q=W8F*L]14?TC[^^';_%V>\(9\/_J1<2_X"S"_PP
M/LLT6T>NB+3,0:8]-UFL<6/%K,]6^Q2]O:WW*X^3!P<Z(K+;"[8'[_S&[)?3
M?I'2Y +.KBHKQ4!XA0HP,) )F:8CEL4<(D,448+)Z8[;UG8K6(OLB/2E1TIZ
M*!7X@)]Q J.$5013,> A<8M6,^D%Z7$6G'D@'T8EP440P:34^F"\!>$(5:&+
MD'O(_;^ZR;XQ\_FLY_GD<YB+JVRT)GK:R<BN-ISVM9Q9<(FS*'7$"!ZA^<OM
M6\#;5R.H_C6D)TH>2WCICM6_>,HPEBPM1*8\64G:<)J$C8$\;K*:,$0?>>M;
MY)5 #O9X35^LWW<4[23]ODV6"FIY+; )K)ZB2FL@'2:^U("TA]2@@\3WJ!#<
M)9M5DLQY(YD.EN#EZ)A):$M![;&4IZP(#T2=]J<'VPBZ\?WURW?_>/.+"!\)
MV6\PNBBP1$?>UA_CR;_N(%[>^I6,J7#0S,9LZA/VM4E,*,P;%8)VW/EX*]%S
MI3N[V^@'-E1W)6Z\5ZDWON&X XFX%!]F$X1S^G4Z2-_1\;OHQEVS,\X_3<:?
M\54IPS3$4;IZ<B> U^29(T.>;$T/U#2%VOD85':Q)/K?L('B-(+S]#7I$+ST
M?03=M//GNRX4KD"IS'RIV7TN" 9166:*"Z$HB19:)V8^ .E9F:X=&>GA^J2^
M#W5+!,N5M FPGLS8M: >@2';E<)QG_+O84=9#U!G2Q"M8-+4"E5+  ,64;N4
M"5#@8L36>\F>%6,;PW9O>K&-V!L;N:^'7S#/\T3_.1G.\)?Q'Z/+<T]Q50K,
M&^X763. D$50R&H@*4,IADZ_#>R1]2/LW\1H1,&XN?SZ"KI='GR+..!E7@*&
M[,A.9E:'2'Z:=Z3$)3(')?.@.?I0-B#VWD&.@=MV4FR\:.=-V%]]&<[F!LT2
M#QG''G-(S"C2-)W(0@4M:7_*&A"R%'B[P' EJZN^?0QD=I99#Y;:HG7^MQ3>
M7\>+5W/F)PTF,") 9-Z&3%Y/;3,;,;-8,CC.4_"V=2N]>^ <NTG?BHD>(F-K
MH"V7PR;@>GM9_1Y@AWI4O1&-FZE'!PYZ,.OO!YD26#UO^!%JB^,H%?,@"Q/2
M%.6"RZ;Y&WX'4) 'GU,_A'YL(_K6=]BT/2Z*P^H=UP?R8VI^:LT.6IZ W$N,
MR($E5>_L<\B+'"$EE; JV&SS)LE7#XUSB/>RFU$R[DF>/?3JK;XJ??"4P/V"
MG_%L_&G^%,>BN<$2HN EBNP-DU"K3664+*10'X1"B3II,J-:IT]L .L8-*0O
M%GHIG3L[JS7B.,()U*K1%_F<)$XVUCSM>8GUTDXN*A5!_\>R4&1T2_)U?!$U
ML9!L;QE<X+QU[Z^M !Z3\O3'S#Y>$[B;2G\5<1E?B[C RHA+RS*$7<;MH5*A
M\_1O%3,498W.FG.5N,ZN!)]X5!9C-IHKR5<4,^P"80_U#E;K)+ F):OZ$(8!
MQ4(HY(M'%Q,(Y+R'5WP/5.]0BG!>V,AH:T^T3!UG8)1DWM!^'XJ5AF.O<WW4
M]0[;:,)&]0[;B+L'*^P]?)W78+\>3V[ &X3@0-2<:BPFT+E@@79K278B3Y*<
M#V]5\S=,UV$Y0E5H(O8]%4)\P-GL#/,_A[/3\<7\M2 Y,#EAR(0P*EU;="12
MV'EP*7EP-@EE5*]%4>NA':&R]$%*#U?$JV!>?Q7;2[ H$Q \K*^MNL1"CI%Q
M,@A$+=+WV.O!<A?2,]&574GHX89X%;R!=I& &,[JB[M,A^!9)$UF7)4  5Q$
M;/U ^"H<!]:&KF1MH A;2;KQ]=XJ/.]Q,ASGNGDMMS-:#?/@UU6%UW20,#JA
M:5<C]<],.^V9)Z@L".#TGZ(Q;E+"O^OXQZ$5>V-@3^?*0(,77F3',B^$"9*E
MLRX%EI+"DG,0RK=^:>#A/6.'NZTM@H9""^-K;T1?.VIH.LY9*/2CUC&K4K@(
MV/QFZXG6DG4Y0?NBY''7DN6"+BJE:YU]#2D%RT),G"$FP!(]3ZKW*I&G$KW?
MBO6-:LFVD?X>2X<V@?5\:\FV(FW#&J)=)+Y'A1#%)16*8[&^SJ<- 8W29Q;1
M:Y6%K?UYG[(B[%1+UH<>;"/HQU%+)L@B"X%S9NLSX]IFP\ [9!*D\HX;A^4Y
MU))M15SW6K)MI/Y(:\F2"[D^A\%LKMT<O"DLS*N7 A9E)?TY;I+6<72U9+MJ
MTB%X.4 M638A0?;(4-M432_#?$VS!:,X&&VC\'ML0?;L3->.C.RUEFP38-]K
MR;:F<..:H5WDO]=:,B 3#KDT#)V@K=99R\!*RZRA/5#:>4?-IZT8'6O)^M&+
M;<3>V,B]OU[&>)U0"F J<K+H#7H6<^U)C"K51JM:J4W*R9Y,U=%61&Q<=;2-
M%!O;IO>4NGG/3:VP8$)S3R<@I[-06L=*B5;8DD*,FW1T?AJE@KL2VTA^^Z@E
M$TZA,63"2%EKVR!*!IF3"YZ,! RT82FQ 9^/O99L5R8[RVP?F9AO1HGVD>%G
M_# ;IW^]GXQ/)G#>H.'S9M_MG$FY _Q;F9+<!R5%*%'8I"%%CS7>YG())F4?
MXV"S(3K&HFCWQI]A6AV&\YJYNR@XH3%&)XMW.[Y>_<HR@>E%C4A>Q5V"BPC"
M>1:$JE=AQK&@$NT54*PCGY7'V[':[B&JSJ@[Q_!V1?#NT]P+_RO]8GT:;1&+
M_>NDO@6?K'6::UJA:$6MV$TL<F%83%+7N"<(T_H)SAZF<8 6^?O5X3NQPP.K
M0@\)HCM/Z=5_7PQG7]^,ZEDVSR.8'T4?3V&T<K(# 3Z'1$Y%\3PPS4-FH$GX
MQ8ELG7<>0_-'TO8TM^_KX#$H31^E2;O.\^UX.:$[$YY/$/. (^?%9<]*)/-,
M@^,L.JX9N4[>&TC%Z.;9'KW-YOL".(QB]-'Q?.>9753&WI7Y/YV^^$P6:[V2
M?CV>S&<V\& $" GUS8?:.Z\(YI4R3)=41"X\Q]MQH ,J_/US^:[NAU"*'M*5
M7Y&3.?Z*N*R>7CU-6K*?R6/'/)_1].-X!F?7_WGUO-^.9_]57[Y(XY/1\']H
M%3NPPJ))3*#T-+L(K!IR#,%R%VL9OVF]O?<VF6>G[H]#+>[JNWZT^KXPU^;5
M3O._JK\G!B;QF+PTS&I(]<FXQ'Q6@CF90\G:)>[44UD$*V?X?64\'@6ZNUQ,
MN^SM!\4^72?W15P^%UKE2@06+9#,I5#TIU)8\!&==4::U#J=O1GX?65^']K&
M.0C9CR5K? &??GD>#XXE.@@Z,Q%KE2IXRZ(IFF5//WL4B>O6Y9\W !P^U6:O
M.C!NQ<4AKD#6"N)J&J-<\]3>PCDNHUV;S*FGC)T^YG.89)\.:K*M>[<OCI^*
M_OHB1(JTIX02!)TSV3#O8J##)@@>/2:/>X^#/1J]?2 7Z9&K[3;4]J"NWPSL
M&@=>W!0N@_I0?$@!:I$;<*:+%RQ"[0.@C15D)>LL6C=$7POF$?H]O7.]SA/J
M1%0?.?O#1*[7'-;"_UK"<D4X9PE6<<+4+F\$BR"Q$K4OZ 4/<N,\_-5#/&.M
M:"G\OI+MKZ#]G7B9_O[A[Y?I0F2,9JLU UD?+/(FUYH$8* $EP0PFMA+K?4Z
M0,]8C]H3=K#\KF5 MW%VUZVO]I/;=1_T6YE=M))3SAE#=)*6=?">8\[@O 1,
MIJ35F5VW!CAX7E<L$'C,Y"/G6F8F+6>0:'LRL5@>@W+8_*71IY_7]>YB-IW!
M*-<JOHM%[JSR$$ @+4FPR]M]@[7W.^>9@S \M;XV:3Z)1[CYMM7?UCE=W=3@
M,65T+2?TZ@M.TG!:K[&6$Q(V2.]!,2&!SAL]?X2]'CJTU7&?'3C;.H[3?!+?
M]7JO:M#734Y\>$+QX87Z3QR>G-8 57UX_H3LG$KHO#1J-)O4TFPX^XB3<SD(
M&HJ)B(RKD)A6"LAN=Y&Y(J4,9-@YWDO2RGZG^3S7QB-6I;[RNCI,^=IVL.&4
MQ0"SR[5JB!6L]Q^AEI@#UPQ=+F"]!9#^D:V>':;Y??4\,E7J(5&LH9%X:\I+
M8>![<O>QYCNG$*5F0M2$!VX3"[1QD'N?M/;<J+C_P$*;J3W/5?+(5*:'E+*&
M9N:]TTRV6.G0,Q?K$WO9U5@Z&9]<V:P\NI14Z_#'GJ;V?64\ I7I(WNLW0;P
MAD[#X6@Z3/^ LPL<T+R,S%PQ:3-GVDMDGH3.G#4V<!NY+H\FE?ZAR7S7_H.H
MQ5U]MX_(P[@Y,3'@- /C1&32I\PT&DO67W!,<.US?<(H-.]+V-]LGJ?&'UXQ
M[JJ\>SP)PM%YP$QF&[<"F';&L1BD9S0)94%)XZ!Y=>PS3!#NI,8'(?MQ)@@'
M)TTRRK,BE&3:.,? D/OADO(\.*V4;!TP/+($X:UTX-X$X6VX>"H)EIO,Z7N"
M\%8)PENIR3XR+7?A^*GH;RG22 ^">6%K(0H9Y3%89%('E,"S3:[U6TA/1V^W
M2A!^=&J[#;5[31#V' 7H%!D'3NX?G1_,9U[J&V&>)YM2Q-:/*1][@O!67&^<
M(+P-46OS0QJF[_V"L5XH5"MY.BXO)YB'L]W3]N[[6N=TO8VAWDK3\]:@$CH+
M+H7V4#R/$2Q:Q0-R'\3@O@]W6[#URU=M/JY<$2^3%?-':XR1U141+#KZ$^UI
MJ" + M_:A%X#I7MV\:?E<Y?O2AUBD V$*$UAM02NMI.US"<56= F^%*2R[S]
ML^XW,>Q_ VK!\]TTX Z2[2&U[.8<WY"C.<'I['>8+9X?KU7<-=L53G! OG16
M6BM6<JE-Y1UM<LD6%BSW+F)(SK?.&=L<W7%H1T]L]&"TW$2Z<( M2IW)J&/!
MZ,1TPLRB35 S8T1T%J0KK4WD%3#V=7?5/__;2_6Q7"W=G,?<ZI>6?LV2ODKG
MR?#2W#!O$5F.42;IO2C8.I/Z+HI#73)UYO5>/=E:OKWO!]<,[DUP]73OLP[3
M8>YNNG)VKPIT%/@^%2)'96-MA*T$^OH.J& AR\B*<TJ7'$W[9V#VJP@/7(;L
M2P^VD7/CMN\OI#&_CD<G-='O[7B&TU\NL)*R])8EC\8**$Q;6:/:PC+PQ3%R
M.)U4PG,=;R7^K*Q;O7^40QN$NS(Q[D6,^[AT>#T<P2@-X>Q:"\Q?<#+\/.]X
M/B5?_#4,)_,P[V\(TPLR;2^30CO4%+88M?,E1O.IW[KL0 /*I" =:JF]%=$[
M51LI..43E&0&+0!TW>^_C?9MJ"NCV"7C9/*6=#Z0B2.!UU?1$E-@/0?O"IG,
MS3?]>P!U/]TN/TX+DY0%SEZ<CR]&LP%@Q&*\8 G)&=/)<A80@#G,W!L$X:%U
MY?4Z+(?8 5OIP-U3KH&\&[=F^(WD>7YQ_BN.3F:G[\I'L@#^AOD$\YM1?9[]
M]=GXC_G/ T_[?N 2F? 8F2Y",W"$D?X4HK32^(WZ-&PZWC'PWIM\>[!T?X,O
M&^$4@\@)9BR<E>+)$,A>LA!R9$8481+PJ$KK6H"-P1V#UO3+2 \E7+?N!<C.
M&RC( 7WDS*=(OH"HUT>)C,60@K?.UZ=%6]^TWT5Q3,K04<8]E!Y=VO3S^W]P
M21L%GGE3MZPL$UGQ4=5>\:2#*AB(K5\RO#[^,3&]LUQ[***YFN4UBYQLEU]P
M.CP9U;O\%].Z!\USOJ]>#" !_CJ>3M_B;%!2G/<?84FZ>;.9>H],4U'<%*.C
MS&!:EUIV!GU,VK1?!GNH5KF:P#(_,8(G6T@S8;(C8:3ZAIP/S-H4K1*.Q]C^
M9+D!87^AF?Z58GN9/I[@S%W%_GTX_=?\*A)!)8'&,S!"UH<_@?F:R4KF4!9&
M@.:Z?0[#>CR'"]ATX'F#C60G>?=R2W^)[?(ZJ*9-+>\M-\'66^AF/:Y#A6]:
ML;A6/1I1L&\UT06B\B*S3(<=TRHEYJ40+(B@ 8-WP;0N=-F_>CP8U#F$=FPC
M^1ZTXO5X@F0*O?J23FM*)OU8\RXOHQ,NJF238Z&&LS1X.F53+6=71J@H4?C4
M.LQW'YY#6J9=F1OW)/8>TLENI"S] 9^6J**N64D>R1FK.3$:#)E<13!'*!6Y
MW-GYUA=?JY$<D1HT$'6O)\4*I^CGKTN':?[Z?"T$/1U^FF^10LL<>>+,B=I-
MM]9_>H-(6Z2-Q8:H0O-;D-V0'JM!VIBC'NY*5\!:KJ)-@/5DIZX%]7B,U-;,
MCONDI8<=:3U U)!%B9FAM[3[TG;+H+9UIZ4#2?!B9&B=DKAG?=G!:CV8NFS#
M1@]J<CTP1 "7IVDH7!CTBG98 _4T!194T35U!URL"?JV];FT$LC^[99&1(U;
M2[D'H_4MSM[,W[>K^G\3F>0"8U&.2>_)B :.+.K(6?)9%BL4J7WK=([U:(Y%
M"1K)NP^/]O*V^"8JG[G.2M<*"\Q,DWW%?%":!8"8/#B71>M0S&HDQZ(!#>3<
MGX5Y&>"I<JW''3BE H;"2L6B4_*,)IM9Y%F* %[QW+JL93628_ ]&LBXAXC\
M751+)=\$5[^NQ1U,A_$L6O#VH"IT$'I_CL-=? :B=DE*9DN6A$_7%V!X8)@P
M60R\*-OZ-FN_RO" V[!/7=A&UKU<9]T3[%^>6E;&8*.JV??!UGBR9Z"%JFLJ
MS%O_@&P?5W\0UL%,A8X<WKFK:DM '^[#>)2_H5Q"(EU7)@3.5'WZ4*N:EJQ+
M85ZHC,9XGWUKOW$%C"/1@:X"[KVZ;;[]6;3UX2A;GP9$FF'F]*>8&*+WP+EP
MMN>ZMF,Q$3O*MI=DOC6579O@>J[%K5MQMFE1XRX"WV=QJXI<2:.0R6)IF[,&
M67186!1>6L4Q"]EO"X3'5]S:BQYL(^?&Q:W_A:-?<#0^'\Z/H^LYQ\NC*86:
M3&XL<[6'OR[2U5@L62<6.<I8BS9OW1FN+/=Y:)Q'5."Z%1OCGD3Y2$M<?ZW*
M1(..R\IHRUX+7S?$<HARV%W$=*M(MIA@>=&^R))U=CI&K<BPI!TG:4 G=RF2
MW1!6GZ6SP7$S?V76.%O3E6.-MM4\,B^"5E+E')YHZ>RW;[^[)MT7TRG.!HFG
MR".9CK&0-Z=+)LO>9,\*_0]ZHZ*,K:]8-L'UV.H;MM&-]5D@C7CHI3O9O1A_
M'4(<G@UG7P?@?(A6 R.WHY @E& Q&,."R=:7B%SJ_FH;[L?VC'1F-SYZS4);
MN*-2050\%!9X[?JI@Z[%8))Q3^8H1(,6GD7I2QONMY?I8RE]67=SC<ZHX,E^
MC8Z$$4E 'D5F,6/D-+N@2NO'2!YWA&\K;C>,\&TAXWT&<S;!]:PC?-OPMG&$
M;P>A[U,IHE6VU!Z.5KG:L0DC02O E)/!2X\ S1\)?A(1OCYT81M9'RC"EXR6
M4FG-I-,UV" E\TI'5HQU" (0BWC6$;ZM.-PAPK<- 7N*\,4(128IF$6CF,ZQ
MOF*@ZN-# EV*4J$VSRK"UT4'N@IX3X4LWRKZ@C?!6!2L8"%LNA L,(65+'RP
M3A7O^O,G'F^5=!>SL9F\>VG3<T\-UR;8OE=);\WB-G6PNU"P[RIIQUU.(EEF
MC$A,T^;%@E.6924)>2D91/O^UT^I2KHW[=A&\CUHQ9HZ38OU$5<+C.9&QZ42
MDH4<.(N<INYIMNW?]GD2);%;L;592>PVHN[!>KRW7CMSCL9QLF>Q-J.Q4A%*
MJY@R7I+-ZS.XUJ[%$RJ3[Z(,S<3>4_[(92);P(2H!9,F<O*I>62^>,N<M2(0
MQH2I?</80^80]$3WCB+MP5K\&<Y@E/##*>+L,GX\/^'("'99Z,!<CK4?F-<L
M8D 6A2R<_B>4TCHI=!V68_ 8FLBYAV*25;B6"KX)LIY\A?6H#N,IM&%O Y7H
M(/H>=O[[$&J=# C:\["^B\F#8,!I%_,Y6S#&9A5;]U':MU(\X!_L72>VD'CC
M+,)?L.!D4CL2I_$Y;89?</IBE-_-3G$RS[R8+L\R'J297W5*7DNCY\]\<>^8
M]J8*)0H!#R6*;3'<_NV!5NR,^Q5MX];Q[R?X"8;YU9?ZK.D5O-_);J'CD0[&
M2XPY:C)[Y#*I4I>,#)*/9!&%E(J(1=]NG+22_DW'.PK^>Q%NX^7_?CR=X?PY
MV7H'\BZ>#4\6]=7W*.]E?NQEELWPVT0B."ERR63FNJJ_Q=#.Z("<&Y)<<CZ9
MI#;1DI:@CD.5#D93#W[)BY0F%YCOXL*BHBE@F0J<W*Y,<@+PM"*,=&@2!NE;
MWT&LP_+DM::IL'ON/7^Y#1(2YWF@TP]J(P>'+-2NU:4(X6/,1JC4F/['4,W0
M$_$=!;RO5O0/=WG*69I4[\12X+IV+U<,,DJ6H@V9%T>@VS_W^Y1;\K6.?C;F
MJ ?-6M\<9A-@WUORM6)VXQYKN]"RWY9\%JT5GM-Q*#S3=""R:)5A.A*R0&N(
MR]99-4?1DJ\?==F&C?UUXZJE?SX(9-;)0%B\92%6-SY)I6*06MZ^$GD.W;BV
MH6JS;ES;R'F_7?FX K!9%F:K^:Q3LBRJ DR3#^6%"3;;UK'S)]*5KX,6-)+W
MVGW@L&6X=0L=3^HFNM>*V[O#'J*X]H')WZJC#3Z!M%9S9:QVTL;HC-;.\IBD
MDSKN4D=[%T&//LVOW^J=%'"3$UGCR&N5$[?D; ?C&(_DR'&NC77M>[)L@JSK
MYCB_:7HY/O\TP=-J6=31ZDU4'>3&$X??3 <LXPDML'0&T^FP#)?!E5'^"%\&
MP&7TY)\P+7PMLR<)0?"1N5R*4R8HEUOWMVPZ@4.F,333O]O[\>$H[N$POXWJ
M-4GT14H7YQ=G->5[W5Q?7DPF)-GW).UQ7LRO3L9C\4H)S@S4?A/>UZKDE)A3
M.=1F$R5@:R^AZ02.4E\/1_&C>,;BYZ^+^7R8T6SKKU_>*?[\=5W:Z_+:J"17
M?(XDY*#(9B-;&Z0D6QNC4L9G5*;U]>O^9K?_LN?>]/N1JL1C*:V^-[=;FZBT
M<[2&"]*$'" +B5O&P9.360\?T5\/D\=8+_.X5&B;4IQMJ-S[2W0;8/M>BK,U
MBUL]2;<#!?M6D^RB C(N6(JN5A;2GR!88(*CRK)$%+Z_W>@IE.+TIAW;2'[?
M#Q9RAR4[,C%3YH7<I*08<*0-U%E'(H@ JOFU\M.IQ-B*N6TJ,;81>R\=IKZ%
MZ:7&Z#$K9H.JKT^0LPQ&2I:LM !1@HS/IA*C"]T[BG1_I7?..>FC5(Q<@42^
M)0&*B@L6!1E+FG8X&5I[7$^B]*X+Z0U$W6OA]E;15"]D<BXGAMX9IB6OK4RC
M8$%B0-J2:O[>P5WR[X[,3HY,8_KW^M#E)L"^9]6T8G;C-(E=:-EK5@UX[Q0W
MM(:XKJ7UM1%C?7S!&VZ#\1H*;YW*=Q19-?VHRS9L[.^A2XU@"G FR_P]C9B9
M#[R^OZ;!&-J"K6H=4GGT#UUN1=1F#UUN(>7]IM3X6.@_$>A<]62I"S+701;'
M1)8AR)P5_>=9IM1T48)&\MY?:IW6:,CL5S1%Z^O+ON2O)0RT_WFN:>?C7C;O
M1O'H4^NZ:$ #.>_OH4N#7/N4"S.B[DYTU-4./)P./N1!D"^?^7-YZ/)1NS4-
MZ-OG&YJ;X'K.'7:WXFWC=Q-W$/I>VRXG&04X9-Z66/.1@,7"+2O2)F<E.&YZ
M<DD>=8?=7G1A&UD?J,.NC\9JVA.9,L$Q74L7O+>968Q"\.R-*^WOWI]2A]VM
M.-RAP^XV!/3@F:PY1>=K @V CQR9X>0J:9<S"SP6IHHR&)&.SMRZ._\]<+[;
M)O?:)JV([*%:<0VTR]*)#<#U9*7<"^PPIDHS&C=3CPX<]!(VO \D",FUI2,Z
M)2^9ANA8!*C]0WC)&= [V=IR.8""/&"^'$8_MA%]'S>GX^GL7?D USK(N!!$
M-(()J*<RZ,1\R, @9F=CM-8W;YUP!\3^C92&)-V^->TDX5[LDD58>]E,Z+*1
M"ZJ(-M8*NVHL(<TS M(QSJ6*H@#JYO6'*X$<$_7=)?U(*P]?PF3RE4RS^5]>
M_X6]%B(^B.(0=8G;B>96F2)/"$+81)Z1T<F"#SP4)U.T/GEKTBYEB@\":G3K
MONA#]V)TLS_0'$-^-_H=T\5D0C#H%]Z.1Y/+'W^&Z?!:,0,I!*KD'2/7S]<>
MQH;5O9(AA@3D+.9D>JN#;S&!5JV,KD(LTX&5(J&+DJ#SVM-/!!:<U2S+Q).V
M)J?8.K5W!8S][\N'TZQU_8]V9:6'0_QZ2Z9O@AH8"$H[KLB4*+4;6S(L!O3,
M^:@2U.Y_NG71ZTH@WY6E"S/]98DO"A/3UQNUMG.)O;B&-23A;-; >.TPKGT)
M#%3DI-H6N1;>)6RM1=O@>\[*U1N//41D[\/Z[57=ZW@QQAB"%P00:4M-M8T@
MHF**ME(TO @M6U^8;XOQN^[UQ&</P=OKZ=LW<A;NKA2-0LB@ZY[L SEY0C#0
MR!G2SU:4;)5N;6)MCNXYZUQ/'/9R$[\.Z<JUX8I4HL14&RO6M1$+B\DGEE2T
M4BFMM&W];L9V"+]K72]<WM4\TRSO[>>OU_N__G4ROOA$<EG$OS(=_(:;NC!2
M85IGVHL-F:-&!'0R*@C-G^;:!->^>BD\'MUJSM9C:99P;6)+@=:OSB4W#Z%8
M*5%X2PXSN%!#*()Y\J%9 G0!$P0>6L>8'H!TJ+!W>Q58KV.=J>C!&7T_GLS%
M?+6%7MU)#J=59PGQY3MW&T#M*82]!<S#!+2;TCS>+T=]YG]? :S;]8OS\46]
M)5^&<Z)-0GEDKB3%M#".15X[R_+Z5('7-F/KQ)M-<!TDX-VG_C0GX\#[D,PI
M%.\U*R+77#(9:QVQHW-?T5_4[/;FKV,?:/_9TEAOQF^'#6@;<GJXB[^,L/V.
MGP@TYH40UL/E6%*$&%F).C$M@V-0,+ B?3:2! 09FM>E;05Q__K4&]UW:MCZ
MXZJ'+>K5=#8\)R_T7=E +KR66;F@%^]^:2T"@Z@B$T$K68I-9%$VUJMM\!VO
M4O7&4@^W\E<QS-HE8W[.*^%B1CK=07A@VJ-B/H%C7D7A9%8YN/:WG[=1'*TS
MUE'@O:O 2U+<D_%D^#_SK*?+YX8W0-A;YO!#Z Z5/MR-QWO5HAD)O:0./XB4
M-D]K#" 3JIZ266H6T "36I<$GNP\VSY_^#!J\F 2\;ZU9!O9]V&A_/?%</;U
M0[TIO?XDG$$E-,C,BN*&)EW38ZQ*3&;!H2AK56RM$:N1'"*?M"UGMXV-[@+O
MP0=:/$5[<C+!DUJ4=2U3:HE/1"MB#.0+YL291D6F%4!F:MXR*WCIBVZL$ ]A
M.CK5:$K"(TT]_AFF.!V7:Q=6>\TY7C_\(9*--Q3&K2SCDC.=.5$JB5Y'6Y.,
M,V2M4HXB")MWR3)>C^0QI1>70,<M)X47F)#IB.3D"6M8+I)C+KYDZ"T&]1C2
MBV^?':\_OQT.K,_<2A#,)%M[@61DGIQAIE!P3NK@?/-&YJMP//6$@VUTZZ$S
M?6M>>BP3JDD05XM_*:IKV0\VIH#!U'I:3?-.$.L-&1#J&"PYQ]PU?[AD0VC/
M6:/Z8._@><FE!*Z+KW5S-8=:%!8-MPQBH"\;B!9[ZF;]+/*2NZA;;SSV</VU
M$-:*"]J!UF0<:AX9-XD\=94]\R@Y"T4*YTTN&EN7OJX%\YRUJ0U#/?6#PF]B
M^7HS-W  5F6:%K(4E"77K0@6"!,KUDBGE H26JO/O8">LPJU8ZKG7.&KP_F:
MJ*[OECQ'4%"?8/<I,<U#9 2UQHL\ J#UA;=NW+T-ON>L9+WQV$>6\+;5&\4G
M!6 BDZX&OH0IS&LZJI,UP@DE=0BM+^R>6S5.7Q979S[OZI_MJG\_7TQIWM/I
MR_%Y'"[:@-7G&D@H.)K1GZ9#&@<6=V9+] ,7I"E 4D&R"&OL-; @8F%@L[;>
M&S2FM0KN /,Y:V'?K-Y51->Y<OI*5*LL3!FX\) -;<Y"D#1"I@U;:):SC *Y
M!VQ?0GTOHN>L7@VYNJM)OEG"<0<Y+?)+N$@FRJB8RY)L Y/K:S(T$:?0"^%K
M2^;6U6#-P#_-$IY.1^]!>'_<=3ZO)_C?%]40F:<\%.VC YN8RIG<=,%EK8BC
M><F"Q3JIL,]JLW6P#IYBME]]V:@H:'?>^JS@6 5PF5.^"<2>,M,V@/>8"H$Z
M4+M.=1KS<B 5"B4:D$ZQ4M]NTU!H%4GM&*TA7K)'&Z"W%R'VK3H[E0#M5W.V
MH6-/&C/]MA=?)LYH&0"494[4[*JLR5U1WK'$G?5&%1=BZR#G)K@.Z!NT(G0#
MA>G$1@^1\6N+YNI>>4A^[B2=?OT5/^/9?-TD9137TK/:RX\.ZV@92.\922 4
M3,&$YBF0FR'[;@<U9J^/YDFKUL%=O,L5MPG8/1I%:X$>W#QJQO@FVU93NO9U
M\JT%C6# UOPC#U"8YDJQD(-E4B3OZH+TSAZ?;FUN/ST.U=J&I3Y5ZLWHT\5L
M.I> N'PW.?#@I!4L)%-+*75DP:O,E%?%>V&*;OX>RCUP'H?IU(C(=2K3D84^
M;:=KT.026B*S+2!8%IW+M3PR,T@R,$,&8P%-!WSJK?GO73C/34%V86%/.XBZ
M;)P?+)9<\V +^9^Z<&10\27E]?_?WI7UMI$CX??]+P1X'R\+.!G/(, F\2:[
MV$>!1S'10I8"'9EX?OT6=?B0++NE9K=L>8%<EIWFQZKJ8MV,(@5A&>]!0,3;
M%)!CN+#7,J[81/(/_/_?ECE&/TZ7XY_#Z61<*.-''_U\#M/9\0TBC1_=NOGC
MN$UL-7:H[*.1"1U@PZ1FU(%),GDC,^,R.3=HO$K;X=0E([Q. T=T[N[R+MQK
MEB6>-YJ7L=G:&.)"H$0*<-1[B,'5-@+VHSE65Z&<;#WUYHO'OS_G*_QTB!YJ
M^>Y'_VMXO;C^,$[#G\.T\*.OPSD,O(LFE>OO3"F^D,%F@F\C)5QH2E7*QAOZ
MC%2V6+Y_G55)%C8*JB_25S1]#H)\V[U7$,\&.1K&A(W$BT*BQ!'R<EB$-BSF
M( !U;DUI>;C\VY*6%J3OP [:@GTW8N0^\H%#:UW[+(BWI91>&4Z\\10M-D5Y
M4-+=N\>Y$W6Z!]BKEYSNV-!!L' +Y$6,4]1Y%_,'5[\,-$NX6<E( LW1;F-H
MMQF'UKU0FBLEI,FU SB-@)VKK%1@0P<M##M[7T?42S5,\)885IH-E;7$::V)
M8D!US *LK3V3['$D?943]2(#1Y'WI13Z[&SEW<TG/T>W\W.^+^7+^&;D#(1R
M1(-'_>>4)PYB)"$X:6E$/Y1U;M7O17>J=%<-47A.NNJPI'OS985RD_YH *VC
M;-43L$Z3F^J*HT\?3:W9T;/$N.@<8TX0&IA:W22"&AD5M.<B)ZY 5!\>T[ND
M/)-I>@&"<@@7*@K(THE#QVQT-9U$@(302NW @_#5Y:\?RY+PS: ;7>8C.%MF
MW$!"(TM*$M"/(SQK$4T4(O&M$J_'_>;#ECVU)=N"79-^:%TQK#*;S@=+9WXE
M\\!,5E8@#UWIZ-0H[BFH$I2VVL3(H-E\9GSJ/>V 7]UIA@<+GH%1<3P!*[JP
MMR VV:<&, ZQ#9KP\Q13)5L0?YM]+2A744MOPPE:&E_NQX3$4"*I3<0ZJ4D,
M-*88/6JA1LG<4S-PS[%<GW^'$*PRWSXBI:X7UYO\7K!4,022LBCN+_[+<8>J
MQ7B9\$3Q7#<:8_ ,YQXLVM_)V8KLDQHTJWP&KJ/7FYFQ@C+J1232>SST.:7$
M29J)%5:K%$2.HI$G_ASS[B_Z"IEW-,WZF(IX-9G-+Z]_C"8WR_LX8(S/G+?(
M8C_]O-:IZP/@;N6KC3&*,B\\OB#2H7$:P3MI8C""H]EH!T\_NIV_^5O9+*3U
M0Z]&?GS767H7"XQ2Q,"90^-6HG%K)!!G>2;)^"00?ZX_W:P1L+;>]NXB7V'Z
M<QCA/9)\D%.Y;[Z,D*4!/4AO.+&0%>%<Z!B=X,K5+K1Y$E#_CE5]Z=CVM.MQ
MH(,RO5UPFUDG*W3*Y\ \NGQ,XA_!*+1W1"+,2J]H=#PU.V5:R<=]1&]#0([F
M00?ANEUTE[]^0)Q#^@+SQ73\>5P^6W5Z#&*2%'#/)+LD2_VS)^BLXI=>"RL<
MLU[63E,?@N]M2$\E_E1T_DNT:1?G)YA?7)>;6_Y:SQ.9S6<783:?^C@?!'#.
M22=)UI81:14G 26=H*'FG0,5+'O.'#I\U7.2CXYIWD'&>A?M?:B?\Q](T%F)
MB\%L$*S0CH(C7&=4B@9=<B\L:D8%+D8;$K?=&RY[X?4G1UUS^5EE4X=%O9Q;
M#Z%>38>3Z3U+[/T4TG ^H$@"*!%5RPU2!U2Y\E>6ZQ6<TT%';7JP>)H@?;,R
M5H%Q'91F/4J@*T"L:1C7GR[-.9.=1\\87PM&+9'24!(RRT1$S6*B)B=1NSJK
M*;9S.OXZY4L'HT*_QN^0%B/XG'<1S^Z(LDX#)9M98D*0#&6T6HJ).!5Y&3D9
MA,E<9E5[E/]! /LJ[NI>?KKCRTLI_T(W8;AJ,2I[NKW-BLN@*#620"S%<2H8
MXI7#,YR%Y$5T68C:KMSC2$Z5@>V0\Y/J'.C @-I%M:XW:(*KH[*N?9A.4]-5
M@V_/BD(+HO<I%-YXG@Q"8[X4AUC$9[,/A!H3\;5 "\QUKRY.6+;5IRP<0NL.
M9.!J19*5'GR@&M=Y-IG0F,K<DZ@UZD+-#7'1,V*]MLKPH"VM[4,]AZE_T[8.
M][8O2Z])^JYN!RS)O.GM[A^<FH]!5MK+ #X2(^DRR,V)YXH2[Z6"P!P7O),+
M P^#>28"U#6#3I<V_^2GT^58_MKY\YT'=Y1(?WH#VQGUR&.4( J_90850(H2
MYRC1%0-N7T9]9XU>4NM*),,5E'XY]*PC^%*S* @5(DL4VJ1<[8LM3I1:+P6;
MTV%8%(&8O;M9T1_?(*M#9%P'?(/2LL442'"HI$,P&:*!Y&+ML<^-P;W8H,\!
M4O-\T*<&9SHX+P_S,;GDFCF="0^E"DJ7OO94IG(HJ[S40?CJ]PZ]YJA/"P'J
MCB\O/.JC!6<LJ42$-N4.<Z1<T(P285)(62?N ^W<C7L]49^#.-\LZG,(!_IT
M\)O@>LM1GX/XUM33/X;H?0H%,&8R<\M&(+V>G<$S)8:!SA"28J;V)2JO(>K3
MB2P<0NM31'T"MT)JY8E2&L];H((X)5D9)&XRM;;<=O]VHSX'<>_0J,\AI'\A
M41\KLP5K'8FB!*HX0WHHB$2QI+5.U(KP_ZA/+0'JFD%]1'W^Y7_!;#*^]--Q
M:58]/LJSYT&MHSI- &Y%<:PMDQ2I=-0+"5[8,G6$@Z B@U=2#_8\LZ73.?PV
M'N9A]./Y^^^ER>;#^-]E^OH$/_X+$JZY"1=]F'T!C^NCK7MS.P?IUL$";H*,
M1I0)LU"T#CI8S*)$ N<V<([*J/;U&I6@MZECO?P583:[6^EW?(6_?O=3>.?1
M>7L_N?Z!VGI9JC1(QG,1A,%SWT0B'6,D6!9)I)EI&9!,43\CK(>MV+^Z.H4L
MW:]P[8@;'1R2B/$B_7<QFR^'N7Z%^7SET9>V^W^/%[/%LA?_Y["<]+.!44X$
M97F)1BD$FPP))CD"W@4!#(+FM8VI@P"^+4GKGH>=%,#&*=+A,#H-A#>6"S D
M0FDY*5/+0KD.B")BQ0+%[]:O?ST"Z-L4P.YYVD%I;#O"K0)M.E#OK)2$EON,
MI7&>>$T9<0XDOD?:6%T[@U(!=E\!\9<@FGUS^=2!](>#(3QZ9X[&1"PM<UFL
M3VA<*$N<X$DJ]*-,;M2/\M+'TO3.Y4=GV!Q"[0Y'GS2!<7XS; XB_IX9*,=0
MKD-&BA2LH<H13U-I5[&.6&-3F:HDLP8I*&ODR9Z:@8UFV-3@WR$$ZW2&C0^>
M^^0DT5H@$(]JQ >=2&2NI/"MD="HF^9US+ YB.Q[9]@<0K-.9]@$!=%K00E5
M@ Y24"7$B Z295 R]5EGVJ@PZ'7,L#F:>4?3K(^P[->5%?5AG"?3ZV6@Y?C(
M[/YGM0[.-H2Y%9\%RI)/V4E.<QFO&:AF*43'LF$R>378_]B6+M/JN5_@1^E\
M''^[M\"=M<XU%3$%28"Q@&Y=*@/&\<LL%9=&2493]7*@!KC:)YM_PG@!)9*W
MK-KR<?Z?X?S[^\5L/KF&Z>6O.%J4>95EI '^*C;GP'E\@XP,1%AED!0QHX>K
M(U'&<*T!WY?J7;M'P#Q!S**V'.UFJ[ME5A?92G1W_(H8J!Y6]SIDSL$Z/ T=
MQW-1.MR]5SK@D9BI!2J!I=K=*X_ .$/Y:$OLRN.%WT^FN%,_AXOQP^K0V1QQ
M48\GL11$^-)!;D,YH%4B+B<!3'*519.1(T^M<48<KDK.#J*.FQE**\$K,W'&
M,_@$\T&*@0;C-('D<+..)^)1( GEU@IOE::A=@/^/BQG) Y5R=[!<)F+T?)G
M(#V>'5P#'3BJ50Z"$R'*@%>6)+K)-A/AO+.!<8_;KRP<S9"=H:ATP)(.!C,\
M'#Z"XHTN78EEKB=J49^THI83*60IO<IXF/D4B3,Q>L^ V68^["$"\R2B<Q24
M>BS8%1#5QIY8%E:5XZ[,SE_)ZZW%@Q]]FHPGFR\'W!@MEA<2BG+?;@"$:84A
MP)U"M]TFS6(#\^* )<](%+HD]JY,Z/;&Q\;:W7A&P_$"<:WQEAXD0,K ZN>6
M55Z7O]![PO6'8S^]61(*-U1R5DC_T9*4JX,5S6<9#0-!5 @H\U$K@EH0B)84
M@%.K>*S=HM'A=LY(1E\:\W?EVK31=1?C<;E@]?:LOOC33]/LRVWN[\/X]^%T
M-O_GPD\1[!5,(U)Y((247&9.4KDL49J 9I\6FBBD80[929U% ZUWU.)G)%O]
M,&!78FQ[3?@344RF-XC3CT8;HPYX2-F6I&\6"I4TS<0+EE"L%911^B'%VN.V
M'T=R1C)2D>2[@N!:"\+U#S^<EIWOFG ?QFO"PVCX$])MU/"/R23].1R-!B%*
M5>XR(HI&0R1EC%C)&:$9N$I&<3S<:XM+"[SG*%1]L>^1B%_%-NLGZ/3N9OW-
M596*DP9?#^4)ZD])I!:^5&\JI)W+H")-S-<.$QT!L[<*LZ[EJVL6O81R,30%
M9Y/1,"WWLB39LB #O-5),4JB+-V"T@<20 @BG!',1QMX:%3;^$P:_/'53]]G
MW1&_)U7I7KF(91?1ILNK ::*)67[</1?7U:#1T^RO 6!^V)^%M:I<IT\FF7E
MED6&\NT2 HP0G)%9>]G(*'Y13'^B)JTOGA]"UPX:,6Z#5&MEMKE/TYF@C6*"
M! GE^E:OB,TF$D@IRT#QEZW=/+\'2K]%477XM"_1W(+('10;W&9(/TW&:V2;
M:QQYEE3H0+)2Q2\OAQFE>*S1C#83PY> UG9I]H(Y _[7(70';_]'Q#0=^E&)
MTXSC<!G-*WO>M%D';[0MP_P2^D<R%/ET,1:P-D8O2ZJKLA@\C>@,9*$BR;MH
MAYHCO&4+_F*&KM-LMM%8J^ILE55T,1'#RL!8DQ*Q9?8B147F1$J.Y>J-3D\!
M.G?_H#Y7NA"9%9;-_,\&8#J:Q/0 R&G&+U5DU+8(M*9R!\?'0U!H#&LNRW@7
MGU6YY$02Z[DB+CI15&)TN79;> \L?V;(4E\</X2XE>L2+V=SU&##&>J\J^\>
MM5N$Q7P8E^WD:1%OK5D)TF1FRP#>F-$UTA+1&4MTV24W4<6X59[T^$2)9LN=
M+(Q]#$,FW5*SHF]0('Y:S*=+6NZ TIJS4,8YLXS[E0 9Y5G2,D#,2/P=(Y@&
M+-Z[P&ME:AV*57YO?QOZ;^/)#(5K"Y,5@4>*;B?G*J"-668_T%+HGB%(RH*0
MWC7@XK[GOU8F5J%710.K8/H(J>B&WZ!<*+;!$\KT6)"X05Z:M7S6Q"7\EX[9
M92:9M3HTX-]CSWZMO&M-I[U5O7O:T=8?ES^"G\'?__8_4$L#!!0    ( ,>
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MBK;!UUNBYJ[1X1\4)SR(>JW]4&Y<[CHW=G0](N(C,_(IL#OB_P-H% "_:Q5
MJX-'TW4@>IYHU77T29ES(#3/R7'H8X;QW^>J?"BT.UD][DVYH6NY62HJ-B;;
M@@4I)UF8PQCG:K-,9 RIQ 0&68282$6(T]"%[/H&FQNS[62M?V&*S6Y$#=;E
M().T%V([SO(%W,@$M14)J 5>% ^$+K4E6 E>K,&'4FVJW_ZX5PNZ(K O0I]B
MD.7/_IC)!B-/--0[U*2<8Z/T<X*QNL>-3;@H%F]7:\5,UYRK-ZK^7-9KLOR_
MBOO7)1<+@GG,\E3"F) $(DPXI"2*(<D8SN,XBGEH933U#S,W!FDD!:VH5Z 1
M%BAI@1;7CD3.(-M/'_[P&IDXAD)E31)V2!RAAUJP/]^4#[^H!S3,H'[8$\*9
MQTY"!7:J;4G \NJA?K9Z76W8>E,5JQOU#U$]",4LU88LK_E_;IH]0+B(,<NC
M7 90<,XAXA&">1+ED(F,JK^H'5;*7,P*NV'G1@]?!%<R:\=**4'550&H?Q1W
M:B?LZOJR0M_6J>4;T]'=55T$6XFO0"LSV OMT__D@I$WSY+5H!/[C%R ./0&
M.=WM1DV$KI\.\%F]-0K4\.M:[:[NU!WBD_QT+RKCB*JO5_S]W;TRD,1;*0M6
MB)7Z__HW<4=%M6!YPJ-89%"R1/&63$*((\Q@("C!28"H),B&MSS*-#]2ZWZ%
M6B\=211>@;UJFN[VR@&RXJ!5#W3UL^,^G]/;3XPO-&F3LN8E\P5^;Y2S/$_V
M.7&\C7(SE\YM I\(-]Y$?KL5SXR(>_5WX[.H.U.YG\=BU?"GOJ+2IH@ 3)F"
MS007[02+[@2K.QY(592;&EQ36J[7@+:GM>:/;+G1<8A@K219;=:5.;PERRMM
MS1"Z+.I;P<']+:GNE :;=<'(LAGL@=1LLR15YW%_OGR1'F&ZFQ5</=BLRD$>
M!V9E]CG2),OV"-!LU_0Q'NV^X'\4&Z5LR?5QDAIFNWQS0FE.,QA'80H1SD.8
MAT+")*%2+>P\12RP7;Z/CC"WQ?B9D/;$?!R_\^OCQ:B,O-H]DV_ DG4<&?L%
MZ&*$)EI.WJ_5HG"OGBBT.]=0^E/)KT M;DQHN3(/]-^%<2IX(NY>F'IH^/A]
MDY%JK]A=BNR_T)WP/I-'/1?UM]($3E7BU6XI->?DKTE]V_Z%*\[5FRSU_%OU
MXQOQ();EO;[[_>IS53)UTX+P, A"$< L$0E4M,@@I;& L4"4IDF<YA+;A3CY
M%VZ& 4[[6+5:?PT=JTB;-VO!;E?ELKQ1*]N5^HS,%\.4SH"T2MO3C^=Y/L_H
M+S!WTRP%6\6T^=LJ /:Z[>*5M'[;O_,KH/0"6QW-Y':TU/9QJ^>+3:C]0O1R
M$SOAALA\9>5F+9?E=T#JNF3%/@M*+UJD$^2K9IOLOMW=A[K>/F;[L39A</K7
M]TK46U*+*_,F5-W7@G=>"S6N6/O:T8PS;3TKJN<!)UN*QP&JNX:/-,*PDY<W
M@JIGZ7V7?JJ)R,<A"7*9Z_R,((,HR@.8)RF!.,!1B)(LR;%3\,;A$'/;[V@)
MP5[$0?D-1X"T.S"Y#)Z15SM'9)Q/0DXK[^G4X\@ DYYPG%;P^6E&SY4#([1:
MGODDWQ0/!1<K7K\N[^[*)BQLD0BAK/68PC04""*4"9BG!,$H9UQ9ZW%,4>R6
MCM _X/SL[YV4X)X4EL:T);AVG[X'P"8V>K5+O^+%BE2/8"?S%6BD;@)*/09F
M6<'C*S2K?[!I@[.L%#\(S[*[:W"XY[VHUH_:+;M6IH@.)S6&R*]5J?8/"99Y
M0((49C%5&_]0D0D.\@1F&<,9)3G%2>(8\-DSW-SLAZVTQH076U&5>;\V1R/.
M49]]2%LRBS?\QF:65M K<X:X-@B^W2-HQ/4:ZFD!B[]@S[[!I@[WM%#\2,"G
MS5V#$VC*._&-_'A3U&Q9UIM*7%-E_A"V7@0LY@%%(<PC72Y$1@FD(DE@Q")*
M!%8;D) [)LN<&FMN7-*(JO/=P%Y897>WXCKN2OI MF,23]"-3".#41N2QW(.
M#W\Y*R='FCH_Y9S*1W)1SMXRX+1"\(*LJX)]W(<);&,Y\CCF&4\3F#"UIT$Q
M4>3!)%;;F4CRD,J(99GM(6W/.'.CBYVHH"NK@Q^Y!U(++[\?H,:V,8YB-. 0
MMP\L!P^Z']!>[$#W?@=G)UJG'O=<UP*S/E]TS]W3.9;/J_#$2VQQN;]@^P6.
MHC ):0Q3B21$* J4Q:6V<B%-(I%31F(<+^Z?E>\:% SN\HX_'W#,LUA6;00'
ME"QU#3>]=:/BIEBM=&1:^T8WTEP>6[] L<@9S1A,8L0@2I,4YHB%,!6"BB 7
M01:3%NQMO:F)H#Y>26MDH(7:\_F&V,ZXO12TD1>NHZD)XZ8A>+9ACP[QXBD&
MIZS6WFN'[G(?U$)85H\?Q7JW\R(4Q9Q&.92!Y(ILD8"Y$!(R3I* B30)D%4^
M0-\@<S-4MS(6HOZ+ZQ[V"(2VF]?+@!E]U]J*UX2-C+-=/8V MWWJD2$FWJ">
M5O)P9]IS[;!O_!TIJG\CRXW8;W;?K\5=6[_J37E'BM4B0%S]G\Y=I+HD @IT
M!5PF(,V"!"4YPR0A+M^\S:!SXP M,S!"@]\$T2(WA\J-M(ZN+2O4[6C"-Y8C
MT\90&)W)PP473V1B->2DY.("PG.R<;KWLE/^=V5E(H($KW55+%,*JZF?I&R9
M:[8N'M0F4M0+QK(L"!,*,\HH1 GGD$JAC_WC,,"!"%)$AQW[6THPOS@ (^FP
MXW];U"U/[49 <N(  5E6X*>M\";D\>>VW-]. ;#7P'^L@"-TGH,';$=_D6@"
M1VA.A1>X/L:-UNIJO?BBWBS1NE5C00(91J&RDW39O#S)(>8Y@1RG,<]D'DAL
M57;YV7/G9AE]U6[<VN0V7F :/0>OGW4N@&1D-AF,AC5MG-"]CP[4+1TJ4/_:
MT\#SITWR>9]08?O9GOKST##A^TKH('A]N$'#F$<1C6"4(65"4$1@3E$$&0Z"
M*):41<3JJ.W8P^?V879E<PT([D!FM_X/!6+DS]$*@P&AOX?*>@OZ[3QZXG#?
M0Z4. WV/7#,@5UE)5*[62CIUP<W[E?H:U!I<FPJJGV1S &_R"=3>8UT5=+--
MG#97?!';+!3]JVT&PNORCA:K)L5ZD05Q&@B*(([R!"*AM@MY2A+(@RS)$DYX
M%J76:<\C"SLWVGBJ+]@I_-__'D=A]H^@UFKI0X^B+7N]S1_2E<QW6NV2B7@7
M%1,CUSR@V@/CD(H\]HO33W9S>QU&)L]3;T)3ZEA/;AN[U"8.OCF8ZN;"CM+F
MM[M^$UV]9_02.*2VS^AEF"S'L*B!6#96[2Z\ IQZ5_[AD"^.$</5(2N85^4H
MM_A*N)]H\OIR]\<68;HR !.!^:2BP%1C^LA/W(KWA:R%WB2:KEQ,?Z\W8A%G
M-&.(<Y@(AG2%?0:)KK"/DC"D09"Q+'8Z5;4?>F[6QU964"DY=4Q%*^<E&8V]
MT-MN;\8 =/3-SY,,R*L=*P,MN*YW9C+#/Y\'^<+D2!N\1DF:[!WX!9,I;0#I
M3[*T>L(PWM(]0?EFJ2CTC:B*!\6%NAG)=N#Z5U*L=&%S7:-?C:M_]TF^4YRY
M4AO#I9)"EM6=CH_Z)GZL7RUU2B%!813%:08IDQE$:1@W.1%AG(:,$1:Q*':A
M-^\2SHT%MPH:.VFG8@UNE&;@IZ72S73!^/3Z?9.W12H=[&=I0X\WSW9<^J*S
M-SKE;C7J$*^R;G\U$_?!3-SOWW23 *#%!T9^C\?>HV'KB9[]RS<IBX\&[W.R
M'V^@@;;L+@C@D]1=JL2J-C;R%V&Z5[TNMW:W[O/,M^=M^ZC!G!"9\!0*&2JK
M-@\D)#@/H X>HD*7&+8K0^A'G-FQO984&E%!*RNXKBI] M)6KAB607?AI%E:
MQI--Q=@G=V867ETR"^YFLA?P?)G.EPDSK3GM!;@#$]O/4X>Z"V2Q$OR56*D?
MUCIO^:-H^_X5K/VMEF A>2P(4M9T&J$(H@@K[D@9AX'@&8X31+*4+-:[EM06
M>UN[@9UH\T3C;;^539L:!> G9MHMG>ZK=!G>MAX"_RB.;JP:D4$KG2ECT(1S
M;^7>_>FUP?GU&9P'N G<0//F)+ <=F(7@1L8APX"Q_N'YN#=[ZNU"+I>Q"B6
M(4H83%,=YY1)!&F8(9@*GN D"Q$/P\6#J&AIW]SFZ1 NWTQWH/$^G;V$S1:=
M.E9*.0#1CF0N 69D,GF*R)L^1 9D>QU7VUNFU[/'3YSE=5RYPPRO$]<-^XS?
M2BF8VC6^_<%NM8VK'8F?5KJ H_Y_72[E@2SU:":SK&#:_M'5'4U5Q\XO.E>^
MW_9#4';4?5F3Y:]5N;G7Q1^5756NUL5J(_B^$/XB0#F2) MAQ&,"$<,YI#JK
M+.9A&H=!RH@4+KO"EU=I;CO+!A']08H6D^9<I?E9?:FKMM#KBC<_B+WJ;H3V
M\MA;4NC+"SHCTMZ_'ULXS-&0?B^TCE=-+>B.JE=@CT)["6GJ0W=_^?2.'3Q@
MBP\P #7%I#L0=5KN^%L[YC/?GE:K&2@TZ?HX WU/K,@SDFR8#?"M,A'JCZ;*
MHDGVVA9OUON$W\3ZMN2+)"$!24D*,XY"W<A60HH"M4K+, NC.$,".V9=V0QK
M19*3IEI];J-%'$L\6&%LMW1YPVV:Q64K;E-;]:I)^[SJ=!8P3H5&;']\[P*2
M)T:V&G)2SG0!X3FK.=T[U(7P(!21?1$Z)48WS-H?6'VBR^+&D)ONFZX9\EMQ
MIR[Y)+_JQ!I)3/M8<X*Z8'E*9(XYI+%FID#$$,L PQ!SF@NJ^$%&;CUU?8@U
MMSU JY6VW%J]0$<QL-?L"FQU XURVB[LJM>>7#N>0GF:;%L'R=13.+I;9;+9
M&^"6\0FV-V>.%Z$F=@'Y!/+0<>3UZ<,H_Z-8-P&Y.FQAD4<L"UE(8)8G!"*2
M*9LRY00&*.5A)G,AD]3E".O)T^=X3O5V4(364]#BC*=QEE$8!E&HFYL0B'$H
M((YY+ -*(AY2E^5N.&B3]'%<#PQK>PJ:W;(Q&(J1V5^CT.;8M,%CU^LFDMV$
MD*U+\)E4PF=_]Z-(>*+FI\^>E&&/JO6<*(]?-(SOKM5>G1?+C0[<^BK8IC*5
M!=[^T-M[P77U 1U@L&FR=3[)+3\H;C8!!DV9E448\)Q$:=QD+R*DFQ)R'3R5
MI23">1PF&7/YY+U(-3>J^+19UVNR,A[&;C</\.F^R43[5_*@__:Q!&]:W4'K
M^/RI6#6)1[5C\("?Z;4CI\DG;612Z^H#]@J!K49-M[F.3L8_W6JEK=\FK? *
M-)KYXSZO0'OB3#\R3<JU7F%\SM%^'^[&[5P4BS=MEN7[E;&A]2@?BI4IC54O
M2!R'(=&EA^,LA8@G%.9)I"PT%**0!B2/ JO>#^<&FAL#;V5M6J"8XMF@([<=
MM9Y%MY\M?6(V,@'NX.K("7[7D@(CJH<MNBT:1UBJ%NS/-^7#+^H1#4&I'_:\
M=/;!DU"-K7I;]K"^?F#&5'&S*F3!R&K]VIP$O5_]=54)5JI?_TWMJ<F/-ORJ
M?E]_$:0N5\I\?_RLK,Q"F?'[-US0/&>,4IC@(-$5HS*( XZAVM]%@M"81[E5
MQ2C/<LV-;CIJ@48OG0S5U<QT4]GJ!HH:[+4#6_7LOKA1Y]O._GN!61R9 *><
M0/<4*K]P^TJ<\B35M.E2?J$\2)+R_'A?<?O*R*S6Q=]:$_1S59355U$]%$SH
M$[0FB'H1,BIHEB501!)#)&@,L4A32#A)29"'$9'8+6IVF"#SBZTU<H*Z$=1O
MA+_5S-BQ\OAHCVV%'HW^[RJA]]W-9+1Z3)<&X(+E:$D!5D*\<(J "U#G$P:<
MGC8P[OB_-FI[J#?IY4I9XVVQ<\0ISD4@($M$!!%)&<0XBI3E&R.<R$"FU*I@
M6^\H<[-C&R'!3LJ!U>2/(VK'8A?C-#))N4/D'B#:!X&OF,VC8TP;1MFGYD%D
M8^_%0]O)-!5+]$GSJM[6^0V3C-*(!S#+XQ0B];5#$A,",Y0(1%,1D31TZR=S
M9)2Y??B[.CRBD=*UJ<PQ(.V^]XOA&?E[WR'3"GB^T^& MC(]$'CK*W-LC(D;
MR_2H>=A9IN]B]P*OORE!V69)JO;E1#C,0H8CF(9"?>418S"G(88!8SFEE.=<
M2MMZK,^>/;=O>R>>?4'+YVCU?\H78C#R![R3;$"/TN<XV-?AO "/%^M%>K>5
M>=SVHR>@Z2E*^?R.R6I(GA"U6_+QU"4#@S3J6JSK(YUN%E'$@DQF'*(P#959
MDH20)D1 D>8"YS&1,4M< M1.CN1$7Q,$JWW38X!&7,>0B)-@VIDF7B :F=T:
M&:] IXW57DZ/@0CGH/ 57'!RG&D#!LZI>Q $</8&#^V%C3_D1U$OTCC(\U $
M,&1Q!%$0(DA9%$ 2Y3*.B*(#X52<]>@H<S-CGO9OU5*"W[6<SL'_QQ"U(X2+
M<1J9#-PANJS-[7,(QNASNQOCY1K=/E>SM]/MP<7#/GP=\/G:I%?>B!5[?%NO
MBSN=S"EWAT4ZECB3/(R#-( ISP-E%*A=#$YC#!'*490P0M/,J0^FU:AS(X96
MRO9XX'Y[%JMKDKI1@QWF=E3A'<F1J4.+ SH"7X&MR.;,90OJASY0G<G$"21/
MY&(WYJ1DXP3#<_)QN]E#5G83T&S,G$7&L@1)DL LRJ0V1&)(@Y1 PB3!"$5I
M3,0%F=B=H:P^E4FSK]O [B98&]R*)=<A(^M6_BM VEIPIDM-](]-B'#]%Z#?
M2/5?%%W%*+E*T_@?]:]"]:LHO KS\"J*\ 4)W=WIL:.JBR!_F<3M1LHV@7ND
M3.TC2(R1G=T=YN4RLH\HVYN%?>SZ@1X/QC9W&U/-TG2_U$<\E;@5J]H4&-XF
MO[PK*U'<K%YOJDK3W+>*K.JE6?2O^7]NZK7V5IG.&M_(CT4:2D$9)C".N**E
ME.NS6T5+>80($0&33+@EJ?B7<6Y&U.M&09T (1LU &OU4)RV4V1;ZIWL%'+U
MR8PPW9;>G)>=Q+']0'OMVA;!3_1[FK-W!5HMP59-T-$3[!6]VC;24LIZ=":-
M-Q.^W% C2#BM VL\B ]<7R,.->J2\BS82/]9";-J[E'6LS+EUD73+%=OZNL=
MWW#">)BJ#3<+,[77SG2@)(T1E"P5.1(XRM+8S>H=6>+Y&<^:5@A;;TA5D&6S
MJ B]K*PXN'\2;/F3MJ';OS0AE^,L.(-?!J^+SZ@3/(^%Z*=&VY^-*^$*'(_Y
M)%+9/"^RZ%PZ ],N0(.EG>-B="GT Q>FBX<=MDC]J^ WNJJ>J-6J:-;!-DR2
M22DQQPE,B"ZFKY83B#GC4*89R:,PPBES.MPY-=#<=B"MG* CZ,#PTY/0VG&U
M#\!&)ME!6#E3YCD@/''=R6$F):ESRCYGE[/7#\W=.6RN]*6H_S"GE!D30413
M!'E$4HB"A$$LTQPF<1!)DK!(4J?0U+[!YD8/1_N8#3H![H78CB)\ 3<R30S"
M;$"NS'DPO&7$] PU<=[+>:4/LULL[AF8[[UONJ;K][Y;EM_W;;-X@$B:RA0&
M2,8021G!/$P%Y$E.!)=$9C)Q2N+N&6QNM+&357NQ3"5P(^[@#F:]0-N1AR_X
M1B:/"Y!SSW"V@,17VG+?4-/F(ELH?9!@;'./>PV9ID+*->?J!:K-&)^JSU7Y
M4"A%%J%,PX@E'*J]!X,()0G$3,0P%30,I> )PE:9<.<&FAMUM&5C6F';YM0*
M4K 5V+Z*3"^^_:SA$[61&6,X8$Y59&S0&%1%IO?!DU61L5&O6T7&ZOIA5L4N
MGO7]ZGZSKC^(![$,MZD0291C&A*(<(0A2N,<YE%&($5AFH993&/NE!_;,];<
MB.%_;4K3I;XJF*AUT,<U,S;V;Z3ZPSE(O0]C.WO"$W(CD\,^0%WW7]&"7@$C
M*@A'2*FSP,23/=$WTJ3FA(7*SZT)FUO<4^UT8OXG^6M9\OIZQ=ML_?IKN>3M
M:QTK]4*&!<QP)"'*L@R2)$Y@SJC$291Q9%=#U&:PN7&'J5=AJEB4?,/6-="B
MVB>DG<6VGS)\(S8R9VS!,L*:(\"MN :V 0E]9_&SS_#SB>-$*7]G\/23WF>+
M2T^^W]E'3)8 :*M,-R/0^I[+JA;HWDX[ M?>:/&A(+18:F-PO?O#(@O"-*-2
ML:O>N*$ IQ"GRF*3N2 )0J%(Q*Y9TC?WJ@9V4@P(0/@V9=4#TX+P5DL/=$\K
MO9M6YLE/]^115S7_62<5%/9U0P?.E)VU-P+P$Q=2,/W\.OF*1GBPDUX'3N__
MZK_*@AMPGLLO6 [^(G49W( Y5;#!\2D#W=V[EO?Z4%^LZB:0K*ITS3V]D+YZ
MW%_RN6E2>_V=5+PMP-XIT/[OHKBY57QS_2 J<K/O2?*ZY8$-62HJNHL6*,Y2
MD;,0JL6*0A2ENBX,XI!FC##$XP1CI]Y.+Z##W(SAIBA^V1;%+_<*78'OK4J0
M-#J!:M=M:%E(Q_HT+_&Z6)X%S/LE&/N(0:L&7VG=0%=_T $ T$?0O:X% 1@4
MKK8=%=0/W;=GBP5HP>CTJNK  30>'@\Q7FXN?9V-O( &TQZYO-P4'9SDO* H
MPQ;=5@@=R6UBX[Z1'Z)>9"*(6)KK786((:*YA#F- Y@D(L\)"=+0K1;!T5'F
MMG!M24CMI4V3\K46TFU-.HZFW:IQ,48C\_I6/IU*U 8!?^M%R)EK>Q'PQ(;'
MQYB4KWK5?,XH_1</3*70C/--W6N"H\(\8UF<9# 16.@B P',\YA#$2OP4$Q#
M'EEU$SGZ]+E]XT8XH*4;%&7V%#F[[WHP'B-_S_90N(?E'U/95Q#]DV=/&_)^
M3*V# /6C%PWN9JD#0LS!+Q?\U>-?E=GP?M4V9E_=F"-*TYEH@0F7% L$!68(
MHB 3, ]B F/) TD)#G,N'5M=6@[M](E/U >SB6S2_;UV H.]Q,Z-'FTGP8X0
MQH%V9+;8H;H56V_A?M*2@V+ULQO,0[I%.B+FKY6D[<!3]YET!.1($TK7)PR-
M0/M0U/J)NGN::9]AULX 1R1FF;(U$B(ATMZW/ @DQ'$<4YZ(  OA%G]V;)BY
MF1]M,-565-U,NQ'6R1HY VT_"_D#;&3&&8S5@+BS/B@NB#H[^MB)8\[Z5#N,
M..N]>FC1L]6-]E2\$73]44EM<L77BX"@)) A@RR+U+:#<@*I=C&@@!/"A4@C
M;E6KN7^8N1& EA*J@>X 5W*Z5C(["J2=T7$Y/"-_[@89+2'0(EZU;5J-<[>1
M%?Q&UFT?3I_%ROI@\5:=[.@@$Y<CZU/TL/Y8[]47G.^].N\<??7<.?IAU\DN
M2:E27G"8X<#X)0G$61+".!92R)B&41@X']==)-+<".;BTY=+^A5>/L$.!VR3
M3=O<S\O&:E#H#62?!UF7"33]N907 (\>,_EYLAN5U]5ZGZWTJRAO*G)_6S"R
M-!L/%N><99)"B1"&B. 0YBG.((U(D.(DC1FW8N?>4>9&N%WYG'9Q_5CV$Z$W
MA$;F-A=PK G*2OD^SE$/Z/"-^M>>:_J?/0E]6*FW902[B[UZG]^O'D3]U$6T
MRY4E&<MQ*#.($640Q:F$.>,88H8CSF4<)8&3?>8NPMSH89=CV[BC]Q[3G0X=
MC^E?O'BF^R;H(@^U)]A?UE-]#/=1TI^'@SBN\[I/@#DXL2T LG1FVSQI&#6^
MVM3*DJKK:_9?FZ*)(O\LU/N[6I,;\4G^6ZE'W0;/-E=5@B\PR_) I@0&5"AZ
MU.G7A& !DR@AC% <Q<B)'H>),3>*W&H!R%Z-*W"_4Z3YO1+<C1T'SI$=0XZ/
M_,@LN0/]N@OZ7@<=!=5H 79J@.MS$^%,DI?AZ(DH!PHQ*5E>!M1SPKSP:4-/
M IL"XR9 O"F<WXEW7" 9ISB52.T920A1FC-%CC&"G(8D(30*I<!N)X)]P\V-
M!-O3KK;_0%L1OY&Z&P7M>D#8B[CM0:$O'*<Y,!P,X8!S0QMD+C@_['W\Q.>(
M-JH>GB=:W75A'8O?3 L#T81)[I*4"E&I1]X^ME4BB0BC.$,YE$)G3"(AU!XU
M1Y FB.<IEB*G^:#*%C:CSXULNGEZ6TE-YO#'ZW\;6)[3;3;LC*S1,!Z9B"Z#
M=WA9#!>8?!?*L!K[94IGN,!RLIB&TT/<RVN\*=2OUJ)^K3BR+5H0<!S+A&@?
MNHGH3)1E%.4!Y") .,$I3H157/;QQ\^-DK82 BVB?>F'([CU<\OE:(Q,'D^
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M4M=BK:YJE03/@??D.K5"L<=;VG__9 Y2*S6Z/E&[&RYL][>-SOS:G&/69@M
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M[Z3V4H.MV.!W+7B3;.A:0-IF!NS(Q3>N8YN8'B!U#X%PP,A7G(/-D-,&,SB
M<!"QX'+OT*,#J=NWOA(K]</ZLWII3!)503?FI.^5VH[?+\M'42TH"H,TEQ',
MTUA9-FF&( EP#O.$93S' 8M2XI8*83VVRX<T37;$9QTK4K8)GEN!7<\7;)&7
M>9*QD$>02JYK[D6B:=%"XRB5B/),9%9NW%%QGR8EWU1QG09UVX.>$; <_>S'
MR Q:H8&6^LK\MPW9:=-FMTH JMW&C1H^3X<<D?-V8&0[[L1G2(YP'!XKN3Y@
MV(KQ]K\VNJJR8&JOK?/9WSU\+!8H"#*<D10F64;4XL 3B"G!, HC$L2(9CR4
M+A1U;)"YL5$C(ZAW0KHQT5$<[4CG4G1&YI<6F+U\5^#=O\&/[Q6M;*JJK^"@
M,XGT(>&)+XX.,2DU]"GYG 5ZKQWJ[E)?DS(_OZ@M\=?OY+X][ NX#J!37SOG
MD>YC%,8PST(!DUC$G(H@QSQV\W0=&V9N'_U62J#%!%I.5[?643!M/5J70C2Z
M,^LY.B,DR?:CX,V%=720B;U7?8H>.JYZK[XTO^A)4UG34+;IFZ:[4S9YC5+M
M"2.>9@I,TI8%HKG ,$YS115,,0)WVJ8XC#TWENBFI#QMD=S4GFG;36KYAZ6K
MNLR+I4-K'+3']FMY!/J"%!]KR+RG\YP?^852=ZPA.9VF8_^(8>3VH5S=?!/5
MG0[(:RW312)"K/@K@'F>BB8_)\<2P92)-!#JGS)R(K$C8\R-K%JQP'U9F7,G
M]2DME=10C7T'N)+;C9J.H6I'01=B-3+5:.F@%@]H^79[&? ;69_;_SDS2P\2
MGACDV B3,D6/BL\9H>_285_^1['6=54_5^5#P05_]?C76O#WJW?%BJR8)ANV
M+A[,G"XB+@0.(@I1B"5$+) PCQ("LU"9.S)- L8SEX0]^Z&=>&*"I#XE>5OL
M6$TF^$G+#8K5SV G.MC+[D89#M-AQR3C@#PRP>SPW8JM_:X#879F''?$/!&1
MP\"3\I,[(,]I:\ 3+K=CWI&B,I%/BX1P1B-&((X0@8BFNF=3IC9F:1!G.24L
MR:5;?N/1<:P^H$FS&)ODXP\[$^;-12;,'E!W(\8-I)<Q8[2,37CC..;+ 08C
M&##[,5[,A#E0L\^(.;S8/:Q]U\#^8ZF(YHL@R^)O>D]DGONU7/(%3J,DR5@&
M0XJ4^<+#'.(\8%"7;PYCK-O)6CEHK4:;VZ9F)S"HE71@?4O6X#NIP7TE'HIR
M4R\?@=I=%G?&/[ NP2UY$&!5FK(MU4X]\-#[80R8E'X2\0[UZ/[>+<H?2Z#M
ME[VX#:< +;!/_.QCTKWB.%$(^K=; 8A)PM>[\,+C.^PI$<D:U)Z(]///F"P
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M/<#JB3LOD612/O4 V7..]?'((:U9_^>&B]\$5\]<J@&WE<4Q06E,=>5@H:S
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MXJD&1U2W23$X=MLP>OFU++GV;JBG"64?-*THV.,W9>S52W,$LN6S1:+[S].
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M/#OTK_<I.H,WFU83Z;SK]#T]$VX_GP1/*/F/A%I,L>MT0=#_]M-J])?:A[I
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M3'PE*/4/-FTZDI7B!\E'=G<-(_"M2^^SJ+8V:\$6N0PR%G"LK$(20B05@^-
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M7E%VE^?7'X 7B;9$"H! FKN[L^.R*2+S@?@P 60^:2Q&L+_KW$):O25:Z.T
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M64EP=MQ<@,I1H#UU.B_U_#TP8[6WF]V1&?%M)M8A26T,_+TEM'DU;N+DMS&
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M:8:7N\V.K,R(]\085DRZ'VF\!_8@)B.:1@V6?<=/P!C%(<V0"D5#%%"(XH1
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M7\6VRN]<1C&*B$S50\^B&"+!U)./<@:3@$E!@XP@8;4W9C;LW*A@;W63L[T
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MJW*JRLM:/* 76+-GWA-<(S_\@_5P>O-D(W6LL0!7N]VVH(^[5OSS*_$;9!C
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M\=1L:B_3((P#19XP1FD&$9-:L!8E4 292$C&F RLDN(=[9@;N;9NU*7?M/%
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MAH&Q9D<1Q>VZD 4CZQWXVWI#=<^%2A2Z-MV.$X8P-N,&3\B-S!&'V'[1X+0
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M&I,$1@3I3 C)(8DH@4SR.(A31L/$*B;9?>JI$8'VG-!CR]PA!L@1]MN.YN'
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M670J06N[*&YFFE^HQ[+@M-2@$2UN!"]W@(!N&W_Q;^/9 ^;9_+.8^$4L0WM
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MKGM#4HRIH&GD9.Y8S#DUVZ<6V3Q"#:'=J,H&;#N.\@SAP.1T#;W:"AK '^P
MD"<RLIEQ5!9R@."4?EQN[5@LU:G+^R?Y:_OM3[G\*7];K[8_-G.$4":I3"%3
M%A1$A'"8X2"'(HUS$N%<I"QUJJ/:2YRIL=7]OLDT7:UT.VG:T*'VVLS XE!M
MSF0,;F9 ?:MCQR*L_1;2CN[&6YZ!F;!4!!I-SJK]S0P?FMS,IE8S\ ^=E/FP
M\KA;] .HK[JO_809MR2L%^#.JL7Z&;5C!^#U1I_NZU"\R@:) BY(EL<0<8DA
MHGD"LP@%4')!LR"3&1>A7<V%JW.X/)/C5% P':S*/:G8<;63VJR7PK%9[AF2
M=O36"YV!&:N&I0S5]&^H7=7=5Y_6L_'';:5Z3;VS;J=7+^Q1<$ZG>Q=RNRBK
M3[^1*YDOMGH+J?.]%RLIJH_JC)\PS8(T1I G-"ZKC9(XR2%-<!X)%A/.J7,5
M.C<9IF9*_2;%@M-EM7-1W+PTSI0NE>D<%\...@:&>&!R*3,KCL4'E; ; _0
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M$ V"EI@B5S[KEG;EWMJ[H>7YI&$;2;EGK%2;^&*.844WA?4A)%% (*M90F[
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MS.8X/INN[X#3]]64LUH!/9O^&L;3:C1_P4(_L\IM:6]-* &B*&0];;W#P1A
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MDO-?PF*<1M$&1HZ!I'"Y1CU*FSKD5$ =()=B2=&QUG9E(R$]#</H$BW'"WP
M-N4A$Z_&DTOR^48V)8Z.!Q"Y3@EC-7J1F0,F$ZM[28RUSI$_04I/XS-.B9Q#
MA#X [/P-ZU.DF%]\)3?N[&I&T/ORJ.%EO3%R1B_K) C-,)' %(DN4=R22Y(2
M=9!JZS2F0Q"U%X$]S>3H$F?=*6@ Z".!S5>B"I.K;JL56R^6R_DX7B[K"T:?
M9]>&&?.'\'TEU_F\#BBIOUV,O*JS:TRJ\R;(5J?((9")!L."M-$P$;NH73R2
MZIXF@G3LGY]2E0, [Q,[\^H@>-PRR%/VBED-7*4J7=J@+E/,$DV2Y*9:PYM7
M:NU)8D]C1WHPGTV4-(" X<5T.<Z5E_%7O!K@-*Z)EUHZBWF=J;GX<KF\JEU[
MZ+2\N*A3\$>Q9+2B5K!%7?U=)X!V(@>=K;/.)6.U;(S,)H3W- :ETUK#DROT
M>7:"5"G,\9Q^A 2U5D2732%;ESM!?\CN[#9J%;E9NQ:\UN5>3/,&(FXP+Y,G
MSS,82$;DFH:K=8N!PAX?I!.:>Q&W-?D=5.&W'XEM,W?68%!2*D!M%"AG&'BF
M',2"UB7:8TZVOJP]('/7E>7K$AW;$WK[R'T /N+J"G"#9)Z^>B9)KOYMLE9F
M_H_+=24$B>%]^1R^?:BUZ/0?[OG5'U9:&W'EG='H0>B:"R^6'&CF \DJE>@\
MBUYO:\<^^%+W5 SVVZ9R2M /%S<#WE2OL(RGF*]NACY,2!K[R4$;H6LK+NCB
MZET2M_4=J CD1&6!AL6DFM>*=L1+OUTX0]@J)T7#(.HSGI)$/3A?AL7YF\GL
MC[]@/L/K\J87A3;E1TR3L%C<O&]5#0D)9BT#IU9O%)%EX+)6] I2C,T!I"NI
M*"E<<MN&2[7<$8=ST6\/T1#VPHD0,."SH3*[RZ:W2O@<HZIOI&B2?G;@M"H0
M%!HGN$6^=9I::\"WLO2=7<H.!=VM=3N W-X&3J^Y'!7MN*YO#BIRST %7H\E
MS2&IB-:JJ'QIG;';0DZ_G5"GA& KG0P 7B]2NKRXG%3O8Y>-=2,^)GEQ/@I(
M4AA0(ECPO@3@1ID87(@)6U<5'$AJOTU7IX3E*70Y@,-]1S8W!<E/A<4CII.V
M+D7R[76=U>@EB<"P6NNCK<G9>]<3G/=AH]]TX$G@=QCD.\/"\]D.#P+A^I]7
M/O[J[]2W N>X'*_O[E=1\HTX?,0@BC9@DW'D^EM&XO >N"PLV9RX;I[C[IBE
M?A.( ]XF)\'(()(D+V9I_"@<?KF6$8GD7F!<&43'<RF)06()01G/(5@?(1<G
M?73U[8'F=^/[D=AOJJ\74'>HPX/M^E><Q]EI+?O-+E3$AU)1@[0ULC6*@XM"
M $9R)GE6RHAMPYI/X)/WFX,;L.4]2(?-PL?!U&RL4S3G=,JD,#EQ <?]M7NN
MYM@BB)Y*.S3/P5O!P"6D3>!B!,>J"27S22H(Q:3FPYM.6]JQ;7]N]87N7B[5
M/2PI6J #14*RO.:!. >/R,'0'Q=47A??>H)(*]J?5T')/IC<)XW<F;:/]7T_
MG^2&9/<[HI5;)9DL.@@(DM694)[4P5R 0GP'Z;C,Y91HWXOXYU5*TA7<N]/W
M,ZHJ_270AD[XZ1QQV;R&=//'N_(Q=F"EO1/Q9CRE1<=A0M9RO-I!U[#U6D>3
M9898'VY4WFN(/#!@AJ,P7CIL/E!K%[J.CLY6<U]O-Z?VEF,P4!SQIJ3VX*W4
M8+5 CM'3GFG=GGN?@L$<W6V0\"B0.ES<0TC2KJB_>@3HAHGLDT.7#/"\JKC3
M 7Q0$41V#+&^U]"\I7LC(3W?&QRAV8T@.4;, \!*/8ZK)T#_>/V?E^.O85+[
MXEXL7X;Y_/MX>O:O87*)HVQK0:9!*,ICK=:DO>1*!)TS<Y5A)5M7*>Y$V!"P
M=!0 'M[U-]?& "#VZ7PV7U(P<7$[8V\Q\H(;<N+J<+/Z$IF('EQFA7C@0ECE
M>6Z>X]Y$1\^W,\T!=+2L!X"7%RG5CK(%Q0-(6R!.:KW+]<OM7!?G-%]UMM5N
M<XI]/2L&A"(#[J21N/5YV@/3SD_2T_-%2'/\-)/](.XTZB:8TH]\)R9N6R5%
M\3%&#BDX#HIQI.!2.G!>E.*4\=JUOKC81$?/MQ/-D7.TK =@>6YX>%/'UY]C
M7CWFLKHNJ4\HS,FDCCQ7T3!GP0L1:L$&TB9PD<RJ3[49+$F[[?6XH^#S-%E]
M/]5TK.Z? E,C10P)6W^;S?_^=OIA/DNX>, 2D<R]*AY2R;6+6T2(*"-D3?_%
MI(A&M6ZFVX&LOE]JZ@I;C10Q)&Q]#'_\%NB[XS!YM%LR&IL4\%"+9C)%#TXS
M"3&XJ*VO$]);1W _IJKO=YNZ0E8;-0P)6,3%R"I-)I<L+$-7B':>22J:8L^D
MBRI&8+#M9XW>KM_WLTQ=@65?T?98QQ_B<O1ACE_"^/J]ENM;R]MX83$J'%%X
M5UL1JA>9)(,0=0)>F(^>&V[D P_IT;W&3@OUVX74SH-N+]5!!%_W!#02,F"T
MB"!D9J!BKK&C]S4Y+[@EY@JV=IOO$=!OOU '@?K!TAU ']"[V?3L89(JEQ *
MXP5$\G0R1NO!&9,A%)V=*#::TMKWW4#&$/*!32XGCA7Q )P/\LR_X'SYO1:_
M+.L38?]Y.5X]7/CKO(YE25R+D GDWN3Z;"$6.GR-AZ*U4B&'K%WK#/)VBH:0
M"VR"G8:"'P",[A3%OD(B(HU7.J'?3_"J]?SN:ZM/,C\2B$4X5J#P**N1+>!J
M0MTESK1CDOZ@PXKGHV@?0K*QS9UK'\H< (B?9*1&#]QX$5 *<#R1'^%EKF_@
M>:A10R;'P%$(<2I+N&N@UK%?WJT=W%?H W"Y'CXA32S<O'9?DZM_C">34;:F
M.*UK3L(8XBDD\B"5!4.A1P@N*(VM7V+>A:XA^.Y- -5<"0.P3#=T%QE=E+[6
M9LJ:,RT! E>&-@2M:HI7F%M'>'L!I+.N^X8 .4B8 P#!JZME[[S$=)W#N$+Z
M;)JN8U6*:V.0=22*4Z"TB^ *X3L(440DUIAN?8._!WG]/H?:$$I=J60 :%O3
M/^(R>W+B5/7>5L-/$+RBW>*CP<RC]DZW?@]UO7*_KY\VKV#<2Y #<&7>C4,<
M3U9#J@G1GY:S]/?SV82$OJ@.VO+[C6C0<!N#2F"DT@1K3SY^C Z0,?+]N4C.
MM:X%WY6VP?2"=%,_W8F*!F!Y[O#U,)F+M-<,KIX?#Q&4PIJ?MQED0D-<.)6:
M6Z.GJ>FW'*0;[3\-L6-4,0!07=?<?0C?5[/CYB'C=6)?>U.T%@%D1B3K[@(X
MK%/UZ4S&F+.1S8>N;2%G,+ Z2N-/E#P>*_X!(.GUQ9?)[#OB1UQER!X+;$0.
M7K::[+GE+H/*=>RRI1UGLF6EB)!$\_="?TA4OV=A1ZAJJXH!8&L=.:0TO]S(
MC12,9!-CO9FNOP@./CB$XC-)2@3#FM_O;J>HW]N8CE#54 D#@-2K\==QQFF^
M-KW7;"@FN5><PE%N*1XQ0H+/DH'G29082S;-'Y%\@I1^[TTZ E$+L0\ /5?;
MX$Y^XYH1:Y'9'#*1KP.0;"(X9T@XTAB?D^*2-:\U>8J8?B]#NG.9&HA^$%5*
MUW42KS#>]+DHST1!K@%+-:.9DY"R3I"Q-L!D&ZQJGC=X3$:_MQX=(>=8<0_
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MC9<CALYHZ30$K4A02AF(BO83E\*7F.I@K-8NX(^IZOOMT,% L;$"!^#0[?M
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MBKKZCI8-R$)6"5BQ'I2J%T84^9/8LI6H:\ZK=9E9_USWZZAVEFWL7[![P6D
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M-E(D-!Y,SA1O))\AVI!!80D\NX#:MKY3W(FPXX=:YG$5[6:!;SJ14U9$J;5
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MRV3E'*^JVRMG:T>9?$PB:@.V3M)01=CZK$/GK$&&(M:2]WMW.QL;!9[Z3D_
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M.JP>DXMRT0:30.9,9Q=GHIY=Q)(H6(P5$H=L4=A&UO._JCT ,#N5DA^NO9X
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M#D[$#[B<7#;[5W:N%Q4*%35C5@&FZM%UM!"TIV.>QQQD\D7*UJ'69DK&1=6
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M:[W!9 L'=V=JP%Z$2K1+$HV& (!H@)8PG0OV9-P5+-=FX;8HC--#M!?6=;=
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MQIO,N=SYSF8#M$"[P\T0G@)MC=\=\IE/<]K?^)50^%[I]+]02P,$%     @
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M+3(P,C(P.3,P+GAS9%!+ 0(4 Q0    ( ,> 85606,[,$QP  *(* 0 4
M          "  ;<B @!A8G0M,C R,C Y,S!?8V%L+GAM;%!+ 0(4 Q0    (
M ,> 8564OQ>I<ET  #\(!  4              "  ?P^ @!A8G0M,C R,C Y
M,S!?9&5F+GAM;%!+ 0(4 Q0    ( ,> 856=--7+"-X  'JI"  4
M      "  :"< @!A8G0M,C R,C Y,S!?;&%B+GAM;%!+ 0(4 Q0    ( ,>
M856MD'5^8H,  "S6!0 4              "  =IZ P!A8G0M,C R,C Y,S!?
M<')E+GAM;%!+ 0(4 Q0    ( ,> 854#N8GEF0<   HE   2
M  "  6[^ P!Q,S(P,C(Q,'%E>#,Q,2YH=&U02P$"% ,4    " #'@&%5GI7I
M)I\'   &)0  $@              @ $W!@0 <3,R,#(R,3!Q97@S,3(N:'1M
M4$L! A0#%     @ QX!A54-[[#O7!   <!,  !(              ( !!@X$
M '$S,C R,C$P<65X,S(Q+FAT;5!+ 0(4 Q0    ( ,> 856GQ0O[W00  '83
M   2              "  0T3! !Q,S(P,C(Q,'%E>#,R,BYH=&U02P4&
/  H "@"$ @  &A@$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
